<SEC-DOCUMENT>0001193125-16-434605.txt : 20160121
<SEC-HEADER>0001193125-16-434605.hdr.sgml : 20160121
<ACCEPTANCE-DATETIME>20160121161800
ACCESSION NUMBER:		0001193125-16-434605
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		23
FILED AS OF DATE:		20160121
DATE AS OF CHANGE:		20160121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merus B.V.
		CENTRAL INDEX KEY:			0001651311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-207490
		FILM NUMBER:		161353665

	BUSINESS ADDRESS:	
		STREET 1:		PADUALAAN 8
		STREET 2:		POSTVAK 133
		CITY:			UTRECHT
		STATE:			P7
		ZIP:			3584 CH
		BUSINESS PHONE:		31 030 253 8800

	MAIL ADDRESS:	
		STREET 1:		PADUALAAN 8
		STREET 2:		POSTVAK 133
		CITY:			UTRECHT
		STATE:			P7
		ZIP:			3584 CH
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>d29248df1a.htm
<DESCRIPTION>FORM F-1/A AMENDMENT 1
<TEXT>
<HTML><HEAD>
<TITLE>Form F-1/A Amendment 1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As filed with the Securities and Exchange Commission on January 21, 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration No.&nbsp;333-207490
</B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Amendment No.&nbsp;1 to </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>Form F-1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="4"><B>REGISTRATION STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>UNDER </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>THE SECURITIES ACT OF 1933 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Merus B.V.* </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in its Charter) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Translation of Registrant&#146;s Name into English) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Netherlands</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other Jurisdiction of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporation or
Organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2834</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Primary Standard Industrial Classification Code Number)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px" align="left"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Padualaan 8 (postvak 133)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>3584&nbsp;CH&nbsp;Utrecht,&nbsp;the&nbsp;Netherlands</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>+31 30 253
8800</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer Identification</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address, including zip
code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>National Corporate Research, Ltd. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>10 E. 40th Street, 10th floor </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>New York, New York 10016
</B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>+1 800 221 0102 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Copies of all communications, including communications sent to agent for service, should be sent to: </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="20%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Peter&nbsp;N.&nbsp;Handrinos<BR>Nathan Ajiashvili<BR>Latham &amp; Watkins LLP<BR>John Hancock Tower<BR>200 Clarendon
Street<BR>Boston,&nbsp;Massachusetts&nbsp;02116<BR>+1 617&nbsp;948&nbsp;6000</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Tom van Wijngaarden</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Eversheds B.V.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>De Cuserstraat 85a</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1081 CN Amsterdam</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>PO Box 7902</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1008&nbsp;AC&nbsp;Amsterdam,&nbsp;the&nbsp;Netherlands</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>+31 20 5600 600</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Roel Botter</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Van Doorne N.V.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Jachthavenweg 121</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1081 KM Amsterdam</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>P.O. Box 75265</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1070&nbsp;AG&nbsp;Amsterdam,&nbsp;the&nbsp;Netherlands</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>+31 20 6789 123</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Divakar Gupta<BR>Marc Recht<BR>Brian F. Leaf<BR>Cooley LLP<BR>1114&nbsp;Avenue&nbsp;of&nbsp;the&nbsp;Americas<BR>New York, New York<BR>10036-7798<BR>+1 212 479
6000</B></FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approximate date of commencement of proposed sale to the
public</B>: As soon as practicable after this registration statement becomes effective. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of the securities being
registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>   <center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:3%"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until
the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall
become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine</B>.<B> </B></FONT></P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to convert the legal form of our company under Dutch law from a private company with limited liability (<I>besloten vennootschap met beperkte
aansprakelijkheid</I>) to a public company with limited liability (<I>naamloze vennootschap</I>) and to change our name from Merus B.V. to Merus N.V. prior to the closing of this offering. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2" COLOR="#de1a1e"><B>The information in this preliminary prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any
state or jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2" COLOR="#de1a1e"><B>SUBJECT TO COMPLETION, DATED JANUARY 21, 2016 </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRELIMINARY PROSPECTUS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g29n63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="7"><B>Merus B.V. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Common Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This is the initial public offering of our common shares. We
are selling &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our common shares in this offering. We currently expect the initial public offering price to be between
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted the underwriters an option to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional common shares to cover over-allotments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied to list our common shares on The NASDAQ Global Market under the symbol &#147;MRUS.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in our common shares involves risks. See
&#147;<A HREF="#toc29248_4">Risk Factors</A>&#148; beginning on page&nbsp;12. </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are an &#147;emerging growth company&#148; under applicable Securities and Exchange Commission rules and will be eligible for reduced public company disclosure requirements. See
&#147;Summary&#151;Implications of Being an Emerging Growth Company and a Foreign Private Issuer.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public Offering Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting Discount(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds to Merus (before expenses)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We refer you to &#147;Underwriting&#148; beginning on page&nbsp;164 for additional information regarding underwriting compensation. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters expect to deliver the shares to purchasers
on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 through the book-entry facilities of The Depository Trust Company. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Jefferies</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Guggenheim Securities
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Wedbush PacGrow </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We are responsible for the information contained in this prospectus. We have not
authorized anyone to provide you with different information, and we take no responsibility for any other information others may give you. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where
the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front cover of this prospectus. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_1a">ABOUT THIS PROSPECTUS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_1">PRESENTATION OF FINANCIAL INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_2">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_3">SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_4">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_5">MARKET AND INDUSTRY DATA</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_6">TRADEMARKS, SERVICE MARKS AND TRADENAMES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_7">EXCHANGE RATE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_8">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_9">DIVIDEND POLICY</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_10">CAPITALIZATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_11">DILUTION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_12">SELECTED FINANCIAL DATA</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_13">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_14">BUSINESS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_15">MANAGEMENT</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_16">PRINCIPAL SHAREHOLDERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_17">RELATED PARTY TRANSACTIONS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_18">DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">136</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_19">SHARES ELIGIBLE FOR FUTURE SALE</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_20">MATERIAL TAX CONSIDERATIONS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_21">UNDERWRITING</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_22">EXPENSES OF THE OFFERING</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_23">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_24">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_25">ENFORCEMENT OF CIVIL LIABILITIES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_26">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc29248_27">INDEX TO FINANCIAL STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For investors outside the United States: Neither we nor
the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction, other than the United States, where action for that purpose is required. Persons outside the United States who
come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common shares and the distribution of this prospectus outside the United States.</B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are incorporated in the Netherlands, and a majority of our
outstanding securities are owned by non-U.S. residents. Under the rules of the United States Securities and Exchange Commission, or SEC, we are currently eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we
will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_1a"></A>ABOUT THIS PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the closing of this offering, we intend to
convert Merus B.V. into Merus N.V. Unless otherwise indicated or the context otherwise requires, all references in this prospectus to the terms &#147;Merus,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this
prospectus refer to (i)&nbsp;Merus B.V. prior to the conversion of Merus B.V. into Merus N.V. and (ii)&nbsp;Merus N.V. after giving effect to the conversion of Merus B.V. into Merus N.V., and such conversion is expected to occur prior to the closing
of this offering.</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_1"></A>PRESENTATION OF FINANCIAL INFORMATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We report under International Financial Reporting Standards,
or IFRS, as issued by the International Accounting Standards Board, or IASB. None of the financial statements were prepared in accordance with generally accepted accounting principles in the United States. We present our financial statements in
euros and in accordance with IFRS. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded
them. All references in this prospectus to &#147;$,&#148; &#147;US$,&#148; &#147;U.S.$,&#148; &#147;U.S. dollars,&#148; &#147;dollars&#148; and &#147;USD&#148; mean U.S. dollars and all references to &#147;&#128;&#148; and &#147;euros,&#148; mean
euros, unless otherwise noted. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_2"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains statements that constitute
forward-looking statements. Many of the forward-looking statements contained in this prospectus can be identified by the use of forward-looking words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;expect,&#148;
&#147;should,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;estimate&#148; and &#147;potential,&#148; among others. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forward-looking statements appear in a number of places in this prospectus and include, but are not limited to, statements regarding our
intent, belief or current expectations. Forward-looking statements are based on our management&#146;s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and
actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, those identified under the section titled &#147;Risk Factors&#148; in this
prospectus. Forward-looking statements include, but are not limited to, statements about: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our operations as a clinical-stage company with limited operating history and a history of operating losses; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the initiation, timing, progress and results of clinical trials of our bispecific antibody candidates, including statements regarding when results of
the trials will be made public; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans to pursue research and development of our lead bispecific antibody candidate, MCLA-128, for the treatment of patients with various solid
tumors; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans to pursue research and development of our second bispecific antibody candidate, MCLA-117, for the treatment of patients with acute myeloid
leukemia, or AML; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential advantages of MCLA-128 for the treatment of patients with various solid tumors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential advantages of MCLA-117 for the treatment of patients with AML; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing or likelihood of regulatory filings and approvals for any of our bispecific antibody candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to establish sales, marketing and distribution capabilities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to establish and maintain manufacturing arrangements for our bispecific antibody candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope of protection we are able to establish and maintain for intellectual property rights covering our bispecific antibody candidates and related
technology; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to defend against any claims by third parties that we are infringing upon their intellectual property rights; </FONT></P></TD></TR></TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the use of proceeds from this offering; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our estimates regarding expenses, future revenues, capital requirements and our needs for additional financing; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rate and degree of market acceptance of our bispecific antibody candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the impact of government laws and regulations on our business; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our competitive position; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other risk factors discussed under &#147;Risk Factors.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forward-looking statements speak only as of the date they are
made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of
unanticipated events. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">iii
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_3"></A>SUMMARY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights information contained elsewhere in
this prospectus. This summary may not contain all the information that may be important to you, and we urge you to read this entire prospectus carefully, including the &#147;Risk Factors,&#148; &#147;Business&#148; and &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations&#148; sections and our audited and condensed unaudited financial statements, including the notes thereto, included in this prospectus, before deciding to invest in our common
shares</I>.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage immuno-oncology company
developing innovative bispecific antibody therapeutics. Our pipeline of full-length human bispecific antibody candidates, which we refer to as Biclonics, are generated from our technology platform. By binding to two different antigens, or targets,
Biclonics can be designed to simultaneously block receptors that drive tumor cell growth and survival and to mobilize the patient&#146;s immune response by activating various killer cells to eradicate tumors. In our pre-clinical studies, our
bispecific antibody candidates were effective in killing tumor cells, a result that we believe supports their potential efficacy in the treatment of cancer. In February 2015, we commenced a Phase 1/2 clinical trial of our lead bispecific antibody
candidate, MCLA-128, for the treatment of <FONT STYLE="white-space:nowrap">HER2-expressing</FONT> solid tumors, and we expect to report top-line results from this trial by the end of 2016. In the first quarter of 2016, we expect to commence a Phase
1/2 clinical trial with our second bispecific antibody candidate, MCLA-117, for the treatment of acute myeloid leukemia, or AML. Additionally, we have several bispecific antibody candidates in pre-clinical development that bind to combinations of
immunomodulatory molecules, including programmed death receptor-1, or PD-1, and programmed death-ligand&nbsp;1, or PD-L1, both of which we believe play a significant role in treating cancer. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Biclonics technology platform enables rapid functional
screening of large collections of Biclonics which allows us to identify lead candidates with multiple mechanisms of action. The Biclonics format retains the Immunoglobulin G, or IgG, format of conventional monoclonal antibodies, or mAbs, and is
designed to preserve the format&#146;s key features, including stability, long half-life and low immunogenicity, when developing our bispecific antibody candidates. We leverage industry-standard manufacturing processes and infrastructure to
efficiently produce Biclonics. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead
bispecific antibody candidate, MCLA-128, is currently in a Phase 1/2 clinical trial in Europe for the treatment of various solid tumors, including breast, colorectal and ovarian cancers. We believe MCLA-128 has the potential to be a more effective
treatment of HER2-expressing solid tumors than existing therapies due to its ability to inhibit cellular growth factor receptors on tumor cells and simultaneously involve immune system cells to attack tumor cells. MCLA-128 is designed to bind to and
block growth factor receptors known as HER2 and HER3, as well as recruit immune killer cells, such as natural killer, or NK, cells and macrophages. In our pre-clinical studies, MCLA-128 was more effective in inhibiting heregulin-driven tumor growth
than HER2 or HER3 mAbs, as well as their combinations and a combination of currently approved HER2 mAbs. The production of heregulin, which is the binding molecule, or ligand, for HER3, has been widely shown to cause cancer cells to grow and become
resistant to treatment with HER2-targeted therapies. Our Phase 1/2 clinical trial of MCLA-128 will assess its safety, tolerability and anti-tumor activity. In the early stages of the dose escalation, we have observed an objective positive effect in
nine out of 22 patients treated to date with MCLA-128 and evaluable for efficacy. In eight of those nine patients, the disease had not progressed at the completion of the first two cycles of treatment, a condition defined as stable disease. In one
patient, we observed reduction in size and disappearance of some metastatic lesions with no new tumors appearing to date, a condition defined as a partial response. The disease progressed in the remaining patients evaluable for a response. Two of
the eight patients initially assessed with stable disease continued without progression of the disease beyond the fourth cycle of their treatment. In the remaining six patients initially assessed with stable disease, the disease progressed at a
later evaluation date. We expect to report top-line results from the Phase 1/2 trial by the end of 2016. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our second bispecific antibody candidate, MCLA-117, is expected to commence a Phase 1/2
clinical trial in Europe for the treatment of AML in the first quarter of 2016. AML generally has a poor prognosis and limited progress has been made in disease outcomes despite a growing AML patient population. Clinical and pre-clinical studies
suggest that treatment-resistent leukemic stem cells are a potential cause of disease relapse. MCLA-117 binds to CD3, a cell-surface molecule present on all T-cells, and to CLEC12A, a cell surface molecule present on approximately 90 to 95% of AML
tumor cells and stem cells in newly diagnosed and relapsed patients. <FONT STYLE="white-space:nowrap">MCLA-117</FONT> is designed to recruit and activate T-cells to kill AML tumor cells and stem cells. In our pre-clinical studies, MCLA-117 killed
tumor cells in blood samples of AML patients. We plan to seek orphan drug designation for MCLA-117 for the treatment of AML from the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA. We are also currently
evaluating MCLA-117 for the treatment of myelodysplastic syndrome, or MDS, in pre-clinical studies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our management team has a broad range of experience in research and late-stage clinical development in the fields of antibody engineering, immunology and medical oncology. Our founder and Chief Executive
Officer, Ton Logtenberg, holds a Ph.D. in medical biology, was a professor in the Department of Immunology at Utrecht University and co-founded the Dutch biotechnology company, Crucell N.V. Dr.&nbsp;Logtenberg has authored more than 80 scientific
publications and is named as an inventor on 20 patent applications and patent families in the field of antibody engineering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Product Pipeline </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use our technology platform to develop Biclonics for the treatment of various types of cancer. The following table summarizes
our bispecific antibody candidate pipeline: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g27z86.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Biclonics
Platform </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a pipeline of Biclonics
generated from our technology platform. Our platform enables the rapid identification of immunotherapeutics with the potential to produce tumor cell-killing activity, and allows for the flexible and rapid generation of Biclonics against any
particular target pair. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By binding to two
different targets, Biclonics can be designed to block receptors that drive tumor cell growth and survival and to mobilize the patient&#146;s immune response by activating various killer cells to eradicate tumors. We believe our Biclonics platform
allows us to approach cancer treatment through multiple modes of action: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Blocking combinations of growth factor receptors that drive tumor cell growth and relapse while simultaneously recruiting immune effector cells
through enhanced ADCC</I></B><B><I>.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Biclonics may be generated for various combinations of growth factor receptors that play a role in tumors with different
</FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
molecular profiles, while a modification in the constant region of the bispecific antibody, known as the Fc region, facilitates the enhanced recruitment of immune effector cells, such as NK cells
and macrophages, to directly kill tumor cells through antibody-dependent cellular cytotoxicity, or ADCC. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Activating T-cells to kill tumor cells by binding to CD3-expressed on T-cells and a tumor-associated target.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>CD3
is a cell-surface molecule present on all T-cells. Biclonics can be designed to simultaneously bind to CD3 and a tumor-associated target, which allows for T-cell recruitment and engagement to selectively kill tumor cells.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Blocking two checkpoint inhibitory pathways for more efficient T-cell activation.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Cancer cells are able to block
the tumor-killing function of T-cells through the expression of inhibitory molecules. Scientific research has shown that combinations of mAbs are more potent than single mAbs when used against these inhibitory molecules to unblock and revive this
mechanism of T-cells which kills tumor cell targets. Biclonics can be designed to prevent the blocking of T-cells by cancer cells while retaining the advantages of specific targeting in the tumor environment. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Blocking a checkpoint inhibitory pathway while simultaneously providing a co-stimulatory signal for more efficient activation of
T-cells.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In addition to being blocked by inhibitory molecules, tumor specific T-cells may simultaneously require an activation signal to engage in tumor cell-killing. Biclonics can be designed to concurrently alleviate
the blocking of T-cells and deliver the signals required to activate the killing potential of <FONT STYLE="white-space:nowrap">T-cells.</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Simultaneously targeting a growth factor receptor expressed by tumor cells and an immunomodulatory molecule involved in blocking tumor-specific
T-cells.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; Growth factor receptors like epidermal growth factor receptors, or EGFR, and HER2 are expressed on many tumors. Biclonics can be designed to target such growth factor receptors while delivering an activation
signal or de-blocking signal to T-cells. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our process to select lead Biclonics for clinical development takes approximately 12 months and is illustrated below. We use our human antibody generation and Biclonics production technologies to rapidly
build large collections of Biclonics directed against particular target pairs. We then test these collections in cell-based functional assays to identify Biclonics that have differentiated modes of action. We select the most potent Biclonics and
evaluate them in multiple <I>in vitro</I> and <I>in vivo</I> assays to identify lead candidates for clinical development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Selection of Lead Biclonics </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g30o93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Biclonics technology platform includes the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Human antibody generation.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our human antibody platform is comprised of genetically modified, or transgenic, mice,
which we refer to as MeMo, used to generate human antibodies and phage display for the generation of panels of common light chain human mAbs. MeMo harnesses the power of the <I>in vivo</I> immune system to directly yield antibodies with high
potency, specificity, solubility and low immunogenicity. Using our human antibody generation technology, we produce large and diverse panels of high-affinity antibodies against a broad variety of targets. We believe this approach enhances the
discovery and development of high-quality human antibodies that, through the common light chain, are ready to be inserted into the Biclonics format. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The full-length Immunoglobulin G format.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The Biclonics format retains several of the favorable attributes of
conventional human IgG mAbs, including their stability and predictability during manufacturing and their long half-life and low immunogenicity during treatment of patients. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>High-throughput functional screening.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The panels of target-specific human antibodies are introduced as pairs of
DNA constructs into mammalian cells. The common light chain format and modified constant region of the IgG antibody ensure the secretion of pure Biclonics&nbsp;into the cell culture medium. The medium of thousands of cell cultures is harvested and
individually used in cell- and tissue-based functional assays to identify Biclonics with differentiated modes of action. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Benefits of Biclonics </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe our Biclonics technology platform provides the following benefits: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biclonics&nbsp;are stable, bispecific, full-length human IgG antibodies with no linkers or fusion proteins.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;
Biclonics retain the IgG format of antibodies that are produced naturally by the immune system. Additionally, in contrast to many other bispecific antibody formats, Biclonics do not require linkers to force the correct pairing of heavy and light
chains or exploit fusion proteins to add functionality to the molecule. These qualities minimize time-consuming engineering efforts and allow us to create Biclonics with predictable behavior during pre-clinical development.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biclonics preserve the stability, behavior and adaptability of normal IgG antibodies.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Biclonics&nbsp;are based on
the robust and commonly used IgG format to yield the favorable <I>in vivo</I>&nbsp;qualities associated with conventional mAbs, such as stability, long half-life and low immunogenicity. As a result, our Biclonics format provides attractive options
for dosage schedules and methods of administration, rendering them compatible with multiple modes of action for the efficient killing of tumor cells. Further, the IgG format allows us to apply previously established technologies to further optimize
our Biclonics for therapeutic use. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biclonics can be reliably manufactured with high yields.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Because our Biclonics retain the IgG format of
antibodies, our Biclonics are manufactured using the large-scale industry-standard processes that are also used for the production of conventional mAbs, and the yields of Biclonics we obtain are comparable to those of normal IgG antibodies. In
stable cell lines, we are able to obtain over 90% of bispecific antibody formation using these processes and the IgG-based purification process results in greater than 99.8% purity for our Biclonics. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Biclonics technology platform allows for functional evaluation of Biclonics&nbsp;in the relevant therapeutic format leading to the discovery
of therapeutic candidates with differentiated properties.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our Biclonics technology platform enables rapid functional screening of large collections of bispecific antibodies which allows us to identify lead candidates
with multiple mechanisms of action that have the potential to effectively kill tumor cells with high potency. This is an important step in the identification of lead bispecific antibody candidates with functionalities that compare favorably against
other forms of immunotherapeutics, such as conventional mAbs as well as their combinations. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our goal is to become a leading immuno-oncology company developing bispecific antibodies to treat and
potentially cure various types of cancer. Our business strategy comprises the following components: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rapidly develop our lead bispecific antibody candidate, MCLA-128, for the treatment of solid tumors</I></B><B>.&nbsp;&nbsp;&nbsp;&nbsp;</B>We are
developing MCLA-128 for the treatment of patients with HER2-expressing solid tumors, including breast, colorectal and ovarian cancers. We commenced a Phase 1/2 clinical trial of MCLA-128 in February 2015. We believe that if MCLA-128 is successfully
developed and obtains regulatory approval, it has the potential to address disease-specific challenges that are not currently being met by existing therapies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Successfully develop our second bispecific antibody candidate, MCLA-117, for the treatment of AML.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>We are
developing MCLA-117 for the treatment of patients with AML with the intent of seeking orphan drug designation from the FDA and the EMA. We submitted a Clinical Trial Application, or CTA, to the EMA in December 2015 and expect to commence a Phase 1/2
clinical trial in Europe in the first quarter of 2016. We believe that if MCLA-117 is successfully developed and obtains regulatory approval, it has the potential to transform the treatment of AML. We are also currently evaluating MCLA-117 for the
treatment of MDS in pre-clinical studies. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accelerate the internal discovery and development of additional immunotherapeutic bispecific antibody
candidates</I></B><B>.&nbsp;&nbsp;&nbsp;&nbsp;</B>We believe we are well positioned to expand our pipeline of Biclonics for the treatment of other forms of cancer. Our platform enables rapid functional screening of large collections of Biclonics
which allows us to identify lead candidates with multiple mechanisms of action that have the potential to kill tumor cells with high potency. We are currently evaluating Biclonics that target various combinations of checkpoint inhibitory,
co-stimulatory and cancer stem cell targets in pre-clinical studies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Seek strategic collaborative relationships.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We intend to seek strategic collaborations to facilitate the
capital-efficient development of our Biclonics technology platform and to identify potential target combinations in immuno-oncology and other therapeutic areas. We believe these collaborations could potentially provide significant funding to advance
our bispecific antibody candidate pipeline while allowing us to benefit from the development expertise of our collaborators. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financing History </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since inception, we have financed our operations primarily through a series of private placements of our Class&nbsp;A, Class B and Class C
preferred shares with a number of European and U.S.-based venture capital firms, providing total gross proceeds of &#128;91.3&nbsp;million in the aggregate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2015, we entered into a subscription agreement pursuant to which we sold an aggregate of 6,268,579 of our Class C preferred
shares for aggregate consideration of &#128;41.6&nbsp;million and fully converted our &#128;8.0&nbsp;million convertible bridge loan into 1,201,201 Class C preferred shares in connection with the consummation of the first tranche of the private
placement, or the Class C Financing. See &#147;Related Party Transactions&#151;Convertible Bridge Loan and Class C Preferred Share Financing.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our outstanding Class&nbsp;A, Class B and Class C preferred shares will be automatically converted into common shares in connection
with this offering. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Information
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the laws of the
Netherlands on June&nbsp;16, 2003 as a private company with limited liability (<I>besloten vennootschap met beperkte aansprakelijkheid</I>), and prior to the closing of this offering, we intend to convert to a Dutch public company with limited
liability (<I>naamloze vennootschap</I>). Our principal executive offices are located at Padualaan 8 (postvak 133), 3584 CH Utrecht, the Netherlands. Our telephone number at this address is +31 30 253 8800. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our website address is www.merus.nl. The information
contained on, or that can be accessed through, our website is not a part of, and shall not be incorporated by reference into, this prospectus. We have included our website address as an inactive textual reference only. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Associated with Our Business </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to a number of risks of which you
should be aware before making an investment decision. You should carefully consider all of the information set forth in this prospectus and, in particular, should evaluate the specific factors set forth under the &#147;Risk Factors&#148; section of
this prospectus in deciding whether to invest in our securities. Among these important risks are the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a limited operating history, have incurred significant losses since our inception, expect to incur losses for the foreseeable future and may
never achieve or maintain profitability. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will need additional funding to complete the development of our bispecific antibody candidates and commercialize our products, if approved, and if
we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Biclonics technology platform is an unproven novel approach to the production of molecules for therapeutic intervention.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are very early in our development efforts and our bispecific antibody candidates, including MCLA-128 and MCLA-117, may not be successful in clinical
trials and, as a result, may never be approved as marketable therapeutics. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We depend heavily on the success of our bispecific antibody candidates, and we cannot give any assurance that any of our bispecific antibody candidates
will receive regulatory approval, which is necessary before they can be commercialized. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may encounter regulatory changes that delay or impede our development and commercialization efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely, and expect to continue to rely, on third parties to conduct our clinical trials and to manufacture our bispecific antibody candidates for
pre-clinical and clinical testing, and those third parties may not perform satisfactorily, which could delay our product development activities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to adequately protect our technology, or to secure and maintain freedom to operate and/or issue patents protecting our bispecific
antibody candidates, others could preclude us from commercializing our technology and products and/or compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and
prospects. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete
effectively. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to compete may be adversely affected if we are unsuccessful in defending against claims that we are infringing on our competitors&#146;
intellectual property rights, including claims and opposition proceedings initiated by Regeneron Pharmaceuticals Inc. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The rights of shareholders in companies subject to Dutch corporate law differ in material respects from the rights of shareholders of corporations
incorporated in the United States. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Implications of Being an Emerging Growth Company and a Foreign Private Issuer </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an &#147;emerging growth company&#148; as defined in
the Jumpstart Our Business Startups Act, or JOBS Act. As such, we are eligible, for up to five years, to take advantage of certain exemptions from various reporting requirements that are applicable to other publicly traded entities that are not
emerging growth companies. These exemptions include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the option to present only two years of audited financial statements and only two years of related Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations in this prospectus; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we are not required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002;
</FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we are not required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory
audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis); </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we are not required to submit certain executive compensation matters to shareholder advisory votes, such as &#147;say-on-pay,&#148;
&#147;say-on-frequency&#148; and &#147;say-on-golden parachutes;&#148; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we are not required to disclose certain executive compensation related items such as the correlation between executive compensation and performance and
comparisons of the chief executive officer&#146;s compensation to median employee compensation. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the closing of this
offering or such earlier time that we no longer qualify as an emerging growth company. As a result, the information we provide to our shareholders may be different than you might receive from other public reporting companies in which you hold equity
interests. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;107 of the JOBS Act also
provides that an emerging growth company can take advantage of the extended transition period provided in Section&nbsp;13(a) of the Exchange Act, for complying with new or revised accounting standards. In other words, an emerging growth company can
delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are choosing to irrevocably opt out of this extended transition period and as a result, we will comply with new or revised
accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. Under federal securities laws, our decision to opt out of the extended transition period is irrevocable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will remain an emerging growth company until the earliest
of: (i)&nbsp;the last day of the first fiscal year in which our annual gross revenues exceed $1 billion; (ii)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of this offering; (iii)&nbsp;the date that we become a
&#147;large accelerated filer&#148; as defined in Rule&nbsp;12b-2 under the Exchange Act, which would occur if the aggregate market value of our common shares that is held by non-affiliates exceeds $700 million as of the last business day of our
most recently completed second fiscal quarter; or (iv)&nbsp;the date on which we have issued more than $1 billion in non-convertible debt securities during any three-year period. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, we will report under the
Exchange Act as a non-U.S. company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, for as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain
provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the
Exchange Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders
who profit from trades made in a short period of time; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specific
information, or current reports on Form 8-K, upon the occurrence of specified significant events. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both foreign private issuers and emerging growth companies are also exempt from certain more stringent executive compensation disclosure
rules. Thus, even if we no longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures required of companies that are neither an emerging growth
company nor a foreign private issuer. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE OFFERING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common shares offered by us </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common shares to be outstanding after this offering </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares ( &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares if the underwriters
exercise their option to purchase additional common shares from us in full) </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option to purchase additional shares </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted the underwriters an option to purchase up to additional common shares from us within 30 days of the date of this prospectus. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of proceeds </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds to us from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming an initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering
expenses payable by us. We intend to use the net proceeds from this offering to advance the clinical development of <FONT STYLE="white-space:nowrap">MCLA-128</FONT> and MCLA-117, to fund our other current and future research and development
activities and for working capital and other general corporate purposes. See &#147;Use of Proceeds.&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dividend policy </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never paid or declared any cash dividends on our common shares, and we do not anticipate paying any cash dividends on our common shares in the foreseeable future.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk factors </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our common shares.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Listing </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied to list our common shares on The NASDAQ Global Market, or NASDAQ, under the symbol &#147;MRUS.&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of our common shares to be outstanding after this offering is based on 17,130,892 common shares
outstanding as of September&nbsp;30, 2015 and excludes the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">700,776 common shares issuable upon the exercise of share options outstanding as of September&nbsp;30, 2015 at a weighted average exercise price of
&#128;2.14 per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,300,000&nbsp;common shares reserved for future issuance under our 2016 Incentive Award Plan, or the 2016 Plan, which will become effective in
connection with this offering, as well as common shares that may become available pursuant to provisions in our 2016 Plan that automatically increase the share reserve under our 2016 Plan as described in &#147;Management&#151;Long-Term Incentive
Plans&#151;2016 Incentive Award Plan&#148;; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">291,525 common shares issuable to the holders of our Class B and C preferred shares in connection with this offering in satisfaction of their
entitlement to distributions in kind accruing from October 1, 2015 to December 31, 2015, plus additional common shares issuable to such holders in satisfaction of their entitlement to distributions in kind accruing after December&nbsp;31, 2015, as
described in more detail in &#147;Capitalization&#151;Preferred Share Distributions.&#148; </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, all information contained in this prospectus assumes or
gives effect to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the automatic conversion of all of our outstanding preferred shares at September&nbsp;30, 2015 into an aggregate of 14,900,456 common shares in
connection with this offering; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the issuance of 1,622,840 common shares to the holders of our Class B and C preferred shares in connection with this offering in satisfaction of their
entitlement to distributions in kind accrued as of September 30, 2015, all of which is described in more detail in &#147;Capitalization&#151;Preferred Share Distributions&#148;; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">no exercise of the outstanding options described above after September&nbsp;30, 2015; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our conversion into a public company with limited liability (<I>naamloze vennootschap</I>) under the laws of the Netherlands and the amendment of our
Articles of Association as adopted by our general meeting of shareholders prior to the closing of this offering; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">no exercise by the underwriters of their option to purchase additional common shares in this offering; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on
the cover page of this prospectus. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUMMARY FINANCIAL DATA </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the following summary financial data together with our financial statements and the related
notes thereto included elsewhere in this prospectus and the &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections of this prospectus. We have derived
the statement of profit or loss and comprehensive loss data for the years ended December&nbsp;31, 2013 and 2014 from our audited financial statements included elsewhere in this prospectus. The statement of profit or loss and comprehensive loss data
for the nine months ended September 30, 2014 and 2015 and the statement of financial position data as of September 30, 2015 have been derived from our unaudited financial statements included elsewhere in this prospectus and have been prepared on the
same basis as the audited financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the financial information in those
statements. Our historical results are not necessarily indicative of the results that should be expected in the future, and results for the nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the
full year ending December 31, 2015 or any other future period. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We maintain our books and records in euros, and we prepare our financial statements under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board,
or the IASB. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine Months Ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Statement of Profit or Loss and Comprehensive Loss Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management and administration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating result</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,420</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income (expenses)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic (and diluted) loss per share(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares outstanding, basic and diluted(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,603,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,093,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,912,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,903,486</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2015, we revised the presentation of our statement of profit or loss and comprehensive loss to categorize expense by function instead of by nature. We decided to
change our presentation format after considering industry factors and the nature, practice and current stage of development of our operations. We believe that this change in accounting policy provides more relevant information and will enable a
better understanding of our business. Consequently, we have retrospectively applied this change in accounting policy to our statement of profit or loss and comprehensive loss for the years ended December&nbsp;31, 2013 and 2014. For more information,
please see our audited and unaudited financial statements included elsewhere in this prospectus. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic loss per share and diluted loss per share are the same because outstanding options would be anti-dilutive due to our net losses in these periods.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes preferred shares issued and outstanding as of September&nbsp;30, 2015. Does not give effect to the 1,622,840 common shares to be issued to the holders of our
Class B and C preferred shares in connection with this offering in satisfaction of their entitlement to distributions in kind accrued as of September 30, 2015, all of which is described in more detail in &#147;Capitalization&#151;Preferred Share
Distributions.&#148; </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of September&nbsp;30, 2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As<BR>Adjusted(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Statement of Financial Position Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> 40,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The as adjusted balance sheet data give effect to the automatic conversion of all of our preferred shares outstanding as of September 30, 2015 into an aggregate of
14,900,456 common shares in connection with this offering, the issuance of 1,622,840 common shares to the holders of our Class B and C preferred shares in connection with this offering in satisfaction of their entitlement to distributions in kind
accrued as of September 30, 2015, all of which is described in more detail in &#147;Capitalization&#151;Preferred Share Distributions,&#148; and the sale by us of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares
in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of
the price range set forth on the cover page of this prospectus, would increase or decrease the as adjusted amount of each of cash and cash equivalents, total assets and total equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million,
assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions. Each increase or decrease of 1,000,000 in the number of
shares we are offering would increase or decrease the as adjusted amount of each of cash and cash equivalents, total assets and total equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial
public offering price per share and after deducting the estimated underwriting discounts and commissions. This as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering
determined at pricing. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_4"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>You should carefully consider the risks and uncertainties
described below and the other information in this prospectus before making an investment in our common shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as
a result, the market price of our common shares could decline and you could lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See &#147;Cautionary Statement Regarding
Forward-Looking Statements.&#148; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors</I>.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Business and Industry </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are a clinical-stage company and have incurred
significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage immuno-oncology company with a limited operating history. We have incurred net losses of &#128;17.4&nbsp;million
and &#128;9.9&nbsp;million for the years ended December&nbsp;31, 2014 and 2013, respectively, and &#128;16.5&nbsp;million and &#128;11.7&nbsp;million for the nine months ended September&nbsp;30, 2015 and 2014, respectively. As of September&nbsp;30,
2015, we had an accumulated loss of &#128;57.1&nbsp;million. Our losses have resulted principally from expenses incurred in research and development of our bispecific antibody candidates and from general and administrative expenses that we have
incurred while building our business infrastructure. We expect to continue to incur significant operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval and
commercialization of our bispecific antibody candidates. We anticipate that our expenses will increase substantially as we: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">conduct the Phase 1/2 clinical trial of MCLA-128, our lead bispecific antibody candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">continue the research and development of our other bispecific antibody candidates, including completing pre-clinical studies and commencing clinical
trials for our second bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-117;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seek to enhance our technology platform, which generates our pipeline of Biclonics, and discover and develop additional bispecific antibody candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seek regulatory approvals for any bispecific antibody candidates that successfully complete clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for
which we may obtain regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain, expand and protect our intellectual property portfolio; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">secure, maintain and/or obtain freedom to operate for our technologies and products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product
development and potential future commercialization efforts and to support our transition to a public company; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or
other regulatory challenges. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To
date, we have financed our operations primarily through private placements of equity securities, upfront and milestone payments, funding from patient organizations and governmental bodies and borrowings from bank and bridge loan financings. We have
devoted a significant portion of our financial resources and efforts to developing our Biclonics technology platform, identifying potential bispecific antibody candidates and conducting pre-clinical studies and initiating our clinical trial of
MCLA-128. We are in the early stages of development of our bispecific antibody candidates, and we have not completed development of any Biclonics or any other drugs or biologics. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To become and remain profitable, we must succeed in developing and eventually
commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing pre-clinical testing and clinical trials of our bispecific antibody candidates, discovering
and developing additional bispecific antibody candidates, obtaining regulatory approval for any bispecific antibody candidates that successfully complete clinical trials, establishing manufacturing and marketing capabilities and ultimately selling
any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to
achieve profitability. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the numerous
risks and uncertainties associated with pharmaceutical product and biological development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by
the FDA, the EMA or other regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our bispecific antibody candidates, our
expenses could increase and revenue could be further delayed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if we do generate product royalties or product sales, we may never achieve or sustain profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price
of our common shares and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of our common shares also could cause you to lose all or a part of
your investment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if this offering is
successful, we will need additional funding in order to complete development of our bispecific antibody candidates and commercialize our products, if approved. If we are unable to raise capital when needed, we could be forced to delay, reduce or
eliminate our product development programs or commercialization efforts. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct the Phase 1/2 clinical trial of MCLA-128, and continue to research, develop and initiate clinical
trials of MCLA-117 and our other bispecific antibody candidates. In addition, if we obtain regulatory approval for any of our bispecific antibody candidates, we expect to incur significant commercialization expenses related to product manufacturing,
marketing, sales and distribution. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection
with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that our existing cash, cash equivalents and
investments, together with anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements through at least
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we
could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost, progress and results of the Phase 1/2 clinical trial of MCLA-128; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of manufacturing clinical supplies of our bispecific antibody candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, progress, results and costs of pre-clinical development, laboratory testing and clinical trials for our other bispecific antibody
candidates, including MCLA-117; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs, timing and outcome of regulatory review of any of our bispecific antibody candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our bispecific
antibody candidates for which we receive marketing approval; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs and timing of securing, maintaining and/or obtaining freedom to operate for our technologies and products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the revenue, if any, received from commercial sales of our bispecific antibody candidates for which we receive marketing approval;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of competing technological and market developments; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for
any of our bispecific antibody candidates, although we currently have no commitments or agreements to complete any such transactions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend heavily on the success of our bispecific antibody candidates, and we cannot give any assurance that any of our bispecific
antibody candidates will receive regulatory approval, which is necessary before they can be commercialized. If we and any strategic partners we may have are unable to commercialize our bispecific antibody candidates, or experience significant delays
in doing so, our business, financial condition and results of operations will be materially adversely affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have invested a significant portion of our efforts and financial resources in the development of bispecific antibody candidates using
our Biclonics technology platform. Our lead bispecific antibody candidate, MCLA-128, is in a Phase 1/2 clinical trial, while our other bispecific antibody candidates are still in pre-clinical development. Our ability to generate royalty and product
revenues, which we do not expect will occur for at least the next several years, if ever, will depend heavily on the successful development and eventual commercialization of these bispecific antibody candidates, which may never occur. We currently
generate no revenues from sales of any products, and we may never be able to develop or commercialize a marketable product. Each of our bispecific antibody candidates will require additional clinical development, management of clinical, pre-clinical
and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenues from product
sales. We are not permitted to market or promote any of our bispecific antibody candidates before we receive regulatory approval from the FDA, the EMA or comparable foreign regulatory authorities, and we may never receive such regulatory approval
for any of our bispecific antibody candidates. The success of our bispecific antibody candidates will depend on several factors, including the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">for bispecific antibody candidates which we license to others, the successful efforts of those parties in completing clinical trials of, receipt of
regulatory approval for and commercialization of such bispecific antibody candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">for the bispecific antibody candidates to which we retain rights under the collaboration, completion of pre-clinical studies and clinical trials of,
receipt of marketing approvals for, establishment of commercial manufacturing capabilities of and successful commercialization of such bispecific antibody candidates; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">for all of our bispecific antibody candidates, if and when approved, acceptance of our bispecific antibody candidates by patients, the medical
community and third-party payors, effectively competing with other therapies, a continued acceptable safety profile following approval and qualifying for, maintaining, enforcing and defending our intellectual property rights and claims.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we or our collaborators, as
applicable, do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our bispecific antibody candidates, which would materially adversely affect
our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have not previously submitted a Biologics License Application, or BLA, to the FDA, or similar regulatory approval filings to comparable foreign authorities, for any bispecific antibody candidate, and
we cannot be certain that any of our bispecific antibody candidates will be successful in clinical trials or receive </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regulatory approval. Further, our bispecific antibody candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for
our bispecific antibody candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of our bispecific antibody candidates, our revenues will be dependent, in part, upon the
size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from
sales of such products, if approved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to
seek regulatory approval to commercialize our bispecific antibody candidates both in the United States and the European Union, or the EU, and potentially in additional foreign countries. While the scope of regulatory approval is similar in other
countries, to obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and
commercial sales, pricing and distribution of our bispecific antibody candidates, and we cannot predict success in these jurisdictions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The Biclonics technology platform is an unproven, novel approach to the production of molecules for therapeutic intervention.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not, nor to our knowledge has
any other company, received regulatory approval for a therapeutic based on a full-length human IgG approach. We cannot be certain that our approach will lead to the development of approvable or marketable products. In addition, our Biclonics may
have different effectiveness rates in various indications and in different geographical areas. Finally, the FDA, the EMA or other regulatory agencies may lack experience in evaluating the safety and efficacy of products based on Biclonics
therapeutics, which could result in a longer than expected regulatory review process, increase our expected development costs and delay or prevent commercialization of our bispecific antibody candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Biclonics technology platform relies on third parties for
biological materials. Some biological materials have not always met our expectations or requirements, and any disruption in the supply of these biological materials could materially adversely affect our business. Although we have control processes
and screening procedures, biological materials are susceptible to damage and contamination and may contain active pathogens. Improper storage of these materials, by us or any third-party suppliers, may require us to destroy some of our raw materials
or products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Failure to successfully
validate, develop and obtain regulatory approval for companion diagnostics could harm our development strategy. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may seek to identify patient subsets within a disease category who may derive selective and meaningful benefit from the bispecific
antibody candidates we are developing. In collaboration with partners, we may develop companion diagnostics to help us to more accurately identify patients within a particular subset, both during our clinical trials and in connection with the
commercialization of our bispecific antibody candidates. Companion diagnostics are subject to regulation by the FDA and comparable foreign regulatory authorities as medical devices and typically require separate regulatory approval prior to
commercialization. We intend to develop companion diagnostics in collaboration with third parties and are dependent on the scientific insights and sustained cooperation and effort of our third-party collaborators in developing and obtaining approval
for these companion diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility or
clinical validation. Any delay or failure by us or our collaborators to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our bispecific antibody candidates. In addition, our collaborators may
encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the clinical community. If such companion
diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales of our products. In addition, the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization
of our bispecific antibody candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for
use in connection with the development and commercialization of our bispecific antibody candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our bispecific antibody
candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our limited operating history
may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since our inception in 2003, we have devoted a significant portion of our resources to developing MCLA-128, MCLA-117 and our other
bispecific antibody candidates, building our intellectual property portfolio, developing our supply chain, planning our business, raising capital and providing general and administrative support for these operations. All but one of our bispecific
antibody candidates, MCLA-128, are still in pre-clinical development. We recently commenced the Phase 1/2 clinical trial of MCLA-128, our lead bispecific antibody candidate, but have not completed any clinical trials for MCLA-128 or any other
bispecific antibody candidate. We have not yet demonstrated our ability to successfully complete any Phase 1 clinical trial, Phase 2 clinical trial or any Phase&nbsp;3 or other pivotal clinical trials, obtain regulatory approvals, manufacture a
commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to
continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Consequently, any predictions you make about our future success or viability may not be as accurate as
they could be if we had a longer operating history. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Raising additional capital may cause dilution to our holders, including purchasers of common shares in this offering, restrict our
operations or require us to relinquish rights to our technologies or bispecific antibody candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of
the net proceeds of this offering, together with our existing cash and cash equivalents. In order to accomplish our business objectives and further develop our product pipeline, however, we will need to seek additional funds and we may raise
additional capital through the sale of equity or convertible debt securities. In such an event, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights
as a holder of our common shares. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring
dividends. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we raise additional funds through
collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or bispecific antibody candidates or to grant licenses
on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and
market bispecific antibody candidates that we would otherwise prefer to develop and market ourselves. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our bispecific antibody candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely
affect the holdings or the rights of our shareholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity
or convertible securities would dilute all of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
our shareholders. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our
ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek
funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or bispecific antibody candidates or otherwise agree to terms
unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research or development programs or the commercialization of any of our bispecific antibody candidates, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our
business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business may become subject to economic, political, regulatory and other risks associated with international operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a company based in the Netherlands, our business is subject to risks associated with conducting business
internationally. Almost all of our suppliers and collaborative and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing regulatory requirements for drug approvals in non-U.S. countries; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing jurisdictions could present different issues for securing, maintaining and/or obtaining freedom to operate in such jurisdictions;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties in compliance with non-U.S. laws and regulations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in non-U.S. regulations and customs, tariffs and trade barriers; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in non-U.S. currency exchange rates of the euro and currency controls; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in a specific country&#146;s or region&#146;s political or economic environment; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing reimbursement regimes and price controls in certain non-U.S. markets; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative consequences from changes in tax laws; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties associated with staffing and managing international operations, including differing labor relations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods
and fires. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exchange rate fluctuations or abandonment of the euro currency may materially affect
our results of operations and financial condition. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Due to the international scope of our operations, fluctuations in exchange rates, particularly between the euro and the U.S. dollar, may adversely affect us. Although we are based in the Netherlands, we
source research and development, manufacturing, consulting and other services from several countries. Further, potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and share price may be
affected by fluctuations in foreign exchange rates between the euro and these other currencies, which may also have a significant impact on our reported results of operations and cash flows from period to period. Currently, we do not have any
exchange rate hedging arrangements in place. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, the possible abandonment of the euro by one or more members of the EU could materially affect our business in the future. Despite measures taken by the EU to provide funding to certain EU member states in financial difficulties and by a
number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of
individual currencies in one or more EU member states, or in more extreme circumstances, the dissolution of the EU. The effects on our business of a potential dissolution of the EU, the exit of one or more EU member states from the EU or the
abandonment of the euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to the Development and Clinical Testing of Our Bispecific
Antibody Candidates </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>All of our
bispecific antibody candidates are in pre-clinical or early-stage clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our bispecific antibody
candidates, particularly MCLA-128, are prolonged or delayed, we or our collaborators may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our bispecific antibody candidates on a timely basis or at all.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To obtain the requisite regulatory
approvals to market and sell any of our bispecific antibody candidates, we or our collaborator for such candidates must demonstrate through extensive pre-clinical studies and clinical trials that our products are safe and effective in humans.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical studies and early-stage clinical trials of our
bispecific antibody candidates may not be predictive of the results of later-stage clinical trials. Bispecific antibody candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed
through pre-clinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding
promising results in earlier trials. Our future clinical trial results may not be successful. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To date, we have not completed any clinical trials required for the approval of any of our bispecific antibody candidates. Although we initiated a Phase 1/2 clinical trial of MCLA-128 in February 2015,
and although we are planning to initiate clinical trials for our other bispecific antibody candidates, we may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be
redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended, or terminated for a variety of reasons, including the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in or failure to obtain regulatory approval to commence a trial; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the
terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in or failure to obtain institutional review board, or IRB, approval at each site; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in or failure to recruit suitable patients to participate in a trial; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to have patients complete a trial or return for post-treatment follow-up; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical sites deviating from trial protocol or dropping out of a trial; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adding new clinical trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">manufacturing sufficient quantities of bispecific antibody candidate for use in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third party actions claiming infringement by our bispecific antibody candidates in clinical trials outside of the United States and obtaining
injunctions interfering with our progress; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods
and fires; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">safety or tolerability concerns could cause us or our collaborators, as applicable, to suspend or terminate a trial if we or our collaborators find
that the participants are being exposed to unacceptable health risks; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in regulatory requirements, policies and guidelines; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lower than anticipated retention rates of patients and volunteers in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our third-party research contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or
at all; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in establishing the appropriate dosage levels in clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the difficulty in certain countries in identifying the sub-populations that we are trying to treat in a particular trial, which may delay enrollment
and reduce the power of a clinical trial to detect statistically significant results; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the quality or stability of the bispecific antibody candidate falling below acceptable standards. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We could encounter delays if a clinical trial is suspended or
terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Review Committee, or DRC, or Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such
authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or
trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our bispecific antibody candidates, the commercial prospects of our bispecific
antibody candidates will be harmed, and our ability to generate product revenues from any of these bispecific antibody candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our
bispecific antibody candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or
shorten any periods during which we have the exclusive right to commercialize our bispecific antibody candidates and impair our ability to commercialize our bispecific antibody candidates and may harm our business and results of operations.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any of these occurrences may harm our business,
financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our bispecific
antibody candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials must be
conducted in accordance with the FDA, the EU and other applicable regulatory authorities&#146; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs at the medical institutions where the
clinical trials are conducted. In addition, clinical trials must be conducted with supplies of our bispecific antibody candidates produced under current good </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
manufacturing practice, or cGMP, requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while
we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with Good Clinical
Practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including
achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. In addition, clinical trials that are conducted in countries outside the EU and the United States may subject us to further delays
and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-EU and non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA or the EMA, and
different standards of diagnosis, screening and medical care. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our bispecific antibody candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the
development of our bispecific antibody candidates or following approval, if any, we may need to abandon our development of such bispecific antibody candidates, the commercial profile of any approved label may be limited, or we may be subject to
other significant negative consequences following marketing approval, if any. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Undesirable side effects that may be caused by our bispecific antibody candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. In February 2015, we commenced a Phase 1/2 clinical trial of our lead bispecific antibody candidate, MCLA-128, for the treatment of
various solid tumors. To date, patients treated with MCLA-128 have experienced mild to moderate adverse reactions that may be related to the treatment, including infusion-related reactions, diarrhea, vomiting, fatigue, skin rash, sore mouth and
shortness of breath. Decreased numbers of neutrophils were also reported. There has been one serious adverse event in the Phase 1/2 clinical trial of MCLA-128, reported as an infusion-related reaction which required overnight hospitalization.
Patients treated with our bispecific antibody candidates may require pre-treatment with corticosteroids to mitigate potential side effects. While we have not yet initiated clinical trials for our other bispecific antibody candidates, as is the case
with all oncology products, it is possible that there may be side effects associated with their use. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials
could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our bispecific antibody candidates for any or all targeted indications. The drug-related
side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.
Additionally, if any of our bispecific antibody candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could
result, including: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may withdraw approvals of such products and require us to take our approved product off the market;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and
pharmacies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a
risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the product outweigh its risks; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to limitations on how we may promote the product; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of the product may decrease significantly; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to litigation or product liability claims; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance
of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Adverse events in the field of oncology could damage
public perception of our bispecific antibody candidates and negatively affect our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The commercial success of our products will depend in part on public acceptance of the use of cancer immunotherapies. Adverse events in
clinical trials of our bispecific antibody candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of oncology that may occur in the future, could result in
a decrease in demand for any products that we may develop. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Future adverse events in immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the
testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining regulatory approval for our bispecific antibody candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend on enrollment of patients in our clinical
trials for our bispecific antibody candidates. If we are unable to enroll patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Successful and timely completion of
clinical trials will require that we enroll a sufficient number of patient candidates. In the Phase 1/2 clinical trial of MCLA-128 that we commenced in February 2015, we plan to enroll up to 120&nbsp;patients with various solid tumors that are
relapsed or refractory to at least one prior regimen of available standard treatment or for whom no curative therapy is available. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated or patient
withdrawal. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patient enrollment depends on many
factors, including the size and nature of the patient population, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical trials, the availability
of new drugs approved for the indication the clinical trial is investigating, and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. These factors may
make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our bispecific antibody candidates will increase our costs, slow down our
bispecific antibody candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or
completion of clinical trials may also ultimately lead to the denial of regulatory approval of our bispecific antibody candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may become exposed to costly and damaging liability claims, either when testing our bispecific antibody candidates in the clinic
or at the commercial stage; and our product liability insurance may not cover all damages from such claims. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development,
manufacturing, marketing and use of pharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the current and future use of bispecific antibody
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
candidates by us and our corporate collaborators in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients
that use the product, healthcare providers, pharmaceutical companies, our corporate collaborators or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially
adversely affect the market for our bispecific antibody candidates or any prospects for commercialization of our bispecific antibody candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even
after regulatory approval, may exhibit unforeseen side effects. If any of our bispecific antibody candidates were to cause adverse side effects during clinical trials or after approval of the bispecific antibody candidate, we may be exposed to
substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our bispecific antibody candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we maintain adequate product liability insurance for
our bispecific antibody candidates, it is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our
bispecific antibody candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or
series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Should any of the events described above occur, this could
have a material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory
approval for our bispecific antibody candidates, our business will be substantially harmed. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to
gain approval may change during the course of a bispecific antibody candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any bispecific antibody candidate and it is possible that none
of our existing bispecific antibody candidates or any bispecific antibody candidates we may seek to develop in the future will ever obtain regulatory approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our bispecific antibody candidates could fail to receive regulatory approval for many reasons, including the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a bispecific antibody candidate is
safe and effective for its proposed indication; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for
approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be unable to demonstrate that a bispecific antibody candidate&#146;s clinical and other benefits outweigh its safety risks;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the data collected from clinical trials of our bispecific antibody candidates may not be sufficient to support the submission of a BLA or other
submission or to obtain regulatory approval in the United States, the EU or elsewhere; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with
which we contract for clinical and commercial supplies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the FDA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing with partners; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our
clinical data insufficient for approval. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our bispecific antibody candidates,
which would significantly harm our business, results of operations and prospects. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be
obtained for any of our bispecific antibody candidates. Even if we believe the data collected from clinical trials of our bispecific antibody candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any
other regulatory authority. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, even if
we were to obtain approval, regulatory authorities may approve any of our bispecific antibody candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval
contingent on the performance of costly post-marketing clinical trials, or may approve a bispecific antibody candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that
bispecific antibody candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our bispecific antibody candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if our bispecific antibody candidates obtain regulatory approval, we will be subject to ongoing obligations and continued
regulatory review, which may result in significant additional expense. Additionally, our bispecific antibody candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we
fail to comply with regulatory requirements or experience unanticipated problems with our products. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the FDA or a comparable foreign regulatory authority approves any of our bispecific antibody candidates, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and
other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to
commercialize such products. In addition, any regulatory approvals that we receive for our bispecific antibody candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of
approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the bispecific antibody candidate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If there are changes in the application of legislation or
regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various
actions. These include imposing fines on us, imposing restrictions on the product or its manufacture and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations,
requiring us to conduct additional clinical trials, change our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur
substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be successful in our efforts to use and expand our technology platform to
build a pipeline of bispecific antibody candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A key element of our strategy is to use and expand our Biclonics technology platform to build a pipeline of bispecific antibody candidates and progress these bispecific antibody candidates through
clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of bispecific antibody candidates directed at various cancers, we may not be able
to develop bispecific antibody candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential bispecific antibody candidates that we identify may not be suitable for clinical development,
including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully
develop and begin to commercialize bispecific antibody candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our share price.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we obtain marketing approval of any
of our bispecific antibody candidates in a major pharmaceutical market such as the United States or Europe, we may never obtain approval or commercialize our products in other major markets, which would limit our ability to realize their full market
potential. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to market any
products in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such countries or territories regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by
regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and
validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and costs for us and may require additional pre-clinical studies or clinical trials which
would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time
consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We currently do not have
any bispecific antibody candidates approved for sale in any jurisdiction, whether in the Netherlands, the United States or any other international markets, and we do not have experience in obtaining regulatory approval in international markets. If
we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Due to our limited resources and access to capital, we
must, and have in the past decided to, prioritize development of certain bispecific antibody candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because we have limited resources and access to capital to
fund our operations, we must decide which bispecific antibody candidates to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward
particular compounds, bispecific antibody candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or
collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our
bispecific antibody candidates or misread trends in the biopharmaceutical industry, in particular for our lead bispecific antibody candidates, our business, financial condition and results of operations could be materially adversely affected.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Because we are subject to environmental, health and safety laws and regulations, we
may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our operations, including our research, development, testing
and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of, and the maintenance of a
registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne
pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and
historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses
in connection with future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed and our financial condition and results of operations may be materially adversely
affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our employees, independent
contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material
adverse effect on our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are
exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include
intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i)&nbsp;the regulations of the FDA, the EMA and other regulatory authorities, including those laws that require the reporting of true, complete and accurate
information to such authorities; (ii)&nbsp;manufacturing standards; (iii)&nbsp;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad; or (iv)&nbsp;laws that require the
reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct,
kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our pre-clinical studies or clinical trials, which could result in
regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in
controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a
person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our
business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. federal
healthcare programs, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business
and our results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our research
and development activities could be affected or delayed as a result of possible restrictions on animal testing. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain laws and regulations require us to test our bispecific antibody candidates on animals before initiating clinical trials involving
humans. Animal testing activities have been the subject of controversy and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by
disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Regulatory Approval of Our Bispecific Antibody Candidates
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Enacted and future legislation may
increase the difficulty and cost for us to obtain marketing approval of and commercialize our bispecific antibody candidates and may affect the prices we may set. The successful commercialization of our bispecific antibody candidates will depend in
part on the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, the EU, and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the
healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs and improve the
quality of healthcare. For example, in March&nbsp;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changes the way
healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, which is apportioned
among these entities according to their market share in certain government healthcare programs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of
applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">new requirements to report certain financial arrangements with physicians and certain others, including reporting &#147;transfers of value&#148; made
or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average
manufacturer price for branded and generic drugs, respectively; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted or injected; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">extension of a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with
income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along
with funding for such research; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">creation of the Independent Payment Advisory Board which, as of 2014, has authority to recommend certain changes to the Medicare program that could
result in reduced payments for prescription drugs and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
those recommendations could have the effect of law unless overruled by a supermajority vote of Congress; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishment of a Center for Medicare Innovation at the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, to test innovative payment and
service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and
amendments to the ACA in the future. At this time, the full effect that the ACA would have on our business remains unclear. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&nbsp;2,
2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the
years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2%&nbsp;per fiscal
year. These reductions went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including without limitation the Bipartisan Budget Act of 2015, will remain in effect through 2025 unless additional
Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers
and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other health care
funding, which could have a material adverse effect on our customers and accordingly, our financial operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may
develop new payment and delivery models, such as bundled payment models. The U.S. Department of Health and Human Services, or HHS, has set a goal of moving 30% of Medicare payments to alternative payment models by 2016 and 50% of Medicare payments
into these alternative payment models by the end of 2018. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. We expect that additional U.S. federal
healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our bispecific antibody
candidates or additional pricing pressures. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third party payors or other restrictions could harm our business, results of operations, financial condition and
prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare
programs. This could reduce the ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the EU, similar political, economic and regulatory
developments may affect our ability to profitably commercialize our current or any future products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in
significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care
and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service
providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our bispecific antibody candidates, restrict or regulate post-approval
activities and affect our ability to commercialize any products for which we obtain marketing approval. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price
ceilings on specific products and therapies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are slow or unable to adapt to changes in
existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our bispecific antibody candidates may lose any regulatory approval that may have been obtained and
we may not achieve or sustain profitability, which would adversely affect our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be subject to healthcare laws, regulation and enforcement; our failure to comply with these laws could harm our results of operations and financial conditions. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we do not currently have any products on the
market, if we obtain FDA approval for any of our bispecific antibody candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers and third-party payors, subject to
various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any
products for which we obtain marketing approval. These laws may impact, among other things, our proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers,
physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the
states in which we conduct our business. Finally, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that
may affect our ability to operate include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering,
receiving or paying any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or
recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of
the statute or specific intent to violate it in order to have committed a violation; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. federal false claims and civil monetary penalties laws, which impose criminal and civil penalties, and includes the civil False Claims Act,
through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent or
from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S.
federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False Claims Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other
things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S.
federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, and
as amended again by the Final HIPAA Omnibus Rule, Modifications to the HIPAA Privacy, Security, Enforcement and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other Modifications to the HIPAA Rules,
published in January 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate
authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually
identifiable health information; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. federal Food, Drug and Cosmetic Act, or FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and
medical devices; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations,
which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report annually to the CMS information related to certain
payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, as well as ownership and investment interests held by physicians and other healthcare providers and their immediate family members;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but
not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply
with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential
referral sources; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare
professionals and entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance
efforts; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare
providers. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ensuring that our
internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do
not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other
governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare
and Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to
do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it
could adversely affect our ability to operate our business and our results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Commercialization of Our Bispecific Antibody Candidates </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We operate in highly competitive and rapidly changing
industries, which may result in others discovering, developing or commercializing competing products before or more successfully than we do. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our
success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense
competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies, academic institutions, government agencies and other private and public
research institutions in Europe, the United States and other jurisdictions. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for
research, development, manufacturing and marketing of products that compete with our bispecific antibody candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies
become available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any bispecific antibody candidates that we successfully develop and commercialize will compete with existing therapies and new
therapies that may become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our bispecific antibody candidates or our technology obsolete, less
competitive or uneconomical. Our competitors may, among other things: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less
severe effects; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain quicker regulatory approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish superior proprietary positions covering our products and technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">implement more effective approaches to sales and marketing; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">form more advantageous strategic alliances. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Should any of these factors occur, our business, financial condition and results of operations could be materially adversely affected.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our collaborators may decide to
market and sell products that compete with the bispecific antibody candidates that we have agreed to license to it, and any competition by our collaborators could also have a material adverse effect on our future business, financial condition and
results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller and other early
stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to obtain orphan drug designation or obtain
or maintain orphan drug exclusivity for our products, our competitors may sell products to treat the same conditions and our revenue will be reduced. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition,
defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales
in the United States. In the EU, the EMA&#146;s Committee for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or
chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or
serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of
diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may
not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the
manufacturer is unable to assure sufficient product quantity. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological
product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to seek orphan drug designation from the
FDA and the EMA for MCLA-117 for the treatment of AML. Even if we are able to obtain orphan designation for MCLA-117 in the United States and/or Europe, we may not be the first to obtain marketing approval for any particular orphan indication due to
the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if
the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we
obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is
approved, the FDA or the EMA can subsequently approve the same drug with the same active moiety for the same condition if the FDA or the EMA concludes that the later drug is safer, more effective, or makes a major contribution to patient care.
Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we intend to seek orphan drug designation for
MCLA-117 for the treatment of AML, we may never receive such designations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The successful commercialization of our bispecific antibody candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate reimbursement levels
and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our bispecific antibody candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The availability and adequacy of
coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford products such as our bispecific antibody
candidates, assuming approval. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully
commercialize, and attract additional collaboration partners to invest in the development of our bispecific antibody candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may
not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for any product that we may develop, and any reimbursement
that may become available may be decreased or eliminated in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for
particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our bispecific antibody candidate and other therapies as substitutable and only offer to reimburse
patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our bispecific antibody candidate, pricing of existing drugs may limit the amount we will be able to charge for our bispecific
antibody candidate. These payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment
in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our bispecific antibody candidates, and may not be able to obtain a satisfactory financial return on
products that we may develop. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is
significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an
important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and
reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse health care providers who use such therapies. It is difficult to
predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our bispecific antibody candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for drug
products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly
process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.
Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outside the United States, international operations are
generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the
pricing and usage of our bispecific antibody candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices
for medical products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our bispecific antibody candidates. Accordingly, in
markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moreover, increasing efforts by governmental and third-party
payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment
for our bispecific antibody candidates. We expect to experience pricing pressures in connection with the sale of any of our bispecific antibody candidates due to the trend toward managed healthcare, the increasing influence of health maintenance
organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers
are being erected to the entry of new products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our products may not gain market acceptance, in which case we may not be able to
generate product revenues, which will materially adversely affect our business, financial condition and results of operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if the FDA, the EMA or any other regulatory authority approves the marketing of any bispecific antibody candidates that we develop on
our own or with a collaboration partner, physicians, healthcare providers, patients or the medical community may not accept or use them. If these products do not achieve an adequate level of acceptance, we may not generate significant product
revenues or any profits from operations. The degree of market acceptance of any of our bispecific antibody candidates will depend on a variety of factors, including: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing of market introduction; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number and clinical profile of competing products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to provide acceptable evidence of safety and efficacy; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the prevalence and severity of any side effects; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">relative convenience and ease of administration; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cost-effectiveness; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">patient diagnostics and screening infrastructure in each market; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">marketing and distribution support; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of adequate coverage, reimbursement and adequate payment from health maintenance organizations and other insurers, both public and
private; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other potential advantages over alternative treatment methods. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our bispecific antibody candidates fail to gain market
acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be large enough to
allow us to generate significant revenues. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution
capabilities on our own or through collaborations, or if we fail to achieve adequate pricing and/or reimbursement we will not be successful in commercializing our bispecific antibody candidates. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no marketing, sales and distribution
capabilities because all of our bispecific antibody candidates are still in clinical or pre-clinical development. If any of our bispecific antibody candidates are approved, we intend either to establish a sales and marketing organization with
technical expertise and supporting distribution capabilities to commercialize our bispecific antibody candidates, or to outsource this function to a third party. Either of these options would be expensive and time consuming. These costs may be
incurred in advance of any approval of our bispecific antibody candidates. In addition, we may not be able to hire a sales force that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or
delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be
lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third-party collaborators, which may not be successful and are generally not within our
control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or
through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have never commercialized a bispecific antibody candidate before and may lack the
necessary expertise, personnel and resources to successfully commercialize our products on our own or together with suitable partners. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never commercialized a bispecific antibody candidate, and we currently have no sales force, marketing or distribution
capabilities. To achieve commercial success for the bispecific antibody candidates which we may license to others, we will rely on the assistance and guidance of those collaborators. For bispecific antibody candidates for which we retain
commercialization rights, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Factors that may affect our ability to commercialize our bispecific antibody candidates on our own include recruiting and retaining
adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our bispecific antibody candidates and other unforeseen costs associated with creating an independent sales
and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our bispecific antibody candidates. We may not be able to build an effective sales and marketing
organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our bispecific antibody candidates, we may not generate revenues from them or be able to reach or
sustain profitability. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our bispecific
antibody candidates for which we intend to seek approval as a biologic products may face competition sooner than anticipated. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Patient Protection and Affordable Care Act, signed into law on March&nbsp;23, 2010, includes a subtitle called the Biologics Price
Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for
a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years
from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product
containing the sponsor&#146;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the
FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse
effect on the future commercial prospects for our biological products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe that any of our bispecific antibody candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity
could be shortened due to congressional action or otherwise, or that the FDA will not consider our bispecific antibody candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner
than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of
our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Dependence on Third Parties </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We rely, and expect to continue to rely, on third
parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to
obtain regulatory approval for or commercialize our bispecific antibody candidates and our business could be substantially harmed. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to
conduct our pre-clinical studies and clinical trials and to monitor and manage data for our ongoing pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials, and control only certain
aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third
parties does not relieve us of our regulatory responsibilities. We and our third party contractors and CROs are required to comply with good clinical practice, or GCP, requirements, which are regulations and guidelines enforced by the FDA, the
Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections
of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign
regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of
our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would
delay the regulatory approval process. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further,
these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our bispecific antibody candidates and clinical trials. If independent
investigators or CROs fail to devote sufficient resources to the development of our bispecific antibody candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any bispecific
antibody candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our CROs have the right to terminate their agreements with us
in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials
warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is
compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully
commercialize our bispecific antibody candidates. As a result, our results of operations and the commercial prospects for our bispecific antibody candidates would be harmed, our costs could increase and our ability to generate revenues could be
delayed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Switching or adding additional CROs
involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical
development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse
impact on our business, financial condition and prospects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Independent clinical investigators and CROs that we engage to conduct our clinical
trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in
the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party
service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including
time, which they devote to our bispecific antibody candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our bispecific antibody candidates, or if their performance is
substandard, it may delay or compromise the prospects for approval and commercialization of any bispecific antibody candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information
to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA and other regulatory authorities require that we comply with standards, commonly referred to as current Good Clinical Practice, or cGCP,
for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs
to meet their obligations to us or comply with cGCP procedures could adversely affect the clinical development of our bispecific antibody candidates and harm our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to enter into new strategic relationships
our business, financial condition, commercialization prospects and results of operations may be materially adversely affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product development programs and the potential commercialization of our bispecific antibody candidates will require substantial
additional cash to fund expenses. Therefore, for some of our bispecific antibody candidates, we may decide to enter into new collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of
those bispecific antibody candidates. For instance, in April 2014, we entered into a strategic research and license agreement with ONO Pharmaceutical Co., Ltd., or ONO, under which we granted ONO an exclusive, worldwide, royalty-bearing license to
research, test, make, use and market bispecific antibody candidates based on our Biclonics technology platform with undisclosed targets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and
document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable terms, or at all.
If that were to occur, we may have to curtail the development of a particular bispecific antibody candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce
the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities
on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our bispecific antibody candidates to market and generate product
revenue. If we do&nbsp;enter into a new collaboration agreement, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects and financial condition: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be able to control the amount and timing of resources that the collaboration partner devotes to the product development program;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the collaboration partner may experience financial difficulties; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to relinquish important rights such as marketing, distribution and intellectual property rights; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a collaboration partner could move forward with a competing product developed either independently or in collaboration with third parties, including
our competitors; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business combinations or significant changes in a collaboration partner&#146;s business strategy may adversely affect our willingness to complete our
obligations under any arrangement. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently rely on third-party suppliers and other third parties for production of our bispecific antibody candidates and our dependence on these third parties may impair the advancement of our
research and development programs and the development of our bispecific antibody candidates. Moreover, we intend to rely on third parties to produce commercial supplies of any approved bispecific antibody candidate and our commercialization of any
of our bispecific antibody candidates could be stopped, delayed or made less profitable if those third parties fail to obtain approval of the FDA or comparable regulatory authorities, fail to provide us with sufficient quantities of bispecific
antibody product or fail to do so at acceptable quality levels or prices or fail to otherwise complete their duties in compliance with their obligations to us or other parties. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely on and expect to continue to rely on third party contract manufacturing organizations, or CMOs, for the
supply of current good manufacturing practice-grade, or cGMP-grade, clinical trial materials and commercial quantities of our bispecific antibody candidates and products, if approved.&nbsp;For the manufacturing of MCLA-128 and MCLA-117, we have
contracted with Boehringer Ingelheim, a biopharmaceuticals CMO, for their production.&nbsp;Reliance on third-party providers may expose us to more risk than if we were to manufacture bispecific antibody candidates ourselves. The facilities used by
our contract manufacturers to manufacture our bispecific antibody candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We do not control the manufacturing process of, and are
completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as cGMPs, for the manufacture of our bispecific antibody candidates. If our contract manufacturers cannot successfully manufacture
material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over
the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our
bispecific antibody candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our
bispecific antibody candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our bispecific antibody
candidates or that obtained approvals could be revoked, which would adversely affect our business and reputation. Furthermore, third-party providers may breach existing agreements they have with us because of factors beyond our control. They may
also terminate or refuse to renew their agreement because of their own financial difficulties or business priorities, at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate replacement or another acceptable
solution in time, our clinical trials could be delayed or our commercial activities could be harmed. In addition, the fact that we are dependent on our collaborators, our suppliers and other third parties for the manufacture, filling, storage and
distribution of our bispecific antibody candidates means that we are subject to the risk that the products may have manufacturing defects that we have limited ability to prevent or control. The sale of products containing such defects could
adversely affect our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Growth in the costs and expenses of components or raw materials may also adversely influence our business, financial condition and results of operations. Supply sources could be interrupted from time to
time and, if interrupted, that supplies could be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our bispecific antibody candidates
for our clinical trials. There are a limited number of suppliers for raw materials </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
that we use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our bispecific
antibody candidates for our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Moreover, we currently do not have
any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a bispecific antibody candidate to complete the clinical trial, any significant
delay in the supply of a bispecific antibody candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product
testing and potential regulatory approval of our bispecific antibody candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our bispecific antibody candidates, the commercial
launch of our bispecific antibody candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our bispecific antibody candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely on our manufacturers and other subcontractors to
comply with and respect the proprietary rights of others in conducting their contractual obligations for us. If our manufacturers or other subcontractors fail to acquire the proper licenses or otherwise infringe third party proprietary rights in the
course of completing their contractual obligations to us, we may have to find alternative manufacturers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or
market our bispecific antibody candidates, if approved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks
Related to Intellectual Property and Information Technology </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We rely on patents and other intellectual property rights to protect our bispecific antibody candidates and Biclonics technology platform, the enforcement, defense and maintenance of which may be
challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and impair our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for our
bispecific antibody candidates, methods used to manufacture those products and the methods for treating patients using those products, or on licensing in such rights. Failure to protect or to obtain, maintain or extend adequate patent and other
intellectual property rights could materially adversely affect our ability to develop and market our products and bispecific antibody candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaboration
partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaboration partners will fail to
identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Further, the issuance, scope, validity, enforceability and commercial value of
our and our current or future licensors&#146;, licensees&#146; or collaboration partners&#146; patent rights are highly uncertain. Our and our licensors&#146; pending and future patent applications may not result in patents being issued which
protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaboration
partners to narrow the scope of the claims of our or our licensors&#146;, licensees&#146; or collaboration partners&#146; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure
you that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if
patents do successfully issue and even if such patents cover our bispecific antibody candidates, third parties may an initiate opposition, interference, re-examination, post-grant review, inter partes review, nullification or derivation action in
court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated. Our and our
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
licensors&#146;, licensees&#146; or collaboration partners&#146; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and
until a patent issues from such applications, and then only to the extent the issued claims cover the technology. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because patent applications are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that
we or our licensors were the first to file any patent application related to a bispecific antibody candidate. Furthermore, if third parties have filed such patent applications on or before March&nbsp;15, 2013, an interference proceeding can be
initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. If third parties have filed such applications after March&nbsp;15, 2013, a derivation proceeding can
be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that
they used the invention in commerce before our filing date or the other party benefits from a compulsory license. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Issued patents covering one or more of our products or the Biclonics technology platform could be found invalid or unenforceable if
challenged in court. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To protect our
competitive position, we may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or
other intellectual property rights of third parties. As enforcement of intellectual property rights is difficult, unpredictable and expensive, we may fail in enforcing our rights&#151;in which case our competitors may be permitted to use our
technology without being required to pay us any license fees. In addition, however, litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held
unenforceable. Such an adverse court ruling could allow third parties to commercialize our products or our Biclonics technology platform, and then compete directly with us, without payment to us. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we were to initiate legal proceedings against a third
party to enforce a patent covering one of our products, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States or in Europe, defendant counterclaims alleging invalidity and/or
unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion
could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. Patent and Trademark Office, or made a misleading statement, during prosecution. The outcome following legal assertions of
invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during
prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our Biclonics
technology platform. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology
without infringing our patents or other intellectual property rights. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual property rights of third parties could adversely affect our ability to commercialize our bispecific antibody candidates, such that we could be required to litigate or obtain licenses
from third parties in order to develop or market our bispecific antibody candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our competitive position may suffer if patents issued to third parties or other third party intellectual
property rights cover our products or elements thereof, our manufacture or uses relevant to our development plans, the targets of our bispecific antibody candidates, or other attributes of our bispecific antibody candidates or our technology. In
such cases, we may not be in a position to develop or commercialize products or bispecific antibody candidates unless we successfully pursue litigation to nullify or invalidate the third party intellectual property right concerned, or enter into a
license agreement with the intellectual property right holder, if available </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
on commercially reasonable terms. In addition, we are aware of issued patents and pending patent applications held by third parties that may be construed as covering some of our bispecific
antibody candidates. We believe that if such patents or patent applications (if issued as currently pending) were asserted against us, we would have defenses against such claims, including defenses under safe harbors designed to protect activity
undertaken to obtain federal regulatory approval of a drug, like 35 U.S.C. &#167; 271(e) and similar foreign statutes, patent invalidity and/or unenforceability. However, if such defenses were not successful and such patents were successfully
asserted against us such that they are found to be valid and enforceable, and infringed by our bispecific antibody candidates, unless we obtain a license to such patents, which may not be available on commercially reasonable terms or at all, we
could be prevented from continuing to develop or commercialize our products. We could also be required to pay substantial damages. Similarly, the targets of our bispecific antibody candidates have also been the subject of research by many companies,
which have filed patent applications or have patents on aspects of the targets or their uses. There can be no assurance any such patents will not be asserted against us or that we will not need to seek licenses from such third parties. We may not be
able to secure such licenses on acceptable terms, if at all, and any such litigation would be costly and time-consuming. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is also possible that we failed to identify relevant patents or applications. For example, U.S. applications filed before
November&nbsp;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately
18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our products or platform technology could have been filed by
others without our knowledge. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications purporting to gain broad coverage in the areas in which we are active.
Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our products or the use of our products. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third party intellectual property right holders, including
our competitors, may actively bring infringement claims against us. The granting of orphan drug status in respect of any of our bispecific antibody candidates does not guarantee our freedom to operate and is separate from our risk of possible
infringement of third parties&#146; intellectual property rights. We may not be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be
required to engage or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our products. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail in any such dispute, in addition to being forced
to pay damages, we or our licensees may be temporarily or permanently prohibited from commercializing any of our bispecific antibody candidates that are held to be infringing. We might, if possible, also be forced to redesign bispecific antibody
candidates so that we no longer infringe the third party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be
able to devote to our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, if
the breadth or strength of protection provided by our or our licensors&#146; or collaboration partners&#146; patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize
current or future bispecific antibody candidates. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be
compromised by disclosure during this type of litigation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our ability to compete may be adversely affected if we are unsuccessful in defending against any claims by competitors or others that we are infringing upon their intellectual property rights, such
as if Regeneron Pharmaceuticals Inc. is successful in an appeal of its lawsuit alleging that we are infringing its U.S. Patent No.&nbsp;8,502,018. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual
property rights.&nbsp;In addition, many companies in intellectual property-dependent </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
industries, including the producing therapeutics to treat and potentially cure cancer, have employed intellectual property litigation as a means to gain an advantage over their competitors. As a
result, we may be required to defend against claims of intellectual property infringement that may be asserted by our competitors against us and, if the outcome of any such litigation is adverse to us, it may affect our ability to compete
effectively. Currently, we are defending against a lawsuit filed by Regeneron Pharmaceuticals Inc., or Regeneron, in the United States, in which it has alleged that we have infringed its U.S. Patent No. 8,502,018 entitled &#147;Methods of Modifying
Eukaryotic Cells.&#148; The European equivalent of this patent has been reinstated by the Technical Board of Appeal for the European Patent Office, or EPO, after an appeal by Regeneron. Regeneron also initiated a lawsuit against us in the
Netherlands which has been stayed pending conclusion of the European opposition. For further descriptions of these legal proceedings, see &#147;Business&#151;Legal Proceedings.&#148; </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our involvement in litigation, and in any interferences, opposition proceedings or other intellectual property
proceedings inside and outside of the United States may divert management time from focusing on business operations, could cause us to spend significant amounts of money and may have no guarantee of success. Any current and potential intellectual
property litigation also could force us to do one or more of the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">stop selling, incorporating, manufacturing or using our products in the United States and/or other jurisdictions that use the subject intellectual
property; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain from a third party asserting its intellectual property rights, a license to sell or use the relevant technology, which license may not be
available on reasonable terms, or at all, or may be non-exclusive thereby giving our competitors access to the same technologies licensed to us; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">redesign those products or processes that use any allegedly infringing or misappropriated technology, which may result in significant cost or delay to
us, or which redesign could be technically infeasible; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully infringed certain intellectual property
rights. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are aware that
significant number of patents and patent applications may exist relating to aspects of therapeutic antibody technologies filed by, and issued to, third parties, including, but not limited to Regeneron. We cannot assure you that we will ultimately
prevail if any of this third-party intellectual property is asserted against us, or in the current U.S., Dutch or Australian patent infringement lawsuits and opposition proceedings initiated by Regeneron. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual property litigation could cause us to
spend substantial resources and distract our personnel from their normal responsibilities. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management
personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be
negative, we could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have
sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially
greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be successful in obtaining or maintaining
necessary rights to our bispecific antibody candidates through acquisitions and in-licenses. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have rights to the intellectual property, including patent applications relating to our bispecific antibody candidates.
Because our programs may require the use of proprietary rights held by third parties, the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, our bispecific antibody candidates may require
specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property
rights from third parties that we identify as necessary for our bispecific antibody candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also
pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical
development and commercialization capabilities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For example, we sometimes collaborate with U.S. and non-U.S. academic institutions to accelerate our pre-clinical research or development
under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such option, we
may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to
pursue our applicable bispecific antibody candidate or program. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms
that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of a bispecific antibody candidate or program, we may
have to abandon development of that bispecific antibody candidate or program and our business and financial condition could suffer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of
interest and our business may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our
rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade
names, then we may not be able to compete effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our
current trademarks throughout the world. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If
we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation for extending the term of patents covering each of our bispecific antibody candidates, our business may be materially harmed. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents have a limited lifespan. In the United States, if
all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is
limited. Even if patents covering our bispecific antibody candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications. Given the
amount of time required for the development, testing and regulatory review of new bispecific antibody candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and
licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depending upon the timing, duration and conditions of FDA marketing approval of our bispecific antibody candidates, one or more of our
U.S. patents may be eligible for limited patent term extension under the Drug </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Price Competition and Patent Term Restoration Act of 1984,
referred to as the Hatch-Waxman Amendments and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term
lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy
applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our
patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We enjoy only limited geographical protection with
respect to certain patents and may face difficulties in certain jurisdictions, which may diminish the value of intellectual property rights&nbsp;in those jurisdictions. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>We generally file our first patent application
(<I>i.e.</I>, priority filing) at the EPO. International applications under the Patent Cooperation Treaty, or PCT, are usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications
may be filed in additional jurisdictions where we believe our bispecific antibody candidates may be marketed. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In
addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some
jurisdictions be refused by the relevant patent offices, while granted by others.&nbsp;It is also quite common that depending on the country, the scope of patent protection may vary for the same bispecific antibody candidate and/or technology.<I>
</I></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Competitors may use our and our
licensors&#146; or collaboration partners&#146; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors
or collaboration partners have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our bispecific antibody candidates, and our and our licensors&#146; or collaboration partners&#146;
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States and the EU,
and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the
intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some countries have compulsory licensing laws under which a
patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies,
which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and
results of operations may be adversely affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The degree of future protection afforded by our intellectual
property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Others may be able to make compounds that are the same as or similar to our bispecific antibody candidates but that are not covered by the claims of
the patents that we own or have exclusively licensed. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patents of third parties may have an adverse effect on our business. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We or our licensors or any future strategic partners might not have been the first to conceive or reduce to practice the inventions covered by the
issued patent or pending patent application that we own or have exclusively licensed. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We or our licensors or any future strategic partners might not have been the first to file patent applications covering certain of our inventions.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property
rights. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that our pending patent applications will not lead to issued patents. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as
a result of legal challenges by our competitors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned
from such activities to develop competitive products for sale in our major commercial markets. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third parties performing manufacturing or testing for us using our products or technologies could use the intellectual property of others without
obtaining a proper license. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not develop additional technologies that are patentable. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Changes in patent laws or patent jurisprudence could
diminish the value of patents in general, thereby impairing our ability to protect our products. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biopharmaceutical industry involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. In
addition, the America Invents Act, or the AIA, has been recently enacted in the United States, resulting in significant changes to the U.S. patent system. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An important change introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned to a
&#147;first-to-file&#148; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after
that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to
filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and
providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to
the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence
would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged
by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The USPTO recently developed new regulations and procedures to govern administration of the
AIA, and many of the substantive changes to patent law associated with the AIA, and, in particular, the first to file provisions, only became effective on March&nbsp;16, 2013. Accordingly, it is not clear what, if any, impact the AIA will have on
the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#146; or collaboration partners&#146; patent applications and the enforcement or
defense of our or our licensors&#146; or collaboration partners&#146; issued patents, all of which could have an adverse effect on our business and financial condition. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Additionally, the U.S. Supreme Court has ruled on
several patent cases in recent years, such as <I>Association for Molecular Pathology</I> v. <I>Myriad Genetics, Inc. (Myriad I)</I>, <I>Mayo Collaborative Services</I> v. <I>Prometheus Laboratories, Inc.</I>, and <I>Alice Corporation Pty. Ltd.</I>
v. <I>CLS Bank International</I>, either narrowing the scope of<I> </I>patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our
ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the U.S. Patent and Trademark
Office, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity
and uncertainty of European patent laws has also increased in recent years.&nbsp;For example, the EPC was amended in April 2010&nbsp;by limiting the time permitted for filing divisional applications. In addition, the EP patent system is relatively
stringent in the type of amendments that are allowed during prosecution. These changes could limit our ability to obtain new patents in the future that may be important for our business.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidentiality agreements with employees and others
may not adequately prevent disclosure of trade secrets and protect other proprietary information. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We consider proprietary trade secrets and/or confidential know-how and unpatented know-how to be important to our business. We may rely on
trade secrets and/or confidential know-how to protect our technology, especially where patent protection is believed to be of limited value. However, trade secrets and/or confidential know-how are difficult to maintain as confidential. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To protect this type of information against disclosure or
appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors and advisers may
unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third
party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Furthermore, if a
competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.
Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure to obtain or maintain trade secrets and/or
confidential know-how trade protection could adversely affect our competitive position. Moreover, our competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the
same. If successful in obtaining such patent protection, our competitors could limit our use of our trade secrets and/or confidential know-how. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under certain circumstances and to guarantee our freedom to operate, we may also decide to publish some know-how to prevent others from
obtaining patent rights covering such know-how. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be subject to claims by third parties asserting that our employees or we have
misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies,
including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not
use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary
information, of any such employee&#146;s former employer. Litigation may be necessary to defend against these claims. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be
available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Periodic maintenance and annuity fees on any issued patent
are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and
other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can
result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent
application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaboration partners fail to maintain the patents
and patent applications covering our bispecific antibody candidates, our competitors might be able to enter the market, which would have an adverse effect on our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our information technology systems could face serious
disruptions that could adversely affect our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could
disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions in our collaborations with our partners and delays in our research and development
work. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Employee Matters and Managing Growth
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our future growth and ability to
compete depends on retaining our key personnel and recruiting additional qualified personnel. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success depends upon the continued contributions of our key management, scientific and technical personnel, many of whom have been
instrumental for us and have substantial experience with our therapies and related technologies. These key management individuals include the members of our management board. For example, our founder and Chief Executive Officer, Ton Logtenberg,
holds a Ph.D. in medical biology, was a professor in the Department of Immunology at Utrecht University and co-founded the Dutch biotechnology company, Crucell N.V. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The loss of key managers and senior scientists could delay our research and development
activities. In addition, the competition for qualified personnel in the biopharmaceutical and pharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly-skilled scientific, technical and
managerial employees. We face competition for personnel from other companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be
difficult for us to implement business strategy, which could have a material adverse effect on our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties
in managing our growth, which could disrupt our operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and sales and marketing. To
manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial
resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The
expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to the Offering and Our Common Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The price of our common shares may be volatile and may
fluctuate due to factors beyond our control. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The share price of publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price
of our common shares may fluctuate significantly due to a variety of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">positive or negative results of testing and clinical trials by us, strategic partners or competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in entering into strategic relationships with respect to development and/or commercialization of our bispecific antibody candidates or entry
into strategic relationships on terms that are not deemed to be favorable to us; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">technological innovations or commercial product introductions by us or competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in government regulations; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments concerning proprietary rights, including patents and litigation matters; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public concern relating to the commercial value or safety of any of our bispecific antibody candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">financing or other corporate transactions; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">publication of research reports or comments by securities or industry analysts; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general market conditions in the pharmaceutical industry or in the economy as a whole; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other events and factors, many of which are beyond our control. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These and other market and industry factors may cause the
market price and demand for our securities to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their common shares and may otherwise negatively affect the liquidity of
our common shares. In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of
these companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will incur increased costs as a result of operating as a public company with
limited liability (naamloze vennootschap), and our management board will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a public company, and particularly after we no longer qualify as an emerging growth company, we will incur
significant legal, accounting and other expenses that we did not incur as a private company. Prior to the closing of this offering, we intend to convert to a Dutch public company with limited liability (<I>naamloze vennootschap</I>). The
Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The NASDAQ Global Market, or NASDAQ, and other applicable securities rules and regulations impose various requirements on non-U.S.
reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management board and other personnel will need to devote a substantial amount of time to
these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make
it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our management board and supervisory board. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overall, we estimate that our incremental costs resulting
from operating as a public company, including compliance with these rules and regulations, will be between &#128;1.0 million and &#128;2.0 million per year. However, these rules and regulations are often subject to varying interpretations, in many
cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and
higher costs necessitated by ongoing revisions to disclosure and governance practices. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we will be required to furnish a report by our management board on our internal control over financial reporting.
However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with
Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate
internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through
testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the
prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a
loss of confidence in the reliability of our financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>There has been no public market for our common shares prior to this offering, and an active market in the shares may not develop in which investors can resell our common shares. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, there has been no public market for
our common shares. We cannot predict the extent to which an active market for our common shares will develop or be sustained after this offering, or how the development of such a market might affect the market price for our common shares. The
initial public offering price of our common shares in this offering will be agreed upon between us and the underwriters based on a number of factors, including market conditions in effect at the time of the offering, which may not be indicative of
the price at which our shares will trade following completion of the offering. Investors may not be able to sell their shares at or above the initial public offering price. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Certain of our existing shareholders and members of our management board will continue
to own a majority of our common shares and as a result, will be able to exercise significant control over us, and your interests may conflict with the interests of our existing shareholders. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following completion of this offering, our existing
shareholders are expected to own approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our common shares. Depending on the level of attendance at our general meetings of shareholders, these shareholders may be in a position to determine the outcome of
decisions taken at any such general meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our general meetings of shareholders may control any shareholder resolution requiring a simple
majority, including the appointment of supervisory board members, certain decisions relating to our capital structure, the approval of certain significant corporate transactions and amendments to our Articles of Association. Among other
consequences, this concentration of ownership may have the effect of delaying or preventing a change in control and might therefore negatively affect the market price of our common shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the event we receive an offer from a third party to acquire us or prior to our soliciting an
offer from, or negotiating terms with, any third party, with respect to a sale or license of two of our undisclosed product candidates in pre-clinical development, we must first notify one of our existing shareholders of such opportunity and
negotiate in good faith with such shareholder the terms of a purchase or license agreement for such product candidates. This obligation may have the effect of delaying or preventing a change in control of us that shareholders may consider favorable,
including transactions in which you might otherwise receive a premium for your shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future sales, or the possibility of future sales, of a substantial number of our common shares could adversely affect the price of the shares and dilute shareholders. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future sales of a substantial number of our common
shares, or the perception that such sales will occur, could cause a decline in the market price of our common shares. Following the completion of this offering, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares outstanding (assuming no exercise of the underwriters&#146; option to purchase additional common shares from us). This includes the issuance and sale of shares in
this offering, which may be resold in the public market immediately without restriction, unless purchased by our affiliates. Approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the shares outstanding will be held by existing shareholders. A significant
portion of these shares will be subject to the lock-up agreements described in the &#147;Shares Eligible for Future Sale&#148; and &#147;Underwriting&#148; sections of this prospectus. If, after the end of such lock-up agreements, these shareholders
sell substantial amounts of shares in the public market, or the market perceives that such sales may occur, the market price of our common shares and our ability to raise capital through an issue of equity securities in the future could be adversely
affected. We also intend to enter into a registration rights agreement upon the closing of this offering pursuant to which we will agree under certain circumstances to file a registration statement to register the resale of the shares held by
certain of our existing shareholders, as well as to cooperate in certain public offerings of such shares. In addition, we intend to register all common shares that we may issue under our equity compensation plans. Once we register these common
shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the &#147;Shares Eligible for Future Sale&#148; section of this prospectus.
</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Provisions of our Articles of
Association or Dutch corporate law might deter acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace or remove the then management board and supervisory board. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions of our Articles of Association may make it more
difficult for a third party to acquire control of us or effect a change in our management board or supervisory board. These provisions include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the authorization of a class of preferred shares that may be issued to a friendly party; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">staggered four-year terms of our supervisory board members, whereby reappointment is limited to two times; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a provision that our management board and supervisory board members may only be removed by the general meeting of shareholders by a two-thirds majority
of votes cast representing more than 50% of our outstanding share capital (unless the removal was proposed by the supervisory board); and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a requirement that certain matters, including an amendment of our Articles of Association, may only be brought to our shareholders for a vote upon a
proposal by our management board that has been approved by our supervisory board. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><B></B><B><I>Our anti-takeover provision may prevent a beneficial change of control. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to adopt an anti-takeover measure pursuant to which our management board may, subject to supervisory board approval but without
shareholder approval, issue (or grant the right to acquire) cumulative preferred shares. We may issue an amount of cumulative preferred shares up to 100% of our issued capital immediately prior to the issuance of such cumulative preferred shares. In
such event, the cumulative preferred shares (or right to acquire cumulative preferred shares) will be issued to a separate, special purpose foundation, which will be structured to operate independently of us. We expect to grant a right to acquire
such number of cumulative preferred shares as we may issue to such special purpose foundation prior to the closing of the offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cumulative preferred shares will be issued to the foundation for their nominal value, of which only 25% will be due upon issuance. The
voting rights of our shares are based on nominal value and as we expect our shares to trade substantially in excess of nominal value, cumulative preferred shares issued at nominal value can obtain significant voting power for a substantially reduced
price and thus be used as a defensive measure. These cumulative preferred shares will have both a liquidation and dividend preference over our common shares and will accrue cash dividends at a fixed rate. The management board may issue these
cumulative preferred shares to protect us from influences that do not serve our best interests and threaten to undermine our continuity, independence and identity. These influences may include a third-party acquiring a significant percentage of our
common shares, the announcement of a public offer for our common shares, other concentration of control over our common shares or any other form of pressure on us to alter our strategic policies. If the management board determines to issue the
cumulative preferred shares to such a foundation, the foundation&#146;s articles of association will provide that it will act to serve the best interests of us, our associated business and all parties connected to us, by opposing any influences that
conflict with these interests and threaten to undermine our continuity, independence and identity. This foundation will be structured to operate independently of us. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If you purchase common shares in this offering, you
will suffer immediate dilution of your investment. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The assumed initial public offering price of our common shares is substantially higher than the net tangible book value per share. Therefore, if you purchase common shares in this offering, you will pay a
price per share that substantially exceeds our net tangible book value per share after this offering. To the extent outstanding options are exercised, you will incur further dilution. Based on the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share, representing the difference between our net tangible book value per share after giving effect to this offering and the assumed initial public offering price. In addition, purchasers of common shares in this offering will have contributed
approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the aggregate price paid by all purchasers of our common shares but will own only approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our common shares outstanding after this offering. See &#147;Dilution.&#148;
</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have broad discretion in the use of
the net proceeds from this offering and may not use them effectively. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our management board will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the
value of our common shares. The failure by our management board to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common shares to decline and delay
the development of our bispecific antibody candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not expect to pay cash dividends in the foreseeable future.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not paid any cash dividends
since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that any earnings will be reinvested in our business and that cash dividends will not be paid until we have an established
revenue stream to support continuing cash dividends. Payment of any future dividends to shareholders will in addition effectively be at the discretion of the general meeting, upon proposal of the management board, which proposal is subject to the
approval of the supervisory board after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. In addition, payment of future cash dividends may be made only if our
shareholders&#146; equity exceeds the sum of our paid-in and called-up share capital plus the reserves required to be maintained by Dutch law or by our Articles of Association. Accordingly, investors cannot rely on cash dividend income from our
common shares and any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Holders of our common shares outside the Netherlands
may not be able to exercise preemptive rights. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event of an increase in our share capital, holders of our common shares are generally entitled under Dutch law to full preemptive rights, unless these rights are excluded either by a resolution of
the general meeting of shareholders, or by a resolution of the management board (if the management board has been designated by the general meeting of shareholders for this purpose). See &#147;Description of Share Capital and Articles of
Association&#151;Comparison of Dutch Corporate Law and Our Articles of Association and U.S. Corporate Law&#151;Preemptive Rights.&#148; Certain holders of our common shares outside the Netherlands, in particular U.S. holders of our common shares,
may not be able to exercise preemptive rights unless a registration statement under the Securities Act is declared effective with respect to our common shares issuable upon exercise of such rights or an exemption from the registration requirements
is available. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Upon the closing of this
offering, we will be a Dutch public company with limited liability (naamloze vennootschap). The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Upon the closing of this offering, we will be a Dutch
public company with limited liability (<I>naamloze vennootschap</I>). Our corporate affairs are governed by our Articles of Association and by the laws governing companies incorporated in the Netherlands. The rights of shareholders and the
responsibilities of members of our management board and supervisory board may be different from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our management
board and supervisory board are required by Dutch law to consider the interests of our company, its shareholders, its employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is
possible that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder. See &#147;Description of Share Capital and Articles of Association&#151;Corporate Governance.&#148;<I>
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are not obligated to and do not
comply with all the best practice provisions of the Dutch Corporate Governance Code. This may affect your rights as a shareholder. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, we will be a Dutch public company with limited liability (<I>naamloze vennootschap</I>) and will be
subject to the Dutch Corporate Governance Code, or DCGC. The DCGC contains both principles and best practice provisions for management boards, supervisory boards, shareholders and general meetings of shareholders, financial reporting, auditors,
disclosure, compliance and enforcement standards. The DCGC applies to all Dutch companies listed on a government-recognized stock exchange, whether in the Netherlands or elsewhere, including NASDAQ. The principles and best practice provisions apply
to our management board and our supervisory board (in relation to role and composition, conflicts of interest and independency requirements, board committees and remuneration), shareholders and the general meeting of shareholders (for example,
regarding anti-takeover protection and our obligations to provide information to our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shareholders) and financial reporting (such as external auditor and internal audit requirements). We do not comply with all the best practice provisions of the DCGC. See &#147;Description of
Share Capital and Articles of Association&#151;Dutch Corporate Governance Code.&#148; This may affect your rights as a shareholder and you may not have the same level of protection as a shareholder in another Dutch public company with limited
liability (<I>naamloze vennootschap</I>) listed in the Netherlands that fully complies with the DCGC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Claims of U.S. civil liabilities may not be enforceable against us. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are incorporated under the laws of the Netherlands.
Substantially all of our assets are located outside the United States. The majority of our management board members and supervisory board members reside outside the United States. As a result, it may not be possible for investors to effect service
of process within the United States upon such persons or to enforce against them or us in U.S. courts, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The United States and the Netherlands currently do not have a
treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United&nbsp;States, whether or not
predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the Netherlands. In order to obtain a judgment which is enforceable in the Netherlands, the party in whose favor a final and conclusive judgment of
the U.S. court has been rendered will be required to file its claim with a court of competent jurisdiction in the Netherlands. Such party may submit to the Dutch court the final judgment rendered by the U.S. court. If and to the extent that the
Dutch court finds that the jurisdiction of the U.S. court has been based on grounds which are internationally acceptable and that proper legal procedures have been observed, the court of the Netherlands will, in principle, give binding effect to the
judgment of the U.S. court, unless such judgment contravenes principles of public policy of the Netherlands. Dutch courts may deny the recognition and enforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of
damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions
of the Dutch Code of Civil Procedure (<I>Wetboek van Burgerlijke Rechtsvordering</I>). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Based on the lack of a treaty as described above, U.S. investors may not be able to enforce against us or members of our management board or supervisory board or certain experts named herein who are
residents of the Netherlands or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are a foreign private issuer and, as a result, we
will not be subject to U.S. proxy rules and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, we will report under the
Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange
Act that are applicable to U.S. domestic public companies, including (i)&nbsp;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;
(ii)&nbsp;the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iii)&nbsp;the rules under the
Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form&nbsp;8-K, upon the occurrence of specified significant events. In addition,
foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material
information. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
As a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers. However, we are subject to Dutch laws and regulations
with regard to such matters and intend to furnish quarterly unaudited financial information to the SEC on Form 6-K. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a foreign private issuer and as permitted by the listing requirements of NASDAQ, we will rely on certain home country governance
practices rather than the corporate governance requirements of NASDAQ. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We qualify as a foreign private issuer. As a result, in accordance with the listing requirements of NASDAQ, we will rely on home country governance requirements and certain exemptions thereunder rather
than relying on the corporate governance requirements of NASDAQ. In accordance with Dutch law and generally accepted business practices, our Articles of Association do not provide quorum requirements generally applicable to general meetings of
shareholders. To this extent, our practice varies from the requirement of NASDAQ Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the
outstanding voting stock. Although we must provide shareholders with an agenda and other relevant documents for the general meeting of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of
proxies is not a generally accepted business practice in the Netherlands, thus our practice will vary from the requirement of NASDAQ Listing Rule 5620(b). In addition, we have opted out of certain Dutch shareholder approval requirements for the
issuance of securities in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain
private placements. To this extent, our practice varies from the requirements of NASDAQ Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. For an overview of
our corporate governance principles, see &#147;Description of Share Capital and Articles of Association&#151;Corporate Governance.&#148; Accordingly, you may not have the same protections afforded to shareholders of companies that are subject to
these NASDAQ requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may lose our
foreign private issuer status which would then require us to comply with the Exchange Act&#146;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a foreign private issuer and therefore we are not
required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We may no longer be a foreign private issuer as of June&nbsp;30, 2016 (the end of our second fiscal
quarter in the fiscal year after this offering), which would require us to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers as of January&nbsp;1, 2016. In order to
maintain our current status as a foreign private issuer, either (a)&nbsp;a majority of our common shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i)&nbsp;a majority of our executive officers
or directors may not be United States citizens or residents, (ii)&nbsp;more than 50 percent of our assets cannot be located in the United States and (iii)&nbsp;our business must be administered principally outside the United States. If we lost this
status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to
make changes in our corporate governance practices in accordance with various SEC and NASDAQ rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a
U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make
some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and
officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of
our supervisory board. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are an &#147;emerging growth company,&#148; and we cannot be certain if the reduced
reporting requirements applicable to &#147;emerging growth companies&#148; will make our common shares less attractive to investors. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. For as long as we continue to be an &#147;emerging growth
company,&#148; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the auditor
attestation requirements of Section&nbsp;404, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an &#147;emerging
growth company,&#148; we are required to report only two years of financial results and selected financial data compared to three and five years, respectively, for comparable data reported by other public companies. We may take advantage of these
exemptions until we are no longer an &#147;emerging growth company.&#148; We could be an &#147;emerging growth company&#148; for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate market
value of our common shares held by non-affiliates exceeds $700&nbsp;million as of any June&nbsp;30 (the end of our second fiscal quarter) before that time, in which case we would no longer be an &#147;emerging growth company&#148; as of the
following December&nbsp;31 (our fiscal year-end). We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be
a less active trading market for our common shares and the price of our common shares may be more volatile. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our
financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common shares. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective internal controls over financial reporting are
necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their
implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&nbsp;404, or any subsequent testing by our independent registered public accounting firm, may reveal
deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement.
Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and
our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an &#147;emerging growth company&#148; under the JOBS Act, our independent registered public accounting firm will not be required
to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&nbsp;404. We could be an &#147;emerging growth company&#148; for up to five years. An independent assessment of the effectiveness of our internal
controls could detect problems that our management&#146;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If securities or industry analysts do not publish
research, or publish inaccurate or unfavorable research, about our business, the price of our common shares and our trading volume could decline. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trading market for our common shares will depend in part on the research and reports that securities or industry analysts publish
about us or our business. Securities and industry analysts do not currently, and may never, publish research on us. If no or too few securities or industry analysts commence coverage on us, the trading price for our common shares would likely be
negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research about our business, the price of our common
shares would likely decline. If </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common shares could decrease, which might cause the price of our common shares and
trading volume to decline. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be
classified as a passive foreign investment company for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax consequences to U.S. investors in the common shares. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the current and anticipated value of our assets,
including goodwill, and the composition of our income, assets and operations, we do not expect to be a &#147;passive foreign investment company,&#148; or PFIC, for the current taxable year or in the foreseeable future. However, the application of
the PFIC rules is subject to uncertainty in several respects, and we cannot assure you that the U.S. Internal Revenue Service, or the IRS, will not take a contrary position. Furthermore, a separate determination must be made after the close of each
taxable year as to whether we are a PFIC for that year. Accordingly, we cannot assure you that we will not be a PFIC for our current taxable year or any future taxable year. A non-U.S. company will be considered a PFIC for any taxable year if (i) at
least 75% of its gross income is passive income, or (ii) at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production
of passive income. The value of our assets generally is determined by reference to the market price of our common shares, which may fluctuate considerably. If we were to be treated as a PFIC for any taxable year during which a U.S. Holder (as
defined below under &#147;Material Tax Considerations&#151; Material U.S. Federal Income Tax Considerations for U.S. Holders&#148;) holds a common share, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder. See
&#147;Material Tax Considerations&#151; Material U.S. Federal Income Tax Considerations for U.S. Holders &#151;Passive Foreign Investment Company Rules.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_5"></A>MARKET AND INDUSTRY DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We obtained the industry, market and competitive position
data in this prospectus from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they
have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we are not aware of any misstatements regarding the market or industry data presented herein, our
estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk Factors,&#148; &#147;Cautionary Statement Regarding Forward-Looking Information&#148; and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_6"></A>TRADEMARKS, SERVICE MARKS AND TRADENAMES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have proprietary rights to trademarks used in this prospectus including Merus, Biclonics and MeMo, which are
important to our business, many of which are registered under applicable intellectual property laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Solely for convenience, the trademarks, service marks, logos and trade names referred to in this prospectus are
without the <FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and &#153; symbols, but such references are not intended to indicate, in any way, that we will not
assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others,
which are the property of their respective owners. All trademarks, service marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other
companies&#146; trademarks, service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_7"></A>EXCHANGE RATE INFORMATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is primarily conducted in the EU, and we
maintain our books and records in euros. We have presented our results of operations in euros. In this prospectus, translations from euros to U.S. dollars were made at the rate of &#128;0.918 to $1.00, the official exchange rate quoted as of
December&nbsp;31, 2015 by the European Central Bank. Such U.S.&nbsp;dollar amounts are not necessarily indicative of the amounts of U.S.&nbsp;dollars that could actually have been purchased upon exchange of euros at the dates indicated. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents information on the exchange
rates between the euro&nbsp;and the U.S.&nbsp;dollar for the periods indicated: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period-end</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average&nbsp;for<BR>period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;per U.S. dollar)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Year Ended December 31:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.672</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.758</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.753</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.901</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.954</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_8"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds to us from this offering
will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming an initial public offering price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which is the midpoint
of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and expenses of the offering that are payable by us. Each $1.00 increase or decrease in the assumed initial
public offering price per share would increase or decrease our net proceeds, after deducting the estimated underwriting discounts and commissions and expenses, by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming
that the number of common shares offered by us, as set forth on the cover of this prospectus, remains the same. Each increase or decrease of 1,000,000 common shares in the number of common shares offered by us would increase or decrease our net
proceeds, after deducting the estimated underwriting discounts and commissions and expenses, by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public
offering price per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use the
net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance clinical development of MCLA-128 for the
treatment of HER2-expressing solid tumors, which we expect will be sufficient to complete our Phase 1/2 clinical trial that we initiated in February 2015; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to advance clinical development of MCLA-117 for the
treatment of AML, which we expect will be sufficient to complete a Phase 1/2 clinical trial that we expect to commence in the first quarter of 2016; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the remainder to fund our other current and future research and development activities and for working capital and other general corporate purposes.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This expected use of the net
proceeds from this offering represents our intentions based upon our current plans and business conditions. We may also use a portion of the net proceeds to in-license, acquire, or invest in additional businesses, technologies, products or assets,
although currently we have no specific agreements, commitments or understandings in this regard. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of
this offering or the amounts that we will actually spend on the uses set forth above. Predicting the costs necessary to develop bispecific antibody candidates can be difficult. The amounts and timing of our actual expenditures and the extent of
clinical development may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from pre-clinical studies and any ongoing clinical trials or clinical trials we may commence in
the future, as well as any collaborations that we may enter into with third parties for our bispecific antibody candidates and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net
proceeds from this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on our planned
use of the net proceeds of this offering and our current cash and cash equivalents described above, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through at least
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pending their use, we plan to invest the net proceeds from
this offering in short- and intermediate-term interest-bearing obligations and certificates of deposit. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_9"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never paid or declared any cash dividends on our
common shares, and we do not anticipate paying any cash dividends on our common shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Under Dutch law,
a Dutch public company with limited liability (<I>naamloze vennootschap</I>) may only pay dividends if the shareholders&#146; equity (<I>eigen vermogen</I>) exceeds the sum of the paid-up and called-up share capital plus the reserves required to be
maintained by Dutch law or our Articles of Association. Subject to such restrictions, any future determination to pay dividends will be at the discretion of our general meeting upon the proposal of the management board, which proposal is subject to
the approval of the supervisory board. Any future approval will depend upon the supervisory board&#146;s review of a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions,
restrictions imposed by applicable law and other factors the supervisory board deems relevant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_10"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below sets forth our cash and cash equivalents
and capitalization as of September&nbsp;30, 2015 derived from our financial statements included elsewhere in this prospectus: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on an actual basis; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on an as adjusted basis to give effect to: (i)&nbsp;the automatic conversion of all outstanding preferred shares as of September&nbsp;30, 2015 into an
aggregate of 14,900,456 common shares in connection with this offering; (ii) the issuance of 1,622,840 common shares to the holders of our Class B and C preferred shares in connection with this offering in satisfaction of their entitlement to
distributions in kind accrued as of September&nbsp;30, 2015; (iii)&nbsp;the amendment of our Articles of Association as adopted by our general meeting of shareholders in connection with this offering; and (iv)&nbsp;the issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the
midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investors should read this table in conjunction with our
audited financial statements included in this prospectus, as well as &#147;Use of Proceeds,&#148; &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148;
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of September&nbsp;30, 2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:66pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euro in&nbsp;thousands)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;Adjusted(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Borrowings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts owed to credit instititions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholders&#146; equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued capital:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class&nbsp;A preferred shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class B preferred shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">351</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class C preferred shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share premium</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,414</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,846</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which
is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the as adjusted amount of each of cash and cash equivalents, share premium, total equity and total capitalization by approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated
underwriting discounts and commissions. An increase or decrease of 1,000,000 shares in the number of common shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the as adjusted amount of each of cash
and cash equivalents, share premium, total equity and total capitalization by approximately &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of our common shares shown as outstanding in the table above excludes:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">700,776&nbsp;common shares issuable upon the exercise of share options outstanding as of September&nbsp;30, 2015 at a weighted average exercise price
of &#128;2.14&nbsp;per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,300,000 common shares reserved for future issuance under our 2016 Plan, which will become effective in connection with this offering, as well as
common shares that may become available pursuant to provisions in our 2016 Plan that automatically increase the share reserve under our 2016 Plan as described in &#147;Management&#151;Long-Term Incentive Plans&#148;; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">291,525 common shares issuable to the holders of our Class B and C preferred shares in connection with this offering in satisfaction of their
entitilement to distributions in kind accruing from October 1, 2015 to December 31, 2015, plus additional common shares issuable to such holders in satisfaction of their entitilement to distributions in kind accruing after December&nbsp;31, 2015, as
described in more detail in &#147;&#151;Preferred Share Distributions&#148;. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Preferred Share Distributions </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Each of our Class B and C preferred shareholders is entitled to receive a per share distribution at the rate of 8% of the original purchase price of such class per annum, compounding annually, and
accruing on a daily basis, whether or not declared. These distributions are payable in kind upon the conversion of our preferred shares into common shares and calculated by dividing the aggregate accumulated accrued distribution amount by the
applicable conversion rate for such class of preferred shares. The aggregate number of common shares issuable upon conversion of our Class B and C preferred shares that were outstanding as of September 30, 2015 is 1,622,840. An additional 291,525
common shares in the aggregate are issuable upon conversion to holders of our Class B and C preferred shares in satisfaction of their entitilement to distributions in kind accrued from October&nbsp;1, 2015 to December 31, 2015. Approximately 3,176
additional common shares will be issuable upon conversion to holders of our Class B and C preferred shares in satisfaction of their entitilement to distributions in kind accrued for each day after December 31, 2015 through the date of the
effectiveness of the registration statement of which this prospectus forms a part. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_11"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you invest in our common shares, your interest will be
diluted to the extent of the difference between the initial public offering price per share and the net tangible book value per share after this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At September 30, 2015, we had a historical net tangible book value (deficit) of $(36.7)&nbsp;million (&#128;33.7&nbsp;million),
corresponding to a net tangible book value (deficit) of $(2.36)&nbsp;per share (&#128;2.17&nbsp;per share). Net tangible book value (deficit) per share represents the amount of our total assets less our total liabilities, excluding goodwill and
other intangible assets, divided by the total number of our common shares and preferred shares outstanding at September&nbsp;30, 2015. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After giving effect to (i) the assumed issuance of 1,622,840 common shares to the holders of our Class B and C preferred shares in
connection with this offering in satisfaction of their entitlement to distributions in kind accrued through September 30, 2015 and (ii)&nbsp;the sale by us of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share), which is the midpoint of the price range set forth on the cover page of
this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma net tangible book value at June 30, 2015 would have been approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million), representing
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share). This represents an immediate increase in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share) to existing shareholders and an immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share) to new investors purchasing common shares in this offering at the assumed
initial public offering. Dilution per share to new investors is determined by subtracting pro forma net tangible book value per share after this offering from the assumed initial public offering price per share paid by new investors. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table illustrates this dilution to new
investors purchasing common shares in the offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed initial public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net tangible book value per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in net tangible book value per share attributable to this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Percentage of dilution in net tangible book value per share for new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters
exercise their option to purchase additional common shares in full, our pro forma net tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share
(&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share), representing an immediate increase in pro forma net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share) to existing shareholders and immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share) in pro forma net tangible book value per share to new investors purchasing
common shares in this offering, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this
prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each $1.00 increase or decrease in
the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share), which is the midpoint of the
price range set forth on the cover page of this prospectus, respectively, would increase or decrease the pro forma net tangible book value after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share
(&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share) and the dilution per share to new investors in the offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share
(&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per&nbsp;share), assuming that the number of common shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase of 1,000,000
in the number of common shares we are offering would increase the pro forma net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and decrease the dilution per share to new
investors participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts
and commissions. A decrease of 1,000,000 in the number of common shares we are offering would decrease the pro forma net </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and increase the dilution per share to new investors participating
in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price per share and after deducting the estimated underwriting discounts and commissions.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes, on the pro
forma basis described above, the number of common shares purchased from us, the total consideration paid to us and the average price per share paid by existing shareholders and by new investors purchasing common shares in this offering. The
calculation below is based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per&nbsp;share
(&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share), which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares purchased</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;consideration</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average price<BR>per&nbsp;share</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each $1.00 increase or
decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share), which is the
midpoint of the price range set forth on the cover page of this prospectus would increase or decrease the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million
(&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million) and, in the case of an increase, would increase the percentage of total consideration paid by new investors by approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points, assuming that the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase or decrease of 1,000,000 in the number of common shares we are offering would increase or decrease the total consideration paid by new investors
by $&nbsp;&nbsp;&nbsp;&nbsp; and, in the case of an increase, would increase the percentage of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points and, in the case of a decrease, would decrease the percentage
of total consideration paid by new investors by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;percentage points, assuming no change in the assumed initial public offering price per share. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters exercise their option to purchase
additional common shares in full, the following will occur: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the percentage of our common shares held by existing shareholders will decrease to approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of our
common shares outstanding after this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the percentage of our common shares held by new investors will increase to approximately &nbsp;&nbsp;&nbsp;&nbsp;% of the total number of our common
shares outstanding after this offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The tables above are based on actual common shares and preferred shares outstanding as of September&nbsp;30, 2015. The tables above exclude: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">700,776&nbsp;common shares issuable upon the exercise of stock options outstanding as of September 30, 2015 at a weighted average exercise price of
&#128;2.14&nbsp;per share; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,300,000 common shares reserved for future issuance under our 2016 Plan, which will become effective in connection with this offering, as well as
common shares that may become available pursuant to provisions in our 2016 Plan that automatically increase the share reserve under our 2016 Plan as described in &#147;Management&#151;Long-Term Incentive Plans&#148;; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">291,525 common shares issuable to the holders of our Class B and C preferred shares in connection with this offering in satisfaction of their
entitlement to distributions in kind accruing from October 1, 2015 to December 31, 2015, plus additional common shares issuable to such holders in satisfaction of their entitlement to distributions in kind accruing after December&nbsp;31, 2015, as
described in more detail in &#147;Capitalization&#151;Preferred Share Distributions.&#148; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_12"></A>SELECTED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the following summary financial data
together with our financial statements and the related notes thereto included elsewhere in this prospectus and the &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; sections of this prospectus. We have derived the statement of profit or loss and comprehensive loss data for the years ended December&nbsp;31, 2013 and 2014 and the statement of financial position data as of December&nbsp;31, 2013
and 2014 from our audited financial statements included elsewhere in this prospectus. The statement of profit or loss and comprehensive loss data for the nine months ended September&nbsp;30, 2014 and 2015 and the statement of financial position data
as of September 30, 2015 have been derived from our unaudited financial statements included elsewhere in this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited data
reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the financial information in those statements. Our historical results are not necessarily indicative of the results that should be
expected in the future, and results for the nine months ended September&nbsp;30, 2014 and 2015 are not necessarily indicative of the results to be expected for the full year ending December 31, 2015 or any other future period. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We maintain our books and records in euros, and we prepare
our financial statements under IFRS, as issued by the IASB. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine Months Ended<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="4"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Statement of Profit or Loss and Comprehensive Loss Data:</B></FONT></P></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management and administration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating result</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,420</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income (expenses)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic (and diluted) loss per share(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average shares outstanding, basic and diluted(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,603,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,093,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,912,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,903,486</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2015, we revised the presentation of our statement of profit or loss and comprehensive loss to categorize expense by function instead of by nature. We decided to
change our presentation format after considering industry factors and the nature, practice and current stage of development of our operations. We believe that this change in accounting policy provides more relevant information and will enable a
better understanding of our business. Consequently, we have retrospectively applied this change in accounting policy to our statement of profit or loss and comprehensive loss for the years ended December&nbsp;31, 2013 and 2014. For more information,
please see our audited and unaudited financial statements included elsewhere in this prospectus. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic loss per share and diluted loss per share are the same because outstanding options would be anti-dilutive due to our net losses in these periods.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Includes preferred shares issued and outstanding as of September&nbsp;30, 2015. Does not give effect to the 1,622,840 common shares to be issued to the holders of our
Class B and C preferred shares in connection with this offering in satisfaction of their entitlement to distributions in kind accrued as of September 30, 2015, all of which is described in more detail in &#147;Capitalization&#151;Preferred Share
Distributions.&#148; </FONT></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December 31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of<BR>September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Statement of Financial Position Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"> 40,103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,137</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_13"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the
information under &#147;Selected Financial Data&#148; and our audited financial statements, including the notes thereto, included in this prospectus. The following discussion is based on our financial information prepared in accordance with IFRS as
issued by the IASB, which might differ in material respects from generally accepted accounting principles in other jurisdictions. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our
actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under &#147;Risk Factors&#148; and elsewhere in this prospectus</I>.<I>
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage immuno-oncology company
developing innovative bispecific antibody therapeutics. Our pipeline of full-length human bispecific antibody candidates, which we refer to as Biclonics, are generated from our technology platform. By binding to two different antigens, or targets,
Biclonics can be designed to simultaneously block receptors that drive tumor cell growth and survival and to mobilize the patient&#146;s immune response by activating various killer cells to eradicate tumors. In our pre-clinical studies, our
bispecific antibody candidates were effective in killing tumor cells, a result that we believe supports their potential efficacy in the treatment of cancer. In February 2015, we commenced a Phase 1/2 clinical trial of our lead bispecific antibody
candidate, MCLA-128, for the treatment of HER2-expressing solid tumors, and we expect to report top-line results from this trial by the end of 2016. In the first quarter of 2016, we expect to commence a Phase 1/2 clinical trial with our second
bispecific antibody candidate, MCLA-117, for the treatment of acute myeloid leukemia, or AML. Additionally, we have several bispecific antibody candidates in pre-clinical development that bind to combinations of immunomodulatory molecules, including
PD-1 and PD-L1, both of which we believe play a significant role in treating cancer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since our inception in June 2003, we have devoted a significant portion of our financial resources and efforts to developing our Biclonics technology platform, identifying potential bispecific antibody
candidates and conducting pre-clinical studies and initiating and conducting our clinical trial of MCLA-128. We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our
operations through (i)&nbsp;private placements of equity securities, (ii)&nbsp;upfront, milestone and expense reimbursement payments received from our collaborator under our research and license agreement, (iii)&nbsp;funding from patient
organizations and governmental bodies and (iv)&nbsp;bank and bridge loans. Since our inception, we have raised gross proceeds of &#128;91.3&nbsp;million from private placements of equity securities, received aggregate gross proceeds of approximately
&#128;4.1&nbsp;million from our collaborator, received &#128;3.7&nbsp;million in grants from patient organizations and governmental bodies and received &#128;1.5&nbsp;million in proceeds from bank loan financings. As of September 30, 2015, we had
cash and cash equivalents of &#128;40.1&nbsp;million. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In August 2015, we entered into a subscription agreement pursuant to which we sold an aggregate of 6,268,579 of our Class C preferred shares to new and existing investors for aggregate gross proceeds of
&#128;41.6&nbsp;million and our &#128;8.0&nbsp;million existing convertible bridge loan fully converted into 1,201,201 Class C preferred shares in connection with the consummation of the first tranche of this private placement. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage company and have not generated
any revenue from product sales. Our ability to generate revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our bispecific antibody candidates. Since our
inception, we have incurred significant operating losses. For the years ended December&nbsp;31, 2014 and 2013, we incurred net losses of &#128;17.4&nbsp;million and &#128;9.9&nbsp;million, respectively, and for the nine months ended September 30,
2015, we incurred a net loss of &#128;16.5&nbsp;million. As of September 30, 2015, we had an accumulated loss of &#128;57.1&nbsp;million. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to incur significant expenses and operating losses for the foreseeable future as
we advance our bispecific antibody candidates from discovery through pre-clinical development and into clinical trials, and seek regulatory approval and pursue commercialization of any approved bispecific antibody candidate. In addition, if we
obtain regulatory approval for any of our bispecific antibody candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In addition, we may incur expenses in connection
with the in-license or acquisition of additional bispecific antibody candidates. Furthermore, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company, including significant legal,
accounting, investor relations and other expenses that we did not incur as a private company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations
through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to
raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that our existing cash and cash equivalents,
together with anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements through at least &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. See
&#147;&#151;Liquidity and Capital Resources.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Collaboration Agreements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of our business strategy, we intend to seek strategic collaborations to facilitate the capital-efficient development of our
Biclonics technology platform and to identify potential target combinations in immuno-oncology and other therapeutic areas. We believe that these collaborations could potentially provide significant funding to advance our bispecific antibody
candidate pipeline while allowing us to benefit from the development expertise of our collaborators. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>ONO Pharmaceutical </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2014, we entered into a strategic research and license agreement with ONO Pharmaceutical Co., Ltd., or ONO, under which we
granted ONO an exclusive, worldwide, royalty-bearing license to research, test, make, use and market bispecific antibody candidates based on our Biclonics technology platform with undisclosed targets. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ONO paid us a non-refundable upfront fee of &#128;1.0
million. We are eligible to receive up to an aggregate of &#128;34.0&nbsp;million in milestone payments upon achievement of specified research and clinical development milestones. To date, we have achieved two of the specified pre-clinical
milestones under this research and license agreement and have received an aggregate of &#128;1.0&nbsp;million in milestone payments. For products commercialized under this agreement, if any, we are also eligible to receive a mid-single digit royalty
on net sales. For a designated period, which may include limited time periods following termination of this agreement, in certain circumstances we and our affiliates are prohibited from researching, developing or commercializing bispecific
antibodies against the undisclosed target combinations that are the subject of this agreement. This research and license agreement will expire after all milestone payments have been received and all related patent rights have expired, unless
terminated earlier. ONO also provides funding for our research and development activities under an agreed-upon plan. ONO has the right to terminate this agreement at any time for any reason, with or without cause. The licenses granted to ONO may
convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for uncured material breach. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes to the Presentation of the Statement of Profit or Loss and Comprehensive Loss Data
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2015, we revised the presentation of our
statement of profit or loss and comprehensive loss to categorize expense by function instead of by nature. We decided to change our presentation format after considering industry factors and the nature, practice and current stage of development of
our operations. We believe that this change in accounting policy provides more relevant information and will enable a better understanding of our business. Consequently, we have retrospectively applied this change in accounting policy to our
statement of profit or loss and comprehensive loss for the years ended December&nbsp;31, 2013 and 2014. This change in accounting policy has no impact on our net result, financial position or cash flows. For more information on this change in
accounting policy, see our audited and unaudited financial statements included elsewhere in this prospectus. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Operations Overview </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To date, our revenue has consisted principally of license revenue and collaboration revenue and revenue from several government grants, primarily with respect to research and development activities
related to the use of our Biclonics technology in various indication areas. For 2014 and the nine months ended September&nbsp;30, 2015, all of our license revenue and collaboration revenue was generated under our agreement with ONO. Our research and
license agreement comprises elements of upfront license fees, milestone payments based on development and sales and royalties based on product sales. In addition, our research and license agreement contemplates our involvement in the ongoing
research and development of our partnered bispecific antibody candidates, for which our collaborator provides funding for the services rendered. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no products approved for sale. Other than the sources of revenue described above, we do not expect to receive any revenue from any
bispecific antibody candidates that we develop, including MCLA-128 and MCLA-117 and our other pre-clinical bispecific antibody candidates, until we obtain regulatory approval and commercialize such products, or until we potentially enter into
collaborative agreements with third parties for the development and commercialization of such candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Costs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs consist principally of: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">salaries for research and development staff and related expenses, including share-based compensation expenses; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs for production of preclinical compounds and drug substances by contract manufacturers; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fees and other costs paid to contract research organizations, or CROs, in connection with additional preclinical testing and the performance of
clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of related facilities, materials and equipment; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs associated with obtaining and maintaining patents and other intellectual property; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">amortization and depreciation of tangible and intangible fixed assets used to develop our product candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We incur various external expenses under our research and
license agreement for material and services consumed in the development of our partnered bispecific antibody candidates. Under our research and license agreement, our collaboration partner reimburses us for these external expenses and compensates us
for time spent on the project by our employees. We recognize these reimbursements and compensation as revenue. External expenses that are not reimbursed are recognized as research and development expenses in the period in which they are incurred.
Government grants are recognized when there is reasonable assurance that the conditions underlying the grant have been met and that the grant will be received. Government grants to cover research and development expenses incurred are recognized as
revenue proportionally over the periods during which the related research and development expenses are incurred. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect our total research and development expenses in 2016 will be approximately in
the range of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and will primarily relate to the following key programs: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MCLA-128</I>.&nbsp;&nbsp;&nbsp;&nbsp;In February 2015, we commenced a Phase 1/2 clinical trial of MCLA-128 in patients with HER-2 expressing solid
tumors, including breast cancer, colorectal cancer and ovarian cancer. We anticipate that our research and development expenses will increase substantially as we continue to enroll patients for the trial. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MCLA-117.&nbsp;&nbsp;&nbsp;&nbsp;</I>We submitted a Clinical Trial Application, or CTA, to the EMA for MCLA-117 in December 2015 and intend to
commence a Phase 1/2 clinical trial of MCLA-117 in patients with AML during the first quarter of 2016. We anticipate that our research and development expenses will increase substantially in connection with the commencement of this clinical trial.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other development programs</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our other research and development expenses relate to our pre-clinical studies of our other
bispecific antibody candidates, MCLA-134, MCLA-145 and MCLA-158, as well as other early research projects. These expenses primarily consist of costs for production of the pre-clinical compounds and costs paid to CROs in conjunction with pre-clinical
studies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the years ended
December&nbsp;31, 2014 and 2013, we spent &#128;12.4&nbsp;million and &#128;8.6&nbsp;million, respectively, on research and development costs. For the nine months ended September&nbsp;30, 2015, we spent &#128;11.5&nbsp;million in research and
development costs. For the same time periods, we spent &#128;5.5&nbsp;million, &#128;3.8&nbsp;million and &#128;2.4&nbsp;million on <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> respectively, and &#128;1.4&nbsp;million, &#128;0.9&nbsp;million
and &#128;4.8&nbsp;million on MCLA-117, respectively. Our research and development expenses may vary substantially from period to period based on the timing of our research and development activities, including due to timing of initiation of
clinical trials and enrollment of patients in clinical trials. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses are expected to increase as we advance the clinical development of MCLA-128 and MCLA-117 and further advance the research and development of our other pre-clinical
bispecific antibody candidates and other earlier stage products. The successful development of our bispecific antibody candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts
that will be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our bispecific antibody candidates. This is due to numerous risks and uncertainties associated with developing
drugs, including the uncertainty of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, rate of progress and expense of our research and development activities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical trials and early-stage results; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and timing of regulatory approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to market, commercialize and achieve market acceptance for MCLA-128, MCLA-117 or any other bispecific antibody candidate that we may
develop in the future. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any of
these variables with respect to the development of MCLA-128, MCLA-117 or any other bispecific antibody candidate that we may develop could result in a significant change in the costs and timing associated with the development of MCLA-128, MCLA-117
or such other bispecific antibody candidate. For example, if the FDA, the EMA or other regulatory authority were to require us to conduct pre-clinical and clinical studies beyond those which we currently anticipate will be required for the
completion of clinical development or if we experience significant delays in enrollment in any clinical trials, we could be required to expend significant additional financial resources and time on the completion of our clinical development
programs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Management and Administration Costs </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management and administration costs consist principally
of salaries for employees other than research and development staff, including share-based compensation expenses. We expect that our management and administration costs will increase in the future as our business expands and we increase our
headcount to support the expected growth in our operating activities. In addition, we expect to grant share-based compensation awards to key management personnel and other employees. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses consist principally of: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">professional fees for auditors and other consulting expenses not related to research and development activities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">professional fees for legal services, including litigation costs, not related to the protection and maintenance of our intellectual property;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cost of facilities, communication and office expenses; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">information technology services; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">amortization and depreciation of tangible and intangible fixed assets not related to research and development activities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect our other expenses will increase in the future as
we expand our operating activities and we incur additional costs associated with operating as a public company. These public company-related increases will likely include costs of additional legal fees, accounting and audit fees, management board
and supervisory board liability insurance premiums and costs related to investor relations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Finance Income and Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Finance income consists of interest earned on our cash and cash equivalents. Finance expenses consist primarily of interest accrued on our outstanding indebtedness. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comparison of Nine Months Ended September 30, 2014
and 2015 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The below table summarizes our
results of operations for the nine months ended September 30, 2014 and 2015. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management and administration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating result</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income (expenses)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue increased &#128;0.8&nbsp;million during the nine months ended September&nbsp;30, 2015 as compared to
the nine months ended September&nbsp;30, 2014. The increase was primarily attributable to the &#128;1.0 million we received for achieving two of the specified pre-clinical milestones under the research and license agreement with ONO, partially
offset by the decrease in subsidy income on research projects of &#128;0.2 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Costs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Research and development costs increased &#128;2.1&nbsp;million during the nine months ended September&nbsp;30, 2015 as compared to the nine months ended September&nbsp;30, 2014. The increase was
primarily due to the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase of &#128;3.7&nbsp;million related to our MCLA-117 program, due primarily to higher manufacturing costs at our CRO and pre-clinical studies;
partially offset by </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a decrease of &#128;1.3&nbsp;million related to our MCLA-128 program, due primarily to lower manufacturing costs at our CRO and pre-clinical studies;
and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a decrease of &#128;0.4&nbsp;million in expenses in connection with various pre-clinical and discovery programs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Management and Administration Costs </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management and administration costs remained consistent
during the nine months ended September&nbsp;30, 2015 as compared to the nine months ended September&nbsp;30, 2014. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses increased &#128;3.5&nbsp;million during the nine months ended September&nbsp;30, 2015 as compared to the nine months ended
September 30, 2014. The increase was primarily attributable to an increase of &#128;2.5&nbsp;million in intellectual property litigation costs associated with our patent infringement lawsuits with Regeneron. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Finance Income and Expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income and expenses decreased &#128;0.2&nbsp;million
during the nine months ended September&nbsp;30, 2015 as compared to the nine months ended September&nbsp;30, 2014. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comparison of Years Ended December&nbsp;31, 2013 and 2014 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The below table summarizes our results of operations for the years ended December&nbsp;31, 2013 and 2014.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management and administration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating result</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,420</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income (expenses)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue increased &#128;0.7&nbsp;million during the year ended December&nbsp;31, 2014 as compared to the year
ended December&nbsp;31, 2013. The increase was primarily attributable to the &#128;0.2&nbsp;million we received as an upfront payment in connection with entering into the research and license agreement with ONO and &#128;0.5&nbsp;million we received
for research and development services rendered under such agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Costs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Research and development costs increased &#128;3.8&nbsp;million during the year ended December&nbsp;31, 2014 as compared to the year ended December&nbsp;31, 2013. The increase was primarily due to the
following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase of &#128;1.8&nbsp;million related to our MCLA-128 program, due primarily to higher manufacturing costs at our CRO and pre-clinical studies;
and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase of &#128;1.4&nbsp;million in expenses in connection with various pre-clinical and discovery programs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Management and Administration Costs </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management and administration costs increased
&#128;0.1&nbsp;million during the year ended December&nbsp;31, 2014 as compared to the year ended December&nbsp;31, 2013. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses increased &#128;4.5&nbsp;million during the year ended December&nbsp;31, 2014 as compared to the year ended
December&nbsp;31, 2013. The increase was primarily attributable to an increase of &#128;4.5&nbsp;million in intellectual property litigation costs associated with our patent infringement lawsuits with Regeneron. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Finance Income and Expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income and expenses for the years ended
December&nbsp;31, 2014 and 2013 was immaterial. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity
and Capital Resources </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Sources of Funds
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since our inception in 2003, we have
devoted substantially all of our resources to developing our bispecific antibody candidates, building our intellectual property portfolio, developing our supply chain, business planning, raising capital and providing for general and administrative
support for these operations. We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations through private placements of equity securities, upfront, milestone and
expense reimbursement payments received from our collaborator under our research and license agreement, as well as funding from patient organizations, governmental bodies and bank and bridge loans. Since our inception, we raised gross proceeds of
&#128;91.3&nbsp;million from private placements of equity securities, received aggregate gross proceeds of approximately &#128;4.1&nbsp;million from our collaborator, received &#128;3.7&nbsp;million in grants from patient organizations and
governmental bodies and received &#128;1.5&nbsp;million in proceeds from bank loan financings. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of September&nbsp;30, 2015, we had cash and cash equivalents of &#128;40.1&nbsp;million. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over
the next five years, other than leases. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash Flows </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below summarizes our cash flows for each of the periods presented. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended<BR>September 30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash from operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash flow (used in) from investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash from financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,842</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,490</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The increase in net
cash used in operating activities to &#128;15.6&nbsp;million for the nine months ended September&nbsp;30, 2015 from &#128;9.3&nbsp;million for the nine months ended September&nbsp;30, 2014 was primarily due to higher research and development
expenses and changes in working capital. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
increase in net cash used in operating activities to &#128;14.6&nbsp;million for the year ended December&nbsp;31, 2014 from &#128;7.0&nbsp;million for the year ended December&nbsp;31, 2013 was primarily due to higher research and development
expenses and changes in working capital. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
decrease in net cash used in investing activities to &#128;(18,000) for the nine months ended September&nbsp;30, 2015 from &#128;(93,000) for the nine months ended September&nbsp;30, 2014 was primarily due to a decrease in investments in laboratory
equipment and office equipment. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The decrease
in net cash from investing activities to &#128;(86,000) for the year ended December&nbsp;31, 2014 from &#128;5,000 for the year ended December&nbsp;31, 2013 was primarily due to investments in laboratory equipment and office equipment in support of
our business operating activities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
increase in net cash from financing activities to &#128;53.9&nbsp;million for the nine months ended September&nbsp;30, 2015 from &#128;5.9&nbsp;million for the nine months ended September&nbsp;30, 2014 was mainly due to the closing of the fifth
tranche of a private placement of our Class&nbsp;B preferred shares, which resulted in &#128;5.0 million in gross proceeds in January 2015 and the receipt of an &#128;8.0 million convertible bridge loan granted by several shareholders in June 2015
in lieu of closing the sixth and seventh tranches of our Class B preferred share private placement. The convertible loan agreement provided that all principal and interest outstanding on the convertible bridge loan would be converted into preferred
shares upon the closing of a Class C preferred share financing round in accordance with the terms and provisions of the convertible loan agreement. The conversion occurred in August 2015 as part of our Class&nbsp;C Financing. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The decrease in net cash from financing activities to
&#128;5.9&nbsp;million for the year ended December&nbsp;31, 2014 from &#128;11.8&nbsp;million for the year ended December&nbsp;31, 2013 was mainly due to the consummation of a private placement of our Class B preferred shares which resulted in
&#128;12.0&nbsp;million in gross proceeds. In 2014, we consummated the fourth tranche of a private placement of our Class B preferred shares which resulted in &#128;6.0&nbsp;million in gross proceeds. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating and Capital Expenditure Requirements
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not achieved profitability
since our inception and, as of September 30, 2015, we had an accumulated loss of &#128;57.1&nbsp;million. We expect to continue to incur significant operating losses for the foreseeable future as we continue our research and development efforts and
seek to obtain regulatory approval and commercialization of our bispecific antibody candidates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect our expenses to increase substantially in connection with our ongoing development
activities related to MCLA-128 and MCLA-117 and our other pre-clinical programs. In addition, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. We anticipate that our expenses will
increase substantially if and as we: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">conduct the Phase 1/2 clinical trial of MCLA-128, our lead bispecific antibody candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">continue the research and development of our other bispecific antibody candidates, including completing our pre-clinical studies and commencing
clinical trials for MCLA-117; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seek to enhance our technology platform, which generates our pipeline of Biclonics, and discover and develop additional bispecific antibody candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seek regulatory approvals for any bispecific antibody candidates that successfully completes clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products for
which we may obtain regulatory approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain, expand and protect our intellectual property portfolio, including litigation costs associated with defending against alleged patent
infringement claims; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product
development and potential future commercialization efforts and to support our transition to a public company; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">experience any delays or encounter any issues any of the above, including but not limited to failed studies, complex results, safety issues or other
regulatory challenges. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
expect that our existing cash and cash equivalents, together with anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements through at least
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect.
Because of the numerous risks and uncertainties associated with the development of MCLA-128, MCLA-117 and our other pre-clinical programs and because the extent to which we may enter into collaborations with third parties for development of these
bispecific antibody candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of our bispecific antibody candidates. Our future capital
requirements for MCLA-128, MCLA-117 or our other pre-clinical programs will depend on many factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the progress, timing and completion of pre-clinical testing and clinical trials for our current or any future bispecific antibody candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of potential new bispecific antibody candidates we identify and decide to develop; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our current
or any future bispecific antibody candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims or infringements raised by third
parties; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the time and costs involved in obtaining regulatory approval for our bispecific antibody candidates and any delays we may encounter as a result of
evolving regulatory requirements or adverse results with respect to any of these bispecific antibody candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any licensing or milestone fees we might have to pay during future development of our current or any future bispecific antibody candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selling and marketing activities undertaken in connection with the anticipated commercialization of our current or any future bispecific antibody
candidates and costs involved in the creation of an effective sales and marketing organization; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of our bispecific antibody
candidates, if approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Identifying potential bispecific antibody candidates and conducting pre-clinical testing and clinical trials is a time-consuming,
expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our bispecific antibody candidates, if approved, may
not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to
achieve our business objectives. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adequate
additional funds may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these
securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interest. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we raise additional funds through collaborations,
strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or bispecific antibody candidates or grant licenses on terms that may not be
favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development programs or any future commercialization efforts or grant
rights to develop and market bispecific antibody candidates that we would otherwise prefer to develop and market ourselves. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations and Commitments </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below summarizes our contractual obligations at December&nbsp;31, 2014. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payments Due by Period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Less&nbsp;than<BR>1 year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1&nbsp;-&nbsp;3<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>3&nbsp;-&nbsp;5<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More<BR>than&nbsp;5<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease obligations(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debt obligations(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts in the table reflect payments due for our office space at Utrecht University in Utrecht, Netherlands under an operating lease agreement that expires on March 1,
2016. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reflects the contractually required principal and interest payments payable pursuant to our bank loan. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We entered into a loan and security agreement with
Co&ouml;peratieve Rabobank Utrechtse Heuvelrug U.A., or Rabobank, on December&nbsp;29, 2009, which provided for total borrowings of &#128;1.5 million. Under the loan and security agreement, we are obligated to make monthly payments of &#128;14,000
until November 2019, the maturity date. The loans bear interest at an annual rate equal to 4.45% until April 1, 2016 and thereafter, at our option, at a fixed or variable rate to be agreed upon by us and Rabobank. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with our entry into the loan and security
agreement, we also provided security to Rabobank in the form of (i) a right of pledge on the account of &#128;500,000, in our name in a new savings account for the benefit of Rabobank, and (ii) a suretyship (<I>borgstelling</I>) of &#128;1,000,000
in the framework of the Small and Medium </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Business Guarantee Decision (<I>Innovative Guaranteed Credit) (Besluit Borgstelling Midden- en Kleinbedrijf (Innovatief Borgsellingskrediet</I>)). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We did not have during the periods presented, and we do not
currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Quantitative and Qualitative Disclosures About Market Risk </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to a variety of financial risks. Our overall risk management program seeks to minimize potential adverse effects of these
financial risks on our financial performance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Credit Risk </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We consider all of our material counterparties to be creditworthy. We consider the credit risk for each of our counterparties to be low
and do not have a significant concentration of credit risk at any of our counterparties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Liquidity Risk </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We manage our liquidity risk by maintaining adequate cash reserves at banking facilities, and by continuously monitoring our cash forecasts, our actual cash flows and by matching the maturity profiles of
financial assets and liabilities. We believe that our existing cash and cash equivalents, along with the proceeds from this offering, will be sufficient to meet our projected cash requirements for at least
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; from the date of this prospectus. See &#147;Use of Proceeds&#148; for further information. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Market Risk </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not subject to any significant foreign exchange risk
and interest rate risk. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and
Significant Judgments and Estimates </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with IFRS as issued by the IASB. The preparation of these financial statements
requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses
during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions. There have been no material adjustments to prior period estimates for any of the periods included in this prospectus. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our significant accounting policies are more fully described
in the notes to our financial statements appearing elsewhere in this prospectus. We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our financial condition and results of
operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We incur research and development
expenses related to our clinical and pre-clinical drug development programs. Expenditure on research activities is recognized as an expense in the period in which it is incurred. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses (or from the development
phase of an internal project) are recognized if, and only if, all of the following have been demonstrated: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the technical feasibility of completing the intangible asset so that it will be available for use or sale; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the intention to complete the intangible asset and use or sell it; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to use or sell the intangible asset; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">how the intangible asset will generate probable future economic benefits; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to measure reliably the expenditure attributable to the intangible asset during its development. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above criteria for capitalization of development costs
have not been met and therefore, all development expenditures relating to internally generated intangible assets to date have been expensed when incurred. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. This process involves
reviewing quotations and contracts, identifying services that have been performed on our behalf, estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of
the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements
based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses
are related to fees paid to CROs in connection with research and development activities for which we have not yet been invoiced. We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes
and contracts with CROs that conduct research and development on our behalf. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will
exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each
period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepayment expense accordingly. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we do not expect our estimates to be materially
different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low
in any particular period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-Based
Compensation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We maintain share option
programs that entitle key management personnel, staff and consultants providing similar services to purchase depositary receipts for our common shares. Under these programs, holders of vested options are entitled to purchase depositary receipts for
common shares at the exercise price determined at the date of grant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Upon exercise of options, Stichting Administratiekantoor Merus, a Dutch foundation that we utilize to facilitate the administration of share-based compensation awards and refer to as the Foundation,
issues to such individuals non-voting depositary receipts representing the underlying common shares, against payment of the option exercise price. The voting rights associated with the common shares remain with the Foundation. In connection with
this offering, we intend to transfer the common shares held by the Foundation to the relevant depositary holders and cancel the corresponding depositary receipts. The Foundation will be dissolved and deregistered once the transfer has been
effectuated. We intend to amend the 2010 Option Plan to reflect that an option entails the right of the holder to purchase common shares rather than depositary receipts. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The options granted under the share option programs vest in
installments over a four-year period from the grant date. 25% of the options vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in 36 monthly installments for each full month of continuous
service provided by the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
option holder thereafter, such that 100% of the options shall become vested on the fourth anniversary of the vesting commencement date. The options granted are exercisable once vested. Options
will lapse on the eighth anniversary of the date of grant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Certain participants who voluntarily leave employment with us are required to offer to the Foundation the depositary receipts acquired from exercising options against payment of the exercise price or the
lower fair market value of the underlying shares. Up to the first anniversary of the date of exercise, the participant has an obligation to offer 100% of his or her depositary receipts to the Foundation. This obligation for a participant to offer
depositary receipts to the Foundation upon resignation is reduced by 25% at each anniversary of the date of exercise, which means that there is no such obligation if a participant leaves after the fourth anniversary of the date of exercise. In
connection with this offering, we intend to amend the 2010 Option Plan to remove this obligation, such that a participant will no longer be required to offer depositary receipts to the Foundation upon resignation. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The option exercise price of each option is specified in the
applicable notice of grant and equals either the fair market value per common share as determined at the date of grant or another price determined by our supervisory board when granting the options. Each option is exercisable at such times and
subject to such terms and conditions as specified in the applicable notice of grant. We may, in the event of a change of control of our company, decide to exchange, cancel and settle in cash and/or accelerate the vesting of the outstanding options
or the supervisory board may consider other appropriate steps with respect to the outstanding options. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based compensation reflects the compensation expense of our share option programs granted to employees or others providing similar
services, which are measured at the grant date fair value of the options. The compensation expense is spread over the vesting period in accordance with each separate vesting tranche of the options granted, taking into consideration actual and
expected forfeitures at each reporting date and at the respective vesting dates. The grant date fair value share-based compensation is recognized as an expense. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate the fair value of each share option grant using the Black-Scholes option-pricing model for members of our executive management
team, which includes our management board and other key personnel, or a binomial option pricing model for other participants, including supervisory board members. Service and non-market performance conditions attached to the transactions were not
taken into account in measuring fair value. In addition to the vesting period of the options, the vesting period for the depositary receipts were also taken into account when allocating the fair values of the options granted over the required
service period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The assumptions we used to
determine the fair value of share options granted to members of our executive management team (Black-Scholes formula) and other participants (binominal option pricing model) are as follows, presented on a weighted average basis: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine months ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September
30, 2015</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Executives</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Executives</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Executives</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility (weighted-average)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected life (weighted-average)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate (based on government bonds)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">1.0%-1.2%</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These assumptions
represented our best estimates, but the estimates involve inherent uncertainties and the application of our judgment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The options outstanding at September 30, 2015 had exercise prices in the range of &#128;1.07 to &#128;7.50 per share. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since we are a private company prior to the closing of this
offering, company-specific historical and implied volatility information is not available. Expected volatility is therefore estimated based on the observed daily </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
share price returns of publicly traded peer companies over a historic period equal to the period for which expected volatility is estimated. The group of comparable listed companies are publicly
traded entities active in the business of developing antibody-based therapeutics, treatments and drugs and are selected taking into consideration the availability of meaningful trading data history and market capitalization. We will continue to use
this group for calculation of expected volatility data until sufficient historical market data is available for estimating the volatility of our common shares after the closing of this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since the options are not transferable, the participants will
tend to exercise the options prior to the maturity date. For participants who are not members of the executive management team, expected early exercises have been incorporated in the option valuation by assuming that the participants will exercise
the options if the share price increases to two times the exercise price at a future point in time. The members of the executive management team are expected to exercise their options immediately after vesting of the final vesting installment.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Valuation of Our Common Shares
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of our common shares is
determined by our management board and supervisory board, and takes into account our most recently available valuation of common shares performed by an independent valuation firm and our assessment of additional objective and subjective factors we
believe are relevant and which may have changed from the date of the most recent valuation through the date of the grant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management board and supervisory board consider numerous objective and subjective factors to determine their best estimate of the fair
value of our common shares as of each grant date, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the progress of our research and development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">achievement of enterprise milestones, including entering into collaboration and licensing agreements, as well as funding milestones;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">contemporaneous third-party valuations of our common shares for our most recent share issuances; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our need for future financing to fund operations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rights and preferences of our preferred shares and our preferred shares relative to our common shares; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the likelihood of achieving a discrete liquidity event, such as a sale of our Company or an initial public offering given prevailing market conditions;
and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">external market and economic conditions impacting our industry sector. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the fair values of our common shares as of each grant date, three generally accepted approaches
were considered: income approach, market approach and cost approach. In addition, the guidance prescribed by the American Institute of Certified Public Accounts, or AICPA, <I>Audit and Accounting Practice Aid, Valuation of Privately-Held-Company
Equity Securities Issued as Compensation</I> has been considered. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The &#147;prior sale of company stock&#148; method, a form of the market approach, has been applied to estimate the total enterprise value. The prior sale of company stock method considers any prior
arm&#146;s length sales of our equity securities. Considerations factored into the analysis include: the type and amount of equity sold, the estimated volatility, the estimated time to liquidity, the relationship of the parties involved, the
risk-free rate, the timing compared to the common shares valuation date and the financial condition and our structure at the time of the sale. As such, the value per share has been benchmarked to the external transactions of our securities and
external financing rounds. Throughout this period, a number of financing rounds were held, which resulted in the issuance of preferred shares. The preferred shares were transacted with numerous existing and new investors, and therefore the pricing
in these financing rounds is considered a strong indication of fair value. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Given that there are multiple classes of equity, the hybrid method has been applied in order
to allocate equity to the various equity classes. The hybrid method is a hybrid between the probability-weighted expected return method, or PWERM, and the Option Pricing Method, or OPM, which estimates the probability weighted value across certain
exit scenarios, but uses the OPM to estimate the remaining unknown potential exit scenarios. As a part of this analysis, we estimated cumulative probabilities of 65% and 35% of an initial public offering and for a sale of our Company, respectively,
from September 2014 onwards. Prior to this date, we estimated cumulative probabilities of 32.5% and 67.5% of an initial public offering and for a sale of our Company, respectively. A discount for lack of marketability, or DLOM, was applied,
corresponding to the time to exit under the various scenarios to reflect the increased risk arising from the inability to readily sell the shares. When assessing the DLOM, the Black-Scholes option pricing model was used. Under this method, the cost
of the put option, which can hedge the price change before the privately held shares can be sold, was considered as the basis to determine the DLOM. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimates by our management board and our supervisory board will not be necessary to determine the fair value of common shares once a
public trading market for our common shares has been established in connection with the completion of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted the following options in the period from January&nbsp;1, 2014 through September&nbsp;30, 2015: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>options&nbsp;granted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise&nbsp;price<BR>per share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated&nbsp;fair<BR>value for&nbsp;each<BR>common&nbsp;share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated&nbsp;fair<BR>value for<BR>each&nbsp;option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 17, 2014 (executive management team)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 17, 2014 (employees)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 17, 2014 (supervisory board)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 16, 2015 (executive management team)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">258,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 16, 2015 (employees)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 4, 2015 (supervisory board)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 21, 2015 (supervisory board)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are subject to income taxes in the
Netherlands. Significant judgment is required in determining the use of net operating loss carry-forwards and taxation of upfront and milestone payments for income tax purposes. There are many transactions and calculations for which the ultimate tax
determination is uncertain. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current and deferred income tax assets and liabilities in the period in which such
determination is made. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No tax charge or
income was recognized during the reporting periods since we are in a loss-making position and have a history of losses. We have tax loss carry-forwards of &#128;49.7 million and &#128;28.0 million as of December&nbsp;31, 2014 and 2013, respectively.
As a result of Dutch income tax law, tax loss carry-forwards are subject to a time limitation of nine years. We do not assume that the public trading of our common shares as such will negatively affect the tax loss carry-forward position of the
Company. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax assets are
recognized for tax losses and other temporary differences to the extent that the realization of the related tax benefit through future taxable profits is probable. We recognize deferred tax assets arising from unused tax losses or tax credits only
to the extent the relevant fiscal unity has sufficient taxable temporary differences or if there is convincing other evidence that sufficient taxable profit will be available against which the unused tax losses or unused tax credits can be utilized
by the fiscal unity. Our judgment is that sufficient convincing other evidence is not available and therefore, a deferred tax asset is not recognized. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to promote innovative technology development activities and investments in new
technologies, a corporate income tax incentive has been introduced in Dutch tax law called the &#147;Innovation Box.&#148; For the qualifying profits, we effectively owe only 5% income tax, instead of the general tax rate of 25.5%, which results in
an estimated effective tax rate of 10%. The agreement with the tax authorities is currently signed for the years 2011 to 2015 but is expected to be extended. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We refer to Note 5 to our audited financial statements for the year ended December 31, 2014 for a discussion of new standards and
interpretations not yet adopted by us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>JOBS Act Exemptions
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;5, 2012, the JOBS Act was
enacted. Section&nbsp;107 of the JOBS Act provides that an &#147;emerging growth company&#148; can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised
accounting standards. As a result, an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of
this extended transition period for complying with new or revised accounting standards and, therefore, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public
companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_14"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics. Our
pipeline of full-length human bispecific antibody candidates, which we refer to as Biclonics, are generated from our technology platform. By binding to two different targets, Biclonics can be designed to simultaneously block receptors that drive
tumor cell growth and survival and to mobilize the patient&#146;s immune response by activating various killer cells to eradicate tumors. In our pre-clinical studies, our bispecific antibody candidates were effective in killing tumor cells, a result
that we believe supports their potential efficacy in the treatment of cancer. In February 2015, we commenced a Phase 1/2 clinical trial of our lead bispecific antibody candidate, MCLA-128, for the treatment of HER2-expressing solid tumors, and we
expect to report top-line results from this trial by the end of 2016. In the first quarter of 2016, we expect to commence a Phase 1/2 clinical trial with our second bispecific antibody candidate, MCLA-117, for the treatment of acute myeloid
leukemia, or AML. Additionally, we have several bispecific antibody candidates in pre-clinical development that bind to combinations of immunomodulatory molecules, including <FONT STYLE="white-space:nowrap">PD-1</FONT> and <FONT
STYLE="white-space:nowrap">PD-L1,</FONT> both of which we believe play a significant role in treating cancer. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Biclonics technology platform enables rapid functional screening of large collections of Biclonics which allows us to identify lead
candidates with multiple mechanisms of action. The Biclonics format retains the IgG format of conventional mAbs and is designed to preserve the format&#146;s key features, including stability, long half-life and low immunogenicity, when developing
our bispecific antibody candidates. We leverage industry-standard manufacturing processes and infrastructure to efficiently produce Biclonics. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead bispecific antibody candidate, MCLA-128, is currently in a Phase 1/2 clinical trial in Europe for the treatment of various solid
tumors, including breast, colorectal and ovarian cancers. We believe MCLA-128 has the potential to be a more effective treatment of HER2-expressing solid tumors than existing therapies due to its ability to inhibit cellular growth factor receptors
on tumor cells and simultaneously involve immune system cells to attack tumor cells. MCLA-128 is designed to bind to and block growth factor receptors known as HER2 and HER3, as well as recruit immune killer cells, such as NK cells and macrophages.
In our pre-clinical studies, MCLA-128 was more effective in inhibiting heregulin-driven tumor growth than HER2 or HER3 mAbs, as well as their combinations and a combination of currently approved HER2 mAbs. The production of heregulin, which is the
ligand for HER3, has been widely shown to cause cancer cells to grow and become resistant to treatment with HER2-targeted therapies. Our Phase 1/2 clinical trial of MCLA-128 will assess its safety, tolerability and anti-tumor activity. In the early
stages of the dose escalation, we have observed an objective positive effect in nine out of 22&nbsp;patients treated to date with MCLA-128 and evaluable for efficacy. In eight of those nine patients, the disease had not progressed at the completion
of the first two cycles of treatment, a condition defined as stable disease. In one patient, we observed reduction in size and disappearance of some metastatic lesions with no new tumors appearing to date, a condition defined as a partial response.
The disease progressed in the remaining seven patients evaluable for a response. Two of the eight patients initially assessed with stable disease continued without progression of the disease beyond the fourth cycle of their treatment. In the
remaining six patients initially assessed with stable disease, the disease progressed at a later evaluation date. We expect to report top-line results from the Phase 1/2 trial by the end of 2016. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our second bispecific antibody candidate, MCLA-117, is
expected to commence a Phase 1/2 clinical trial in Europe for the treatment of AML in the first quarter of 2016. AML generally has a poor prognosis and limited progress has been made in disease outcomes despite a growing AML patient population.
Clinical and pre-clinical studies suggest that treatment-resistant leukemic stem cells are a potential cause of disease relapse. MCLA-117 binds to CD3, a cell-surface molecule present on all T-cells, and to CLEC12A, a cell surface molecule present
on approximately 90 to 95% of AML tumor cells and stem cells in newly diagnosed and relapsed patients. <FONT STYLE="white-space:nowrap">MCLA-117</FONT> is designed to recruit and activate T-cells to kill AML tumor cells and stem cells. In our
pre-clinical studies, MCLA-117 killed tumor cells in blood samples of AML patients. We plan to seek orphan drug </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
designation for MCLA-117 for the treatment of AML from the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA. We are also currently evaluating MCLA-117 for the
treatment of myelodysplastic syndrome, or MDS, in pre-clinical studies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our goal is to become a leading immuno-oncology company developing bispecific antibodies to treat and potentially cure various types of cancer. Our business strategy comprises the following components:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rapidly develop our lead bispecific antibody candidate, MCLA-128, for the treatment of solid tumors</I></B><B>.&nbsp;&nbsp;&nbsp;&nbsp;</B>We are
developing MCLA-128 for the treatment of patients with HER2-expressing solid tumors, including breast, colorectal and ovarian cancers. We commenced a Phase 1/2 clinical trial of MCLA-128 in February 2015. In the early stages of the dose escalation
phase of the trial, we have observed an objective positive effect in 9 out of 22 patients treated to date with MCLA-128 and evaluable for efficacy. We expect to report top-line data from this Phase 1/2 trial by the end of 2016. We plan to submit an
IND application to the FDA for MCLA-128 to initiate a Phase 1/2 combination clinical trial in the United States in the fourth quarter of 2016. If the results of the Phase 1/2 single agent and combination clinical trials are favorable, we intend to
commence pivotal Phase 2 and Phase 3 clinical trials for MCLA-128. We believe that if MCLA-128 is successfully developed and obtains regulatory approval, it has the potential to address disease-specific challenges that are not currently being met by
existing therapies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Successfully develop our second bispecific antibody candidate, MCLA-117, for the treatment of AML.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>We are
developing MCLA-117 for the treatment of patients with AML. We submitted a CTA to the EMA in December 2015. We expect to commence a Phase 1/2 clinical trial of MCLA-117 in the first quarter of 2016 for the treatment of patients with AML to assess
its safety, tolerability and anti-tumor activity. If the results of this clinical trial are favorable, we intend to submit an IND to the FDA and initiate a Phase 2 clinical trial in the United States, as well as to commence a Phase 1/2 combination
trial and a Phase 2/3 single agent trial in Europe. We plan to seek orphan drug designation from the FDA and the EMA for MCLA-117 for the treatment of AML. We believe that if MCLA-117 is successfully developed and obtains regulatory approval, it has
the potential to transform the treatment of AML. We are also currently evaluating MCLA-117 for the treatment of MDS in pre-clinical studies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accelerate the internal discovery and development of additional immunotherapeutic bispecific antibody
candidates</I></B><B>.&nbsp;&nbsp;&nbsp;&nbsp;</B>We believe we are well positioned to expand our pipeline of Biclonics for the treatment of other forms of cancer. Our platform enables rapid functional screening of large collections of Biclonics
which allows us to identify lead candidates with multiple mechanisms of action that have the potential to kill tumor cells with high potency. We are currently evaluating Biclonics that target various combinations of checkpoint inhibitory molecules,
such as PD-1, PD-L1 and other checkpoint inhibitors, as well as combinations of checkpoint inhibitory and co-stimulatory molecules, and combinations of molecules present on cancer stem cells in pre-clinical studies. We believe that binding to
combinations of checkpoint inhibitory and/or co-stimulatory molecules provides Biclonics with the potential to activate tumor-specific T-cells to effectively kill tumor cells. In addition, by developing Biclonics that attack and kill cancer stem
cells, we believe that we may be able to eliminate the cells that cause relapse of tumor growth. In addition to these target combinations, we intend to use our platform to evaluate new Biclonics combinations. We intend to advance at least one of our
bispecific antibody candidates through pre-clinical development and into clinical trials by the end of 2018. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Seek strategic collaborative relationships.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We intend to seek strategic collaborations to facilitate the
capital-efficient development of our Biclonics technology platform and to identify potential target combinations in immuno-oncology and other therapeutic areas. We have entered into a collaboration with ONO Pharmaceutical Co., Ltd., a Japanese
pharmaceutical company, to develop bispecific antibody candidates based on our Biclonics technology platform and plan to work with other collaborators to validate and expand the use of our Biclonics platform and the development of bispecific
antibody candidates. We believe these collaborations could potentially provide significant funding to advance our bispecific antibody candidate pipeline while allowing us to benefit from the development expertise of our collaborators.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Product Pipeline </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use our technology platform to develop
Biclonics for the treatment of various types of cancer. The following table summarizes our bispecific antibody candidate pipeline: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g27z86.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview of Existing
Immunotherapeutics </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite a number of
advances in the past decade, a significant unmet need in cancer still exists. While targeted antibody therapeutics have been successful in treating some cancers, the therapeutic effects of almost all such therapies are transient. Cancer cells are
able to adapt in order to escape recognition and elimination by the immune system, thereby contributing to tumor growth and progression. Acquired resistance to cancer therapies remains a significant clinical problem with patients frequently
relapsing and the tumors metastasizing to other organs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Immunotherapy is a new class of cancer treatment that works to harness the intrinsic powers of the immune system to fight tumor cells. There are several immunotherapies that engage various aspects of the
immune system such as: (1) monoclonal antibodies with enhanced ADCC, (2) bispecific T-cell engaging molecules, (3) immunomodulatory monoclonal antibodies and (4) CAR-T and TCR therapies. While each of these therapies varies in its mechanism of
action, these therapies rely on specific components of the innate or adaptive immune system to kill tumor cells or counteract signals produced by cancer cells that suppress immune responses. The potential of immunotherapeutic approaches is best
demonstrated by the long durable remissions, exceeding 10 years, observed after checkpoint inhibitor treatment in a subset of patients with advanced melanoma. More recent evidence from clinical trials suggests that a growing list of cancers will
respond to checkpoint inhibitors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Monoclonal Antibodies with Enhanced ADCC.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Monoclonal antibodies bind to a single target expressed by
tumor cells and have been modified to more efficiently attract immune effector cells, such as NK cells and macrophages, to effectively kill tumor cells. Several mAbs with enhanced ADCC for the treatment of solid and leukemic tumors have yielded
promising results in clinical trials. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By
binding to a single target, mAbs with enhanced ADCC depend on the expression of that target on the tumor and normal tissues to leverage the advantage of enhanced tumor cell-killing while minimizing toxicity. Ideal targets for antibodies would be
solely expressed by the diseased cell and not by normal cells. Unfortunately, many of these targets are also expressed by healthy tissues. By binding to a single target, mAbs with enhanced ADCC potentially can induce autoimmune toxicity, so-called
&#147;on-target, off-tumor&#148; toxicity. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Bispecific T-Cell Engaging Molecules.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Bispecific T-cell
engaging molecules enhance a patient&#146;s immune response to tumors by re-targeting T-cells to tumor cells. These molecules have been developed for a variety of both hematological and solid tumors and are currently in clinical trials. We are aware
of a bispecific T-cell engaging molecule therapeutic that has received regulatory approval for the treatment of acute lymphoblastic leukemia as well as additional bispecific T-cell engaging molecules that are currently in clinical development.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Most T-cell engaging molecules in development are
currently based on antibody fragments connected by a flexible linker and, unlike Biclonics, do not utilize the advantages of the full-length IgG format. These molecules may have shorter half-lives than conventional mAbs, which could require
continuous infusion of the molecule or could pose manufacturing and immunogenicity challenges. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Immunomodulatory mAbs</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Immunotherapeutic strategies have been shown in clinical trials to increase the ability of the immune system to recognize and eradicate tumor
cells. Among these treatment strategies, immunomodulatory mAbs that enhance the function of T-cells have achieved noteworthy results for multiple types of cancers. Immunomodulatory mAbs that bind to molecules involved in T-cell inhibition are called
checkpoint inhibitors because they block normally negative regulators of T-cell immunity. These checkpoint inhibitors target molecules such as the cytotoxic T-lymphocyte antigen 4, or CTLA-4, and <FONT STYLE="white-space:nowrap">PD-1.</FONT>
Additionally, immunomodulatory mAbs that bind to co-stimulatory molecules involved in T-cell activation, such as the tumor necrosis factor receptors OX40 and CD137, have shown tumor cell-killing activity in pre-clinical animal models of cancer and
are currently being evaluated in early-stage clinical trials. Combinations of immunomodulatory mAbs have been observed to enhance the anti-cancer response in pre-clinical studies and in clinical trials of patients with various tumor types, but have
also been observed to result in more pronounced toxicities. We believe that Biclonics have the potential to capture the benefits of combinations of immunomodulatory mAbs, combined with more specific targeting to tumor-specific T-cells and tumor
cells, thereby potentially diminishing the toxic side effects and providing a cost-effective two-in-one therapeutic for the treatment of cancer patients. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>CAR-T and TCR Therapies</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;T-cells recognize diseased cells by receptors engaging with antigens that
are present on cancer cells. CAR-T therapy entails genetically engineering T-cells to express synthetic chimeric antigen receptors, or CARs, that direct T-cells to antigens on the surface of cancer cells. The T-cell receptor, or TCR, modifies
T-cells to express high-affinity tumor specific TCRs that recognize intra-cellular antigens present on the surface of target cells. In early-stage clinical trials, CAR-T and TCR therapies have been observed to have anti-tumor activity in a narrow
spectrum of hematologic cancers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe a key
limitation of CAR-T and TCR therapies is the need to retrieve non-compromised immune effector cells from a cancer patient, which requires a complex and costly individualized process to develop the therapy. These challenges limit their potential and
use in a variety of indications, including the treatment of solid tumors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To address patient populations not responding to single-antibody based drugs, there is an increased focus on synergistically combining immunotherapeutics in the scientific community and from
biopharmaceutical companies. Opportunities to create innovative antibody-based therapeutics lie in several technology advances, including bispecific antibodies that bind to multiple targets, Fc-optimization, which enhances the body&#146;s immune
system to mediate the killing of cancer cells, and antibody drug conjugates, or ADCs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Background on Antibodies </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The conventional antibody is a Y-shaped molecule that
consists of two identical heavy chains and two identical light chains, as shown in the figure below. These four chains pair to form two variable regions that bind to antigens, or targets, and a constant region known as the Fc region, that binds to
receptors present on effector cells in the immune system. In conventional mAbs, the variable regions are identical and bind to the same targets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g42k09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In bispecific antibodies,
the variable regions can be modified to bind to two different targets. To achieve this in the full-length IgG format, two different heavy chains and two identical light chains, also referred to as the common light chain, are combined. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In both conventional mAbs and IgG bispecific antibodies, the
Fc region can bind to Fc receptors present on effector cells. This binding results in the recruitment and activation of immune effector cells and amplifies the immune system&#146;s response to antigens bound by the variable region of the antibody.
This process is called antibody dependent cytotoxicity, or ADCC. The Fc region can be modified to enhance ADCC so as to generate a more potent immune response against a particular target. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Biclonics Platform </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a pipeline of Biclonics generated from our technology platform. Our platform enables the rapid identification of
immunotherapeutics with the potential to produce tumor cell-killing activity, and allows for the flexible and rapid generation of Biclonics against any particular target pair. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By binding to two different targets, Biclonics can be
designed to block receptors that drive tumor cell growth and survival and to mobilize the patient&#146;s immune response by activating various killer cells to eradicate tumors. We believe our Biclonics platform allows us to approach cancer treatment
through multiple modes of action: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Blocking combinations of growth factor receptors that drive tumor cell growth and relapse while simultaneously recruiting immune effector cells
through enhanced ADCC.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Biclonics may be generated for various combinations of growth factor receptors that play a role in tumors with different molecular profiles, while a modification in the Fc region of the Biclonics
facilitates the enhanced recruitment of immune effector cells, such as NK cells and macrophages, to directly kill tumor cells through ADCC. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Activating T-cells to kill tumor cells by binding to CD3 expressed on T-cells and a tumor-associated target.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>CD3
is a cell-surface molecule present on all T-cells. Biclonics that are designed to simultaneously bind to CD3 and a tumor-associated target, which allows for T-cell recruitment and engagement to selectively kill tumor cells.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Blocking two checkpoint inhibitory pathways for more efficient T-cell activation.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Cancer cells are able to block
the tumor-killing function of T-cells through the expression of inhibitory molecules. Scientific research has shown that combinations of mAbs are more potent than single mAbs when used against these inhibitory molecules to unblock and revive this
mechanism of T-cells which kills tumor cell targets. Biclonics can be designed to prevent the blocking of T-cells by cancer cells while retaining the advantages of specific targeting in the tumor environment. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Blocking a checkpoint inhibitory pathway while simultaneously providing a co-stimulatory signal for more efficient activation of
T-cells.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In addition to being blocked by inhibitory molecules, tumor specific T-cells may simultaneously require an activation signal to engage in tumor cell-killing. Biclonics can be designed to concurrently alleviate
the blocking of T-cells and deliver the signals required to activate the killing potential of <FONT STYLE="white-space:nowrap">T-cells.</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Simultaneously targeting a growth factor receptor expressed by tumor cells and an immunomodulatory molecule involved in blocking tumor-specific
T-cells.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Growth factor receptors like epidermal growth factor receptors, or EGFR, and HER2 are expressed on many tumors. Biclonics can be designed to target such growth factor receptors while delivering an activation
signal or de-blocking signal to T-cells. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our process to select lead Biclonics for clinical development takes approximately 12 months and is illustrated below. We use our human antibody generation and Biclonics production technologies to rapidly
build large collections of Biclonics directed against particular target pairs. We then test these collections in cell-based functional assays to identify Biclonics that have differentiated modes of action. We select the most potent Biclonics and
evaluate them in multiple <I>in vitro</I> and <I>in vivo</I> assays to identify lead candidates for clinical development. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Selection of Lead Biclonics </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g30o93.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Biclonics technology
platform includes the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Human antibody generation.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our human antibody platform is comprised of transgenic mice, which we refer to as MeMo,
used to generate human antibodies and phage display&nbsp;for the generation of panels of common light chain human mAbs. MeMo harnesses the power of the <I>in vivo</I> immune system to directly yield antibodies with high potency, specificity,
solubility and low immunogenicity. Using our human antibody generation technology, we produce large and diverse panels of high-affinity antibodies against a broad variety of targets. We believe this approach enhances the discovery and development of
high-quality human antibodies that, through the common light chain, are ready to be inserted into the Biclonics format. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The full-length Immunoglobulin G format.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The Biclonics format retains several of the favorable attributes of
conventional human IgG mAbs, including their stability and predictability during manufacturing as well as their long half-life and low immunogenicity during treatment of patients. Biclonics consist of two different heavy chains that need to stably
form, or heterodimerize, inside a manufacturing cell line. We insert amino acids with opposite charges in each of these heavy chains to efficiently drive this process. The use of a single, or common, light chain in all human antibodies derived from
MeMo is designed to have the heavy chains pair with the correct, common light chain to form functional antigen binding regions. The combination of these approaches prevents the need for additional, more artificial techniques, such as the use of
linkers or chemical reactions, to force the pairing of different parts of the bispecific antibody. The resulting Biclonics are bispecific heterodimeric IgG antibodies that closely mimic IgG antibodies that are produced naturally by the immune
system. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Biclonics format
enables us to make modifications to the Fc region of the IgG antibody in order to enhance or limit effector functions associated with this part of the molecule. This strategy has been successfully executed with conventional therapeutic mAbs. In
order to enhance efficacy and promote immunotherapeutic activity, we can use genetically altered cell lines used in production to generate Biclonics that are enhanced for ADCC, resulting in the improved ability to recruit NK cells and macrophages.
This ADCC enhancement has been made to our lead bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-128.</FONT> In order to improve safety and tolerability, we can modify our Biclonics to prevent the excessive release of signaling
proteins called cytokines which can overstimulate the immune system. This process is called Fc-silencing as it blocks the ability of our Biclonics to bind to certain protein receptors on cells, known as Fc receptors, which are associated with
cytokine release. We utilize Fc silencing in the design of our bispecific antibody candidate, MCLA-117. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>High-throughput functional screening.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The panels of target-specific human antibodies are introduced as pairs of
DNA constructs into mammalian cells. The common light chain format and modified Fc region of the IgG antibody ensure the secretion of pure Biclonics&nbsp;into the cell culture medium. The medium of thousands of cell cultures is harvested and
individually used in cell- and tissue-based functional assays to identify Biclonics with differentiated modes of action. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For example, the chart below shows the results of a pre-clinical study in which 495 different Biclonics targeting HER2 and HER3 were
functionally screened against tumor cell samples, with and without heregulin present. From the 80 candidates depicted in the chart, 40 exhibited superior inhibition of cell growth compared to Herceptin, a drug commonly prescribed for the treatment
of breast cancer, and were selected in the process leading to identification of MCLA-128. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g13y89.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Benefits of Biclonics </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe our Biclonics technology platform provides the
following benefits: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biclonics&nbsp;are stable, bispecific, full-length human IgG antibodies with no linkers or fusion
proteins.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Biclonics retain the IgG format of antibodies that are produced naturally by the immune system. Additionally, in contrast to many other bispecific antibody formats, Biclonics do not require linkers to force
the correct pairing of heavy and light chains or exploit fusion proteins to add functionality to the molecule. These qualities minimize time-consuming engineering efforts and allow us to create Biclonics with predictable behavior during pre-clinical
development. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biclonics preserve the stability, behavior and adaptability of normal IgG antibodies.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Biclonics&nbsp;are based on
the robust and commonly used IgG format to yield the favorable <I>in vivo</I>&nbsp;qualities associated with conventional mAbs, such as stability, long half-life and low immunogenicity. As a result, our Biclonics format provides attractive options
for dosage schedules and methods of administration, rendering them compatible with multiple modes of action for the efficient killing of tumor cells. Further, the IgG format allows us to apply previously established technologies to further optimize
our Biclonics for therapeutic use. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biclonics can be reliably manufactured with high yields.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Because our Biclonics retain the IgG format of
antibodies, our Biclonics are manufactured using the large-scale industry-standard processes that are also used for the production of conventional mAbs, and the yields of Biclonics we obtain are comparable to those of normal IgG antibodies. In
stable cell lines, we are able to obtain over 90% of bispecific antibody formation using these processes and the IgG-based purification process results in greater than 99.8% purity for our Biclonics. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Biclonics technology platform allows for functional evaluation of Biclonics&nbsp;in the relevant therapeutic format leading to the discovery
of therapeutic candidates with differentiated </I></B><B><I>properties.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our Biclonics technology platform enables rapid functional screening of large collections of bispecific antibodies which allows us to identify
lead candidates with multiple mechanisms of action that have the potential to effectively kill tumor cells with high potency. This is an important step in the identification of lead bispecific antibody candidates with functionalities that compare
favorably against other forms of immunotherapeutics, such as conventional mAbs as well as their combinations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Bispecific Antibody Candidate Portfolio </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead bispecific antibody candidate, MCLA-128, commenced a Phase 1/2 clinical trial for the treatment of patients with solid tumors in
February 2015. Additionally, we expect to commence a Phase 1/2 clinical trial of MCLA-117 for the treatment of patients with AML in the first quarter of 2016, and we have several other bispecific antibody candidates in pre-clinical development.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>MCLA-128 </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MCLA-128 is an ADCC-enhanced Biclonics that is designed to
bind to HER2 and HER3-expressing solid tumor cells, including breast, colorectal and ovarian tumor cells. The scientific rationale for targeting HER2, or human epidermal growth factor receptor 2, and HER3, or human epidermal growth factor receptor
3, is that HER2 is amplified in many solid tumors and is associated with poor prognosis and the activation of HER3 causes cancer cells to be or to become resistant to treatment. On the surface of tumor cells, HER2 preferably pairs, or dimerizes,
with HER3, and the resulting pair drives malignant progression of HER2-expressing cancer cells. Heregulin, which is the ligand for HER3, causes cancer cells to grow and become resistant to treatment with HER2-targeted therapies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have designed MCLA-128 to overcome the inherent and acquired resistance of tumor cells to
HER2-targeted therapies using two different mechanisms. The first mechanism blocks growth and survival pathways to stop tumor expansion, while preventing tumor cells from escaping through activation of the HER3/heregulin pathway. The second
mechanism, enhanced ADCC, involves the recruitment and enhancement of immune effector cells, such as NK cells and macrophages, to directly kill the tumor through a modification of the Fc region. This dual mechanism of action is illustrated in the
graphic below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>MCLA-128 Mechanism of Action
</U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g10p58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that MCLA-128
has the potential to be a more effective treatment of HER2-expressing solid tumors than existing therapies due to its ability to inhibit cellular growth factor receptors on tumor cells and simultaneously recruit cells of the immune system to attack
tumor cells. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Market Overview </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The National Cancer Institute estimates that 231,840 new
cases of breast cancer, 132,700 new cases of colorectal cancer, 221,200 new cases of lung cancer, 21,290 new cases of ovarian cancer, 74,000 new cases of bladder cancer and 24,590 new cases of stomach cancer will be diagnosed in the United States in
2015. Based on a market survey we commissioned from Specialized Medical Services-oncology BV in 2012, we estimate that HER2 is expressed in 28% of cases of breast cancer, 34% of cases of colorectal cancer, 22% of cases of lung cancer, 25% of cases
of ovarian cancer, 45% of cases of bladder cancer and 23% of cases of stomach cancer. Herceptin, Avastin, and Erbitux are drugs commonly prescribed for the treatment of these types of cancers. Worldwide sales of these drugs in 2014 were
approximately $6.8&nbsp;billion, $7.0 billion and $1.9&nbsp;billion, respectively. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Pre-Clinical Studies </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In our pre-clinical studies of HER2-expressing tumor cell lines, we measured the impact of MCLA-128 on heregulin-driven growth and cellular changes, characterized by a metastatic phenotype. In these
studies, we observed that both growth and metastatic characteristics were poorly blocked by therapeutic mAbs targeting HER2 and HER3, while the application of MCLA-128 resulted in the inhibition of heregulin induced changes in cultures of cancer
cells. MCLA-128 also blocked activation of two key signaling pathways for the growth and survival of tumor cells more effectively than the combination of the currently approved therapeutic HER2 mAbs, Herceptin (trastuzumab) and Perjeta (pertuzumab).
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As shown in the chart below, the administration of MCLA-128 reduced heregulin-driven tumor
growth at significantly lower concentrations than mAbs targeting HER2 or HER3 and the combination of Herceptin and Perjeta. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g90v08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MCLA-128 also blocked
phosphorylation and activation of key proteins in the signaling pathways for the cell growth and survival of cancer cell lines, a result that was not observed with the combination of HER2 mAbs, Herceptin and Perjeta. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also studied the ADCC activity of MCLA-128 in cell lines
expressing different types of Fc receptors. As shown in the two charts below, because MCLA-128 is ADCC enhanced, it was able to bind and activate Fc receptors required for the recruitment of immune killer cells regardless of the receptor affinity of
the patient. Studies have estimated that more than 50% of the patient population carry Fc receptors that are of low affinity and are poorly activated by therapeutic antibodies such as Herceptin. We have observed in our pre-clinical studies that
MCLA-128 was also more potent than Herceptin in activating immune killer cells carrying low affinity Fc receptors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Fc Receptor Activation by MCLA-128
(Fc</U></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><B></B><B>R Subtype) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g80p21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g86z12.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the pre-clinical studies, we also compared the ability of MCLA-128 to inhibit the <I>in
vivo</I> growth of cell lines such as JIMT-1, which is an aggressive breast cancer line resistant to HER2-targeted therapies. In these studies, we administered four doses of MCLA-128 at 2.5 mg/kg. The MCLA-128-treated mice experienced as high as a
58% reduction of their tumor size during the 21-day treatment period, compared to a less than 11% reduction after administration of a combination of Herceptin and Perjeta. Regrowth of the tumor was observed after treatment was halted on day 21. This
result is illustrated in the chart below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g08g41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Analysis of tumors taken
from mice at day 21 showed that HER3 signaling was effectively blocked when treated with MCLA-128 whereas no effect was observed with the combination of Herceptin and Perjeta. Pre-clinical studies are currently being conducted to evaluate whether
tumor suppression can be sustained by continuing treatment over the 60 day observation period. In addition, a higher percentage (60%) of mice treated with MCLA-128 survived beyond 60 days than mice receiving either the vehicle or the combination of
Herceptin and Perjeta. This result is illustrated in the chart below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g95h87.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Clinical Development of MCLA-128 </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2015, we commenced an open-label Phase 1/2
clinical trial of MCLA-128 for the treatment of HER2-expressing solid tumors. To date, we are currently engaged in the dose escalation phase of the trial and have observed early positive data based on doses below the optimal dose range projected
from our pre-clinical studies. The trial is designed to enroll up to 120&nbsp;patients with solid tumors that are relapsed or refractory to at least one prior regimen of available standard treatment or for whom no curative therapy is available. We
plan to conduct the trial in at least six clinical sites in Europe. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The first part of the trial is a dose escalation study, in which we intend to enroll at least 24 evaluable patients with advanced solid tumors, followed by a second part of the trial, in which we intend
to enroll up to 68&nbsp;evaluable patients with breast, ovarian and colorectal cancers, to further study the safety, tolerability and clinical efficacy of MCLA-128. For this Phase 1/2 trial, we have implemented an exploratory biomarker investigation
using tumor tissue and blood samples from patients. The biomarkers we are evaluating include heregulin expression, HER2 and HER3 receptor expression and PI3K/AKT pathway activation status, which refers to an intracellular pathway regulating
processes such as cell survival, cell proliferation and cell growth. We believe this approach, in conjunction with genetic profiling, will allow for the validation of biomarker assays and will provide guidance for enrolling additional patients based
on relevant biomarkers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The primary endpoint of
Part 1 of our clinical trial is to determine the maximum recommended dose of MCLA-128. The secondary endpoints of Part 1 consist of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the pharmacodynamic, or PD, response to MCLA-128 in tumor tissue and/or surrogate tissues; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the pharmacokinetic, or PK, profile, including total exposure, maximum concentration clearance, volume of distribution and half-life;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the serum concentration of anti-drug antibodies to MCLA-128; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the frequency and nature of adverse events. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also plan to evaluate other anti-tumor parameters, such as: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the objective response rate, or ORR, which is the proportion of patients in whom a complete response or partial response was observed;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the clinical benefit rate, or CBR, which is proportion of patients in whom a complete response, partial response, or stable disease was observed (where
the stable disease duration is a minimum of 16 weeks/4 months) according to standard criteria; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the duration of response, or DOR, which is the time from the initial response until documented tumor progression; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">progression free survival, or PFS, which is the time from treatment initiation to objective tumor progression or death from any cause; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">patient survival rates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 10, 2015, we have enrolled 28 patients with metastatic cancers of the breast, stomach, colon, lung, ovary, gallbladder,
salivary gland, skin (melanoma or non-melanoma), oral cavity, duodenum or gastro-esophageal junction in the trial, all of whom are currently evaluable for interim safety. In these patients, the administration of MCLA-128 has been well-tolerated up
to a dose of 900&nbsp;mg. The most frequent adverse events in the trial were mild to moderate infusion-related reactions, diarrhea, vomiting, fatigue, skin rash, sore mouth and shortness of breath. Decreased numbers of neutrophils were also
reported. There has been one serious adverse event in Part 1 of the trial, reported as an infusion-related reaction which required overnight hospitalization. In the early stages of the dose escalation phase of the trial, we have observed an
objective positive effect in nine out of the 22 patients treated to date and evaluable for efficacy. In eight of those nine </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
patients, treated with doses ranging between 80&nbsp;mg and 750&nbsp;mg of MCLA-128, the disease had not progressed at completion of the first two cycles of treatment, a condition defined as
stable disease, and in one patient with lung cancer, who was treated with a dose of 360 mg of MCLA-128, we observed reductions in tumor size and disappearance of some metastatic lesions with no new tumors appearing, a condition defined as a partial
response. This partial response has been confirmed at later evaluation dates. The disease progressed in the remaining patients evaluable for a response. Two of the eight patients initially assessed with stable disease continued without progression
of the disease beyond the fourth cycle of their treatment. In the remaining six patients initially assessed with stable disease, the disease progressed at a later evaluation date. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In Part 2 of the clinical trial, we plan to treat patients
with the HER2-expressing cancer cells of three distinct tumor types, with the option to enroll patients with additional tumor types. We intend to enroll up to 100&nbsp;patients in this part of the trial, consisting of approximately 40 patients with
metastatic breast cancer, 20 patients with metastatic colorectal cancer and 40 patients with metastatic ovarian cancer. The primary endpoints of Part 2 of the trial are the frequency and nature of adverse events and the CBR. The secondary endpoints
of Part 2 are equivalent to those established for Part 1 of the trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect to report interim safety, PK profile and efficacy results from Part 1 of this Phase 1/2 trial in the first quarter of 2016 and interim safety and efficacy results from Part 2 of this trial in
the second half of 2016. However, interim results of a clinical trial do not necessarily predict final results. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to report top-line data from this Phase 1/2 trial by the end of 2016. We plan to submit an IND application to the FDA for
MCLA-128 to initiate a Phase 1/2 combination clinical trial in the United States in the fourth quarter of 2016. If the results of the Phase 1/2 single agent and combination clinical trials are favorable, we intend to commence pivotal Phase 2 and
Phase 3 clinical trials. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>MCLA-117
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MCLA-117 for AML </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MCLA-117 is a Biclonics&nbsp;that is designed to bind to
CD3, a cell-surface molecule present on all T-cells, and to CLEC12A, a cell surface molecule present on AML tumor cells and stem cells. CLEC12A is not found on normal blood stem cells nor on cells that give rise to red blood cells and platelets nor
is it present on other non-hematopoietic cells in the body. This is in contrast to the expression patterns of CD123 and CD33, which are present on normal blood stem cells, and in the case of CD33, also the cells that give rise to red blood cells and
platelets. Both CD123 and CD33 are being explored as targets for AML therapy. We believe that the expression pattern of CLEC12A makes it an attractive and differentiated molecule for targeted therapy in cancer patients. Moreover, CLEC12A is
expressed on approximately 90 to 95% of newly diagnosed and relapsed cases of AML, and we believe that many patients with AML could potentially benefit from treatment with MCLA-117. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By binding to CD3 and CLEC12A, MCLA-117 is designed to recruit and activate T-cells to kill
CLEC12A-expressing AML tumor cells and stem cells. AML tumor stem cells are thought to be resistant to current chemotherapeutic treatment regimens, and the inability to eliminate these cells with conventional therapies is thought to significantly
contribute to disease relapse in AML patients. We believe that elimination of this leukemic stem cell population by treatment with MCLA-117 may prevent recurrence of the tumor. The mechanism of action of MCLA-117 is illustrated in the graphic below.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>MCLA-117 Mechanism of Action
</U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g68t71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unlike some other
bispecific antibody formats, the full-length IgG format of MCLA-117 and its associated longer half-life keeps it from having to be administered through continuous infusion using infusion pumps. In addition, through Fc-silencing, MCLA-117 is designed
to avoid binding to Fc receptors present on macrophages and other blood cells that could result in toxicity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that MCLA-117 could be developed as induction therapy, as consolidation therapy to treat minimal residual disease and as rescue
therapy for patients with relapsed or refractory AML. We intend to explore its use both as a single agent and in combination with commonly used chemotherapy agents and other treatment regimens of AML. We expect the safety profile of MCLA-117 to be
favorable based on the restricted expression of CLEC12A in human tissues which is anticipated to result in manageable neutropenia. We also expect infusion related reactions based on the observed level of cytokine release upon co-culture with blood
cells, which can be mitigated by gradual dose increments and by providing co-medication when required. As CLEC12A is not expressed on megakaryocyte and erythroid progenitor cells, we expect the application of MCLA-117 would not result in a decrease
of platelet counts or red blood cells. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our
pre-clinical studies, MCLA-117 specifically targeted and killed AML tumor cells mediated by a high affinity of the Biclonics for CLEC12A and a relatively low affinity for CD3. In these studies, MCLA-117 recruits T-cells to selectively kill tumor
cells in blood samples of AML patients containing an unfavorable ratio of T-cells to AML tumor cells. We observed that 1,000 ng/ml of MCLA-117 was sufficient to induce the elimination of tumor cells. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As shown in the figure below, treatment of an AML
patient&#146;s blood samples with MCLA-117 resulted in the efficient killing of AML tumor cells in our pre-clinical studies. An unmanipulated primary blood sample containing both CLEC12A positive patient tumor cells and T-cells was cultured for 10
days with either a dosage </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of 1,000 ng/ml of MCLA-117 or a dosage of a control Biclonics that does not bind to CLEC12A but retains CD3 binding activity. On day 10, the percentage of AML tumor cells in the culture dish
dosed with MCLA-117 had decreased from 93% to 1% while the proportion of T-cells had increased from 5% to 95%, indicating that CD3 positive T-cells had been effectively activated to proliferate, engage and kill the AML tumor cells by MCLA-117. In
contrast, the percentage of AML tumor cells in the culture dish dosed with a control Biclonics had slightly decreased from 93% to 81% while the proportion of T-cells had only increased from 5% to 16%, indicating that binding to CLEC12A by MCLA-117
was required to result in the efficient killing of AML tumor cells. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g87h41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We submitted a CTA to
the EMA in December 2015 and intend to commence a Phase 1/2 clinical trial of MCLA-117 in the first quarter of 2016 for the treatment of patients with AML to assess its safety, tolerability and anti-tumor activity. For the anticipated Phase 1/2
clinical trial, we plan to enroll adult patients with tumors of all AML subtypes. Patients with relapsed or refractory disease, newly diagnosed, or untreated AML patients who are older than 65 years and are usually not eligible as candidates for
intensive or conventional approved treatments would all be eligible for enrollment in the trial. We expect to enroll up to 50 patients in this trial, consisting of up to 31 patients in Part 1, the dose escalation phase, and up to 15 patients in Part
2, the safety dose expansion phase. We expect the primary endpoints of the Phase 1/2 trial to be the assessment of the safety and tolerability of MCLA-117 in order to determine the maximum tolerated dose and frequency of administration and to
evaluate the preliminary anti-leukemic activity of MCLA-117 in AML. The secondary endpoints will include: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the assessment of the PK profile of an MCLA-117 intravenous infusion as a single agent; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the investigation of the PD effects of MCLA-117; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the determination of incidence and serum titer of anti-drug antibodies against MCLA-117; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the evaluation of the preliminary efficacy and anti-leukemic activity of MCLA-117. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the results of the clinical trial are favorable, we intend
to submit an IND to the FDA and initiate a Phase 2 clinical trial in the United States, as well as to commence a Phase 1/2 combination trial and a Phase 2/3 single agent trial in Europe. We believe MCLA-117 may qualify for orphan drug designation in
the United States and in Europe for the treatment of AML, and we plan to seek orphan drug designation from the FDA and the EMA for the treatment of AML. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MCLA-117 for MDS </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are also currently evaluating MCLA-117 for the treatment of MDS in pre-clinical studies. MDS is a disease
that occurs when the blood-forming cells in the bone marrow lose the ability to develop normally. Patients with MDS have lower numbers of one or more types of cells in the blood such as red blood cells and platelets and are at higher risk to develop
AML. Similar to AML, we believe that the expression pattern of CLEC12A makes it an attractive and differentiated molecule for targeted therapy in patients with MDS. CLEC12A is expressed on approximately 89% of patients with MDS, and we believe that
many patients with MDS could potentially benefit from treatment with <FONT STYLE="white-space:nowrap">MCLA-117.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Bispecific Antibody Candidates </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MCLA-158 </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MCLA-158 is an ADCC-enhanced Biclonics that is designed to
bind to Lgr5 and EGFR targets expressed by cancer stem cells. MCLA-158 is designed to kill cancer stem cells using two different mechanisms of action. The first mechanism of action involves blocking growth and survival pathways in tumor stem cells.
The second mechanism of action involves the recruitment and enhancement of immune effector cells, and is similar to the mechanism of action used by MCLA-128. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MCLA-134 </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MCLA-134 is a Biclonics&nbsp;that is designed to bind to
a combination of two immunomodulatory targets expressed by <FONT STYLE="white-space:nowrap">T-cells,</FONT> PD-1 and TIM-3. MCLA-134 is designed to activate unresponsive tumor infiltrating T-cells to kill cancer cells. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MCLA-145 </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MCLA-145 is a Biclonics&nbsp;that is designed to bind to
a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition. MCLA-145 is designed to simultaneously reverse immune system suppression at the tumor site while attracting immune effector cells to directly kill the
targeted tumor. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-Clinical Discovery
Programs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to leverage our
Biclonics technology platform to identify multiple additional bispecific antibody candidates and advance them to clinical development. Our current focus is on a number of immunotherapeutic targets and pathways that have demonstrated promising tumor
killing ability in early-stage clinical trials and scientific literature. We are currently evaluating Biclonics that target combinations of checkpoint inhibitory molecules, such as PD-1, PD-L1 and other checkpoint inhibitors, as well as combinations
of checkpoint inhibitory and co-stimulatory molecules, and combinations of molecules present on cancer stem cells. Using our platform, we will continue to evaluate new targets and combinations to identify potential candidates with the highest
immunotherapeutic potential and select those candidates to be advanced into clinical trials. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Collaboration Agreements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As part of our business strategy, we intend to increase the number of our research collaborations in order to derive further value from our Biclonics platform and more fully exploit its potential.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>ONO Pharmaceutical </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2014, we entered into a strategic research and
license agreement with ONO, under which we granted ONO an exclusive, worldwide, royalty-bearing license to research, test, make, use and market bispecific antibody candidates based on our Biclonics technology platform with undisclosed targets.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ONO paid us a non-refundable upfront fee of
&#128;1.0&nbsp;million, and we are eligible to receive up to an aggregate of &#128;34.0&nbsp;million in milestone payments upon achievement of specified research and clinical development </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
milestones. To date, we have achieved two of the specified pre-clinical milestones under this research and license agreement and have received an aggregate of &#128;1.0&nbsp;million in milestone
payments. For products commercialized under this agreement, if any, we are also eligible to receive a mid-single digit royalty on net sales. For a designated period, which may include limited time periods following termination of this agreement, in
certain circumstances we and our affiliates are prohibited from researching, developing or commercializing bispecific antibodies against the undisclosed target combinations that are the subject of this agreement. ONO also provides funding for our
research and development activities under an agreed-upon plan. This research and license agreement will expire after all milestone payments have been received and all related patent rights have expired, unless terminated earlier. ONO has the right
to terminate this agreement at any time for any reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for uncured material breach. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Manufacturing </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Biclonics technology platform relies on third parties
for biological materials. We currently generate batches of lead bispecific antibody candidates in our own laboratories for initial pre-clinical studies using standardized procedures. We rely on and expect to continue to rely on third party contract
manufacturing organizations, or CMOs, for the supply of current good manufacturing practice-grade, or cGMP-grade, clinical trial materials and commercial quantities of our bispecific antibody candidates and products, if approved. We currently do not
have any agreements for the commercial production of raw materials, but we have contracted with Boehringer Ingelheim, a biopharmaceuticals CMO, for the manufacturing of MCLA-128 and MCLA-117. We believe that the standardized Biclonics manufacturing
process can be transferred to a number of other CMOs for the production of clinical and commercial supplies of our Biclonics in the ordinary course of business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sales and Marketing </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not yet defined our sales, marketing or product distribution strategy for MCLA-128, MCLA-117 or any of our other bispecific
antibody candidates because our bispecific antibody candidates are still in pre-clinical or early-stage clinical development. Our commercial strategy may include the use of strategic partners, distributors, a contract sale force, or the
establishment of our own commercial and specialty sales force. We plan to further evaluate these alternatives as we approach approval for one of our bispecific antibody candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We compete directly with companies that focus on immuno-oncology and companies dedicating their resources to
novel forms of cancer therapies. We also face competition from academic research institutions, governmental agencies and other various public and private research institutions. With the proliferation of new drugs and therapies into oncology, we
expect to face increasingly intense competition as new technologies become available. Any bispecific antibody candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available
in the future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our competitors have
significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being
concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also
compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary
for, our programs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The key competitive factors
affecting the success of all of our therapeutic bispecific antibody candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third-party payors. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial opportunity could be reduced or eliminated if
our competitors develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe effects than any products that we may develop. Our competitors also may obtain
FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if our bispecific
antibody candidates achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to currently marketed therapies, there are also a number of products in late-stage clinical development to treat cancer,
including other bispecific antibodies or similar molecules. Our closest competitors in this area include Affimed N.V., OncoMed Pharmaceuticals, Inc., Genmab A/S, MacroGenics, Inc., Merrimack Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc. and
Xencor, Inc. These bispecific antibody candidates in development may provide efficacy, safety, dosing convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any
of our bispecific antibody candidates for which we obtain marketing approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We strive to protect and enhance the proprietary technologies, inventions, and improvements that we believe are important to our business, including seeking, maintaining, and defending patent rights,
whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United
States related to our proprietary technology, inventions, improvements, platforms and bispecific antibody candidates that are important to the development and implementation of our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2015, our patent portfolio consisted of eight issued U.S. patents, 12&nbsp;pending U.S.
patent applications (three of which we have received a notice of allowance from the USPTO), and 27 issued foreign patents including four issued European patents that have been validated in many European countries, and 71 pending foreign
applications. These patents and patent applications include claims directed to specific bispecific antibody candidates, our technology platform and products based on our technology platform. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2015, our patent portfolio related to our bispecific antibody candidate MCLA-128 is at the
stage of PCT filing (PCT filed February 27, 2015; expected expiry not earlier than February 27, 2035) and is expected to enter national phases in early 2016. Claims are directed to MCLA-128 composition of matter and methods of using MCLA-128 to
treat subjects (at risk of) having a ErbB-2 and/or ErbB3 positive tumor. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2015, our patent portfolio related to our bispecific antibody candidate MCLA-117 consists of 1&nbsp;PCT application, filed on September&nbsp;27, 2013, which entered national phases in
the United States, Europe and 14&nbsp;other foreign countries with an expected expiry not earlier than September&nbsp;27, 2033. In addition, we filed a new priority patent application related to MCLA-117 on July&nbsp;10, 2015, which we plan to file
as a PCT filing no later than July&nbsp;10, 2016. Claims are directed to the <FONT STYLE="white-space:nowrap">MCLA-117</FONT> composition of matter and methods of using MCLA-117 in the treatment or prevention of MDS, chronic myelogenous leukemia, or
CML, or AML. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2015, our patent
portfolio related to our bispecific antibody candidate MCLA-158 is at the stage of priority filing (filed on October 23, 2015; PCT filing date no later than October 23, 2016) and is expected to enter national phases in the United States, Europe and
approximately 14 other foreign countries with an expiry no earlier than October 23, 2036. Claims are directed to the MCLA-158 composition of matter and methods of using MCLA-158 in the treatment or prevention of various solid tumors. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2015, our patent portfolio related to our MeMo mouse consists of four
pending U.S. applications, nine issued foreign patents including one issued European patent that has been validated in many countries, and 10 pending foreign applications, all with an expected expiry not earlier than June&nbsp;29, 2029. Claims are
directed to a common light chain mouse and methods of producing antibodies by exposing the mouse to an antigen. Opposition against our issued Australian patent has been filed by Regeneron Pharmaceuticals Inc. and is currently ongoing. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to continue to expand our intellectual property
estate by filing patent applications directed to dosage forms, methods of treatment and additional compositions created or identified from our technology platforms and ongoing development of our bispecific antibody candidates. Specifically, we seek
patent protection in the United States and internationally for novel compositions of matter directed to aspects of the molecules, basic structures and processes for manufacturing these molecules and the use of these molecules in a variety of
therapies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our patent portfolio is intended to
cover, but is not limited to, the composition of matter of our bispecific antibody candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to
our business. We also rely on trademarks, trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also rely on know-how, continuing technological innovation
and in-licensing opportunities to develop, strengthen, and maintain our proprietary positions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and
enforce our patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third
parties. For important factors related to our proprietary technology, inventions, improvements, platforms and bispecific antibody candidates, please see the section entitled &#147;Risk Factors&#151;Risks Related to Intellectual Property and
Information Technology.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also rely on
trade secret protection for our confidential and proprietary information. Although we take steps to protect our confidential and proprietary information as trade secrets, including through contractual means with our employees and consultants, third
parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our
policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements
provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third
parties except in specific circumstances. In the case of employees, such agreements provide that all inventions conceived by the individual. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are subject to extensive regulation. We expect our bispecific antibody candidates to be regulated as biologics. Biological products are
subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&amp;C Act and the PHS Act and
their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological
products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. Biological Products Development Process </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process required by the FDA before a biologic may be
marketed in the United States generally involves the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, and pre-clinical animal trials and applicable requirements
for the humane use of laboratory animals and formulation studies in accordance with applicable regulations, including good laboratory practices, or GLPs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of an investigational new drug, or IND, application, which must become effective before human clinical trials may begin;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">performance of adequate and well-controlled human clinical trials according to the FDA&#146;s regulations commonly referred to as good clinical
practice, or GCP, regulations and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity, and potency from results of nonclinical
testing and clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance
with current Good Manufacturing Practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s identity, strength, quality and purity; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">FDA review and approval, or licensure, of the BLA. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before testing any biological bispecific antibody candidate
in humans, the bispecific antibody candidate enters the pre-clinical testing stage. Pre-clinical tests, also referred to as nonclinical trials, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies
to assess the potential safety and activity of the bispecific antibody candidate. The conduct of the pre-clinical tests must comply with federal regulations and requirements including GLPs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The clinical trial sponsor must submit the results of the pre-clinical tests, together with manufacturing
information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some pre-clinical testing may continue even after the IND is submitted. The IND automatically becomes effective
30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The
FDA may also impose clinical holds on a biological bispecific antibody candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA
authorization and then only under terms authorized by the FDA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Clinical trials involve the administration of the biological bispecific antibody candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not
employed by or under the trial sponsor&#146;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND.
Clinical trials must be conducted and monitored in accordance with the FDA&#146;s regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent. Further, each clinical trial must be
reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers
such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Human clinical trials are typically conducted in three
sequential phases that may overlap or be combined: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 1. The biological bispecific antibody candidate is initially introduced into healthy human subjects and tested for safety. In the case of some
products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 2. The biological bispecific antibody candidate is evaluated in a limited patient population to identify possible adverse effects and safety
risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at
geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Post-approval clinical trials, sometimes referred to as Phase
4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During all phases of clinical development,
regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND
safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other trials, tests in laboratory animals or<I> in vitro</I> testing that suggest a significant risk for human
subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor
determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the
information. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.
Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the biological bispecific antibody candidate has been
associated with unexpected serious harm to patients. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical trials of FDA-regulated products, including
biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and
investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be
delayed until the new product or new indication being studied has been approved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Concurrent with clinical trials, companies usually complete additional animal trials and must also develop additional information about the physical characteristics of the biological bispecific antibody
candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act
emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the bispecific antibody candidate and, among other
things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to
demonstrate that the biological bispecific antibody candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. Review and Approval Processes </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the completion of clinical trials of a biological
bispecific antibody candidate, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal trials, human trials, information on the
manufacture and composition of the product, proposed labeling and other relevant information. In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the
biological bispecific antibody candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. A sponsor who is
planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP,
within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been
granted. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Prescription Drug User Fee
Act, or PDUFA, as amended, each BLA must be accompanied by a user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first
application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is
substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be
resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA
reviews the BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP
requirements to assure and preserve the product&#146;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or
efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the
recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS,
is necessary to assure the safe use of the biological bispecific antibody candidate. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before approving a BLA, the FDA will inspect the facilities
at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product
within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the submission of relevant data
and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than the
applicant interprets the same data. If the FDA decides not to approve the BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified by the FDA. The
deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to
place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a product receives regulatory approval, the approval may be significantly limited to
specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the
product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical
trials, sometimes referred to as Phase IV clinical trials, designed to further assess a biological product&#146;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been
commercialized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">One of the performance goals
agreed to by the FDA under the PDUFA is to review 90% of standard BLAs in 10 months from the filing date and 90% of priority BLAs in six months from the filing date, whereupon a review decision is to be made. The FDA does not always meet its PDUFA
goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional
information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Orphan Drug Designation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000
individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and marketing the drug for this type of disease or condition will be recovered from
sales in the United States. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.
Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may
not approve any other application to market the same drug for the same indication for a period of seven&nbsp;years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the
manufacturer with orphan exclusivity is unable to assure sufficient quantities of the approved orphan designated product. Competitors, however, may receive approval of different products for the indication for which the orphan product has
exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains
approval of the same biological product as defined by the FDA or if our bispecific antibody candidate is determined to be contained within the competitor&#146;s product for the same indication or disease. If a drug or biological product designated
as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan product exclusivity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Expedited Development and Review Programs </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has a Fast Track program that is intended to
expedite or facilitate the process for reviewing new biological products that meet certain criteria. Specifically, new biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or
condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new
biologic may request that the FDA designate the biologic as a Fast Track product at any time during the clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a
rolling basis before the complete application is submitted, if the sponsor provides a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any
required user fees upon submission of the first section of the application. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review
and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or
prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new biological product designated for priority review in an effort to facilitate the review.
Additionally, a product may be eligible for accelerated approval. Biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing
treatments may be eligible for accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to
predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the
availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biological product subject to accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition,
the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast Track designation, priority review and accelerated
approval do not change the standards for approval but may expedite the development or approval process. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted in 2012, the FDA
established a Breakthrough Therapy Designation which is intended to expedite the development and review of products that treat serious or life-threatening diseases or conditions. A breakthrough therapy is defined as a drug that is intended, alone or
in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more
clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the features of Fast Track designation, as well as more intensive FDA interaction and guidance. The
Breakthrough Therapy Designation is a distinct status from both accelerated approval and priority review, but these can also be granted to the same bispecific antibody candidate if the relevant criteria are met. The FDA must take certain actions,
such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. All requests for breakthrough therapy designation will be reviewed within 60 days of
receipt, and FDA will either grant or deny the request. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Fast Track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Even if we
receive one of these designations for our bispecific antibody candidates, the FDA may later decide that our bispecific antibody candidates no longer meet the conditions for qualification. In addition, these designations may not provide us with a
material commercial advantage. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Post-Approval Requirements </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of
substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to cGMP requirements. We will rely, and expect to continue to rely, on third parties for the
production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance
and maintenance of records and documentation. Other post-approval requirements applicable to biological products include record-keeping requirements, reporting of adverse effects, and reporting updated safety and efficacy information. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also must comply with the FDA&#146;s advertising and promotion requirements, such as
those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#146;s approved labeling (known as &#147;off-label use&#148;), industry-sponsored
scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a
product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may
subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled
letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution,
disgorgement of profits, or civil or criminal penalties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register their establishments with the FDA and certain
state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of
production and quality control to maintain cGMP compliance. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as
adding new indications and additional labeling claims, are also subject to further FDA review and approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.S. Patent Term Restoration and Marketing Exclusivity </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depending upon the timing, duration and specifics of the FDA
approval of the use of our bispecific antibody candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman
Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the
remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time
between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved biological product
is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent and within a 60 day period from the date the product is first approved for commercial marketing. The U.S. PTO, in
consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for one of our currently owned patents to add patent life beyond its current
expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA; however, there can be no assurance that any such extension will be granted to us. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biosimilars and Exclusivity </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Biologics Price Competition and Innovation Act of 2009,
or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, only one biosimilar has been licensed under the BPCIA, although
numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product
in terms of safety, purity, and potency, can be shown through analytical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
studies, animal studies, and a clinical trial or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be
expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has
been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological
products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the BPCIA, an application for a biosimilar product may
not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which
the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s
own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products.
At this juncture, it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity,
if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial
in accordance with an FDA-issued &#147;Written Request&#148; for such a trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The BPCIA is complex and only beginning to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the 12-year reference product exclusivity period. Other
aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and meaning of the BPCIA is subject to significant uncertainty.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA Regulation of Companion Diagnostics
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that our bispecific antibody
candidates may require use of an <I>in vitro</I> diagnostic to identify appropriate patient populations for our products. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the United States, the
FD&amp;C Act and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration
and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA
prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval. We expect that any companion
diagnostic developed for our bispecific antibody candidates will utilize the PMA pathway. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If use of companion diagnostic is essential to safe and effective use of a drug or biologic product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the
approval of the therapeutic product. On August&nbsp;6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#147;<I>In Vitro</I> Companion Diagnostic Devices.&#148; According to the guidance, for novel
candidates such as our bispecific antibody candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling.
The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device, unless it is
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be
considered a significant risk device under the FDA&#146;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a
diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations.
The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has generally required companion diagnostics intended to select the patients who will respond to cancer treatment to obtain
approval of a PMA for that diagnostic simultaneously with approval of the therapeutic. The review of these <I>in vitro</I> companion diagnostics in conjunction with the review of a cancer therapeutic involves coordination of review by the FDA&#146;s
Center for Biologics Evaluation and Research and by the FDA&#146;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several
years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s safety and effectiveness and information about the device and its components
regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive pre-clinical and adequate and
well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible
results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will typically inspect the manufacturer&#146;s facilities for compliance with the Quality System Regulation, or QSR,
which imposes elaborate testing, control, documentation and other quality assurance requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of
conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA concludes
that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary
to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not
approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary,
in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval
requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable
determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After a device is placed on the market, it remains subject to
significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device
manufacturer&#146;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality
assurance, labeling, packaging and shipping of medical devices. Domestic facility records and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Government Regulation Outside of the United States
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to regulations in the United
States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Because biologically sourced raw materials are subject to unique
contamination risks, their use may be restricted in some countries. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of
the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the European
Union, for example, a CTA must be submitted to each country&#146;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved in accordance with a country&#146;s requirements,
clinical trial development may proceed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To obtain regulatory approval of an investigational biological product under European Union regulatory systems, we must submit a marketing authorization application. The application used to file the BLA
in the United States is similar to that required in the European Union, with the exception of, among other things, country-specific document requirements. The European Union also provides opportunities for market exclusivity. For example, in the
European Union, upon receiving marketing authorization, new chemical entities generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents regulatory authorities in the
European Union from referencing the innovator&#146;s data to assess a generic application. During the additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#146;s data may be
referenced, but no generic product can be marketed until the expiration of the market exclusivity. However, there is no guarantee that a product will be considered by the European Union&#146;s regulatory authorities to be a new chemical entity, and
products may not qualify for data exclusivity. Products receiving orphan designation in the European Union can receive ten years of market exclusivity, during which time no similar medicinal product for the same indication may be placed on the
market. An orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan
indications. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The criteria for designating an
&#147;orphan medicinal product&#148; in the European Union are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1)&nbsp;it is intended for the
diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (2)&nbsp;either (a)&nbsp;such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b)&nbsp;the
product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment; and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such condition
authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial
incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan drug designation must be submitted
before the application for marketing authorization. The applicant will receive a fee reduction for the marketing </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan drug
designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer
meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at
any time if: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicant consents to a second orphan medicinal product application; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicant cannot supply enough orphan medicinal product. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For other countries outside of the European Union, such as
countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in
accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or
withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Healthcare Laws </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to FDA restrictions on marketing of pharmaceutical and biological products, other U.S. federal and state healthcare regulatory
laws restrict business practices in the biopharmaceutical industry, which include, but are not limited to, state and federal anti-kickback, false claims, data privacy and security, and physician payment transparency laws. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal Anti-Kickback Statute prohibits, among other
things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for
or recommending the purchase, lease, or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything
of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory
exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases,
or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe
harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have
interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, the intent standard under the Anti-Kickback
Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law
that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. The majority of states also have anti-kickback laws,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal false claims and civil monetary penalties laws,
including the civil False Claims Act prohibits any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government or
knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the U.S.
government. Actions under the civil False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the civil False Claims Act can result in very significant
monetary penalties and treble damages. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would
bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of products for unapproved (<I>e.g.</I>, off-label) uses. In addition, the civil monetary
penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed
or is false or fraudulent. Many states also have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Given the
significant size of actual and potential settlements, it is expected that the government authorities will continue to devote substantial resources to investigating healthcare providers&#146; and manufacturers&#146; compliance with applicable fraud
and abuse laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program,
including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or
covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, the ACA
broadened the reach of certain criminal healthcare fraud statutes created under HIPAA by amending the intent requirement such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to
have committed a violation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, there
has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers. The ACA imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine
Act for covered manufacturers for certain payments and &#147;transfers of value&#148; provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to
submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an aggregate of
$1&nbsp;million per year for &#147;knowing failures.&#148; Covered manufacturers must submit reports by the 90th&nbsp;day of each subsequent calendar year. In addition, certain states require implementation of compliance programs and compliance with
the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices, and/or tracking and reporting of gifts, compensation and other
remuneration or items of value provided to physicians and other healthcare professionals and entities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our
business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, including the Final HIPAA Omnibus Rule published on January&nbsp;25, 2013, impose
specified requirements relating to the </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">privacy, security and transmission of individually identifiable health information held by covered
entities and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
their business associates. Among other things, HITECH made HIPAA&#146;s security standards directly applicable to &#147;business associates,&#148; defined as independent contractors or agents of
covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against
covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#146;s fees and
costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same
requirements, thus complicating compliance efforts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be
subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our
operations, exclusion from participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent that any of our bispecific antibody candidates,
once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and
implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Coverage and Reimbursement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological products for which we
obtain regulatory approval. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on
<FONT STYLE="white-space:nowrap">third-party</FONT> payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant
portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party
payors include government authorities, managed care providers, private health insurers and other organizations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process for determining whether a third-party payor will provide coverage for a pharmaceutical or biological product typically is
separate from the process for setting the price of such product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved
list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. A decision by a third-party payor not to cover our bispecific antibody candidates could reduce physician utilization of our
products once approved and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor&#146;s decision to provide coverage for a pharmaceutical or biological product does not imply that
an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally,
coverage and reimbursement for new products can differ significantly from payor to payor. One third-party payor&#146;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the
medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately
and will be a <FONT STYLE="white-space:nowrap">time-consuming</FONT> process. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of pharmaceutical or biological products have been a focus in this effort. Third-party
payors are </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical or biological products,
medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA
approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Healthcare Reform </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount
of reimbursement for particular medical products. For example, in March 2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; introduced a new
methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid Drug Rebate Program to utilization of prescriptions
of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#146; outpatient drugs coverage under Medicare Part D; subjected drug manufacturers to new
annual fees based on pharmaceutical companies&#146; share of sales to federal healthcare programs; created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
research, along with funding for such research; and imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices, which excise tax has been suspended by the Consolidated Appropriations Act of 2016 through
December&nbsp;31, 2017. There have been judicial and Congressional challenges to other aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that the ACA, as well as other healthcare reform
measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare
or other government-funded programs may result in a similar reduction in payments from private payors. Moreover, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products.
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, on August&nbsp;2, 2011, the Budget Control Act
of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach
required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of up to 2%&nbsp;per fiscal year, which went into effect on
April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including without limitation the Bipartisan Budget Act of 2015, will stay in effect through 2025 unless additional Congressional action is taken. On January&nbsp;2,
2013, the American Taxpayer Relief Act was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals and imaging centers. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of
which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>   <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employees </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December 31, 2015, we had 37 employees, 19 of whom
hold M.D. or Ph.D. degrees. Thirty-one of our employees work in research and development and six work in management and administrative areas. None of our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
employees is subject to a collective bargaining agreement or represented by a trade or labor union. We are in the process of establishing a workers&#146; council for our employees. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Facilities </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We lease approximately 6,800 square feet of office and laboratory space in Utrecht, the Netherlands. This
facility serves as our corporate headquarters and central laboratory facility. Our current lease had an initial term through December&nbsp;31, 2015, after which it converted to a lease eligible for renewal every three months. We plan to lease office
space in Boston, Massachusetts to serve as our U.S. headquarters. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Proceedings </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;11, 2014, Regeneron Pharmaceuticals Inc., or Regeneron, filed a complaint in the United States District Court for the Southern District of New York, or the Court, alleging that we were
infringing one or more claims in their U.S. Patent No.&nbsp;8,502,018, entitled &#147;Methods of Modifying Eukaryotic Cells.&#148; On July&nbsp;3, 2014, we filed a response to the complaint, denying Regeneron&#146;s allegations of infringement and
raising affirmative defenses, and filed counterclaims seeking, among other things, a declaratory judgment that we did not infringe the patent and that the patent was invalid. We subsequently filed amended counterclaims during the period from August
to December 2014, seeking a declaratory judgment of unenforceability of the patent due to Regeneron&#146;s commission of inequitable conduct. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;21, 2014, the Court found that there was clear and convincing evidence that a claim term present in each of the patent
claims was indefinite and granted our proposed claim constructions.&nbsp;On February&nbsp;24, 2015, the Court entered partial judgment in the proceeding, on the grounds that we did not infringe each of the patent claims, and that each of the patent
claims were invalid due to indefiniteness. On November 2, 2015, the Court found Regeneron had withheld material information from the USPTO during prosecution of the patent, and Regeneron had engaged in inequitable conduct and affirmative egregious
misconduct in connection with the prosecution of the patent. On December 18, 2015, Regeneron filed an appeal of the Court&#146;s decision, which is currently pending. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;11, 2014, Regeneron served a writ in the
Netherlands alleging that we were infringing one or more claims in their European patent EP&nbsp;1&nbsp;360&nbsp;287&nbsp;B1. We had opposed that patent in June 2014 and the Dutch litigation is currently stayed. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;17, 2014, Regeneron&#146;s patent EP
1&nbsp;360 287&nbsp;B1 was revoked in its entirety by the European Opposition Division of the European Patent Office, or the EPO. An appeal hearing occurred in October and November 2015 at the Technical Board of Appeal for the EPO at which time the
patent was reinstated to Regeneron with amended claims. We believe that our current business operations do not infringe the patent reinstated to Regeneron with amended claims. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may be involved in various other claims
and legal proceedings relating to claims arising out of our operations. We are not currently a party to any other material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_15"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Management Board, Key Employees and Supervisory Board </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents information about our
management board, key employees and supervisory board, including their ages as of the date of this prospectus: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:27pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Management Board Members</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ton Logtenberg, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shelley Margetson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Key Employees</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Throsby, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Scientific Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Setareh Shamsili, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hui Liu, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT><BR></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT><BR></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Business Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Supervisory Board Members</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Iwicki</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman of the Board</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wolfgang Berthold, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lionel Carnot</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gabriele Dallmann, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John de Koning, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Florent Gros(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anand Mehra, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jack Nielsen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Florent Gros will resign from the supervisory board contingent upon, and effective immediately prior to, the effectiveness of the registration statement of which this
prospectus forms a part. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless
otherwise indicated, the current business addresses for the members of our management board and supervisory board is c/o Merus B.V., Padualaan 8 (postvak 133), 3584 CH Utrecht, the Netherlands. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Structure </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a two-tier board structure consisting of a
management board (<I>raad van bestuur</I>) and a separate supervisory board (<I>raad van commissarissen</I>). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Management Board </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The management board is in charge of managing the Company under the supervision of the supervisory board. Pursuant to our Articles of Association, the supervisory board determines the number of management
board members and nominates members for shareholder approval at a general meeting of shareholders. Under our Articles of Association, such nomination is binding, but shareholders may resolve to render the nomination to be non-binding by the vote of
a majority of a quorum, consisting of at least two-thirds of the votes cast representing more than half of the issued share capital. If a nomination is rendered non-binding, a new nomination shall be made each time by the supervisory board.
Shareholders may suspend or remove any management board member at a general meeting. In addition, the supervisory board may at any time suspend a management board member, and such suspension can be lifted by shareholders at a general meeting.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Articles of Association provide that the
management board shall draw up rules concerning the organization, decision-making and other internal matters of the management board. In performing their duties, the management board members are required to observe and comply with such rules.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a brief summary of the business experience of the members of our management
board. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ton Logtenberg, Ph.D.</I></B> has
served as our Chief Executive Officer and a management board member since co-founding our Company in June 2003. Prior to joining Merus, Dr.&nbsp;Logtenberg co-founded Crucell N.V., a biotechnology company specializing in vaccines and
biopharmaceutical technology, and served as its executive vice president and chief scientific officer from July 2000 until November 2003. Dr.&nbsp;Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008 and a
member of the board of directors of Utrecht Science Park since November 2014. Dr.&nbsp;Logtenberg holds a Ph.D. in medical biology from Utrecht University. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shelley Margetson</I></B> has served as our Chief Financial Officer since 2010 and a management board member since June 2012. Her
responsibilities include financial, treasury, tax, budgeting and external reporting. Prior to joining Merus, from June 2006 to October 2010, Ms.&nbsp;Margetson served as vice president of finance of PanGenetics B.V., a therapeutic antibody
development company that specializes in research of antibodies. Ms.&nbsp;Margetson has worked in the biotechnology industry since 2001 for companies located in the United Kingdom, France and the Netherlands. Ms.&nbsp;Margetson holds a B.A. in
business economics from the Higher Economics School, is an Associate of the Chartered Institute of Management Accountants, and holds the Chartered Global Management Accountants designation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Key Employees </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a brief summary of the business experience of certain of our key employees. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Mark Throsby, Ph.D. </I></B>has served as our Chief
Scientific Officer since January 2013 and previously served as our Chief Operating Officer from October 2008 to January 2013. His responsibilities include strategic scientific leadership, management of discovery, pre-clinical research and
translational research, business development support, external collaborations and partnerships management. Before joining Merus, from October 2000 to October 2008, he served as a senior scientist and then as director of antibody discovery for
Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. Dr.&nbsp;Throsby holds a Ph.D. in neuro-immunology from Monash University. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Setareh Shamsili, M.D., Ph.D. </I></B>has served as our
Chief Medical Officer and Head of Clinical Development since December 2012. Dr.&nbsp;Shamsili has more than 25 years of experience in general medicine, internal medicine and medical oncology and approximately 12 years of experience in the
pharmaceutical industry, including drug development, research and development, medical affairs, drug safety and clinical operation, as well as experience with business development and product portfolio strategy. Prior to joining Merus,
Dr.&nbsp;Shamsili worked as an independent oncology consultant from June 2012 to December 2012, and as the Global Medical Leader of Oncology for Astellas Pharma, Inc. from March 2006 to June 2012. Dr.&nbsp;Shamsili holds a Ph.D. in neuro-oncology
from Erasmus University Rotterdam, and a Ph.D. in head and neck-oncology and an M.D. from the National University of Medical Sciences, both with distinction. <B><I> </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Hui Liu, Ph.D.</I></B><B></B> has served as
our Chief Business Officer since December 2015. Dr. Liu has 15 years of experience in the pharmaceutical industry. Prior to joining Merus, Dr. Liu was at Novartis AG, a pharmaceutical company, serving its Vice President and Global Head, Business
Development &amp; Licensing, Oncology, from 2013 to 2015, and as Vice President and Global Head, Business Development &amp; Licensing, Vaccines &amp; Diagnostics, from 2009 to 2012. In these positions, Dr. Liu was responsible for all aspects of
business development, including in- and out- licensing, acquisitions and alliance management. Prior to his time at Novartis, Dr. Liu held various management positions at Pfizer, Inc., a pharmaceutical company, from 2004 to 2009 and at Pfizer, Inc.
and its predecessor company Warner-Lambert from 1997 to 2001. Dr. Liu worked at Goldman Sachs and Citigroup as an investment banker between 2001 and 2004. Dr. Liu holds a Ph.D. in molecular biology and an M.B.A. in finance from the University of
Michigan and a B.S. in biology from Peking University. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supervisory Board </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our supervisory board supervises the management board
and the general course of affairs of the Company. The supervisory board gives advice to the management board and is guided by the interests of the business when performing its duties. The management board communicates regularly with the supervisory
board. Members of the supervisory board are appointed by shareholders at a general meeting upon a binding nomination of the supervisory board. The nominating and corporate governance committee of the supervisory board recommends members for
nomination to the supervisory board. The members of the supervisory board are not authorized to represent us in dealings with third parties. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a supervisory board consisting of at least three members, up to a maximum of seven members. A supervisory board member must be an
individual. The supervisory board determines the number of supervisory board members pursuant to our Articles of Association. The general meeting appoints our supervisory board members at general meetings of shareholders and may at any time suspend
or remove any supervisory board member. The general meeting can only appoint a supervisory board member upon a binding nomination of the supervisory board. The general meeting may resolve to render the nomination to be non-binding by a majority of
at least two-thirds of the votes cast representing more than half of the issued share capital. If a nomination is rendered non-binding, a new nomination shall be made each time by the supervisory board. If the nomination comprises one candidate for
a vacancy, a resolution concerning the nomination will result in the appointment of the candidate, unless the nomination is rendered non-binding. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of appointment of our supervisory board members is up to four years. Supervisory board members may be re-appointed twice for
additional terms of four years each. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
supervisory board meets as often as a supervisory board member deems necessary or as often as the management board shall request. At a meeting of the supervisory board, each supervisory board member has a right to cast one vote. All resolutions by
the supervisory board are adopted by an absolute majority of the votes cast. In the event the votes are equally divided, the chairman has the deciding vote. A supervisory board member may grant another supervisory board member a written proxy to
represent him at the meeting, but a supervisory board member cannot represent more than one supervisory board member. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our supervisory board can pass resolutions outside of meetings, provided that (i)&nbsp;the resolution is adopted in writing, (ii) all
supervisory board members are familiar with the resolution to be passed and (iii)&nbsp;there are no objections to this decision making process. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is no retirement age requirement for our supervisory board under our Articles of Association. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Articles of Association provide that our supervisory
board shall draw up rules concerning the organization, decision-making and other internal matters of the supervisory board and its committees. In performing their duties, the supervisory board members are required to observe and comply with such
rules. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a brief summary of the
business experience of our supervisory board members. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Mark Iwicki </I></B>is Chairman of our supervisory board and has been a member of the supervisory board since June 2015. Mr.&nbsp;Iwicki also serves as the executive chairman of the board of
directors of Kala Pharmaceuticals, Inc. and as a member of the boards of directors of Aimmune Therapeutics, Inc., Nimbus Therapeutics, TARIS Biomedical and Oxeia Biopharmaceuticals. In addition, Mr.&nbsp;Iwicki has served on the board of the
Wellesley Youth Hockey Association. Mr.&nbsp;Iwicki served as president and chief executive officer and a member of the board of directors of Civitas Therapeutics, Inc. from January 2014 until its acquisition by Acorda Therapeutics, Inc. in October
2014. From December 2012 to January 2014, Mr.&nbsp;Iwicki served as president and chief executive officer and director at Blend Therapeutics, Inc. From 2007 to June 2012, Mr.&nbsp;Iwicki was president and chief executive officer and director of
Sunovion Pharmaceuticals, Inc., formerly Sepracor, Inc. Mr.&nbsp;Iwicki has an M.B.A. from Loyola University. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">117
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Wolfgang Berthold, Ph.D. </I></B>has been a member of the supervisory board since
September 2010. Dr.&nbsp;Berthold has held senior positions at Boehringer Ingelheim, GMBH, and BiogenIdec International, CH (now Biogen, Inc.), where he was responsible for various aspects of manufacturing operations, process development and
facilities and engineering. He has over 30 years of experience in the industry. Since 2011, Dr.&nbsp;Berthold has served as president of Berthold BioPharm Consulting GmbH, Switzerland, a biotechnology consulting company. From February 2000
until<B><I> </I></B>March 2011, Dr.&nbsp;Berthold held positions of increasing seniority at<B><I> </I></B>BiogenIdec International, CH, including serving as its chief technology officer. During that time, Dr.&nbsp;Berthold also served on the
executive board of BiogenIdec International GMBH from February 2009 until his retirement in March 2011. Dr.&nbsp;Berthold received his Ph.D. in biochemistry from the University of London. <B><I> </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lionel Carnot</I></B> was nominated to serve as a
member of the supervisory board by Bay City Capital Co&ouml;peratief U.A., one of our shareholders, and has been a member of the supervisory board since January 2010. Mr.&nbsp;Carnot is a managing director at Bay City Capital LLC, a global life
sciences investment firm, a position he has held since March 2005. Mr.&nbsp;Carnot currently serves on the boards of directors of Madrigal Pharmaceuticals, Inc., Tallikut Pharmaceuticals and Interleukin Genetics, Inc. Mr.&nbsp;Carnot holds an M.B.A.
with distinction from INSEAD and an M.S. with honors in molecular biology from the University of Geneva. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Gabriele Dallmann, Ph.D. </I></B>has been a member of the supervisory board since September 2011. Dr.&nbsp;Dallmann has more than 30
years of experience in regulatory affairs and drug development of medicinal products with a focus on biopharmaceuticals. Dr.&nbsp;Dallmann served at the German Federal Agency for Biopharmaceuticals and Vaccines from 1994 to 2005. She co-founded
Biopharma Excellence GbR, a drug development planning consulting company, in October 2013 and co-founded EUCRAF Ltd., or the European Center for Regulatory Affairs, a training firm focusing on regulatory affairs for biopharmaceuticals and drug
development, in June&nbsp;2009. Prior to founding EUCRAF Ltd. and Biopharma-Excellence GbR, Dr.&nbsp;Dallmann founded and served as the chief executive officer of Pharmatching GmbH, from September 2009 to September 2013. Dr.&nbsp;Dallmann has also
served on the board of directors of EUCRAF Ltd. since its inception in June 2009 and has served on the board of directors of Biopharma Excellence GbR since its inception in October 2013. Dr.&nbsp;Dallmann has a Ph.D. in immunology from Berlin
University and a B.Sc. and M.Sc. in biology from University Leipzig. <B><I> </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>John de Koning, Ph.D.</I></B> was nominated to serve on the supervisory board by Co&ouml;peratief LSP&nbsp;IV&nbsp;U.A., one of our shareholders, and has been a member of the supervisory board since
January 2010. Dr.&nbsp;de Koning has been a partner at Life Sciences Partners since January 2006. Since September 2009, Dr.&nbsp;de Koning has also served as a member of the board of directors of arGEN-X since July 2014. Previously, he served on the
supervisory boards of BMEYE (acquired by Edwards Lifesciences), Prosensa (acquired by BioMarin) and Skyline Diagnostics, and as a non-executive director on the boards of Pronota (now MyCartis) and Innovative Biosensors Inc. Dr.&nbsp;de Koning has an
M.Sc. in medical biology from Utrecht University and a Ph.D. in oncology from the Erasmus University Rotterdam. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Florent Gros </I></B>was nominated to serve on the supervisory board by Novartis Bioventures Ltd., one of our shareholders, and has
been a member of the supervisory board since January 2010. Mr.&nbsp;Gros has served as a managing director of the Novartis Venture Fund, a venture fund investing in life sciences companies, since January 2007 and is an employee of a corporation that
is affiliated with Novartis Bioventures Ltd. Previously, Mr.&nbsp;Gros worked in various global leadership positions in intellectual property, venture and transaction matters at Nestl&eacute;, Pasteur Merieux Connaught (Sanofi Pasteur) and Novartis.
Mr.&nbsp;Gros currently serves on the boards of Anokion S.A., Applied Immune Technologies Ltd., Atlas Genetics Ltd., Gensight S.A., MyoPowers Medical Technologies S.A., Kanyos Bio Inc., Opsona Therapeutics Ltd. and Altimmune Inc. Mr.&nbsp;Gros is a
Kaufmann Fellow (Class of 2012) and received an M.S. in biotechnology engineering from Strasbourg School of Biotechnology in France. He also holds European and French patent law degrees and an M.A. in private law. Mr.&nbsp;Gros will resign from the
supervisory board contingent upon, and effective immediately prior to, the effectiveness of the registration statement of which this prospectus forms a part. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Anand Mehra, M.D. </I></B>was nominated to serve on the supervisory board by Sofinnova
Venture Partners IX, L.P., one of our shareholders, and has been a member of the supervisory board since August 2015. Dr.&nbsp;Mehra has been with Sofinnova Ventures since 2007, most recently holding the position of a general partner where he
focuses on working with entrepreneurs to build drug development companies. He has led the firm&#146;s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., and Prothena Corporation PLC.
He currently serves as a member of the boards of directors of Spark Therapeutics, Inc., Aerie Pharmaceuticals Inc. and Marinus Pharmaceuticals Inc. as well as the boards of several private companies. Dr.&nbsp;Mehra received his M.D. from Columbia
University&#146;s College of Physicians and Surgeons. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Jack B. Nielsen</I></B> was nominated to serve on the supervisory board by Novo A/S, one of our shareholders, and has been a member of the supervisory board since August 2015. Mr.&nbsp;Nielsen has
worked within Novo A/S and its venture activities since 2001 in several roles, and since 2012, he has been employed as a partner based in Copenhagen, Denmark. Novo A/S is a Denmark limited liability company that manages investments and financial
assets. From 2006 to 2012, Mr.&nbsp;Nielsen was employed as a partner at Novo Ventures of Novo A/S (US) Inc. in San Francisco, where he established the office which provides certain consultancy services to Novo A/S. Mr.&nbsp;Nielsen previously
served as a member of the board of directors of Akebia Therapeutics, Inc. He currently serves on the board of directors of a number of private companies in the biopharmaceutical and biotechnology industries. Mr.&nbsp;Nielsen received an M.Sc. in
chemical engineering from the Technical University of Denmark, and an M.S. in management of technology from the Technical University of Denmark. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Composition and Election of Supervisory Board Members After This Offering </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, our supervisory board will be comprised of seven members. Each
supervisory board member is elected for a term of up to four years. A supervisory board member may be re-appointed for up to two subsequent terms. Supervisory board members must retire periodically in accordance with a rotation plan to be drawn up
by the supervisory board. Our supervisory board members do not have a retirement age requirement under our Articles of Association. Our supervisory board members will be elected, or re-appointed as the case may be, by our general meeting of
shareholders in accordance with the Articles of Association prior to the closing of this offering to serve until their successors are duly elected and qualified. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a foreign private issuer. As a result, in accordance
with NASDAQ rules, we will comply with home country governance requirements and certain exemptions thereunder rather than complying with NASDAQ corporate governance standards. In accordance with Dutch law and generally accepted business practices,
our Articles of Association do not provide quorum requirements generally applicable to general meetings of shareholders in the United States. To this extent, our practice varies from the requirement of NASDAQ Listing Rule 5620(c), which requires an
issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting stock. Although we must provide shareholders with an agenda and other relevant documents for the general
meeting of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, thus our practice will vary from the requirement
of NASDAQ Listing Rule 5620(b). As permitted by the listing requirements of NASDAQ, we have also opted out of the requirements of NASDAQ Listing Rule 5605(d), which requires an issuer to have a compensation committee that consists entirely of
independent directors, and NASDAQ Listing Rule 5605(e), which requires an issuer to have independent director oversight of director nominations. We will also rely on the phase-in rules of the SEC and NASDAQ with respect to the independence of our
audit committee. These rules require that all members of our audit committee must meet the independence standard for audit committee members within one year of the effectiveness of the registration statement of which this prospectus forms a part. In
addition, we have opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based
compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the requirements of NASDAQ Listing Rule 5635, which generally requires an issuer to obtain shareholder approval for
the issuance of securities in connection with such events. For an overview of our corporate governance principles, see &#147;Description of Share Capital and Articles of Association.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">119
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Audit Committee of the Supervisory Board </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The audit committee, which is expected to consist of
Lionel Carnot, Jack Nielsen and John de Koning, will assist the supervisory board in overseeing our accounting and financial reporting processes and the audits of our financial statements.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will serve as Chairman of the committee. The audit committee will consist exclusively of members of our supervisory board who are
financially literate, and Lionel Carnot is considered an &#147;audit committee financial expert&#148; as defined by the SEC. Our supervisory board has determined that
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;satisfies the &#147;independence&#148; requirements set forth in Rule 10A-3 under the Exchange Act. We will rely on the phase-in
rules of the SEC and NASDAQ with respect to the independence of our audit committee. These rules require that all members of our audit committee must meet the independence standard for audit committee membership within one year of the effectiveness
of the registration statement of which this prospectus forms a part. The audit committee will be governed by a charter that complies with NASDAQ rules. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the completion of this offering, the audit committee&#146;s responsibilities will include: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">recommending the appointment of the independent auditor to the general meeting of shareholders; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or
performing other audit services; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pre-approving the audit services and non-audit services to be provided by our independent auditor before the auditor is engaged to render such
services; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluating the independent auditor&#146;s qualifications, performance and independence, and presenting its conclusions to the full supervisory board on
at least an annual basis; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and discussing with the management board, the supervisory board and the independent auditor our financial statements and our financial
reporting process; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approving or ratifying any related person transaction (as defined in our related person transaction policy) in accordance with our related person
transaction policy. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The audit
committee will meet as often as one or more members of the audit committee deem necessary, but in any event will meet at least four times per year. The audit committee will meet at least once per year with our independent accountant, without our
management board being present. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation Committee of the Supervisory Board </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The compensation committee, which is expected to consist
of Mark Iwicki, Lionel Carnot and Anand Mehra, will assist the supervisory board in determining management board compensation. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will serve as Chairman of the committee. The
compensation committee will prepare a proposal for the supervisory board concerning the compensation of each of our management board members to be proposed for adoption by the general meeting of shareholders. Under SEC and NASDAQ rules, there are
heightened independence standards for members of the compensation committee, including a prohibition against the receipt of any compensation from us other than standard supervisory board member fees. Although foreign private issuers are not required
to meet this heightened standard, we expect that all of our expected compensation committee members will meet this heightened standard. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the completion of this offering, the compensation committee&#146;s responsibilities will include: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identifying, reviewing and proposing policies relevant to management board compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">evaluating each management board member&#146;s performance in light of such policies and reporting to the supervisory board;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">analyzing the possible outcomes of the variable remuneration components and how they may affect the remuneration of the management board members;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">120
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">recommending any equity long-term incentive component of each management board member&#146;s compensation in line with the remuneration policy and
reviewing our management board compensation and benefits policies generally; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and assessing risks arising from our compensation policies and practices. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nominating and Corporate Governance Committee of the
Supervisory Board </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The nominating and
corporate governance committee, which is expected to consist of Mark Iwicki, Anand Mehra and John de Koning, will assist our supervisory board in identifying individuals qualified to become members of our supervisory board and management board
consistent with criteria established by our supervisory board and in developing our corporate governance principles. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will serve as Chairman of the nominating and corporate
governance committee. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the completion of
this offering, the nominating and corporate governance committee&#146;s responsibilities will include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">drawing up selection criteria and appointment procedures for supervisory board members and management board members; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and evaluating the size and composition of our supervisory board and management board and making a proposal for a composition profile of the
supervisory board at least annually; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">recommending nominees for election to our supervisory board, its corresponding committees and our management board; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assessing the functioning of individual members of the management and supervisory board and reporting the results of such assessment to the supervisory
board; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing and recommending to the supervisory board our rules governing the supervisory board, reviewing and reassessing the adequacy of such rules
governing the supervisory board and recommending any proposed changes to the supervisory board. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Business Conduct and Ethics </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, we will adopt a Code of Business Conduct and Ethics which will cover a broad range of matters including the handling of conflicts of interest, compliance issues and
other corporate policies such as equal opportunity and non-discrimination standards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation of Management Board Members </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the approximate remuneration paid during our 2015 fiscal year to our management board members. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus&nbsp;(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation&nbsp;(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ton Logtenberg, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">236,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,791,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,046,555</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shelley Margetson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">299,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">472,871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount of any bonus plan awards to be made to our management board members for services performed in 2015 has not yet been determined. We expect that the amount of
any such bonus plan awards will be determined in the first quarter of 2016. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amount shown represents pension contributions made by us. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">121
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Below is a brief description of the compensation plans and arrangements in which our
management board members participate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employment Agreements
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each of our management board members has
entered into an employment agreement with us for an indefinite period of time. These agreements provide for benefits upon a termination of service. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Short-Term Incentive Plan </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We maintain a short-term incentive plan pursuant to which we may grant our employees, including our management board members, incentive
cash bonuses based upon corporate and/or individual performance. Members of our management board are eligible to receive an incentive cash bonus in an amount up to 20% of their annual base salary based upon achievement of corporate and individual
objectives. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of the date of this
prospectus, we have not determined the amounts payable to employees, including our management board members, under our 2015 bonus program. We expect the amount of any payments under the 2015 bonus program will be determined in the first quarter of
2016. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The incentive bonus award for
Dr.&nbsp;Logtenberg is determined by the supervisory board on a discretionary basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Incentive Plans </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>2010 Option Plan </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In 2010, we established the Merus B.V. 2010 Employee Option Plan, or the 2010 Option Plan, under which certain participants (key management personnel, including our management board members and key
employees, supervisory board members, staff and consultants) may be granted the right to acquire (non-voting) depositary receipts, or Depositary Receipts, issued in respect of our common shares and/or cash settled instruments the value of which is
linked to our common shares. Under these programs, holders of vested options are entitled to purchase Depositary Receipts for shares at the exercise price determined at the date of grant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the exercise or award or vesting of a non-cash settled award under the 2010 Option Plan, common shares are
issued to the Foundation. The purpose of the Foundation is to facilitate administration of share-based compensation awards and pool the voting interests of the underlying shares. The Foundation thereupon grants a Depositary Receipt for each issued
common share to the person entitled to such common share under an award. The Depositary Receipt holder is entitled to any dividends or other distributions paid on the shares for which the Depositary Receipts are granted. The voting rights attached
to the shares are exercised by the Foundation at its own discretion. The Depositary Receipt holders do not have meeting rights: they are not entitled to attend a general meeting of shareholders or to cast a vote. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The board members of the Foundation are Ton Logtenberg, our
Chief Executive Officer, and John de Koning, one of our supervisory board members. The articles of association of the Foundation provide that the board members of the Foundation shall be appointed by the management board of the Foundation.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, we intend
to transfer the common shares held by the Foundation to the relevant depositary holders and cancel the corresponding depositary receipts. The Foundation will be dissolved and deregistered once the transfer has been effectuated. Furthermore, we
intend to amend the 2010 Option Plan to reflect that an option entails the right of the holder to purchase common shares rather than depositary receipts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">122
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The options granted under the share option programs vest in installments over a
four-year period from the grant date. 25% of the options vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in 36 monthly installments for each full month of continuous service provided by the
option holder thereafter, such that 100% of the options shall become vested on the fourth anniversary of the vesting commencement&nbsp;date. The options granted are exercisable once vested. Options will lapse on the eighth anniversary of the date of
grant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain participants who voluntarily leave
employment with the Company are required to offer to the Foundation the Depositary Receipts acquired from exercising options against payment of the exercise price or the lower fair market value of the underlying shares. Up to the first anniversary
of the date of exercise, the participant has an obligation to offer 100% of his or her Depositary Receipts to the Foundation. This obligation for a participant to offer Depositary Receipts to the Foundation upon resignation is reduced by 25% at each
anniversary of the date of exercise, which means that there is no such obligation if a participant leaves after the fourth anniversary of the date of exercise. In connection with this offering, we intend to amend the 2010 Option Plan to remove this
obligation, such that a participant will no longer be required to offer Depositary Receipts to the Foundation upon resignation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following the effectiveness of the 2016 Plan described below, we will not make any further grants under the 2010 Option Plan. However, the
2010 Option Plan will continue to govern the terms and conditions of the outstanding awards granted under it. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2016 Incentive Award Plan </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective the day prior to the first public trading date of our common stock, we intend to adopt and ask our shareholders to approve the
2016 Incentive Award Plan, or the 2016 Plan, under which we may grant cash and equity-based incentive awards to eligible service providers in order to attract, retain and motivate the persons who make important contributions to our company. The
material terms of the 2016 Plan are summarized below. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Eligibility and Administration </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our employees, consultants, management board members and supervisory board members, and employees and consultants of our subsidiaries, if any, will be eligible to receive awards under the 2016 Plan. The
2016 Plan will be administered by our supervisory board with respect to members of the management board and by our management board with respect to any other service providers who are not members of the supervisory board, each of which may delegate
its duties and responsibilities to one or more committees of our supervisory board, management board and/or officers (referred to collectively as the plan administrator below), subject to the limitations imposed under the 2016 Plan, our Articles of
Association and applicable laws. The plan administrator will have the authority to take all actions and make all determinations under the 2016 Plan, to interpret the 2016 Plan and award agreements and to adopt, amend and repeal rules for the
administration of the 2016 Plan as it deems advisable. The plan administrator will also have the authority to determine which eligible service providers receive awards, grant awards and set the terms and conditions of all awards under the 2016 Plan,
including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2016 Plan. Notwithstanding the foregoing, all actions taken by the management board under the 2016 Plan shall be subject to the conditions
and limitations set forth in the management board rules of procedures. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Shares Available for Awards </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An aggregate of 2,300,000 shares of our common stock will initially be available for issuance under the 2016 Plan. The number of shares initially available for issuance will be increased by an annual
increase on January 1 of each calendar year beginning in 2017 and ending in and including 2026, equal to the least of (A)&nbsp;4% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&nbsp;a
smaller number of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">123
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shares determined by our supervisory board. No more than 2,300,000 shares of common stock may be issued under the 2016 Plan upon the exercise of incentive stock options. Shares issued under the
2016 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If an award under the 2016 Plan expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having
been fully exercised or forfeited, any unused shares subject to the award will again be available for new grants under the 2016 Plan. Awards granted under the 2016 Plan in substitution for any options or other stock or stock-based awards granted by
an entity before the entity&#146;s merger or consolidation with us or our acquisition of the entity&#146;s property or stock will not reduce the shares available for grant under the 2016 Plan, but will count against the maximum number of shares that
may be issued upon the exercise of incentive stock options. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Awards </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The 2016 Plan provides for the grant of stock options, including incentive stock options, or ISOs, and nonqualified stock options, or NSOs, stock appreciation rights, or SARs, restricted stock, dividend
equivalents, restricted stock units, or RSUs, and other stock or cash based awards. Certain awards under the 2016 Plan may constitute or provide for payment of &#147;nonqualified deferred compensation&#148; under Section 409A of the Internal Revenue
Code of 1986, as amended. All awards under the 2016 Plan will be set forth in award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms and post-termination exercise limitations. A
brief description of each award type follows. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Options and SARs</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock options provide for the purchase of shares of our common stock in the future at an exercise
price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Internal Revenue Code are satisfied.
SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The plan administrator will determine the number of shares covered by
each option and SAR, the exercise price of each option and SAR and the conditions and limitations applicable to the exercise of each option and SAR. Unless otherwise determined by the plan administrator, the exercise price of a stock option or SAR
will not be less than 100% of the fair market value of the underlying share on the grant date (or 110% in the case of ISOs granted to certain significant shareholders), except with respect to certain substitute awards granted in connection with a
corporate transaction. The term of a stock option or SAR may not be longer than ten years (or five years in the case of ISOs granted to certain significant shareholders). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restricted Stock and RSUs.</I>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock is an award of nontransferable shares of our common stock that remain
forfeitable unless and until specified conditions are met and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until specified
conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. The plan administrator may provide that the delivery of the shares
underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to restricted stock and RSUs will be determined by the plan administrator, subject to the conditions and limitations
contained in the 2016 Plan. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other Stock or Cash Based Awards.</I>&nbsp;&nbsp;&nbsp;&nbsp;Other stock or cash based awards are awards of cash, fully vested shares of our common
stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock or other property. Other stock or cash based awards may be granted to participants and may also be available as a payment form in
the settlement of other awards, as standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled. The plan administrator will determine the terms and conditions of other stock or cash based awards, which may
include any purchase price, performance goal, transfer restrictions and vesting conditions. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">124
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Performance Criteria </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The plan administrator may select performance criteria for an award to establish performance goals for a
performance period. Performance criteria under the 2016 Plan may include, but are not limited to, the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based
compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit
or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or
cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on shareholders&#146; equity; total shareholder return; return on sales; costs, reductions in costs and cost control measures; expenses;
working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation,
completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals;
customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios
(including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and
marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the company&#146;s performance or the performance of a
subsidiary, division, business segment or business unit of the company or a subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other
companies. When determining performance goals, the plan administrator may provide for exclusion of the impact of an event or occurrence which the plan administrator determines should appropriately be excluded, including, without limitation,
non-recurring charges or events, acquisitions or divestitures, changes in the corporate or capital structure, events unrelated to the business or outside of the control of management, foreign exchange considerations, and legal, regulatory, tax or
accounting changes. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Certain Transactions
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with any spin-off, change
in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2016 Plan to prevent the dilution or enlargement of intended benefits, facilitate the transaction or event or
give effect to the change in applicable laws or accounting principles. This includes canceling awards for cash or property, accelerating the vesting of awards, providing for the assumption or substitution of awards by a successor entity, adjusting
the number and type of shares subject to outstanding awards and/or with respect to which awards may be granted under the 2016 Plan and replacing or terminating awards under the 2016 Plan. In addition, in the event of certain non-reciprocal
transactions with our shareholders, the plan administrator will make equitable adjustments to the 2016 Plan and outstanding awards as it deems appropriate to reflect the transaction. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Plan Amendment and Termination </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The plan administrator may amend or terminate the 2016
Plan at any time; however, no amendment, other than an amendment that increases the number of shares available under the 2016 Plan, may materially and adversely affect an award outstanding under the 2016 Plan without the consent of the affected
participant and shareholder approval will be obtained for any amendment to the extent necessary to comply with our Articles of Association or applicable laws. Further, the plan administrator cannot, without the approval of our shareholders, amend
any outstanding stock option or SAR to reduce its price per share or cancel any outstanding stock option or SAR in exchange for cash or another award under the 2016 Plan with an exercise price per share that is less
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">125
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
than the exercise price per share of the original stock option or SAR. The 2016 Plan will remain in effect until the tenth anniversary of the earlier of its effective date or the date our
shareholders approve the 2016 Plan, unless earlier terminated by the plan administrator. No awards may be granted under the 2016 Plan after its termination. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Foreign Participants, Claw-Back Provisions,
Transferability and Participant Payments </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The plan administrator may modify awards granted to participants who are employed outside the Netherlands or establish subplans or
procedures to address differences in laws, rules, regulations or customs of such foreign jurisdictions. All awards will be subject to any company claw-back policy as set forth in such claw-back policy or the applicable award agreement. Except as the
plan administrator may determine or provide in an award agreement, awards under the 2016 Plan are generally non-transferrable, except by will or the laws of descent and distribution, or, subject to the plan administrator&#146;s consent, pursuant to
a domestic relations order, and are generally exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2016 Plan, and exercise price obligations arising in connection with the
exercise of stock options under the 2016 Plan, the plan administrator may, in its discretion, accept cash, wire transfer or check, shares of our common stock that meet specified conditions, a promissory note, a &#147;market sell order,&#148; such
other consideration as the plan administrator deems suitable or any combination of the foregoing. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Remuneration of Management Board Members Following this Offering </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dutch law provides that we must establish a policy in respect of the remuneration of our management board members. The general meeting
shall, upon the proposal of the supervisory board, determine our policy concerning the compensation of the management board members pursuant to the relevant statutory requirements. The compensation of the management board members shall be determined
by the supervisory board pursuant to our Articles of Association. The supervisory board shall submit proposals concerning arrangements in the form of shares or rights to subscribe for shares to the general meeting for approval. This proposal must at
least include the number of shares or rights to subscribe for shares that may be awarded to the management board members and which criteria apply for such awards or changes thereto. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The remuneration policy for the management board members will provide the supervisory board with a
framework within which the supervisory board will determine the remuneration of the management board members. The remuneration policy for the management board members will be adopted by the general meeting upon the proposal of the supervisory board
and approved prior to the closing of this offering. We expect that the remuneration policy for our management board members will provide the supervisory board with the authority to enter into management services agreements with management board
members that provide for compensation consisting of base compensation, performance-related variable compensation, long-term equity incentive compensation (as detailed in the terms of the 2016 Plan described above), pension and other benefits and
severance pay and benefits. We expect that the remuneration policy for the management board members will provide that the annual cash bonus payable to management board members may not exceed &nbsp;&nbsp;&nbsp;&nbsp;% of the annual base gross salary
and will be based upon the achievement of set financial and operating goals for the period. The bonus payments may be increased in any given year by the supervisory board upon a proposal of the compensation committee based on any exceptional
achievements of that management board member. In addition, we expect that the remuneration policy for management board members will allow for cash termination payments, which may not exceed &nbsp;&nbsp;&nbsp;&nbsp;% of the management board
member&#146;s base salary. We also expect the policy will allow for additional compensation and benefits to our management board members following a change of control. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">126
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation of Supervisory Board Members </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the remuneration paid during our 2015 fiscal year to our supervisory board
members. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;earned&nbsp;or&nbsp;paid<BR>in&nbsp;Cash</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in euros)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Iwicki(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wolfgang Berthold, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lionel Carnot</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gabriele Dallmann, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John de Koning, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Florent Gros(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anand Mehra, M.D.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jack B. Nielsen(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gerard van Odijk(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Iwicki, Dr.&nbsp;Mehra and Mr.&nbsp;Nielsen became members of our supervisory board in 2015. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Florent Gros will resign from the supervisory board contingent upon, and effective immediately prior to, the effectiveness of the registration statement of which this
prospectus forms a part. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gerard van Odijk was chairman of our supervisory board until January&nbsp;6, 2015. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Remuneration of Supervisory Board Members Following this Offering
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Dutch law, we are not required to
establish a remuneration program for our supervisory board members, but we expect to adopt an official remuneration program effective as of the date of the effectiveness of this prospectus, subject to approval by our shareholders. We expect that
remuneration for the supervisory board members will consist of cash and initial and annual equity awards. We expect that each supervisory board member will be entitled to receive an annual retainer of $35,000. The chairman of the supervisory board
will be entitled to an additional annual retainer of $28,000 and the chairman of the audit committee, compensation committee and nominating and corporate governance committee will each be entitled to an additional annual retainer of $15,000, $10,000
and $7,500, respectively. A supervisory board member serving as a member of a committee other than the chairman will be entitled to receive an additional annual retainer of $7,500 for service on the audit committee, $5,000 for service on the
compensation committee, and $3,750 for service on the nominating and corporate governance committee. Retainers under the program will be payable in arrears in four equal quarterly installments within 15&nbsp;days following the end of each calendar
quarter, provided, that the amount of each payment will be prorated for any portion of a quarter that a supervisory board member is not serving on our supervisory board and no retainer will be payable in respect of any period prior to the effective
date of the registration statement of which this prospectus is a part. Each annual retainer shall, without further action taken by our shareholders, be automatically increased on the first day of each calendar year beginning in 2017 by an amount
equal to 3% of the value of such annual retainer in effect as of the immediately preceding calendar year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that each supervisory board member who is initially elected or appointed to our supervisory board after the effective date of
the program shall be eligible to receive, on the date of such initial election or appointment, an option to purchase the number of common shares of our company having an aggregate grant date fair value of $200,000 on the date of grant. In addition,
if a supervisory board member has served on the supervisory board for at least six months as of the date of an annual meeting of shareholders and will continue to serve as a supervisory board member following such annual meeting, we expect that we
will grant such supervisory board member, on the date of such annual meeting or as soon as practical thereafter, an option to purchase the number of common shares of our company having an aggregate grant date fair value of $100,000 on the date of
grant. Options granted to our supervisory board members under the program will have an exercise </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">127
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
price equal to the fair market value of our common shares on the date of grant and will expire not later than ten years after the date of grant. The options granted upon a supervisory board
member&#146;s initial election or appointment will vest as to 33% of the shares subject to the award on the first anniversary of the date of grant and in 24 substantially equal monthly installments thereafter. The options granted annually to
supervisory board members will vest in 12 substantially equal monthly installments following the date of grant. In addition, all unvested options will vest in full upon the occurrence of a change in control. The grant date fair value of each initial
award and annual award shall, without further action taken by our shareholders, be automatically increased on the first day of each calendar year beginning in 2017 by an amount equal to 3% of the grant date fair value in effect as of the immediately
preceding calendar year, provided, that in no event shall the number of shares awarded pursuant to an initial award exceed 30,000 common shares and an annual award exceed 15,000 common shares, in each case, subject to adjustment as provided in the
2016 Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each supervisory board member is
entitled to be reimbursed for reasonable travel and other expenses incurred in connection with attending meetings of the supervisory board and any committee of the supervisory board on which he or she serves. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Insurance and Indemnification </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management board members and supervisory board members have
the benefit of indemnification provisions set forth in our Articles of Association. These provisions give management board members and supervisory board members the right, to the fullest extent permitted by law, to recover from us amounts, including
but not limited to litigation expenses, and any damages they are ordered to pay, in relation to acts or omissions in the performance of their duties. However, no indemnification shall be given to a member of the management board and supervisory
board if a Dutch court has established, without possibility for appeal, that the acts or omissions of such indemnified officer that led to the financial losses, damages, suit, claim, action or legal proceedings result from either an improper
performance of his or her duties as an officer of the Company or an unlawful or illegal act; and to the extent that his financial losses, damages and expenses are covered by an insurance policy and the insurer has settled these financial losses,
damages and expenses, or has indicated that it would do so. There is generally no entitlement to indemnification for acts or omissions that amount to willful (<I>opzettelijk</I>), intentionally reckless (<I>bewust roekeloos</I>) or seriously
culpable (<I>ernstig verwijtbaar</I>) conduct. In addition, upon the closing of this offering, we intend to enter into agreements with our management board members and supervisory board members to indemnify them against expenses and liabilities to
the fullest extent permitted by law. These agreements will also provide, subject to certain exceptions, for indemnification for related expenses including, among other expenses, attorneys&#146; fees, judgments, penalties, fines and settlement
amounts incurred by any of these individuals in any action or proceeding. In addition to such indemnification, we provide our management board members and supervisory board members with directors&#146; and officers&#146; liability insurance.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification of liabilities arising
under the Securities Act may be permitted to supervisory board members, management board members or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">128
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_16"></A>PRINCIPAL SHAREHOLDERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information relating to
the beneficial ownership of our common shares as of December&nbsp;31, 2015 by: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding common shares;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each of our management board members and supervisory board members; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all management board members and supervisory board members as a group. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of common shares beneficially owned by each entity, person, management board member or
supervisory board member is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which
the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days of December 31, 2015 through the exercise of any option, warrant or other right. Except as otherwise
indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all common shares held by that person. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The percentage of shares beneficially owned before the offering is computed on the basis of 15,508,052 of our
common shares as of December&nbsp;31, 2015, after giving effect to the automatic conversion of all of our outstanding preferred shares as of December 31, 2015 into an aggregate of 14,900,456 common shares in connection with this offering. The
percentage of shares beneficially owned after the offering is based on the number of our common shares outstanding before the offering above plus (1) the common shares that we are selling in this offering, assuming no exercise of the
underwriters&#146; option to purchase additional common shares from us, and (2)&nbsp;1,905,523 common shares that will be issued to holders of our Class B and C preferred shares in connection with this offering in satisfaction of their entitlement
to distributions in kind accrued as of December&nbsp;31, 2015, as described in more detail in &#147;Capitalization&#151;Preferred Share Distributions&#148;. Common shares that a person has the right to acquire within 60 days of December 31, 2015 are
deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage
ownership of all management board members and supervisory board members as a group. As of December 31, 2015, after giving effect to the automatic conversion of all of our outstanding preferred shares into an aggregate of 14,900,456 common shares in
connection with this offering, 6,733,962 common shares, representing 43.4% of our issued and outstanding common shares, were held by 7 U.S. record holders. Unless otherwise indicated below, the address for each beneficial owner listed is c/o Merus
B.V., at Padualaan 8 (postvak 133), 3584 CH Utrecht, the Netherlands.</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares beneficially<BR>owned before the<BR>offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares beneficially<BR>owned after the<BR>offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:129pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and address of beneficial owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5% or Greater Shareholders</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novartis Bioventures Ltd.(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,124,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,547,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bay City Capital Co&ouml;peratief U.A.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,124,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,547,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aglaia Oncology Fund B.V./Aglaia Oncology Seed Fund B.V.(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,711,440</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,957,262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Johnson&nbsp;&amp; Johnson Innovation&#151;JJDC, Inc.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,643,390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,832,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer, Inc.(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,416,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,698,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sofinnova Venture Partners IX, L.P.(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,275,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,312,293</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novo A/S(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,206,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,240,714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baker Brothers Life Sciences L.P.(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,113,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,145,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co&ouml;peratief LSP IV U.A.(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,062,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,273,787</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">129
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares beneficially<BR>owned before the<BR>offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares beneficially<BR>owned after the offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:129pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and address of beneficial owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number**</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Management Board Members and Supervisory Board Members</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ton Logtenberg, Ph.D.(10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">431,365</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">431,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shelley Margetson(11)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Iwicki</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wolfgang Berthold, Ph.D.(12)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lionel Carnot(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,124,412</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,547,577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gabriele Dallmann, Ph.D.(13)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John de Koning, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Florent Gros</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anand Mehra, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jack Nielsen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All management board members and supervisory board members as a group (10 persons)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,602,714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates beneficial ownership of less than 1% of the total outstanding common shares. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficial ownership includes common shares issuable to holders of our Class&nbsp;B and C preferred shares in connection with this offering in satisfaction of their
entitlement to distributions in kind accrued as of December 31, 2015. Additional common shares are issuable as distributions to holders of our Class&nbsp;B and C preferred shares as their entitlement to distributions in kind continues to accumulate
on these preferred shares after December&nbsp;31, 2015 and until conversion, which is described in more detail in &#147;Capitalization&#151;Preferred Share Distributions.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 2,124,412 common shares following conversion of convertible preferred shares held directly by Novartis Bioventures Ltd. (&#147;Novartis&#148;) and 423,165
common shares to be issued to Novartis in satisfaction of its entitlement to distributions in kind accrued as of December&nbsp;31, 2015. Novartis is a wholly owned subsidiary of Novartis AG. The board of directors of Novartis has sole voting and
investment control and power over such shares and is comprised of Simon Zivi, Michael Jones and Timothy Faries. None of the members of its board of directors has individual voting or investment power with respect to such shares and each disclaims
beneficial ownership of such shares except to the extent of any pecuniary interest therein. Florent Gros, a managing director of the Novartis Venture Fund and an employee of a corporation that is affiliated with Novartis, is a member of our
supervisory board and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest arising as a result of his employment by such affiliate of Novartis. Novartis&#146; mailing address is 131 Front Street, Hamilton,
Bermuda. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 2,124,412 common shares following the conversion of convertible preferred shares held directly by Bay City Capital Co&#246;peratief U.A. (&#147;COOP&#148;)
and 423,165 common shares to be issued to COOP in satisfaction of its entitlement to distributions in kind accrued as of December&nbsp;31, 2015. Bay City Capital Fund V, L.P. (&#147;Fund V&#148;) and Bay City Capital Fund V Co-Investment Fund, L.P.
(&#147;Fund V-SBS&#148;) are the two sole investors of COOP. Bay City Capital Management V LLC (&#147;BCCM V&#148;) is the general partner of Fund V and Fund V-SBS. Bay City Capital LLC (&#147;BCC LLC&#148;, and together with COOP, Fund V, Fund
V-SBS, and BCCM V, &#147;Bay City Capital&#148;) is the adviser and manager of BCCM V. Because COOP requires two members, BCCM V and BCC LLC represent Fund V and Fund V-SBS, respectively, as members of COOP. Thus, BCCM V and BCC LLC share voting and
investment power over the shares held by COOP. Lionel Carnot, a member of our supervisory board, is employed as a managing director of BCC LLC together with Fred Craves, Carl Goldfischer and Dayton Misfeldt. As such, each of these individuals may be
deemed to share voting and investment power over these entities, and they disclaim beneficial ownership of all shares except to the extent of any pecuniary interest therein. Bay City Capital&#146;s mailing address is De Boeleaan&nbsp;7, 1083 HJ
Amsterdam, Netherlands. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (a)&nbsp;1,112,753 common shares following the conversion of convertible preferred shares held directly by Aglaia Oncology Fund B.V.
(&#147;AOF&#148;), (b)&nbsp;598,687 common shares following the conversion of convertible preferred shares held directly by Aglaia Oncology Seed Fund B.V. (&#147;AOSF&#148;), (c)&nbsp;136,717&nbsp;common shares to be issued to AOF in satisfaction of
its entitlement to distributions in kind </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">130
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
accrued as of December&nbsp;31, 2015 and (d) 109,105 common shares to be issued to AOSF in satisfaction of its entitlement to distributions in kind accrued as of December&nbsp;31, 2015. AOSF is a
wholly owned subsidiary of AOF. Aglaia BioMedical Ventures B.V. (&#147;ABV&#148;) is the sole director of AOF and AOSF. The managing directors of ABV are Mark Krul and Karl Rothweiler. As such, ABV, Mark Krul and Karl Rothweiler may be deemed to
have voting and investment power over the shares held by AOF and AOSF. Mark Krul and Karl Rothweiler disclaim beneficial ownership of all shares held by AOF and AOSF except to the extent of any pecuniary interest therein. The address for each of
these entities is Professor Bronkhorstlaan 10-92, 3723 MB Bilthoven, Netherlands. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,643,390 common shares following conversion of convertible preferred shares held directly by Johnson &amp; Johnson Innovation - JJDC, Inc.
(&#147;JJDC&#148;) and 189,178 common shares to be issued to JJDC in satisfaction of its entitlement to distributions in kind accrued as of December 31, 2015. The board of directors of JJDC, which consists of Tomas Heyman and Steven Rosenberg, has
shared investment and voting control with respect to the shares held by JJDC and has delegated responsibility therefor to the management of JJDC to take such actions on behalf of JJDC. As such, no individual member of the JJDC board of directors or
individual representative of JJDC is deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by JJDC. The address of JJDC is 410&nbsp;George Street, New&nbsp;Brunswick, NJ 08901. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,416,276 common shares following conversion of convertible preferred shares held directly by Pfizer Inc. (&#147;Pfizer&#148;) and 282,111 common shares to
be issued to Pfizer in satisfaction of its entitlement to distributions in kind accrued as of December 31, 2015. As of January 2016, the board of directors of Pfizer Inc. is comprised of the following individuals: Dennis A. Ausiello, W. Don
Cornwell, Joseph J. Echevarria, Frances D. Fergusson, Helen H. Hobbs, James M. Kilts, Shantanu Narayen, Suzanne Nora Johnson, Ian C. Read, Stephen W. Sanger and James C. Smith. Pfizer is a publicly-traded company. Pfizer&#146;s address is
235&nbsp;East&nbsp;42nd Street, New&nbsp;York, NY 10017. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,275,894 common shares following conversion of convertible preferred shares held directly by Sofinnova Venture Partners IX, L.P. (&#147;Sofinnova VP&#148;)
and 36,399 common shares to be issued to Sofinnova VP in satisfaction of its entitlement to distributions in kind accrued as of December 31, 2015. Sofinnova Management IX, L.L.C. (&#147;Sofinnova Management&#148;) is the general partner of Sofinnova
VP and Anand Mehra, Michael Powell, Srinivas Akkarju and James Healy are the managing members of Sofinnova Management. Sofinnova Management, Anand Mehra (a member of our supervisory board), Michael Powell, Srinivas Akkarju and James Healy may be
deemed to have shared voting and dispositive power over the shares owned by Sofinnova VP. Such entities and individuals disclaim beneficial ownership over all shares except to the extent of any pecuniary interest therein. The address for Sofinnova
VP and Sofinnova Management is 3000&nbsp;Sand Hill Road, Building&nbsp;4, Suite&nbsp;250, Menlo&nbsp;Park, California 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,206,300 common shares following conversion of convertible preferred shares held directly by Novo A/S, a Danish limited liability company that manages
investments and financial assets, and 34,414 common shares to be issued to Novo A/S in satisfaction of its entitlement to distributions in kind accrued as of December&nbsp;31, 2015. The board of directors of Novo A/S, which is currently comprised of
Sten Scheibye, G&#246;ran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared voting and investment power with respect to these shares and may exercise such control only with the support of a majority of the board. As such, no
individual member of the board is deemed to hold any beneficiary ownership in these shares. Jack Nielsen, a member of our supervisory board, is employed as a partner by Novo A/S and Mr. Nielsen has no beneficial ownership of or pecuniary interest in
these shares. The address of Novo A/S is Tuborg Havnevej 19, 2900 Hellerup, Denmark. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (a)&nbsp;1,029,081 common shares following conversion of convertible preferred shares held directly by Baker Brothers Life Sciences, L.P.
(&#147;Life Sciences&#148;), (b)&nbsp;84,427 common shares following conversion of convertible preferred shares held directly by 667, L.P. (&#147;667&#148;, and together with Life Sciences, the &#147;Baker Funds&#148;), (c)&nbsp;29,358 common shares
to be issued to Life Sciences in satisfaction of its entitlement to distributions in kind accrued as of December 31, 2015 and (d) 2,409 common shares to be issued to 667 in satisfaction of its entitlement to distributions in kind accrued as of
December 31, 2015. Baker Bros. Advisors LP is the Investment Adviser for the Baker Funds and has sole voting and investment power with respect to the shares held by the Baker Funds.&nbsp;Baker Bros. Advisors (GP) LLC is the sole general partner of
Baker Bros. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">131
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
Advisors LP. The managing members of Baker Bros. Advisors (GP) LLC are Julian C. Baker and Felix J. Baker. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of all shares except to
the extent of any pecuniary interest therein. The address for each of these entities is 667 Madison Avenue, 21st Floor, New&nbsp;York, NY 10065. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 1,062,205 common shares following conversion of convertible preferred shares held directly by Co&#246;peratief LSP IV U.A. (&#147;LSP&#148;) and 211,582
common shares to be issued to LSP in satisfaction of its entitlement to distributions in kind accrued as of December 31, 2015. LSP IV Management BV (&#147;LSP Management&#148;) is the sole director of LSP. The managing directors of LSP Management
are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe,. As such, LSP Management, Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to beneficially own and share voting power over these shares. John de Koning, a member of our
supervisory board, is employed as a partner at LSP. Mr. de Koning has no beneficial ownership of these shares, but he has a pecuniary interest in these shares pursuant to his employment at LSP. LSP&#146;s mailing address is Johannes Vermeerplein 9,
1071 DV Amsterdam, Netherlands. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (a)&nbsp;272,698 common shares following the conversion of convertible preferred shares held by BioPhrase, B.V., (&#147;BioPhrase&#148;), Dr.
Logtenberg&#146;s personal holding company, (b)&nbsp;16,000 depositary receipts of the Foundation held by BioPhrase, (c)&nbsp;11,774 depositary receipts of the Foundation held by Dr.&nbsp;Logtenberg, (d)&nbsp;82,782 options to purchase depositary
receipts held by BioPhrase that vest within 60&nbsp;days of December 31, 2015, (e)&nbsp;48,111 options to purchase depositary receipts held by Dr.&nbsp;Logtenberg that vest within 60 days of December 31, 2015 and (f)&nbsp;364 common shares to be
issued to BioPhrase in satisfaction of its entitlement to distributions in kind accrued as of December 31, 2015. As a holder of depositary receipts of the Foundation, Dr. Logtenberg holds no voting power over the shares underlying such receipts. See
&#147;Management&#151;Long-Term Incentive Plans&#151;2010 Option Plan.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 6,800 depositary receipts of the Foundation and 15,116 options to purchase depositary receipts that vest within 60 days of December 31, 2015. As a holder of
depositary receipts of the Foundation, Ms.&nbsp;Margetson holds no voting power over the shares underlying such receipts. See &#147;Management&#151;Long-Term Incentive Plans&#151;2010 Option Plan.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 19,562 options to purchase depositary receipts of the Foundation that vest within 60 days of December 31, 2015. As a holder of depositary receipts of the
Foundation, Dr. Berthold holds no voting power over the shares underlying such receipts. See &#147;Management&#151;Long-Term Incentive Plans&#151;2010 Option Plan.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 5,459 options to purchase depositary receipts of the Foundation that vest within 60 days of December 31, 2015. As a holder of depositary receipts of the
Foundation, Dr.&nbsp;Dallmann holds no voting power over the shares underlying such receipts. See &#147;Management&#151;Long-Term Incentive Plans&#151;2010 Option Plan.&#148; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">132
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_17"></A>RELATED PARTY TRANSACTIONS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a description of related party transactions
we have entered into since January&nbsp;1, 2012 with any members of our supervisory board or management board and the holders of more than 5% of our common shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Class B Preferred Share Financing </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2012, we issued an aggregate of 1,082,666 Class B
preferred shares at a price per share of &#128;7.50 for an aggregate purchase price of &#128;8.1 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2013, we issued an aggregate of 1,600,000 Class B preferred shares at a price per share of &#128;7.50 for an aggregate
purchase price of &#128;12.0 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August
2014, we issued an aggregate of 800,000 of our Class B preferred shares at a price per share of &#128;7.50 for an aggregate purchase price of &#128;6.0 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2015, we issued an aggregate of 886,524 of our Class&nbsp;B preferred shares at a price per share of &#128;5.64 for an
aggregate purchase price of &#128;5.0&nbsp;million. In connection with this purchase of Class&nbsp;B preferred shares, we also issued an additional 1,520,700 of our Class&nbsp;B preferred shares pursuant to anti-dilution provisions included in the
subscription agreement for our Class&nbsp;B preferred shares. These additional shares were issued for no cash consideration. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2015, the Class B preferred shareholders waived their rights to the remaining tranches of the Class B preferred share financing.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the aggregate
number of our Class B preferred shares issued to our management board members, supervisory board members and 5% shareholders and their affiliates. Each Class&nbsp;B preferred share is convertible into one common share. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:51pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Participants(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class B<BR>Preferred&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novartis Bioventures Ltd.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,574,039</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bay City Capital Co&ouml;peratief U.A.(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,574,039</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Johnson &amp; Johnson Innovation&#151;JJDC, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,217,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,049,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aglaia Oncology Fund B.V./Aglaia Oncology Seed Fund B.V.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">816,287</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co&ouml;peratief LSP IV U.A.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">787,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional details regarding these shareholders and their equity holdings is provided in &#147;Principal Shareholders.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Florent Gros, a member of our supervisory board, is a managing director of the Novartis Venture Fund and is an employee of a corporation that is affiliated with
Novartis Bioventures Ltd. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lionel Carnot, a member of our supervisory board, is a managing director of Bay City Capital LLC. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John de Koning, a member of our supervisory board, is a partner of Life Sciences Partners, which is affiliated with Co&ouml;peratief LSP IV U.A.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Convertible Bridge Loan and Class C Preferred
Share Financing </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2015, we entered
into a convertible loan agreement with Johnson&nbsp;&amp; Johnson Innovation&#151;JJDC, Inc., an affiliate of Novartis Bioventures Ltd., Co&ouml;peratief LSP IV U.A., Bay City Capital Co&ouml;peratief U.A., Pfizer, Inc., and Aglaia Oncology Fund
B.V., in the amount of &#128;8.0&nbsp;million with interest at 12%&nbsp;per annum. The convertible loan agreement provided that all principal and interest outstanding on the convertible loan would be
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">133
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
converted into shares upon the closing of a Class C preferred share financing round in accordance with the terms and provisions of the convertible loan agreement. As of June&nbsp;30, 2015, the
convertible loan had been drawn in the total amount of &#128;8.0 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In August 2015, we entered into a subscription agreement pursuant to which we issued and sold an aggregate of 7,469,780 of our Class C preferred shares at a price per share of &#128;6.66 for an aggregate
purchase price of &#128;49.7&nbsp;million, which includes the contribution of the existing &#128;8.0&nbsp;million convertible bridge loan and interest thereon. The Class C preferred share financing is divided into two tranches. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the first tranche, the lenders of the convertible bridge
loan agreed to contribute the principal amount of the existing &#128;8.0&nbsp;million convertible bridge loan and interest thereon and invest, together with certain new investors, an additional &#128;41.6&nbsp;million in cash. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the terms of the subscription agreement, the
second tranche of the Class C preferred share financing will automatically be cancelled upon the closing of this initial public offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the aggregate number of our Class C preferred shares purchased by our management board members, supervisory
board members and 5% shareholders and their affiliates, including shares issued upon conversion of the convertible bridge loan. Each Class C preferred share is convertible into one common share. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:51pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Participants(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class C<BR>Preferred&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sofinnova Venture Partners IX, L.P.(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,275,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novo A/S(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,206,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Baker Brothers Life Sciences L.P.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,113,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novartis Bioventures Ltd.(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">550,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bay City Capital Co&ouml;peratief U.A.(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">550,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Johnson &amp; Johnson Innovation&#151;JJDC, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">425,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aglaia Oncology Fund B.V./Aglaia Oncology Seed Fund B.V.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">416,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">366,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co&ouml;peratief LSP IV U.A.(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275,186</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional details regarding these shareholders and their equity holdings is provided in &#147;Principal Shareholders&#148;. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anand Mehra, a member of our supervisory board, is a general partner of Sofinnova Ventures. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jack Nielsen, a member of our supervisory board, is employed as a partner of Novo A/S. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Florent Gros, a member of our supervisory board, is a managing director of the Novartis Venture Fund and is an employee of a corporation that is affiliated with
Novartis Bioventures Ltd. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lionel Carnot, a member of our supervisory board, is a managing director of Bay City Capital LLC. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John de Koning, a member of our supervisory board, is a partner of Life Sciences Partners, which is affiliated with Co&ouml;peratief LSP&nbsp;IV U.A.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholders&#146; Agreement </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and all of our then-existing shareholders entered into a
shareholders&#146; agreement on August&nbsp;20, 2015. While the shareholders&#146; agreement will terminate upon the closing of this offering, certain provisions of this agreement, including our obligation to enter into a registration rights
agreement with certain of our existing shareholders upon the closing of this offering, will survive upon the closing of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration Rights Agreement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective upon the closing of this offering, we will enter into a registration rights agreement, pursuant to which we will grant demand
registration rights, short-form registration rights and piggyback registration rights to certain of our existing shareholders. All fees, costs and expenses of underwritten registrations are expected to be borne by us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">134
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Option Plan Foundation </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our 2010 Option Plan utilizes the Foundation to facilitate
administration of share-based compensation awards and pool the voting interests of the underlying shares. Upon the exercise or award or vesting of a non-cash-settled award under the 2010 Option Plan, common shares are issued to the Foundation, which
thereupon grants a non-voting depositary receipt representing the underlying common shares against payment of the option exercise price. All options vest 25% on the first anniversary of the grant date and the remaining 75% vest monthly over the next
three years, provided that the employee is still employed at the time of vesting. The depositary receipt holder is entitled to any dividends or other distributions paid on the shares for which the depositary receipts are granted. The voting rights
attached to the shares are exercised by the Foundation at its own discretion. The depositary receipt holders do not have meeting rights and they are not entitled to attend a general meeting of shareholders or to cast a vote. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The board members of the Foundation are Ton Logtenberg, our
Chief Executive Officer, and John de Koning, one of our supervisory board members. The articles of association of the Foundation provide that the board members of the Foundation shall be appointed by the management board of the Foundation.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, we intend
to transfer the common shares held by the Foundation to the relevant depositary holders and cancel the corresponding depositary receipts. The Foundation will be dissolved and deregistered with the trade register of the Dutch Chamber of Commerce once
the transfer has been effectuated. In addition, we intend to amend the 2010 Option Plan to reflect that an option entails the right of the holder to purchase common shares rather than depositary receipts. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Agreements with Management Board Members </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For a description of our agreements with our management
board members, please see &#147;Management&#151;Management Board Member Employment Agreements.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification Agreements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We intend to enter into indemnification agreements with our management board members and supervisory board members. Our Articles of Association require us to indemnify our management board members and
supervisory board members to the fullest extent permitted by law. See &#147;Management&#151;Insurance and Indemnification&#148; for a description of these indemnification agreements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Related Person Transaction Policy </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the closing of this offering, we intend to enter
into a related person transaction policy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">135
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_18"></A>DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>We were incorporated on June&nbsp;16, 2003 as a
private company with limited liability (<I>besloten vennootschap met beperkte aansprakelijkheid</I>) under Dutch law. Prior to the closing of this offering, we intend to convert into a public company with limited liability (<I>naamloze
vennootschap</I>) pursuant to a Deed of Amendment and Conversion, and our legal name will be Merus N.V.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>We are registered with the Trade Register of the Chamber of Commerce Den Haag, the Netherlands (<I>handelsregister van de Kamer van
Koophandel en Fabrieken Den Haag</I>) under number 30189136. Our corporate seat is in Utrecht, the Netherlands, and our registered office is Padualaan 8 (postvak 133), 3584 CH Utrecht, the Netherlands.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of September 30, 2015, our share capital was divided
into several series of preferred shares and common shares. All of our outstanding preferred shares will be converted into common shares in connection with this offering. Additionally, we will issue 1,622,840 common shares to the holders of our Class
B and C preferred shares in satisfaction of their entitlement to distributions in kind accrued as of September 30, 2015. An additional 291,525 common shares are issuable to these holders in satisfaction of their entitlement to distributions in kind
that accrued from October 1, 2015 to December 31, 2015, and distributions will continue to accrue until conversion of the preferred shares, all of which is described in more detail in &#147;Capitalization&#151;Preferred Share Distributions.&#148;
After giving effect to this offering and the automatic conversion of our outstanding preferred shares as of September 30, 2015 into 14,900,456 common shares and the additional 1,622,840 common shares issuable to holders of our Class B and C
preferred shares in satisfaction of their entitlement to distributions in kind as of September 30, 2015, our issued share capital will be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the execution of the Deed of Amendment and Conversion
upon the effectiveness of the registration statement of which this prospectus forms a part, our authorized share capital will be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , divided
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares, each with a nominal value of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cumulative preferred shares, each with a nominal value of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We have adopted an anti-takeover measure pursuant to which
our management board may, subject to supervisory board approval but without shareholder approval, issue (or grant the right to acquire) cumulative preferred shares. Under our Articles of Association, the general meeting is authorized to issue common
shares and preferred shares, but the general meeting may authorize another body to issue such shares. Subject to the prior approval of the supervisory board, the management board may authorize the issue of an amount of cumulative preferred shares up
to 100% of our issued capital immediately prior to the issuance of such preferred shares for a period of five years. In such event, the cumulative preferred shares will be issued to a separate, newly established foundation. If the management board
determines to issue the cumulative preferred shares to such a foundation, the foundation&#146;s articles of association will provide that it will act to serve the best interests of us, our associated business and all parties connected to us, by
opposing any influences that conflict with these interests and threaten to undermine our continuity, independence and identity. This foundation will be structured to operate independently of us. Our Articles of Association state that any transfer of
preferred shares requires the prior approval of our management board. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The cumulative preferred shares will be issued to the foundation for their nominal value, of which only 25% will be due upon issuance. The voting rights of our shares are based on nominal value and as we
expect our shares to trade substantially in excess of nominal value, cumulative preferred shares issued at nominal value can obtain significant voting power for a substantially reduced price and thus can be used as a defensive measure. These
cumulative preferred shares will have both a liquidation and dividend preference over our common shares and will accrue cash dividends at a fixed rate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The management board may issue these cumulative preferred shares to protect us from influences that do not serve our best interests and
threaten to undermine our continuity, independence and identity. These influences may include a third-party acquiring a significant percentage of our common shares, the announcement </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">136
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of a public offer for our common shares, other concentration of control over our common shares or any other form of pressure on us to alter our strategic policies. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Dutch law, our authorized share capital is the maximum
capital that we may issue without amending our Articles of Association. An amendment of our Articles of Association would require a resolution of the general meeting of shareholders upon proposal by the management board with the prior approval of
the supervisory board. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied to list
our common shares on NASDAQ under the symbol &#147;MRUS.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Initial settlement of the common shares issued in this offering will take place on the closing of this offering through The Depository Trust Company, or DTC, in accordance with its customary settlement
procedures for equity securities. Each person owning common shares held through DTC must rely on the procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the common shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Articles of Association and Dutch law </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Articles of Association as are in force as of the date
of this prospectus are referred to herein as our &#147;Current Articles.&#148; When we refer to our Articles of Association in this prospectus, we refer to our Articles of Association as they will be in force after the expected execution of the Deed
of Amendment and Conversion prior to the closing of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I>Our Current Articles were last amended by Deed of Amendment on August&nbsp;21, 2015. We shall further amend our Current Articles and convert our Company into a public company with limited liability
effective prior to the closing of this offering. On &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016, the general meeting of shareholders, with the prior written approval
of the preferred majority of the Class&nbsp;A, Class B and Class C shareholders meeting jointly, resolved to amend the Current Articles and to convert our company into a public company with limited liability (<I>naamloze venootschap</I>), prior to
the closing of this offering. The draft Deed of Amendment and Conversion was made available to the shareholders prior to the date of such resolution and remains available for inspection by interested parties at our offices in Utrecht up to and
including the date of closing of this offering.<I> </I></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Set forth below is a summary of relevant information concerning our share capital and material provisions of our Articles of Association and applicable Dutch law. This summary does not constitute legal
advice regarding those matters and should not be regarded as such. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendment of Articles of Association </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The general meeting of shareholders may resolve to amend the Articles of Association, at the proposal of the management board, with the prior approval of the supervisory board. A resolution by the general
meeting of shareholders to amend the Articles of Association requires a simple majority of the votes cast. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Company&#146;s Shareholders&#146; Register </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Subject to Dutch law and the Articles of Association,
we must keep our shareholders&#146; register accurate and up-to-date. The management board keeps our shareholders&#146; register and records names and addresses of all holders of shares, showing the date on which the shares were acquired, the date
of the acknowledgement by or notification of us as well as the amount paid on each share. The register also includes the names and addresses of those with a right of use and enjoyment (<I>vruchtgebruik</I>) in shares belonging to another or a pledge
in respect of such shares.<I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">137
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Corporate Objectives </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our corporate objectives are: (1)&nbsp;to develop products and services in the area of biotechnology,
(2)&nbsp;to finance enterprises and companies, (3)&nbsp;to borrow, to lend to raise funds, including the issue of bonds, promissory notes or other securities or evidence of indebtedness as well as to enter into agreements in connection with the
aforementioned, (4)&nbsp;to supply advice and to render services to enterprises and companies with which the Company forms a group and to third parties, (5)&nbsp;to render guarantees, to bind the Company and to encumber its assets for obligations of
the companies and enterprises with which it forms a group and on behalf of third parties, (6)&nbsp;to incorporate, to participate in any way whatsoever, to manage and to supervise enterprises and companies and businesses, (7)&nbsp;to obtain,
alienate, manage and exploit registered property and items of property in general, (8)&nbsp;to trade in currencies, securities and items of property in general, (9)&nbsp;to develop and trade in patent, trademarks, licenses, know-how and other
industrial property rights, (10)&nbsp;to perform any and all activity of industrial, financial or commercial nature, with all of the foregoing whether independently or in cooperation with third parties and including the performance and support of
everything which in the broadest sense is connected directly or indirectly with the above-mentioned objects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Limitation on Liability and Indemnification Matters </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Dutch law, management board members, supervisory board
members and certain other officers may be held liable for damages in the event of improper or negligent performance of their duties. They may be held jointly and severally liable for damages to the Company and to third parties for infringement of
the Articles of Association or of certain provisions of the Dutch Civil Code. In certain circumstances, they may also incur additional specific civil and criminal liabilities. Management board members, supervisory board members and certain other
officers are insured under an insurance policy taken out by us against damages resulting from their conduct when acting in the capacities as such directors or officers. In addition, our Articles of Association provide for indemnification of our
management board members and supervisory board members, including reimbursement for reasonable legal fees and damages or fines based on acts or failures to act in their duties. No indemnification shall be given to a member of the management board or
supervisory board if a Dutch court has established, without possibility for appeal, that the acts or omissions of such indemnified officer that led to the financial losses, damages, suit, claim, action or legal proceedings resulted from either an
improper performance of his or her duties as an officer of the Company or an unlawful or illegal act, and only to the extent that his or her financial losses, damages and expenses are covered by an insurance and the insurer has settled these
financial losses, damages and expenses (or has indicated that it would do so). Furthermore, such indemnification will generally not be available in instances of willful (<I>opzettelijk</I>), intentionally reckless (<I>bewust roekeloos</I>) or
seriously culpable (<I>ernstig verwijtbaar</I>) conduct unless Dutch law provides otherwise for additional information, please see &#147;Management&#151;Insurance and indemnification.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shareholders&#146; Meetings and Consents </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>General Meeting </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General meetings of shareholders are held in Utrecht,
Amsterdam, Rotterdam, The Hague or in the municipality of Haarlemmermeer (Schiphol Airport), all of which are in the Netherlands. The annual general meeting of shareholders must be held within six months of the end of each financial year. Additional
extraordinary general meetings of shareholders may also be held, whenever considered appropriate by the management board or the supervisory board. Pursuant to Dutch law, one or more shareholders, who jointly represent at least one-tenth of the
issued capital may request us to convene a general meeting. If we refuse to convene a meeting, such shareholder may, on their application, be authorized by Court to convene a general meeting of shareholders. The Court shall disallow the application
if it does not appear that the applicants have previously requested the management board and the supervisory board to convene a general meeting of shareholders and neither the management board nor the supervisory board has taken the necessary steps
so that the general meeting of shareholders could be held within six weeks after the request. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">138
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General meetings of shareholders can be convened by a notice, which shall include an agenda
stating the items to be discussed, including for the annual general meeting of shareholders, among other things, the adoption of the annual accounts, appropriation of our profits and proposals relating to the composition of the management board or
supervisory board, including the filling of any vacancies in the management board or supervisory board. In addition, the agenda shall include such items as have been included therein by the management board or supervisory board. The agenda shall
also include such items requested by one or more shareholders, and others entitled to attend general meetings of shareholders, representing at least 3% of the issued share capital. Requests must be made in writing and received by the management
board at least 60 days before the day of the convocation of the meeting. No resolutions shall be adopted on items other than those which have been included in the agenda. In accordance with the Dutch Corporate Governance Code, or DCGC, a shareholder
shall exercise the right of putting an item on the agenda only after consulting the management board in that respect. If one or more shareholders intend to request that an item be put on the agenda that may result in a change in the company&#146;s
strategy, the management board may invoke a response time of a maximum of 180 days until the day of the general meeting of shareholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The general meeting is presided over by the chairman of the supervisory board. However, the chairman may charge another person to preside
over the general meeting in his place even if he himself is present at the meeting. If the chairman of the supervisory board is absent and he has not charged another person to preside over the meeting in his place, the supervisory board members
present at the meeting shall appoint one of them to be chairman. If no members of the supervisory board are present at the general meeting, the general meeting is to be presided over by the chairman of the management board or, if the chairman of the
management board is absent, by one of the other management board members designated for that purpose by the management board or, if no member of the management board is present, by any other person appointed by the general meeting. Management board
members and supervisory board members may attend a general meeting of shareholders. In these meetings, they have an advisory vote. The chairman of the meeting may decide at its discretion to admit other persons to the meeting. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All shareholders and others entitled to attend general
meetings of shareholders are authorized to attend the general meeting of shareholders, to address the meeting and, in so far as they have such right, to vote. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Quorum and Voting Requirements </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Each common share confers the right on the holder to cast one vote at the general meeting of shareholders. Shareholders may vote by
proxy. The voting rights attached to any shares held by us are suspended as long as they are held in treasury. Nonetheless, the holders of a right of use and enjoyment (<I>vruchtgebruik)</I> in shares belonging to another and the holders of a right
of pledge in respect of common shares held by us are not excluded from any right they may have to vote on such common shares, if the right of use and enjoyment (<I>vruchtgebruik</I>) or the right of pledge was granted prior to the time such common
share was acquired by us. We may not cast votes in respect of a share in respect of which there is a right of use and enjoyment (<I>vruchtgebruik</I>) or a right of pledge. Shares which are not entitled to voting rights pursuant to the preceding
sentences will not be taken into account for the purpose of determining the number of shareholders that vote and that are present or represented, or the amount of the share capital that is provided or that is represented at a general meeting of
shareholders.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with Dutch law
and generally accepted business practices, our Articles of Association do not provide quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of NASDAQ Listing Rule
5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting stock. Decisions of the general meeting of shareholders are taken by an
absolute majority of votes cast, except where Dutch law or the Articles of Association provide for a qualified majority or unanimity. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">139
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Management Board Members and Supervisory Board Members </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Election of Management Board Members and Supervisory
Board Members </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under our Articles of
Association, the management board members and supervisory board members are appointed by the general meeting of shareholders upon nomination by our supervisory board. However, the general meeting of shareholders may at all times overrule the binding
nomination by a resolution adopted by at least a two-thirds majority of the votes cast, provided such majority represents more than half of the issued share capital. If the general meeting of shareholders overrules the binding nomination, the
supervisory board shall make a new nomination. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Duties and Liabilities of Management Board Members and Supervisory Board Members </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Dutch law, the management board is responsible for our
management, strategy, policy and operations. The supervisory board is responsible for supervising the conduct of and providing advice to the management board and for supervising our business generally. Furthermore, each management board member and
supervisory board member has a duty to act in the corporate interest of the company. Under Dutch law, the corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers.
The duty to act in the corporate interest of the company also applies in the event of a proposed sale or break-up of the company, whereby the circumstances generally dictate how such duty is to be applied. Any resolution of the management board
regarding a significant change in our identity or character requires shareholder approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dividends and Other Distributions </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Amount Available for Distribution </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a Dutch public Company with limited liability (<I>naamloze vennootschap</I>), we may only make distributions to our shareholders if our shareholders&#146; equity exceeds the sum of the paid-in and
called-up share capital plus the reserves as required to be maintained by Dutch law or by the Articles of Association. Under the Articles of Association, a dividend is first paid out of the profit, if available for distribution, on any preferred
shares. After that, the management board shall determine which part of the remaining profit shall be added to our reserves. After reservation by the management board of any profit, the remaining profit will be at the disposal of the general meeting
of shareholders. However, a distribution to the holders of common shares can only be resolved upon by the general meeting upon a proposal of the management board, subject to the approval of the supervisory board. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We only make a distribution of dividends to our shareholders
after the adoption of our annual accounts demonstrating that such distribution is legally permitted. The management board is permitted, subject to certain requirements and subject to approval of the supervisory board, to declare interim dividends
without the approval of the general meeting of shareholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I>Dividends and other distributions shall be made payable not later than the date determined by the management board. Claims to dividends and other distributions not made within five years from the
date that such dividends or distributions became payable, will lapse and any such amounts will be considered to have been forfeited to us (<I>verjaring</I>).<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not anticipate paying any cash dividends for the
foreseeable future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exchange Controls
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under existing laws of the Netherlands,
there are no exchange controls applicable to the transfer to persons outside of the Netherlands of dividends or other distributions with respect to, or of the proceeds from the sale of, shares of a Dutch company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">140
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Squeeze out Procedures </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Pursuant to Section&nbsp;92a, Book 2, Dutch Civil Code, a shareholder who for his own account
contributes at least 95% of our issued share capital may initiate proceedings against our minority shareholders jointly for the transfer of their shares to the claimant. The proceedings are held before the Enterprise Chamber and can be instituted by
means of a writ of summons served upon each of the minority shareholders in accordance with the provisions of the Dutch Code of Civil Procedure (<I>Wetboek van Burgerlijke Rechtsvordering</I>). The Enterprise Chamber may grant the claim for squeeze
out in relation to all minority shareholders and will determine the price to be paid for the shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise Chamber on the value to be paid for the shares of
the minority shareholders. Once the order to transfer<I> </I>becomes final before the Enterprise Chamber, the person acquiring the shares shall give written notice of the date and place of payment and the price to the holders of the shares to be
acquired whose addresses are known to him. Unless the addresses of all of them are known to the acquiring person, such person is required to publish the same in a daily newspaper with a national circulation.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Obligation to Disclose Holdings and Transactions
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Pursuant to the Dutch Financial
Markets Supervision Act (<I>Wet op het financieel toezicht</I>), or FMSA, any management board member or supervisory board member and any other person who has managerial or co-managerial responsibilities in respect of us or who has the authority to
make decisions affecting our future developments and business prospects and who may have regularly access to inside information relating, directly or indirectly, to us, must give written notice to the Netherlands Authority for the Financial Markets,
or NAFM, by means of a standard form of any transactions conducted for his own account relating to our shares or in financial instruments the value of which is also based on the value of our shares.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, in accordance with the FMSA and the regulations
promulgated thereunder, certain persons who are closely associated with members of our supervisory board or any of the other persons as described above, are required to notify the NAFM of any transactions conducted for their own account relating to
our shares or in financial instruments the value of which is also based on the value of our shares. The FMSA and the regulations promulgated thereunder cover the following categories of persons: (1)&nbsp;the spouse or any partner considered by
national law as equivalent to the spouse, (2)&nbsp;dependent children, (3)&nbsp;other relatives who have shared the same household for at least one year at the relevant transaction date, and (4)&nbsp;any legal person, trust or partnership whose,
among other things, managerial responsibilities are discharged by a person referred to under (1), (2)&nbsp;or (3)&nbsp;above or by the relevant supervisory board member or other person with any authority in respect of us as described above.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The NAFM must be notified no later than the fifth
business day following the relevant transaction date. Under certain circumstances, notification may be postponed until the date the value of the transactions performed for that person&#146;s own account, together with transactions carried out by the
persons closely associated with that person, amounts to &#128;5,000 or more in the calendar year in question. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-compliance with the notification obligations under the FMSA could lead to criminal fines, administrative fines, imprisonment or other
sanctions. In addition, non-compliance with some of the notification obligations under the FMSA may lead to civil sanctions, including suspension of the voting rights relating to our shares held by the offender for a period of not more than three
years and a prohibition to own shares or voting rights on our shares for a period of not more than five years. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The NAFM does not issue separate public announcements of notifications received by it. It does, however, keep a public register of all
notifications under the FMSA on its website, http://www.afm.nl. Third parties can request to be notified automatically by e-mail of changes to the public register in relation to a particular company&#146;s shares or a particular notifying party.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FMSA contains rules intended to prevent
market abuse, such as insider trading, tipping and market manipulation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">141
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the DCGC and in accordance with the rules intended to prevent market abuse,
prior to the closing of this offering we intend to adopt an insider trading policy in respect of the holding of and carrying out of transactions by management board members, supervisory board members and employees in our shares or in financial
instruments the value of which is determined by the value of our shares. Furthermore, we have drawn up a list of those persons working for us who could have access to inside information on a regular or incidental basis and have informed such persons
of the rules on insider trading and market manipulation, including the sanctions which can be imposed in the event of a violation of those rules. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Comparison of Dutch Corporate Law and Our Articles of Association and U.S. corporate law </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following comparison between Dutch corporation law, which applies to us, and Delaware corporation law, the
law under which many publicly listed corporations in the United States are incorporated, discusses additional matters not otherwise described in this prospectus. Although we believe this summary is materially accurate, the summary is subject to
Dutch law, including Book 2 of the Dutch Civil Code and Delaware corporation law, including the Delaware General Corporation Law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Corporate Governance </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Duties of Management Board Members and Supervisory Board Members </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;We have a two-tier board structure consisting of our management
board (<I>raad van bestuur</I>) and a separate supervisory board (<I>raad van commissarissen</I>).<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Dutch law, the management board is responsible for the management and the strategy, policy and operations of the company. The
supervisory board is responsible for supervising the conduct of and providing advice to the management board and for supervising the business generally. Furthermore, each management board member and supervisory board member has a duty to act in the
corporate interest of the company. Under Dutch law, the corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers. The duty to act in the corporate interest of the
company also applies in the event of a proposed sale or break-up of the company, whereby the circumstances generally dictate how such duty is to be applied. Any resolution of the management board regarding a significant change in the identity or
character of the company requires shareholders&#146; approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a
Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise informed business judgment in the
performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of
a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation,
the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Management Board Member and Supervisory Board Member Terms </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the
Netherlands, management board members and supervisory board members of a listed company are generally appointed for an individual term of a maximum of four years. There is no limit in the number of consecutive terms management board members may
serve. For supervisory board members, a limit of twelve years generally applies. Each of our management board members currently has an employment agreement for an indefinite period of time. Our supervisory board members are appointed by the general
meeting of shareholders for a term of up to four years. A supervisory board member may be reappointed for a term of up </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">142
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to four years at a time. A supervisory board member may be a supervisory board member for a period not longer than twelve years, which period may or may not be interrupted, unless the general
meeting of shareholders resolves otherwise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
general meeting of shareholders shall at all times be entitled to suspend or dismiss a management board member or supervisory board member. The general meeting of shareholders may only adopt a resolution to suspend or dismiss such management board
member or supervisory board member by at least a two thirds majority of the votes cast, if such majority represents more than half of the issued share capital, unless the proposal was made by the supervisory board, in which case a simple majority of
the votes cast is sufficient. The supervisory board may at all times suspend (but not dismiss) a management board member. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law generally provides for a one-year term for directors, but
permits directorships to be divided into up to three classes with up to three-year terms, with the years for each class expiring in different years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted by the
stockholders. A director elected to serve a term on a &#147;classified&#148; board may not be removed by stockholders without cause. There is no limit in the number of terms a director may serve. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Management Board Member and Supervisory Board Member
Vacancies </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The
Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under Dutch law, new management board members and supervisory board members are appointed by the general meeting of shareholders. Under our Articles of Association, management board members and supervisory
board members are appointed by the general meeting of shareholders upon the binding nomination by our supervisory board. However, the general meeting of shareholders may at all times overrule the binding nomination by a resolution adopted by at
least a two-thirds majority of the votes cast, provided such majority represents more than half of the issued share capital. If the general meeting of shareholders overrules the binding nomination, the supervisory board shall make a new
nomination.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law provides that vacancies and newly created directorships may
be filled by a majority of the directors then in office (even though less than a quorum) unless (i)&nbsp;otherwise provided in the certificate of incorporation or bylaws of the corporation or (ii)&nbsp;the certificate of incorporation directs that a
particular class of stock is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy. <I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Conflict-of-Interest Transactions </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under Dutch
law and our Articles of Association, management board members and supervisory board members shall not take part in any discussion or decision-making that involves a subject or transaction in relation to which he or she has a conflict of interest
with us. Our Articles of Association provide that if as a result thereof no resolution of the management board can be adopted, the resolution is adopted by the supervisory board. If as a result of the conflict of interest of supervisory board
members no resolution of the supervisory board can be adopted, the resolution can nonetheless be adopted by the supervisory board. In that case, <I></I>each supervisory board member is entitled to participate in the discussion and decision making
process and to cast a vote.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law generally permits transactions involving a Delaware
corporation and an interested director of that corporation if:<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the material facts as to the director&#146;s relationship or interest are disclosed and a majority of disinterested directors consent;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the material facts are disclosed as to the director&#146;s relationship or interest and a majority of shares entitled to vote thereon consent; or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of the board of directors or the
stockholders. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">143
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Proxy Voting by Management Board Members and Supervisory Board Members
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The
Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;An absent management board member may issue a proxy for a specific management board meeting but only to another management board member in writing. An absent supervisory board member may issue a proxy for a
specific supervisory board meeting but only to another supervisory board member in writing.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;A director of a Delaware corporation may not issue a proxy representing the director&#146;s voting rights as a director.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shareholder Rights </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Voting Rights </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;In accordance
with Dutch law and our Articles of Association, each issued common share confers the right to cast one vote at the general meeting of shareholders. Each holder of common shares may cast as many votes as it holds shares. Shares that are held by us or
our direct or indirect subsidiaries do not confer the right to vote.&nbsp;<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For each general meeting of shareholders, a record date will be applied with respect to common shares in order to establish which shareholders are entitled to attend and vote at the general meeting of
shareholders, which date is set by the management board. The record date and the manner in which shareholders can register and exercise their rights will be set out in the notice of the meeting. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware
General Corporation Law, each stockholder is entitled to one vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of
directors of the corporation, or at elections held under specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in
order to constitute a quorum, but in no event will a quorum consist of less than one third of the shares entitled to vote at a meeting.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders as of the record date for the meeting are entitled to vote at the meeting, and the board of directors may fix a record date
that is no more than 60 nor less than 10&nbsp;days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given, or if notice is waived then the
record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the stockholders of record entitled to notice or to vote at a meeting of stockholders shall apply to any adjournment of the
meeting, but the board of directors may fix a new record date for the adjourned meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Shareholder Proposals </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands.&nbsp;&nbsp;&nbsp;&nbsp;</I>Pursuant to our Articles of Association, extraordinary general meetings of shareholders will be held whenever our supervisory board or management board deems
such to be necessary. Pursuant to Dutch law, one or more shareholders representing at least one-tenth of the issued share capital may request the Dutch courts to order that a general meeting of shareholders be held and may, on their application, be
authorized by the court to convene a general meeting of shareholders if we refuse to convene a general meeting at their request. The court shall disallow the application if it does not appear that the applicants have previously requested the
management board and the supervisory board to convene a general meeting of shareholders and neither the management nor the supervisory board has taken the necessary steps so that the general meeting of shareholders could be held within six weeks
after the request.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also, the agenda for a
general meeting of shareholders shall include such items requested by one or more shareholders, and others entitled to attend general meetings of shareholders, representing at least 3% of the issued
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">144
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
share capital, except where the articles of association state a lower percentage. Our Articles of Association do not state such lower percentage. Requests must be made in writing and received by
the management board at least 60 days before the day of the convocation of the meeting. In accordance with the DCGC, a shareholder shall exercise the right of putting an item on the agenda only after consulting the management board in that respect.
If one or more shareholders intend to request that an item be put on the agenda that may result in a change in the company&#146;s strategy, the management board may invoke a response time of a maximum of 180 days until the day of the general meeting
of shareholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware law does not specifically grant stockholders the right to bring business before an
annual or special meeting. However, if a Delaware corporation is subject to the SEC&#146;s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation&#146;s securities entitled to vote, may propose a matter for a
vote at an annual or special meeting in accordance with those rules.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Action by Written Consent </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under our Articles of Association, shareholders&#146; resolutions may be adopted in writing without holding a meeting of shareholders, provided that
(i)&nbsp;all shareholders agree on this practice for decision making and, (ii)&nbsp;the resolution is adopted unanimously by all shareholders that are entitled to vote. For a listed company, this method of adopting resolutions is not feasible.<I>
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Although permitted by Delaware law, publicly listed companies do not typically permit stockholders
of a corporation to take action by written consent.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Appraisal Rights </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;The concept of appraisal rights is not known as such under Dutch law. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">However, pursuant to Dutch law a shareholder who for his own
account contributes at least 95% of our issued share capital may initiate proceedings against our minority shareholders jointly for the transfer of their shares to the claimant. The proceedings are held before the Enterprise Chamber. The Enterprise
Chamber may grant the claim for squeeze out in relation to all minority shareholders and will determine the price to be paid for the shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise Chamber
on the value to be paid for the shares of the minority shareholders. Once the order to transfer becomes final before the Enterprise Chamber, the person acquiring the shares shall give written notice of the date and place of payment and the price to
the holders of the shares to be acquired whose addresses are known to him. Unless the addresses of all of them are known to the acquiring person, such person is required to publish the same in a daily newspaper with a national circulation.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, in accordance with the directive
2005/56/EC of the European Parliament and the Council of October&nbsp;26, 2005 on cross-border mergers of limited liability companies, Dutch law provides that, to the extent that the acquiring company in a cross-border merger is organized under the
laws of another EU member state, a shareholder of a Dutch disappearing company who has voted against the cross-border merger may file a claim with the Dutch company for compensation. Such compensation to be determined by one or more independent
experts. The shares of such shareholder that are subject to such claim will cease to exist as of the moment of entry into effect of the cross-border merger. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment by the acquiring company is only possible if the resolution to approve the cross-border merger by the corporate body of the other
company or companies involved in the cross-border merger includes the acceptance of the rights of the shareholders of the Dutch company to oppose the cross-border merger. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General
Corporation Law provides for stockholder appraisal rights, or the right to demand payment in cash of the judicially determined fair value of the stockholder&#146;s shares, in connection with certain mergers and consolidations.<I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">145
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Shareholder Suits </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event a third party is liable to a Dutch company, only
the company itself can bring a civil action against that party. The individual shareholders do not have the right to bring an action on behalf of the company. Only in the event that the cause for the liability of a third party to the company also
constitutes a tortious act directly against a shareholder does that shareholder have an individual right of action against such<I> </I>third party in its own name. The Dutch Civil Code provides for the possibility to initiate such actions
collectively. A foundation or an association whose objective is to protect the rights of a group of persons having similar interests can institute a collective action. The collective action itself cannot result in an order for payment of monetary
damages but may only result in a declaratory judgment (<I>verklaring voor recht</I>). In order to obtain compensation for damages, the foundation or association and the defendant may reach&#151;often on the basis of<I> </I>such declaratory
judgment&#151;a settlement. A Dutch court may declare the settlement agreement binding upon all the injured parties with an opt-out choice for an individual injured party. An individual injured party may also itself institute a civil claim for
damages.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf
of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action under Delaware law
have been met. A person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a stockholder
at the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate
claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Repurchase of Shares </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under Dutch law, a company such as ours may not subscribe for newly issued shares in its
own capital. Such company may, however, subject to certain restrictions of Dutch law and its Articles of Association, acquire shares in its own capital. We may acquire fully paid shares in our own capital at any time for no valuable consideration.
Furthermore, subject to certain provisions of Dutch law and our Articles of Association, we may repurchase fully paid shares in our own capital if (i)&nbsp;such repurchase would not cause our shareholders&#146; equity to fall below an amount equal
to the sum of the paid-up and called-up part of the issued share capital and the reserves we are required to maintain pursuant to applicable law and (ii)&nbsp;we would not as a result of such repurchase hold more than 50% of our own issued share
capital.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other than shares acquired for no
valuable consideration, common shares may only be acquired following a resolution of our management board, acting pursuant to an authorization for the repurchase of shares granted by the general meeting of shareholders. An authorization by the
general meeting of shareholders for the repurchase of shares can be granted for a maximum period of 18 months. Such authorization must specify the number and class of shares that may be acquired, the manner in which these shares may be acquired and
the price range within which the shares may be acquired. Our management board has been authorized, acting with the approval of our supervisory board, for a period of 18 months to cause the repurchase of common shares by us of up to 50% of our issued
share capital, for a price per share not exceeding 110% of the average closing price of the common shares on the NASDAQ Global Market for the five trading days prior to the day of purchase. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No authorization of the general meeting of shareholders is required if common shares are acquired by us with
the intention of transferring such common shares to our employees under an applicable employee stock purchase plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares
unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of<I>
</I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">146
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
</I>its preferred shares or, if no preferred shares are outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in
accordance with specified limitations. <I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Anti-takeover Provisions </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under Dutch law, various protective measures are possible and permissible within the
boundaries set by Dutch law and Dutch case law. We have adopted several provisions that may have the effect of making a takeover of our company more difficult or less attractive, including:<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the authorization of a class of cumulative preferred shares that may be issued by our management board to a friendly party, subject to the approval of
our supervisory board, in such a manner as to dilute the interest of any potential acquirer; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the staggered four-year terms of our supervisory board members, as a result of which only approximately one-fourth of our supervisory board members
will be subject to election in any one year; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a provision that our management board and supervisory board members may only be removed at the general meeting of shareholders by a two-thirds majority
of votes cast representing more than half of our outstanding share capital if such removal is not proposed by our supervisory board; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">requirements that certain matters, including an amendment of our Articles of Association, may only be brought to our shareholders for a vote upon a
proposal by our management board that has been approved by our supervisory board. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains
a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;203 of the Delaware General Corporation Law
prohibits &#147;business combinations,&#148; including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that beneficially owns 15% or more of a
corporation&#146;s voting stock, within three years after the person becomes an interested stockholder, unless: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the transaction that will cause the person to become an interested stockholder is approved by the board of directors of the target prior to the
transactions; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">after the completion of the transaction in which the person becomes an interested stockholder, the interested stockholder holds at least 85% of the
voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">after the person becomes an interested stockholder, the business combination is approved by the board of directors of the corporation and holders of at
least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A Delaware corporation may elect not to be governed by Section&nbsp;203 by a provision contained in the original certificate of
incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board
of directors of the corporation. Such an amendment is not effective until twelve months following its adoption. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Inspection of Books and Records </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;The management board and the supervisory board provide the general meeting of shareholders
in good time with all information that the shareholders require for the exercise of their powers, unless this would be contrary to an overriding interest of us. If the management board or supervisory board invokes an overriding interest, it must
give reasons.<I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">147
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, any
stockholder may inspect for any proper purpose certain of the corporation&#146;s books and records during the corporation&#146;s usual hours of business.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Removal of Management Board Member and Supervisory Board Member </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under our Articles of Association, the general meeting of
shareholders shall at all times be entitled to suspend or dismiss a management board member or supervisory board member. The general meeting of shareholders may only adopt a resolution to suspend or dismiss such a member by at least a two thirds
majority of the votes cast, provided such majority represents more than half of the issued share capital, unless the proposal was made by the supervisory board in which case a simple majority of the votes cast is sufficient.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware
General Corporation Law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i)&nbsp;unless the certificate of
incorporation provides otherwise, in the case of a corporation whose board is classified, stockholders may effect such removal only for cause, or (ii)&nbsp;in the case of a corporation having cumulative voting, if less than the entire board is to be
removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an
election of the class of directors of which he is a part.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Preemptive Rights </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under Dutch law, in the event of an issuance of common shares, each shareholder will have a pro rata preemptive right in proportion to the aggregate nominal
value of the common shares held by such holder (with the exception of common shares to be issued to employees or common shares issued against a contribution other than in cash). Under our Articles of Association, the preemptive rights in respect of
newly issued common shares may be restricted or excluded by a resolution of the general meeting of shareholders upon proposal of the management board, subject to the approval of the supervisory board.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The management board, subject to approval of the supervisory
board, may restrict or exclude the preemptive rights in respect of newly issued common shares if it has been designated as the authorized body to do so by the general meeting of shareholders. Such designation can be granted for a period not
exceeding five years. A resolution of the general meeting of shareholders to restrict or exclude the preemptive rights or to designate the management board as the authorized body to do so requires a two-thirds majority of the votes cast, if less
than one&nbsp;half of our issued share capital is represented at the meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At our annual general meeting held on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016, our shareholders authorized our
management board acting with the approval of our supervisory board for a period of five years from the closing of this offering to limit or exclude preemptive rights accruing to shareholders in connection with the issue of common shares or rights to
subscribe for common shares. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No preemptive
rights apply in respect of cumulative preferred shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, stockholders have no preemptive rights to subscribe for additional issues of stock or to any security convertible into
such stock unless, and to the extent that, such rights are expressly provided for in the certificate of incorporation.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dividends </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Dutch law provides that dividends may be distributed after adoption of the annual accounts
by the general meeting of shareholders from which it appears that such dividend distribution is allowed. Moreover, dividends may be distributed only to the extent the shareholders&#146; equity exceeds the amount of the<I>
</I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">148
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
</I>paid-<I></I>up and called-up part of the issued share capital and the reserves that must be maintained under Dutch law or the Articles of Association. Interim dividends may be declared as
provided in the Articles of Association and may be distributed to the extent that the shareholders&#146; equity exceeds the amount of the issued and paid-up and called-up part of the issued share capital and the required legal reserves as described
above as apparent from our financial statements. Under Dutch law, the Articles of Association may prescribe that the management board decides what portion of the profits are to be held as reserves.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Articles of Association, a dividend is first paid
out of the profit, if available for distribution, on any preferred shares. After that, the management board shall determine which part of the remaining profit shall be added to our reserves. After reservation by the management board of any profit,
the remaining profit will be at the disposal of the general meeting of shareholders. However, a distribution to the holders of common shares can only be resolved upon by the general meeting at the proposal of the management board, subject to the
approval of the supervisory board. We only make a distribution of dividends to our shareholders after the adoption of our annual accounts demonstrating that such distribution is legally permitted. The management board is permitted, subject to
certain requirements and subject to approval of the supervisory board, to declare interim dividends without the approval of the general meeting of shareholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Dividends and other distributions shall be made payable not later than the date determined by the management board. Claims to
dividends and other distribution not made within five years from the date that such dividends or distributions became payable, will lapse and any such amounts will be considered to have been forfeited to us (<I>verjaring</I>).<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware
General Corporation Law, a Delaware corporation may pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the
preceding fiscal year (provided that the amount of the capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of
assets). In determining the amount of surplus of a Delaware corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors,
without regard to their historical book value. Dividends may be paid in the form of common shares, property or cash.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shareholder Vote on Certain Reorganizations </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under Dutch
law, the general meeting of shareholders must approve resolutions of the management board relating to a significant change in the identity or the character of the company or the business of the company, which includes:<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a transfer of the business or virtually the entire business to a third party; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the entry into or termination of a long-term cooperation of the company or a subsidiary with another legal entity or company or as a fully liable
partner in a limited partnership or general partnership, if such cooperation or termination is of a far-reaching significance for the company; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the acquisition or divestment by the company or a subsidiary of a participating interest in the capital of a company having a value of at least one
third of the amount of its assets according to its balance sheet and explanatory notes or, if the company prepares a consolidated balance sheet, according to its consolidated balance sheet and explanatory notes in the last adopted annual accounts of
the company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Under Dutch
law, a shareholder who owns shares representing at least 95% of the nominal value of a company&#146;s issued share capital may institute proceedings against the company&#146;s other shareholders jointly for the transfer of their shares to that
shareholder. The proceedings are held before the Enterprise Chamber (<I>Ondernemingskamer</I>), which may grant the claim for squeeze-out in relation to all minority shareholders and will determine the price to be paid for the shares, if necessary
after appointment of experts who will offer an opinion to the Enterprise Chamber on the value of the shares.<I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">149
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, the vote
of a majority of the outstanding shares of capital stock entitled to vote thereon generally is necessary to approve a merger or consolidation or the sale of all <I></I>or substantially all of the assets of a corporation. The Delaware General
Corporation Law permits a corporation to include in its certificate of incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required.<I>
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Delaware General Corporation Law,
no vote of the stockholders of a surviving corporation to a merger is needed, however, unless required by the certificate of incorporation, if (i)&nbsp;the agreement of merger does not amend in any respect the certificate of incorporation of the
surviving corporation, (ii)&nbsp;the shares of stock of the surviving corporation are not changed in the merger and (iii)&nbsp;the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations
to be issued in the merger may be converted does not exceed 20% of the surviving corporation&#146;s common stock outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be entitled to vote in certain
mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such corporation, but the stockholders will be entitled to appraisal rights. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration of Management Board Members and Supervisory Board Members </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The Netherlands</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under Dutch
law and our Articles of Association, we must adopt a remuneration policy for management board members. Such remuneration policy shall be adopted by the general meeting of shareholders upon the proposal of the supervisory board. The supervisory board
determines the remuneration of the management board members in accordance with the remuneration policy. A proposal by the supervisory board with respect to remuneration schemes in the form of shares or rights to shares is submitted by the
supervisory board to the general meeting for its approval. This proposal must set out at least the maximum number of shares or rights to shares to be granted to the management board and the criteria for granting or amendment.<I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The general meeting may determine the remuneration of
supervisory board members. The supervisory board members shall be reimbursed for their expenses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Delaware</I>.&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, the stockholders do not generally have the right to approve the compensation policy for directors or the senior
management of the corporation, although certain aspects of executive compensation may be subject to stockholder vote due to the provisions of U.S. federal securities and tax law, as well as exchange requirements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dutch Corporate Governance Code </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The DCGC contains both principles and best practice
provisions for management boards, supervisory boards, shareholders and general meetings of shareholders, financial reporting, auditors, disclosure, compliance and enforcement standards. A copy of the DCGC can be found on <I>www.corpgov.nl</I>. As a
Dutch company, we are subject to the DCGC and are required to disclose in our annual report, filed in the Netherlands, whether we comply with the provisions of the DCGC. If we do not comply with the provisions of the DCGC (for example, because of a
conflicting NASDAQ requirement or otherwise), we must list the reasons for any deviation from the DCGC in our annual report. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We acknowledge the importance of good corporate governance. However, at this stage, we do not comply with all the provisions of the DCGC,
to a large extent because such provisions conflict with or are inconsistent with the corporate governance rules of NASDAQ and U.S. securities laws that apply to us, or because such provisions do not reflect best practices of global companies listed
on NASDAQ. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">150
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The discussions below summarize the most important differences between our expected
governance structure following this offering and the principles and best practices of the DCGC: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>The company shall have an internal risk management and control system that is suitable for the company (section II.1.3 of the DCGC)
</I></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently in the
process of reviewing and implementing such internal risk management and control system that is suitable for us. We intend to comply with this best practice provision as soon as reasonably possible after the closing of the offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>The best practice provisions regarding the grant of options, such as that they shall, in any event, not be exercised in the first three years
after the date of granting and the number of options to be granted shall be dependent on the achievement of challenging targets specified beforehand, (section II.2.4 and II.2.6 of the DCGC), </I></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The options granted under the 2010 Option Plan vest in
installments over a four-year period from the grant date. 25% of the options vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in 36 monthly installments for each full month of continuous
service provided by the option holder thereafter, such that 100% of the options shall become vested on the fourth anniversary of the vesting commencement date. The options granted are exercisable once vested. Options will lapse on the eighth
anniversary of the date of grant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>Shares granted to management board members without financial consideration shall be retained for a period of at least five years or until at
least the end of the employment, if this period is shorter (section II.2.5 of the DCGC.) </I></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently in the process of reviewing and implementing the 2016 Incentive Award Plan under which shares may be granted (including
to the management board). We believe that shares held by the management board should be retained for a certain period, however, such period may be shorter than five years. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>Neither the exercise price of options granted nor the other conditions may be modified during the term of the options, except in so far as
prompted by structural changes relating to the shares or the company in accordance with established market practice. (section II.2.7 of the DCGC). </I></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our 2010 Option Plan, including the exercise price, is
currently under review and may be amended prior to the closing of the offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>All supervisory board members, with the exception of not more than one person, shall be independent within the meaning of the DCGC (section
III.2.1 of the DCGC). </I></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, certain members of our supervisory board are not independent within the meaning of the DCGC. These supervisory board members
are representatives of (and/or employed by) some of our shareholders. We have the intention to increase the number of independent members on our supervisory board over time. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>A supervisory board member may not be granted any shares and/or rights to shares by way of remuneration. Any shares held by a supervisory
board member in the company on whose board he sits are long-term investments (section III.7.1 of the DCGC). </I></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our supervisory board members receive rights to acquire depositary receipts for shares in our capital as a part of their remuneration.
Although the DCGC discourages such remuneration, we believe that such remuneration is appropriate due to our anticipated listing on NASDAQ. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The cancellation of the binding nature of a nomination for the appointment of a member of the management board or the supervisory board and/or a
resolution to dismiss a member of the management board or of the supervisory board by an absolute majority of the votes cast (Section IV.1.1 of the DCGC) </I></FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Articles of Association provide that the binding
nomination of the supervisory board for the appointment of a member of the management board or the supervisory board may be overruled by the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">151
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
general meeting with a majority of at least two third of the votes cast representing more than half of the issued share capital. The dismissal of a member of the management board or supervisory
board also requires a majority of two third of the votes cast representing more than half of the issued share capital. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>The company shall formulate an outline policy on bilateral contacts with the shareholders and publish this policy on its website (section
IV.3.13 of the DCGC). </I></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
believe we should be reluctant in maintaining bilateral contracts with some of our shareholders. However, we are still considering this topic and if we believe such bilateral contracts should be entered into with the shareholders, we shall formulate
an outline policy and publish such policy on our website. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Listing </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied to list our common shares on The NASDAQ Global Market under the symbol &#147;MRUS.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The U.S. transfer agent and registrar for the common shares
is American Stock Transfer &amp; Trust Company, LLC. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">152
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_19"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, there has been no market for our
common shares. Future sales of substantial amounts of our common shares in the public market could adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of common shares will be available for sale
shortly after this offering due to existing contractual and legal restrictions on resale as described below, there may be sales of substantial amounts of our common shares in the public market after such restrictions lapse. This may adversely affect
the prevailing market price of our common shares and our ability to raise equity capital in the future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares
outstanding, or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares outstanding if the underwriters exercise their option in full to purchase additional common shares, and assuming: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the automatic conversion of all outstanding preferred shares as of September 30, 2015 into 14,900,456 common shares in connection with this offering;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the issuance of 1,622,840 common shares to the holders of Class B and C preferred shares in connection with this offering in satisfaction of their
entitlement to distributions in kind accrued as of September&nbsp;30, 2015, as described in more detail in &#147;Capitalization&#151;Preferred Share Distributions;&#148; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">no exercise of options outstanding as of September 30, 2015. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Of these shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares, or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares if the underwriters exercise their option in full to purchase additional common shares, sold in this offering will be freely transferable without restriction or
registration under the Securities Act, except for any shares purchased by one of our existing &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. The
remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;common shares are &#147;restricted securities&#148; as defined in Rule 144 and we expect that all or substantially all of these restricted securities will be
subject to the contractual 180-day lock-up period described below. These restricted shares may be sold in the public market only if registered or if they qualify for an exemption from registration under Rules 144 or 701 of the Securities Act.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rule 144 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, a person who has beneficially owned our common
shares that are restricted shares for at least six months would be entitled to sell such securities, provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a
sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned our common shares that are restricted shares for at least six months but who are our
affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three month period only a number of securities that does not exceed
the greater of either of the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1% of the number of our common shares then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional common shares; or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the average weekly trading volume of our common shares on NASDAQ during the four calendar weeks preceding the filing of a notice on Form 144 with
respect to the sale; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">provided, in each case,
that we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by non-affiliates must also comply with the manner of sale, current public information and notice
provisions of Rule 144 to the extent applicable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rule 701
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, under Rule 701, any of our
employees, management board members, supervisory board members, officers, consultants or advisors who purchases shares from us in connection with a compensatory </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">153
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
share or option plan or other written agreement before the effective date of this offering is entitled to resell such shares 90 days after the effective date of this offering in reliance on Rule
144, without having to comply with the holding period requirements or other restrictions contained in Rule 701. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The SEC has indicated that Rule 701 will apply to typical share options granted by an issuer before it becomes subject to the reporting
requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after the date of this prospectus. Securities issued in reliance on Rule 701 are restricted securities and, subject to the
contractual restrictions described below, beginning 90 days after the date of this prospectus, may be sold by persons other than &#147;affiliates,&#148; as defined in Rule 144, subject only to the manner of sale provisions of Rule 144 and by
&#147;affiliates&#148; under Rule 144 without compliance with its one-year minimum holding period requirement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Regulation S </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Regulation S provides generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration Rights </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will enter into a registration rights agreement upon the
closing of this offering pursuant to which we will agree under certain circumstances to file a registration statement to register the resale of the shares held by certain of our existing shareholders, as well as to cooperate in certain public
offerings of such shares. Registration of these shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for
shares purchased by affiliates. See &#147;Related Party Transactions&#151;Registration Rights Agreement.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Lock-up Agreements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All of our supervisory board members, management board members and the holders of all or substantially all of our common shares have agreed, subject to limited exceptions, not to offer, pledge, announce
the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap
or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common shares or such other securities for a period of 180 days after the date of this prospectus, subject to certain exceptions, without
the prior written consent of Citigroup Global Markets Inc. and Jefferies LLC. See &#147;Underwriting.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">154
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_20"></A>MATERIAL TAX CONSIDERATIONS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following summary contains a description of certain
Dutch and U.S. federal income tax consequences of the acquisition, ownership and disposition of common shares. Please note that this summary should not be considered a comprehensive description of all the tax considerations that may be relevant to
the decision to purchase common shares. The summary is based upon the tax laws of the Netherlands and regulations thereunder and on the tax laws of the United States and regulations thereunder as of the date hereof, which are subject to
change</I>.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Material Dutch Tax Considerations
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following paragraphs summarize a number
of material Dutch tax considerations relating to the purchase, ownership and disposition of our common shares. The following is intended as general information only, and is in no way a comprehensive or complete description of all aspects of Dutch
tax law that may be relevant for a holder of common shares, shareholder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prospective shareholders should consult their tax advisor regarding the tax consequences of any purchase, ownership or disposal of common shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following summary is based on the Dutch tax law as applied and interpreted by Dutch tax courts, and as
published and effective on the date hereof, without prejudice to any amendments introduced at a later date and implemented with or without retroactive effect. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of this paragraph, &#147;Dutch Taxes&#148; shall mean taxes of whatever nature levied by or on behalf of the Netherlands
or any of its subdivisions or taxing authorities. The Netherlands means the part of the Kingdom of the Netherlands located in Europe. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where in this Dutch taxation paragraph reference is made to &#147;Shareholder,&#148; that concept includes, but is not limited to:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">an owner of one or more common shares who has both an economic interest in those common shares, as well as the title to those common shares; </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a person who, or an entity that, holds the entire economic interest in one or more common shares; </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a person who, or an entity that, holds an interest in an entity, that is transparent for Dutch tax purposes, such as a partnership or a mutual fund, the assets of which
comprise of one or more common shares, within the meaning of items (1) or (2) above: or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a person who is deemed to hold an interest in common shares, as referred to under items (1) through (3), pursuant to the attribution rules of article 2.14a, of the
Dutch Income Tax Act 2001 (<I>Wet inkomstenbelasting 2001</I>, or ITA), with respect to property that has been segregated, for instance in a trust or a foundation. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Taxes on Income and Capital Gains </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This section provides an overview of general Dutch tax
consequences that may be relevant for Shareholders, but does not describe the possible Dutch tax considerations or consequences that may be relevant to a Shareholder who is: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an individual for whom the income or capital gains derived from the common shares is attributable to employment activities, the income from which is
taxable in the Netherlands; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an entity that is not subject to Dutch corporate income tax or is in full or in part exempt from Dutch corporate income tax (such as pension funds);
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an investment institution (<I>beleggingsinstelling</I>) as defined in article 6a or 28 of the Dutch 1969 Corporate income tax act (<I>Wet op de
vennootschapsbelasting 1969</I>, or CITA); </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">155
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">entitled to the participation exemption (<I>deelnemingsvrijstelling</I>) with respect to the common shares as defined in article 13, CITA. A
participation generally exists in case of a shareholding of at least 5% of the company&#146;s paid-in share capital; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a holder of a lucrative interest (<I>lucratief belang</I> as defined in article 3.92b ITA), as we assume no employees of the company will purchase the
common shares issued in this offering; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a holder of a substantial interest <I>(</I><I>aanmerkelijk belang</I> as defined in chapter 4 ITA), which is generally the case when the Shareholder,
alone, or where such shareholder is an individual, together with his or her partner (statutorily defined term), directly or indirectly, holds or is deemed to hold (a) an interest of at least 5% in either the capital or the voting rights of any class
of shares in the Company, (b) rights or options to obtain such interest or (c) certain profit sharing rights in the Company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dutch Residents </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The description of certain Dutch tax consequences in this paragraph is only intended for Shareholders that are either individuals who are
resident or deemed to be resident in the Netherlands for Dutch income tax purposes, or Dutch Individuals, or entities that are subject to the CITA and are resident or deemed to be resident in the Netherlands for corporate income tax purposes, or
Dutch Corporate Entities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Dutch resident individuals
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dutch Individuals that derive or are deemed
to derive any benefits from common shares (including any capital gains realized on the disposal of such common shares) which benefits are attributable to an enterprise from which the Dutch Individual derives profits, whether as an entrepreneur
(<I>ondernemer</I>) or pursuant to a co-entitlement to the net value of an enterprise, other than as a shareholder, are generally subject to Dutch income tax on those benefits at progressive rates with a maximum of 52%. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dutch Individuals that derive or are deemed to derive any
benefits from common shares, including any gains realized on the disposal of such common shares, that constitute benefits from miscellaneous activities (<I>resultaat uit overige werkzaamheden</I>), are generally subject to Dutch income tax at
progressive rates on such benefits with a maximum of 52%. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dutch Individuals may, among other things, derive, or be deemed to derive, benefits from common shares that are taxable as benefits from miscellaneous activities in case the investment activities go
beyond the activities of an active portfolio investor, due to, for instance, the use of insider knowledge (<I>voorkennis</I>) or comparable forms of special knowledge. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dutch Individuals, whose common shares are not attributable
to an enterprise, and whose common shares do not qualify as generating income from miscellaneous activities will not be subject to Dutch income tax on the actual income (including capital gains) derived from the common shares. Instead, those Dutch
Individuals will be taxed at a flat rate of 30% on the deemed income from savings and investments (<I>sparen en beleggen</I>). This deemed income is set at 4% of the yield basis (<I>rendementsgrondslag</I>) of the Dutch Individual. The yield basis
would normally consist of the fair market value of the common shares generally to be determined at the beginning of the year to the extent that such yield basis exceeds the exempt net asset amount (<I>heffing</I><I>s</I><I>vrij vermogen</I>) for the
relevant year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of 2017 the tax regime for
income from savings and investments will be amended. The amount of deemed income will no longer be calulated at 4% of the yield basis. Instead, the amount of deemed income will depend on the total net value of all savings and investments of a
taxpayer that are subject to the tax regime applicable to savings and investments. The total net value in excess of the exempt net asset amount and up to and including &#128;100,000 will be deemed to yield a return of 2.9%. A 4.7% deemed return
applies to the total net value </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">156
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
in excess of &#128;100,000 up to and including and &#128;1,000,000. Insofar as the total net value exceeds &#128;1,000,000, a deemed return of 5.5% will apply. These percentages will be revised
annually, and even the 2017 percentages may be amended during 2016. The tax rate remains unchanged at 30%. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Dutch resident entities </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dutch Corporate Entities may be subject to corporate income tax on income, including capital gains, derived from the common shares. The first &#128;200,000 profits are taxable at a rate of 20%, while any
profits in excess of &#128;200,000 are taxable at a rate of 25%. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Non-Dutch residents </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Non-Dutch resident individuals </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A Shareholder that is an individual and not a resident or deemed resident of the Netherlands, or Non-Resident Individuals, for Dutch tax
purposes, will not be subject to any Dutch taxes on income (other than the dividend withholding tax described below) or capital gains in respect of dividends distributed by the Company or in respect of any gains realized on the disposal of common
shares unless: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Non-Resident Individual derives profits from an enterprise directly, or pursuant to a co-entitlement to the net value of such enterprise, other
than as a holder of securities, which enterprise either is managed in the Netherlands or carried out, in whole or in part, through a permanent establishment or a permanent representative which is taxable in the Netherlands and the common shares are
attributable to such enterprise; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Non-Resident Individual derives benefits or is deemed to derive benefits from common shares that are taxable as benefits from miscellaneous
activities in the Netherlands. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If either of the conditions above apply, income or capital gains in respect of dividends distributed by the Company or in respect of any
gain realized on the disposal of common shares will in general be subject to Dutch income tax at the progressive rates with a maximum of 52%, on the understanding that such benefits derived as benefits from miscellaneous activities will only be
taxable in the Netherlands if such activities are performed or deemed to be performed in the Netherlands. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Non-Dutch resident entities </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A Shareholder, other than an individual, that is not a resident or deemed resident of the Netherlands for Dutch tax purposes, will not be subject to any Dutch taxes on income or capital gains (other than
the dividend withholding tax described below) in respect of dividends distributed by the Company or in respect of any gain realized on the disposal of common shares, unless that Shareholder derives profits from an enterprise directly, or pursuant to
a co-entitlement to the net value of such enterprise other than as a holder of securities, which enterprise either is managed in the Netherlands or carried out, in whole or in part, through a permanent establishment or a permanent representative
which is taxable in the Netherlands and the common shares are attributable to such enterprise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If the condition above applies, income and capital gains derived from the common shares will, in general, be subject to regular Dutch corporate income tax. The first &#128;200,000 profits are taxable at a
rate of 20%, while any profits in excess of &#128;200,000 are taxable at a rate of 25%. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dividend withholding tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dividends payments, or Dividend Payments, made by the Company are generally subject to 15% Dutch dividend withholding tax. The Company is responsible for withholding the Dutch dividend withholding tax,
while the tax is ultimately for the account of the Shareholder. The term &#145;Dividend Payments&#146; includes, but is not limited to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">distributions in cash or in kind, as well as deemed or constructive distributions; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">157
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">liquidation proceeds, proceeds of redemption of common shares or, generally, considerations in excess of the average paid-in capital recognized for
Dutch dividend withholding tax purposes, paid upon the repurchase of common shares by the company; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the nominal value of common shares issued to a holder of common shares or an increase of the nominal value of common shares, to the extent that it does
not appear that a contribution, recognized for Dutch dividend withholding tax purposes, has been made or will be made; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">partial repayment of paid-in capital, recognized for Dutch dividend withholding tax purposes, if and to the extent that there are Net Profits
(<I>zuivere winst</I>), unless </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT>
</SUP>&nbsp;</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the general meeting of the shareholders has resolved in advance to make such repayment; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#161;</FONT>
</SUP>&nbsp;</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the nominal value of the common shares concerned has been reduced by a corresponding amount by way of an amendment of the Company&#146;s articles of
association. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term Net
Profits includes anticipated profits and losses that have yet to be realized but that are reasonably certain and determinable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a Shareholder is a resident for Dutch tax purposes of a country other than the Netherlands, and is considered to be a resident of
Aruba, Curacao or St. Martin under the provisions of a Tax Convention for the Kingdom of the Netherlands (<I>Belastingregeling voor het Koninkrijk</I>), or is considered to be a resident of a country other than the Netherlands under the provisions
of the double taxation convention between that country of residence and the Netherlands, that Shareholder may be eligible for a full or partial exemption from, or refund of Dutch dividend withholding tax, depending on the terms of the applicable
double taxation convention. In addition, subject to certain conditions and based on Dutch legislation implementing the EU Parent Subsidiary Directive (Directive 90/435/EEG, as amended), an exemption from Dutch dividend withholding tax may exist for
Dividend Payments to certain qualifying entities that are resident in another EU Member State or in a State of the EEA appointed by Ministerial Decree, if that entity holds at least 5% of the share capital of the Company. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A qualifying tax-exempt entity that is a resident of a Member
State of the EU, or that is a resident of a State of the EEA that has been specifically designated in a Ministerial Regulation (e.g. Norway, Iceland and Liechtenstein), may be eligible for a refund of withheld Dutch dividend withholding taxes, if
the entity is not subject to Dutch corporate income tax had it been a tax resident of the Netherlands. Such refund is not available to entities that are engaged in similar activities as investment institutions (<I>beleggingsinstellingen</I>) as
referred to in Section 6a or 28 CITA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Qualifying
investors (such as pension funds, sovereign wealth funds and exempt government bodies) from outside the EU and the EEA (so-called third countries) may be eligible for a refund of Dutch dividend withholding tax. The refund only applies to portfolio
investments when the following conditions are cumulatively met: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Shareholder is resident in a designated country with which the Netherlands has concluded adequate arrangements for the exchange of information; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Shareholder is not subject to any profits tax or is exempt from any profits tax in the country of its residence and would not have been subject to
Dutch corporate income tax, if the Shareholder had been resident in the Netherlands. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dutch Individuals and Dutch Corporate Entities can generally credit Dutch dividend withholding tax against their personal income tax or
corporate income tax liability. The same generally applies to Shareholders that are neither resident nor deemed resident of the Netherlands if the common shares are attributable to a Dutch permanent establishment of such a non-resident Shareholder
to which the common shares are attributable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">158
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to legislation introduced to counteract the practice of dividend stripping, a reduction,
exemption, credit or refund of Dutch dividend withholding tax is denied if the recipient of the Dividend Payment does not qualify as the beneficial owner (<I>uiteindelijk gerechtigde</I>) of that Dividend Payment. The anti-dividend stripping
legislation generally targets situations in which shareholders retain their economic interest in common shares but reduce the withholding tax due on the Dividend Payment by entering into a transaction with another party with (mainly) that intent.
The Dutch Ministry of Finance takes the position that the definition of beneficial ownership introduced by this legislation will also be applied in the context of a double taxation convention. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Gift tax and inheritance tax </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Dutch Residents </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gift or inheritance taxes will arise in the Netherlands with
respect to a transfer of the common shares by way of a gift by, or, on the death of, a holder of common shares who is resident or deemed to be resident in the Netherlands at the time of the gift or his/her death. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Netherlands gift tax will arise in case of a gift of the
common shares under a condition precedent (<I>opschortende voorwaarde</I>) by an individual who at the date of the gift was resident or deemed to be resident, but at the date of the fulfillment of the condition was neither resident nor deemed to be
resident in the Netherlands, unless such individual deceases within 180 days after the date of the fulfillment of the condition, while being resident or deemed to be resident in the Netherlands. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of Netherlands gift and inheritance taxes,
amongst others, a person that holds the Dutch nationality will be deemed to be resident in the Netherlands if that person has been resident in the Netherlands at any time during the ten years preceding the date of the gift &#151; in case of a gift
under a condition precedent, the date of the fulfillment of the condition &#151; or the date of the death of this person. Additionally, for purposes of Dutch gift tax, a person not holding the Dutch nationality will be deemed to be resident in the
Netherlands if that person has been resident in the Netherlands at any time during the 12 months preceding the date of the gift or - in case of a gift under a condition precedent - the date of the fulfillment of the condition. Applicable tax
treaties may override the tax implications of deemed residency. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Non-Dutch Residents </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Dutch gift or inheritance tax will arise on the transfer of common shares by way of a gift by, or on the death of, a holder of common
shares who is neither resident nor deemed to be resident in the Netherlands, unless: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in case of a gift of the common shares under a condition precedent (<I>opschortende voorwaarde</I>) by an individual who at the date of the gift was
neither resident nor deemed to be resident in the Netherlands, such individual is resident or deemed to be resident in the Netherlands at the date of the fulfillment of the condition; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in case of a gift of the common shares by an individual who at the date of the gift or, in case of a gift under a condition precedent, at the date of
the fulfillment of the condition was neither resident nor deemed to be resident in the Netherlands, such individual is deceased within 180 days after the date of the gift or the fulfillment of the condition, while being resident or deemed to be
resident in the Netherlands. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, Dutch inheritance tax will arise in case of a gift under a condition precedent by an individual who, at the date of the gift,
was neither resident nor deemed resident of the Netherlands, but at the date of his or her death was resident or deemed to be resident in the Netherlands, and the condition was fulfilled after the date of his or her death. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">159
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Value added tax </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Dutch value added tax will be due in the Netherlands in
respect of payments made in consideration for the issue of common shares, or in respect of the transfer of common shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other taxes </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Dutch registration tax, customs duty, stamp duty, real estate transfer tax or any other similar documentary tax or duty will be due in
the Netherlands in respect of or in connection with the mere issue, transfer or delivery of the common shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Residency </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A Shareholder will not become, and will not be deemed to be, resident in the Netherlands merely by virtue of holding a common share or by virtue of the execution, performance and/or delivery of any
relevant documents related thereto. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Material U.S. Federal
Income Tax Considerations for U.S. Holders </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders described below of owning and
disposing of common shares. It is not a comprehensive description of all tax considerations that may be relevant to a particular person&#146;s decision to acquire securities. This discussion applies only to a U.S. Holder that holds common shares as
a capital asset for tax purposes (generally, property held for investment). In addition, it does not describe all of the tax consequences that may be relevant in light of a U.S. Holder&#146;s particular circumstances, including state and local tax
consequences, estate tax consequences, alternative minimum tax consequences, the potential application of the provisions of the Code known as the Medicare contribution tax, and tax consequences applicable to U.S. Holders subject to special rules,
such as: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">dealers or traders in securities who use a mark-to-market method of tax accounting; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons holding common shares as part of a hedging transaction, &#147;straddle,&#148; wash sale, conversion transaction or integrated transaction or
persons entering into a constructive sale with respect to the common shares; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons whose &#147;functional currency&#148; for U.S. federal income tax purposes is not the U.S. dollar; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">tax exempt entities, including &#147;individual retirement accounts&#148; and &#147;Roth IRAs&#148;; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">entities classified as partnerships for U.S. federal income tax purposes; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulated investment companies or real estate investment trusts; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons who acquired our common shares pursuant to the exercise of an employee stock option or otherwise as compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons that own or are deemed to own ten percent or more of our voting shares; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">persons holding common shares in connection with a trade or business conducted outside the United States. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If an entity that is classified as a partnership for U.S.
federal income tax purposes holds common shares, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such
partnerships are encouraged to consult their tax advisers as to the particular U.S. federal income tax consequences of holding and disposing of common shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">160
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The discussion is based on the Code, administrative pronouncements, judicial decisions,
final, temporary and proposed Treasury Regulations, and the income tax treaty between the Netherlands and the United States (the &#147;Treaty&#148;) all as of the date hereof, changes to any of which may affect the tax consequences described
herein&#151;possibly with retroactive effect. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
&#147;U.S. Holder&#148; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of common shares who is eligible for the benefits of the Treaty and is: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a citizen or individual resident of the United States; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia;
or </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Holders are encouraged to consult their tax advisers
concerning the U.S. federal, state, local and foreign tax consequences of owning and disposing of common shares in their particular circumstances. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Taxation of Distributions </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the discussion below under &#147;Passive Foreign Investment Company Rules,&#148; distributions paid on common shares, other
than certain <I>pro rata</I> distributions of common shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not
calculate our earnings and profits under U.S. federal income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations, dividends paid to certain non-corporate U.S.
Holders may be taxable at preferential rates applicable to &#147;qualified dividend income.&#148; The amount of a dividend will include any amounts withheld by us in respect of Dutch income taxes. The amount of the dividend will be treated as
foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will be included in a U.S. Holder&#146;s income on the date of the U.S.
Holder&#146;s receipt of the dividend. The amount of any dividend income paid in foreign currency will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of
whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A
U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. Such gain or loss would generally be treated as U.S.-source ordinary income or loss. The amount of any distribution of
property other than cash (and other than certain pro rata distributions of common shares or rights to acquire common shares) will be the fair market value of such property on the date of distribution. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to applicable limitations, some of which vary
depending upon the U.S. Holder&#146;s particular circumstances, Dutch income taxes withheld from dividends on common shares at a rate not exceeding the rate provided by the Treaty will be creditable against the U.S. Holder&#146;s U.S. federal income
tax liability. The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S.
Holders may, at their election, deduct foreign taxes, including any Dutch income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax
credits applies to all foreign taxes paid or accrued in the taxable year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Sale or Other Taxable Disposition of Common Shares </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the discussion below under &#147;Passive Foreign Investment Company Rules,&#148; gain or loss realized on the sale or other
taxable disposition of common shares will be capital gain or loss, and will be long-term </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">161
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
capital gain or loss if the U.S. Holder held the common shares for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#146;s tax basis in the
common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is
subject to limitations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Passive Foreign
Investment Company Rules </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the
current and anticipated value of our assets, including goodwill, and the composition of our income, assets and operations, we do not expect to be a PFIC for the current taxable year or the foreseeable future. However, the application of the PFIC
rules is subject to uncertainty in several respects, and we cannot assure you that the IRS will not take a contrary position. A non-U.S. corporation will be classified as a PFIC for any taxable year in which, after applying certain look-through
rules, either: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at least 75% of its gross income is passive income; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">at least 50% of its gross assets (determined on the basis of a quarterly average) is attributable to assets that produce passive income or are held for
the production of passive income. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other
corporation in which we own, directly or indirectly, 25% or more (by value) of the equity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A separate determination must be made after the close of each taxable year as to whether we are a PFIC for that year. As a result, our PFIC status may change. In particular, the total value of our assets
for purposes of the asset test generally will be calculated using the market price of our common shares, which may fluctuate considerably. Fluctuations in the market price of our common shares may result in our being a PFIC for any taxable year. In
addition, the composition of our income and assets is affected by how, and how quickly, we spend the cash we raise in any offering, including this one. If we are classified as a PFIC in any year with respect to which a U.S. Holder owns the common
shares, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns the common shares, regardless of whether we continue to meet the tests described above unless (1) we cease to
be a PFIC and (2) the U.S. Holder has made a &#147;deemed sale&#148; election under the PFIC rules. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we are a PFIC for any taxable year during which you hold common shares, you will be subject to special tax rules with respect to any &#147;excess distribution&#148; that you receive and any gain you
realize from a sale or other disposition (including a pledge) of common shares. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable
years or your holding period for the common shares will be treated as an excess distribution. Under these special tax rules: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the excess distribution or gain will be allocated ratably over your holding period for the common shares; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we became a PFIC, will be treated as
ordinary income; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to
underpayments of tax will be imposed on the resulting tax attributable to each such year. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The tax liability for amounts allocated to years prior to the year of disposition or &#147;excess distribution&#148; cannot be offset by
any net operating losses for such years, and gains (but not losses) realized on the sale of the common shares cannot be treated as capital, even if you hold the common shares as capital assets. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain elections may be available that would result in
alternative treatments (such as mark-to-market treatment of the common shares). The adverse consequences of owning stock in a PFIC could be mitigated if a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">162
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
U.S. Holder makes a valid &#147;qualified electing fund&#148; election, or QEF election, which, among other things, would require a U.S. Holder to include currently in income its pro rata share
of the PFIC&#146;s net capital gain and ordinary earnings, based on earnings and profits as determined for U.S. federal income tax purposes. We intend to provide the information necessary for U.S. Holders of our common shares to make qualified
electing fund elections. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are considered a
PFIC, a U.S. Holder will also be subject to information reporting requirements on an annual basis. If we are or become a PFIC, you should consult your tax advisor regarding any reporting requirements that may apply to you. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Holders are urged to consult their tax advisors
regarding the application of the PFIC rules to the ownership and disposition of the common shares and the potential availability of a mark-to-market or QEF election </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Information Reporting and Backup Withholding
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments of dividends and sales proceeds
that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other
exempt recipient or (ii)&nbsp;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a U.S.
Holder will be allowed as a credit against the holder&#146;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Information with Respect to Foreign Financial Assets
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain U.S. Holders who are individuals
(and, under proposed regulations, certain entities) may be required to report information relating to the common shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain U.S. financial
institutions). U.S. Holders should consult their tax advisers regarding their reporting obligations with respect to their ownership and disposition of the common shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">163
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_21"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc. and Jefferies LLC are acting as
joint book-running managers of this offering and as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus, each of the underwriters named below has
severally agreed to purchase, and we have agreed to sell to that underwriter, the number of common shares indicated below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number <BR>of&nbsp;Common<BR>Shares</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jefferies LLC.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Guggenheim Securities, LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wedbush Securities Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriting agreement
provides that the obligations of the underwriters to purchase the common shares included in this offering are subject to approval of legal matters by counsel and to other conditions. The underwriters are obligated to purchase all of the common
shares (other than those covered by the underwriters&#146; option to purchase additional common shares described below) if they purchase any of the common shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common shares sold by the underwriters to the public will
initially be offered at the initial public offering price set forth on the cover page of this prospectus. Any common shares sold by the underwriters to securities dealers may be sold at a discount from the initial public offering price not to exceed
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. If all the common shares are not sold at the initial offering price, the underwriters may change the initial offering price and the other selling terms. The
representatives have advised us that the underwriters do not intend to make sales to discretionary accounts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters sell more common shares than the total number set forth in the table above, we have granted to the underwriters an
option, exercisable for 30 days from the date of this prospectus, to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional common shares at the initial public offering price less the underwriting
discount. The underwriters may exercise the option solely for the purpose of covering over-allotments, if any, in connection with this offering. To the extent the option is exercised, each underwriter must purchase a number of additional common
shares approximately proportionate to that underwriter&#146;s initial purchase commitment set forth in the table above. Any common shares issued or sold under the option will be issued and sold on the same terms and conditions as the other common
shares that are the subject of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We,
our management board members, our supervisory board members and all of our other shareholders and optionholders have agreed that, subject to specified limited exceptions, for a period of 180 days from the date of this prospectus, we and they will
not, without the prior written consent of Citigroup Global Markets Inc. and Jefferies LLC, offer, sell, contract to sell, pledge or otherwise dispose of any common shares or any securities convertible into, or exercisable or exchangeable for, our
common shares. Citigroup Global Markets Inc. and Jefferies LLC in their sole discretion may release any of the securities subject to these lock-up agreements at any time, which, in the case of our management board members and supervisory board
members, shall be with notice. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this
offering, there has been no public market for our common shares. Consequently, the initial public offering price for our common shares will be determined by negotiations between us and the representatives. Among the factors considered in determining
the initial public offering price will be our results of operations, our current financial condition, our future prospects, our markets, the economic conditions in and future prospects for the industry in which we compete, our management board, and
currently prevailing general </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">164
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
conditions in the equity securities markets, including current market valuations of publicly traded companies considered comparable to our Company. We cannot assure you, however, that the price
at which our common shares will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in our common shares will develop and continue after this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have applied to list our common shares on The NASDAQ
Global Market under the symbol &#147;MRUS.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the per share and total underwriting discounts and commissions that we are to pay to the underwriters in
connection with this offering. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional common shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Paid by Merus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Full&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that our
portion of the total expenses of this offering, exclusive of underwriting discounts and commissions payable by us, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also agreed to reimburse the
underwriters for expenses in an amount of up to $35,000 relating to the clearance of this offering with the Financial Industry Regulatory Authority, Inc. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, the underwriters may purchase and sell our common shares in the open market. Purchases and sales in the
open market may include short sales, purchases to cover short positions, which may include purchases pursuant to the underwriters&#146; option to purchase additional common shares, and other transactions that would stabilize, maintain or otherwise
affect the price of our common shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short sales involve secondary market sales by the underwriters of a greater number of common shares than they are required to purchase in this
offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Covered&#148; short sales are sales of common shares in an amount up to the number of common shares represented by the underwriters&#146; option
to purchase additional common shares. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Naked&#148; short sales are sales of common shares in an amount in excess of the number of common shares represented by the underwriters&#146;
option to purchase additional common shares. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Covering transactions involve purchases of common shares either pursuant to the underwriters&#146; option to purchase additional common shares or in
the open market in order to cover short positions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a naked short position, the underwriters must purchase common shares in the open market. A naked short position is more likely to be created
if the underwriters are concerned that there may be downward pressure on the price of the common shares in the open market after pricing that could adversely affect investors who purchase in this offering. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a covered short position, the underwriters must purchase common shares in the open market or must exercise their option to purchase additional
common shares. In determining the source of common shares to close the covered short position, the underwriters will consider, among other things, the price of common shares available for purchase in the open market as compared to the price at which
they may purchase common shares through the underwriters&#146; option to purchase additional common shares. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stabilizing transactions involve bids to purchase common shares so long as the stabilizing bids do not exceed a specified maximum, to stabilize the
price of the common shares. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases to cover short positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts, may
have the effect of preventing or retarding a decline in the market price of our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">165
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
common shares. They may also cause the price of the common shares to be higher than the price that would otherwise exist in the open market in the absence of these transactions. The underwriters
may conduct these transactions on The NASDAQ Global Market, in the over-the-counter market or otherwise. The underwriters are not required to engage in any of these transactions, and they may discontinue them at any time. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify the underwriters against certain
liabilities, including liabilities under the Securities Act or the Exchange Act, and to contribute to payments the underwriters may be required to make because of any of those liabilities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A prospectus in electronic format may be made available on websites maintained by one or more of the
underwriters or their respective affiliates. The representatives may agree with us to allocate a number of common shares to underwriters for sale to their online brokerage account holders. Any such allocation for online distributions will be made by
the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; or their respective affiliates&#146; websites and any information contained in any other website
maintained by any of the underwriters or their respective affiliates is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors in this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conflicts of Interest </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are full-service financial institutions
engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriters and their
respective affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary course of their
various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include
bank loans and/or credit default swaps) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investments and securities activities may involve
securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and
may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The address of Citigroup Global Markets Inc. is 388 Greenwich Street, New York, New York 10013. The address of Jefferies LLC is 520
Madison Avenue, New York, New York 10022. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to
Prospective Investors in the European Economic Area </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In relation to each member state of the European Economic Area that has implemented the Prospectus Directive (each, a relevant member state), with effect from and including the date on which the
Prospectus Directive is implemented in that relevant member state (the relevant implementation date), an offer of common shares described in this prospectus may not be made to the public in that relevant member state other than: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to fewer than 100 or, if the relevant member state has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal
persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us for any such offer; or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">provided that no such offer of our common shares shall require us or any
underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">166
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of this provision, the expression an &#147;offer of securities to the
public&#148; in any relevant member state means the communication in any form and by any means of sufficient information on the terms of the offer and the common shares to be offered so as to enable an investor to decide to purchase or subscribe for
the common shares, as the expression may be varied in that member state by any measure implementing the Prospectus Directive in that member state, and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments
thereto, including the 2010 PD Amending Directive, to the extent implemented in the relevant member state) and includes any relevant implementing measure in the relevant member state. The expression &#147;2010 PD Amending Directive&#148; means
Directive 2010/73/EU. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The sellers of our common
shares have not authorized and do not authorize the making of any offer of common shares through any financial intermediary on their behalf, other than offers made by the underwriters with a view to the final placement of the common shares as
contemplated in this prospectus. Accordingly, no purchaser of the common shares, other than the underwriters, is authorized to make any further offer of the common shares on behalf of the sellers or the underwriters. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the United Kingdom </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus is only being distributed to, and is only
directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, or the Order, or (ii)&nbsp;high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order (each such person being
referred to as a &#147;relevant person&#148;). This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any
person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Australia </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No prospectus or other disclosure document, as defined in the Corporations Act 2001 (Cth) of Australia, or Corporations Act, in relation
to our common shares has been or will be lodged with the Australian Securities&nbsp;&amp; Investments Commission, or ASIC. This document has not been lodged with ASIC and is only directed to certain categories of exempt persons. Accordingly, if you
receive this document in Australia: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">you confirm and warrant that you are either: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) a &#147;sophisticated investor&#148; under section
708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s certificate to us which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the
offer has been made; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) a person associated
with the company under section 708(12) of the Corporations Act; or </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iv) a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act, and to the extent that you are unable to confirm or warrant that you are an exempt
sophisticated investor, associated person or professional investor under the Corporations Act, any offer made to you under this document is void and incapable of acceptance; and </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">you warrant and agree that you will not offer any of our common shares for resale in Australia within 12 months of that common shares being issued unless any such
resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">167
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Canada </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The common shares may be sold only to purchasers purchasing,
or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 <I>Prospectus Exemptions </I>or subsection 73.3(1) of the <I>Securities Act </I>(Ontario), and are permitted clients, as defined in
National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the common shares must be made in accordance with an exemption from, or in a
transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a
misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any
applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to section&nbsp;3A.3 (or, in the case of securities
issued or guaranteed by the government of a non-Canadian jurisdiction, section&nbsp;3A.4) of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105</FONT> <I>Underwriting Conflicts
</I>(<B><FONT STYLE="white-space:nowrap">NI&nbsp;33-105</FONT></B>), the underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105</FONT> regarding underwriter conflicts of interest
in connection with this offering. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective
Investors in Chile </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The common shares are not
registered in the Securities Registry (Registro de Valores) or subject to the control of the Chilean Securities and Exchange Commission (Superintendencia de Valores y Seguros de Chile). This prospectus and other offering materials relating to the
offer of the common shares do not constitute a public offer of, or an invitation to subscribe for or purchase, the common shares in the Republic of Chile, other than to individually identified purchasers pursuant to a private offering within the
meaning of Article 4 of the Chilean Securities Market Act (Ley de Mercado de Valores) (an offer that is not &#147;addressed to the public at large or to a certain sector or specific group of the public&#148;). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in France </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither this prospectus nor any other offering material
relating to the common shares described in this prospectus has been submitted to the clearance procedures of the <I>Autorit&eacute; des March&eacute;s Financiers</I> or of the competent authority of another member state of the European Economic Area
and notified to the <I>Autorit&eacute; des March&eacute;s Financiers.</I> The common shares have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other
offering material relating to the common shares has been or will be: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">released, issued, distributed or caused to be released, issued or distributed to the public in France; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">used in connection with any offer for subscription or sale of the common shares to the public in France. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such offers, sales and distributions will be made in France
only: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to qualified investors (<I>investisseurs qualifi&eacute;s</I>) and/or to a restricted circle of investors (<I>cercle restreint
d&#146;investisseurs</I>), in each case investing for their own account, all as defined in, and in accordance with articles L.411-2, D.411-1, D.411-2, D.734-1, D.744-1, D.754-1 and D.764-1 of the French <I>Code mon&eacute;taire et financier</I>;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to investment services providers authorized to engage in portfolio management on behalf of third parties; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">168
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in a transaction that, in accordance with article L.411-2-II-1&deg;-or-2&deg;-or 3&deg; of the French <I>Code mon&eacute;taire et financier </I>and
article 211-2 of the General Regulations (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) of the <I>Autorit&eacute; des March&eacute;s Financiers</I>, does not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>).
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The common shares may be resold
directly or indirectly, only in compliance with articles L.411-1, L.411-2, L.412-1 and L.621-8 through L.621-8-3 of the French <I>Code mon&eacute;taire et financier</I>. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Hong Kong </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The common shares may not be offered or sold in Hong Kong by
means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the
meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies
Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the common shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere),
which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to common shares which are or are intended to be disposed
of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Japan </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The common shares offered in this prospectus have not been
and will not be registered under the Financial Instruments and Exchange Law of Japan. The common shares have not been offered or sold and will not be offered or sold, directly or indirectly, in Japan or to or for the account of any resident of Japan
(including any corporation or other entity organized under the laws of Japan), except (i)&nbsp;pursuant to an exemption from the registration requirements of the Financial Instruments and Exchange Law and (ii)&nbsp;in compliance with any other
applicable requirements of Japanese law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective
Investors in Singapore </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus has
not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the common shares may
not be circulated or distributed, nor may the common shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional
investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the
conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where the common shares are subscribed or
purchased under Section&nbsp;275 of the SFA by a relevant party which is: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and
the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual
who is an accredited investor, </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">169
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">common shares, debentures and units of common shares and debentures of that corporation or the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the common shares pursuant to an offer made under Section&nbsp;275 of the SFA
except: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person defined in Section&nbsp;275(2) of the SFA,
or to any person pursuant to an offer that is made on terms that such common shares, debentures and units of common shares and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than
$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in
Section&nbsp;275 of the SFA; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where no consideration is or will be given for the transfer; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where the transfer is by operation of law. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Switzerland </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This document as well as any other material relating to our common shares that are the subject of the offering contemplated by this
prospectus do not constitute an issue prospectus pursuant to Article&nbsp;652a or Article&nbsp;1156 of the Swiss Code of Obligations. Our common shares will not be listed on the SWX Swiss Exchange and, therefore, the documents relating to our common
shares, including, but not limited to, this document, do not claim to comply with the disclosure standards of the listing rules of SWX Swiss Exchange and corresponding prospectus schemes annexed to the listing rules of the SWX Swiss Exchange. Our
common shares are being offered in Switzerland by way of a private placement, i.e. to a small number of selected investors only, without any public offer and only to investors who do not purchase our common shares with the intention to distribute
them to the public. The investors will be individually approached by us from time to time. This document as well as any other material relating to our common shares is personal and confidential and does not constitute an offer to any other person.
This document may only be used by those investors to whom it has been handed out in connection with the offering described herein and may neither directly nor indirectly be distributed or made available to other persons without our express consent.
It may not be used in connection with any other offer and shall in particular not be copied and/or distributed to the public in (or from) Switzerland. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">170
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_22"></A>EXPENSES OF THE OFFERING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that our expenses in connection with this
offering, other than underwriting discounts and commissions, will be as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:31pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securities and Exchange Commission registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The NASDAQ Global Market listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Printing and engraving expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Miscellaneous costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be filed by amendment. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All amounts in the table are estimates except the SEC registration fee, The NASDAQ Global Market listing fee and the FINRA filing fee. We
will pay all of the expenses of this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">171
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_23"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of our common shares and certain other matters
of Dutch law will be passed upon for us by Eversheds B.V. with the address of De Cuserstraat 85a, 1081&nbsp;CN Amsterdam, P.O. Box 7902, 1008 AC Amsterdam, the Netherlands. Certain matters of U.S. federal law will be passed upon for us by
Latham&nbsp;&amp; Watkins LLP. Legal counsel to the underwriters in connection with this offering are Van Doorne N.V. with respect to Dutch law and Cooley&nbsp;LLP, New York, New York, with respect to U.S. federal law. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_24"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements of Merus B.V. as of December 31,
2014 and 2013 and January 1, 2013, and for each of the years in the two-year period ended December 31, 2014, have been included herein and in the registration statement in reliance upon the report of KPMG Accountants N.V., independent registered
public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">172
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_25"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>We are a private company with limited liability
(<I>besloten vennootschap met beperkte aansprakelijkheid</I>) incorporated under the laws of the Netherlands. Substantially all of our assets are located outside the United States. The majority of our management board members and supervisory board
members reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce against them or us in U.S. courts, including judgments predicated upon
the civil liability provisions of the federal securities laws of the United States.<I> </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The United States and the Netherlands currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters.
Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the Netherlands. In order to obtain a judgment
which is enforceable in the Netherlands, the party in whose favor a final and conclusive judgment of the U.S. court has been rendered will be required to file its claim with a court of competent jurisdiction in the Netherlands. Such party may submit
to the Dutch court the final judgment rendered by the U.S. court. If and to the extent that the Dutch court finds that the jurisdiction of the U.S. court has been based on grounds which are internationally acceptable and that proper legal procedures
have been observed, the court of the Netherlands will, in principle, give binding effect to the judgment of the U.S. court, unless such judgment contravenes principles of public policy of the Netherlands. Dutch courts may deny the recognition and
enforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement
and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Civil Procedure Code. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dutch civil procedure differs substantially from U.S. civil procedure in a number of respects. Insofar as the production of evidence is
concerned, U.S. law and the laws of several other jurisdictions based on common law provide for pre-trial discovery, a process by which parties to the proceedings may prior to trial compel the production of documents by adverse or third parties and
the deposition of witnesses. Evidence obtained in this manner may be decisive in the outcome of any proceeding. No such pre-trial discovery process exists under Dutch law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">173
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_26"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed with the SEC a registration statement
(including amendments and exhibits to the registration statement) on Form F-1 under the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and
the exhibits and schedules to the registration statement. For further information, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to
the registration statement, we refer you to the copy of the document that has been filed. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the filed exhibit. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of this offering, we will become subject to
the informational requirements of the Exchange Act. Accordingly, we will be required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. You may inspect and copy reports and other
information filed with the SEC at the Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains
an Internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a foreign private issuer, we are exempt under the Exchange
Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our management board members, supervisory board members and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities
are registered under the Exchange Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will
send our transfer agent a copy of all notices of our general meetings of shareholders and other reports, communications and information that are made generally available to shareholders. The transfer agent has agreed to mail to all shareholders a
notice containing the information (or a summary of the information) contained in any notice of a meeting of our shareholders received by the transfer agent and will make available to all shareholders such notices and all such other reports and
communications received by the transfer agent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">174
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_27"></A><A NAME="index"></A>INDEX TO FINANCIAL STATEMENTS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements as of December 31,
2014 and 2013 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_2">Independent Auditor&#146;s Report</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_3">Statement of Financial Position</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_4">Statement of Profit or Loss and Comprehensive Loss</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_5">Statement of Changes in Equity</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_6">Statement of Cash Flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_7">Notes to Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial
Statements as of September 30, 2015 and 2014 </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_8">Statement of Financial Position</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-34</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_9">Statement of Profit or Loss and Comprehensive Loss</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_10">Statement of Changes in Equity</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_11">Statement of Cash Flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin29248_12">Notes to Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_2"></A>Report of Independent Registered Public Accounting Firm
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Supervisory Board and Management Board of Merus B.V. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have audited the accompanying statements of financial position of Merus B.V. as of 31 December 2014, as of 31 December 2013 and as of 1 January 2013, and the related statements of profit or loss and
comprehensive loss, changes in equity and cash flows for each of the years in the two-year period ended 31 December 2014. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion
on these financial statements based on our audits. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted
our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Merus B.V. as of 31
December 2014, as of 31 December 2013 and as of 1 January 2013, and the results of its operations and its cash flows for each of the years in the two-year period ended 31 December 2014, in conformity with International Financial Reporting Standards
as issued by the International Accounting Standards Board (IASB). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As discussed in Note 2 to the financial statements, the Company has changed its presentation of expenses in its Statement of Profit or Loss and
Comprehensive Loss from the nature of expense method to the function of expense method. The Company has retrospectively applied this change to all periods presented in these financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ KPMG Accountants N.V. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rotterdam, The Netherlands </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 January 2016 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_3"></A>STATEMENT OF FINANCIAL POSITION AS AT DECEMBER&nbsp;31, 2014
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(after appropriation of result for the year) </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>January&nbsp;1,&nbsp;2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Non-current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>7</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>353</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>8</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>497</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>850</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">946</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,127</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade and other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>10</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>849</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>11</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,841</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,690</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,540</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholders&#146; equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>15</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued and paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>282</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share premium account</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36,924</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(40,765</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(23,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,559</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,662</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Non-current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Borrowings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>13</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>652</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>14</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>613</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts owed to credit institutions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>13</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>167</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,409</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Taxes and social security liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>131</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>14</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>223</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities and accruals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>12</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,904</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">955</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5,834</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,943</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7,099</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total equity and liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,540</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_4"></A>STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE LOSS
</B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014(*)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013(*)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenue</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>16</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,303</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,303</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>17</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(12,388</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management and administration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>17</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(550</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>17</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,785</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total operating expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(18,723</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating result</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,420</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>19</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>50</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>19</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(39</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total finance income (expenses)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Result before tax</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,409</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>20</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Result after taxation</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>15</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,409</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other comprehensive income</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total comprehensive loss for the year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,409</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic (and diluted) loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>21</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3.42</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The results for the
year and the comprehensive loss for the year are fully attributable to the owners of the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(*)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">As adjusted to reflect change in accounting policy. Reference is made to note 2 of the financial statements. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_5"></A>STATEMENT OF CHANGES IN EQUITY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class A<BR>pref.&nbsp;share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class B<BR>pref.&nbsp;share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class A<BR>pref.&nbsp;share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class
B</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>pref.&nbsp;share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>loss</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total equity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at January&nbsp;1, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>28,230</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>20,615</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>110,558</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,450,857</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,334,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>16,219,660</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(13,784,510</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>5,379,796</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Result</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(9,907,570</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(9,907,570</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Total comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(9,907,570</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(9,907,570</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Transactions with owners the Company:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>15</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">62,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">11,863,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12,007,735</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Equity settled shared-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>18</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">181,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>181,468</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total contributions by and distributions to owners of the Company</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,254</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>80,000</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>62,908</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>11,863,573</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>181,468</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>12,189,203</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at December&nbsp;31, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>29,484</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>20,615</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>190,558</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,513,765</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,334,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>28,083,233</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(23,510,612</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>7,661,429</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at January&nbsp;1, 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>29,484</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>20,615</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>190,558</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,513,765</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,334,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>28,083,233</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(23,510,612</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>7,661,429</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Result</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(17,408,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(17,408,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Total comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(17,408,841</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(17,408,841</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Transactions with owners the Company:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>15</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">40,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">50,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,942,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>6,033,693</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Equity settled shared-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>18</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">154,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>154,468</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total contributions by and distributions to owners of the Company</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>896</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>40,000</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>50,388</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>5,942,409</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>154,468</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>6,188,161</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at December&nbsp;31, 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>30,380</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>20,615</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>230,558</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,564,153</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,334,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>34,025,642</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(40,764,985</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(3,559,251</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_6"></A>STATEMENT OF CASH FLOWS FOR THE YEAR ENDED DECEMBER&nbsp;31,
2014 </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Result after taxation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,409</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments for:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortisation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>7,&nbsp;8</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>253</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share option expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>18</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>155</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net finance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>19</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(11</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,012</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,460</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in working capital:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade and other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>10</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(39</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,451</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities and accruals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>12</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>202</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>14</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>836</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax and social security liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash used in operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(14,548</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest paid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>19</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(39</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax paid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>9</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used in operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(14,587</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flow from investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisition of property, plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>7</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(157</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>10,&nbsp;19</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>71</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash flow used in investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(86</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flow from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuing shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>15</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6,034</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayment of borrowings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>13</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(167</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5,867</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,842</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net (decrease)/increase in cash and cash equivalents</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(8,806</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4,884</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents as at January&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>11</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,763</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents as at December&nbsp;31</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,841</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_7"></A>NOTES TO THE FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. General information </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merus B.V. (the Company), headquartered in Utrecht, the
Netherlands, is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics. The Company has a pipeline of full-length human bispecific antibodies generated from its proprietary technology platform. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is a limited liability company incorporated in
the Netherlands, with its statutory seat in Utrecht. The address of the registered office is Padualaan 8, 3584CH Utrecht, the Netherlands. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Basis of preparation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Statement of compliance </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These non-statutory financial statements have been prepared in accordance with International Financial Reporting Standards as issued by
the International Accounting Standards Board. These financial statements are the first financial statements of the Company prepared in accordance with IFRSs and IFRS 1 <I>First time adoption of </I>IFRSs has been applied. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The disclosures required by IFRS 1 concerning the transition
from the previous accounting principles to IFRSs are given in note 27. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Date of authorization </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These non-statutory financial statements were authorized for issuance by the supervisory board on 21&nbsp;January 2016. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Change in accounting policy </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsequent to the initial authorization for issuance date of
4&nbsp;September 2015, the Company has decided to change its presentation format for the Statement of profit or loss and comprehensive loss from the nature of expense method to the function of expense method. The Company chose to change its
presentation format considering industry factors and the nature, practice and current stage of development of the Company&#146;s operations. The Company is of the opinion that the revised presentation provides more relevant information than the
previous presentation. In accordance with the SEC&#146;s requirements on retrospective adjustments to previously issued financial statements included in a registration statement, the Company has prepared these non-statutory financial statements to
present such retrospective application of this change in accounting policy. This change in accounting policy has no retrospective impact on net result, the financial position nor cash flows. Reference is made to Note 17 total operating expenses in
which the expense by nature disclosures are presented. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The impact of the reclassification on the statement of comprehensive loss for the years ended 31&nbsp;December 2014 and 2013 is summarized as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Initial presentation (nature of expense method)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs of outsourced work and other external costs:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(14,099</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,054</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1,203</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,168</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortisation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(253</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total operating expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(18,723</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revised presentation (function of expense method)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(12,388</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management&nbsp;and administration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(550</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,785</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total operating expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(18,723</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Basis of
preparation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements
have been prepared under the historical cost convention unless otherwise stated in below accounting policies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Functional and presentation currency </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements are presented in euros, which is
the Company&#146;s functional and presentation currency. All amounts are rounded to the nearest euro, except otherwise indicated. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Going concern </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2014, the Company suffered losses from its operations, which further weakened the shareholders&#146; equity. In view of its
financial position at the end of 2014, the Company exercised its right to request the issuance of new Class B preferred shares in January 2015, which increased the Company&#146;s shareholders&#146; equity and cash position by &#128;5.0&nbsp;million.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the then existing agreement with Class B
preferred shareholders, the Company had the right to request the issuance of new Class B preferred shares up to an amount of &#128;8.0&nbsp;million, with &#128;4.0&nbsp;million between 1&nbsp;September 2015 and 31&nbsp;December 2016 (Tranche 6) and
&#128;4.0&nbsp;million between 1&nbsp;March 2016 and 31&nbsp;December 2016 (Tranche 7). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On 11&nbsp;June 2015, the Company reached an agreement with the Class B preferred shareholders to provide the Company with a convertible bridge loan of &#128;8.0&nbsp;million in lieu of Tranches 6 and 7,
and to cancel these two tranches. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 16&nbsp;June
2015, the Company reached an agreement with existing and new shareholders to provide the Company with additional funding up to an amount of approximately &#128;73.0&nbsp;million of which approximately &#128;50.0&nbsp;million would be contributed in
August 2015 in connection with the issuance of new Class C preferred shares. In connection with this Class C preferred share financing, the convertible bridge loan was repaid in August 2015 by converting the principal and interest thereon into Class
C preferred shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company expects to incur
significant expenses and operating losses for the foreseeable future as its bi-specific antibody candidates advance from discovery through preclinical development and into clinical trials, and it seeks regulatory approval and pursues
commercialization of any approved bi-specific antibody candidate. In addition, the Company may incur expenses in connection with the in-license or acquisition of additional bi-specific antibody candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result, the Company will need additional financing to
support its continuing operations. Until such time as it can generate significant revenue from product sales, if ever, the Company expects to finance its operations through a combination of public or private equity or debt financings or other
sources, which may include collaborations with third parties. Adequate additional financing may not be available to the Company on </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
acceptable terms, or at all. The Company&#146;s inability to raise capital as and when needed would have a negative impact on the financial condition and ability to pursue its business strategy.
The Company will need to generate significant revenue to achieve profitability, and may never do so. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company expects that its existing cash and cash equivalents, together with the net proceeds from the issuance of Class C preferred
shares in August 2015, will enable the Company to fund its operating expenses and capital expenditure requirements for at least the next twelve months. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the assumption that the Company will be able to continue as a going concern, the accounting principles as disclosed in note 4
have been applied in these financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. Use of
estimates, judgements and assumptions </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from
these estimates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimates and underlying
assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following are the critical judgments and assumptions, apart from those involving estimations (see below), that management has made in
the process of applying the Company&#146;s accounting policies and that have the most significant effect on the amounts recognised in the financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Capitalization of development costs </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Determination whether the capitalization criteria for
development costs are met or not. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The criteria
for capitalization of development costs are disclosed in note 4 &#147;Significant accounting policies&#148; and were not met in 2014. Therefore, all development expenditures relating to internally generated intangible assets in 2014 were expensed
when incurred. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income tax
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Determination whether the criteria for
the recognition of unused tax losses are met or not. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The criteria for the recognition of unused tax losses are disclosed in note 4 &#147;Significant accounting policies&#148;. As at 31&nbsp;December 2014, deferred tax assets have not been recognised in
respect of tax losses, because the Company has no history of generating taxable profits and at the balance sheet date, there is no convincing evidence that sufficient taxable profit will be available against which the tax losses can be utilised. The
amount of the unutilised tax losses is disclosed in note 9. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounting for upfront license fees </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company entered into a contract and license agreement with a customer in April 2014. In connection with this arrangement, the Company received an upfront fee, which relates to the integrated package
of deliverables under the contract (one single performance obligation). The applicable period over which to recognise the upfront payment is a significant judgment. Revenue related to this upfront fee is deferred and amortised on a straight-line
basis over the contract period, as that is the period over which the Company performs its integrated service activities to the third-party </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Equity settled share-based payments </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share options granted to employees and consultants providing
similar services are measured at the grant date fair value of the equity instruments granted. The grant date fair value is determined through the use of an option-pricing model considering the following variables: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the exercise price of the option; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expected life of the option; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the current value of the underlying shares; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expected volatility of the share price; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the dividends expected on the shares; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">f)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the risk-free interest rate for the life of the option. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the Company&#146;s share option plans, management&#146;s judgment is that the Black-Scholes valuation formula and the binomial option
pricing model are the most appropriate methods for determining the fair value of the Company&#146;s share options considering the terms and conditions attached to the grants made and to reflect exercise behaviour. Since the Company is a private
company, there is no published share price information available. Consequently, the Company needs to estimate the fair value of its share and the expected volatility of that share value. These assumptions and estimates are further discussed in Note
15 to the financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The result of the
share option valuations and the related compensation expense that is recognised for the respective vesting periods during which services are received is dependent on the model and input parameters used. Even though management considers the fair
values reasonable and defensible based on the methodologies applied and the information available, others might derive at a different fair value for the Company&#146;s share options. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Significant accounting policies </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accounting policies set out below have been consistently
applied to all periods presented in these financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Income and expenses are accounted for on the accruals basis. Profit is only included when realised at balance sheet date. Losses originating before the end of the financial year are taken into account if
they have become known before preparation of the financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign currency transactions </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Transactions in foreign currencies are translated to the respective functional currency of the Company at exchange rates at the dates of the transactions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Monetary assets and liabilities denominated in foreign
currencies are translated into the functional currency at the exchange rate at the reporting date. Foreign currency differences are generally recognised in profit or loss. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Property, plant and equipment </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment are measured at cost less
accumulated depreciation and accumulated impairment losses (if any). Cost includes expenditure that is directly attributable to the acquisition of the items. Depreciation of property, plant and equipment is charged to the income statement on a
straight-line basis over estimated useful lives of generally five years. If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property,
plant and equipment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsequent expenditure is capitalized only when it is probable that the future economic
benefits associated with the expenditure will flow to the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intangible assets </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Intangible assets are identifiable non-monetary assets without physical substance. An asset is a resource that is controlled by the enterprise as a result of past events (for example, purchase or
self-creation) and from which future economic benefits (inflows of cash or other assets) are expected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Patents </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents acquired separately by the Company are reported at cost less accumulated amortisation and accumulated impairment losses.
Amortisation is charged on a straight-line basis over the estimated useful lives of the patents. The estimated useful life and amortisation method are reviewed at the end of each annual reporting period, with the effect of any changes in estimates
being accounted for on a prospective basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
useful lives of intangible assets are assessed to be finite and amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents are amortised on a straight-line basis over the
shorter of their estimated economic or legal lives. Amortisation begins when the asset is available for use. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research and development </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company incurs research and development expenses related to its clinical trials and preclinical drug development programs. Development
expenses are defined as expenses incurred to achieve technical and commercial feasibility. Expenditure on research activities is recognised as an expense in the period in which it is incurred. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development is recognised if, and only if, all of the following have been demonstrated: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the technical feasibility of completing the intangible asset so that it will be available for use or sale; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the intention to complete the intangible asset and use or sell it; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to use or sell the intangible asset; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">how the intangible asset will generate probable future economic benefits; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to measure reliably the expenditure attributable to the intangible asset during its development. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financial instruments </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company classifies non-derivative financial assets into
the following categories: loans and receivables. The Company classifies non-derivative financial liabilities into the other financial liabilities category. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Non-derivative financial assets and financial liabilities </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company initially recognises loans and receivables
issued on the date when they are originated. All other financial assets and financial liabilities are initially recognised on the trade date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company derecognises a financial asset when the contractual rights to the cash flows
from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains
substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognised financial assets that is created or retained by the Company is recognised as a separate asset or
liability. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company derecognises a financial
liability when its contractual obligations are discharged or cancelled, or expire. Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company has a legal
right to offset the amounts and intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Loans and receivables </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These assets are initially recognised at fair value plus any directly attributable transaction costs. Subsequent to initial recognition,
they are measured at amortised cost using the effective interest method. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Non-derivative financial liabilities </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Non-derivative financial liabilities are initially recognised at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortised
cost using the effective interest method. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share capital </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Common shares </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incremental costs directly attributable to the issue of common shares, net of any tax effects, are recognised as a deduction from equity.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Preference shares </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-redeemable preference shares are classified as equity,
because they bear discretionary dividends, do not contain any obligations to deliver cash or other financial assets and do not require settlement in a variable number of the Company&#146;s equity instruments. Discretionary dividends thereon are
recognised as equity distributions on approval by the Company&#146;s shareholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Provisions </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A provision is recognised if the following applies: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the company has a legal or constructive obligation, arising from a past event; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the amount can be estimated reliably; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If all or part of the payments that are necessary to settle a
provision are likely to be fully or partially compensated by a third party upon settlement of the provision, then the compensation amount is presented separately as an asset. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions are determined by discounting the expected future
cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognised as finance cost. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Impairment </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Financial assets measured at amortised cost </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company considers evidence of impairment for these assets at both an individual asset and a collective
level. All individually significant assets are individually assessed for impairment. Those found not to be impaired are then collectively assessed for any impairment that has been incurred but not yet individually identified. Assets that are not
individually significant are collectively assessed for impairment. Collective assessment is carried out by grouping together assets with similar risk characteristics. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In assessing collective impairment, the Company uses
historical information on the timing of recoveries and the amount of loss incurred, and makes an adjustment if current economic and credit conditions are such that the actual losses are likely to be greater or lesser than suggested by historical
trends. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An impairment loss is calculated as the
difference between an asset&#146;s carrying amount and the present value of the estimated future cash flows discounted at the asset&#146;s original effective interest rate. Losses are recognised in profit or loss and reflected in an allowance
account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event
occurring after the impairment was recognised, then the previously recognised impairment loss is reversed through profit or loss. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Non-financial assets </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At each reporting date, the Company reviews the carrying amounts of its non-financial assets to determine whether there is any indication
of impairment. If any such indication exists, then the asset&#146;s recoverable amount is estimated. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that
are largely independent of the cash inflows of other assets or cash generating units (CGU). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present
value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An impairment loss is recognised if the carrying amount of an asset or CGU exceeds its recoverable amount. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Impairment losses are recognised in profit or loss. They are
allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets in the CGU on a pro rata basis. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An impairment loss is reversed only to the extent that the
asset&#146;s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fees and royalties </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees and royalties paid for the use of the Company&#146;s
assets (such as patents) are normally recognised in accordance with the substance of the agreement. As a practical matter, this may be on a straight-line basis over the life of the agreement, for example, when a licensee has the right to use certain
technology for a specified period of time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An assignment of rights for a fixed fee or non-refundable guarantee under a
non-cancellable contract which permits the licensee to exploit those rights freely and the licensor has no remaining obligation to perform is, in substance, a sale. In some cases, whether or not a license fee or royalty will be received is
contingent on the occurrence of a future event. In such cases, revenue is recognised only when it is probable that the fee or royalty will be received which is normally when the event has occurred. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Services </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues from services rendered are recognised in the profit
and loss account in proportion to the stage of completion of the transaction as at reporting date. The stage of completion is assessed by reference to assessments of the work performed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Government grants </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Government grants are initially recognised in the balance
sheet as deferred income at fair value when there is reasonable assurance that they will be received and the Company will comply with the conditions associated with the grant. Grants that compensate the Company for expenses incurred are recognised
in the profit and loss on a systematic basis in the same period in which the expenses are recognised. Grants that compensate the Company for the cost of an asset are recognised in the profit and loss account on a systematic basis over the useful
life of the asset. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employee benefits
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Short-term employee benefits
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term employee benefits are expensed as
the related service is provided. A liability is recognised for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation
can be estimated reliably. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share-based payment
transactions </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The grant-date fair value of
equity-settled share-based payment awards granted to employees is recognised as an expense, with a corresponding increase in equity, over the vesting period of the awards. Service provisions and non-market related conditions are not taken into
account in determining the fair value. The amount recognised as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately
recognised is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. For any share-based payment awards with market conditions or non-vesting conditions, the grant-date fair value of
the share-based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcomes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Post-employment benefit plans </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company contributes to a post-employment benefit plan that entitles directors, executive officers and other staff members to retire at
the age of 67 and receive annual payments based upon the average salary earned during the service period. The Company has insured the liabilities from the defined benefit plan with an insurance company and has no other obligation than to pay the
annual insurance premiums to the insurance company. The annual pension payments are conditional; the Company will have no further obligation (legal or constructive) to pay further amounts if the insurance fund has insufficient assets to pay all
employee benefits relating to current and prior service. Based on its characteristics the Company&#146;s post-employment benefit plan is classified as a defined contribution plan. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Obligations for contributions to defined contribution plans
are expensed as the related service is provided. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in future payments is available. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-14
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Leases </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Determining whether an arrangement contains a lease </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At inception of an arrangement, the Company determines
whether such an arrangement is or contains a lease. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At inception or on reassessment of the arrangement, the Company separates payments and other consideration required by such an arrangement
into those for the lease and those for other elements on the basis of their relative fair values. If the Company concludes for a finance lease that it is impracticable to separate the payments reliably, then an asset and a liability are recognised
at an amount equal to the fair value of the underlying asset. Subsequently the liability is reduced as payments are made and an imputed finance cost on the liability is recognised using the Group&#146;s incremental borrowing rate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Leased assets </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets held by the Company under leases that transfer to the
Company substantially all of the risks and rewards of ownership are classified as finance leases. The leased assets are measured initially at an amount equal to the lower of their fair value and the present value of the minimum lease payments.
Subsequent to initial recognition, the assets are accounted for in accordance with the accounting policy applicable to that asset. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets held under other leases are classified as operating leases and are not recognised in the Group&#146;s statement of financial
position. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Lease payments </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments made under operating leases are recognised in
profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognised as an integral part of the total lease expense, over the term of the lease. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Minimum lease payments made under finance leases are apportioned between the finance expense and the reduction
of the outstanding liability. The finance expense is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Finance income and finance expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s finance income and finance expenses
include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>interest income; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>interest expense; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>the foreign currency gain or loss on financial assets and financial liabilities. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income or expense is recognised using the effective
interest method. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income tax
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax expense comprises current and
deferred tax. It is recognised in profit or loss except to the extent that it relates to a business combination, or items recognised directly in equity or in other comprehensive income (OCI). Current tax comprises the expected tax payable or
receivable on the taxable income or loss for the year and any adjustment to tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date. Current tax also includes any
tax arising from dividends. Current tax assets and liabilities are offset only if certain criteria are met. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-15
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax is recognised in respect of temporary differences between the carrying
amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognised for: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither
accounting nor taxable profit or loss; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">temporary differences related to investments in subsidiaries, associates and joint arrangements to the extent that the group is able to control the
timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">taxable temporary differences arising on the initial recognition of goodwill. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets are recognised for unused tax losses,
unused tax credits and deductible temporary differences to the extent that it is probable that future taxable profits will be available against which they can be used. Deferred tax assets are reviewed at each reporting date and are reduced to the
extent that it is no longer probable that the related tax benefit will be realised; such reductions are reversed when the probability of future taxable profits improves. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unrecognised deferred tax assets are reassessed at each
reporting date and recognised to the extent that it has become probable that future taxable profits will be available against which they can be utilised. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax rates
enacted or substantively enacted at the reporting date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets
and liabilities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. New standards and interpretations not yet
adopted </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A number of new standards,
amendments to standards and interpretations are effective for annual periods beginning on or after 1&nbsp;January 2015, and have not been applied in preparing these financial statements. Those which may be relevant to the Company are set out below.
The Company does not plan to adopt these standards early. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>IFRS 9 Financial Instruments </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">IFRS 9, published in July 2014, replaces the existing guidance in IAS 39 Financial Instruments: Recognition and Measurement. IFRS 9 includes revised guidance on the classification and measurement of
financial instruments, including a new expected credit loss model for calculating impairment on financial assets, and the new general hedge accounting requirements. It also carries forward the guidance on recognition and derecognition of financial
instruments from IAS 39. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 9 is effective for
annual reporting periods beginning on or after 1&nbsp;January 2018, with early adoption permitted. The Company is assessing the potential impact on its financial statements resulting from the application of IFRS 9. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>IFRS 15 Revenue from Contracts with Customers
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 15 establishes a comprehensive
framework for determining whether, how much and when revenue is recognised. It replaces existing revenue recognition guidance, including IAS 18 Revenue, IAS 11 Construction Contracts and IFRIC 13 Customer Loyalty Programs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-16
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 15 is effective for annual reporting periods beginning on or after 1&nbsp;January
2017, with early adoption permitted. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
is assessing the potential impact on its financial statements resulting from the application of IFRS 15. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>6. Segment reporting </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company operates in one reportable segment, which comprises the discovery and development of innovative bispecific therapeutics.<B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notes to the statement of financial position as at 31&nbsp;December 2014 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Property, plant and equipment </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Movements in property, plant and equipment were as follows:
</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plant and<BR>equipment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other&nbsp;fixed<BR>assets</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance as at 1&nbsp;January 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>134</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,169</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,303</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(121</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(794</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(915</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Book value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>375</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>388</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes in book value</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>125</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>32</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>157</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(24</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(168</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(192</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>101</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(136</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(35</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance as at 31&nbsp;December 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>259</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,201</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,460</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(145</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(962</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1,107</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Book value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>114</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>239</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>353</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plant and<BR>equipment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other&nbsp;fixed<BR>assets</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance as at 1&nbsp;January 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>134</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,086</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,220</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(106</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(606</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(712</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Book value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>480</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>508</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes in book value</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>83</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>83</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(15</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(188</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(203</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(15</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(105</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(120</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance as at 31&nbsp;December 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>134</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,169</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,303</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(121</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(794</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(915</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Book value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>375</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>388</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-17
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation rates are based on the following estimated economic useful lives of the
tangible fixed assets concerned: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plant and equipment: 5 years </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other fixed assets: 5 years </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. Intangible assets </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The intangible assets related to acquired intellectual property rights. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The movements are as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance as at 1&nbsp;January</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historical cost</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>860</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated amortisation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(302</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Book value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>558</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">619</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital expenditures</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortisation charge for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(61</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Book value as at 31&nbsp;December</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>497</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance as at 31&nbsp;December</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historical cost</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>860</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated amortisation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(363</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Book value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>497</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
purchased at 23&nbsp;January 2009 the patents regarding the recombinant production of mixtures of antibodies from Crucell Holland B.V. The majority of the patents were filed by Crucell Holland B.V. at 15&nbsp;July 2003 and have an economic life of
20 years. Therefore, the Company decided to amortise over the remaining economic life of 14 years. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>9. Taxation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets have not been recognised in respect of tax losses, because the Company has no history of generating taxable profits and at the balance sheet date, there is no convincing evidence that
sufficient taxable profit will be available against which the tax losses can be utilised. As at 31&nbsp;December 2014, the tax losses carried forward amount to &#128;43.5&nbsp;million as compared to &#128;28.2&nbsp;million in 2013. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to promote innovative technology development
activities and investments in new technologies, a corporate income tax incentive has been introduced in Dutch tax law called the Innovations Box. For the qualifying profits, the company effectively owes only 5% income tax, instead of the general tax
rate of 25%, which results in an estimated effective tax rate of 10%. The agreement with the tax authorities is currently signed for the years 2011 to 2015 but is expected to be extended. Taxable profits will only qualify for the Innovations Box
once the tax losses carried forward are completely utilised. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-18
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Trade and other receivables </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All trade and other receivables are short term debtors and due within 1 year. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>172</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Taxation and social security premiums</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>269</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid general expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>292</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest bank</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>86</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>849</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Cash and cash equivalents
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cash and cash equivalents balance
includes an amount of &#128;273&nbsp;thousand (2013: &#128;453 thousand) that is not immediately accessible as it is pledged to the bank as a security for a loan received. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">See also note 13. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Other liabilities and accruals </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities and accruals is analysed below:
</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued auditor&#146;s fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrual for holiday expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>117</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>43</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D studies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>388</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IP&#151;Legal fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>858</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bonuses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>276</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidy advance received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,057</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other accruals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>131</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,904</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,701</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. Borrowings </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Movements in borrowings were as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Rabobank</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in<BR>thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance January&nbsp;1, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,152</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(166</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance portion December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>986</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short term portion December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(167</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long term portion December&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>819</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-19
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in<BR>thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance January&nbsp;1, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>986</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(167</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>819</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short term portion December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(167</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long term portion December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>652</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rabobank
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company entered into a financing
agreement with Rabobank Utrechtse Heuvelrug U.A. (Rabobank) on 29&nbsp;December 2009, which provided for total borrowings of &#128;1.5&nbsp;million for the financing of its business activities. The duration of this agreement is 12 years. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the agreement, the loans are to be repaid in monthly
instalments of &#128;14&nbsp;thousand, beginning on 31&nbsp;January 2009. Repayments were deferred in January 2010 for a period of 2 years. Repayment recommenced in January 2012. The loans bear interest at an annual rate equal to 4.45% and is fixed
until 1&nbsp;April 2016 and thereafter, at our option, at a fixed or variable rate to be agreed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the financing agreement, the Company provided security in the form of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a right of pledge on the account of &#128;500&nbsp;thousand, in the Company&#146;s name in a new savings account for the benefit of Rabobank; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a suretyship of &#128;1&nbsp;million within the framework of the Royal Decree &#147;Borgstelling
<FONT STYLE="white-space:nowrap">MKB-krediet&#148;.</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">See also note 11. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. Deferred revenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 8&nbsp;April 2014, the Company entered into a research and license agreement with ONO Pharmaceutical Co, Ltd. As part of this
agreement, the Company received a non-refundable upfront payment of &#128;1.0 million. This upfront payment is amortised on a straight-line basis, and presented as revenue, over a period from 8&nbsp;April 2014 through 30&nbsp;September 2018, the end
of the research term. The Company is eligible to receive milestone payments upon achievement of specified research and clinical development milestones. For products commercialized under this agreement, if any, the Company is also eligible to receive
a mid-single digit royalty on net sales. ONO also provides funding for the Company&#146;s research and development activities under an agreed-upon plan. ONO has the right to terminate this agreement at any time for any reason, with or without cause.
</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014 </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013 </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#128;000&#146;s</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#128;000&#146;s</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue&#151;current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>223</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>613</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>836</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-20
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. Shareholders&#146; equity </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in shareholders&#146; equity were as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class A<BR>pref.&nbsp;share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class B<BR>pref.&nbsp;share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common&nbsp;A<BR>pref. share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common B<BR>pref. share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>loss</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total equity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at 1&nbsp;January 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28,230</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20,615</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>110,558</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,450,857</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,334,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16,219,660</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(13,784,510</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5,379,796</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,863,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12,007,735</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Result for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,907,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(9,907,570</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">181,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>181,468</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at 31&nbsp;December 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29,484</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20,615</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>190,558</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,513,765</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,334,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28,083,233</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(23,510,612</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7,661,429</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at 1&nbsp;January 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29,484</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20,615</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>190,558</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,513,765</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,334,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28,083,233</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(23,510,612</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7,661,429</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,942,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6,033,693</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Result for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,408,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,408,841</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>154,468</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at 31&nbsp;December 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>30,380</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20,615</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>230,558</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,564,153</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,334,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34,025,642</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(40,764,985</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,559,251</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Issued and
paid-in share capital </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Common shares
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2013, 25,082 options were exercised at an
average price of &#128;2.56&nbsp;per share; as a consequence 25,082 common shares were issued, share capital increased by &#128;1,254 and share premium increased by &#128;62,908. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2014, 17,915 options were exercised at an average price of
&#128;2.86&nbsp;per share; as a consequence 17,915 common shares were issued, share capital increased by &#128;896 and share premium increased by &#128;50,388. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Class&nbsp;A preferred shares </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no changes in 2013 and 2014. The Class&nbsp;A preferred shares are convertible into common shares only. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Class B preferred shares </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2010, the Company closed a
&#128;21.7&nbsp;million ($30.7 million) Class B preferred share financing led by new investors Novartis Bioventures Ltd, Pfizer Inc., Bay City Capital , and Life Sciences Partners. Merus&#146; seed investor Aglaia Oncology Fund also participated in
this financing. The first tranche of the Class B preferred share financing (&#128;8.5 million) was drawn down in January 2010. The second tranche of the Class B preferred share financing (&#128;8.1 million) was drawn down in April 2012. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The initial Class B preferred share financing commitment was
reduced in 2013 by cancellation of the third tranche in relation with the closing of the Class B preferred share extension on 30&nbsp;September 2013. Johnson&nbsp;&amp; Johnson Development Corporation joined the existing investor group and a total
of &#128;31.0&nbsp;million was committed in addition to the &#128;16.6&nbsp;million already drawn down from the original Class B preferred share financing. The Class B preferred share extension consists of up to a further 5 tranches (tranches 3 to
7) over and above the initial Class B preferred share tranches 1 and 2 already drawn down. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Tranche 3 of &#128;12.0&nbsp;million was drawn down at the time of closing of the Class B preferred share extension (30 September 2013) and a total of 1,600,000 Class B preferred shares were issued.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tranche 4 of &#128;6.0&nbsp;million was drawn
down on 29&nbsp;August 2014 and a total of 800,000 Class B preferred shares were issued. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-21
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Class B preferred shares are convertible into common shares only and carry an annual
cumulative profit entitlement of 8% of the amount paid on such shares. The dividend entitlement rights are at all times senior to the dividend entitlement rights of the Class&nbsp;A preferred shares and the common shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Conversion </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares of Class&nbsp;A and Class B preferred (together with
any accrued and unpaid dividends) are convertible into common shares only. Conversion is at the option of the holders of the Class&nbsp;A and Class B preferred shares, although conversion is mandatory and automatic in any of the following events:
(i)&nbsp;the affirmative vote of specified Class B preferred shareholders to convert all (and not less than all) of the issued and outstanding Class&nbsp;A and Class B preferred shares or (ii)&nbsp;the consummation of an initial public offering
resulting in gross proceeds to the Company of &#128;30.0&nbsp;million or more and a price per share to the public of not less than four times the original issue price of the Class B preferred shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Conversion rate preferred shares </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The conversion rate (excluding accumulated dividend) for
each class of preferred shares is as follows: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Conversion rate in EUR</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;A</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;B</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;C</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series 1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series 2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">C Tranche 1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Situation as at
31&nbsp;December 2014 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At 31&nbsp;December
2014, a total of 4,611,156 Class B preferred shares, 412,296 Class&nbsp;A preferred shares and 607,596 common shares with a par nominal of &#128;0.05 each were issued and paid up. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share premium reserve </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The share premium reserve relates to amounts contributed by
shareholders at the issue of shares in excess of the par value of the shares issued. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All share premium can be considered as free share premium as referred to in the Netherlands Income tax act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foundation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company established a foundation &#147;Stichting Administratiekantoor Merus&#148; (Foundation). The Foundation has an agreement with
the Company to facilitate the administration of share-based compensation awards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Options granted under the Company&#146;s share option programs entitle the eligible participant to purchase depositary receipts for common shares in the Company, subject to meeting the vesting conditions.
The ownership of such depositary receipts is conditional to the terms and conditions of the foundation&#146;s Conditions of Administration. Under defined circumstances, the participants are obliged to offer the acquired depositary receipts to the
Foundation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-22
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-based payment arrangements </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At 31&nbsp;December 2014, the Company operated the following
share-based payment arrangements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share option
program (equity-settled) </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2010, the
Company established share option programs that entitle key management personnel, staff and consultants providing similar services to purchase depositary receipt for common shares in the Company. Under these programs, holders of vested options are
entitled to purchase depositary receipts for common shares at the exercise price determined at the date of grant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon exercise of options, the Foundation issues to such individuals non-voting depositary receipts representing the underlying common
shares, against payment of the option exercise price. The voting rights associated with the common shares remain with the Foundation. The Options granted under the share option programs vest in instalments over a four-year period from the grant
date. 25% of the options vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in 36 monthly installments for each full month of continuous service provided by the option holder thereafter, such
that 100% of the options shall become vested on the fourth anniversary of the vesting commencement date. The options granted are exercisable once vested. Options will lapse on the eighth anniversary of the date of grant. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For participants who are not members of the Supervisory
Board, a participant who voluntarily leaves employment with the Company, is required to offer to the Foundation the Depositary Receipts acquired from exercising options against payment of the exercise price or the lower fair market value of the
underlying shares. Up to the first anniversary of the date of exercise, the participant has an obligation to offer 100% of his Depositary Receipts to the Foundation. This obligation for a participant to offer Depositary Receipts to the Foundation
upon resignation is reduced by 25%&nbsp;per year, which means that there is no such obligation if a participant leaves after the fourth anniversary of the date of exercise, and is treated as a vesting condition. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following number of options are outstanding as per
year-end: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:96pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Group of employees entitled</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>January&nbsp;1,<BR>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Executives</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>226,996</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">210,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">218,082</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>46,537</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supervisory Board members</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>72,563</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>346,096</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">287,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">294,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Measurement of
fair values of the Equity-settled share-based payment arrangements </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The fair value of the employee share options has been measured using the Black-Scholes formula (members of the Executive Management team) or a binomial option pricing model (other participants, including
Supervisory Board members). Service and non-market performance conditions attached to the transactions were not taken into account in measuring fair value. In addition to the vesting period of the options, the vesting period for the depositary
receipts were also taken into account when allocating the fair values of the options granted over the required service period. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-23
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The inputs used in the measurement of the fair values and the related fair values at the
grant dates were as follows for respectively options granted to members of the Executive Management team (Black-Scholes formula) and other participants (binominal option pricing model): </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Executives</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Executives</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#128;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#128;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#128;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#128;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.39</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">2.45-2.71</FONT></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share price at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.70</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.40-3.70</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.58</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.58</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility (weighted-average)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>101.1</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>%&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>101.1</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>%&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected life (weighted-average)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4&nbsp;year</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8 year</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4&nbsp;year</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8&nbsp;year</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>%&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>%&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate (based on government bonds)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.2</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>%&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">1.0%-1.2</FONT></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>%&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since the Company is
a private company, company-specific historical and implied volatility information is not available. Expected volatility is therefore estimated based on the observed daily share price returns of publicly traded peer companies over a historic period
equal to the period for which expected volatility is estimated. The group of comparable listed companies are publicly traded entities active in the business of developing antibody-based therapeutics, treatments and drugs and are selected taking into
consideration the availability of meaningful trading data history and market capitalization. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since the options are not transferable, the participants will tend to exercise the options prior to the maturity date. For participants, not being members of the Executive Management team, expected early
exercises have been incorporated in the option valuation by assuming that the participants will exercise the options if the share price increases to two times the exercise price at a future point in time. The members of the Executive Management team
are expected to exercise their options immediately after vesting of the final vesting instalment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since the Company is a private company, the share price is not readily available at the valuation date of the share option. In determining the fair values of the Company&#146;s common shares as of each
grant date, three generally accepted approaches were considered: income approach, market approach and cost approach. In addition, the guidance prescribed by the American Institute of Certified Public Accounts (AICPA) Audit and Accounting Practice
Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation has been considered. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The &#147;prior sale of company stock&#148; method, a form of the market approach, has been applied to estimate the total enterprise
value. The prior sale of company stock method considers any prior arm&#146;s length sales of the Company&#146;s equity securities. Considerations factored into the analysis include: the type and amount of equity sold, the estimated volatility, the
estimated time to liquidity, the relationship of the parties involved, the risk-free rate, the timing compared to the common shares valuation date and the financial condition and structure of the Company at the time of the sale. As such, the value
per share has been benchmarked to the external transactions of company stock and external financing rounds. For determining the value of the Company&#146;s shares for 2010 through 2014, the prior sale of company stock method has been relied on to
estimate the total value of the company&#146;s equity. Throughout this period, a number of financing rounds were held, which resulted in the issuance of preferred shares. The preferred shares were transacted with numerous existing and new investors,
and therefore the pricing in these financing rounds is considered a strong indication of fair value. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Given that there are multiple classes of equity, the hybrid method has been applied in order to allocate equity to the various equity
classes. The Hybrid method is a hybrid between the probability-weighted expected return method (PWERM) and the Option Pricing Method (OPM), which estimates the probability weighted value across certain exit scenarios, but uses the OPM to estimate
the remaining unknown potential exit scenarios. A discount for lack of marketability (DLOM) was applied, corresponding to the time to exit under the various </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-24
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
scenarios to reflect the increased risk arising from the inability to readily sell the shares. When assessing the DLOM, the Black-Scholes option pricing model was used. Under this method, the
cost of the put option, which can hedge the price change before the privately held shares can be sold, was considered as the basis to determine the DLOM. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Reconciliation of outstanding share options </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number and weighted average exercise prices of share
options granted under the share option programs were as follows: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>average<BR>exercise<BR>price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>options <BR></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>average<BR>exercise<BR>price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>options <BR></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in euros)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in euros)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at 1&nbsp;January</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.93</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>287,400</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">294,872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.58</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(13,562</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,280</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.86</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,915</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,082</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted during the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.58</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>90,173</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at 31&nbsp;December</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.86</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>346,096</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">287,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable at 31&nbsp;December</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>249,247</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">189,683</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The options
outstanding at 31&nbsp;December 2014 had an exercise price in the range of &#128;2.13 to &#128;7.50 (2013: &#128;2.13 to &#128;7.50) and a weighted-average remaining contractual life of 4.4 years (2013: 4.6 years). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted-average share price at the date of exercise for
share options exercised in 2014 was &#128;3.40 (2013: &#128;3.80). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Expense recognised in profit or loss </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For details on the related option expenses recognised as employee benefit expenses, see note 17. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. Revenue </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be
reliably measured. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amgen evaluation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">GSK evaluation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ONO Pharmaceutical Co., Ltd.&#151;research funding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>677</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smithkline Beecham&#151;exclusivity fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>100</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidy income on research projects</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>526</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">369</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,303</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-25
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17. Total operating expenses </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A breakdown of total operating expenses is presented as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manufacturing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,646</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IP and license costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(822</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(845</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel related R&amp;D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(2,618</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,302</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Total research and development costs</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(12,388</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management and administration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(550</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Management and administration costs</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(550</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Litigation costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,582</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1,203</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other expenses</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,785</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,294</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total operating expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(18,723</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2014
Regeneron Pharmaceuticals Inc. (Regeneron) filed a complaint in the United States District Court for the Southern District of New York, alleging that the Company was infringing one or more claims in their U.S. Patent No.&nbsp;8,502,018, entitled
&#147;Methods of Modifying Eukaryotic Cells.&#148; On 3&nbsp;July 2014, the Company filed a response to the complaint, denying Regeneron&#146;s allegations of infringement and raising affirmative defenses, and filed counterclaims seeking, among
other things, a declaratory judgment that the Company did not infringe the patent and that the patent was invalid. The Company subsequently filed amended counterclaims during the period from August to December 2014, seeking a declaratory judgment of
unenforceability of the patent due to Regeneron&#146;s commission of inequitable conduct. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On 21&nbsp;November 2014, the District Court found that there was clear and convincing evidence that a claim term present in each of the patent claims was indefinite and granted the Company&#146;s
proposed claim constructions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 11&nbsp;March
2014, Regeneron served a writ in the Netherlands alleging that we were infringing one or more claims in their European patent EP 1 360 287 B1. The Company had opposed that patent in June 2014 and the Dutch litigation is currently stayed. On
17&nbsp;September 2014, Regeneron&#146;s patent EP 1 360 287 B1 was revoked in its entirety by the European Opposition Division of the European Patent Office (EPO). An appeal has been set for October 2015 at the Technical Board of Appeal for the
EPO. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The costs incurred in the above litigation
and opposition (&#128;5.4 million; 2013 no litigations were incurred) are included in the profit and loss statement for the year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses presented by nature are outlined below: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs of outsourced work</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other external costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortisation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total operating expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(18,723</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(10,464</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18. Employee benefits </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Details of the employee benefits read as follows:
</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Salaries and wages</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(2,645</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">WBSO subsidy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>276</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Social security premiums</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(318</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Health insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(40</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pension costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(286</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(155</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,168</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The average number
of personnel during the year was approximately 32 (2013: 27), all employed in the Netherlands, principally in the area of research and development. The Company&#146;s chief executive officer, chief financial officer and finance employee are devoted
to activities other than research and development and are included under management and administration costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>19. Finance income and expense </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income and similar income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>50</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expenses and similar expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(39</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20. Income taxes </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As disclosed in note 9, the Company has tax losses available
which have not been recognised. As a result no income tax is recognised in profit or loss. Taking into account the general tax rate applicable in the Netherlands of 25%, the income tax benefit that has not been recognised in 2014 amounts to
&#128;4.1&nbsp;million (2013: &#128;2.4 million). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21. Loss per
share </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Basic and diluted loss per
share </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic loss per share are
calculated by dividing the loss attributable to equity holders of the Company by the weighted average numbers of shares outstanding during the year. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>January&nbsp;1-</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;
31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>January&nbsp;1-</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;
31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss attributable to equity holders of the Company</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,409</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average number of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5,093,258</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,603,827</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic (and diluted) loss per share (&#128;per share)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3.42</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Diluted loss per share </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the periods included in these financial statements, the
share options are not included in the diluted loss per share calculation as the Company was loss-making in all these periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted loss per share are equal. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(c) Dividends per share </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company did not declare dividends for any of the years
presented in these financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22. Financial
instruments </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financial risk management
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is exposed to a variety of
financial risks: credit risk, liquidity risk and market risk. The Company&#146;s overall risk management program seeks to minimize potential adverse effects of these financial risk factors on the Company&#146;s financial performance. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Credit risk </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Credit risk is the risk of financial loss to the Company if
a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company&#146;s receivables from customers and investments in debt securities. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The carrying amount of financial assets represents the
maximum credit exposure. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>172</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>150</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,841</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10,647</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,013</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10,797</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At year-end, there
is no significant concentration of credit risk at any of the counterparties regarding financial instruments and cash and cash equivalents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At 31&nbsp;December 2014, the ageing of trade and other receivables that were not impaired was as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither past due nor impaired</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>172</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Past due</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>172</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is no
allowance for impairment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Liquidity risk
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prudent liquidity risk management
implies maintaining sufficient funds and marketable securities. Management considers the existing funding per 31&nbsp;December 2014 to provide sufficient time to create shareholder value before a next funding round is carried out. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following are the remaining contractual maturities of financial liabilities at the
reporting date. The amounts are gross and undiscounted, and include estimated interest payments and excluding the impact of netting agreements: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31, 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Carrying<BR>amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&lt; 12<BR>months</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1 - 2<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2 - 5<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More<BR>than</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>5&nbsp;
years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Non-derivative financial liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secured bank loans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade and other payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6,263</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6,356</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5,644</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>193</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>519</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December 31, 2013</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Carrying<BR>amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&lt; 12<BR>months</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1 - 2<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2 - 5<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More<BR>than</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>5 years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Non-derivative financial liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secured bank loans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade and other payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,776</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4,762</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4,896</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,984</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>200</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>556</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>156</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The secured bank
loans have an interest rate that is fixed until 2016. The interest payable on the loans in the table above assumes continuation of this interest rate. These amounts may change as market interest rates change. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Market risk </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign exchange risk arises from future commercial
transactions and recognised assets and liabilities in foreign currencies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company is not exposed to equity securities price risk, since it does not hold any such investments, or commodity price risk. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market risk is the risk that changes in market
prices&#151;such as foreign exchange rates and interest rates&#151;will affect the Company&#146;s income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures
within acceptable parameters, while optimising the return. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s market risk is limited and originates mainly from currency risk and interest risks. Due to the limited impact of currency risk on the Company no summary quantitative data is provided.
Furthermore, the sensitivity analysis resulting from a change in foreign exchange rates is not material and therefore omitted. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exposure to interest rate risk </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The interest rate profile of the Company&#146;s interest-bearing financial instruments is as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Carrying amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros&nbsp;in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fixed-rate instruments</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(986</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Variable rate instruments</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the limited impact of changes in interest rates on the Company no sensitivity
data is provided. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounting
classifications and fair values </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company classifies financial assets and financial liabilities into the loans and receivables and other financial liability categories only. These financial assets and financial liabilities are not measured at fair value and as such information on
the fair value hierarchy is omitted. The carrying amount of the financial assets and financial liabilities is a reasonable approximation of the fair value. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23. Compensation of Management Board and Supervisory Board </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Management Board </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2014 the following amounts were charged to the profit and
loss statement for the remuneration of the statutory directors: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Gross<BR>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pension</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Crisis<BR>tax</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>cost</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ton Logtenberg, CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">199,997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">345,499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shelley Margetson, CFO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">149,322</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208,578</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>554,077</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2014, Ton
Logtenberg was granted 11,250 options over common shares and Shelley Margetson 9,000 options over common shares. The exercise price of each option is &#128;2.58. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2013, the following amounts were charged to the statement
of profit or loss for the remuneration of the statutory directors: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Gross<BR>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Bonus</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pension</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Crisis</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>tax</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>cost</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ton Logtenberg, CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">191,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">323,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shelley Margetson, CFO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">122,304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,936</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">171,694</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>495,081</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2013, no options
were granted to the statutory directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As at
31&nbsp;December 2014, Ton Logtenberg holds 98,758 options (2013: 102,720) with an average exercise price of &#128;2.58 (2013: &#128;2.58) and Shelley Margetson holds 19,000 options (2013: 10,000) with an average exercise price of &#128;2.56 (2013:
&#128;2.54). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Supervisory Board
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2014, the Company granted
options to the following (former) members of the Supervisory Board members as remuneration for their work in 2013 and 2014: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wolfgang Berthold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gabrielle Dallmann</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,938</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gerard van Odijk</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13,125</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exercise price
of each option is &#128;2.58. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-30
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2014, the following amounts were charged to the profit and loss statement for the
remuneration of the (former) members of the Supervisory Board: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cash&nbsp;compensation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;cost</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wolfgang Berthold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gabriele Dallmann</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gerard van Odijk</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>59,470</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2013, the
following amounts were charged to the profit and loss statement for the remuneration of the (former) members of the Supervisory Board: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cash&nbsp;compensation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;cost</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wolfgang Berthold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gabriele Dallmann</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gerard van Odijk</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,720</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>31,294</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The other members of
the Supervisory Board did not receive any remuneration from the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As at 31&nbsp;December 2014 and 2013, (former) members of the Supervisory Board hold the following number of options: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>31&nbsp;December 2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>31&nbsp;December 2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average<BR>exercise&nbsp;price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average<BR>exercise&nbsp;price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wolfgang Berthold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.54</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gabriele Dallmann</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7,688</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.49</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gerard van Odijk</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>39,375</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.47</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>72,563</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.04</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24. Related party disclosures
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transactions with the Management Board and
Supervisory Board are set out in note 23. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
2010, the Company entered into an option agreement with the Novartis Bioventures Ltd for an exclusive license to one of Merus&#146; oncology programs. The agreement includes upfront and potential milestones payments totalling over $200 million plus
royalties. In the current year nothing was received under this agreement. In January 2015, the option expired without Novartis Bioventures Ltd having exercised it. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 30&nbsp;September 2013, the Company entered into a right
of first negotiation agreement under which the Company granted Johnson&nbsp;&amp; Johnson Development Corporation (JJDC), or an affiliate nominated by JJDC, rights of first negotiation to acquire or license two undisclosed product candidates in
pre-clinical development. Pursuant to this agreement, prior to soliciting an offer from, or negotiating terms with, any third party, with respect to a sale or license for such product candidates, the Company must first notify JJDC of such
opportunity and negotiate in good faith with JJDC the terms of a purchase or license agreement for such product candidates. This agreement is effective until 30&nbsp;September 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has agreed to reimburse investors&#146; external expenses which are directly relating to the legal
proceedings of Regeneron Pharmaceuticals Inc. against the Company, subject to agreed terms and conditions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-31
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
An amount &#128;76&nbsp;thousand was included in the trade payables at 31&nbsp;December 2014 to the Company&#146;s investor Bay City Capital. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25. Operating leases </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rent </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merus B.V. has a contract for the rent of housing facilities
with the University of Utrecht, seated in Utrecht. The duration of this contract is 2 years, until 31&nbsp;December 2015. The total annual obligation is &#128;256 thousand. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26. Auditor&#146;s fees </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With reference to Section&nbsp;2:382a(1) and (2)&nbsp;of the
Netherlands Civil Code, the following fees for the financial year have been charged by KPMG Accountants N.V. to the Company: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>KPMG<BR>Accountants<BR>N.V.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other&nbsp;KPMG<BR>network</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total <BR>KPMG</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit of the financial statements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other audit engagements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax-related advisory services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>KPMG<BR>Accountants<BR>N.V.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Other&nbsp;KPMG<BR>network</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total <BR>KPMG</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit of the financial statements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other audit engagements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax-related advisory services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27. Adoption of IFRS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has adopted International
Financial Standards (&#147;IFRS&#148;) as issued by the International Accounting Standards Board, including International Accounting Standards (&#145;IAS&#146;) as its primary accounting basis for the financial statements from 1&nbsp;January 2014.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until 2013, the Company prepared financial
statements in accordance with Generally Accepted Accounting Principles in the Netherlands (&#147;Dutch GAAP&#148;). Adoption of IFRS resulted in an increase in the share option expense by an amount of &#128;128&nbsp;thousand, which affected the
Statement of profit or loss: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in<BR>thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net result reported under previous GAAP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase of share option expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net result reported under IFRS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-32
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28. Subsequent events </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 26&nbsp;January 2015 the Company drew down tranche 5 of
the existing Class B preferred share financing. Shareholders contributed &#128;5.0&nbsp;million and a total of 2,407,224 Class B preferred shares were issued. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 16&nbsp;March 2015, the Company granted 301,018 options over common shares to its executives and other staff members with an exercise
price of &#128;1.07&nbsp;per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 4 June
2015, the Company granted 66,500 options over common shares to the Chairman of the Supervisory Board with an exercise price of &#128;3.30. On 21 August 2015, the Company granted a further 65,938 options to the Chairman of the Supervisory Board with
an exercise price of &#128;4.00 per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
11&nbsp;June 2015, the Company entered into a convertible bridge loan in the amount of &#128;8.0&nbsp;million with its Class B preferred shareholders in lieu of closing Tranche 6 and 7 of the extended Class B preferred share financing. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 16&nbsp;June 2015, the Company reached an agreement with
existing and new shareholders that additional funding up to an amount of approximately &#128;73&nbsp;million will be provided to the Company on terms to be agreed. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 21&nbsp;August 2015, closed a &#128;73&nbsp;million ($80.5
million) Class C preferred share financing led by new investors Sofinnova Venture Partners and Novo A/S. Existing investors Novartis Bioventures Ltd, Pfizer Inc., Bay City Capital, Life Sciences Partners and Aglaia Oncology Fund also participated in
this financing. Other new investors joining this round are Tekla, Rocksprings, RA Capital and an US-based life sciences-focused investor. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The first tranche of the Class C preferred share financing of &#128;49.7&nbsp;million ($55 million) was drawn down on 21&nbsp;August 2015
and 7,469,780 Class C preferred shares were issued. The convertible bridge loan entered into on 11&nbsp;June 2015 was repaid by converting the outstanding principal and interest thereon into Class C preferred shares under the terms of the agreement,
bringing the net cash inflow to the Company to &#128;41.6 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On 5 October 2015, the Company amended the exercise price of options granted under the 2010 Employee Option Plan prior to January 2015 to be &#128;1.07 per share. All option holders were non-U.S.
citizens. Those employees that had already exercised options under this plan were reimbursed the excess paid over &#128;1.07 per share, which amounted to a total reimbursement of &#128;60,935. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 30 October 2015, the Company granted 778,983 options over common shares to its executives and other staff
members with an exercise price of &#128;4.00 per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On 16 December 2015, the Company appointed a new Chief Business Officer as its first U.S.-based employee. A total of 176,553 options over common shares were granted to its Chief Business Officer with an
exercise price of &#128;4.00 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-33
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_8"></A>MERUS B.V. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UNAUDITED CONDENSED STATEMENT OF FINANCIAL POSITION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(after appropriation of result for the period) </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Non-current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>287</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>450</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total non-current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>737</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade and other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>5</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>390</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>6</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>40,103</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>40,493</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41,230</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholders&#146; equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued and paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>775</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">282</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share premium account</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>90,414</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(57,053</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>10</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34,137</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Non-current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Borrowings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>8</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>542</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">652</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>9</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>446</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts owed to credit institutions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>167</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,620</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Taxes and social security liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>119</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>9</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>223</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities and accruals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>7</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,977</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6,106</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7,094</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,099</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total equity and liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41,230</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,540</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-34
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_9"></A>MERUS B.V. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UNAUDITED CONDENSED STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE LOSS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(euros in thousands, except per share data) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Note</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;months&nbsp;ended<BR>September 30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenue</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&nbsp;</I></B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>11</I></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&nbsp;&nbsp;</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,604</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>762</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>12</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(11,506</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management&nbsp;and administration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>12</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(400</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;</I></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>12</I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6,063</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total operating expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&nbsp;</I></B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>12</I></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&nbsp;&nbsp;</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,969</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(12,438</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating result</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(16,364</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(11,676</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total finance income (expenses)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(173</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Result before tax</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(16,537</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(11,658</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Result after taxation</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(16,537</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(11,658</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other comprehensive income</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total comprehensive loss for the period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(16,537</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(11,658</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic (and diluted) loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The results for the
period and the comprehensive loss for the period are fully attributable to the owners of the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-35
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_10"></A>MERUS B.V. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UNAUDITED CONDENSED STATEMENT OF CHANGES IN EQUITY </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(euros) </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;A,&nbsp;B,&nbsp;C<BR>pref. share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;A,&nbsp;B,&nbsp;C<BR>pref. share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>loss</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total<BR>equity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at January&nbsp;1, 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>29,484</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>211,173</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,513,765</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>29,417,619</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(23,510,612</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>7,661,429</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Result</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(11,658,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(11,658,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Total comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(11,658,189</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(11,658,189</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Transactions with owners the Company:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">40,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">50,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5,942,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>6,033,693</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Equity settled shared-based payments (note&nbsp;10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">115,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>115,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total contributions by and distributions to owners of the Company</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>896</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>40,000</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>50,388</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>5,942,409</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>115,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>6,149,193</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at September&nbsp;30, 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>30,380</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>251,173</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,564,153</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>35,360,028</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(35,053,301</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2,152,433</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at January&nbsp;1, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>30,380</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>251,173</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,564,153</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>35,360,028</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(40,764,985</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(3,559,251</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Result</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(16,537,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(16,537,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Total comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(16,537,402</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(16,537,402</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Transactions with owners the Company:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Issuance of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">493,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">54,045,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>54,539,598</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Equity settled shared-based payments (note&nbsp;10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">249,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>249,426</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">IPO Related Costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">(555,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(555,783</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total contributions by and distributions to owners of the Company</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">493,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>53,489,965</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>249,426</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>54,233,241</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Balance at September&nbsp;30, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>30,380</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>745,023</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1,564,153</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>88,849,993</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(57,052,961</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>34,136,588</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-36
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_11"></A>MERUS B.V. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UNAUDITED CONDENSED STATEMENT OF CASH FLOWS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(euros in thousands) </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Result after taxation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(16,537</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments for:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortisation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>145</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share option expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>249</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net finance costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>172</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(15,971</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,365</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in working capital:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade and other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>459</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>211</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax and social security liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(12</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(167</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">892</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities and accruals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>73</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">229</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash used in operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(15,406</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest paid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(187</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used in operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(15,594</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flow from investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquisition of property, plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(32</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(140</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash flow used in investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(18</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flow from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuing shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>53,984</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,033</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase/(decrease) of borrowings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(110</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>53,873</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net (decrease)/increase in cash and cash equivalents</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>38,262</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,490</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)</B>&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents as at January&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents as at September&nbsp;30</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>40,103</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-37
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MERUS B.V. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin29248_12"></A>NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. General information </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merus B.V. (&#147;the Company&#148;), headquartered in Utrecht, the Netherlands, is a clinical-stage immuno-oncology company developing
innovative bispecific antibody therapeutics. The Company has a pipeline of full-length human bispecific antibodies generated from its proprietary technology platform. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is a limited liability company incorporated in
the Netherlands, with its statutory seat in Utrecht. The address of the registered office is Padualaan 8, 3584CH Utrecht, the Netherlands. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These unaudited interim condensed financial statements have been prepared in accordance with International Accounting Standard 34, or IAS
34, &#147;Interim Financial Reporting&#148;. Certain information and disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted. Accordingly, these condensed financial statements should be
read in conjunction with the Company&#146;s annual financial statements for the year ended 31 December 2014 included elsewhere in the prospectus. In the opinion of management, all adjustments, consisting of normal recurring nature, considered
necessary for a fair presentation have been included in the condensed financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment on the process of applying
the Company&#146;s accounting policies. The areas involving a higher degree of judgment or complexity or areas where assumptions and estimates are significant to these unaudited interim condensed financials are disclosed in Note 4. The results of
operations for the nine months ended 30 September 2015 are not necessarily indicative of operations to be expected for the full fiscal year ending 31 December 2015. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements are presented in euros, which is the
Company&#146;s functional and presentation currency. All amounts are rounded to the nearest euro, except otherwise indicated. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s financial results have varied substantially, and are expected to continue to vary, from period to period. The Company
believes that its ordinary activities are not linked to any particular seasonal factors per IAS 34.16. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company operates in one reportable segment, which comprises the discovery and development of innovative bispecific therapeutics.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Change in accounting policy (IAS 8)
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has changed the presentation
format of the unaudited condensed statement of comprehensive loss from the nature of expense method to the function of expense method. The Company chose to change its presentation format of the unaudited condensed statement of comprehensive loss
considering industry factors, and the nature, practice and current stage of development of the Company&#146;s operations. The Company is of the opinion that the revised presentation provides more relevant information than the previous presentation.
This change in accounting policy has no impact on net result, the financial position nor cash flows, both in these unaudited condensed financial statements and retrospectively. The impact of the change in presentation on the unaudited condensed
statement of comprehensive loss for the nine month period ended 30&nbsp;September 2015 and nine month period ended 30&nbsp;September 2014 is explained in Note 12 total operating expenses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-38
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. Adoption of New and Revised International Financial Reporting Standards </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accounting policies adopted in the preparation of the
condensed interim financial statements are consistent with those applied in the preparation of the Company&#146;s annual financial statements for the year ended 31 December 2014 included elsewhere in the prospectus. New Standards and
Interpretations, which became effective as of 1 January 2015, did not have a material impact on our condensed interim financial statements. The Company does not plan to adopt new standards early. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Critical Accounting estimates and Judgements </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In application of the Company&#146;s accounting policies,
management is required to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses that are not readily apparent from other sources. The estimates and associated assumptions are based on
historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised prospectively. No
changes were identified compared to previous financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following are the critical judgments and assumptions that management has made in the process of applying the Company&#146;s accounting policies and that have the most significant effect on the amounts
recognised in the financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a)
Equity settled share-based payments </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share options granted to employees and consultants providing similar services are measured at the grant date fair value of the equity
instruments granted. The grant date fair value is determined through the use of an option-pricing model considering the following variables: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the exercise price of the option; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expected life of the option; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the current value of the underlying shares; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expected volatility of the share price; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the dividends expected on the shares; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">f)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the risk-free interest rate for the life of the option. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the Company&#146;s share option plans, management&#146;s judgment is that the Black-Scholes valuation formula and the binomial option
pricing model are the most appropriate methods for determining the fair value of the Company&#146;s share options considering the terms and conditions attached to the grants made and to reflect exercise behaviour. Since the Company is not listed,
there is no published share price information available. Consequently, the Company needs to estimate the fair value of its shares and the expected volatility of that share value. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The result of the share option valuations and the related
compensation expense that is recognised for the respective vesting periods during which services are received is dependent on the model and input parameters used. Even though management considers the fair values reasonable and defensible based on
the methodologies applied and the information available, others might apply a different fair value for the Company&#146;s share options. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Income tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets in respect of tax losses have not been recognised, because the Company has no history of generating taxable profits
and at the balance sheet date, there is no convincing evidence that sufficient taxable profit will be available against which the tax losses can be utilised. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-39
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(c) Convertible bridge loan </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 11&nbsp;June 2015, the Company entered into a convertible
bridge loan in the amount of &#128;8.0&nbsp;million with its Class B preferred shareholders in lieu of closing Tranche 6 and 7 of the extended Class B preferred share financing. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2015, the convertible loan fully converted in class
C preferred shares. More information can be found in notes 8 and 10. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>(d) Capitalization of development costs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The criteria for capitalization of development costs have not yet been met. Therefore, all development expenditures relating to internally generated intangible assets have been expensed as incurred.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(e) Accounting for upfront license fees
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company entered into a contract and
license agreement with a customer in April 2014. In connection with this arrangement, the Company received an upfront fee, which relates to the integrated package of deliverables under the contract (one single performance obligation). The applicable
period over which to recognise the upfront payment is a significant judgment. Revenue related to this upfront fee is deferred and amortised on a straight-line basis over the contract period, as that is the period over which the Company performs its
integrated service activities to the third-party. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(f) Treatment of expenses relating to an equity transaction </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company incurred costs relating to preparation of an Initial Public Offering (&#147;IPO&#148;) </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The costs of an IPO that involves both issuing new shares and
a stock market listing have been accounted for as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incremental costs that are directly attributable to issuing new shares should be deducted from equity (net of any income tax benefit)&#151;IAS 32.37;
and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs that relate to the stock market listing, or are otherwise not incremental and directly attributable to issuing new shares, should be recorded as
an expense in the statement of comprehensive income. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs that relate to both share issuance and listing should be allocated between those functions on a rational and consistent basis (IAS 32.38).
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Going concern
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2014, the Company suffered losses
from its operations, which further weakened the shareholders&#146; equity. In view of its financial position at the end of 2014, the Company exercised its right to request the issuance of new Class B preferred shares in January 2015, which increased
the Company&#146;s shareholders&#146; equity and cash position by &#128;5.0&nbsp;million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Based on the then existing agreement with Class B preferred shareholders, the Company had the right to request the issuance of new Class B preferred shares up to an amount of &#128;8.0&nbsp;million, with
&#128;4.0&nbsp;million between 1&nbsp;September 2015 and 31&nbsp;December 2016 (Tranche 6) and &#128;4&nbsp;million between 1&nbsp;March 2016 and 31&nbsp;December 2016 (Tranche 7). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 11&nbsp;June 2015, the Company reached an agreement with
the Class B preferred shareholders to provide the Company with a convertible bridge loan of &#128;8.0&nbsp;million in lieu of Tranches 6 and 7, and to cancel these two tranches. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-40
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 16&nbsp;June 2015, the Company reached an agreement with existing and new
shareholders to provide the Company with additional funding up to an amount of approximately &#128;73.0&nbsp;million of which approximately &#128;50.0&nbsp;million would be contributed in August 2015 in connection with the issuance of new Class C
preferred shares. In connection with this Class C preferred share financing, the convertible bridge loan was repaid in August 2015 by converting the principal and interest thereon into Class C preferred shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company expects to incur significant expenses and
operating losses for the foreseeable future as its bi-specific antibody candidates advance from discovery through preclinical development and into clinical trials, and it seeks regulatory approval and pursues commercialization of any approved
bi-specific antibody candidate. In addition, the Company may incur expenses in connection with the in-license or acquisition of additional bi-specific antibody candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until such time as it can generate significant revenue from
product sales, if ever, the Company expects to finance its activities through raising capital. The Company&#146;s inability to raise capital as and when needed would have a negative impact on the financial condition and ability to pursue its
business strategy. The Company expects that its existing cash and cash equivalents, together with the net proceeds from the issuance of Class C preferred shares in August 2015, will enable the Company to fund its operating expenses and capital
expenditure requirements for at least the period ending 31&nbsp;December 2016. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>5. Trade and other receivables </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All trade and other receivables are short term debtors and due within 1 year. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Taxation and social security premiums</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>258</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid general expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>56</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest bank</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>67</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>390</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">849</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Cash and cash equivalents
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cash and cash equivalents balance
includes an amount of &#128;236,000 (2014: &#128;273,000) that is not immediately accessible as it is pledged to the bank as a security for a loan received. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Other liabilities and accruals </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other liabilities and accruals is analysed below: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued auditor&#146;s fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>55</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrual for holiday expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>58</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>69</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D studies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>530</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IP&#151;Legal fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>275</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">858</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bonuses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>275</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidy advance received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,567</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,057</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other accruals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>147</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,977</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-41
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. Borrowings </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Movements in borrowings were as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Bank loan </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Rabobank</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in<BR>thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance January 1, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>986</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(110</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance portion September&nbsp;30, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>876</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short term portion September&nbsp;30, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(167</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long term portion September&nbsp;30, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>709</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in<BR>thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance January&nbsp;1, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>819</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repayments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(110</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance September&nbsp;30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>709</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short term portion September&nbsp;30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(167</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Long term portion September 30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>542</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rabobank
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company entered into a financing
agreement with Rabobank Utrechtse Huevelrug U.A. (Rabobank) on 29&nbsp;December 2009, which provided for total borrowings of &#128;1.5&nbsp;million for the financing of its business activities. The duration of this agreement is 12 years. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the agreement, the loans are to be repaid in monthly
instalments of &#128;14,000, beginning on 31&nbsp;January 2009. Repayments were deferred in January 2010 for a period of two years. Repayment recommenced in January 2012. The interest percentage amounts to 4.45% and is fixed until 1&nbsp;April 2016
and thereafter, at the Company&#146;s option, at a fixed or variable rate to be agreed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the financing agreement, the Company provided security in the form of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a right of pledge on the account of &#128;500&nbsp;thousand, in the Company&#146;s name in a new savings account for the benefit of Rabobank; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a suretyship of &#128;1&nbsp;million within the framework of the Royal Decree &#147;Borgstelling MKB-krediet&#148;. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Convertible bridge loan </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 11&nbsp;June 2015, the Company entered into a convertible
bridge loan in the amount of &#128;8.0&nbsp;million with its Class B preferred shareholders in lieu of closing Tranche 6 and 7 of the extended Class B preferred share financing. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the previous interim accounts this loan was accounted for
as a hybrid financial instrument, a liability instrument of &#128;7.6&nbsp;million and an equity instrument of &#128;0.4 million. In August 2015, the bridge loan was fully converted into Class C preferred shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">December&nbsp;31,</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bank loan Rabobank</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>709</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>709</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">819</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-42
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. Deferred revenue </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 8&nbsp;April 2014, the Company entered into a research
and license agreement with ONO Pharmaceutical Co, Ltd. As part of this agreement, the Company received a non-refundable upfront payment of &#128;1.0 million. This upfront payment is amortised on a straight-line basis, and will be presented as
revenue, over a period from 8&nbsp;April 2014 through 30&nbsp;September 2018, the end of the research term. The Company is eligible to receive milestone payments upon achievement of specified research and clinical development milestones. For
products commercialized under this agreement, if any, the Company is also eligible to receive a mid-single digit royalty on net sales. ONO also provides funding for the Company&#146;s research and development activities under an agreed-upon plan.
ONO has the right to terminate this agreement at any time for any reason, with or without cause. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue&#151;current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>223</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue&#151;non-current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>446</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>669</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Shareholders&#146; equity
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in shareholders&#146; equity were as
follows: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class<BR>ABC<BR>pref.<BR>share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Common<BR>share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class ABC<BR>pref. share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>loss</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total equity</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at January&nbsp;1, 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29,484</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>211,173</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,513,765</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29,417,619</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(23,510,612</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7,661,429</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,942,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6,033,693</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Result for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,658,189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(11,658,189</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>115,500</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at Sept 30, 2014</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">251,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,564,153</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35,360,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,053,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,152,433</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at January&nbsp;1, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>30,380</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>251,173</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,564,153</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>35,360,028</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(40,764,985</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,559,251</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">493,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,045,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>54,539,598</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Result for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,537,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(16,537,402</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">249,426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>249,426</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IPO Related Costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(555,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(555,783</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at Sept 30, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>30,380</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>745,023</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,564,153</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>88,849,993</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(57,052,961</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34,136,588</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Issued and
paid-in share capital </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Common shares
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the first nine months of 2014, 17,915
options were exercised with an average exercise price &#128;2.86 per share; as a consequence 17,915 common shares were issued , share capital increased by &#128;896 and share premium increased by &#128;50,388. In the first nine months of 2015 no
common shares were issued. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Class&nbsp;A
preferred shares </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no changes in
2014 and in the first nine months of 2015. The Class&nbsp;A preferred shares are convertible into common shares only. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-43
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Class B preferred shares </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2010, the Company closed a
&#128;21.7&nbsp;million ($30.7 million) Class B preferred share financing led by new investors Novartis Bioventures Ltd, Pfizer Inc., Bay City Capital, and Life Sciences Partners. Merus&#146; seed investor Aglaia Oncology Fund also participated in
this financing. The first tranche of the Class B preferred share financing (&#128;8.5 million) was drawn down in January 2010. The second tranche of the Class B preferred share financing (&#128;8.1 million) was drawn down in April 2012. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The initial Class B preferred share financing commitment was
reduced in 2013 by cancellation of the third tranche in relation with the closing of the Class B preferred share extension on 30&nbsp;September 2013. Johnson&nbsp;&amp; Johnson Development Corporation joined the existing investor group and a total
of &#128;31.0&nbsp;million was committed in addition to the &#128;16.6&nbsp;million already drawn down from the original Class B preferred share financing. The Class B preferred share extension consists of up to a further 5 tranches (tranches 3 to
7) over and above the initial Class B preferred share tranches 1 and 2 already drawn down. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Tranche 3 of &#128;12.0&nbsp;million was drawn down at the time of closing of the Class B preferred share extension (September 30, 2013) and a total of 1,600,000 Class B preferred shares were issued.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tranche 4 of &#128;6.0&nbsp;million was drawn
down on 29 August 2014 and a total of 800,000 Class B preferred shares were issued. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Tranche 5 of &#128;5.0&nbsp;million was drawn down on 26 January 2015 and a total of 886,524 Class B preferred shares were issued and a further 1,520,700 Class B preferred shares were issued on this date
as anti-dilution shares for previous tranches. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Class B preferred shares are convertible into common shares only and carry an annual cumulative profit entitlement of 8% of the amount
paid on such shares. The dividend entitlement rights are at all times senior to the dividend entitlement rights of the Class&nbsp;A preferred shares and the common shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Class C preferred shares </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2015, the Company closed a &#128;72.8&nbsp;million
($80.5 million) Class C preferred share financing co-led by Sofinnova Ventures and Novo A/S, along with RA Capital Healthcare Fund, Rock Springs Capital, Tekla Capital Management and an unnamed U.S.-based life sciences-focused investor. The existing
Class B preferred shareholders also participated in this round. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The first tranche of the Class C preferred share financing of &#128;49.7 million ($55.0 million) was drawn down on 21 August 2015 and 7,469,780 of our Class C preferred shares were issued. The convertible
bridge loan entered into on 11 June 2015 was repaid by converting the outstanding principal and interest thereon into Class C preferred shares under the terms of the agreement, bringing net cash inflow to the Company to &#128;41.6 million.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Conversion </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares of Class&nbsp;A, Class B and Class C preferred
(together with any accrued and unpaid dividends) are convertible into common shares only. Conversion is at the option of the holders of the Class&nbsp;A, Class B and Class&nbsp;C preferred shares, although conversion is mandatory and automatic in
any of the following events: (i)&nbsp;the affirmative vote of specified Class C preferred shareholders to convert all (and not less than all) of the issued and outstanding Class&nbsp;A, Class B and Class C preferred shares or (ii)&nbsp;the
consummation of an initial public offering resulting in gross proceeds to the Company of $50.0 million or more and at a price per share to the public of not less than one and a half times the original issue price of the Class C preferred shares,
subject to appropriate adjustment for any stock split, stock dividend, combination or other similar recapitalization. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-44
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Conversion rate preferred shares </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The conversion rate (excluding accumulated dividend) for
each class of preferred shares is as follows: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Conversion rate in EUR</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;A</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;B</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Class&nbsp;C</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series 1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series 2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B Tranche 5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">C Tranche 1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Situation as at
30 September 2015 </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At 30 September 2015, a
total of 7,469,780 Class C preferred shares, 7,018,380 Class B preferred shares, 412,296 Class&nbsp;A preferred shares and 607,596 common shares with a par value of &#128;0.05 each were issued and paid up. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share premium reserves </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The share premium reserve relates to amounts contributed by
shareholders at the issue of shares in excess of the par value of the shares issued. All share premium can be considered as free share premium as referred to in the Netherlands Income tax act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share option program (equity-settled) </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2010, the Company established share option programs that entitle key management personnel, staff and
supervisory board members to purchase shares in the Company. Under these programs, holders of vested options are entitled to purchase Depositary Receipts for shares at the exercise price determined at the date of grant. The compensation expenses
included in personnel expenses were &#128;115&nbsp;thousand in the nine months ended 30&nbsp;September 2014 and &#128;249&nbsp;thousand in the nine months ended 30 September 2015. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options granted under this plan are exercisable once vested.
Any vesting schedule may be attached to the granted options, however the typical vesting period is four years. 25% of the options vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in 36 monthly
instalments for each full month of continuous service provided by the option holder thereafter, such that 100% of the options shall become vested on the fourth anniversary of the vesting commencement date. Options will lapse on the eighth
anniversary of the date of grant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-45
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Measurement of fair values of the equity-settled share-based payment arrangements
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of the employee share options
has been measured using the Black-Scholes formula (members of the Executive Management team) or a binomial option pricing model (other participants, including Supervisory Board members). Service and non-market performance conditions attached to the
transactions were not taken into account in measuring fair value. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to the vesting period of the options, the vesting periods for the Depositary Receipts were also taken into account when allocating the fair values of the options granted over the required
service period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The inputs used in the
measurement of the fair values and the related fair values at the grant dates were as follows for respectively options granted to members of the Executive Management team (Black-Scholes formula) and other participants (binominal option pricing
model): </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options&nbsp;granted&nbsp;in&nbsp;the&nbsp;nine</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>months&nbsp;ended&nbsp;September&nbsp;30,&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executives&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#128;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#128;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">2.66-2.81</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">2.24-2.81</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share price at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.30-3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.07-3.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected volatility (weighted-average)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98.98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected life (weighted-average)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected dividends</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free interest rate (based on government bonds)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Reconciliation of
outstanding share options </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in the
number of options outstanding and their related weighted average exercise prices are follows: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nine&nbsp;months&nbsp;ended&nbsp;September&nbsp;30,&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>average</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;exercise&nbsp;price&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&#128;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;Number&nbsp;of&nbsp;&nbsp;&nbsp;&nbsp;<BR>options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at January&nbsp;1, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.86</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>346,096</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited during the nine month period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.58</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(12,838</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised during the nine month period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted during the nine month period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.47</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>367,518</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at Sept 30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.14</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>700,776</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercisable at Sept 30, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.93</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>272,595</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>IPO related
costs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial public offering related
costs deducted from equity relate to incremental costs directly attributable to the issuance of new shares and the proposed stock market listing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-46
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Revenue </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue is recognised to the extent that it is probable that
the economic benefits will flow to the Company and the revenue can be reliably measured. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,<BR>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ONO Pharmaceutical Co., Ltd.&#151;research funding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,259</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidy income on research projects</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>346</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,604</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue includes
government grants and other subsidy income and is initially recognised in the balance sheet as deferred income at fair value when there is reasonable assurance that it will be received and the Company will comply with the conditions associated with
the grant. Refer to note 9 for further details. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grants that compensate the Company for expenses incurred are recognised in the profit and loss on a systematic basis in the same period in
which the expenses are recognised. Grants that compensate the Company for the cost of an asset are recognised in the profit and loss account on a systematic basis over the useful life of the asset. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Total operating expenses </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs comprise allocated employee
costs, the costs of materials and laboratory consumables, IP and license costs and allocated other costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A breakdown of the total operating expenses is presented as follows: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manufacturing costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,415</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IP and license costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(891</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,409</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel related R&amp;D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(2,277</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,169</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other research and development costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,923</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Total research and development costs</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(11,506</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management and administration costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(400</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Management and administration costs</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(400</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Litigation costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,100</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1,963</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other expenses</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6,063</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,604</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,969</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2014
Regeneron Pharmaceuticals Inc. (Regeneron) filed a complaint in the United States District Court for the Southern District of New York, alleging that the Company was infringing on one or more claims in their U.S. Patent No.&nbsp;8,502,018, entitled
&#147;Methods of Modifying Eukaryotic Cells.&#148; On 3&nbsp;July 2014, the Company filed a response to the complaint, denying Regeneron&#146;s allegations of infringement and raising affirmative defenses, and filed counterclaims seeking, among
other things, a declaratory judgment that the Company did not infringe the patent and that the patent was invalid. The Company subsequently filed amended counterclaims during the period from August to December 2014, seeking a declaratory judgment of
unenforceability of the patent due to Regeneron&#146;s commission of inequitable conduct. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-47
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 21&nbsp;November 2014, the District Court found that there was clear and convincing
evidence that a claim term present in each of the patent claims was indefinite and granted the Company&#146;s proposed claim constructions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 11&nbsp;March 2014, Regeneron served a writ in the Netherlands alleging that we were infringing one or more claims in their European
patent EP 1 360 287 B1. The Company had opposed that patent in June 2014 and the Dutch litigation is currently stayed. On September 17, 2014, Regeneron&#146;s patent EP 1 360 287 B1 was revoked in its entirety by the European Patent Office (EPO). An
appeal has been set for October 2015 at the Technical Board of Appeal for the EPO. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The costs incurred in the above litigation and opposition (&#128;4.1 million) are included in the line item other expenses in the profit and loss statement for the nine months ended 30 September 2015
(&#128;2.7 million for the nine months ended 30 September 2014). Litigation costs for the year ended 31 December 2014 amounted to &#128;5.4&nbsp;million (2013: &#128;0.0 million). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses presented by nature are outlined below:
</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs of outsourced work</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,415</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other external costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(10,877</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Personnel expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(2,532</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortisation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(145</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total operating expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(17,969</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(12,438</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. Employee benefits
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The average number of personnel during the
nine month period ended 30&nbsp;September 2015 was approximately 30 (2014: 28), all employed in the Netherlands principally in the area of research and development. The Company&#146;s chief executive officer, chief financial officer and finance
employee are devoted to activities other than research and development and are included under management and administration costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Details of the total employee benefits are presented as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>September&nbsp;30,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2014</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(euros in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Salaries and wages</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(2,139</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,982</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">WBSO subsidy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>271</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Social security premiums</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(200</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Health insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(42</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pension costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(171</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(249</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(2,532</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,373</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-48
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. Related party disclosures </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2010, the Company entered into an option agreement with the Novartis Bioventures Ltd for an exclusive
license to one of Merus&#146; oncology programs. The agreement includes upfront and potential milestones payments totalling over $200 million plus royalties. In the current year nothing was received under this agreement. In January 2015, the option
expired without Novartis Bioventures Ltd having exercised it. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On 30 September 2013, the Company entered into a right of first negotiation agreement under which the Company granted Johnson &amp; Johnson Development Corporation (JJDC), or an affiliate nominated by
JJDC, rights of first negotiation to acquire or license two undisclosed bispecific antibody candidates in pre-clinical development. Pursuant to this agreement, prior to soliciting an offer from, or negotiating terms with, any third party, with
respect to a sale or license for such bispecific antibody candidates, the Company must first notify JJDC of such opportunity and negotiate in good faith with JJDC the terms of a purchase or license agreement for such bispecific antibody candidates.
This agreement is effective until 30 September 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15.
Operating leases </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rent
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merus B.V. has a contract for the rent
of housing facilities with the University of Utrecht, seated in Utrecht. The duration of this contract is two years, until 31&nbsp;December 2015. The total annual obligation is &#128;256 thousand. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. Subsequent events </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 5 October 2015, the Company amended the exercise price of
options granted under the 2010 Option Plan prior to January 2015 to be &#128;1.07 per share. All option holders were non-U.S. citizens. Those employees that had already exercised options under this plan were reimbursed the excess paid over
&#128;1.07 per share, which amounted to a total reimbursement of &#128;60,935. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On 30 October 2015, the Company granted 778,983 options over common shares to its executives and other staff members with an exercise price of &#128;4.00 per share. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On 16 December 2015, the Company appointed a new Chief
Business Officer as its first U.S.-based employee. A total of 176,553 options over common shares were granted to its Chief Business Officer with an exercise price of &#128;4.00 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-49
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2px;margin-top:0px;margin-bottom:0px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="7"><B>Merus B.V. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Common Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g29248g29n63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRELIMINARY PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016
</B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Citigroup </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Jefferies </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Guggenheim Securities </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Wedbush PacGrow </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 (25 days after the commencement of this offering), all dealers that buy, sell or trade our common shares, whether or not
participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or
subscriptions. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:4px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II&#151;INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;6. Indemnification of directors and officers </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Members of our management board and supervisory board have
the benefit of the following indemnification provisions in our Articles of Association: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Current and former management board members and supervisory board members shall be reimbursed for: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">any financial losses or damages incurred by such indemnified officer; and </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">any expense reasonably paid or incurred by such indemnified officer in connection with any threatened, pending or completed suit, claim, action or legal proceedings,
whether civil, criminal, administrative or investigative and whether formal or informal, in which he or she becomes involved, to the extent this relates to his or her position or former position with the Company, in each case to the fullest extent
permitted by applicable law. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There
shall be no entitlement to reimbursement as referred to above if and to the extent that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">if a Dutch court has established, without possibility for appeal, that the acts or omissions of such indemnified officer that led to the financial losses, damages,
suit, claim, action or legal proceedings as described above results from either an improper performance of his or her duties as an officer of the Company or an unlawful or illegal act; and </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">his or her financial losses, damages and expenses are covered by an insurance and the insurer has settled these financial losses, damages and expenses (or has indicated
that it would do so). </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
underwriting agreement we will enter into in connection with the offering of common shares being registered hereby provides that the underwriters will indemnify, under certain conditions, our management board members and supervisory board members
(as well as certain other persons) against certain liabilities arising in connection with this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7. Recent sales of unregistered securities </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Class B Investment Agreement </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;27, 2012, the registrant issued 1,082,666 Class B preferred shares to certain investors for aggregate consideration of
&#128;8.1&nbsp;million in cash. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September&nbsp;30, 2013, the registrant issued 1,600,000 Class B preferred shares to certain investors for aggregate consideration of
&#128;12.0&nbsp;million in cash. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;29, 2014, the registrant issued 800,000 Class B preferred shares to certain investors for aggregate consideration of
&#128;6.0&nbsp;million in cash. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January 26, 2015, the registrant issued 886,524 Class B preferred shares to certain investors for aggregate consideration of &#128;5.0 million in
cash. In connection with this purchase of Class B preferred shares, we also issued an additional 1,520,700 of the registrant&#146;s Class B preferred shares pursuant to anti-dilution provisions included in the subscription agreement for the
registrant&#146;s Class B preferred shares. These additional shares were issued for no cash consideration. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of the foregoing issuances were made outside of the United States pursuant to Regulation S or to U.S. entities pursuant to
Section&nbsp;4(a)(2) of the Securities Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Class C Investment Agreement </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August 21, 2015, the registrant issued 7,469,780 Class C preferred shares to certain investors in exchange for an aggregate
consideration of &#128;49.7 million, which includes the conversion of the registrant&#146;s existing &#128;8.0&nbsp;million convertible bridge loan and interest thereon into Class C preferred shares. The foregoing issuance was made outside of the
United States pursuant to Regulation S or to U.S. entities pursuant to Section&nbsp;4(a)(2) of the Securities Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Option Grants </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below summarizes the share options we granted to our management board members, supervisory board
members and our employees within the past three years.&nbsp;The grant of the options and the issuance of common shares upon the exercise of options described in the table below were or will be made pursuant to Regulation&nbsp;S under the Securities
Act or Section&nbsp;4(a)(2) of the Securities Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:38pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>underlying<BR>options</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>price&nbsp;per<BR>share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;17, 2013 (employees)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;17, 2014 (management board members)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;17, 2014 (employees)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">July&nbsp;17, 2014 (supervisory board members)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;16, 2015 (management board members)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">175,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;16, 2015 (employees)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 4, 2015 (supervisory board members)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 21, 2015 (supervisory board members)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 30, 2015 (management board members)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">501,789</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">October 30, 2015 (employees)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">277,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">December 16, 2015 (employee)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">176,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#128;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8. Exhibits </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following documents are filed as part of this registration statement: </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deed of Amendment of Articles of Association and Articles of Association of the Registrant.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Deed of Conversion and Amendment of the Articles of Association and Form of Articles of Association of Merus N.V. to be effective upon the effectiveness of this
registration statement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Registration Rights Agreement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Eversheds B.V., counsel of the Registrant, as to the validity of the common shares.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of KPMG Meijburg &amp; Co, tax counsel of the Registrant, as to Dutch tax matters.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1#**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merus B.V. 2010 Employee Option Plan.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2#*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merus N.V. 2016 Incentive Award Plan.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3#*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supervisory Board Member Compensation Program.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4#*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Supervisory Board Member and Management Board Member Indemnification Agreement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5#**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Contract between the Registrant and Ton Logtenberg, Chief Executive Officer, dated January 21, 2010.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6#**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">English language translation of Employment Contract between the Registrant and Shelley Margetson, Chief Financial Officer, dated October 1, 2010.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">English language translation of Lease Agreement between the Registrant and The University of Utrecht, dated July 30, 2014.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">English language translation of Loan Agreement between the Registrant and Co&ouml;peratieve Rabobank Utrechtse Heuvelrug U.A., dated December 29, 2005.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">English language translation of letter amendment to Loan Agreement between the Registrant and Co&#246;peratieve Rabobank Utrechtse
Heuvelrug U.A.</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10&#134;**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contract Research and License Agreement and Addendum between the Registrant and ONO Pharmaceutical Co., Ltd., dated April&nbsp;8,
2014.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholders&#146; Agreement, dated August 20, 2015, by and between the Registrant, all shareholders of the Registrant, and Mr. T. Logtenberg.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of KPMG Accountants N.V.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.2*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Eversheds B.V., counsel of the Registrant (included in Exhibit 5.1).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.1**</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Powers of attorney (included on signature page to the registration statement).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Request for Waiver from Requirements of Form 20-F, Item 8.A.4, dated January&nbsp;21, 2016</FONT></TD></TR></TABLE>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be filed by amendment.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;**</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates management contract or compensatory plan.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financial Statement Schedules </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9. Undertakings </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements, certificates in such denominations
and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling&nbsp;person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned registrant hereby undertakes that: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration
statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the
time it was declared effective. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a
new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_28"></A>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of
1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Utrecht, the Netherlands on January 21, 2016. </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MERUS B.V.</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Ton Logtenberg</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ton Logtenberg</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Shelley Margetson</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shelley Margetson</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, as amended, this
registration statement has been signed by the following persons on January 21, 2016 in the capacities indicated: </FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:20pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Ton
Logtenberg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ton Logtenberg</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Management Board Member</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive Officer)</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Shelley
Margetson&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shelley Margetson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer and Management Board Member</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Financial Officer and Principal Accounting Officer)</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mark Iwicki</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman of the Supervisory Board</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wolfgang Berthold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Supervisory Board</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lionel Carnot</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Supervisory Board</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gabriele Dallmann</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Supervisory Board</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">John de Koning</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Supervisory Board</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Florent Gros</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Supervisory Board</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anand Mehra</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Supervisory Board</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jack Nielsen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Member of the Supervisory Board</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Shelley Margetson</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shelley Margetson</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Attorney-in-fact</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Signature of Authorized U.S. Representative of Registrant</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of
1933, as amended, the undersigned, the duly authorized representative in the United States of Merus B.V. has signed this registration statement on January 21, 2016. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Colleen A. DeVries</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Colleen A. DeVries</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: SVP on behalf of National Corporate Research, Ltd.</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc29248_29"></A>EXHIBIT INDEX </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following documents are filed as part of this
registration statement: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;1.1*&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.1**</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deed of Amendment of Articles of Association and Articles of Association of the Registrant.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.2*&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Deed of Conversion and Amendment of the Articles of Association and Form of Articles of Association of Merus N.V. to be effective upon the effectiveness of this
registration statement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Registration Rights Agreement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;5.1*&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Eversheds B.V., counsel of the Registrant, as to the validity of the common shares.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;8.1*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of KPMG Meijburg &amp; Co, tax counsel of the Registrant, as to Dutch tax matters.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1#**</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merus B.V. 2010 Employee Option Plan.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2#*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merus N.V. 2016 Incentive Award Plan.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3#*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supervisory Board Member Compensation Program.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4#*</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Supervisory Board Member and Management Board Member Indemnification Agreement.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5#**</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employment Contract between the Registrant and Ton Logtenberg, Chief Executive Officer, dated January 21, 2010.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6#**</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">English language translation of Employment Contract between the Registrant and Shelley Margetson, Chief Financial Officer, dated October 1, 2010.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7**</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">English language translation of Lease Agreement between the Registrant and The University of Utrecht, dated July 30, 2014.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8**</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">English language translation of Loan Agreement between the Registrant and Co&ouml;peratieve Rabobank Utrechtse Heuvelrug U.A., dated December 29, 2005.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">English language translation of letter amendment to Loan Agreement between the Registrant and Co&#246;peratieve Rabobank Utrechtse Heuvelrug U.A.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10&#134;**</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contract Research and License Agreement and Addendum between the Registrant and ONO Pharmaceutical Co., Ltd., dated April 8, 2014.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholders&#146; Agreement, dated August 20, 2015, by and between the Registrant, all shareholders of the Registrant, and Mr. T. Logtenberg.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of KPMG Accountants N.V.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.2*&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Eversheds B.V., counsel of the Registrant (included in Exhibit 5.1).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.1**</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Powers of attorney (included on signature page to the registration statement).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Request for Waiver from Requirements of Form 20-F, Item 8.A.4, dated January&nbsp;21, 2016</FONT></TD></TR></TABLE>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be filed by amendment. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">**</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously filed. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">#</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates management contract or compensatory plan. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-7
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d29248dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>dated as of<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2016<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>among<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B><B>MERUS N.V. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE SHAREHOLDERS PARTY HERETO </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION RIGHTS AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>AGREEMENT dated as of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2016 (this
&#147;<B>Agreement</B>&#148;) among Merus N.V., a public company with limited liability incorporated under the laws of the Netherlands, (the &#147;<B>Company</B>&#148;), and the Shareholders party hereto as listed on the signature pages, including
any Permitted Transferees (collectively, the &#147;<B>Shareholders</B>&#148;). <B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual promises made
herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 1 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D<SMALL>EFINITIONS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Section&nbsp;1.01<I>. Definitions. </I>(a)&nbsp;The following terms, as used herein, have the following meanings:<I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person directly or indirectly controlling, controlled by or
under common control with such Person, <B></B><I>provided</I><B></B> that no securityholder of the Company shall be deemed an Affiliate of any other securityholder solely by reason of any investment in the Company. For the purpose of this
definition, the term &#147;<B>control</B>&#148; (including, with correlative meanings, the terms &#147;<B>controlling</B>&#148;, &#147;<B>controlled by</B>&#148; and &#147;<B>under common control with</B>&#148;), as used with respect to any Person,
shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Business Day</B>&#148; means any day except a Saturday, Sunday or other day on which commercial banks in New York City are
authorized by law to close.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Common Shares</B>&#148; means common shares, nominal value &#128;0.05&nbsp;per share,
of the Company and any shares into which such Common Shares may thereafter be converted or changed.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Company
Securities</B>&#148; means the Common Shares and, for purposes of the definitions of &#147;Permitted Transferees&#148; and &#147;Transfer&#148;, shall also mean any other securities of the Company that are convertible or exercisable into or
exchangeable for Common Shares.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended.<B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>FINRA</B>&#148; means the Financial Industry Regulatory Authority (formerly, the National Association of Securities
Dealers, Inc.) and any successor thereto.<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Initial Public Offering</B>&#148; means the Company&#146;s initial Public
Offering.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Permitted Transferee</B>&#148; means in the case of any Shareholder, a Person to whom Registrable
Securities are Transferred by such Shareholder; <B></B><I>provided that</I><B></B> (i)&nbsp;such Transfer does not violate any agreements between such Shareholder and the Company or any of the Company&#146;s subsidiaries, (ii)&nbsp;such Transfer is
not made in a registered offering or pursuant to Rule 144, (iii)&nbsp;such transferee shall only be a Permitted Transferee if and to the extent the transferor designates the transferee as a Permitted Transferee entitled to rights hereunder pursuant
to Section&nbsp;5.01(b), and (iv)&nbsp;such transferee is (A)&nbsp;an affiliate of the Shareholder or (B)&nbsp;acquires at least 20% of the Shareholder&#146;s Registrable Securities.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Person</B>&#148; means an individual, corporation, limited liability company, partnership, association, trust or other entity
or organization, including a government or political subdivision or an agency or instrumentality thereof.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Public
Offering</B>&#148; means an underwritten public offering of Company Securities (or any securities representing Company Securities) pursuant to an effective registration statement under the Securities Act, other than pursuant to a registration
statement on Form S-4, Form F-4 or Form S-8 or any similar or successor form.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Registrable Securities</B>&#148;
means, at any time, any Company Securities and any other securities issued or issuable by the Company or any of its successors or assigns in respect of any such Company Securities by way of conversion, exchange, exercise, dividend, split, reverse
split, combination, recapitalization, reclassification, merger, amalgamation, consolidation, sale of assets, other reorganization or otherwise until (i)&nbsp;a registration statement covering such Company Securities or such other securities has been
declared effective by the SEC and such Company Securities or such other securities have been disposed of pursuant to such effective registration statement, (ii)&nbsp;such Company Securities or such other securities are sold under circumstances in
which all of the applicable conditions of Rule 144 are met or (iii)&nbsp;all of such Company Securities or such other securities held by the holder thereof are eligible for sale by such holder under Rule 144 without any limitation thereunder
(including with respect to volume or manner of sale) or need for current public information.<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Registration
Expenses</B>&#148; means any and all expenses incident to the performance of, or compliance with, any registration or marketing of securities (other than transfer taxes, if any), including all (i)&nbsp;registration and filing fees, and all other
fees and expenses payable in connection with the listing of securities on any securities exchange or automated interdealer quotation system, (ii)&nbsp;fees and expenses of compliance with any securities or &#147;blue sky&#148; laws (including
reasonable fees and disbursements of counsel in connection with &#147;blue sky&#148; qualifications of the securities registered), (iii)&nbsp;expenses in connection with the preparation, printing, mailing and delivery of any registration statements,
<B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectuses and other documents in connection therewith and any amendments or supplements thereto, (iv)&nbsp;security engraving and printing expenses, (v)&nbsp;internal expenses of the Company
(including all salaries and expenses of its officers and employees performing legal or accounting duties), (vi)&nbsp;reasonable fees and disbursements of counsel for the Company and customary fees and expenses for independent certified public
accountants retained by the Company (including the expenses relating to any comfort letters or costs associated with the delivery by independent certified public accountants of any comfort letters requested pursuant to Section&nbsp;2.04(h)),
(vii)&nbsp;reasonable fees and expenses of any special experts retained by the Company in connection with such registration, (viii)&nbsp;reasonable fees and disbursements of one counsel for all of the Shareholders participating in the offering
selected by the Shareholders holding the majority of the Registrable Securities to be sold for the account of all Shareholders in the offering, in an amount not to exceed $50,000, (ix)&nbsp;fees and expenses in connection with any review by FINRA of
the underwriting arrangements or other terms of the offering, and all fees and expenses of any &#147;qualified independent underwriter,&#148; including the fees and expenses of any counsel thereto, (x)&nbsp;fees and disbursements of underwriters
customarily paid by issuers, but excluding any underwriting fees, discounts and commissions attributable to the sale of Registrable Securities, (xi)&nbsp;costs of printing and producing any agreements among underwriters, underwriting agreements, any
&#147;blue sky&#148; or legal investment memoranda and any selling agreements and other documents in connection with the offering, sale or delivery of the Registrable Securities, (xii)&nbsp;transfer agents&#146; and registrars&#146; fees and
expenses and the fees and expenses of any other agent or trustee appointed in connection with such offering, (xiii)&nbsp;expenses relating to any analyst or investor presentations or any &#147;road shows&#148; undertaken in connection with the
registration, marketing or selling of the Registrable Securities, and (xiv)&nbsp;all out-of pocket costs and expenses incurred by the Company or its appropriate officers in connection with their compliance with Section&nbsp;2.04(m). Except as set
forth in clause (viii)&nbsp;above, Registration Expenses shall not include any out-of-pocket expenses of the Shareholders (or the agents who manage their accounts). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Rule 144</B>&#148; means Rule 144 (or any successor or similar provisions) under the Securities Act.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>SEC</B>&#148; means the Securities and Exchange Commission.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Shareholder</B>&#148; means at any time, any Person (other than the Company) who shall then be a party to or bound by this
Agreement, so long as such Person shall &#147;beneficially own&#148; (as such term is defined in Rule 13d-3 of the Exchange Act) any Company Securities.<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>&#147;<B>Transfer</B>&#148; means, with respect to any Company Securities, (i)&nbsp;when used as a verb, to sell, assign, dispose of,
exchange, pledge, encumber, hypothecate or <B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise transfer such Company Securities or any participation or interest therein, whether directly or indirectly, or agree or commit to do any of the foregoing and (ii)&nbsp;when used as a
noun, a direct or indirect sale, assignment, disposition, exchange, pledge, encumbrance, hypothecation, or other transfer of such Company Securities or any participation or interest therein or any agreement or commitment to do any of the foregoing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Section&nbsp;1.02. <I>Other Definitional and Interpretative Provisions. </I>The words &#147;hereof&#148;, &#147;herein&#148; and
&#147;hereunder&#148; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be
ignored in the construction or interpretation hereof. References to Articles, Sections or Exhibits are to Articles, Sections and Exhibits of this Agreement unless otherwise specified. All Exhibits annexed hereto or referred to herein are hereby
incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized term used in any Exhibit but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement
shall be deemed to include the plural, and any plural term the singular. Whenever the words &#147;include&#148;, &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they shall be deemed to be followed by the words &#147;without
limitation&#148;, whether or not they are in fact followed by those words or words of like import. &#147;Writing&#148;, &#147;written&#148; and comparable terms refer to printing, typing and other means of reproducing words (including electronic
media) in a visible form. References to any agreement or contract are to that agreement or contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the
successors and permitted assigns of that Person. References from or through any date mean, unless otherwise specified, from and including or through and including, respectively.<I> </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 2 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">R<SMALL>EGISTRATION</SMALL> R<SMALL>IGHTS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B></B>Section&nbsp;2.01. <B></B><I>Demand Registration</I><B></B>. (a)&nbsp;If at any time after the date six months after the completion of
the Initial Public Offering, the Company shall receive a request from a Shareholder or group of Shareholders (the requesting Shareholder(s) shall be referred to herein as the &#147;<B>Requesting Shareholder</B>&#148;), holding at least thirty
percent (30%)&nbsp;of the Registrable Securities then outstanding, that the Company effect the registration under the Securities Act (i)&nbsp;for the first Public Offering of the Company after the completion of the Initial Public Offering (the
&#147;<B>Follow-On Offering</B>&#148;), at least twenty percent (20%)&nbsp;of the Requesting Shareholder&#146;s Registrable Securities then outstanding (or any lesser percentage if the anticipated aggregate offering price, net of underwriting
discounts and commissions, would exceed $10,000,000), or (ii)&nbsp;after the completion of the Follow-On Offering, all or any portion of the Requesting Shareholder&#146;s Registrable Securities and, in each case, specifying the intended method of
disposition thereof, <B> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
</B>then the Company shall as promptly as practicable following the date of receipt by the Company of such request give notice of such requested registration (each such request shall be referred
to herein as a &#147;<B>Demand Registration</B>&#148;) at least fifteen (15)&nbsp;business days after receipt of such Demand Registration to the other Shareholders and thereupon shall use its commercially reasonable efforts to effect, as
expeditiously as possible, and in any event within ninety (90)&nbsp;days after the date the Demand Registration is given by the Requesting Shareholder, the registration under the Securities Act of:<B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) subject to the restrictions set forth in Sections 2.01(e), all Registrable Securities for which the Requesting Shareholder
has requested registration under this Section&nbsp;2.01, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) subject to the restrictions set forth in Sections
2.01(e) and 2.02, all other Registrable Securities of the same class as those requested to be registered by the Requesting Shareholder that any other Shareholders (all such Shareholders, together with the Requesting Shareholder, the
&#147;<B>Registering Shareholders</B>&#148;) have requested the Company to register pursuant to Section&nbsp;2.02, by request received by the Company within seven Business Days after such Shareholders receive the Company&#146;s notice of the Demand
Registration, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I>all to the extent necessary to permit the disposition (in accordance with the intended methods thereof as aforesaid) of the
Registrable Securities so to be registered, <I>provided</I> that, the Company shall not be obligated to effect a Demand Registration unless the aggregate proceeds expected to be received from the sale of the Registrable Securities requested to be
included in such Demand Registration equals or exceeds $10,000,000. In no event shall the Company be required to effect more than two (2)&nbsp;Demand Registrations pursuant to this Section 2.01.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Promptly after the expiration of the seven-Business Day period referred to in Section&nbsp;2.01(a)(ii), the Company will notify all
Registering Shareholders of the identities of the other Registering Shareholders and the number of shares of Registrable Securities requested to be included therein. At any time prior to the effective date of the registration statement relating to
such registration, the Requesting Shareholder may revoke such request, without liability to any of the other Registering Shareholders, by providing a notice to the Company revoking such request. Notwithstanding clause (d)&nbsp;below, a request, so
revoked, shall be considered to be a Demand Registration unless (i)&nbsp;such revocation arose out of the fault of the Company (in which case the Company shall be obligated to pay all Registration Expenses in connection with such revoked request),
or (ii)&nbsp;the Requesting Shareholder reimburses the Company for all Registration Expenses (other than the expenses set forth under clause (v)&nbsp;of the definition of the term Registration Expenses) of such revoked request.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company shall be liable for and shall pay all Registration Expenses in connection with
any Demand Registration, regardless of whether such Registration is effected, unless the Requesting Shareholder elects to pay such Registration Expenses as described in the last sentence of Section&nbsp;2.01(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>(d) A Demand Registration shall not be deemed to have occurred unless the registration statement relating thereto (i)&nbsp;has become
effective under the Securities Act and (ii)&nbsp;has remained effective for a period of at least 180 days (or such shorter period in which all Registrable Securities of the Registering Shareholders included in such registration have actually been
sold thereunder), <I>provided</I> that a Demand Registration shall not be deemed to have occurred if, after such registration statement becomes effective, such registration statement is interfered with by any stop order, injunction or other order or
requirement of the SEC or other governmental agency or court.<I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) If a Demand Registration involves an underwritten Public Offering
and the managing underwriter advises the Company and the Requesting Shareholder that, in its view, the number of shares of Registrable Securities requested to be included in such registration (including any securities that the Company proposes to be
included that are not Registrable Securities) exceeds the largest number of shares that can be sold without having an adverse effect on such offering, including the price at which such shares can be sold (the &#147;<B>Maximum Offering
Size</B>&#148;), the Company shall include in such registration, in the priority listed below, up to the Maximum Offering Size: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) first, all Registrable Securities requested to be included in such registration by all Registering Shareholders (allocated,
if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such Shareholders on the basis of the relative number of Registrable Securities held by each such Shareholder, or in such other proportion as shall mutually be
agreed to by all such Registering Shareholders); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) second, any securities proposed to be registered by the Company
(including for the benefit of any other Persons not party to this Agreement). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Upon notice to the Requesting Shareholder, the Company
may postpone effecting a registration pursuant to this Section&nbsp;2.01 on two occasions during any period of twelve consecutive months for a reasonable time specified in the notice but not exceeding 90 days in the aggregate in any period of twelve
consecutive months (which period may not be extended or renewed), if (i)&nbsp;the Company reasonably determines that effecting the registration would materially and adversely affect an offering of securities of the Company the preparation of which
had then been commenced, (ii)&nbsp;the Company reasonably determines that effecting the registration would materially and adversely interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company, (iii)&nbsp;the Company is in possession of material non-public information the disclosure of which during the period specified in such notice the Company reasonably believes in good
faith would not be in the best interests of the Company, or (iv)&nbsp;the Company would be rendered unable to comply with the requirements under the Securities Act or the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02. <I>Piggyback Registration</I>. (a)&nbsp;If at any time after the completion of the Initial Public Offering the Company
proposes to register any Company Securities under the Securities Act (other than (i)&nbsp;a Shelf Registration, which will be subject to the provisions of Section&nbsp;2.03; <I>provided </I>that any Underwritten Takedown will be subject to this
Section&nbsp;2.02, or (ii)&nbsp;a registration on Form S-8, F-4 or S-4, or any successor or similar forms, relating to Common Shares issuable upon exercise of employee stock options or in connection with any employee benefit or similar plan of the
Company or in connection with a direct or indirect acquisition by the Company of another Person), whether or not for sale for its own account, the Company shall each such time give prompt notice at least ten (10)&nbsp;Business Days prior to the
anticipated filing date of the registration statement relating to such registration to each Shareholder, which notice shall set forth such Shareholder&#146;s rights under this Section&nbsp;2.02 and shall offer such Shareholder the opportunity to
include in such registration statement the number of Registrable Securities of the same class or series as those proposed to be registered as each such Shareholder may request (a &#147;<B>Piggyback Registration</B>&#148;), subject to the provisions
of Section&nbsp;2.02(b). Upon the request of any such Shareholder made within five (5)&nbsp;Business Days after the receipt of notice from the Company (which request shall specify the number of Registrable Securities intended to be registered by
such Shareholder), the Company shall use all commercially reasonable efforts to effect the registration under the Securities Act of all Registrable Securities that the Company has been so requested to register by all such Shareholders, to the extent
required to permit the disposition of the Registrable Securities so to be registered, <I>provided</I> that (A)&nbsp;if such registration involves an underwritten Public Offering, all such Shareholders requesting to be included in the Company&#146;s
registration must sell their Registrable Securities to the underwriters selected as provided in Section&nbsp;2.04(f) on the same terms and conditions as apply to the Company or the Requesting Shareholders, as applicable, and (B)&nbsp;if, at any time
after giving notice of its intention to register any Company Securities pursuant to this Section&nbsp;2.02(a) and prior to the effective date of the registration statement filed in connection with such registration, the Company shall determine for
any reason not to register such securities, the Company shall give notice to all such Shareholders and, thereupon, shall be relieved of its obligation to register any Registrable Securities in connection with such registration. No registration
effected under this Section&nbsp;2.02 shall relieve the Company of its obligations to effect a Demand Registration to the extent required by Section&nbsp;2.01 or a Shelf Registration to the extent required by Section&nbsp;2.03. The Company shall pay
all Registration Expenses in connection with each Piggyback Registration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If a Piggyback Registration involves an underwritten Public Offering (other than any Demand
Registration, in which case the provisions with respect to priority of inclusion in such offering set forth in Section&nbsp;2.01(e) shall apply) and the managing underwriter advises the Company that, in its view, the number of Shares that the
Company and such Shareholders intend to include in such registration exceeds the Maximum Offering Size, the Company shall include in such registration, in the following priority, up to the Maximum Offering Size: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) first, so much of the Company Securities proposed to be registered for the account of the Company (or, if such registration
is pursuant to a demand by a Person that is not a Shareholder, for the account of such other Person) as would not cause the offering to exceed the Maximum Offering Size, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) second, all Registrable Securities requested to be included in such registration by any Shareholders pursuant to this
Section&nbsp;2.02 (allocated, if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such Shareholders on the basis of the relative number of Registrable Securities held by each such Shareholder, or in such other
proportion as shall mutually be agreed to by all such Registering Shareholders), and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) third, any securities proposed
to be registered for the account of any other Persons with such priorities among them as the Company shall determine; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that,
notwithstanding the foregoing, in no event shall the number of Registrable Securities included in the underwritten Public Offering be reduced below 25% of the total number of securities included in such Public Offering.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03. <I>Shelf Registration</I>. (a)&nbsp;At any time after the first anniversary of the Initial Public Offering, if the Company
is eligible to use Form F-3 or Form S-3, a Shareholder or group of Shareholders may request the Company (the requesting Shareholder(s) shall be referred to herein as the &#147;<B>Shelf Requesting Shareholder</B>&#148;) to effect a registration of
some or all of the Registrable Securities held by such Shelf Requesting Shareholder under a Registration Statement pursuant to Rule 415 under the Securities Act (or any successor or similar rule) (a &#147;<B>Shelf Registration</B>&#148;);<I>
provided</I> that, the Company shall not be obligated to effect a Shelf Registration unless the aggregate proceeds expected to be received from the sale of the Registrable Securities requested to be included in such Shelf Registration equals or
exceeds $1,000,000 (net of discounts and commissions). The Company shall only be required to effectuate two Public Offerings from such Shelf Registration (an &#147;<B>Underwritten Takedown</B>&#148;) within any twelve-month period. The provisions of
Section&nbsp;2.01 shall apply <I>mutatis mutandis</I> to each Underwritten Takedown, with references to &#147;filing of the registration statement&#148; or &#147;effective date&#148; being deemed references to filing of a prospectus or supplement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for such offering and references to &#147;registration&#148; being deemed references to the offering; <I>provided</I> that Registering Shareholders shall only include Shareholders whose
Registrable Securities are included in such Shelf Registration or may be included therein without the need for an amendment to such Shelf Registration (other than an automatically effective amendment). So long as the Shelf Registration is effective,
no Shareholder may request any Demand Registration pursuant to Section&nbsp;2.01 with respect to Registrable Shares that are registered on such Shelf Registration but instead shall have the right to request an Underwritten Takedown as set forth
above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Company shall receive a request from a Shelf Requesting Shareholder that the Company effect a Shelf Registration, then
the Company shall as promptly as practicable following the date of receipt by the Company of such request give notice of such requested registration and at least ten (10)&nbsp;Business Days prior to the anticipated filing date of the registration
statement relating to such Shelf Registration to the other Shareholders and thereupon shall use its reasonable best efforts to effect, as expeditiously as possible, the registration under the Securities Act of: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) all Registrable Securities for which the Shelf Requesting Shareholder has requested registration under this
Section&nbsp;2.03, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all other Registrable Securities of the same class as those requested to be registered by the
Shelf Requesting Shareholder that any other Shareholders (all such Shareholders, together with the Shelf Requesting Shareholder, the &#147;<B>Shelf Registering Shareholders</B>&#148;) have requested the Company to register by request received by the
Company within five (5)&nbsp;Business Days after such Shareholders receive the Company&#146;s notice of the Shelf Registration, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">all to the extent
necessary to permit the registration of the Registrable Securities so to be registered on such Shelf Registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) At any time prior
to the effective date of the registration statement relating to such Shelf Registration, the Shelf Requesting Shareholder may revoke such request, without liability to any of the other Shelf Registering Shareholders, by providing a notice to the
Company revoking such request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company shall be liable for and pay all Registration Expenses in connection with any Shelf
Registration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Upon notice to the Shelf Registering Shareholders, the Company may postpone effecting a registration pursuant to this
Section&nbsp;2.03 on two occasions during any period of twelve consecutive months for a reasonable time specified in the notice but not exceeding 90 days in the aggregate in any period of twelve consecutive months (which period may not be extended
or renewed), if (i)</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company reasonably determines that effecting the registration would materially and adversely affect an offering of securities of the Company the preparation of which had then been commenced,
(ii)&nbsp;the Company reasonably determines that effecting the registration would materially and adversely interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company, (iii)&nbsp;the Company
is in possession of material non-public information the disclosure of which during the period specified in such notice the Company reasonably believes in good faith would not be in the best interests of the Company, or (iv)&nbsp;the Company would be
rendered unable to comply with the requirements under the Securities Act or the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04. <I>Registration
Procedures</I>. Whenever Shareholders request that any Registrable Securities be registered pursuant to Section&nbsp;2.01 or 2.02, or the Company prepares a Shelf Registration pursuant to Section&nbsp;2.03, subject to the provisions of such
Sections, the Company shall use all commercially reasonable efforts to effect the registration and the sale of such Registrable Securities in accordance with the intended method of disposition thereof as quickly as practicable, and, in connection
with any such request: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company shall as expeditiously as possible prepare and file with the SEC a registration statement on any
form for which the Company then qualifies or that counsel for the Company shall deem appropriate and which form shall be available for the sale of the Registrable Securities to be registered thereunder in accordance with the intended method of
distribution thereof, and use all commercially reasonable efforts to cause such filed registration statement to become and remain effective for a period of not less than 180 days, or in the case of a Shelf Registration, three years (or such shorter
period in which all of the Registrable Securities of the Shareholders included in such registration statement shall have actually been sold thereunder or cease to be Registrable Securities). Any such registration statement shall be an automatically
effective registration statement to the extent permitted by the SEC&#146;s rules and regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Prior to filing a registration
statement or prospectus or any amendment or supplement thereto (other than any report filed pursuant to the Exchange Act that is incorporated by reference therein), the Company shall, if requested, furnish to each participating Shareholder and each
underwriter, if any, of the Registrable Securities covered by such registration statement copies of such registration statement as proposed to be filed, and thereafter the Company shall furnish to such Shareholder and underwriter, if any, such
number of copies of such registration statement, each amendment and supplement thereto (in each case including all exhibits thereto and documents incorporated by reference therein), the prospectus included in such registration statement (including
each preliminary prospectus and any summary prospectus) and any other prospectus filed under Rule 424, Rule 430A, Rule 430B or Rule 430C under the Securities Act and such other documents as such Shareholder or underwriter may reasonably request in
order to facilitate the disposition of the Registrable Securities owned by such Shareholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) After the filing of the registration statement, the Company shall (i)&nbsp;cause the related
prospectus to be supplemented by any required prospectus supplement and, as so supplemented, to be filed pursuant to Rule 424 under the Securities Act, (ii)&nbsp;comply with the provisions of the Securities Act with respect to the disposition of all
Registrable Securities covered by such registration statement during the applicable period in accordance with the intended methods of disposition by the Shareholders thereof set forth in such registration statement or supplement to such prospectus
and (iii)&nbsp;promptly notify each Shareholder holding Registrable Securities covered by such registration statement of any stop order issued or threatened by the SEC or any state securities commission and take all reasonable actions required to
prevent the entry of such stop order or to remove it if entered. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company shall use all commercially reasonable efforts to
(i)&nbsp;register or qualify the Registrable Securities covered by such registration statement under such other securities or &#147;blue sky&#148; laws of such jurisdictions in the United States as any Registering Shareholder holding such
Registrable Securities reasonably (in light of such Shareholder&#146;s intended plan of distribution) requests and (ii)&nbsp;cause such Registrable Securities to be registered with or approved by such other governmental agencies or authorities as
may be necessary by virtue of the business and operations of the Company and do any and all other acts and things that may be reasonably necessary or advisable to enable such Shareholder to consummate the disposition of the Registrable Securities
owned by such Shareholder, <I>provided</I> that the Company shall not be required to (A)&nbsp;qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section&nbsp;2.04(d),
(B)&nbsp;subject itself to taxation in any such jurisdiction or (C)&nbsp;consent to general service of process in any such jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company shall promptly notify each Shareholder holding such Registrable Securities covered by such registration statement, at any time
when a prospectus relating thereto is required to be delivered under the Securities Act, of the occurrence of an event requiring the preparation of a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of
such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein in the light of the
circumstances under which they were made at such time not misleading and promptly prepare and make available to each such Shareholder and file with the SEC any such supplement or amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The Company shall have the right to select an underwriter or underwriters in connection with
any Public Offering resulting from any exercise of a Demand Registration (including any Underwritten Takedown), which underwriter or underwriters shall be reasonably acceptable to the Requesting Shareholder. In connection with any Public Offering,
the Company shall enter into customary agreements (including an underwriting agreement in customary form) and take such all other actions as are reasonably required in order to expedite or facilitate the disposition of such Registrable Securities in
any such Public Offering, including the engagement of a &#147;qualified independent underwriter&#148; in connection with the qualification of the underwriting arrangements with FINRA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Upon execution of confidentiality agreements in form and substance reasonably satisfactory to the Company, the Company shall, in connection
with a Public Offering make available for inspection by any Shareholder and any underwriter participating in any disposition pursuant to a registration statement being filed by the Company pursuant to this Section&nbsp;2.04 and any attorney,
accountant or other professional retained by any such Shareholder or underwriter (collectively, the &#147;<B>Inspectors</B>&#148;), all financial and other records, pertinent corporate documents and properties of the Company (collectively, the
&#147;<B>Records</B>&#148;) as shall be reasonably necessary or desirable to enable any of the Inspectors to exercise its due diligence responsibility, and cause the Company&#146;s officers, directors and employees to supply all information
reasonably requested by any Inspectors in connection with such registration statement. Records that the Company determines, in good faith, to be confidential and that it notifies the Inspectors are confidential shall not be disclosed by the
Inspectors unless (i)&nbsp;the disclosure of such Records is necessary to avoid or correct a material misstatement or omission in such registration statement or (ii)&nbsp;the release of such Records is ordered pursuant to a subpoena or other order
from a court of competent jurisdiction. Each Shareholder agrees that information obtained by it as a result of such inspections shall be deemed confidential and shall not be used by it or its Affiliates as the basis for any market transactions in
the Company Securities unless and until such information is made generally available to the public. Each Shareholder further agrees that, upon learning that disclosure of such Records is sought in a court of competent jurisdiction, it shall give
notice to the Company and allow the Company, at its expense, to undertake appropriate action to prevent disclosure of the Records deemed confidential. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) In connection with any Public Offering, the Company shall use its reasonable best efforts to furnish to each underwriter, if any, a signed
counterpart, addressed to such underwriter, of (i)&nbsp;an opinion or opinions of counsel to the Company and (ii)&nbsp;a comfort letter or comfort letters from the Company&#146;s independent public accountants, each in customary form and covering
such matters of the kind customarily covered by opinions or comfort letters, as the case may be, as the managing underwriter therefor reasonably requests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall otherwise use its reasonable best efforts to comply with all applicable
rules and regulations of the SEC, and make available to its security holders, as soon as reasonably practicable, an earnings statement or such other document covering a period of twelve months, beginning within three months after the effective date
of the registration statement, which earnings statement satisfies the requirements of Rule 158 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) The Company
may require each Shareholder promptly to furnish in writing to the Company such information regarding the distribution of the Registrable Securities as the Company may from time to time reasonably request and such other information as may be legally
required in connection with such registration. In connection with a Shelf Registration, any Shareholder that does not provide such information within five (5)&nbsp;Business Days of a request by the Company (which request is made before filing of the
Shelf Registration) may have its Registrable Securities excluded from such Shelf Registration; <I>provided</I> that such securities shall be added within fifteen Business Days after the Shareholder provides such information if the Company may add
such securities to such Shelf Registration without the need for a post-effective amendment (other than an automatically effective amendment) to the Shelf Registration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Each Shareholder agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in
Section&nbsp;2.04(e), such Shareholder shall forthwith discontinue disposition of Registrable Securities pursuant to the registration statement covering such Registrable Securities until such Shareholder&#146;s receipt of the copies of the
supplemented or amended prospectus contemplated by Section&nbsp;2.04(e), and, if so directed by the Company, such Shareholder shall deliver to the Company all copies, other than any permanent file copies then in such Shareholder&#146;s possession,
of the most recent prospectus covering such Registrable Securities at the time of receipt of such notice. If the Company shall give such notice, the Company shall extend the period during which such registration statement shall be maintained
effective (including the period referred to in Section&nbsp;2.04(a)) by the number of days during the period from and including the date of the giving of notice pursuant to Section&nbsp;2.04(e) to the date when the Company shall make available to
such Shareholder a prospectus supplemented or amended to conform with the requirements of Section&nbsp;2.04(e). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The Company shall use
its reasonable best efforts to list all Registrable Securities covered by such registration statement on any securities exchange or quotation system on which the Common Shares are then listed or traded. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) In any Public Offering pursuant to a Demand Registration, the Company shall have appropriate officers of the Company (i)&nbsp;prepare and
make presentations at any &#147;road shows&#148; and before analysts and (ii)&nbsp;otherwise use their reasonable best efforts to cooperate as reasonably requested by the underwriters in the offering, marketing or selling of the Registrable
Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) Each Shareholder agrees that, in connection with any offering pursuant to this Agreement, it
will not prepare or use or refer to, any &#147;free writing prospectus&#148; (as defined in Rule 405 of the Securities Act) without the prior written authorization of the Company (which authorization shall not be unreasonably withheld), and will not
distribute any written materials in connection with the offer or sale of the Registrable Securities pursuant to any registration statement hereunder other than the Prospectus and any such free writing prospectus so authorized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05<I>. Participation In Public Offering. </I>No Shareholder may participate in any Public Offering hereunder unless such
Shareholder (a)&nbsp;agrees to sell such Shareholder&#146;s Registrable Securities on the basis provided in any underwriting arrangements approved by the Persons entitled hereunder to approve such arrangements and (b)&nbsp;completes and executes all
questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required under the terms of such underwriting arrangements that are consistent for all similarly situated Shareholders and the provisions of this
Agreement in respect of registration rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.06<I>. Rule 144 Sales; Cooperation By The Company. </I>If any Shareholder
shall transfer any Registrable Securities pursuant to Rule 144, the Company shall cooperate, to the extent commercially reasonable, with such Shareholder and shall provide to such Shareholder such information as such Shareholder shall reasonably
request. Without limiting the foregoing, the Company shall at any time after any of the Company&#146;s Common Shares are registered under the Securities Act or the Exchange Act, use commercially reasonable efforts to: (i)&nbsp;make and keep
available public information, as those terms are contemplated by Rule 144; (ii)&nbsp;timely file with the SEC all reports and other documents required to be filed under the Securities Act and the Exchange Act; and (iii)&nbsp;furnish to each
Shareholder forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of the Securities Act and the Exchange Act, a copy of the most recent annual or quarterly report of the Company, and such
other information as such Shareholder may reasonably request in order to avail itself of any rule or regulation of the SEC allowing such Shareholder to sell any Registrable Securities without registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 3 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">I<SMALL>NDEMNIFICATION</SMALL> <SMALL>AND</SMALL> C<SMALL>ONTRIBUTION</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01. <I>Indemnification by the Company</I>. The Company agrees to indemnify and hold harmless each Shareholder beneficially
owning any Registrable Securities covered by a registration statement, its officers, directors, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees, partners and agents, and each Person, if any, who controls such Shareholder within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act from and
against any and all losses, claims, damages, liabilities and expenses (including reasonable expenses of investigation and reasonable attorneys&#146; fees and expenses) (collectively, &#147;<B>Damages</B>&#148;) caused by or relating to any untrue
statement or alleged untrue statement of a material fact contained in any registration statement or prospectus relating to the Registrable Securities (as amended or supplemented if the Company shall have furnished any amendments or supplements
thereto) or any preliminary prospectus or free-writing prospectus (as defined in Rule 405 under the Securities Act), or caused by or relating to any omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, except insofar as such Damages are caused by or related to any such untrue statement or omission or alleged untrue statement or omission so made based upon information furnished in writing to
the Company by such Shareholder or on such Shareholder&#146;s behalf expressly for use therein. The Company also agrees to indemnify any underwriters of the Registrable Securities, their officers and directors and each Person who controls such
underwriters within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act on substantially the same basis as that of the indemnification of the Shareholders provided in this Section&nbsp;3.01. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02. <I>Indemnification by Participating Shareholders</I>. Each Shareholder holding Registrable Securities included in any
registration statement agrees, severally but not jointly, to indemnify and hold harmless the Company, its officers, directors and agents and each Person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or
Section&nbsp;20 of the Exchange Act to the same extent as the indemnity from the Company to such Shareholder provided in Section&nbsp;3.01, but only to the extent such Damages arise out of or are based upon actions and omissions made in reliance
upon and in conformity with information about such Shareholder furnished in writing by such Shareholder or on such Shareholder&#146;s behalf expressly for use in any registration statement or prospectus relating to the Registrable Securities, or any
amendment or supplement thereto, or any preliminary prospectus or free-writing prospectus. Each such Shareholder also agrees to indemnify and hold harmless underwriters of the Registrable Securities, their officers and directors and each Person who
controls such underwriters within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act on substantially the same basis as that of the indemnification of the Company provided in this Section&nbsp;3.02. As a
condition to including Registrable Securities in any registration statement filed in accordance with Article 2, the Company may require that it shall have received an undertaking reasonably satisfactory to it from any underwriter to indemnify and
hold it harmless to the extent customarily provided by underwriters with respect to similar securities. No Shareholder shall be liable under this Section&nbsp;3.02 for any Damages in excess of the net proceeds realized by such Shareholder in the
sale of Registrable Securities of such Shareholder to which such Damages relate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.03. <I>Conduct of Indemnification Proceedings</I>. If any proceeding (including
any governmental investigation) shall be brought or asserted against any Person in respect of which indemnity may be sought pursuant to this Article 3, such Person (an &#147;<B>Indemnified Party</B>&#148;) shall promptly notify the Person against
whom such indemnity may be sought (the &#147;<B>Indemnifying Party</B>&#148;) in writing and the Indemnifying Party shall assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Party, and shall
assume the payment of all fees and expenses, <I>provided</I> that the failure of any Indemnified Party so to notify the Indemnifying Party shall not relieve the Indemnifying Party of its obligations hereunder except to the extent that the
Indemnifying Party is materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such
Indemnified Party unless (a)&nbsp;the Indemnifying Party and the Indemnified Party shall have mutually agreed to the retention of such counsel, (b)&nbsp;in the reasonable judgment of such Indemnified Party representation of both parties by the same
counsel would be inappropriate due to actual or potential differing interests between them, including one or more defenses or counterclaims that are different from or in addition to those available to the Indemnifying Party, or (c)&nbsp;the
Indemnifying Party shall have failed to assume the defense within 30 days of notice pursuant to this Section&nbsp;3.03. It is understood that, in connection with any proceeding or related proceedings in the same jurisdiction, the Indemnifying Party
shall not be liable for the reasonable fees and expenses of more than one separate firm of attorneys (in addition to one local counsel per jurisdiction) at any time for all such Indemnified Parties, and that all such fees and expenses shall be
reimbursed as they are incurred. In the case of any such separate firm for the Indemnified Parties, such firm shall be designated in writing by the Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any proceeding
effected without its written consent, but if settled with such consent, or if there be a final judgment for the plaintiff, the Indemnifying Party shall indemnify and hold harmless such Indemnified Parties from and against any loss or liability (to
the extent stated above) by reason of such settlement or judgment. Without the prior written consent of the Indemnified Party, no Indemnifying Party shall effect any settlement of any pending or threatened proceeding in respect of which any
Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement (A)&nbsp;includes an unconditional release of such Indemnified Party from all liability arising out of
such proceeding, and (B)&nbsp;does not include any injunctive or other equitable or non-monetary relief applicable to or affecting such Indemnified Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.04. <I>Contribution</I>. If the indemnification provided for in this Article 3 is unavailable to or unenforceable by the
Indemnified Parties in respect of any Damages, then each Indemnifying Party, in lieu of indemnifying the Indemnified Parties, shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect
the relative fault of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Damages as well as any other relevant equitable considerations. The
relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged
omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or
prevent such action, statement or omission. The amount paid or payable by a party as a result of any Damages shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys&#146; or other reasonable fees
or expenses incurred by such party in connection with any proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Article 3 was available to such party in accordance with
its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;3.04 were
determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this Section&nbsp;3.04, no
Shareholder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Shareholder from the sale of the Registrable Securities subject to the proceeding exceeds the amount of
any damages that such Shareholder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, except in the case of fraud by such Shareholder. Each Shareholder&#146;s obligation to
contribute pursuant to this Section&nbsp;3.03 is several in the proportion that the proceeds of the offering received by such Shareholder bears to the total proceeds of the offering received by all such Shareholders and not joint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to
contribution from any Person who was not guilty of such fraudulent misrepresentation. The indemnity and contribution agreements contained in this Article 3 are in addition to any liability that the Indemnifying Parties may have to the Indemnified
Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.05. <I>Other Indemnification</I>. Indemnification similar to that provided in this Article 3 (with appropriate
modifications) shall be given by the Company and each Shareholder participating therein with respect to any required registration or other qualification of securities under any foreign, federal or state law or regulation or governmental authority
other than the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 4 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">T<SMALL>ERMINATION</SMALL> <SMALL>OF</SMALL> R<SMALL>EGISTRATION</SMALL> R<SMALL>IGHTS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01. <I>Termination of Registration Rights</I>. The rights of any Shareholder to request registration or inclusion of
Registrable Securities in any registration pursuant to this Agreement shall terminate upon the earlier to occur of: (a)&nbsp;the fourth anniversary of the Initial Public Offering, and (b)&nbsp;such time as Rule 144 or another similar exemption under
the Securities Act is available for the sale of all such Shareholder&#146;s Company Securities without limitation during a three-month period without registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ARTICLE 5 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">M<SMALL>ISCELLANEOUS</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.01<I>. Binding Effect; Assignability; Benefit. </I>(a)&nbsp;This Agreement shall inure to the benefit of and be binding upon
the parties hereto and their respective heirs, successors, legal representatives and permitted assigns. Any Shareholder that ceases to own beneficially any Registrable Securities shall cease to be bound by the terms hereof (other than (i)&nbsp;the
provisions of Article 3 applicable to such Shareholder with respect to any offering of Registrable Securities completed before the date such Shareholder ceased to own any Registrable Securities and (ii)&nbsp;this Article 5). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by any
party hereto pursuant to any Transfer of Registrable Securities or otherwise, except that each Shareholder may assign rights hereunder to any Permitted Transferee of such Shareholder. Any such Permitted Transferee shall (unless already bound hereby)
execute and deliver to the Company an agreement to be bound by this Agreement in the form of Exhibit A hereto (a &#147;<B>Joinder Agreement</B>&#148;) and shall thenceforth be a &#147;<B>Shareholder</B>&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Nothing in this Agreement, expressed or implied, is intended to confer on any Person other than the parties hereto, and their respective
heirs, successors, legal representatives and permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.02. <I>Notices</I>. All notices, requests and other communications (each, a &#147;<B>Notice</B>&#148;) to any party shall be in
writing and shall be delivered in person, mailed by certified or registered mail, return receipt requested, or sent by facsimile transmission or email transmission so long as receipt of such email is requested and received, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to the Company to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Merus N.V. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Padualaan 8 (postvak
133) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">3584&nbsp;CH&nbsp;Utrecht,&nbsp;the&nbsp;Netherlands </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Fax: [&nbsp;&nbsp;&nbsp;&nbsp;] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Attention: Shelley Margetson, Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Email: s.margetson@merus.nl </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">John Hancock Tower, 27<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">200 Clarendon Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Boston,
Massachusetts 02116 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Facsimile: (617)&nbsp;948-6001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Attention: Peter Handrinos, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Email: peter.handrinos@lw.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if to any Shareholder, at the address for such Shareholder listed on the signature pages below or otherwise provided to the Company as set
forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Notice shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. in the
place of receipt and such day is a Business Day in the place of receipt. Otherwise, such Notice shall be deemed not to have been received until the next succeeding Business Day in the place of receipt. Any Notice sent by facsimile transmission also
shall be confirmed by certified or registered mail, return receipt requested, posted within one Business Day after the date of the sending of such facsimile transmission, or by personal delivery, whether courier or otherwise, made within two
Business Days after the date of such facsimile transmission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Person that becomes a Shareholder after the date hereof shall provide
its address, fax number and email address to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.03. <I>Waiver; Amendment</I>. (a)&nbsp;The provisions of this
Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given without the written consent of holders of a majority of the
Registrable Securities then outstanding; <I>provided</I>, however, that in no event shall the obligations of any holder of Registrable Securities be materially increased or the rights of any Stockholder be adversely affected (without similarly
adversely affecting the rights of all Stockholders), except upon the written consent of such holder. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the
rights of holders of Registrable Securities whose securities are being sold pursuant to a Registration Statement and that does not directly or indirectly affect the rights of other holders of Registrable Securities may be given by holders of at
least a majority of the Registrable Securities being sold by such holders pursuant to such Registration Statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.04. <I>Governing Law</I>. This Agreement shall be governed by, and construed and
enforced in accordance with, the laws of the State of New York, without regard to the conflicts of laws rules of such state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.05. <I>Jurisdiction</I>. The parties hereby agree that any suit, action or proceeding seeking to enforce any provision of, or
based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby shall be brought in any state or federal court in The City of New York, Borough of Manhattan, so long as one of such courts shall have
subject matter jurisdiction over such suit, action or proceeding, and that any cause of action arising out of this Agreement shall be deemed to have arisen from a transaction of business in the State of New York, and each of the parties hereby
irrevocably consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection that it may now or
hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding which is brought in any such court has been brought in an inconvenient form. Process in any such suit,
action or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each party agrees that service of process on such party as provided in
Section&nbsp;5.02 shall be deemed effective service of process on such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.06. <I>WAIVER OF JURY TRIAL</I>. EACH OF THE
PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.07. <I>Specific Enforcement</I>. Each party hereto acknowledges that the remedies at law of the other parties for a breach or
threatened breach of this Agreement would be inadequate and, in recognition of this fact, any party to this Agreement, without posting any bond or furnishing other security, and in addition to all other remedies that may be available, shall be
entitled to obtain equitable relief in the form of specific performance, a temporary restraining order, a temporary or permanent injunction or any other equitable remedy that may then be available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.08. <I>Counterparts; Effectiveness</I>. This Agreement may be executed (including by facsimile or other electronic image scan
transmission) with counterpart signature pages or in any number of counterparts, each of which shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">be deemed to be an original, and all of which shall, taken together, be considered one and the same agreement, it
being understood that each party need not sign the same counterpart. This Agreement shall become effective when each party hereto shall have executed and delivered this Agreement. Until and unless each party has executed and delivered this
Agreement, this Agreement shall have no effect and no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.09. <I>Entire Agreement</I>. This Agreement constitutes the entire agreement and understanding among the parties hereto and
supersedes all prior and contemporaneous agreements and understandings, both oral and written, among the parties hereto with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.10. <I>Severability</I>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent
jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated
so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such a determination, the parties shall negotiate in good faith to modify this Agreement so as to
effect the original intent of the parties as closely as possible in an acceptable manner so that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.11<I>. Other Registration Rights. </I>From and after the date of this Agreement, the Company shall not, without the prior
written consent of holders of a majority of the Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder any registration rights the terms of
which are equivalent to or more favorable than the registration rights granted to Shareholders hereunder, or which would reduce the amount of Registrable Securities the Shareholders can include in any registration filed pursuant to this Agreement,
unless such rights are subordinate to those of the Shareholders hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.12<I>. Confidentiality. </I>Each Shareholder
agrees that any notice received pursuant to this Agreement, including any notice of a proposed underwritten public offering or postponement of an offering or effecting of a registration, is confidential information and that any trading in securities
of the Company following receipt of such information may only be done in compliance with all applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.13<I>. Independent Nature of Shareholders&#146; Obligations and Rights. </I>The obligations of each Shareholder hereunder are
several and not joint with the obligations of any other Shareholder hereunder, and no Shareholder shall be responsible in any way for the performance of the obligations of any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shareholder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Shareholder pursuant hereto or thereto, shall be deemed
to constitute the Shareholders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Shareholders are in any way acting in concert with respect to such obligations or the transactions
contemplated by this Agreement. Each Shareholder shall be entitled to protect and enforce its rights, including the rights arising out of this Agreement, and it shall not be necessary for any other Shareholder to be joined as an additional party in
any proceeding for such purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature pages follow.] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement or have caused this
Agreement to be duly executed by their respective authorized officers as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MERUS N.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>SOFINNOVA VENTURE PARTNERS IX, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">3000 Sand Hill Road, Bldg. 4 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Suite 250 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Anand Mehra </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: anand@sofinnova.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NOVO A/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Tuborg Havnevej 19 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">2900 Hellerup, Denmark </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Jack B. Nielsen </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: jabn@novo.dk </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BAKER BROTHERS INVESTMENTS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>667, L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Baker Brothers Life Sciences, L.P. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">667 Madison Avenue, 21st floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">New York, NY 10065 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Kelvin Neu </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: kneu@BBInvestments.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA CAPITAL MANAGEMENT, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RA CAPITAL HEALTHCARE FUND,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;L.P.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BLACKWELL PARTNERS LLC-</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;SERIES A</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">20 Park Plaza, Suite 1200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Boston, MA 02116 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Nick McGrath </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: nmcgrath@racap.com with a copy to rshah@racap.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TEKLA HEALTHCARE INVESTORS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">SVP Research </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">100 Federal Street, 19th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Boston, MA 02110 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Chris Richard </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: crichard@teklacap.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TEKLA LIFE SCIENCES INVESTORS</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">SVP Research </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">101 Federal Street, 19th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Boston, MA 02110 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Chris Richard </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: crichard@teklacap.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TEKLA WORLD HEALTHCARE FUND</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">SVP Research </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">102 Federal Street, 19th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Boston, MA 02110 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Chris Richard </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: crichard@teklacap.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ROCK SPRINGS CAPITAL MASTER</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;FUND LP</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">650 South Exeter Street, Suite 1070 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Baltimore, MD 21202 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Dave Gardner </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: dave@rockspringscapital.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CRUCELL HOLLAND B.V</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Archimedesweg 4 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">2333 CN Leiden </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Managing Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: jbolger@janimm.com with a copy to: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">SRosenB@its.jnj.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">and: lvogel@its.jnj.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOHNSON &amp; JOHNSON INNOVATION</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;JJDC, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">410 George Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">New Brunswick, NJ 08901 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Managing Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: jbolger@janimm.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">with a copy to: SRosenB@its.jnj.com and: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">lvogel@its.jnj.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NOVARTIS BIOVENTURES LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">131 Front Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Hamilton HM12 Bermuda </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Managing Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: david.middleton@novartis.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">with a copy to: florent.gros@nvfund.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CO&Ouml;PERATIEF LSP IV U.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Johannes Vermeerplein 9 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">1071 DV Amsterdam </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Managing Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: jdekoning@lspvc.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BAY CITY CAPITAL CO&Ouml;PERATIEF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;U.A.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">De Boelelaan 7 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">1083 HJ Amsterdam </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Managing Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: adnl-cms-a@alterdomus.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PFIZER INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">235 East 42nd Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">New York, NY 10017 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Andew Muratore and Elaine Jones </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: elaine.jones@pfizer.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AGLAIA ONCOLOGY FUND B.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>AGLAIA ONCOLOGY SEED FUND</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;B.V.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Professor Bronkhorstlaan 10 92 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">3732 MB Bilthoven </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Managing Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: kr@aglaia-biomedical.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>BIOPHRASE B.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>TON LOGTENBERG</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Koningin Wilhelminalaan 22 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">3972 EX Driebergen-Rijsenburg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: T. Logtenberg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: T.Logtenberg@merus.nl </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STICHTING</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;ADMINISTRATIEKANTOOR</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;MERUS</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><U>Address for Notices</U>: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Padualaan 8, postvak 133 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">3584 CH Utrecht </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Attn: Managing Director </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Email: T.Logtenberg@merus.nl </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature page to the
Registration Rights Agreement</I>] </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>JOINDER TO REGISTRATION RIGHTS AGREEMENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Joinder Agreement (this &#147;<B>Joinder Agreement</B>&#148;) is made as of the date written below by the undersigned (the
&#147;<B>Joining Party</B>&#148;) in accordance with the Registration Rights Agreement dated as of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 2016 (as the same may be
amended from time to time, the &#147;<B>Registration Rights Agreement</B>&#148;), among Merus N.V. and the Shareholders party thereto. Capitalized terms used, but not defined, herein shall have the meaning ascribed to such terms in the Registration
Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Joining Party hereby acknowledges, agrees and confirms that, by its execution of this Joinder Agreement, the
Joining Party shall be deemed to be a party to the Registration Rights Agreement as of the date hereof as a &#147;<B>Permitted Transferee</B>&#148; of a Shareholder thereto, and shall have all of the rights and obligations of a
&#147;<B>Shareholder</B>&#148; thereunder as if it had executed the Registration Rights Agreement. The Joining Party hereby ratifies, as of the date hereof, and agrees to be bound by, all of the terms, provisions and conditions contained in the
Registration Rights Agreement (including, without limitation, Section&nbsp;5.01 thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned has
executed this Joinder Agreement as of the date written below. </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="5">[NAME OF JOINING PARTY]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="6"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">Address for Notices:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">[Address]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">[Fax number]</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5">[Email address]</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>d29248dex109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.9 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rabobank Utrechtse Heuvelrug </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Big Business (<I>Groot
Zakelijk</I>) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g97787g70z47.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Address</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>P.O. Box 82, 3700 AB Zeist</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Merus B.V.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Address</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Utrechtseweg 25, Zeist</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ms S.J. Margetson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Phone&nbsp;number</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>(030)&nbsp;221 23 25</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">P.O. Box 133</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Fax</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>(030)&nbsp;221 22 45</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Padualaan 8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Email</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Bedrijven@uhr.rabobank.nl</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3584 CH Utrecht</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Bank account</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>3751.29.000</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Our reference</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">GZ/PH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Direct dial </I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(030)&nbsp;221 23 25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Date </I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">21&nbsp;October 2015</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Subject</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual accounts 2014</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Dear Ms Margetson, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Thank you very much for the annual accounts for the financial year 2014. As discussed during our phone call of this week, I would like to
confirm the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The existing provision regarding the change of control as included in the financing agreement dated
29&nbsp;December 2005 shall herewith cease to apply. The financing agreement shall further be continued unchanged. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Please note that the
following administration conditions shall apply: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top">a copy of the annual accounts of Merus B.V. as soon as possible after the relevant period, but no later than <U>1&nbsp;September</U> of each year; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top">a copy of the half-year figures of Merus B.V. upon first request; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">-</TD>
<TD ALIGN="left" VALIGN="top">the profitability- and liquidity forecast for the coming year upon first request. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If you
have any further questions, please do not hesitate to contact me. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Best regards, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><U>/s/ Pieter van Hulsen </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Pieter van Hulsen </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">sr. account
manager Big Business (<I>Grootzakelijk</I>) </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>4
<FILENAME>d29248dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2">


<IMG SRC="g97787g40a05.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.11</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Eversheds B.V.</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">De Cuserstraat 85a</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1081 CN Amsterdam</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Postbus/PO Box 7902</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1008 AC Amsterdam</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Netherlands</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T: +31 20 5600 600</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F: +31 20 5600 500</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">eversheds.nl</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated</B>: 20&nbsp;August 2015 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Merus B.V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">All Shareholders of
Merus B.V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mr.&nbsp;T.
Logtenberg </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHAREHOLDERS&#146; AGREEMENT </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Clause</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DEFINITIONS AND OTHER RULES OF CONSTRUCTION</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLES. OWNERSHIP STRUCTURE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CAPITAL AND SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">USE OF PROCEEDS. DIVIDEND POLICY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ISSUE OF SHARES. PRE-EMPTIVE RIGHTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TRANSFER OF SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MANAGEMENT BOARD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SUPERVISORY BOARD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GENERAL MEETING</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REGISTRATION RIGHTS.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EMPLOYEE STOCK OPTION PLAN AND OTHER MATTERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VARIOUS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schedules </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">:&nbsp;&nbsp;Definitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 2.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">:&nbsp;&nbsp;Amendment Deed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 2.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">:&nbsp;&nbsp;Capitalization table</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 4.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">:&nbsp;&nbsp;Business plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 7.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">:&nbsp;&nbsp;Management rights letter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 11.1a</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">:&nbsp;&nbsp;ESOP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 12.1a</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">:&nbsp;&nbsp;FCPA Certification form</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schedule 12.1b</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">:&nbsp;&nbsp;ROFN Letter Agreement and nomination letter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SHAREHOLDERS AGREEMENT </B>(this &#147;<B>Agreement</B>&#148;) is made as of 20&nbsp;August 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"><B>Merus B.V.</B>, a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) organized and existing under the laws of the Netherlands, with its corporate seat in Utrecht, The
Netherlands, with address Padualaan 8, postvak 133, 3584 CH Utrecht, The Netherlands, registered with the Trade Register of the Chamber of Commerce under file number 30189136 (the &#147;<B>Company</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"><B>Sofinnova Venture Partners IX, L.P.</B>, a limited partnership organized and existing under the laws of the state of Delaware in the United States of America, having its business offices at 3000 Sand Hill Road, Bldg.
4, Suite 250, Menlo Park, CA 94025 (&#147;<B>Sofinnova</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"><B>Novo A/S</B>, a limited liability company organized and existing under the laws of Denmark, with its registered address at Tuborg Havnevej 19, 2900 Hellerup, Denmark (&#147;<B>Novo</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"><B>Baker Brothers Life Sciences, L.P.</B>, a limited partnership under the laws of the state of Delaware, having its place of business at 667 Madison Avenue, 21st Floor, New York, NY 10065, United States of America
(&#147;<B>Baker Life Sciences</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"><B>667, L.P.</B>, a limited partnership under the laws of the state of Delaware, having its place of business at 667 Madison Avenue, 21st Floor, New York, NY 10065, United States of America (&#147;<B>Baker
667</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"><B>RA Capital Healthcare Fund, L.P.</B>, a limited liability company organized and existing under the laws of the United States of America, having its business offices at 20 Park Plaza, Suite 1200, Boston, MA 02116
(&#147;<B>RA Capital</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"><B>Blackwell Partners LLC - Series A</B>, a limited liability company organized and existing under the laws of the United States of America, with an address for notice purposes of 20 Park Plaza, Suite 1200, Boston, MA
02116 (&#147;<B>Blackwell Partners</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"><B>Tekla Healthcare Investors</B>, a registered investment company under the Investment Company Act of 1940 and incorporated under the laws of the Commonwealth of Massachusetts, having its place of business at 100
Federal Street, 19<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston 02110 (&#147;<B>Tekla Healthcare</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"><B>Tekla Life Sciences Investors</B>, a registered investment company under the Investment Company Act of 1940 Act and incorporated under the laws of the Commonwealth of Massachusetts, having its place of business at
101 Federal Street, 19<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston 02110 (&#147;<B>Tekla Life Sciences</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"><B>Tekla World Healthcare Funds</B>, a registered investment company under the Investment Company Act of 1940 Act and incorporated under the laws of the Commonwealth of Massachusetts, having its place of business at 102
Federal Street, 19<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston 02110 (&#147;<B>Tekla World Healthcare</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"><B>Rock Springs Capital Master Fund LP</B>, an exempted limited partnership, organized under the laws of the Cayman Islands, having its registered office at 650 South Exeter Street, Suite 1070 Baltimore, MD 21202,
United States of America (&#147;<B>Rock Springs</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"><B>Johnson&nbsp;&amp; Johnson Innovation &#150; JJDC, Inc.</B>, a corporation organized and existing under the laws of New Jersey, United States of America, having its registered and business offices at 410 George
Street, New Brunswick, NJ 08901 (&#147;<B>JJDC</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"><B>Novartis Bioventures Ltd., </B>a limited liability company organized and existing under the laws of Bermuda, having its registered and business offices at Canon&#146;s Court, 22, Victoria Street, Hamilton, HM 12,
Bermuda (&#147;<B>Novartis</B>&#148;); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"><B>Co&ouml;peratief LSP IV U.A., </B>a co-operative (<U>co&ouml;peratie met uitgesloten aansprakelijkheid</U>) organized and existing under the laws of the Netherlands, with its seat in Amsterdam, The Netherlands, with
address at Johannes Vermeerplein 9, 1071 DV Amsterdam, The Netherlands, registered with the Trade Register of the Chamber of Commerce under file number 34329760 (&#147;<B>LSP</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"><B>Bay City Capital Co&ouml;peratief U.A.</B>, a co-operative (<U>co&ouml;peratie met uitgesloten aansprakelijkheid</U>) organized and existing under the laws of the Netherlands, with its seat in Amsterdam, The
Netherlands, with address at De Boelelaan 7, 1083 HJ Amsterdam, The Netherlands, registered with the Trade Register of the Chamber of Commerce under file number 34376064 (&#147;<B>BCC</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"><B>Pfizer Inc.</B>, a corporation organized and existing under the laws of the state of Delaware in the United States of America, with its corporate seat in the state of Delaware, with address at 235 East 42<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> Street, New York, NY 10017 (&#147;<B>Pfizer</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"><B>Aglaia Oncology Fund B.V.</B>, a private limited liability company (<U>besloten vennootschap met beperkte aansprakelijkheid</U>) organized and existing under the laws of the Netherlands, with its corporate seat in
Bilthoven, The Netherlands, with address Professor Bronkhorstlaan 10-92, 3723 MB Bilthoven, The Netherlands, registered with the Trade Register of the Chamber of Commerce under file number 34202861 (&#147;<B>Aglaia</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"><B>Aglaia Oncology Seed Fund B.V.</B>, a private limited liability company (<U>besloten vennootschap met beperkte aansprakelijkheid</U>) organized and existing under the laws of the Netherlands, with its corporate seat
in Bilthoven, The Netherlands, with address Professor Bronkhorstlaan 10-92, 3723 MB Bilthoven, The Netherlands, registered with the Trade Register of the Chamber of Commerce under file number 34229600 (&#147;<B>Aglaia Seed</B>&#148;);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"><B>BioPhrase B.V.,</B> a private limited liability company (<U>besloten vennootschap met beperkte aansprakelijkheid</U>) organized and existing under the laws of the Netherlands, with its corporate seat in Werkhoven,
The Netherlands, with address Koningin Wilhelminalaan 22, 3972 EX Driebergen-Rijsenburg, The Netherlands, registered with the Trade Register of the Chamber of Commerce under file number 30184039 (&#147;<B>BioPhrase</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"><B>Crucell Holland B.V.,</B> a private limited liability company (<U>besloten vennootschap met beperkte aansprakelijkheid</U>) organized and existing under the laws of the Netherlands, with its corporate seat in Leiden,
The Netherlands, with address Archimedesweg 4, 2333 CN Leiden, The Netherlands, registered with the Trade Register of the Chamber of Commerce under file number 28074607 (&#147;<B>Crucell</B>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"><B>Stichting Administratiekantoor Merus</B>, a foundation (<U>stichting</U>) organized and existing under the laws of the Netherlands, with its seat in Utrecht, The Netherlands, with address Padualaan 8, postvak 133,
3584 CH Utrecht, The Netherlands, registered with the Trade Register of the Chamber of Commerce under file number 30249438 (&#147;<B>Stichting AK</B>&#148;); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(22)</TD>
<TD ALIGN="left" VALIGN="top"><B>Ton Logtenberg</B>, born in Geldrop on the 22nd day of July, 1958, residing at Koningin Wilhelminalaan 22, 3972 EX Driebergen-Rijsenburg, The Netherlands (&#147;<B>Logtenberg</B>&#148;); </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All parties hereinafter collectively and individually referred to as: &#147;Parties&#148; and &#147;Party&#148; respectively. Baker Life Sciences and Baker
667 collectively also referred to as &#147;Baker&#148;. BioPhrase and Logtenberg collectively and individually also referred to as: &#147;Founders&#148; or &#147;Founder&#148; respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top">The Company is involved in the discovery, development and commercialization of innovative human therapeutics antibodies, being the Oligoclonics&#153;, Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
and MeMo&#153; Technologies (the &#147;<B>Business</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top">As per 20&nbsp;August 2015, the relevant Parties have executed an agreement (the &#147;<B>Subscription Agreement</B>&#148;) with regard to, among other things, the issue of a first tranche (&#147;<B>First
Tranche</B>&#148;) of Class C Shares (&#147;<B>First Tranche Shares</B>&#148;), as well as a second tranche (the &#147;<B>Second Tranche</B>&#148;) upon completion of certain milestones in accordance with the terms and conditions as reflected in the
Subscription Agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top">the Subscription Agreement replaces the tranches 6 and 7 of the subscription agreement dated 30&nbsp;September 2013 (the &#147;<B>2013 Subscription Agreement</B>&#148;), whereby any and all rights and obligations of the
Company and the Existing Investors related to the tranches 6 and 7 of the 2013 Subscription Agreement have ceased to be of any force or effect as of Completion and are replaced by the Subscription Agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top">Pursuant to the Subscription Agreement, the parties thereto have, among other things, executed on the date hereof a notarial deed effectuating the issue of the First Tranche Shares as a result of which the Parties (with
the exception of the Company itself, and Logtenberg) are the sole shareholders of the Company (the &#147;<B>Shareholders</B>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top">This Agreement replaces the shareholders&#146; agreement dated 30&nbsp;September 2013 (the &#147;<B>2013 Shareholders&#146; Agreement</B>&#148;), which is terminated prematurely and replaced in its entirety by this
Agreement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top">The Parties now wish to set forth the terms and conditions between the Shareholders and the terms and conditions in relation to the operations of the Company. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual promises, covenants, and conditions contained herein, the Parties hereto hereby agree as follows: </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEFINITIONS AND OTHER RULES OF CONSTRUCTION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Definitions</U>. In this Agreement, unless the context otherwise requires, the words and expressions shall have the meanings set out in <B><U>Schedule 1.1.</U></B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Documents</U>. References to any document, including this Agreement, are references to that document as amended, supplemented, novated or replaced from time to time. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"><U>Recitals, Clauses, Paragraphs and Schedules</U>. References in this Agreement to Recitals, Clauses, Paragraphs and Schedules are to clauses and paragraphs in and recitals and schedules to this Agreement. The Recitals
and Schedules to this Agreement shall be deemed to form part of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"><U>Headings.</U> Headings are inserted for convenience only and shall not affect the construction of this Agreement. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B></B>2.</TD>
<TD ALIGN="left" VALIGN="top"><B>ARTICLES. OWNERSHIP STRUCTURE </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Articles of the Company</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The articles of association of the Company as currently in
force are set forth in a deed executed on the date hereof before mr. F. Volders, a civil law notary in Amsterdam, The Netherlands, or his deputy, substantially in accordance with the draft attached hereto as <B><U>Schedule 2.1</U></B>
(&#147;<B>Amendment Deed</B>&#148;). The articles of association of the Company as amended pursuant to the Amendment Deed will be referred to as the &#147;<B>New Articles</B>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Existing subscription and purchase rights</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Parties acknowledge that the following
rights to subscribe for or purchase shares in the capital of the Company or depositary receipts thereof exist after Completion (as defined in the Subscription Agreement): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursuant to the ESOP, the Company has, after the issuance of the First Tranche Shares, a pool of Options of up to 2,206,919 Common Shares, of which a total of 693,898 Options were already granted to employees and remain
outstanding, whilst a total of 1,513,021 Options are still available. Upon the completion of the Second Tranche, the number of Common Shares authorized to be issued under the ESOP will be 2,637,110, without any guaranteed minimum for any employee.
The Common Shares that have or may be issued in connection with the ESOP will hereinafter be referred to as the &#147;<B>ESOP Shares</B>&#148;. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the right of the Investors (as defined in the Subscription Agreement) to acquire additional Class C Shares in the Second Tranche, subject to the terms and conditions set forth in the Subscription Agreement, at the issue
price and consisting of a total number of Class C Shares as specified in clause 1 of the Subscription Agreement. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Each Party
hereby agrees that the 2013 Shareholders Agreement shall cease to be of any further force or effect as of the date of this Agreement. Furthermore, to the extent necessary or required, the parties to the 2013 Shareholders Agreement hereby grant
discharge to each other from any and all obligations and liabilities in relation to the 2013 Shareholders Agreement and hereby waive any rights they may have in relation to the 2013 Shareholders Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the existing rights of Aglaia Seed as stated in this Shareholders Agreement shall not be diminished or affected in
any way by Aglaia having effectively taken over the pro rata commitment part of Aglaia Seed for its own account in this Series C financing round (and Aglaia Seed not participating in the subscription for Class C Shares), including (without
limitation) the Anti-Dilution Protection and the pre-emptive-rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Capitalization after completion of the First Tranche Shares and
the Second Tranche Shares</U>. The current capitalization of the Company (after the New Articles have come into force and the issue of the First Tranche Shares, the issue of the Second Tranche and if all ESOP Shares would have been issued, as well
as the voting interests, are as set forth in the table in <B><U>Schedule 2.3</U></B>. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B></B>3.</TD>
<TD ALIGN="left" VALIGN="top"><B>CAPITAL AND SHARES </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Type of shares </U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In accordance with the New Articles, the Company&#146;s capital is
divided into the following types of shares (hereinafter collectively and individually referred to as the &#147;<B>Shares</B>&#148; and the &#147;<B>Share</B>&#148; respectively): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Common Shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class&nbsp;A Shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class B Shares; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Class C Shares. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">each Share with a nominal value of EUR 0.05. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;A Shares, the Class B Shares and Class C Shares will jointly also be referred to as the &#147;<B>Preferred Shares</B>&#148;).
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><U>Rights attached to the Shares.</U> Each Common Share shall entitle its holder to cast one vote. Each Preferred Share shall entitle the holder to
cast a number of votes equal to the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
number of Common Shares issuable upon conversion of such Preferred Share at the time of such vote. The Common Shares and the Preferred Shares shall have the rights as allocated to them in this
Agreement and the New Articles. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3<U></U></TD>
<TD ALIGN="left" VALIGN="top"><U>Special rights Preferred Shares</U>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Dividend rights</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Class C Shares shall have the dividend rights as set forth in the
New Articles, meaning in summary that the issued Class C Shares will carry an annual cumulative preferred profit entitlement of 8% of the amount paid on such Shares (nominal value plus share premium). Said rights attached to the Class C Shares are
at all times senior to any rights of the Class B Shares, Class&nbsp;A Shares and the Common Shares. After the Class C Shares have fully received the above cumulative preferred profit entitlement, the Class B Shares shall have the dividend rights as
set forth in the New Articles, meaning in summary that the issued Class B Shares will carry an annual cumulative preferred profit entitlement of 8% of the amount paid on such Shares (nominal value plus share premium). Said rights attached to the
Class B Shares are at all times senior to any rights of the Class&nbsp;A Shares and the Common Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">After the Class C Shares and Class
B Shares have fully received the above cumulative preferred profit entitlement, the Class C Shares and Class B Shares shall participate in any other dividend distributions with the Class&nbsp;A Shares and Common Shares on an as-if converted basis
(without any preferred dividend rights of the Class&nbsp;A Shares and the Common Shares). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, Parties acknowledge
that as per the date hereof, the Class&nbsp;A Shares and the Common Shares shall have no accumulated dividend rights in relation to past periods and waive any preferred dividend rights they may have under documentation in effect prior to the date
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">All profits allocated to the Class C Shares, the Class B Shares, the Class&nbsp;A Shares and the Common Shares will be credited on
separate profit reserves for such Shares. Without the prior written approval of the Preferred Supermajority (as defined below), no dividends will be paid on the Class&nbsp;A Shares and the Common Shares, so long as the Class C Shares and Class B
Shares are outstanding. Furthermore, no dividends will be distributed to the Shareholders unless in accordance with Clauses 3.3.2 and 4.2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Any of the foregoing dividends shall be payable (i)&nbsp;in cash, if and when declared by the Management Board, subject to the prior approval
of the Preferred Majority, (ii)&nbsp;in kind upon any Liquidation Event (being in Shares of the relevant class of Shares on which the dividends have accrued), or (iii)&nbsp;in kind upon the occurrence of a conversion of Preferred Shares into Common
Shares (except in case as a result of a Pay to Play). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Liquidation preference rights Preferred Shares</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">1. Class C Shares Liquidation Preference
Rights </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Exclusively upon the occurrence of any of the following events (each a &#147;<B>Liquidation Event</B>&#148;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">a liquidation, dissolution or the winding-up of the Company (&#147;<I>ontbinding</I>&#148;) or any other voluntary or involuntary dissolution of the Company; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">a merger or other event pursuant to which the Shareholders will have less than 50% of the total voting power of the surviving or acquiring company; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">a sale, lease transaction, transfer or other disposition of all Shares (including pursuant to the exercise of the drag-along right as referred to in Clause 6.5), or of all or substantially all of the Company&#146;s
assets, including, without limitation, the core intellectual property rights owned, co-owned or controlled by the Company, or the grant to a single third party of an exclusive (sub)license under such core intellectual property rights,
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">the holders of Class C Shares (the &#147;<B>C-Shareholders</B>&#148;) shall first be entitled to
receive in relation to each Class C Share an amount equal to the original issue price (which is the price per Share at which the relevant Tranche of Shares of the relevant class were originally issued, comprising of the formal nominal share capital
plus share premium paid per Share (hereinafter the &#147;<B>Original Issue Price</B>&#148;)), as adjusted proportionately for, stock dividends, stock splits, combinations, recapitalizations and similar events, as well as for any share issue pursuant
to the Anti-Dilution Protection described in Clause 3.3.4, if any, increased by the amount of any accrued or declared but unpaid dividends calculated from the date on which the payment has been made on the relevant Class C Shares until the date of
the Liquidation Event (whereby such dividend will be paid in accordance with Clause 3.3.1) (&#147;<B>Class C Liquidation Proceeds</B>&#148;), payable in proportion to the Class C Liquidation Proceeds each such Class C Share is otherwise entitled to
receive. For the avoidance of doubt, the Original Issue Price for the Class C Shares issued in the First Tranche shall be EUR 6.66&nbsp;per Share, and the Original Issue Price for the Class C Shares issued in the Second Tranche shall be EUR
7.65&nbsp;per Share, but in each case, could change in the future pursuant to adjustment for any recapitalization, stock split, stock dividend or the like (including Anti-Dilution Protection). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">For the above calculation, interim payments (e.g. dividends and share premium repayments) made by the Company to the <FONT
STYLE="white-space:nowrap">C-Shareholders</FONT> shall be taken into account and be deemed to already form part thereof, so that these should be subtracted. For the avoidance of doubt, it is hereby confirmed and agreed that the calculation of the
Class C Liquidation Proceeds shall be made separately for two Tranches of issue of the Class C Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The C-Shareholders hereby in
advance waive their right to any liquidation preference pursuant to this Clause 3.3.2 in the event that they, on an as-if-converted basis, would otherwise receive or have received, at the closing of such Liquidation Event or have received an amount
greater than (i)&nbsp;three (3)&nbsp;times the Original Issue Price per Share (as adjusted proportionately for, stock dividends, stock splits, combinations, recapitalizations and similar events, as well as for any share issue pursuant to the
Anti-Dilution Protection described in Clause 3.3.4, if any) plus (ii)&nbsp;any accrued or declared but unpaid dividends (together: the &#147;<B>C Cap</B>&#148;). For the sake of clarity, the C Cap thus increases each year with any accrued but unpaid
dividends. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If no sufficient proceeds are available to fully pay the Class C Liquidation Proceeds, the available proceeds shall be paid to
the C-Shareholders pro rata to the amounts that should have been paid if sufficient proceeds would be available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">2. Class B Shares
Liquidation Preference Rights </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">After full payment of the Class C Liquidation Proceeds in accordance with the procedure set forth in Clause
3.3.2.1, the holders of Class B Shares (the &#147;<B>B-Shareholders</B>&#148;) shall be entitled to receive in relation to each Class B Share an amount equal to (a)&nbsp;one and a half (1.5)&nbsp;times the Original Issue Price, as adjusted
proportionately for stock dividends, stock splits, combinations, recapitalizations and similar events, as well as for any share issue pursuant to the Anti-Dilution Protection described in Clause 3.3.4, if any, increased by an amount equal to one and
a half times (1.5)&nbsp;the amount of any accrued or declared but unpaid dividends calculated from the date on which the payment has been made on the relevant Class B Shares until the date of the Liquidation Event (whereby such dividend will be paid
in accordance with Clause 3.3.1) (&#147;<B>Class B Liquidation Proceeds</B>&#148;), payable in proportion to the Class B Liquidation Proceeds each such Class B Share is otherwise entitled to receive. For the avoidance of doubt, the Original Issue
Price for all of the Class B Shares (including, without limitation, any Class B Shares issued up to the date hereof pursuant to the Anti-Dilution Protection described in Clause 3.3.4) shall be EUR 5.64&nbsp;per share at the closing of the First
Tranche, but could change in the future subject to adjustment for any recapitalization, stock split, stock dividend or the like (including anti-dilution protection). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">For the above calculation, interim payments (e.g. dividends and share premium repayments) made by
the Company to the <FONT STYLE="white-space:nowrap">B-Shareholders</FONT> shall be taken into account and be deemed to already form part thereof, so that these should be subtracted. For the avoidance of doubt, it is hereby confirmed and agreed that
the calculation of the Class B Liquidation Proceeds shall be made separately for any (tranche of) issue of Class B Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The
B-Shareholders hereby in advance waive their right to any liquidation preference pursuant to this Clause 3.3.2 in the event that they, on an as-if-converted basis, would otherwise receive or have received an amount greater than (i)&nbsp;four
(4)&nbsp;times the Original Issue Price per Share (as adjusted proportionately for, stock dividends, stock splits, combinations, recapitalizations and similar events, as well as for any share issue pursuant to the Anti-Dilution Protection described
in Clause 3.3.4, if any) plus (ii)&nbsp;any accrued or declared but unpaid dividends (together: the &#147;<B>B Cap</B>&#148;). For the sake of clarity, the B Cap thus increases each year with any accrued but unpaid dividends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If no sufficient proceeds are available to fully pay the Class B Liquidation Proceeds after the Class C Liquidation Proceeds have been paid to
the C-Shareholders in accordance with the procedure set forth in Clause 3.3.2.1, the remaining available proceeds shall be paid to the B-Shareholders pro rata to the amounts that should have been paid if sufficient proceeds would be available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">3. Class&nbsp;A Liquidation Preference Rights </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">After full payment of the Class C Liquidation Proceeds and Class B Liquidation Proceeds in accordance with the procedures set forth in Clauses
3.3.2.1 and 3.3.2.2, the holders of Class&nbsp;A Shares (the &#147;<B>A-Shareholders</B>&#148;) shall be entitled to receive, in preference over the holders of Common Shares (the &#147;<B>Common-Shareholders</B>&#148;), from the remaining proceeds
(if any) an amount equal to one (1)&nbsp;time the Original Issue Price of the relevant Class&nbsp;A Shares, as adjusted proportionately for stock dividends, stock splits, combinations, recapitalizations and similar events (&#147;<B>Class A
Liquidation Proceeds</B>&#148;), payable in proportion to the Class&nbsp;A Liquidation Proceeds each such Class&nbsp;A Share is otherwise entitled to receive. For the avoidance of doubt, the Original Issue Price per share (as adjusted
proportionately for stock dividends, stock splits, combinations, recapitalizations and similar events) of (i)&nbsp;the 47,334 Class&nbsp;A Shares held by Aglaia shall be deemed to be EUR 7.50, (ii)&nbsp;the 36,496 Class&nbsp;A Shares held by
BioPhrase shall be deemed to be EUR 2.74, and (iii)&nbsp;the 328,466 Class&nbsp;A Shares held by Aglaia Seed shall be deemed to be EUR 2.74. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The A-Shareholders hereby in advance waive their right to any liquidation preference pursuant to this Clause 3.3.2 in the event that they, on
an as-if-converted basis, would otherwise receive or have received an amount greater than four (4)&nbsp;times the Original Issue Price per Share, as adjusted proportionately for, stock dividends, stock splits, combinations, recapitalizations and
similar events (the &#147;<B>A Cap</B>&#148;). For the sake of clarity, the A Cap is a fixed amount that in contrast with the C Cap or B Cap is not subject to any possible increase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If no sufficient proceeds are available to fully pay the Class&nbsp;A Liquidation Proceeds, the remaining available proceeds shall be paid to
the A-Shareholders pro rata to the amounts that should have been paid if sufficient proceeds would be available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">4. Remaining Liquidation
Proceeds </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">After full payment of the Class C Liquidation Proceeds, Class B Liquidation Proceeds and Class&nbsp;A Liquidation Proceeds, the
Class C Shares, the Class B Shares and the Class&nbsp;A Shares shall participate with the Common Shares on an as-if-converted basis in the remaining liquidation proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3.3</TD>
<TD ALIGN="left" VALIGN="top">Conversion rights </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>1. Conversion events</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The issued Preferred Shares (together with any accrued but unpaid dividends) are convertible into Common Shares only. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Conversion may voluntarily occur at any time at the option of the Shareholder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Conversion of the Preferred Shares (together with any accrued and unpaid dividends) shall mandatorily and automatically occur with regard to
all the issued Preferred Shares, in any of the following events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">in the event of an underwritten public offering of the Common Shares on the NASDAQ Global Market, the NASDAQ Capital Market or the New York Stock Exchange with minimum aggregate proceeds to the Company of at least USD
50,000,000 at a price per Common Share not less than one and a half (1.5)&nbsp;times the Original Issue Price of the Class C Shares in relation the First Tranche or, if the Second Tranche has been consummated, the Original Issue Price of Class C
Shares in relation to the Second Tranche, as adjusted proportionately for (a)&nbsp;stock dividends, stock splits, combinations, recapitalizations and similar events, and (b)&nbsp;any share issue pursuant to the Anti-Dilution Protection described in
Clause 3.3.4, (&#147;<B>Qualifying IPO</B>&#148;); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the date upon which the Company obtains the vote or written consent of holders of at least 70% of the Preferred Shares, voting together as a single class (such approval being the &#147;<B>Preferred Majority</B>&#148;),
which approval must also include the vote of either Sofinnova or Novo (together with the Preferred Majority, the &#147;<B>Preferred Supermajority</B>&#148;), to convert all (and not fewer than all) of the Preferred Shares into Common Shares and the
Parties acknowledge that the conversion may also occur through a contribution in kind in the capital of a new company upon issuance of new shares in the new company, for example, for the effectuation of an underwritten public offering of the Common
Shares (an &#147;<B>IPO</B>&#148;). </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In addition, conversion of all Preferred Shares held by a Shareholder that does not fund
its respective commitment set forth for such Shareholder in the table in Clause 1.1 of the Subscription Agreement under the heading &#147;Tranche 2&#148; when approved by the Investor Majority (as defined in and in accordance with the Subscription
Agreement) shall mandatorily occur pursuant and in accordance with Clause 3.5 of the Subscription Agreement, such that all Preferred Shares held by such Shareholder shall convert into Common Shares in a ratio of one (1)&nbsp;Common Share for each
five (5)&nbsp;Preferred Shares. For example, to effectuate the foregoing, such Shareholder shall be obliged to transfer the Shares to which such Shareholder is no longer entitled to the Company for no consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>2. (Adjustment of) Conversion Rate</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The conversion shall take place at a rate (the &#147;<B>Conversion Rate</B>&#148;) calculated by dividing the Original Issue Price of the
relevant Preferred Shares by the applicable conversion price (the &#147;<B>Conversion Price</B>&#148;). The Conversion Price shall be equal to the Original Issue Price of the relevant Preferred Shares, subject, however, to an adjustment in the
following events: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any subdivision (stock split) or combination of Shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any distribution by the Company of a dividend in Shares to Shareholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all other events that are similar to the above events; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in relation to the Class C Shares and the Class B Shares, in case the adjustment of the Conversion Price in connection with the Anti-Dilution Protection (set forth in the Clause 3.3.4 below) applies. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, as of the date hereof, (i)&nbsp;the Conversion Price for all of the Class&nbsp;A Shares shall be equal to the
Original Issue Price for such Shares as described in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Clause 3.3.2.3 hereof, (ii)&nbsp;the Conversion Price for all of the Class B Shares (including,
without limitation, any Class B Shares issued up to the date hereof pursuant to the Anti-Dilution Protection described in Clause 3.3.4) shall be EUR 5.64&nbsp;per Share, (iii)&nbsp;the Conversion Price for the Class C Shares issued in the First
Tranche shall be EUR 6.66&nbsp;per Share, (iv)&nbsp;the Conversion Price for the Class C Shares issued in the Second Tranche shall be EUR 7.65 and no Conversion Price shall be adjusted as a result of any of the transactions contemplated by the
Subscription Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If pursuant to an adjustment of the Conversion Price, a Shareholder is entitled to more Shares than originally
held by such Shareholder and the reserves of the Company are not sufficient to fully pay up the additional Shares, the Shareholders shall effectuate a transfer of Shares among them in order to achieve the correct percentages of ownership.
Furthermore, the Shareholders shall effectuate an amendment of the New Articles to the extent that such amendment should be required in order to create sufficient Shares as needed for the issue of the additional Shares. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3.4</TD>
<TD ALIGN="left" VALIGN="top"><U>Anti-dilution protection </U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>1. General provisions</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; margin-right:2%; font-size:10pt; font-family:Times New Roman">The C-Shareholders and B-Shareholders shall be protected against dilution of their shareholding in the Company on a full
ratchet basis (&#147;<B>Anti-Dilution Protection</B>&#148;), such that in the event the Company issues additional shares or options or securities which are convertible into Shares against a price (the &#147;<B>Dilutive Price</B>&#148;) which is less
than the applicable Original Issue Price of the Class C Shares and Class B Shares respectively issued in the relevant tranche or created pursuant to a particular conversion event, or, if applicable, the then valid Conversion Price of the relevant
Preferred Shares, the <FONT STYLE="white-space:nowrap">C-Shareholders</FONT> and/or B-Shareholders, as the case may be, shall be irrevocably entitled to a full ratchet anti-dilution scheme, reducing the Conversion Price of the relevant Class to the
price at which the new shares are (to be) issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; margin-right:2%; font-size:10pt; font-family:Times New Roman">Instead of adjusting the Conversion Price, the majority of the Class C
Meeting and/or Class B Meeting, as the case may be, participating in the dilutive issuance may decide to cause the Company (and all Shareholders will co-operate in such issuance) to issue, to all C-Shareholders and/or B-Shareholders, as the case may
be, participating in the dilutive issuance, additional Shares of the same class as to which the Anti-Dilution Protection applies (with exclusion of any pre-emptive rights of all other Shareholders), to the extent that the Company is lawfully able to
do so. The issue to the <FONT STYLE="white-space:nowrap">C-Shareholders</FONT> and/or B-Shareholders shall occur by way of capitalization of the Company&#146;s relevant share premium account or otherwise in accordance with all applicable laws and in
a manner approved by the majority of the Class C Meeting and/or Class B Meeting, of such number of additional Shares of the relevant class, creating a similar anti-dilution protection as pursuant to adjustment of the Conversion Price (and the
Original Issue Price and the Conversion Price of the applicable class of Shares will be appropriately adjusted). If the reserves of the Company are not sufficient to fully pay up the additional Shares to which the C-Shareholders and/or
B-Shareholders are entitled, the Shareholders shall effectuate a transfer of Shares among them in order to achieve the correct percentages of ownership. Furthermore, the Shareholders shall effectuate an amendment of the New Articles to the extent
that such amendment should be required in order to create sufficient Shares as needed for the share issue. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>2. Exemptions</U>. The
Anti-Dilution Protection will not apply in the event of issuance of (i)&nbsp;securities issuable upon conversion of any of the Preferred Shares, or as a dividend or distribution on the Preferred Shares; (ii)&nbsp;Shares issuable upon a stock split,
stock dividend, or any subdivision of Shares; (iii)&nbsp;Common Shares (or options to purchase Common Shares) issued or issuable to employees or directors of, or consultants to, the Company pursuant to the ESOP (as referred to in Clause 11);
(iv)&nbsp;no more than 10,000 Common Shares (or options to purchase Common Shares) issued to a financial institution in connection with equipment financing arrangements approved by Requisite Board Approval (as defined below); and (v)&nbsp;Common
Shares (or options to purchase Common Shares) issued in connection with entering into acquisitions approved by Requisite Board Approval (the &#147;<B>Excluded Securities</B>&#148;). For purposes of this Agreement, &#147;<B>Requisite Board
Approval</B>&#148; shall mean the votes of at least six (6)&nbsp;Supervisory Directors at such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">
time as there are nine (9)&nbsp;Supervisory Directors and also the votes of at least five (5)&nbsp;Supervisory Directors, including at least one (1)&nbsp;Supervisory Director who is appointed by
the Class A/B Meeting and one (1)&nbsp;Supervisory Director who is appointed by the Class C Meeting, at such time as there are eight (8)&nbsp;Supervisory Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>3. Pay to Play.</U> In order to benefit from the Anti-Dilution Protection and if and to the extent Shares are made available for
subscription by the C-Shareholders and/or B-Shareholders, such C-Shareholders and/or B-Shareholders are required to participate in any dilutive issuance to which the Anti-Dilution Protection applies in an amount equal to the amount made available
for subscription by the C-Shareholder and/or B-Shareholders multiplied by a fraction, the numerator of which is the number of Class C Shares and/or Class B Shares held by such Shareholder that would benefit from the Anti-Dilution Protection and the
denominator of which is all of the Preferred Shares of the Company. In the event and to the extent that a <FONT STYLE="white-space:nowrap">C-Shareholder</FONT> and/or B-Shareholder fails to participate in accordance with the previous sentence, the
Class C Shares and/or Class B Shares held by such Shareholder will automatically and proportionally, lose their Anti-Dilution Protection with respect to such dilutive issuance. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.3.5</TD>
<TD ALIGN="left" VALIGN="top"><U>Redemption rights. </U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">None of the Shareholders will have redemption rights. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B></B>4.</TD>
<TD ALIGN="left" VALIGN="top"><B>USE OF PROCEEDS. DIVIDEND POLICY </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Use of proceeds.</U> The Company will apply the net proceeds of the issue of Class C Shares in accordance with the Business Plan, attached hereto as <U><B>Schedule 4.1</B>. </U> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Dividend policy.</U> The Parties acknowledge that the Company may only distribute profits to the Shareholders provided that the Company has distributable reserves available for distribution in accordance with article
2:216 of the Netherlands Civil Code and if such distribution is consistent with the Company&#146;s funding needs reflected in the Business Plan, as applicable at that time. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><I>Note: This means that no distributions will be made that would require the Company to make use of the Second Tranche due to lack of
sufficient financial means. </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top">Except with respect to the cumulative preferred profit entitlement, which shall follow the provisions of the New Articles, distributions from equity may only be made pursuant to a resolution by the General Meeting, with
the prior written approval of (a)&nbsp;the Preferred Majority (in absence of which approval no distributions may be made), and (b)&nbsp;the Management Board (in accordance with article 2:216 sub 2 of the Netherlands Civil Code). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top">Nothing in this Article 4 shall diminish the rights of the C-Shareholders and B-Shareholders to cumulative dividends as described in Article 3.3.1 and the New Articles. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"><B>ISSUE OF SHARES. PRE-EMPTIVE RIGHTS</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Issue of Shares</U>. Without prejudice to Clause 5.2, the Company shall only issue Shares if such issuance is consistent with the Company&#146;s funding needs reflected in the Business Plan, as applicable at that
time. Any issue of Shares shall occur pursuant to a resolution by the General Meeting adopted with a simple majority of the votes cast in the meeting, provided that such resolution shall require the prior written approval of the Preferred Majority,
and sets outs in reasonable details the reasons for the Share issue, including the anticipated future cash needs of the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Pre-emptive rights.</U> Without prejudice to the Anti-Dilution Protection, upon the issue of new Shares each holder of Preferred Shares shall have the right to participate in any issuance of Shares or other equity
securities or securities convertible into or exercisable or exchangeable for, equity securities (the &#147;<B>Equity Securities</B>&#148;), except for Excluded Securities, up to that amount equal to such holder&#146;s pro rata ownership of Preferred
Shares of the Company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Company shall give written notice of the proposed issuance of Equity Securities to each
Preferred Shareholder not later than twenty-five (25)&nbsp;days prior to such intended issuance. Such notice shall contain all material terms and conditions of the issuance and of the Equity Securities. Each Preferred Shareholder may elect to
exercise all or any portion of its rights under this Clause 5 by giving written notice to the Company within twelve (12)&nbsp;days after the Company&#146;s notice. If the consideration paid by others for the Equity Securities is not cash, the value
of the consideration shall be determined in good faith by the Supervisory Board, and any electing Preferred Shareholder that cannot for any reason pay for the Equity Securities in the form of non-cash consideration may pay the cash equivalent
thereof, as determined by the Supervisory Board. All payments shall be delivered by electing Preferred Shareholders to the Company not later than the date specified by the Company in its notice. Each Preferred Shareholder shall have a right of
overallotment such that, if any other Preferred Shareholder fails to exercise the right to purchase its full portion of the Equity Securities in accordance with this Clause 5. The Company shall give written notice thereof to the other participating
Preferred Shareholder within two (2)&nbsp;days following the expiration of the twelve (12)&nbsp;days period set forth above and such other participating Preferred Shareholders may, within five (5)&nbsp;days following the date of the Company&#146;s
written notice, exercise an additional right to purchase, on a pro rata basis, the Equity Securities not previously purchased by so notifying the Company, in writing, within five (5)&nbsp;day period. Each Preferred Shareholder shall be entitled to
apportion Equity Securities to be purchased among its partners and affiliates, provided that such Preferred Shareholder notifies the Company of such allocation. The portion of the Equity Securities that is not purchased by the Preferred Shareholders
may be offered to other third parties on terms no less favorable to the Company for a period of three (3)&nbsp;days thereafter. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B></B>6.</TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSFER OF SHARES </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Restrictions in general</U>. No Party shall transfer any Shares in a manner inconsistent with this Agreement. A Share transfer is only permitted if the party that acquires the Shares agrees to be bound by this
Agreement, and any related agreements referred to herein, if applicable, and agrees to fulfill all obligations of the transferor in that respect, as its own. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Permitted transfers</U>. Without prejudice to any other rights under this Agreement, any Shareholder may transfer all of its Shares to one of its wholly owned subsidiaries, and any Shareholder may transfer all of its
Shares to a (direct or indirect) wholly owned subsidiary of any Shareholder&#146;s ultimate parent company, provided, however, that a Shareholder may not transfer any Shares to (designated holding companies for specific) portfolio companies. If a
Shareholder is the personal holding company, all Shares held by such Shareholder or all Shares in such Shareholder may be transferred to another, successive, personal holding company. In addition, BioPhrase is entitled to transfer all or part of its
Shares to its sole managing director and sole shareholder Logtenberg and vice versa. In case of a transfer permitted under the previous sentences, the transferring Shareholder shall cause the transferee to accede to this Agreement and to assume any
and all obligations and liabilities of the transferring Shareholder under this Agreement. The transferring Shareholder shall remain jointly and severally liable with the transferee, provided that at the request of the transferring Shareholder the
other Shareholders agree to waive the benefit of said joint and several liability, which waiver shall not be unreasonably withheld if the transferee has a sustainable financial capability at least equal to that of the transferring Shareholder.
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In addition, each of the Preferred Shareholders that is an investment fund or a fund manager, shall be entitled to transfer
(some or all of) its Shares to a fund or entity that is under the same (ultimate) management as itself (it being understood that LSP is under the management of LSP IV Management B.V., BCC is under the management of Bay City Capital Management V LLC
and Bay City Capital LLC, and Aglaia and Aglaia Seed are under the management of Aglaia BioMedical Ventures B.V.). In case of a transfer permitted under the previous sentence, the transferor shall cause the transferee to accede to this Agreement and
to assume any and all obligations and liabilities of the transferring Shareholder under this Agreement (or in case of a partial transfer, a proportionate part of the obligations and liabilities). Upon the accession by the transferee, the transferor
shall be released from its liabilities assumed by the transferee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary herein, a Preferred Shareholder may transfer all of its
Shares (A)&nbsp;to its current and/or former partners, current and/or former members, and current and/or former shareholders, (B)&nbsp;an individual transferring to such Shareholder&#146;s family member or trust for the benefit of an individual
Shareholder, or (C)&nbsp;to an &#147;affiliate&#148; of such Shareholder; provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if he were an original Shareholder
hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; margin-right:2%; font-size:10pt; font-family:Times New Roman">If Shares are transferred in accordance with this Clause 6.2, none of the Right of First Refusal, the Right of
Co-Sale, <FONT STYLE="white-space:nowrap">Tag-along</FONT> Right or Drag-along Right shall apply to such permitted transfer. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"><U>Right of First Refusal.</U> If at any time a Shareholder (&#147;<B>Proposed Seller</B>&#148;) shall have identified a bona fide third party (&#147;<B>Proposed Purchaser</B>&#148;) who has proposed in writing to
purchase and acquire Shares held by the Proposed Seller (&#147;<B>Offered Shares</B>&#148;), the Proposed Seller shall give notice in writing (&#147;<B>Sale Notice</B>&#148;) to the Company and the Shareholders (&#147;<B>the Offerees</B>&#148;),
specifying: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">the name of the Proposed Purchaser; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">the number of Offered Shares; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">the price and all other economic relevant terms and conditions of the proposed disposal of the Offered Shares to the Proposed Purchaser, and if any, related parties thereof (e.g. kickback or placement fees).
</TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Sale Notice shall constitute an offer to the Offerees, to purchase the Offered Shares (the &#147;<B>Offer</B>&#148;).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Upon receipt of the Sale Notice, the Offerees in the aggregate shall have the right to purchase all (and not fewer than all) of the
Offered Shares at the price and on the other terms and conditions set out in the Sale Notice (the &#147;<B>Right of First Refusal</B>&#148;), by serving a notice to the Proposed Seller, with a copy to the Company and all Preferred Shareholders
(&#147;<B>Exercise Notice</B>&#148;). A qualified acceptance of the Offer, or a failure by the Offerees to timely accept the Offer, shall be deemed a rejection of the Offer. The procedure in relation to the Offer is set out below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If the Company or any of the Preferred Shareholders wish to purchase some or all of the Offered Shares, it shall within a period of twenty-one
(21)&nbsp;days following the date of receipt of the Sale Notice send its Exercise Notice, stating the aggregate maximum number of Shares it wishes to purchase, it being understood, however, that the Company shall have the first right to purchase the
Offered Shares. If any Offered Shares remain that the Company is not interested in purchasing, such remaining Offered Shares shall be allocated to the accepting Preferred Shareholders (and among them in proportion to the number of Preferred Shares
held by them). An accepting Preferred Shareholder cannot be allocated more Shares than he wished to purchase in accordance with his Exercise Notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If the Company and the Preferred Shareholders in the aggregate have served Exercise Notices in relation to fewer than all Offered Shares, each
Preferred Shareholder (and among them in proportion to the number of Preferred Shares held by them) shall have the right to purchase the Offered Shares for which no Exercise Notices have been received (the &#147;<B>Remaining Shares</B>&#148;) by
serving an Exercise Notice within a fourteen (14)&nbsp;days&#146; period following lapse of the previously mentioned twenty-one (21)&nbsp;days&#146; period, stating the number of Remaining Shares he wishes to purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In case the relevant Preferred Shareholders in the aggregate wish to purchase all Remaining Shares, the receipt of the Exercise Notices shall
constitute a binding agreement between the Proposed Seller and each of the accepting Offerees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If the relevant Preferred Shareholders in
the aggregate wish to purchase more than the number of Remaining Shares, the Remaining Shares shall be allocated among them in proportion to the number of Preferred Shares held by them, provided always, however, that an accepting Preferred
Shareholder cannot be allocated more Shares than he wished to purchase in accordance with his Exercise Notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If pursuant to the above the Company and the Preferred Shareholders in the aggregate have served
Exercise Notices in relation to fewer than all Remaining Shares within the fourteen (14)&nbsp;days&#146; period, each of the Offerees other than the Company and the Preferred Shareholders shall have the right to purchase the Remaining Shares for
which no Exercise Notices from the Company or the Preferred Shareholders have been received by serving an Exercise Notice within a seven (7)&nbsp;days&#146; period following lapse of the previously mentioned fourteen (14)&nbsp;days&#146; period,
stating the number of available Remaining Shares it wishes to purchase, provided however, that if the relevant Offerees in the aggregate wish to purchase more than the number of such available Remaining Shares, such available Remaining Shares shall
be allocated among them in proportion to the number of Shares held by them, and provided that an accepting Offeree cannot be allocated more Shares than he wished to purchase in accordance with his Exercise Notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If pursuant to the above, the Offerees have submitted Exercise Notices in relation to all and not fewer than all of the Offered Shares, the
transfer of the Offered Shares to the accepting Offerees shall take place no later than twenty-one (21)&nbsp;days from the final date on which acceptance notices may be sent and the requested approval as mentioned in article 13 of the New Articles
shall be given by the Preferred Majority. In such event, the Tag-along Right (as defined below) shall not apply. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If pursuant to the above,
the Offerees have not, or not timely, submitted Exercise Notices in relation to all and not fewer than all of the Offered Shares, the Right of First Refusal and all Exercise Notices shall lapse and become void. In such event, the Proposed Seller
shall be free to transfer the Offered Shares to the Proposed Purchaser at the price and on the terms and conditions set out in the Sale Notice, subject, however, to the Tag-along Right. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"><U>Rights of Co-Sale and Tag along rights.</U> If the Company and the other Shareholders decline to exercise any rights of first refusal in accordance with Clause 6.3, the Proposed Seller shall deliver to the Preferred
Shareholders at least twenty (20)&nbsp;days prior to the closing of such proposed sale written notice (the &#147;<B>Co-Sale Notice</B>&#148;) of the terms and conditions of the offer, including the purchase price and material terms and the identity
of the third-party offeror (such information being identical to the information provided in the Sale Notice), and then the Preferred Shareholders shall have the right, exercisable by written notice to the Proposed Seller within fifteen
(15)&nbsp;days after receipt of the Co-Sale Notice, to participate in such sale of Shares on the same terms and conditions and as set forth in this Clause 6.4. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Each Preferred Shareholder may sell all or any part of that number of Shares equal to the product obtained by multiplying (i)&nbsp;the
aggregate number of Shares covered by the Co-Sale Notice by (ii)&nbsp;a fraction, the numerator of which is the number of Common Shares issuable upon conversion of Preferred Shares owned by the Preferred Shareholder at the time of the Co-Sale Notice
and the denominator of which is the sum of (X)&nbsp;the number of Shares owned by the Proposed Seller and (Y)&nbsp;the number of Common Shares issuable upon conversion of Preferred Shares owned by all Preferred Shareholders at the time of the
Co-Sale Notice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Preferred Shareholders shall effect their participation in the sale by procuring all necessary (legal) actions,
including but not limited to promptly delivering to the Proposed Seller, a written notice including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">the number of Common Shares that the Preferred Shareholder elects to sell; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">that number of Preferred Shares that is at such time convertible into the number of Common Shares that the Preferred Shareholder elects to sell; provided, however, that if the Proposed Purchaser objects to the delivery
of Preferred Shares in lieu of Common Shares, the Preferred Shareholder shall convert such Preferred Shares into Common Shares and deliver Common Shares as provided in clause (a)&nbsp;above. The Company agrees to make any such conversion concurrent
with the actual transfer of such shares to the Proposed Purchaser. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Shares that the Preferred Shareholder wishes to sell pursuant to this Clause 6.4 shall be
sold and transferred to the Proposed Purchaser upon the consummation of the sale of the Shares pursuant to the terms and conditions specified in the <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Notice, and the Proposed Seller shall concurrently
therewith remit to the Preferred Shareholder that portion of the sale proceeds to which the Preferred Shareholder is entitled by reason of its participation in such sale. To the extent that any Proposed Purchaser prohibits such assignment or
otherwise refuses to purchase Shares or other securities from the Preferred Shareholder exercising its right of co-sale hereunder, the Proposed Seller shall not sell to such Proposed Purchaser any Shares unless and until, simultaneously with such
sale, the Proposed Seller shall purchase such Shares or other securities from the Preferred Shareholder for the same purchase price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The
exercise or non-exercise of the right of the Preferred Shareholders hereunder to participate in one or more sales of Shares made by a Proposed Seller shall not adversely affect its right to participate in subsequent sales of Shares subject to Clause
6.4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If any Preferred Shareholder (the &#147;<B>Selling Holder</B>&#148;) proposes to transfer equity securities representing 25% or more
of the outstanding capital of the Company to, other than the permitted transfers pursuant to Clause 6.2, an unaffiliated purchaser or purchasers in a single transaction or a series of transactions, each other holder of Preferred Shares shall have
the right to require the purchase of their share capital of the Company (pro rata on an as-if-converted to Common Shares basis) by such purchaser(s), such sale to be on the same terms and conditions applicable, and for the same type and amount of
consideration payable, to the Selling Holder on a pro rata basis (&#147;<B>Tag-along Right</B>&#148;). This Tag-along Right is not applicable to any Liquidation Event and shall terminate upon the completion of a Qualifying IPO. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If a Preferred Shareholder wishes to exercise its Tag-along Right, it shall serve on the Proposed Seller and the Proposed Purchaser a written
notice (the &#147;<B>Tag-along Notice</B>&#148;) within ten (10)&nbsp;business days from the date that the Right of First Refusal has been fully observed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If a Preferred Shareholder has failed to serve its Tag-along Notice within said ten (10)&nbsp;business days&#146; period, it shall be deemed to
have waived its Tag-along Right. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"><U>Drag-along Right</U>. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.5.1</TD>
<TD ALIGN="left" VALIGN="top">In the event that the C-Shareholders would receive at the closing of such Liquidation Event (i)&nbsp;less than two and a half times on their investment in Class C Shares or two and a half times or more on their
investment in Class C Shares other than in cash and/or freely-tradable securities, the Preferred Supermajority, or (ii)&nbsp;two and a half times or more on their investment in Class C Shares in cash and/or freely-tradable securities, the Preferred
Majority votes in favor of any Liquidation Event, then all then outstanding voting shares shall vote in favor of any such Liquidation Event and shall further comply with the following provisions (the &#147;<B>Drag Along Right</B>&#148;):
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">If the Liquidation Event is structured as a merger or consolidation of the Company or a sale of all or substantially all of the Company&#146;s assets, then each Shareholder shall take all actions necessary to approve
the Liquidation Event and cause the Liquidation Event to be consummated including, but not limited to: (i)&nbsp;voting all shares then beneficially held by such Shareholder in favor of the Liquidation Event at any meeting of the Company&#146;s
Shareholders called to vote on the Liquidation Event or, in the alternative, approve the Liquidation Event by written consent of the Company&#146;s Shareholders and raise no objections to the Liquidation Event or the process pursuant to which the
Liquidation Event was arranged, (ii)&nbsp;waiving any dissenters&#146; rights, appraisal rights or similar rights in connection with such Liquidation Event, if applicable, and (c)&nbsp;taking all other necessary and desirable actions reasonably
requested by the C-Shareholders to cause the Liquidation Event to be consummated; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">In the event that the Liquidation Event involves a sale of securities, then, at the closing of the Liquidation Event, against payment of the purchase price for the securities to be sold by the Shareholder, each
Shareholder shall transfer to the third party purchaser the Shares held by such Shareholder, free and clear of all liens, claims and encumbrances, together with all other documents which are necessary to effect such Liquidation Event.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.5.2</TD>
<TD ALIGN="left" VALIGN="top">Notwithstanding the foregoing, the Shareholders will not be required to comply with this Clause 6.5 in connection with any proposed Liquidation Event (a &#147;<B>Proposed Liquidation Event</B>&#148;) unless:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">the liability for indemnification, if any, of such Shareholder in the Proposed Liquidation Event and for the inaccuracy of any representations and warranties made by the Company in connection with such Proposed
Liquidation Event, is several and not joint with any other person (other than a joint escrow on a pro rata basis); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">liability shall be limited to such Shareholder&#146;s applicable share (determined based on the respective proceeds payable to each Shareholder in connection with such Proposed Liquidation Event) of any claim; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">upon the consummation of the Proposed Liquidation Event, the aggregate consideration receivable by all Shareholders shall be allocated among the holders of Preferred Shares and Common Shares on the basis of the relative
liquidation preferences to which the holders of each respective series of Preferred Shares and the holders of Common Shares are entitled in a Liquidation Event. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">To secure the obligations to vote the Shares in accordance with the provisions of this Clause 6.5, the Shareholders hereby appoint the then
current Chief Executive Officer of the Company and a designee of the C-Shareholders as their respective true and lawful proxy and attorney-in-fact, with full power of substitution, to vote all of their respective Shares in favor of such Liquidation
Event and all such other matters as provided for in this Clause 6.5, but only to the extent provided herein. The then current Chief Executive Officer of the Company and any designee of the C-Shareholders may exercise the irrevocable proxy granted to
them hereunder, in their sole discretion, at any time any Shareholder fails to comply with the provisions of this Clause 6.5. The proxies and powers granted pursuant to this Clause 6.5 are coupled with an interest and are given to secure the
performance of each of the obligations of the Shareholders hereunder. Such proxies and powers shall be irrevocable for the term of this Agreement and shall survive the death, incompetency, disability, bankruptcy or dissolution of such Shareholder
and bind the subsequent holders of such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Founders and key managers of the Company shall enter into an agreement to the effect
of this Clause 6.5 and a similar provision shall be added to the ESOP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If the Drag Along Right is exercised, a notice shall be served to
the Company (the &#147;<B>Drag Along Notice</B>&#148;), specifying the name of the Proposed Purchaser and the price and other terms and conditions of the proposed transaction. The Company shall inform the other Shareholders of the Drag Along Notice
and its contents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Each of the dragged Shareholders shall, for the benefit of each of the non-defaulting Shareholders, forfeit a directly
due and payable penalty &#150; provided that a prior notice of default is sent stating a period to remedy the default of at least three business days &#150; in the amount of EUR 50,000 (fifty thousand Euro) for any violation of the obligations, set
out in this Clause 6.5 by it and/or any of the persons or legal entities it is liable for as well as a penalty in the amount of EUR 10,000 (ten thousand Euro) for each day that the violation continues, without prejudice to the right of each of the
Shareholders to claim performance of this Agreement and/or its actual damages under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"><U>Transfer of Shares and New Articles</U>. The Shareholders shall at all times exercise their voting rights with respect to their Shares and shall at all times exercise or waive any other rights under the New Articles
in such manner as to give full effect to this Clause 6. Pursuant to the foregoing, the Preferred Shareholders shall apply the transfer restrictions contained in the New Articles (approval by the Preferred Majority) in a way consistent with and
giving effect to this Clause 6. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><I>If for example, a transfer qualifies as a Permitted Transfer, the Preferred Majority
shall approve the transfer to the permitted transferee and the Right of First Refusal, Tag-Along Right and Drag-Along Right are not applicable. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman"><I>If for example, an Exercise Notice has not been served, the Preferred Majority shall approve the transfer of the Offered Shares to the
Proposed Purchaser in accordance with the Sale Notice; if, however, Exercise Notices in relation to the Offered Shares has been served, the Preferred Majority shall approve the transfer of the Offered Shares to the Offerees in accordance with the
Exercise Notices and at the same time shall resolve not to approve the sale to the Proposed Purchaser and shall simultaneously inform the Proposed Seller that the Offered Shares shall be sold and transferred to the Offerees in accordance with the
Offer, and the Proposed Seller shall waive any right to have the value of the Offered Shares determined by independent experts. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Any
transfer of Shares permitted under this Agreement shall be formalized by means of a notarial transfer deed, in accordance with Dutch law and the New Articles. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.7</TD>
<TD ALIGN="left" VALIGN="top"><U>Transfer of shares in personal holding companies.</U> Without prejudice to a Permitted transfer in accordance with Clause 6.2, the Parties acknowledge that for the purposes of this Clause 6, the relevant incorporator
/ shareholder of BioPhrase shall be deemed to be a shareholder of the Company, in such manner that in case any of these persons (the &#147;<B>Indirect Shareholders</B>&#148;) wishes to transfer his or her shares or indirect interest in his/her
relevant personal holding company, respectively, each of the other Shareholders may require the relevant direct Shareholder of the Company (the relevant personal holding company) to offer for sale such number of Shares that corresponds to the
percentage of the issued share capital of the relevant personal holding company that is being transferred, and provided further that in case more than 50% of the shares in the personal holding company, whether pursuant to one transaction or a series
of transactions, shall be held by other persons than the present Indirect Shareholder(s), the relevant direct Shareholder shall be under the obligation to offer all his Shares to the other Shareholders. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Any offer of Shares pursuant to the above shall occur in accordance with Clause 6.3 (Right of First Refusal). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Parties acknowledge that in the event of a permitted transfer as described in Clause 6.2, this Clause 6.7 shall not apply; in such case
this Clause 6.7 shall apply to the successive personal holding company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>If for example, Logtenberg wishes to transfer 30% of his
shares in BioPhrase, any of the Shareholders may require BioPhrase to offer 30% of its Shares for sale to the other Shareholders, provided, however, that in case Logtenberg wishes to transfer 51% of his shares in BioPhrase, BioPhrase may be required
to offer all its Shares for sale. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In addition, the Tag-along Right shall apply mutatis mutandis, such that the relevant purchaser may
be required to purchase a pro rata number of Shares from the other Shareholders. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"><B>MANAGEMENT BOARD</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Management Board. Number of Managing Directors</U>. The management of the Company shall be entrusted to the Management Board consisting of one or more Managing Directors. The Company shall be represented by two
(2)&nbsp;Managing Directors acting jointly. The Management Board shall be constituted and regulated in accordance with articles 14 up to and including 21 of the New Articles. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Parties acknowledge that as per the date hereof the Management Board shall consist of the
following Managing Directors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;T. Logtenberg (CEO); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ms.&nbsp;S.J. Margetson (CFO). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Appointment of the Managing Directors</U>. The General Meeting, upon a non-binding recommendation by the Supervisory Board as set forth in article 15 of the New Articles, shall appoint the Managing Directors.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"><U>Term.</U> The Managing Directors shall be appointed for an indefinite period, unless the General Meeting resolves otherwise. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"><U>Remuneration</U>. The Supervisory Board shall determine the remuneration of the Managing Directors. The Managing Directors shall be entitled to be paid or reimbursed for their reasonable expenses incurred in the
discharge of their duties as Managing Directors, subject to production of all necessary vouchers and receipts. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"><U>Decision making</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Voting at Management Board meetings</U>. At each meeting of the
Management Board and in respect of each resolution proposed to the Management Board at a meeting of the Management Board each Managing Director shall have one (1)&nbsp;vote. All resolutions of the Management Board at a meeting of the Management
Board shall be passed by an absolute majority of the votes cast, unless this Agreement and/or the New Articles require a greater majority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Tie in votes</U>. In the case of an equality of votes at any meeting of the Management Board in relation to a proposal on a matter requiring
the absolute majority of the votes, each Managing Director shall be authorized to refer the matter to the Supervisory Board. The relevant proposal shall be deemed adopted in case the Supervisory Board adopts a resolution to that effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Resolutions without holding a meeting</U>. The Management Board may adopt resolutions without holding a meeting of the Management Board,
provided that such resolutions shall only be validly passed if the text of the resolution has been signed by all Managing Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Further rules and regulations</U>. Subject to the prior written approval from the Supervisory Board, the Management Board may adopt further
rules and regulations as to its decision making process, which rules and regulations may, without limitation, regard the frequency and location of meetings and the notice period. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"><U>Approvals by the Supervisory Board</U>. Any resolution by the Management Board with respect to the matters described below or any other matters the Supervisory Board deems necessary in its own discretion and put in
writing and informing the Management Board thereof (the &#147;<B>Supervisory Board Approval Matters</B>&#148;) shall require Requisite Board Approval, in the absence of which approval no action shall be made to carry out such resolution:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">make any loan or advance to any person, including, any employee or director, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by
the Supervisory Board; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">enter into or permit any guarantee or indemnity or otherwise commit the Company in respect of the payment of money, or the performance of any contract by any other person (other than in the ordinary course of business);
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">incur any aggregate indebtedness in excess of &#128;50,000 that is not already included in a Supervisory Board-approved budget, other than trade credit incurred in the ordinary course of business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">incur any indebtedness for borrowed money or grant, create or permit the imposition of any lien, charge, security interest or other encumbrance upon any of the assets or properties of the Company or any subsidiary or
guaranty or provide surety for the obligations of any third party, other than (a)&nbsp;ordinary course trade payables, (b)&nbsp;financings of budgeted capital expenditures reflected in annual budgets approved by the Supervisory Board and
(c)&nbsp;not more than &#128;1,000,000 of traditional working capital financing from commercial lenders based on a borrowing base and secured only by the Company&#146;s accounts receivable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">enter into or be a party to any transaction with any director, or officer of the Company or any related party, or enter into any contracts, agreements or arrangements which are not at arm&#146;s length nature;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">entering into agreements with related parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">appointment of an investment banker or M&amp;A adviser; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">hire, fire, or change the compensation of the executive officers, including approving any option plans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top">approve or materially modify the annual budget, any clinical plan or change the principal business or strategy of the Company, enter new lines of business, or exit the current line of business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top">sell, transfer, license, pledge or encumber technology or intellectual property, other than licenses granted in the ordinary course of business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top">dispose or acquire any asset (other than in accordance with a Supervisory Board-approved budget) having a book or market value of more than &#128;50,000; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top">conduct any litigation on behalf of the Company, other than in relation to the collection of debts and taking measures which cannot be delayed, and making settlements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xiii)</TD>
<TD ALIGN="left" VALIGN="top">subscribe or otherwise acquire, or dispose of any securities in the capital of any other company, corporation, partnership, or other entity; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xiv)</TD>
<TD ALIGN="left" VALIGN="top">appoint proxy holders and determine their authority and title; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xv)</TD>
<TD ALIGN="left" VALIGN="top">enter into, terminate or continue any material contracts or agreements outside the ordinary course of business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xvi)</TD>
<TD ALIGN="left" VALIGN="top">implement or amend terms of any stock option plan and grant any options, bonuses or similar rights to the personnel of the Company (including to the Management Board); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xvii)</TD>
<TD ALIGN="left" VALIGN="top">exercise voting rights in the shareholders&#146; meeting of any subsidiary or affiliate of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xviii)</TD>
<TD ALIGN="left" VALIGN="top">undertake such legal acts as will be determined and defined by the Supervisory Board and notified to the Management Board in writing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xix)</TD>
<TD ALIGN="left" VALIGN="top">changing the accounting policies; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(xx)</TD>
<TD ALIGN="left" VALIGN="top">modify the Business Plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"><U>Preferred Majority Approval Matters</U> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.7.1</TD>
<TD ALIGN="left" VALIGN="top">Any resolution by the <U>Management Board</U> with respect to the matters described below shall require the prior written approval by the Preferred Majority, whether or not such matter is also a Supervisory Board
Approval Matter, in the absence of which approval no action shall be made to carry out such resolution, without prejudice (to the extent applicable) to the rights of other Shareholders or of the General Meeting: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">amend, alter, or repeal any provision of the articles of association of any of the Company&#146;s subsidiaries or documentation relating to indebtedness for borrowed money of the Company or any subsidiary, other than
indebtedness permitted under Clause 7.7 (ii)&nbsp;below; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">incur any indebtedness for borrowed money or grant, create or permit the imposition of any lien, charge, security interest or other encumbrance upon any of the assets or properties of the Company or any subsidiary or
guaranty or provide surety for the obligations of any third party, other than (a)&nbsp;ordinary course trade payables, (b)&nbsp;financings of budgeted capital expenditures reflected in annual budgets approved by the Supervisory Board and
(c)&nbsp;not more than &#128;10,000,000 of traditional working capital financing from commercial lenders based on a borrowing base and secured only by the Company&#146;s accounts receivable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">authorize, issue or agree to issue any equity securities (including convertible and exchangeable securities) of the Company or any subsidiary other than Common Shares under the ESOP; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">limitation or exclusion of pre-emptive rights in respect of any issuance of Shares or other equity securities (including convertible and exchangeable securities) of any subsidiary of the Company; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">sale, transfer, license, pledge or encumbrance of technology or intellectual property, other than licences granted in the ordinary course of business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">alters or changes the rights, preferences or privileges of any series of the Preferred Shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">increases or decreases the authorized number of shares of Common Shares or Preferred Shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">creates (by reclassification or otherwise) any new class or series of shares having rights, preferences or privileges senior to or on a parity with any series of the Preferred Shares; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top">redeem, purchase or otherwise acquire any Shares except in connection with the repurchase of Common Shares issued to or held by employees, consultants, officers and directors upon termination of their employment or
services pursuant to agreements providing for the right of said repurchase; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top">results in the redemption of any shares of Common Shares (other than pursuant to equity incentive agreements with service providers giving the Company the right to repurchase shares upon the termination of services or
upon exercise of contractual rights of first refusal); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top">results in any Liquidation Event; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top">results in any voluntary dissolution or liquidation of the Company; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiii)</TD>
<TD ALIGN="left" VALIGN="top">increases or decreases the authorized size of the Supervisory Board; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiv)</TD>
<TD ALIGN="left" VALIGN="top">results in the payment or declaration of any dividend on any shares of Common Shares or Preferred Shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xv)</TD>
<TD ALIGN="left" VALIGN="top">results in the Company issuing equity to acquire all of the equity of another entity or all or substantially all of the assets of another entity and the Company equity so issued exceeds 10% of the shares of the
Company&#146;s Common Shares outstanding immediately prior to such transaction (calculated on a fully diluted basis); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xvi)</TD>
<TD ALIGN="left" VALIGN="top">increases the option or any equity incentive pool; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.7.2</TD>
<TD ALIGN="left" VALIGN="top">Any resolution by the General Meeting with respect to the matters described below shall require the prior written approval by the Preferred Majority, without prejudice (to the extent applicable) to the rights of other
Shareholders: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">liquidate, dissolve or wind-up the affairs of the Company, or effect any Liquidation Event or any acquisition of another entity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">amend, alter, or repeal any provision of the articles of association of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">create or authorize the creation of or issue any other security convertible into or exercisable for any equity security, having rights, preferences or privileges senior to or on parity with any class of the Preferred
Shares, or increase the authorized number of shares of any class of the Preferred Shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">purchase or redeem or pay any dividend on any capital stock prior to the Preferred Shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">limitation or exclusion of pre-emptive rights in respect of any issuance of Shares or other equity securities (including convertible and exchangeable securities) of the Company or any subsidiary; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">reduction of the Company&#146;s issued capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">listing of any equity security of the Company at a stock exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top">approve or modify the annual budget, or change the principal business or strategy of the Company, enter new lines of business, or exit the current line of business. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">A resolution to amend, alter or repeal a provision of the articles of association of the Company in a way that is specifically detrimental to
the existing economic rights of a specific class of Shares only (and not generally affecting the rights of Shareholders, including for example the introduction of a new, more senior class of Shares) shall require the prior written approval of the
meeting of the holders of such class of Shares whose economic rights will be affected. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"><U>Implementation at future subsidiaries.</U> The Parties shall cause the Company to implement such procedures at the level of any future subsidiaries in such manner that each such company cannot resolve upon any of the
Supervisory Board Approval Matters and/or Preferred Majority Approval Matters without the prior written approval of the Supervisory Board and the Preferred Majority, respectively, as contemplated by Clauses 7.6 and 7.7. </TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B></B>8.</TD>
<TD ALIGN="left" VALIGN="top"><B>SUPERVISORY BOARD </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top">The Supervisory Board shall supervise the policies of the Management Board and shall have all such other tasks as assigned to it in this Agreement and/or the New Articles. The Supervisory Board shall be constituted and
regulated in accordance with articles 22 up to and including 27 of the New Articles. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Upon the completion of the First Tranche, the Supervisory Board shall consist of nine
(9)&nbsp;members, appointed in accordance with the following rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">two (2)&nbsp;members shall be appointed by the Class C Meeting: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one (1)&nbsp;member shall be appointed upon the binding nomination of Sofinnova; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one (1)&nbsp;member shall be appointed upon the binding nomination of Novo; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">four (4)&nbsp;members shall be appointed by the Class&nbsp;A Meeting and the Class B Meeting voting together: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one (1)&nbsp;member shall be appointed upon the binding nomination of JJDC; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one (1)&nbsp;member shall be appointed upon the binding nomination of Novartis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one (1)&nbsp;member shall be appointed upon the binding nomination of BCC; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">one (1)&nbsp;member shall be appointed upon the binding nomination of LSP. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">three (3)&nbsp;members, not being an employee of the Company or a partner of any Investor and are nominated by all of the other board members, shall be appointed by the General Meeting (&#147;<B>Independent
Member</B>&#148;). </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Parties have agreed that as of the date of this Agreement, the Supervisory Board shall consist of the
following members: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Anand Mehra (nominated by Sofinnova); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Jack Nielsen (nominated by Novo); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Jeanne Bolger (nominated by JJDC); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Florent Gros (nominated by Novartis); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">Lionel Carnot (nominated by BCC); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">John de Koning (nominated by LSP); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">Wolfgang Berthold (Independent Member); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">Gabriele Dallmann (Independent Member); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">Mark Iwicki (Independent Member). </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">As of the date of this Agreement, Mark Iwicki will be the
chairman, it being understood, however, that the chairman of the Supervisory Board can be changed, upon a resolution of the Supervisory Board with a simple majority, provided that the chairman will always be an Independent Member. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In addition: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aglaia and Pfizer and Baker will each have the right to designate one (1)&nbsp;observer to the Supervisory Board and any committees of the Supervisory Board, who may attend and participate during meetings of the
Supervisory Board and any committees of the Supervisory Board. The observer shall have no vote in matters submitted to vote of the Supervisory Board. The observer shall receive copies of all notices, written materials and other documentation
provided for any reason to the Supervisory Directors. However, in relation to the observer designated by Pfizer and Baker, the Company reserves the right to withhold any information and to exclude the observer from any meeting or portion thereof if
access to such information or attendance would adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets or an actual conflict of interest. </TD></TR></TABLE>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">JJDC will have the right to designate one (1)&nbsp;observer to each of the meetings of (i)&nbsp;the Scientific Advisory Board, and (ii)&nbsp;the CMC Technical Advisory Board, which observers may attend and participate
during such meetings of these respective advisory board and/or panel; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each Investor who has the right to nominate a member shall have the right to appoint its nominated member to two committees of the Supervisory Board. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The right of either JJDC, Novartis, BCC or LSP (to be determined before the completion of the Second Tranche) to nominate a member of the
Supervisory Board to be appointed by the Class&nbsp;A Meeting and the Class B Meeting voting together shall lapse upon the completion of the Second Tranche (in accordance with the Subscription Agreement) and the Supervisory Board member nominated by
such party shall resign as per the completion of the Second Tranche and the Supervisory Board shall be reduced to eight (8)&nbsp;members. The party who nominated such member shall have the right to designate one (1)&nbsp;observer to the Supervisory
Board and any committees of the Supervisory Board, who may attend and participate during meetings of the Supervisory Board and any committees of the Supervisory Board; provided, however, that the Company reserves the right to withhold any
information and to exclude the observer from any meeting or portion thereof if access to such information or attendance could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets
or a conflict of interest, or if such observer is a competitor of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If a Shareholder has not funded its respective full equity
commitment in the Company in accordance with the terms and conditions of the Subscription Agreement, then such Shareholder shall (a)&nbsp;lose its right to appoint a member of the Supervisory Board upon binding nomination pursuant to this Clause
8.1, and (b)&nbsp;cause the relevant member of the Supervisory Board nominated by it to resign from the Supervisory Board with immediate effect. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Nominations and Shareholder voting</U>. The Shareholders shall at all times exercise their voting rights with respect to their Shares in such a manner that the person nominated in accordance with this Clause (or the
first person on the list, in case the nomination consists of more than one person) shall be appointed. Furthermore, the person nominated by a company body shall be suspended and removed by the General Meeting at that company body&#146;s request.
Without prejudice to the relevant Shareholders&#146; ultimate and own discretion to bindingly recommend a person for appointment in accordance with the above, each of the Parties undertakes to reasonably consult the other Parties prior to making a
recommendation in order to reach an agreement on the persons to be appointed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"><U>Term</U>. The Supervisory Directors will be appointed for a term of one (1)&nbsp;year. Each Supervisory Director may be <FONT STYLE="white-space:nowrap">re-appointed,&nbsp;in</FONT> accordance with this Clause 8.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"><U>Remuneration</U>. All Supervisory Directors and observers, if any, shall be entitled to be paid or reimbursed for their reasonable expenses incurred in attending meetings of the Supervisory Board, including committee
meetings, or otherwise acting for the Company, subject to production of all necessary vouchers and receipts. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The General
Meeting shall determine the remuneration of the Supervisory Directors. In principle, said remuneration shall be an equal amount for all members, provided that any deviation from such equal amount shall be (i)&nbsp;on commercially reasonable grounds
and (ii)&nbsp;approved by the Preferred Majority. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"><U>Decision making by the Supervisory Board. </U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Meetings</U>. The Supervisory Board shall
meet as often as it sees fit but in any case at least once per quarter to discuss the affairs of the Company and the performance of the Management Board, unless otherwise agreed by majority vote of the Supervisory Board. The meetings may be held by
telephone and videoconference if so agreed by all members of the Supervisory Board. If the Company opens an office in Boston, the Company will use its best efforts to hold two Supervisory Board meetings a year in Boston. A quorum of the Supervisory
Board shall require a majority of the non-Independent members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Voting at Supervisory Board meetings</U>. At each meeting of the Supervisory Board and in
respect of each resolution proposed to the Supervisory Board at a meeting of the Supervisory Board each Supervisory Director shall have one (1)&nbsp;vote. All resolutions of the Supervisory Board at a meeting of the Supervisory Board shall be passed
by an absolute majority of the votes cast, unless this Agreement and/or the New Articles require a greater majority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Tie in votes</U>.
In the case of an equality of votes at any meeting of the Supervisory Board in relation to a proposal on a matter requiring the absolute majority of the votes, each Supervisory Director shall be authorized to refer the matter to and for resolution
by the General Meeting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Notice of meetings.</U> Unless waived by all of the Supervisory Directors, not less than ten (10)&nbsp;business
days&#146; notice of all meetings of the Supervisory Board shall be given to each Supervisory Director and shall be accompanied by an agenda of the business to be transacted at such meeting together with all papers to be circulated or presented to
the same. Within no more than ten (10)&nbsp;business days after each such meeting, a copy of the minutes of that meeting shall be delivered to each Supervisory Director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Resolutions outside a meeting.</U> The Supervisory Board may adopt resolutions outside a meeting, provided that such resolutions shall only
be validly passed if all Supervisory Directors have signed the text of the resolution. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Committees.</U> The Supervisory Board may
install committees from among its members and determine the tasks of each committee, subject, however, to the prior written approval of the Preferred Majority. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"><U>Information for the benefit of the Supervisory Board.</U> The Management Board shall provide members of the Supervisory Board and observers, if any, with the following information regarding the Company:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">Notices, agendas and minutes of meetings of the Management Board and the management team, Supervisory Board and the Shareholders Meetings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">Unaudited summarized P&amp;L and cash flow of the Company on a monthly basis within thirty (30)&nbsp;days from the end of the relevant month; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">Unaudited quarterly reports (balance sheet, profit and loss statement, cash-flow statements, explanatory notes and a report of the Management Board, including estimates for the remaining part of the current financial
year) within forty-five (45)&nbsp;days of the end of the respective quarter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">Audited financial statements of the Company within ninety (90)&nbsp;days after the end of the financial year; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">Annual budgets (no later than thirty (30)&nbsp;days before the end of the current financial year, to be submitted for approval), as well as all such other information as is reasonably requested; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top">All such other information as the Supervisory Board may reasonably request from time to time. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"><B>GENERAL MEETING</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"><U>General Meeting</U>. The General Meeting shall have all powers that are not specifically assigned to the meeting of Common-Shareholders (the &#147;Common Meeting&#148;), the Class&nbsp;A Meeting, the Class B Meeting,
the Class C Meeting, the Management Board or the Supervisory Board. The General Meeting will be regulated in accordance with article 33 up to and including 43 of the New Articles. To the extent not stipulated otherwise, these provisions shall
similarly apply to the Common Meeting, the Class&nbsp;A Meeting, the Class B Meeting and the Class C Meeting. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Shareholder delegates</U>. Each Shareholder being a legal entity shall give notice to the other Shareholders which natural person or persons shall represent it for purposes of the meetings of the Shareholders.
</TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"><U>Decision making</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Voting rights per Share</U>. Each fully paid up Share on an as
converted basis will entitle the registered holder thereof to vote on all matters to be decided by the General Meeting. Unless specifically agreed otherwise in this Agreement or in the New Articles, the General Meeting, the Class C Meeting, the
Class B Meeting, the Class&nbsp;A Meeting and the Common Meeting shall adopt their resolutions by a simple majority of the votes cast. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Certain resolutions of the Preferred Majority shall be adopted by a majority, which must also include the vote of either Sofinnova or Novo
provided that such Preferred Shareholders are only allowed an affirmative vote if such Preferred Shareholder have funded their respective full equity commitment in the Company in accordance with the terms and conditions of the Subscription
Agreement. If either Sofinnova or Novo would not fund its respective full equity commitment in the Company at such times as required by the terms and conditions of the Subscription Agreement, the Preferred Supermajority will be replaced by the
Preferred Majority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Resolutions outside a meeting</U>. The General Meeting may adopt resolutions outside a meeting if the proposed
written resolution is circulated to all Shareholders and approved in writing by Shareholders representing the number of Shares that would be required to adopt such resolution in a meeting at which valid decisions can be made. Resolutions may be
circulated by facsimile. Such resolutions shall constitute a valid and binding resolution of the Shareholders when signed by the last to sign of all the Shareholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Shareholder voting</U>. The Shareholders agree that when called to a vote at the General Meeting, they shall vote in accordance with the
terms and conditions of this Agreement and to ensure that none of the Parties to this Agreement shall be deprived of its rights pursuant to this Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"><U>Information rights</U>. Each Investor (except an Investor that has Preferred Shares converted into Common Shares pursuant to the Pay to Play) will be granted access to Company facilities and personnel during normal
business hours and with reasonable advance notification. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Company will deliver to each holder of Preferred Shares or
holder of Common Shares issued upon conversion of Preferred Shares (except such a Shareholder that has Preferred Shares converted into Common Shares pursuant to the Pay to Play) (i)&nbsp;audited annual statements within ninety (90)&nbsp;days after
the Company&#146;s financial year, (ii)&nbsp;unaudited quarterly financial statements within thirty (30)&nbsp;days after such period, (iii)&nbsp;unaudited monthly summarized P&amp;L and cash flow statements within thirty (30)&nbsp;days after such
period, (iv)&nbsp;at the latest thirty (30)&nbsp;days before the end of each financial year, a comprehensive operating budget forecasting the Company&#146;s revenues, expenses, and cash position on a month-to-month basis for such financial year;
(v)&nbsp;a report setting forth in detail all equity and debt holders of the Company within twenty (20)&nbsp;days after the end of the financial year, and (vi)&nbsp;promptly following the end of each quarter an up-to-date capitalization table and
all other information as determined by the Supervisory Board. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">If the Company has any subsidiaries, the Company shall deliver the
information as set forth in this Clause 9.4 on a consolidated basis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">In connection with the investment made by LSP, of which a portion is
coming from the EIF-ERP facility and from the <FONT STYLE="white-space:nowrap">LfA-EIF</FONT> facility, the Company acknowledges and agrees that EIF, LfA, the German Ministry of Economic Affairs (<I>Bundesministerium f&uuml;r Wirtschaft and
Technologie</I>) and the German Federal Court of Auditors will have the right to have unlimited access to the premises of the Company and to examine all relevant books and documents of the Company and the management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"><B>REGISTRATION RIGHTS.</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Registration Rights</U>. In the event that the Company consummates an initial public offering of its Shares on a U.S. stock exchange (a &#147;<B>Registration</B>&#148;), the Shareholders will enter into a
registration rights agreement, in customary form acceptable to the Preferred Supermajority in the event of an IPO and to the Preferred Majority in the event of a Qualified IPO pursuant to which Investors (except an Investor that has Preferred Shares
converted into Common Shares pursuant to the Pay to Play), <FONT STYLE="white-space:nowrap">C-Shareholders</FONT> and B-Shareholders will have registration rights, which contains in any event the following rights. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Demand Rights</U>: If, upon the earlier of three (3)&nbsp;years from the closing of the First Tranche or six months after the effective date
of any Registration, Investors holding at least 30% of the Common Shares issued or issuable upon conversion of the Preferred Shares, except resulting from the Pay to Play provision (&#147;<B>Registrable Securities</B>&#148;), make a written request
that the Company file a registration statement under the Securities Act of 1933 for at least 20% of their shares for the first registered offering of the Company (or any lesser percentage if the anticipated aggregate offering price, net of
underwriting discounts and commissions, would exceed USD $10,000,000), or any amount of Common Shares after the first registered offering of the Company, the Company will promptly give notice of such requested registration (each such request
referred to herein as a &#147;<B>Demand Registration</B>&#148;) at least fifteen (15)&nbsp;business days after receipt of a Demand Registration to the other shareholders and thereupon will use its commercially reasonable efforts to effect, as
expeditiously as possible, the registration under the Securities Act of 1933 of all Registrable Securities for which the requesting Investor has requested registration under this Clause 10.1 within ninety (90)&nbsp;days after such request. This
registration right shall be limited to two (2)&nbsp;Demand Registrations (in addition to S-3 registrations described below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Company
Registration</U>: The holders of Registrable Securities shall be entitled to &#147;piggyback&#148; registration rights on any registered offering proposed to be effected by the Company on its own behalf or on behalf of selling Shareholders (other
than an offering related solely to employee benefit plans or a Rule 145 transaction). In an underwritten offering, however, the managing underwriters shall have the right, in the event of marketing limitations, to limit the number of shares included
in the offering on behalf of holders of Registrable Securities, provided that in any offering other than an initial public offering, Registrable Securities may not be limited to less than 25% of the total offering. In the event of such marketing
limitations, each holder of Registrable Securities shall have the right to include shares on a pro rata basis based on the requested number of shares as among all such holders desiring to participate in such offering and to include shares in
preference to any other holders of securities other than Registrable Securities. No person shall be granted demand or S-3 rights, or piggyback registration rights on parity with or superior to those of the Investors, without the consent of the
Preferred Majority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>S-3 Registrations:</U> Holders of Registrable Securities will be entitled to registration of their shares on Form
S-3 (if such form of registration is available to the Company) provided that the anticipated aggregate offering price net of discounts and commissions would exceed USD $1,000,000. There will be no limit on the aggregate number of such Form S-3
registrations, provided that there are no more than two per year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Expenses:</U> The Company will bear the registration expense
(exclusive of underwriting discounts and commissions of a selling holder of Registrable Securities) of all registrations described above, as well as in the case of an IPO, including the expenses of one counsel to all of the selling holders (not to
exceed USD $50,000). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Transfer of Rights</U>: The registrations rights may be transferred to a transferee who acquires at least 20% of
an Investor&#146;s shares as well as to any affiliate of any such Investor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Termination</U>: Registration rights will terminate on the
third anniversary of an IPO, or earlier as to any Investor when all shares can be sold under Rule 144 promulgated under the U.S. Securities Act of 1933, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Other Provisions</U>: The registration rights will be subject to such additional terms and
conditions as are reasonable and customary, including cross-indemnification, 180-day underwriter lock-up upon an IPO, the Company&#146;s ability to delay the filing of demand registrations for at least 90 days, the period of time in which the
registration statement will be kept effective, reporting obligations under the U.S. Securities Exchange Act of 1934, as amended, limitations on subsequent registration rights, underwriting arrangements and the like. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"><U>&#147;Market Stand-Off&#148; Agreement</U>. Each Shareholder hereby agrees that such Shareholder shall not sell, lend, offer, pledge, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, make any short sale of, grant any option for the purchase of, or otherwise transfer or dispose of or enter into any hedging or similar transaction with the same economic effect as a
sale, any Common Shares (or other securities) of the Company held by such Shareholder (other than those included in the registration) during the 180-day period following the effective date of the IPO (or such longer period as the underwriters or the
Company shall request in order to facilitate compliance with (i)&nbsp;regulatory restrictions on the publication or other distribution of research reports and (ii)&nbsp;analyst recommendations and opinions including but not limited to restrictions
contained in FINRA Rule 2711(f)(4) or NYSE Member Rule 472(f)(4) or any successor or similar rule or regulation); provided, that all officers and directors of the Company and holders of at least 1% of the Company&#146;s voting securities are bound
by and have entered into similar agreements. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The foregoing provisions of this Clause 10.2 shall apply only to the IPO
(including a Qualifying IPO) and shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, the sale of any shares acquired in or after the IPO (including a Qualifying IPO), the sale in relation to a third
party bona fide tender offer or the transfer of any shares to any trust for the direct or indirect benefit of the Shareholder or the immediate family of the Shareholder, provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The obligations described in this Clause 10.2 shall not apply to a registration relating solely to employee
benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the future. Any discretionary waiver or
termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply to all Investors subject to such agreements pro rata based on the number of shares subject to such agreements. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"><U>Agreement to Furnish Information</U>. Each Shareholder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter that are consistent with the
Shareholder&#146;s obligations under Clause 10.2 or that are necessary to give further effect thereto. The Company may impose stop-transfer instructions with respect to the Common Shares (or other securities) subject to the foregoing restriction
until the end of said period. Each Shareholder agrees that any transferee of any shares shall be bound by Clauses 10.2 and 10.3. The underwriters of the Company&#146;s stock are intended third party beneficiaries of Clauses 10.2 and 10.3 and shall
have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"><B>EMPLOYEE STOCK OPTION PLAN AND OTHER MATTERS</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><U>Employee Stock Option Plan / Stock Option Agreements</U>. The Company has adopted an ESOP (attached hereto as <B><U>Schedule&nbsp;11.1a</U></B>),
pursuant to which such Company&#146;s officers and employees are granted the right (&#147;<B>Stock Option</B>&#148;) to acquire ESOP Shares, it being understood, however, that legal title to the ESOP Shares shall be held by Stichting AK, which shall
issue (non-voting) depositary receipts to the officers and employees. Each such option award will vest as follows: <FONT STYLE="white-space:nowrap">(i)&nbsp;twenty-five</FONT> percent (25%)&nbsp;on the first anniversary of the date of the grant,
provided that on that date the relevant Supervisory Director, officer or employee is still employed by the Company, (ii)&nbsp;and the remaining seventy-five percent (75%)&nbsp;shall vest balanced on a monthly basis over the following three years of
employment of the relevant Supervisory Director, officer or employee. The further terms and conditions of this plan and any future amendments to this plan, shall be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
recommended by the Management Board and approved by the Supervisory Board and by the Preferred Majority. An overview of the number of Stock Options granted at the date hereof is attached hereto
as Schedule 11.1b. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Number of ESOP Shares</U>. Stock Options will be added to the option pool so that the unallocated option pool together with any outstanding options and Common Shares already held by the Stichting AK will represent
2,206,919 Common Shares upon the completion of the First Tranche and 2,637,110 Common Shares upon the completion of the Second Tranche. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"><U>Stichting AK Board.</U> The board of directors of the Stichting AK shall be appointed by the board of directors of the Stichting AK, subject to prior written approval from the Supervisory Board and shall be comprised
of one or more natural persons. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Parties have agreed that the board of directors of the Stichting AK shall consist of the
CEO of the Company and one Investor Supervisory Director (as designated to that effect by the Supervisory Board). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"><U>Founder&#146;s Shares.</U> When Logtenberg ceases to be a manager or employee of the Company, then Logtenberg shall be obliged to cause the transfer (but not the sale) of all Shares held by him or his personal
holding company to the Stichting AK in exchange for depositary receipts for such Shares. For the sake of clarity, the transfer is solely meant to make sure that Logtenberg will keep the economic rights attached to such shares and other rights
(including voting rights in the Company) will be with the Stichting AK. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top">The Company shall ensure that the employment contracts with all senior employees will at least contain provisions with regard to non-disclosure, non-competition, non-solicitation, confidentiality and assignment of
proprietary rights. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"><U>Proprietary Information and Inventions Agreements</U>. The Company shall require all employees and consultants to execute and deliver a Proprietary Information and Inventions Agreement substantially in a form
approved by the Company&#146;s Supervisory Board. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"><B>VARIOUS</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"><U>Giving effect to this Agreement </U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Undertaking by all Parties. </U>The Parties shall
exercise all voting and other rights and powers available to them so as to give effect to the provisions of this Agreement, to the fullest extent possible under law. The Parties waive, and shall from time to time waive, any rights that they may
have, under the New Articles or otherwise, which may be inconsistent with the terms of this Agreement, and to the extent such rights cannot be waived, they shall exercise such rights in a way consistent with and to the fullest extent possible under
the law in order to give effect to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">The Parties undertake, among other things, to do everything within their power, to the
fullest extent possible under the law, to procure that the Management Board and the Supervisory Board shall be composed and constituted in accordance with this Agreement, and that the Management Board and the Supervisory Board shall exercise their
powers in a manner consistent with the objects, wishes and intentions of the Shareholders as expressed in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Without
prejudice to the generality of the foregoing, the (relevant) Parties shall only adopt resolutions to convert Shares, declare dividends, issue Shares, approve transfers of Shares and amend the New Articles, if that would be compliant with the
relevant provisions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Undertakings by the Company.</U> By executing this Agreement, the Company undertakes to the
Shareholders that to the fullest extent permitted under law, it shall at all times: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">carry on its business in accordance with the Business Plan and corresponding financial planning; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">implement such procedures at the level of all of its future subsidiaries, if any, in such a way that each such company cannot resolve upon any of the Supervisory Board Approval Matters, and/or Preferred Majority
Approval Matters without the Requisite Board Approval and Preferred Majority, respectively, as contemplated by Clauses 7.6 and 7.7; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">generally act in accordance with the terms of this Agreement, including but not limited to obtaining the required approvals in relation to the Supervisory Board Approval Matters and/or Preferred Majority Approval
Matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">indemnify to the fullest extent possible under law and obtain D&amp;O insurance for all Supervisory Directors with a carrier and in an amount satisfactory to the Supervisory Board. Furthermore, the Company shall obtain
key man insurance with a carrier and in an amount satisfactory to the Supervisory Board. In the event the Company merges with another entity and is not the surviving corporation, or transfers all of its assets, proper provisions shall be made so
that successors of the Company assume Company&#146;s obligations with respect to indemnification of Supervisory Directors and Managing Directors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top">until such time as there is an IPO, renounce any interest or expectancy of the Company in, or in being offered an opportunity to participate in, business opportunities that are from time to time being presented to its
officers, directors or Shareholders, other than (i)&nbsp;those officers, directors or Shareholders who are employees of the Company, and (ii)&nbsp;those opportunities demonstrated by the Company to have been presented to such officers, directors or
Shareholders expressly as a result of their activities as a director, officer or Shareholder. No amendment or repeal of this provision shall apply to or have any effect on the Company, the liability or alleged liability of any officer, director or
Shareholder for or with respect to any opportunities which such officer, director or Shareholder becomes aware prior to such amendment or repeal. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Undertakings by the Company in relation to the U.S. Foreign Corrupt Practices Act.</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top">The Company covenants and agrees that the Company, its subsidiaries, affiliates, and any director, officer, employee, independent contractor, representative or agent (collectively &#147;Representatives&#148;) of the
Company shall at all times comply in all material respects with all anti-bribery laws and anti-corruption laws of the Netherlands and the U.S. Foreign Corrupt Practices Act (&#147;<B>FCPA</B>&#148;) and the U.K. Bribery Act (collectively,
&#147;<B>Anti-Corruption Laws</B>&#148;). The Company further represents, covenants and agrees that neither it, nor its subsidiaries or affiliates, or any director, officer or employee of the Company or, to the knowledge of the Company,
representative of the Company, has or shall, in such capacity, directly or indirectly make, give, pay, agree, offer or promise to give any gift, contribution, payment, bribe, kickback, anything of value or similar benefit to any person or entity,
including any (i)&nbsp;elected or appointed government official or person acting for or on behalf of a government official, (ii)&nbsp;employee or person acting for or on behalf of a government official, agency, or enterprise performing a
governmental function, (iii)&nbsp;political party, candidate for public office, officer, employee, or person acting for or on behalf of a political party or candidate for public office, (iv)&nbsp;employees or persons acting for or on behalf of
international public organizations, or (v)&nbsp;any other person to the extent that it would result in a violation of Anti-Corruption Laws; in each case in order to gain an improper business advantage. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt">The Company covenants and agrees that it will maintain books, records, and accounts in reasonable detail, which accurately and fairly reflect the
transactions and dispositions of the Company&#146;s assets. The Company and each of its affiliates and subsidiaries will maintain systems or internal controls (including, but not limited to, accounting systems, purchasing systems and billing
systems) to ensure compliance with Anti-Corruption Laws. Neither the Company, nor any director, officer or employee of the Company or, to the knowledge of the Company, Representative of the Company, acting in such capacity, has or shall establish or
maintain any unrecorded pool of the Company funds or assets or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
make any false, incomplete or misleading entries on any books or records of the Company for any purpose in any case which could result in a violation by or liability of the Company pursuant to
any applicable Anti-Corruption Laws. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top">The Company agrees to (i)&nbsp;provide Pfizer and Sofinnova with an annual compliance certification in the form attached hereto as <B><U>Schedule 12.1a</U></B> and (ii)&nbsp;provide any other Investor upon written
request by such Investor with an annual certification in the form of Schedule 12.1a or a similar certification in all material respects. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Undertakings by the Company and JJDC.</U> The Parties acknowledge that the Company has granted a right of first negotiation to JJDC with
regard to two (2)&nbsp;oncology bi-specific antibody discovery or early development programs (&#147;<B>Target Pairs</B>&#148;) which have been nominated by JJDC, on the terms and conditions of the letter agreement and the nomination letter, both
attached hereto as <B><U>Schedule 12.1b</U></B>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"><U>Conflict with New Articles</U>. The Parties agree that in the event of a conflict between the terms of this Agreement and the New Articles, the provisions of this Agreement shall prevail as far as possible between
the Parties. The Parties undertake to cause the New Articles to be consistent with this Agreement, and to the extent such is not the case, all Parties undertake, at any Party&#146;s first request, to amend the New Articles in order to make them
consistent with this Agreement. If pursuant to law such amendment is not possible, the Parties shall use all their rights to the fullest extent possible in such manner as to give effect to this Agreement. The New Articles shall not be amended in any
way if such amendment would cause any explicit rights of the Parties under this Agreement (particularly the rights to dividends and rights to liquidation proceeds as described in Clause 3.3) to be terminated or negatively affected.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"><U>Entire Agreement</U>. This Agreement (together with any documents referred to herein or executed contemporaneously in connection herewith) constitutes the whole agreement between the Parties and supersedes any
previous agreements or arrangements between them relating to the subject matter of this Agreement (including the Company&#146;s prior investment and shareholders agreements). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"><U>Severability</U>. If any provision or part of a provision of this Agreement shall be, or be found by any authority or court of competent jurisdiction to be, invalid or unenforceable, such invalidity or
unenforceability shall not affect the other provisions or parts of such provisions of this Agreement, all of which shall remain in full force and effect, and the Parties hereto shall consult with each other in order to replace the invalid or
unenforceable provisions by provisions which comply with the objects, wishes and intentions of the Parties as expressed in this Agreement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.5</TD>
<TD ALIGN="left" VALIGN="top"><U>Termination</U>. The Parties acknowledge and agree that this Agreement shall only terminate in the event of a Liquidation Event or completion of a Qualifying IPO, provided that the rights and obligations under the
Shareholders Agreement which are triggered by the Liquidation Event or Qualifying IPO shall remain in force until they are fully effectuated, and with respect to individual Parties, from the date such Party ceases to hold any Shares. The
Registration Rights shall also survive a Qualifying IPO. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.6</TD>
<TD ALIGN="left" VALIGN="top"><U>Consequences of termination. Survival</U>. Upon termination of this Agreement the provisions of this Agreement shall cease to have effect save in relation to any existing claims which may have arisen prior to
termination, and provided, however, that Clause 10 (Registration Rights), Clause 12.7 (Notices), Clause 12.9 (Confidentiality), Clause 12.16 (Governing Law) and Clause 12.17 (Dispute Resolution) shall survive the termination. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.7</TD>
<TD ALIGN="left" VALIGN="top"><U>Notices</U>. Each notice, demand or other communication given or made under this Agreement shall be in writing and delivered or sent to the relevant Party at its address or email address set out below (or such other
address or email address as the addressee has specified to the other Parties by five (5)&nbsp;days&#146; prior written notice): </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">To: <B>Merus B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>Co&ouml;peratief LSP IV U.A.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Padualaan 8, postvak 133</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Johannes Vermeerplein 9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3584 CH Utrecht</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1071 DV Amsterdam</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Attn.: Managing Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn.: Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>s.margetson@merus.nl</U> and <U>T.Logtenberg@merus.nl</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Email: <U>jdekoning@lspvc.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">To: <B>Johnson&nbsp;&amp; Johnson Innovation &#150; JJDC, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">To: <B>Bay City Capital Co&ouml;peratief U.A.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">410 George Street</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">De Boelelaan 7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New Brunswick, NJ 08901 &#150; USA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">1083 HJ Amsterdam</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn. Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn.: Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>jbolger@janimm.com</U> with a copy to <U>SRosenB@its.jnj.com</U> and lvogel@its.jnj.com</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Email: <U>adnl-cms-a@alterdomus.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">To: <B>Novartis Bioventures Ltd.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Copy to: <B>Bay City Capital Fund V, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">131 Front Street</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">750 Battery Street, Suite 400</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Hamilton, HM12 Bermuda</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">San Francisco, CA 94111 &#150; USA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn. Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn.: General Partner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>david.middleton@novartis.com</U> with copy to <U>florent.gros@nvfund.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Email: <U>lionel@baycitycapital.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>Pfizer Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>Crucell Holland B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">235 East 42nd Street</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Archimedesweg 4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New York, NY 10017 - USA</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2333 CN Leiden</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn. Andrew Muratore and Elaine Jones</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn.: Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Email: <U>Elaine.Jones@pfizer.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>jbolger@janimm.com</U> with a copy to <U>SRosenB@its.jnj.com</U> and lvogel@its.jnj.com</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">To: <B>Aglaia Oncology Fund B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>Aglaia Oncology Seed Fund B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Professor Bronkhorstlaan 10 92</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Professor Bronkhorstlaan 10 92</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3732 MB Bilthoven</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3732 MB Bilthoven</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn: Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn: Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>kr@aglaia-biomedical.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>kr@aglaia-biomedical.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">To: <B>BioPhrase B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>To: <B>Stichting Administratiekantoor Merus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Koningin Wilhelminalaan 22</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Padualaan 8, postvak 133</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3972 EX Driebergen-Rijsenburg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">3584 CH Utrecht</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn.: T. Logtenberg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn.: Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>T.Logtenberg@merus.nl</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>T.Logtenberg@merus.nl</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>Sofinnova Venture Partners IX, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>Novo A/S</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3000 Sand Hill Road, Bldg. 4</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 250</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Menlo Park, CA 94025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tuborg Havnevej 19,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2900 Hellerup,
Denmark</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn: Anand Mehra</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn: Jack B. Nielsen</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>anand@sofinnova.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>jabn@novo.dk</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>Baker Brothers Life Sciences, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>667, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">667 Madison Avenue, 21st Floor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">667 Madison Avenue, 21st Floor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New York, NY 10065</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">New York, NY 10065</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn. Kelvin Neu</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn. Kelvin Neu</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: kneu@BBInvestments.com</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: kneu@BBInvestments.com</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">To: <B>Blackwell Partners LLC - Series A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>RA Capital Healthcare Fund, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">20 Park Plaza, Suite 1200</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">20 Park Plaza, Suite 1200</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Boston, MA 02116</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Boston, MA 02116</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn. Nick Mcgrath</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn.: Nick Mcgrath</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>nmcgrath@racap.com</U> with copy to <U>rshah@racap.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Email: <U>nmcgrath@racap.com</U> with copy to <U>rshah@racap.com</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>Rock Springs Capital Master Fund LP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">To: <B>Tekla Healthcare Investors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">650 South Exeter Street, Suite 1070</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVP Research</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">100 Federal Street, 19th
Floor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Baltimore, MD 21202</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Boston, MA 02110</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn. Dave Gardner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Attn.: Chris Richard</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: <U>dave@rockspringscapital.com</U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: <B>Tekla Life Sciences Investors</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVP Research</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">101 Federal Street, 19th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02110</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn.: Chris Richard</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: <U>crichard@teklacap.com</U></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: <U>crichard@teklacap.com</U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: <B>Tekla World Healthcare Funds</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SVP Research</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">102 Federal Street, 19th Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02110</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn.: Chris Richard</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Email: <U>crichard@teklacap.com</U></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Any notice, demand or other communication so addressed to the relevant Party shall be deemed to have been
delivered (a)&nbsp;if given or made by letter, when actually delivered to the relevant address; or (b)&nbsp;if given or made by fax, when dispatched. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.8</TD>
<TD ALIGN="left" VALIGN="top"><U>Restrictions on announcements.</U> Each of the Parties, hereto undertake that it will not (save as required by law) issue any press release in connection with this Agreement or with respect to other Parties, unless
the Company and the Preferred Majority have given their written consent to such announcement (which consent may not be unreasonably withheld and may be given either generally or in a specific case or cases and may be subject to conditions).
</TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.9</TD>
<TD ALIGN="left" VALIGN="top"><U>Confidential information</U> </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Non-disclosure.</U> The Parties undertake that they shall
treat as strictly confidential any and all data and information, whether provided orally, in writing or electronically, received or obtained by them or their employees, agents or advisers as a result of entering into or performing this Agreement
including information relating to the provisions of this Agreement, the negotiations leading up to this Agreement, the subject matter of this Agreement or the business or affairs of each of the Parties or the Company and its subsidiaries, and
information which is expressly stated as being &#147;confidential&#148; (the &#147;<B>Confidential Information</B>&#148;) and that they will not at any time hereafter make use of or disclose or divulge to any person outside of such Party, their
agents or advisors, any such Confidential Information and shall use their best endeavours to prevent the publication or disclosure of any such information by such Party, their agents and advisors. The Parties acknowledge that they have received
Confidential Information with regard to the Company and its subsidiaries during the review process and negotiations leading up to this Agreement and that such information may not be used for any other purposes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman"><U>Exceptions</U>. The restrictions contained in this Clause 12.9 shall not apply so as to prevent the Parties from making any disclosure
(i)&nbsp;to the Shareholders, (ii)&nbsp;with regard to customary information to the investors of the Investors or any other entity to which the Shares may be transferred to as a permitted transfer under Clause 6.2 hereof, (iii)&nbsp;as otherwise
required by law, or as requested or required by any securities exchange or supervisory or regulatory or governmental body or court pursuant to rules to which the relevant Party is subject, or from making any disclosure to any professional adviser
(including, without limitation, legal counsel, financial advisors and auditors) for the purposes of obtaining advice (provided always that the provisions of this Clause shall apply to and the Parties shall procure that they apply to, and are
observed in relation to, the use or disclosure by such professional adviser of the information provided to him) , (iv)&nbsp;to any prospective purchaser of any Shares from such Investor, if such prospective purchaser agrees to be bound by the
provisions of this Clause 12.9, (v)&nbsp;to any existing, former or prospective affiliate, partner, limited partner, general partner, member, stockholder or wholly owned subsidiary of such Party in the ordinary course of business, provided that such
Party informs such person that such information is confidential and directs such person to maintain the confidentiality of such information, (vi)&nbsp;as may otherwise be required by law, provided that the Party promptly notifies the Company of such
disclosure and takes reasonable steps to minimize the extent of any such required </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">
disclosure, (vii)&nbsp;in connection with the enforcement of this Agreement or the Subscription Agreement or rights under this Agreement or the Subscription Agreement, (viii)&nbsp;pursuant to any
direction, request or requirement (whether or not having the force of law but if not having the force of law being of a type with which institutional investors in the relevant jurisdiction are accustomed to comply) of any self-regulating
organization or any governmental, fiscal, monetary or other authority, (ix)&nbsp;for internal market, industry and investment analyses, (x)&nbsp;to officers, employees, agents, directors, partners, parent or subsidiaries to the extent necessary to
obtain their services in connection with monitoring its investment in the Company or (xi)&nbsp;of information that has been independently developed or conceived by any of the Parties without using Confidential Information, nor shall said
restrictions apply in respect of any information which comes into the public domain other than by a breach of this Clause by any of the Parties. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.10</TD>
<TD ALIGN="left" VALIGN="top"><U>Amendments</U>. No amendment or variation of this Agreement shall be effective unless it is made or confirmed in a written document signed by the Company and the Preferred Majority, provided, however, that
(a)&nbsp;any amendment to Section&nbsp;6.5.2 that makes an adverse change to the obligations of any Shareholder shall also require the written consent of all the C-Shareholders, (b)&nbsp;any provision requiring the consent of the Preferred
Supermajority may only be amended with the consent of the Preferred Supermajority, and (b)&nbsp;any provision requiring the consent of a specific Party may only be amended with the consent of such specific party. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:6%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, no provision of this Agreement may be amended and the observance of any term hereof may not be waived (either
generally or in a particular instance and either retroactively or prospectively) with respect to any Shareholder and/or specific class of Shares without the written consent of such Shareholder and/or specific class of Shares, unless such amendment
or waiver applies to all Shareholders in the same fashion. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.11</TD>
<TD ALIGN="left" VALIGN="top"><U>Conflicts of interests</U>. Notwithstanding anything contained in this Agreement, no Shareholder, Supervisory Director or Supervisory Board observer shall receive any relevant Confidential Information from the
Company as soon as he, or the person represented by him and/or at whose nomination/recommendation he has been appointed has become aware of a conflict of interest with the Company. Such conflicts of interest could arise, for example, if the person
who nominated a Supervisory Director is involved in a potential acquisition of the Company or a substantial portion of its assets, or if a Shareholder acquires an interest in another company that directly competes with the Company by using similar
technology or wishes to set up a competing business by using similar technology as used by the Company. As soon as awareness of a (potential) conflict of interest arises, the involved person shall report such fact to the Chairman of the Supervisory
Board and shall provide all relevant information. The Chairman of the Supervisory Board shall then assess whether and, if so, to which reasonable extent the relevant Confidential Information shall henceforth be withheld from the involved person.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.12</TD>
<TD ALIGN="left" VALIGN="top"><U>Assignment</U>. Except as expressly contemplated in this Agreement (including a transfer contemplated in accordance with Clause 6 of this Agreement), none of the Parties shall be entitled to assign or transfer its
rights and/or obligations under this Agreement to any Third Party without the prior written consent of the other Parties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.13</TD>
<TD ALIGN="left" VALIGN="top"><U>No partnership</U>. Nothing in this Agreement shall constitute or be deemed to constitute a partnership between the Shareholders and/or between any of them and the Company nor constitute any Party the agent of any
other for any purpose. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.14</TD>
<TD ALIGN="left" VALIGN="top"><U>Language</U>. The language of this Agreement and the transactions envisaged by it is English and all notices, demands, requests, statements, certificates or other documents or communications issued under, pursuant
to, or which relate to, this Agreement shall be in English. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.15</TD>
<TD ALIGN="left" VALIGN="top"><U>Governing law</U>. This Agreement shall be governed by and construed in accordance with the laws of The Netherlands. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.16</TD>
<TD ALIGN="left" VALIGN="top"><U>Dispute resolution</U>. All disputes arising in connection with this Agreement, or further agreements or contracts resulting thereof, shall in first instance be referred exclusively to the Court of Amsterdam.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">12.17</TD>
<TD ALIGN="left" VALIGN="top"><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[SIGNATURE PAGE FOLLOWS] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B> the Parties hereto have signed this Agreement as of the day and year first written
above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Merus B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ T. Logtenberg</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ S. Margetson</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">T. Logtenberg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">S. Margetson</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Sofinnova Venture Partners IX, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Novo A/S</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Anand Mehra</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jack Nielsen</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Anand Mehra</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jack Nielsen</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Partner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Baker Brothers Life Sciences, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>667, L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Lessing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Scott Lessing</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors L.P., management company and advisor to Baker Brothers Life Sciences L.P., pursuant to authority granted to it by
Baker Brother Life Sciences Capital L.P., general partner to Baker Brother Life Sciences L.P.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">and not as the general partner</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Baker Bros. Advisors L.P., management company and advisor to 667, L.P.,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">pursuant to authority granted to it by Baker Biotech Capital L.P.,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">general partner to 667, L.P.,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">and not as the general
partner,</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Scott Lessing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Scott Lessing</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>RA Capital Healthcare Fund, L.P.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>RA Capital Management, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rajeev Shah</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Rajeev Shah</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Rajeev Shah</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Tekla Healthcare Investors (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Tekla Life Sciences Investors (2)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura Woodward</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura Woodward</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Laura Woodward</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Laura Woodward</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Treasurer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Treasurer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Rock Springs Capital Master Fund LP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Tekla World Healthcare Funds (3)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Graham McPhail</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura Woodward</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Rock Springs GP LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Laura Woodward</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">its:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Partner</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Treasurer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Graham McPhail</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rock Springs Capital</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">650 S. Exeter St.,
Suite 1070</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Baltimore, MD 21202</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The name Tekla Healthcare Investors is the designation of the Trustees for the time being under an
Amended&nbsp;&amp; Restated Declaration of Trust dated April&nbsp;21, 1987, as amended, and all persons dealing with Tekla Healthcare Investors must look solely to the trust property for the enforcement of any claim against Tekla Healthcare
Investors, as neither the Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The name Tekla Life Sciences Investors is the designation of the Trustees for the time being under a Declaration of Trust dated February&nbsp;20, 1992, as
amended, and all persons dealing with Tekla Life Sciences Investors must look solely to the trust property for the enforcement of any claim against Tekla Life Sciences Investors, as neither the Trustees, officers nor shareholders assume any personal
liability for the obligations entered into on behalf of Tekla Life Sciences Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The name Tekla World Healthcare Fund is the designation of the
Trustees for the time being under an Amended&nbsp;&amp; Restated Declaration of Trust dated March&nbsp;18,2015, and all persons dealing with Tekla World Healthcare Fund must look solely to the trust property for the enforcement of any claim against
Tekla World Healthcare Fund, as neither the Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla World Healthcare Fund. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Johnson &amp; Johnson Innovation JJDC, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Blackwell Partners LLC - Series A</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ V. Kadir Kadhiresan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Justin B. Nixon /s/ David R. Shumate</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">V. Kadir Kadhiresan</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Justin B. Nixon </TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">VP, Venture Investments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Investment Manager</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DUMAC, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized Agent</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David R. Shumate </TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President DUMAC, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized Agent</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Novartis Bioventures Ltd.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ H.S. Zivi</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laurieann Chaikowsky</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">H.S. Zivi</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Laurieann Chaikowsky</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorised Signatory</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Co&ouml;peratief LSP IV U.A.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Bay City Capital Co&ouml;peratief U.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ren&eacute; Kuijten /s/ Joachim Rothe</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ K.F.J. Jansen</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">LSP IV Management B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">K.F.J. Jansen</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">On behalf of LSP IV Management B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ren&eacute; Kuijten and Joachim Rothe</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Pfizer Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Aglaia Oncology Fund B.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barbara Dalton</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karl Rothweiler</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Barbara Dalton</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Aglaia BioMedical Ventures B.V.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Venture Capital</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Worldwide Business Development</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">On behalf of Aglaia BioMedical Ventures B.V.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Karl Rothweiler</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Aglaia Oncology Seed Fund B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>BioPhrase B.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karl Rothweiler</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ T. Logtenberg</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Aglaia BioMedical Ventures B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">T. Logtenberg</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">On behalf of Aglaia BioMedical Ventures B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Karl Rothweiler</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Crucell Holland B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Stichting Administratiekantoor Merus</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maarten Santman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ T. Logtenberg</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Maarten Santman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">T. Logtenberg</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Legal Counsel &amp; Corporate</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>T. Logtenberg</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ T. Logtenberg</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">T. Logtenberg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 1.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Definitions </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The below capitalized
terms used in the Shareholders Agreement and/or Subscription Agreement shall have the meaning as set forth opposite such term or as defined in the clauses of the Shareholders Agreement and/or Subscription Agreement mentioned opposite such term. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">2013 Subscription Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Recital D</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Cap</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A-Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Affiliate Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">any transferee as referred to in Clause 6.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">this Shareholders Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment Deed</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 2.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anti-Corruption Laws</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 12.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anti-Dilution Protection</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.4.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">B Cap</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">B-Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">C-Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chairman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the chairman of the Supervisory Board</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class&nbsp;A Liquidation Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class&nbsp;A Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the meeting of holders of Class A Shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class&nbsp;A Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the class A shares of the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class B Liquidation Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class B Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the meeting of holders of Class B Shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class B Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the class B shares of the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class C Liquidation Proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class C Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the meeting of holders of Class C Shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class C Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the class C shares of the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CMC Technical Advisory Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">a panel or other meeting of relevant experts being convened from time to time to advise the Company on the scale-up for clinical and commercial stage manufacturing of the Company&#146;s products</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 9.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common-Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the common shares of the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">see Parties</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Completion</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.2 of the Subscription Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Confidential Information</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 12.9</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conversion Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.3.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Conversion Rate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.3.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Convertible Bridge Loan</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the convertible bridge loan pursuant to the Convertible Bridge Loan Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Convertible Bridge Loan Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">convertible bridge loan agreement between the Company and certain <FONT STYLE="white-space:nowrap">B-Shareholders</FONT> (or their affiliate) dated 11 June 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dilutive Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.4.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Drag-along Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.5</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Drag-along Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.5</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ESOP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the Company&#146;s employee stock option plan, currently the Merus B.V. 2010 Employee option plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ESOP Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 2.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Excluded Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.4.2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Exercise Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">FCPA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 12.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">First Tranche Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined in article 1.1 of the Subscription Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">General Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the general meeting of the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Individual Loan Amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the individual loan amount of the Existing Investors as set out in the capitalization table in schedule 2.1 including accrued interest under the Convertible Bridge Loan Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Indirect Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in &#147;Parties&#148; of the Subscription Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Milestone-Based Second Tranche Investment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As defined in article 3.5 of the Subscription Agreement</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor Majority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As defined in article 3.5 of the Subscription Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor Supervisory Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 8.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IPO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.3.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liquidation Event</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Management Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the board of managing directors of the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Managing Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the managing directors of the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Milestone-Based Second Tranche Investment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.5 of the Subscription Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New Articles</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 2.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Offer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Offered Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Offerees</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">rights to acquire depositary receipts for Common Shares to be issued by the Company;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Original Issue Price</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.2.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Party/Parties</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the party/parties of this Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Pay to Play</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined in Clause 3.5 of the Subscription Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preferred Majority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.3.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preferred Majority Approval Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">As defined and described in Clause 7.7</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preferred Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the holders of Class A Shares, Class B Shares and Class C Shares taken together</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preferred Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Class A Shares, Class B Shares and Class C Shares taken together</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Preferred Supermajority</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.3.1 of the Shareholders Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposed Purchaser</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proposed Seller</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Qualifying IPO</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.3.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Remaining Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 12.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Requisite Board Approval</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.3.3.2</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Right of First Refusal</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sale Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Scientific Advisory Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">a panel or other meeting of relevant experts being convened from time to time to advise the Company on the development and planning for clinical development of the lead programs</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Share / Shares</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 3.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Recital C</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Stock Option</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 11.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Subscription Agreement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Recital B</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Supermajority Supervisory Board Approval Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 7.6</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Supervisory Board</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">the board of supervisory directors of the Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Supervisory Board Approval Matters</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 7.6</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tag-along Notice</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tag-along Right</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 6.4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Target Pair</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as defined and described in Clause 12.1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Third Party</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">any other person or entity that is neither a Party nor an Affiliate Party</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tranche</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">an instalment of issuance of Class C Shares</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 2.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Amendment Deed </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 2.3 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Capitalization Table </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 4.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Business Plan </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 7.1 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Management Rights Letter </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 11.1a </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ESOP </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 12.1.a </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FCPA Certification form </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Schedule 12.1b </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ROFN Letter Agreement / Nomination Agreement] </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>d29248dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 23.1 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consent of Independent Registered Public Accounting Firm </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Supervisory Board and Management Board
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merus B.V.: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We consent to the use of our report dated January 21, 2016, with respect to the statements of financial position of Merus B.V. as of December&nbsp;31,
2014,&nbsp;December&nbsp;31, 2013 and January&nbsp;1, 2013 and the related statements of profit or loss and comprehensive loss, changes in equity and cash flows for each of the years in the two-year period ended December&nbsp;31, 2014, included
herein and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. Our report refers to a change in the presentation of expenses in the Statement of profit or loss and comprehensive loss from the nature of expense
method to the function of expense method. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">/s/ KPMG Accountants N.V. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rotterdam, The Netherlands </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 21, 2016 </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>d29248dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" NOWRAP>


<IMG SRC="g97787g13r37.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g97787g78y06.jpg" ALT="LOGO">
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;21, 2016 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation
Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of the Chief Accountant </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street NE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, DC 20549 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Merus B.V. Registration Statement on Form F-1 (333-207490) </B></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Application for Waiver of Requirements of Form 20-F, Item&nbsp;8.A.4 </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I am the Chief Executive Officer of Merus B.V., a limited liability company incorporated under the laws of the Netherlands (the &#147;Company&#148;). In
connection with a proposed initial public offering of the Company&#146;s common shares, we hereby respectfully request that the Securities and Exchange Commission (the &#147;Commission&#148;) waive the requirement of Item&nbsp;8.A.4 of Form 20-F,
which states that in the case of a company&#146;s initial public offering (&#147;IPO&#148;) the Registration Statement on Form F-1 (the &#147;Registration Statement&#148;) must contain audited financial statements of a date not older than 12 months
from the date of the offering unless a waiver is obtained. See also Division of Corporation Finance, Financial Reporting Manual, Section&nbsp;6220.3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At
the time of initial public filing on October&nbsp;19, 2015, the Company&#146;s Registration Statement satisfied Item&nbsp;8.A.4 of Form 20-F, which is applicable to the Registration Statement pursuant to Item&nbsp;4(a) of Form F-1, because it
contained audited financial statements for the two years ended December&nbsp;31, 2014 and 2013 prepared in accordance with International Financial Reporting Standards. However, because the Company&#146;s audited financial statements for the year
ended December&nbsp;31, 2015 will not be available until approximately April&nbsp;1, 2016, at the time of the First Amendment on January&nbsp;21, 2016, the Company&#146;s Registration Statement contains only audited financial statements for the two
years ended December&nbsp;31, 2014 and 2013 and unaudited financial statements for the nine months ended September&nbsp;30, 2015 and 2014, in each case prepared in accordance with International Financial Reporting Standards. Additionally, the
Company may need to make at least one amendment after the date hereof and prior to the availability of the audited financial statements for the year ended December&nbsp;31, 2015 containing the same financial statements as those that are contained in
its most recent filing. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g97787g13r37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is submitting this waiver request pursuant to Instruction 2 to Item&nbsp;8.A.4 of Form 20-F, which provides
that the Commission will waive the 12-month age of financial statements requirement &#147;in cases where the company is able to represent adequately to us that it is not required to comply with this requirement in any other jurisdiction outside the
United States and that complying with this requirement is impracticable or involves undue hardship.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See also the Commission&#146;s November&nbsp;1,
2004 release entitled International Reporting and Disclosure Issues in the Division of Corporation Finance (available on the Commission&#146;s website at http://www.sec.gov/divisions/corpfin/internatl/cfirdissues1104.htm) at Section III.B.c, in
which the Commission notes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;the instruction indicates that the staff will waive the 12-month requirement where it is not applicable in the
registrant&#146;s other filing jurisdictions and is impracticable or involves undue hardship. As a result, we expect that the vast majority of IPOs will be subject only to the 15-month rule. The only times that we anticipate audited financial
statements will be filed under the 12-month rule are when the registrant must comply with the rule in another jurisdiction, or when those audited financial statements are otherwise readily available.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this request, on behalf of the Company, I represent to the Commission that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The Company is not currently a public reporting company in any other jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. The Company is not required by any jurisdiction outside the United States to prepare, and has not prepared, financial statements audited under any generally
accepted auditing standards for any interim period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Compliance with Item&nbsp;8.A.4 is impracticable and involves undue hardship for the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The Company does not anticipate that its audited financial statements for the year ended December&nbsp;31, 2015 will be available until April&nbsp;1, 2016.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. In no event will the Company seek effectiveness of the Registration Statement if its audited financial statements are older than 15&nbsp;months at the
time of the offering. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g97787g13r37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will file this letter as an exhibit to the Registration Statement pursuant to Instruction 2 to Item&nbsp;8.A.4 of Form
20-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please do not hesitate to contact our Chief Financial Officer, Shelley Margetson, at s.margeston@merus.nl if you have any questions regarding the
foregoing or if we can provide any additional information. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ton Logtenberg</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Ton Logtenberg</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g29248g08g41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g08g41.jpg
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M],*1\#X ]G/KW[B--?IA2/@? 'LY]>_<1IK],*1\#X ]G/KW[B--?IA2/@?
M'LY]>_<1IK],*1\#X ]G/KW[B--?IA2/@? 'LY]>_<1IK],*1\#X ]G/KW[B
M--?IA2/@? 'LY]>_<1IK],*1\#X ]G/KW[B--?IA2/@? 'LY]>_<1IK],*1\
M#X ]G/KW[B--?IA2/@? 'LY]>_<1IK],*1\#X ]G/KW[B--?IA2/@? 'LY]>
M_<1IK],*1\#X ]G/KW[B--?IA2/@? 'LY]>_<1IK],*1\#X ]G/KW[B--?IA
M2/@? 'LY]>_<1IK],*1\#X ]G/KW[B--?IA2/@? 'LY]>_<1IK],*1\#X ]G
M/KW[B--?IA2/@? 'LY]>_<1IK],*1\#X ]G/KW[B--?IA2/@? 'LY]>_<1IK
M],*1\#X ]G/KW[B--?IA2/@? 'LY]>_<1IK],*1\#X ]G/KW[B--?IA2/@?
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M].3.J6R1NX=0=K@FNP)BS!:5N"I[,V*7B:9WM)MB!(:SMT/6-5<DD:]8H<<
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M^P^E>^?=EW?^?];O\@^!"U7?V'TKWS[LN[_S_K=_D'P(6J[^P^E>^?=EW?\
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MM_H8%P<GB^+\DT\$' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' .<7OG]K#:O\#?MM3^#M1]J
MY^6;T>MOV=M"?@MJW^A@7!R>+XOR33P0< < < < < < < < < < < < < <
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M8(BWE>J*D$><Z_Q,GJM=)8[7K%OMLAL1,I;-GL;\&N6A58B-'@^G5Y?I7/\
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M%[Y_:PVK_ W[;4_@[4?:N?EF]'K;]G;0GX+:M_H8%P<GB^+\DT\$' ' ' '
M/&L1.>% ERXNNE[<1&CY4R%5P$@!$-GY,=I3C(D5)M1NMUMB?-6G#$9TX?#B
MT.K2J81B,X6\D"L71N9)(]:JB0FB9X"9.N6[IDL$5=%ODPTF3O39+SXHB^#(
MF KTX>ZM426Z(+%!CC[+BX!";%RU)<%>/)>$6VX(. . . . . . . . . .
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M+XOR33P0< < < < < JSTQ^S^$_$+?7[^[-X*\>2\(M-P0< < < < < < <
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M4K&/_CP#S -JK=H3(773@PTB)EO$E8V6U*2QEY3R&\.*:4K"<K5'?3CRY_\
M4RYC_E.<<0UBH$IX.3(. ?1*DL0HTB9)<PU&B,.R9#N<*5AMAAM3KKF4HPI:
ML(;2I6<)2I6?)Y$XSGR8X!CH*ZU:S27X8(Q')28J'%R&F6Y*<LX9<::=PXIU
MEM"7&W'VDK:RKTB?/QG*/)Y<XK36*(FG@4"V[OV^/=D@M"UP7$,Q(RHM#9)1
M!L2Q+1-N3H;-@(9PIW#:YE?EQHB4Q/3-,1I05]N?A;3LMKG:FBG_ !NJJ?W8
MQA,+#/\ -C#J>U">[W[E[:'KX!KX8_#$)DS"!*1F?8;&6>S.L-F*KQGTI,V2
M7C#LE]65+]"RGS(D-M668;##7^W/*JIU._)*R7!&TH_+U,YYDHX X X X X
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MKT6_62%=Q&=N]V]8W36NBZFU2-26L.Y%?W9ME@Y75W9N.^R1A0=;4F,PBRJ
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M<M-SB&9.'_5T,,(VZJ_\:IBVN>S:/FB,PMOOSP^="YG.1T' ' ' ' ' ' '
M' ' ' ' ' ' ' .<7OG]K#:O\#?MM3^#M1]JY^6;T>MOV=M"?@MJW^A@7!R>
M+XOR9OL8W+K6O;W8X$Z"+G5^FV@W")E(,\F,'2Q02=/C3B(T4APF0@Q'F$2)
M<$<VY/EQVW(\-"I#C:<B'/+X,#&P2]Y [;M5;[C!2N\-'0]A[&/W[I!TUZ[]
M<[W;[!&K)_Y>KNR])U2N[;MC<B44(S];M7%7E+UJ9()'HD8JAMEMR\'3U,8M
M9POJJ;YRX6^%B=)G!S' ' ' *L],?L_A/Q"WU^_NS>"O'DO"+3<$' ' ' '
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MD9-F0Q\R6/:EY=1#DRH$*0_'2VZ]$CN*4R@1X\EX1;?@@X X X X X!XIVN
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M^C1B$E25?^K.5JQGZL8YV]/TU6FVVKQV7N<ZJVG"@@C_ *A%T]WU7_,BW_\
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MQ+37TO4=&RQ&2K9"KO&68[\><  (MA\-\H/X;$.V(!5'$VH]6F"#E@"UGRV
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MO?!VF_F;W'_=7!)>[HO8>R;5O?!VF_F;W'_=7 E[NB]A[)M6]\':;^9O<?\
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M.%C8S$(>,@0H[3$(?"A14-1X42)%0RS%B,--LL1TM-M-H;2C&!#]W ' ' '
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MHOA_=7Z'U8UM:K;=*A0"%R(#;%>,A\V2:[=;B<ND]$[($:(%^CB3SLB+$]!
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g29248g10p58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g10p58.jpg
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MXV;#E*C(7(^8;"M#.L;+1[B?AV+.JK! NW+^E<X4YQW#/-XG;N([^[OZ=>^
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M ,I4?^L=/U5#_?>C_P"/4/\ I]/UC+_=6I_X+/\ YVGZ09/_ (7Y)_Y2H_\
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M-'^P-O$%N7!>2VN+HJ7*('1 S#FR) _2#)_\+\D_\I4?^L=8C]50_P!]Z/\
MX]0_Z?61_6,O]U:G_@L_^=I^D&3_ .%^2?\ E*C_ -8Z?JJ'^^]'_P >H?\
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M9Y]0TBX:RMW=6O[7DNK,QJ2%G9H2SPPN &!N4A(R!(BME169>0'GL;I_>/\
MIWY#V_#4;DN>N^?C@[GX]Q_,U 7F\_8!U\>[NWSL*X[.=>1,I&SD:[683$,^
M:R<3)M5!1?1LBS6(NT>L7)!!5NY;K)D5352.4Y3%Y ?;5H9\21S#:6!UEAE
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MR^>I';6@7&VV?G^9\AOCP[XYJ.K <RJW*HSW]<>.XR1UQTZ9K-V4'STCT_D
M?]_\^W(:RT=OY>\^[W#(]_=N!4,N]8Y<^MO[=^NWAX8VQL?"LJ9P8=N$_7[A
M]/7U'CCGGO[A^ ZODMB,;>'Y_D<]VQ\*C5UK!P<-CX'V>W!VSO7=IP)__A\>
MWO[>W A^78?WAJN+;OQM]=^_UBL3)K&WWR?#Z./;X5*=5P#DZ[I)K5BCSDDV
M5[)OQ:? QB@]N>B3D3M(\WW]+GMZCZ:Y,"KU(]FWX8\L'ICY5@;SC/2=/8K>
M:E!$Z]8^T,LP]L,0>3_VU-T5L S7*IE.[-38(Q@#J2E)YPNJ3[C?0L9+("/
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MPQI-?H[W#XJ(Z,Y-2,B,VB;HCZ)55 JS^DW6-.E9:9+?UJ2\>X<1AW3F0AI
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M$USBVUTU2'<RSD92W0@OC?#29VCC[N9LDXRJO@XV.XTV\X\HY6[I*&1G)H@
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M)[-6C.W)FV3:II)-R%030*0B1$2@FFB1, !--(A  J92%*4I"D "D*  4
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M@UK1KS?[WN&!]>W-5[S- II()VEB0$S>:FUE2IAP!_-Y*W>FZ>>#]8%;*FY
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ML00$6Z:@=)B-B_JN5B"!O_11,505%$<FD7+[<==MO+P]G]!6K^(^)#:HT,+
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M,0WMV_?K+I9@@' &>_\ IT^O=6OVCD5F0DCE9@P"]",CQS^)]O6NC5EU#"(
M;I[??^7R#M^/[N-7"VZ#KCN&P^NO?MT[^^NRVTDAV1VWW)W'=UQ@_P#N[_;F
M+\MU\V1<:7>E"*8K6"NR3)@93@"HRH(&6B'(F[]!FLFBT<%. @)#)@8! 0Y"
M]M"MM<PSCF_9R*3@[\I.'Q_NDCY5/O1OK-WP5QWPEQ5&981HFN6%[.\+%)/L
MBS+'>JK*V26M'F7EZ.#RG8FI+VN>$UO^W6;=\;[A<-X=B[Q1KU%R!63YOD_&
M$/(A+UB:DZE9V#V)LMMA9%B\CK+!2S%5%V@D8WD%73ZT%4E#[!^P73@/'%SQ
MN Z,'CP589!W8$;'P&^:_3CH?IQX OM*TVYN-8E@FGL;664/I^H3+SO"C,1+
M;VLJ2!B>8,I(((KU!> #X=.Z?9G:]Q]ZW,XW0QFK=8"B5"F1:ULI]HE9(D3)
MS\O89 1I<[8F#.-(9>%;MS.WZ+ITX!<4VODH><?*:9:S0-*\J<G,JJH)!)W)
M)]4G;IUZ]U:J]-''7#O%5MH5GH%\U^+2:\NKN06UU;QQF2.&*!!]JA@=W($S
M-RH55>7+9; ])=BKT-;8";JUCCV\M 6.)D(.;BW9 4:R$5*M%63]FX(/8R3E
MJNJD<.P])A$! >!UG()I;>:*XA<QS0R)+$Z]4DC8,C#V, :\_P B+*CQN.9'
M5D8>*L,$>/0]1N.ZOS_/$EV WK9+F:8:$C9&4PY:Y!Y*8VNA6YE&2\8NL97Z
M#DW*)?(;3T-UE:OVI@0$X B]00(Q>L3JXK7M*4<VL:=$!IUPX^T01C/ZJNY#
MZULXR66TE?+V$S#D:)A:L[7%O*6^V_Z'7Z36G^E'AG3_ $>\9:I'#Z4>&;%;
M16OI@DO'.BV,2I!K]B[A5N=8@MU6/B.QC9[E;B)]82-;&]Y+76WJ+U[DKV'>
M!4X8X2VGVV=L;*:?3V3<AN)J)@(B/\UR%>A8EI'LI!Z^?+,8B.!Z^<21$4'T
MBW>+)-?/0;+(&(H?8$=NUKI&D6KX$KQ7&HRH?O1&^E40(V.][.VMKD#N6=0=
M\@? /],CC73>-OTA^-;O29DNM/X<M]'X+ANX762&ZN= MY9-7:)E/*5M=;U'
M4M-)!8.]BSJ2K"MIF3LGS%_BXIBQH_T:>(L#2<;N)*S-/.-Y3*1C'"!VS*,>
MHE,LQE'12&*^.4BG2(]0>O15P<Y^5>7F;.V.^HP^G7[<HFDZW+-DR_KN&!FD
MRB4/<008+FE5/P2BSCQW'CTUWKI7;1\I'RJ1EH]VBZ(F;RU03-PJW5X 11=(
M' J[5<H" F0<)I+$Y^T0-*58[;M(G*VNE:.H8R4;--)Y@F(CTMF=F;*"X03#
MV*I.14R_-QP'F/C]N>1&FXW!\?R^OE51#L1X?G5D=4ZJ4TI32E-*4TI32E-*
M4TI32E4WW\[@#;;-JV4LBQ[SX.UN(<:C1#E$//)<;7U1,4^;E,/!U(,BSJPF
M*("44HE0# (#P.'UZ^-AIEQ,AY97400$=1++ZH8><:\TG^Y6VO0=P,/2%Z3.
M&]!GB[73([K]:ZTI^X=*TO%S<PN>Y;QUBL<C!!N@00:\*Y14<+G55.9110YE
M%%%#"<ZBBAA$QSF-R8YCF$3&,(B)A$1$1$=:HM(^:08Z# ^L^7XU]H2 JJJ@
M*J@ *  H&,* !C  !P ,# K.H5K^KV]?N'WX$?7T_?\ /4XTV#[NW=X#N^NF
M_E7#N(HF<]PS[ST]N_MS\JEJ#9@(E[<A^?M[=N>/P_'U#4QMHP,>6-A\O/KW
MC?W5KS6;O)<\V_7J-_HY[O"IB@F0'$GV?D =O<?0?\O<.>-9ZWC\0?A]=3[M
MP:U7JUT?6];&<D]>GL'SV%6#H=4/.2C&/2 2E54 5U0* ^4@0.I93CCIY*0!
M @"/!E!(3^UP&:AC( VR3T'UX=WR[JUGK>IBWAFE8YY00JY^\QV \\]^.[)&
M0*H3B*_WW:[O"W7;D7<_,2>UYGNECMO.X.K.7#EW&8MKLW3*(_QGG&-0.<P,
MXVIW*Q2$!>S)@;BNVD'J+-RX0.LVL TEO<W,Q8F'[0()ESLF54I+CP1B5;;H
MV1G&:\I76HW=MKNN:K),\MK+JIM+Z-F++ K0PM;W:9V58I7:*0#I'(, XR+P
M9 E)7]/7C,D9S<B9A#^'1CN:@@;2;GX2/=N<29Y<_2<0"2WE-'"YV[9Q\:R\
MM50R2*OFF$A!"E.V9;S!P/LZ8WV!Y'W&^/Z=.ZL7?7#?;-;/:$@Z?!RD,0 3
M%<;KOCP]88]_?$VVC="_\06G[._#;P_ER<P_1D-HF+);<UG(IYB%R1FA2@8^
MHT-E# .W">D68(.IN.EG;AAEZ]D>+2,:Q;6%"(92+"+E33N/,W:+'&&( C3G
M8YRQ"CF52?>&/@#C(ZX5;][N*UL8Y3%&MK%]HF]8/+R(BR0Q,>\'/:.-QOC(
M!SZF\;8GJ6+*-5\=T*$1@*?3H=G!5^(17<N@:1[$G0F*[Y^NZD)%ZX,)W,A)
MR3IW)2;Y9S(2+MT]<KN%'.NPZ8V&,]!Y[Y]O4^-9%)UC540X5!R@;XP._).2
M3MDDY/4Y.YU1O?$5W&7&I9 W%[>=E YFV<XRO%LJ2]X9Y<-&YSRY"8[M+JG9
M%R'@_"[#'\XPL=;KLW%V D%&3MXAK'=DH-R5BPB'"Q44Z1D/4#*C/O[L@8VV
M[LCYU;C5)R&ECMNT@1BI828E<(V':.,*00I!P&8%L;8Z5).0]Y><[EFS(>#-
MEFW*M9OE,'UNASV:KQEC+#G"5/KLYDJNEN5-Q=6DDZ#>+!8+])5!9K.S)WD;
M"05.3D(UE./?I!X+9MR';/*H![SD^._7?KY].G7K?C49GE:.T@68Q*CRO)+V
M* NH98UPCLSE=R2%5"1D@]*AY-W/M]S-@\*/)U=B++C:1E-\.1L=Y3QG+2::
MDQ2LA8YQ+FVJWW'MC<Q9TH^<3@;5 N#,7H)%:RT?]%S)&;,[DK5N+<QC/3UC
MD>!&QJL;W[4VCRCFB)OY(Y8R?622."=71N78X<9'<1AL#H(NP?N_EMMF$,Q.
MD(!KD?(68?%MW:8"Q7%7G(2./:/'SDIDJYS+)Q<\AR\=8"U6HP,%6)+X=I'0
MLM)R+X8V"A(DRKTSAISS<H;O)D8#? SD]3X;5>6.I-96LV$$TUSKE[:P++-V
M,09YI&4R3,'Y$54. %8L<*HWR-F6WC,>>;]-9$H^X3 *.'K=0PJS^)ME*M\A
MDC"V4H"UM)!PD_H-YDJA2) 9BNN8U6/ME9E8%![%"ZAWZ#IZTEB@VX?)!YE(
MQ@9'W3MG8D#<'N/S%2[2[J[F>>*\L_L\D/9%9(I&GM;A'#>M%,T<;<T9&)8W
M4,N4.2&VL>X. =O40_U_GO\ ?VYXUA[E<Y]AQY>/AM@]WSZU)(1_,?(5 &X;
M"]?S]BZP8]F2HHNW*7TA69@Z8'5@+.S34&+E$A /,!$3'.RD4R"4SJ*>/6P"
M4RI3EC-_ )D93LQR5)Z<V^,^X[]=B=LU-N#.)KS@_7K/6;7F9(V[&_M@V%O+
M"5AV]NV=N?"B6!CLEQ'&YR%(/EB<)6W%5],01>5J[X_M!3D.0PI/H6R5J3*H
MDJDH7L"S*19E524((D,)"*$$Q# (P.96AFYE)1@W,I&Q5U.<CS5M^_>O?B?J
MSB+1V4B*_P!(UK3V5E8!H;JPOX"KHRD?<EAD(92,@-@X->]?;9F-AN!P/BS,
M<>1)$+W48V5D6B!A.E'6!(IH^S1:9A[F)%V%G)QY#F !.5L!Q .KC6XM-O!?
MV%K=X ,T0+@=%E4E)5'D)%8#RQ7Q(](?"4_ O&W$O"<Y9_U+JEQ;6\KC#3V#
MXN-.N6'0-<6$UO,P&0&<@$XJJ>U1DWM5VW5YR,8[ISE#<=>8!BZ5.)P1KF#@
M88'B6D:8>0+$N@QLK.ID2_J59"7?NR\G<JG-G+, =I)W^K&O7PYSX=Y&?9UK
M5<([?5=3N2O]@;;3H&.1E(XA=S%1TWFO#&Y[V@P=UVNTF3T#T]Q^X/EJH[9/
MD/HFLP!@ 56 =^&QINNHW<[S=J#==NH=%=!?<3B!)5)9,PIG252/<"G342.4
MQ5"'*!R' 2F !#C5NSKGKO[1];?$$^57"QMTP<=3L=O$9\^G7! VZY$]XMS#
MA_-D2_G\-Y6QMEJ!B9'Z(E)K&5ZJ]\B8V7!L@]&,D)&JRDJS9R(,W39W\"Y6
M3<@V<(+BEY*J9CT6;N!]XKOCO.P'U@?7F:DITY*V()0XZQ#_ /@'^8_?]X<<
M\ZZ*.8XJC+)RC;_+RSW=_G\:P&5D![\F[CSP C^T1_#^(A[\ZNXTP/#!ZXW^
MCN,#'MP*P-Y=$9 (\OY^/L_F:C>6EO+Z@*</?GO[]^WK^SOV_?J[1<^/EGR\
M?/Q\!L/"HS<W(7))S]?GY?A4=R,L)NK[7/Y@'S]?7^0[:NDC[^@_'ZZYWZ^X
M1RZOLYW'7??8?0\-MMZP:0E@#G[?(]QYZO3_ /S^>JZKW =_3Z^']36 GN<Y
M).!D[D[GV>[ZZ&L,=RX\C]OY\<CV_+T^_P"7X"&JZQ>_Y#^NX\QXXK#S7P4D
M+M[>N=L_7QK&7<P <\GY_ >P=^_R_P !Y]M5@BC'X#I\/ZUB)K\G.^?;\S["
M/=X^-8T[L23=)9PNX20003.JLLJH5-))),HG4455.)2$33(4QSG.8"$( F,(
M 4=50AP=L#<[]!_+\*QSWK$X!)).% R3OT&._/EN=JCMCF3'DV:I)PU_I<P>
M_P =)3%$)&6J#?'NL3#)M5IB4J)6CY8UDC8E%ZS4DGT.#ULQ3=M3NE4BN$A/
MRO(Q7$BGG!*!2"6QN>0Y)8#;)&<=^,UQ-]LB^T]K:W40M'2*[YX)4%K)*66*
M.Y#*.P>7D81K)R%RK!02IK7WO>B0:6JL75NFB1&=B3PS\Y  ISR,,J95%PN;
M@!.HO'OD6Q##R8J,:4@CTE* :A](NBC]8V6HJF%N;=K>8A<%I;9B5=R/O,T4
MJ(#C980,["O+/IRS8ZCI>LQ\BQW]L]G.5(4_:;-^=)'V]8O!,L8/4);@'  Q
M18\QQQ]LH?\ W#_GQ^_6OET[?[GQ7X8!\Z\_2<0'OE7?O[3?_P"0]U49R?%R
MTEDR<9045(RSI^=D[19Q3)R^<K&<L&PJF(W:)**G,9R"P#P01$P&#YZHRP2)
M*8EC8G *@ D[XZ8![SCIUVWWQ.^&[-M<LH;BT@>[E=I$=;:)YWYT<H 5C#-S
M'"GQ.0>_%1%)"]BWKR-DVKJ.D6#E9F]CW[=9H^9/&RAD7+5VU<$37;.6ZI#I
M+H+$(HDH4Q%"E, EU0*N#RL"&!(((*L/:-QGR(^=2$Z4\$KPRP2131.T<L4D
M;1R1R1MRO'(CJKQNC#E9&P58$$ BNK&3 !$.OT^\.?W\Z")NN#CV8Z>8P!CQ
MVWJL-/V^X/>1[\@Y/NWKUV?T8^]H36QK,6-!= 9YAW=]F2&0CQ5ZSLJ]>V=4
MR?"J$3]4FSMW;IH4O[)UT'1BCSU &W=%D[72[)B<D0JA]J97'4^'YU]4_1=?
MC4?1[PA<AN9OU'8P2'/,>VM(A:RJ3WL'A8'S\\UZ.-92I[32E1_D[%6.<T4Z
M4Q_E2G0=YI\P3I?0<\S*Z;"H4IR).VJH"1U'2#<%#_"R4>NU?M#',9LY2,(C
MJXM[J>TD,EO)R,RM&X*J\<L3[/%-#(KQ3PN-I(9D>)QLZ$5WAEFMY[>[M9[B
MTO+.>.ZL[VSN)K.]LKJ%@\%U97EM)%<VEU X#PW-M+%/$X#QR*P!K49:O UV
M*09[-?H"FW]Y(QL1,R\/2%[JLYJ2DBU8N'#%G\$6,+.+-P<$2*1'Z=\]00 I
MEQ$PB/99-/643KH6D+<\W,)NSO602$YY_L$E\^E>R(V!MQW0C QO*Y_2@_2)
MNN'9.%KCTP<6/H\EN;63EBT"'6WM^3D,;<70:)%QB78??NOU_P#;9,D/<,&8
M&PE6AX*OUR%AZRT:,H"/C6;>);,4TTVI&)$">09(J8 0043X4$X!RH8PG$1$
MPCH[O([22,SN[%W=B2S,QRS,3N22<DFM @   # &P Z 5W^NM<TTI70RL(1Z
MH$@Q4".G4$^EK)I%[G*7DQ6<BD42!(QJ@B(*-' F!(3"X9G;/").$U*GO; J
MI,J7:SB@9LFHG6ZRN@(]8(3,']-OIAH"O!06^#/.M4!4* %,8!Y # 8I:<G<
M/;\#C%5(^_W5+UXR]6*6X/$E!S8;,"8'^KT+Y*CAJ50G6BK,O5E$F$(@H40.
MG\<N5VY2ZCL&3T2B374*3[/&NQ8#S/@/SJ!)3,>3Y8_4S<U^HMA]&L='&L$@
MGZ\=4Q+F;L5>W')2UM+@W/"ABAW[A!W[_(?7OKH7/=M\ZXK#+64HE<KI2;C[
M6W(/4M$S,1'1BCD@=Q29RT$V8!'KF]$UW4?*(@/8[?@WF$Y*#V5P'/MK*++G
M^0G0:ML< T8MQCHYW+3DTR,]=L'TDS1?_0#2)*X;MRR,>T<MSR3UVX=-6SA8
MC-%D[.5=5OU">/P'EY_7MKL7\/+>H2R1G_*V-J18+FG;6LPM#MD#(1TU6X,6
M#ET\>-H]LDI]#MX5\5,7#I,Q^A[U@0IN!'UU1NG$$$DH RH'+DG',2%'S/2I
M=P#PZ.+^+]"X=EEDBM]1NF%U)"%[5+2V@FO+LQ%E95E-O;R+$SJRK(5+(X'*
M9-PINS"\4NM62^5LL(G,-.'$[6U'$M$-WC9RLP>GD8HZ7TQ$-_BVRIBG;C.M
MFZ @J]>MDRF.'6W8SP1R[99?6'3# D'&?,$CRQUIQUP\G"/%VN\.QO)+!IUY
MRVLLN#*]I<11W=H92JJK2BWGB61D15:0,51 >463N[BUV#&%P<8<FZR2]2M*
ML(XRL$P<9&H)6YS#/"U.3ES,$GQG<"C-&8KR(-6[LZC$BY4D5CB"9JJX##FS
MRY',!UQG?'GBH[9M:B[M6O5EDLA<0F[2 J)GMA(IG6$L0HE:+G$9+ !R,D#>
MM.@8A\?YZ >?NMV.0O(\C]'4"QOCD ?4"@_Q*H0W3[<CWX[F]]7G/8?_ (K@
M^UU'YULC]8^B5>F@<4R?[=Y O_POQ^%:,]YOBI^+ALYW"WO;E=]R..)NT41*
MLJR$[2L.XX/ O"VJIPEN9FCQL=!0D!^&9SB#5?XEDD ND%N@%$>A0^0@M+2:
M-91&X#<V SMD88C?!\O'ICOS6TN&N O1]Q)H]KK-KHU]%!=&<+%<ZE>=JOV>
MXEMVY^QNBGK-$6'*Q]4C.#D526:\1[>1O,D8VD;C<OFOM4K2,A9H2#;TG'E0
M:-)[EG&ED5E*54Z\[D%$F#MXV03D7+M!N5TL=!)-10QQAG']E;Q:-!+&A#KJ
M$2@\[D<KP7'-ZI;E.ZK@D$C?! )KTQ^C[P?P[PQQAJ$VBZ>+2:[T&YAGE:XN
MKIVC2]L9 BM=3S=D"^&?LN3GY5#\W*N/N9%ZE"A_\P?PUK+3ER?'ULCVC'3\
M?9FO8#;MMX@?A4H0J8#T=@[<#W^\?\M3[3EVSX_B ,#Z\ZM-3?DMSUR2>GD,
MU,,$@ E*/H/(>W?V_+WY_P!>^I7;*/5QCI_3'CU/X5J?6IR.89R#D?#N.#OT
M\?D:FVN,P'H$ ].!]OO^8=O?G_0=9ZW3H-^G?GR\O'X>TUJS5KC[_7.X'3N]
MGUO["+GX6B"I XD#$#K.8C5,WN!"="JH /R.8R?H(]TQ#U[ZS4*]^-E[_$[?
M#S\<UIWBB[YBL63@ NP]N0._N&?\1KK-K6V&8;6/?K$YIIT5(XXW*YPEIR'B
MG<A'2S2VXWG<75*G2A))HP=K.(P'CEA*LC-'P,I!,A2NDBD*=NJ-CV#(UX)%
MRD\K,H+ AD,:J<@=#UZX./C6C6MWCDUHW$:F"^O'D12RL)(&@CC)(!RO,58$
M'E; R,;5 VV3PZ]V^+F_B;42VK,\BUC)>TICMMVE7I[9X M@O-8K='S!"X[K
M]T26D47$+.5.-NU8H\G-S;.(BW_T-])(+.&I59!;#-%+']H5CS QB.-LC)0!
M@H8 ]P8*2<=.^H28+B$WJ.PD1X%M[=RREFB19%C#[[,@94+$ 'ESTJ]%C\-&
M[W;PY]G="H)(;"V^79?B/$EMP9=84\05E4<_U&A0#;(-0FY.(\Z*FJ/E><9R
M\!D(Q3R,+/+O4+3)MI\K+X9]9N,(N?59  /)@-^G7.">_P!]6$Q @@0826!$
MY6&!RNJ@,,CJ'.>;KS==ZW#X'<Y6MN'<>V+.&-V^)LO25:8GR-CYE886UQE<
MMJ &;3"$+8:_)R\;*0+MT@I)P"Y7QWQ(=XQ1ED6DLF]:H6Y<]WU[]JI#4!MS
M'#'J.H&<#K@YR=O9L>F^D[#^*/$UV8[?)?85M_VZU2TI5R^9$C]ON]F6RQC-
M+&=.Q;DO)T_?VEIRIB*=>$RC(9 QZSMTI'+U:NU&QUZQOV$<HC,N6(.U'0,<
M8'LS[3X?0KFWGE2/LH0-B0DA9>50S%B64G.5R=@#GXU%6>?#OG:5NYW#YMG=
MA-1\1BE[D&^-+1$2QLCXSQ?D3$F2:=1(ZAW"(GH[)$]5:])4._+0T7;F$K4W
M[V1J[U23BE:R\:$9N#=L;DE>;(&.[&/(^/OP-M\UD$A_;R2FT6\67D..9$=&
M5>5L\Y"\C;'(R5.1@[&LGJVQK,M0K?AUE;XDPOCM_B+=M?\ /V;J-A-RE#T#
M&U>N>.<F5Z)C8E>PR02=\GX<D]48*S3D8V \]-)R4PRC$(@J:NJZH3V>PV;+
M ;;8^OY=:S5M:RK^KB(H8^RNWGF2$X2-9(I5 ',<NPYU5F'4Y8 #>HU6VK[E
MZ5@[*55D-M^'-QE8N?B#[G,V7W;IDJ2HCI?)V",HV^R3%&L./[78W3NG4_(T
M&\?0EE9,[.M$N0:)R,:O)04CY J]Q&W*?55OVC$J2-UR<8.X!SX^&]9**SNT
MM98S:6UXDFJ7=Q-9S&(F:UE=FC:%WS'',K%7 <KWJ65L9SKP^-MF2,)Y6S==
MFN&Y_:1MTN%6HT+0-J\[F=MF(S"^1,A/OKAE-JC!6>Y4[&K.:CG\+7FM3JME
M?DD C5I*3;1GP\:T+P(R _J\B[87FYCG.[;9 SX BLYP[93VUU<S"V?3[*6.
M)(;![D7.)E+F2X 622.!65D01H[<V.9@"% VGN%B]S<\\]OG_A_'O[_=K$W(
M'K#'].N_NZ;XWJ?0*V0?(#Q]O\A\NE=6=P '[=N?W?L_9_KVU'[L=?K^H_#W
M"LFB$K@^>/#K];_RKS\^)UCAO5<X1-XCFX(,LEUM)\^$I>E,]DKQR1$F8H
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M'\/4%4?V^8@LVXG,5'Q#5 .60MDNDW>R (J+HP, U 7<]8'A0  ^'B(I%TZ
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M$$C3F QS&.;=2DF-?'IMUVV'Y U\C,#G/QWZ;[GY9Q[*F= G!0#\ _Q'^/\
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M6KE8).O \9.4"%GZ[+%> U;N5182(B[8N2@#ID[9]%/*2I]Q_#W$8]E=V',
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M!LC*XD-M$Q#\I6XZ'E-0P)O7\_7V^_VZ??CU'\N-:H2(GKG?V[Y_'XUZ@M[
M #;P.<>SWG?W>=?!1P8P$ QSG!,HD3 QA$$R=9E!(3GL0@J***=)> $YS&X$
MQA$;E8QTQX#QP#O[OA[<5EH[38#ER ,#O &2<#N&Y)Z]<GJ35Q/#@V<.?$%W
MJ8RP5*0\T^P11I)KD_=%/L&#D8*.I%<3&:K..IJ>Y191KW+%A:QT 1FD[^F#
M0!Y>2:MS-6RRA9+H&G\\WVN5#V46>RS]UI!@>60HSY X[Q6QN!.'GN+X:C+
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M))!#&R0B1Q&&:[;>*:1D26(@FS2':M69FD:V8MD6S-@4$S$0!!JB0J*::)A
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M X_Q#VU.M-F^[Y^ [QN/CTZX[N^NLB"6%EQU78;C<=,=:JWFRC)Y4S^VH1E
M2<V3:SDMG$NQ.*?P%@0NE5?UN3!0! 2'C)]G&R!3E$HE.V*)3%-]H)=;L&0>
MS ]X)&_EYXP:\=^E;AL<2>DF/0/N2ZAZ*^)TM9,E>POX]<TN?3[@-U!MKZ.W
MG##!!CV(.]1S=\A.=R>)\N9-DD5$V^$]JCBH/&:Z1DBL\W9(^%6R9\,4 * *
MP$+6(V%.4_!DTY]P02 *ABDR8;M(W8]$B*C/\;XYL>Q0!MW5HSB#5GXZT+7^
M()HV5.%N ETVYC9.3LN+-9"R:\J  #FL8+&"U8$ H+MA@9/+=M"8/<,ZUN%H
MF.L03M^QMMGH*D_=<_S<VZJ4)5+.[=OBM:90(V->)O9$ZS$ZEHMHOX42,?@8
M)R\!--%-;+(_:3*$CA,D<"AFN&8J$)R D8&YS]Y_5]7U<XZ\ZI!]OUV&SL=.
MTJ:_TWA/3'NK_7;B8VL%G>%Y%6PT^.)P\G,A-U=F2$!.SMV; 4-%F-[#%2&V
MN@5.URU2>[?YKQ8IR!RP6I)*1&'WN,W%@EYZ"AD(M=^^:PF%IR]A7W:4:^?+
M1:#%Q%HO'RQ5U%U^T3 VL:.4-N=6(F"[0]D69E7&2%A+\IQG &,G?)U1V*/I
M,:.]L^G-QQ=VMU):@QZ<;0S2/$(E+.L6G2W!B**S,BHT89SDEMK&:8[:C47V
M[AGBN/95/.CWPZLTHW2KXYBF4+CYSC?Z+E2UN6N\? QB$"6]HRQU&527>.$;
M"K5%98B"*\,D4Z&0NXK56NNQPLWV"9G6-<)V8!Y2_+ZH?/W<GF*YZJ*[ZO8:
M=%+J"0*L=XFCW$DL4*A85A 8QO,$4*)N;:+F(<IS8'**A\^,<&8[P1X2,'-T
M:FUW &7+UARQ[KII[&1Z;7+&1QP+/6K#A,YSSE+S[I O\NRSQP$?=7;ZN(NU
M64:1LW8ILFA,<UO%'#I^4"Q2F,SL0!SN82T?:-MD&0_O' ) VP!47FTZ."VT
M9F1%M[DV[7#D8#RO;EX1,YQS*TI..?*YP-A@5+NZL<>4G=/G>'VZ1-5K#>R^
M%ENM4W3US'C",AZN9*.B4DL$SELAX!)O#(WPSM];(V&?O4"V)>H'<I$,>$*4
M0Z7$2)-((@H_T.9I@N   /V9(7;F)YL=_+Y;U2NK,)=3QP*,KIMS+<J@ "A1
M^Q+\N ')Y@,X8IO]VH:O58VR07A)[/[CM_@L<([CU9+9^^P=?:LQ@RY:FMRC
M^_8Z#(2 V)FF%FD["J96^MKK$/7:R3./:/&3EJBA%1Z3;HT,(LH'B"F5NP$9
M4#G,Q=>89&Y/W@PW( (QMMP;.']56DT'9F=VLQ;E>4RR7+R1AU&Y9G'[3G7N
M"D'H +4X*Q)A;)&_'Q0;EDK&M(R),#D3!=0CE;S6HBUMXJO/=N=%<S#*(9SK
M-\UC?IY8&I9U9FDDM*H1<4W=G51CVY"7EO;(]S>F1%8J\2GF ("F)2<9SNV=
M]M\=V,5(-,TN"?4=7$D*2F.:UB':1JX5'M8V95#*0O-GUL#<* >@K7_A.X,K
M!ME\+C#3;&5)RSE*0F=S5AQ.7.-UG8?"U.98CM=UK9G]F@(Z(L;C(-AA*K/,
M8G'-=",4/!';K3"3^)*Q17/:QD?9[!.S660_:&C$K%8U$;NN6 YBY ("*!@8
MSD8KMI<(GL^&[1+6&YO)Y-1EM?MLTD=G&+-Y8V:1%25KB18W"P1A24(9\H%!
MJ.96=R+%0OC2Q=-E,3I7EOA_ "\K'[:(R2@:%$OC53)#/)'T(Q6DG[PUL;T]
ML[;VR81,S?K3#02+-&3QD5!*VE=@;X#LPQ6+/8C" X8/C?9L$\QZY'0'89&.
M&[2#C]+9[0W5OIVF.ZZ6K)!&6AN_M@0<SN9E@5NV<$-SJ00K+@3;N7J6T>NP
M_AJ36%X/&<!)NMV.V%OC.2I+*#8SEHQZ>7:/)LL@YB$TW\_"^<V@)68?2AG8
MHV=.,5=."2CTWQ%A.4 4IC &1@#H!\]ZEVJZ=P_ G TNG1V4<D_$G#Z6+VPB
M66XLWE1I>8QX>6+(B>1WYL3"/F82/@P90*U:\B0&^2P9#J>RZ><NL[9SB<S6
MG<1(7'])U.KT0\7CJFU*Z8UB8^K=/KM,0B76-E81^@B1),LC%#])>8H&(N)
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M #X$.>.%0G;'7&V_\\5*(+7H2/+Q \,_RZ>^L9LEA1KD,^FG"#AT1D1+I:-
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MIQ$>L8$&K0 Y0\]9VN[]4<!<$VW#MC'>7<22:S=1AYY6'-]E1P"+6$[@!?\
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MDD[GV#).V:UUJMXHD8R-A0< ;G+'NQWG&P\!S$]]48REN%4F&+B(J23Z-17
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M!"R &'D> '8/HSTE-5XIMFE4-#IT4E^ZD9#/&4C@!_V9I4E'_IU&>(IS'8+
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,:4II2FE*:4II2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g29248g13y89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g13y89.jpg
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M  (1 0,1 ?_$ !X  0 #  ,! 0$!           '" D%!@H$ P(!_\0 7!
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M)?7I("0F!3B,B/8RW-1'_=[MC[-C,R[.[YA46.:-V[ (CHNW2/4N?;'H->:
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MRD!06OY[]_F';N #@ X . #@ X . #@ X . 'FZO/Y;+B]*=@^MKOP+Y=Q?
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M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
M#@ X . #@ X . #@!YNKS^6RXO2G8/K:[\"^7<7P%\PWFU[^0.C_ $05IZF,
MO LGWG\)_.)?X% X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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M8WN-OZ5$[M+DQ32(2!F4IEB8L>3$.3B^V0:48(!D9=A^]\I;E\@E+@4#@ X
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M]UF67$<S)_>ZZ>ONAS'@KLN86'+U\!/SEEEPY"$X8:_$^!PN%E7@CO\ .3.
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MLLB2E);$22+L(B(B(NPAY:8S.HJS,S,SKX9F9GN9GU=OM,S[Q:#D5&2#@ X
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M5%C8"X:6M:W$R]YL6ZJY]F)HU9L>6M(:$,2H8J";#7,0)62[KG,<:3I9-F)
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M*X:JE-:'4%#([N8E+[)K62UR%> U'&<2@FU);;3)2I2EI-Q)()2[;5-H.;U
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M)I0;IN5[LNZB43:KI)H2EA)2Y:5JZJN49,)-1;K];$FLW6?O1[NNHZ,2:1P
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M@DTK)Y!MH:,S2HU$DMK/=%K-7M;8>DQ7% 610\;F7YR>9+.L7!EU$:Z)!/\
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M1YP$LHO$_</*,T>?($L&/^L0LXQC_P"O-A8W7V%KIUK=7U<&993Y6GK[,6%
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MHS:Y">>:.)A"WBW;2:BYHN<WPM70RT^JTY?BZK.SUXO95;7)OZDY]A%9QN5
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MZ,EIPB2DB5LDMK*]#1B8WR%;BIWIF:G@@=>A$,ET;D;@2(29_L(].(1:LDX
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M>$F41TI80T1<M+*2:2DD$21>Z(06$$=5*P&XB'14EO9M0XLZLZ$J/-!:-J=
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M>YYT']*?_I!#:$/W0/JA7H<SGZ>V*75]\Q3<']^J+_6R3\W[$]UMJAZ/:O[
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MQ$DFXZ(,QM"6R/\ *X2(B(N_8A;C2:GHO:>V.]"I=%V=\G4;U4TA1UJ[.7E
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M#KGIG^V?BOHDT]^KY(THY/QR,*:=0OYE.QOHZ7?TY!R*9S[$K[] 7_QH&_\
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M/[0#I*?Y<<D^R6#CJ9/\F^KS_H5D?UU:+YT3"]UKISZ&:#Z'9CCNY_L\F_\
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MZ*YCA6/DQ#DRRDW]RW'3!CO*CH645EPVU$N2_P #+?9QJ(76Y+AST' !P <
M' !P \W5Y_+9<7I3L'UM=^!?+N+X"^8;S:]_('1_H@K3U,9>!9/O/X3^<2_P
M*#$+=?IM9VKV?'9H;!U[$P/B6C&AX0S]JL)9:,,S2LZ>)6[1" '0FTXC&%3+
M=B9Q!")V?*(\IDS$S*' YD6N*DF/)6(/LE;%MMV]OP=I=F_P=_9W]QC7*EX,
M\UA3M3UI(Y>Y6%(:\K2"09]GSQ@X+O.'F)19J8'27NH5"M>H"Y25<WGO2[!Z
MY:=A4M-P:K4#[1PP^#$E\ /(K_=!_P \75'T2N/K^X<FU5[5^NWHYD_2DC9V
M@?NC] /293_,X(S8/I,<?=AH+_A\-',#<>Q#H;?K#-?I=(.@*+\W>J<?KC$O
MMWF HO&/H[G?[XFJ_J#M=R>1_;EZ8?HUO_LQ"&(M_:W]3)^//_N?0B\L'^D/
MZ=WH6U"]?%_-067N>=!_2G_Z00VA#]T#ZH5Z',Y^GMBEU??,4W!_?JB_ULD_
M-^Q/=;:H>CVK^P,8<]Y-[BWHF>E74+^("Q/;M\M?3"]"C9_7;NOG.D3W(N.^
MF^J^A6(ZQF?V@'24_P N.2?9+!QU,G^3?5Y_T*R/ZZM%\Z)A>ZUTY]#-!]#L
MQQW<_P!GDW_FBN_LJ^-/(?\ 0:/?I7:?U7BG.'K;VN\A^-,[Z_0._:OW>.!^
MB:!_#:R%@>JS\KUF_P#AH[!?[Q?^;LT^]T3IM_A,_6@XS1[@[5KTPT?V;ABL
M>FWT)6U'[[!]5Z%YKK,_ZG7+TG9K]>,#I6K]T3T&_P#+GI9]09B(VUWCC+,.
MLP_1&2H"W6.2F#1Z./[6<8<44Y,KWHDH;'5 ::F-)4%EK$*H].,Q.<4< )F1
M%&EF8"/&W<WDOPJWHG3(KALR8E!G<F.ZDDF;3[#T1UEPB42DF:'$)41*2:3,
MNTC+L&AL3;0[I'ZH4TXGB;=U!TM;6D]]E(7G]@E23VV/M29EV&1^87QJ6 0^
MJ]?NK_7%?LB>-0F%N%HQ^,,"4]8I3M#.WUF_%(T))[@H5K32R"\8"$:E2>=G
M'^68+/Q\TQ,L9MN6LMG8OJE3IUA;2)4A:4)4\\Y"?-;BDMI0@C4?;LA"4^8B
M&UY3#4;*/4\H["";99H\";;01F9(0G+*HB21J,S/8O.9G[X[V[_R9Z)_^>O_
M -'XASRN?Z/I'_\ 1?5<44A?GCU0_P"')_MY?"0X3\Y?J_\ H[I?]!IESWP_
M9%JC^@5'U+*$5R+VH.@?\:]0OXEX^.@5G35@7'HSTW 0!H3NPJVOZK;5EV%#
MHVM?F^%1.0SW#VY$Y<E27"X]-EP2]VW(N_7*.WGN"!]@7D\-=53K7#L ZDTE
MWP?=UME*W<;;X(D9^;SG"YBD\:D\:=FT;K5OXJ3V,2;+\_Q? >DATME91/=@
MEENF&:851<J%,F=:R&\J\9.NB.=49>ZLV[U5[BE2.7&:X2YCJ>(M]<F^JX T
MV-([<;HVE36-*V!MC,AE 5+@)6YL3.(LQM;C4IBL;<44D&46(!B=&2>+(?X0
MT?E%Y=GMUL)J>_:-QTIGR66X[\@E+-3C+1D;;9I-1MD23(MC2@C\YF.&)>:9
M1.Q.JP:5;O/8G264RXJZ9344F(=E/2M,N6AY#"9:UOI6HE)=D.-IW\1">P49
MZ2'S$*E_UO9?ZE2KD.TQ]AE9_BV'UA)'2'3E]TKG/Z#B'V0I!_*WZ7%G^X0;
M^N;IRB_;/9^)9_7#HK&]PS/_ ,S:/X;PASW57^8-?G_]5:?K%7W+^I/L*NO@
MK_K6",=T*/=.:9?^;,/L#E0Z-.OI%-'ON^VWZNF\\<WV=8=^I+3Z.8DF.>Y2
MZ1OI2P?ZV;&HG-BCC,. $&;0?-IV']!EM>H,@YA\A_,%Y^I[/Z$^-D:-^V]I
M5Z2,&^T]6(^T/^9KK7Z(XC_N\'/#AGL4Q_\ 5<7_ )9"4])?V_M7/CS>?23%
M@[$^3^=?N=)O]R+N9R=_H4S]%D?\I8U;BGLIQO\ 7]/]8QA@D'Z,+I]?>JK;
M]3;5YI;_ %=X1\8Z_P"L+$?IHKW8W2D]"F7?8_"1Z'N;S'Y6"/JQJJOZ:BI4
M)K.-I8I%B'!R=2F=&I<%9('!X5#6N2G!SFK7*LB5JC!G##D_)81"S@L  _L\
M\-?6P:J,4.OCIC1B6XX32%+41+=4:W%;N*6K=2C,S\;;S$0E.8YKE&?W2\BS
M"W>N[IR+$A+GOLQ6'%18#*8\1DVX;$9GA892EM)DUQ&1%QJ4?:)!Y[A%A'U>
M577]3HY(WU[&TL91R^8/<^D9"52X*0NDOD84@7I[-$XJU@RCU^$*3O"4PB48
M.YQDE.7D0\B\,&MA5B)"(,=,=$J4]-?)*EJYDI_AYSQ\Q2S)2^!.Y)V06W8D
MMSWE.59KE&;R*F5E-N]</T5#78Q4N/,Q63A4-2;YU]<@HK#"5M1CDO\  XZ3
MCZN8?,=7LG8_557\GGT%M!]C:5QGM:$R)/!I&:I<"U,>)EC=EID):9.0K*0*
M,.;<+*4[*Y(J$6#]I/DDS&!\/5L&1-AV+T=+DVO)],-\U.$I@I+?*?)*4K)"
MN8CQ3XTJV+\G8^T*S-<HI\8R3#:VW>BXSE[E4[DE2AF*MFU<HY93JI3SKK"Y
M+1PY9$\WU9]DEJ['2<3XHD'GN$6#@ X . #@ X . #@ X =3G4%B=F1%^@<Y
M9B)#$9.A$V/S*I.5IR'%",PLT2<TY"H2JRP"&46+.2%!0_V?)VO)G.,^:9#C
M6$5Z%,:)^+(0;;S*C4E+B#,C-)FA25$6Y%W*(QG,;R2[Q"]K,FQN>Y5WM-)3
M,K+!IMAUR))2E2$NH;DM/,*425J(B<:6GMWVWV,<PQLK7&F1GCC&D WLK UM
M[*T("QFF%HFMJ2$H6]( P\PT\P"9(042$9QIAH@@P(PP8\Y%FZRRW'9:8922
M&6&T,M((S,D-MI)"$D:C,S)*4D6YF9GMVF9CP65C,M[&?;6+ZI5A9S95C/DJ
M2A"I$R:^Y)E/J0TE#:5//NK<-+:$(2:MD)2DB(N4Y<'B#@ X 4HWEIJP;L@]
M.LM=-"=X<8CLA5-B/Q*AT;6D*6*18;X)Y7EFN:I*4I.3^-38+0IQF+%&3,]P
M2/ !]F(YA4SK>)5-06DNKBW];/>)3C;7#&C&\;JR-Q224:>-.R$[J5OV$>QC
MH;HXY_B^GF19]897.=@1;W27-L4K'&H4N<;UW=)K2KXRT0V7ELMN]7=XI+J4
ML-<)<QQ/$G>+XK]*]:7W-(O^I;3S'1O;+LOBI&^L&A,[OW$>&>G^X^R$\?GU
M9?F=OOI'JGUT;>-2_8J]^GUGTQL??0?]ONM^*>:_9^4-*^3\<AAP < ,U-#/
MEDZA/WKW[^AF\@&&?G7./C*]_P  Z[Z3'L Z+/H2K?I#8TKY/QR(' !P < '
M !P < ' !P \W5Y_+9<7I3L'UM=^!?+N+X"^8;S:]_('1_H@K3U,9>!9/O/X
M3^<2_P "@\J6QT:U^I+JKQN/R%GJAPFDKMJG[Q+<C-0NGL@GZ^3W#LG$8[&V
M"%R.05CC8:P'EJ4/ZR1R"W&R1$SDD4:?5L>=7^=M3@)N=PND9FCO/N,ORE;;
M$7F[?@V[O@(>JW@6@X >17^Z#_GBZH^B5Q]?W#DVJO:OUV]',GZ4D;.T#]T?
MH!Z3*?YG!;RX:8K.&S/I]W%&HL2UV3<NO,O3V7)P.+RH.E!->ZD1*/PXLYO6
M.*AH;L,K0>:C*RSM[=E4$>3E^5:CR&XTW&N[2;:='JEE2U.UE))D*JXIMLI3
M$58QJJ1--+B&TO.<]Y)+/G..<&W"WP)[!T_ AQF<1]4;EMM$F1+NZ0I#O$LS
M<)C43+T-;I-1H3P([/$2G?O5N?:,#XQ]'<[_ 'Q-5_4':[G04?VY>F'Z-;_[
M,0A";?VM_4R?CS_[GT(O+!_I#^G=Z%M0O7Q?S4%E[GG0?TI_^D$-H0_= ^J%
M>AS.?I[8I=7WS%-P?WZHO];)/S?L3W6VJ'H]J_L#&'/>3>XMZ)GI5U"_B L3
MV[?+7TPO0HV?UV[KYSI$]R+COIOJOH5B.L9G]H!TE/\ +CDGV2P<=3)_DWU>
M?]"LC^NK1?.B87NM=.?0S0?0[,<=W/\ 9Y-_YHKO[*OC3R'_ $&CWZ5VG]5X
MISAZV]KO(?C3.^OT#OVK]WC@?HF@?PVLA8'JL_*]9O\ X:.P7^\7_F[-/O=$
MZ;?X3/UH.,T>X.U:],-']FX8K'IM]"5M1^^P?5>A>:ZS/^IUR])V:_7C Z5J
M_=$]!O\ RYZ6?4&8B?-9M*MCV;J6-&V3C!$I%$/<7A"UMF&);#C5)Z;X*1<!
M[W,9)?1R@G_E2>4W]@YG+,[ O&]CP01*,;/RJ2S>4W1^16*ZPK#<?RR/D6Z5
M,]1=NBCN5R4\\F^M\Y*3-2HG/2UW.F@<Q5F8X]C6'=,_#KF<J+D.HV?87(Q"
M"F++D)LVL7S:=.NE+E1V'8D#JL8^-*;!^,J09&B,3J]DG+K-\FO6G_>FW?TW
M?^:99_-^K?Z39_07QT!8^R[U/;]38)]K:H?4[_R9Z)_^>O\ ]'XAS[<_T?2/
M_P"B^JXHLPOSQZH?\.3_ &\OA(<)^<OU?_1W2_Z#3+GOA^R+5'] J/J64(KD
M7M0= _XUZA?Q+Q\68Z<'S(-=OW+5>LCYR08%[#Z+]$5](>&G^EG[HO5;XPM?
M5-<+MY_BS_FS_P#YR7CG89L])#YB%2_ZWLO]2I5R :8^PRL_Q;#ZPDCKCIR^
MZ5SG]!Q#[(4@DU53EA&=0]MOL#(7FK4^I0ZL-D/G5HP<&;BM-?)\-7F7*[#X
M(KS,>4I\XA;LMO;%X?Q7B,"+QD%54X\Z;NB9+P<G&3KC?YC6_7/"*Y'*Y/'S
MMN4HE<PFS;W\7BWW(H>SGN+(Z*TO3)5BLLS=UQ3FB*KJ4XVSQTL*BTYS?"!1
MO!Q+\(-K9ZH<LI?"7-Y/*,EGRV_E33R\M2+;JRLV<M_F\I!" LC0:YM;.6KR
MSV1#Y X]IR>EC>V)O#M+2O4X\2K*[W)."">\4&E%#NYM63;C&+.MKVB?F22A
M\EHW&VB5RI\5]SUQY:&T\+32U>,HM]N$MU&1'XNC#G&-:;ZYX-FF83UU>.4I
MY(=C.1#FSU,>$,1OZJ)M$KX\J8[S9TZ,R?)87P$X;CG"TA:TP-8B8Y%U'M)T
M:D'=J$E"7 F/!@01]@XAA/*-!VP9$ 79& 6.T 0@B\GE#G.,XSS#3TFC/<00
MHME)IK5*B[]C2P9&6Y=G>0V9BKS<CHF=(>0TKB:?U-P1YI1D:>)MVS96A7"H
MB46Z5$>QD1EW&1&-/>;#'' < (JO:,O4UI"Y(;&T@5\BEM56'&6%")0F1A6O
M3]$7=J:T@E:PTA&E"I7*B"<J%9Y*8C ^]/-+*"(>,;<QW9=1:Q8Z>-^36SH[
M*.)*>-UZ*ZVVGB6:4)XEJ(N)2B26^ZC(MS$UTUN*_'M1<!O[9\XM51YKBMQ9
MR2:>?./7UE[ FS7R8CMNR'C:C,..$TPTX\YP\#3:UFE)]0U/@<HJ_6NDZ\FK
M>!IEL.KR/,$A;2UJ)Q B=$",)2I.%<VJ%:!4$LS&<8.2*3R!_P 8#!8^/GEQ
MJ%(KJ"H@RT$U)B0([#[9+0X2'$((E));:E(5L?E2HR/R&,]K?DU-F6KNHF58
M]*5.H[_*K6SJI:H\B(J1"DOFMETXTMIB2P:T]O+?9;<3W*01B>7! D=$"UL7
MDX4(7%(I0+4^1#!@](K)&G4$Y&4(!@,&DF#!D18P##@7E ((L8SC-+0EQ"VU
MEQ(<2I"T[F6Z5$:5%N1D9;D9EN1D?F,:SBR7X4F/,C.&U)B/LR8[I$E1MOL.
M)=:<)*R4A1H<0E6RTJ2>VRB,MR&>^S^JBQ51U T]KE!DR>.5;L56<ZS' R$E
M.2QPYE=).\21>4XR]Z\4O$4O>A'A187K' X2K):-.(DGL%0?(L;6JGI:JAAI
M2Q77M?,Y'/)),Q&7)#LA9.2G>)>RW=^#C4L^+9"=BV+J71S6N.SJ-J?GFK&2
M/.VV9Z49AC96QU3CJ[&_L(5/ J(RXM%7\F*E<:N)HY!Q6(J"9)4AU+CG$O1/
MDZ'*8< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ,V(K]*]:7W-
M(O\ J6T\@$;VR[+XJ1OK!H=<W?N(\,]/]Q]D)X_/JR_,[??2/5/KHV\:E^Q5
M[]/K/IC8^^@_[?=;\4\U^S\H:5\GXY##@ X 9J:&?+)U"?O7OW]#-Y ,,_.N
M<?&5[_@'7?28]@'19]"5;](;&E?)^.1 X . #@ X . #@ X . 'FZO/Y;+B]
M*=@^MKOP+Y=Q? 7S#>;7OY Z/]$%:>IC+P+)]Y_"?SB7^!09:["ZU;7S_;:,
MV76<OK,NNTCEKDM(DLBL::1ZP:&::PL1]DMPL,)JMFK:30ZSDNQ4+=CX>^KI
M//H H2DA1@5A<TD881%A]$9;>7?M\G8>_=OV^3R=AC4K@?(< /(W_=!2<\_<
M35;)))IV$]/NB@_)18QX)(+G[ADPXW(<9[!8/B[0Q>0.,YQCR^7.,9ED.="A
MZ9:TM2YD6(Y8X*NN@(DR&6%39\F6DF(<4G5H-^2[LHT,M\3AI2M7#PI4993#
M-3,#T?U:T?U$U*R:OQ'#<8SROM+J[LC?6U%AQ6GGGC:BQ&9,^?(Y:%&S!KHD
MN=(47!'CNK,DG-MQ7C/+&;>G^C@E(39D# :?LN.1R1VN45"H]9*H%#1EGF#E
M$B@&+W53'8^V-YKFVOAZ=.1(C%:-.C*+#WIF.>($Z<_?Z5%7U[B)]>\VS6IL
MR5&AV4Q,. VO9UOC<1$:-LE&_P &[J5IY9=AC+0.D=K!J'B?3.G:!]'6ZRG3
MG,[2NM;?5+4K)X&F-=CU&]FF1V%+85^&6,27EN4^'E3"981$8KS@)C2')Y(,
MVVU8F,(7#&EKD%(-"*K<;+Z^Y/-4 4XGHIWB'[#>XT)!1><Q\,2&V>[3W2B,
M-R\@7XB_FL TXG;L[U9<U*/4WI++1&PI%ZO!KC\.F')-VJL8J54$4I)XL\AC
MK#]BW$Y:FTVJ&HRY!.)-1-\!G&;*5TY6\&Z",F33]%F32M99S-):V%;ZJM7\
MN<C/:A2F-09LJN\$16GK8HS3;F/-O\J ;KSBEO\ "VFU<8G8X3N5IG9%I(28
MHSP&K=<58B6DY3*5;A6T<EBMU1SCPK6D$J)4+D@5Q:B-DD*W-*>@SV._"K3A
MYK2==6J=&=)*^=CS\''ZS/\ PI7Y2<^+(CVO!6\$B 5<R1S8<Z.R92"2Z2T2
M&R<-I6Z.$YDGI,ZFZ6:Q],N5TA^C[E]1+RG37+,<R3(]%W#U9P?")TV6WP7V
M4/16JZ^H<-*274W;F172W(TAV*EV.:'S<;KU!4YZ;1C< I02:09[MJ&-[LX
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M,FXTMEIS;9UMPC,CD;GO$3#@ X . #@ X . #@ X . #@ X . #@ X . #@
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MMN%8IAV$ GEP,<JX$M/5;2)!FM\J7&>:W=C(2O@XVS6VI*CN_P F YT#@ X
M. #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
M!FQ%?I7K2^YI%_U+:>0"-[9=E\5(WU@T.N;OW$>&>G^X^R$\?GU9?F=OOI'J
MGUT;>-2_8J]^GUGTQL??0?\ ;[K?BGFOV?E#2OD_'(8< ' #-30SY9.H3]Z]
M^_H9O(!AGYUSCXRO?\ Z[Z3'L Z+/H2K?I#8TKY/QR(' !P < ' !P < ' !
MP \W5Y_+9<7I3L'UM=^!?+N+X"^8;S:]_('1_H@K3U,9>!9/O/X3^<2_P*#
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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MEKY(:K\UUOZ!#^CMC3^?>SO-?C;D?UQ,$C\]XB0< ' !P < ' !P < ' !P
M< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ,V
M(K]*]:7W-(O^I;3R 1O;+LOBI&^L&AUS=^XCPST_W'V0GC2?D_'(P< ' !P
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M;^@0_H[8T_GWL[S7XVY']<3!(_/>(D' !P < ' !P < ' !P < ' !P < '
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M !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
M< ' #S=7G\MEQ>E.P?6UWX%\NXO@+YAO-KW\@='^B"M/4QEX%D^\_A/YQ+_
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M@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
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M@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
M. #@ X . #@ X . #@ X . &0_58;=O7$BBL:I&786:2;9?NZ]YQVD[7G)9@
M(#[FO=%[G%J3!^," _>:?&]YDO\ QGX;L=XH[6K]26\H65-^#1VY&1V'7/!3
MDAOL,H75^?R%)W[GN5Q[[>N<.VZM^Z^A1,T)B.:D_CL1IVI#B,0_!K\/H-/-
MV4E63^%_!7A:.^;>Y*K.O=7X>/\ H?.XN%K:@.J#!U/4VR-,GVT?MJ*MBIVS
MCF89C);!51;+'@8_%X?D[@ZG(3FWR=GQ %90R,A\G>!SCD)QIG4,K^I.T/)O
M!Y3&CE]:?G*C<GMXN<E;AH-ONXB41I\XZ?UNM.AR[I+J W@[6AQ9<O&IZ<?.
M@J,79NBLC2GD^#'8L)N2W+[^4IA:72/\@R,:!=49VW6CCWK-C41^L-O17-*I
M?JU8A\(BY4M25<ZW2DCXZXV7D27+2Y#9&6DE$4E8W-^6#(82"Y6F(=PG&C;@
M<Z&'X\)X>WB\FQ]^V^W>DO?/L_[#)=0GZA>T%>UC/[M@UWM$KL^O^H?%DT1S
M4*(F6TZ3"-&()5#&UL;NN@BV0P0Z]]A(G9SXU*B%C2=:#1+FA V!6-QC8G+#
MZ\4C[#(]C3V[]A^-OW;]NQ&1'OW;#J-/UUMW 8U8NP5'27<B+RZO]:^BVP,L
M:7U2Y(@76](K#F%=W[";"C$WJ$F72EII2)2"8-JAHC0H_B-L;@VRR2JGA*1'
MWO@5,T]A'P]Z_+W;[;&7:??W]N_=V>46)17!U+7:TYLRQR0[;+[_ %Z_J'-5
MUU _4H)FU?J2M8Q!K8%I#*]>[*6U:U1Q_E<CDK?2X8RK8;)GCY.E+_,_=JUI
MDS:)8D"FR=O[NWB['OVF?9Q;EOOY3[R+;8O.(,O.U-K=L:V:'%S*W@:JPJ6+
M]'R=R\]NUVMB&2@=P1Z^Y8AW#E,;C3Q3QDOG+A!$1;-)W_W'Q]]:DS_"6-W;
M4;G'0&E/8"(B/^Z9GS/[Q&6W#XN_;L7;O^\:3=2>H;ML+;'7N84W)[\KU17N
MB_4 =DMETJP)5#OB=@QKP]UQ 71Z>H3+6UO5S=]8/%IX\F2-LFE9,><F=L.\
M$)Y(&%$&1$>^WY2.P_+^5O\ NW_8*15W?'5CEFT]+8G3Y<,+$[-^H[H.OSZB
MLDJKI?3\JUGALBV2=WQ!'M8GJOF"?H+8<Y\4L>9OL)7DGKV<,D=A+; #6!2G
M"Z4\WS"NR.$^XS\;REOOOL7][?;;M[C(^WM$<3B;=6"%ZUZ6/KM=VW07V[-?
M+#M:RY<;5TC6S"#[7"8ZL8ZHI1\@]-:@W/*VF%-K2AD<A;:\G,2B;=9LZ<IP
M=-;::A 9F='4/$,U;$1;'L7:7:GM[2-2B[>[MW["VV(22[;/;UQK:^K&.Y;;
MV0A5CROJ#:M4DHJZ*5*F2Z7O^LDMIZ)/<@7-EDK:X4IB+3D5K8F9+_'QVF&?
M(&U.O:3X20Q,ICDQT/[OG[?D%-D[=A$?BF>^_C$K?REOW;;>3;W]Q"$ZN'>W
M9K4W%-SJ$[82N1,'3O.;]A667:ZV5&4C[N-%-X=:4WA&MR7UXR(YI+FFKQRY
MS * *G:-*(P<YN"<U4:SNXFBHKLDC,]R_*[/&W\4R5[_ ,'?V_O%L#F'=M[N
M2:UU"G_8C7NN)=M!U?)K*9-2M3QJ&JI0FAK50SSK,Z.4E<:J>4"KW8/ZF5>Y
MR8"+')+.(3OS:FD3QW*@:2A?]3^?L^0"X=MSV,_$[SW\^_E\A;=G<0W0TNE5
MISG3_5B:7DF=T=TRO7BFI%;:60, HH_$62\5Y'E\W+>XN-$V9CKOB2'N7G)D
M\VM^&M9WR(*%($C"<NHMJVXCV[MSV^#?L&*5Y_+9<7I3L'UM=^!>+N+X"^8;
MS:]_('1_H@K3U,9>!9/O/X3^<2_P*!P < ' "J((U(L;QGS'+$[^Y,6J*2-8
MDWFY7YAS(@V\M=!,6';NO Y=PMHP.&6[O_%X1B"IR5W.<#X 6NX . #@ X .
M #@ X 9O[*TM9-,6@NWDU+C2F2V'YK:VO:'7=H,)1IMKZNCA(BD+G'R#ADMR
M/9BKFO)YE5250(CW;,@%%2RA9EK7QIQC ?1&1^*?[#_V>_Y#/O\ WBYM)W36
MVP]70^XZCDJ:5P&;MGG%F="2SDJDDPD\U$Z,KTUJRR7%ADL>=4RUCDT<=DR1
MXC[ZWN#.ZI$J]&H( 'R9;'L?D$I\ ' !P < ' !P < ' !P < ' !P < ' !
MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
M' !P < ' !P < ' "N)FG^K9UW!V3-H&JC+X"L*=,6H.',XI?YZ3LN8V1(LN
M64WE%)R(YG,>)DX@9D!3%Y&<MR"W8PFP%=SVVW/;S?+\_;\/:+'<"@< ' #S
M=7G\MEQ>E.P?6UWX%\NXO@+YAO-KW\@='^B"M/4QEX%D^\_A/YQ+_ H' !P
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MY_+9<7I3L'UM=^!?+N+X"^8;S:]_('1_H@K3U,9>!9/O/X3^<2_P*!P < '
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M !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
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M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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M<N]1/Z)TD<D>761.#<HK!^>((C;E;J:@9HPO.:F5.WINP  -SWWW[?\ OO\
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MF+[8$W>C C&/.5LDF<G?Y$Y#QG 3'%U5&  6 00!"@[+P < ' !P < ' !P
M< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < '
M!P < ' !P < ' !P < ' !P < /-U>?RV7%Z4[!];7?@7R[B^ OF&\VO?R!T
M?Z(*T]3&7@63[S^$_G$O\"@< ' !P < ' !P < ' !P < ' !P < ' !P <
M' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
M < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < /-U>?RV7
M%Z4[!];7?@7R[B^ OF&\VO?R!T?Z(*T]3&7@63[S^$_G$O\  H' !P < ' !
MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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-  /E\@ A#C&,!]#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g29248g27z86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g27z86.jpg
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MI04D#GG<2T89DLQ''<-#[^YRVD,MK0=U^= MY#2F6C)%C'2ZX@O I+84%"^
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M<,+D<7O=KP*>9-,_)&L?0$5]DTYXXARZ9WR]X=-PPN1Q>]VO IYDTS\D:Q]
M17V33GCB'+IG?+WATW#"Y'%[W:\"GF33/R1K'T!%?9-.>.(<NF=\O>'3<,+D
M<7O=KP*>9-,_)&L?0$5]DTYXXARZ9WR]X=-PPN1Q>]VO IYDTS\D:Q] 17V3
M3GCB'+IG?+WATW#"Y'%[W:\"GF33/R1K'T!%?9-.>.(<NF=\O>'3<,+D<7O=
MKP*Y$IE/2.11.J5I-1,Q3IJ$@HLAR'((&*<ABM0,4Q3 !BF*(" @ @("&H.(
M3R"#-ED$$$&2\00=A!!78@CA%2(4,$$1(P(-P0PT"". @Y-A%#4NG',8YZG6
MCG.83&,:"BS&,8P[F,8PM1$QC"(B(B(B(CN.I&(3P !.F #8 )+P  X !GJ#
M"ADDF)%).TDL-$DGA).2N/F33/R1K'T!%?9-.>.(<NF=\O>'3<,+D<7O=KP*
M>9-,_)&L?0$5]DTYXXARZ9WR]X=-PPN1Q>]VO IYDTS\D:Q] 17V33GCB'+I
MG?+WATW#"Y'%[W:\"GF33/R1K'T!%?9-.>.(<NF=\O>'3<,+D<7O=KP*>9-,
M_)&L?0$5]DTYXXARZ9WR]X=-PPN1Q>]VO IYDTS\D:Q] 17V33GCB'+IG?+W
MATW#"Y'%[W:\"GF33/R1K'T!%?9-.>.(<NF=\O>'3<,+D<7O=KP*J$IU13!4
MJ=6KB95D^TL4D'&%!5+N$5[:H%:@"B?=234X'W+W$R'VY$*(09\XV)FRR4G,
MDF2\<IL4W%U[#8D7&VQ(X":D0X8N!%C *&50##0S"X58V3M%P#8[+@'A JGY
MDTS\D:Q] 17V34\\<0Y=,[Y>\.HW#"Y'%[W:\"GF33/R1K'T!%?9-.>.(<NF
M=\O>'3<,+D<7O=KP*>9-,_)&L?0$5]DTYXXARZ9WR]X=-PPN1Q>]VO IYDTS
M\D:Q] 17V33GCB'+IG?+WATW#"Y'%[W:\"GF33/R1K'T!%?9-.>.(<NF=\O>
M'3<,+D<7O=KP*>9-,_)&L?0$5]DTYXXARZ9WR]X=-PPN1Q>]VO IYDTS\D:Q
M] 17V33GCB'+IG?+WATW#"Y'%[W:\"GF33/R1K'T!%?9-.>.(<NF=\O>'3<,
M+D<7O=KP*J#3JB*1$!JU<%!-155-$8.,%)-58J1%E2)BUX%45(@@54Y0 RA4
M4BF$03( 1N^=<JW;+S$!)5NEZY"2HI!.>Y"2I1 X 5*MPFIW'#L$[DC9020G
M4-6!4 %$#+8$A*03PD)%^ 53\R:9^2-8^@(K[)J>>.(<NF=\O>'4;AA<CB][
MM>!3S)IGY(UCZ BOLFG/'$.73.^7O#IN&%R.+WNUX%/,FF?DC6/H"*^R:<\<
M0Y=,[Y>\.FX87(XO>[7@4\R:9^2-8^@(K[)ISQQ#ETSOE[PZ;AA<CB][M>!3
MS)IGY(UCZ BOLFG/'$.73.^7O#IN&%R.+WNUX%/,FF?DC6/H"*^R:<\<0Y=,
M[Y>\.FX87(XO>[7@4\R:9^2-8^@(K[)ISQQ#ETSOE[PZ;AA<CB][M>!3S)IG
MY(UCZ BOLFG/'$.73.^7O#IN&%R.+WNUX%:.6V+C$+59D48YBBBC8)I))))H
MW32223DG)$TTTR)@4B9"@!2$* %*4      ->F0'G5082E.N*4J)&4I2EJ)4
M2R@DDDW))VDG:371I;329<I*6FP!(>  0D  .*   %@ -@ X*] 'WXD\_JKC
M^Z/KRIOS1OV:?VA7H*_**]BKYC6A'4[TBS74TETP6NOVO&,))8+=66P)U_,>
M&C9PQW;TKYC-S0W#2>IQ;[C\%CPR$DI-1*JDHLFG--8YT=$09BFMW3!-)FL
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MU.3[XU _$S9--L8I@ 3()D1.7@4"A6B)%R(O&C^4 \Q;X,@01M3>V4!-C_)
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M!^JG">[GP*>-?\4%ZTVE_>"/KJ>FUTG^_>A?2*_V73HE:!^JG">[GP*>-?\
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M<I  'D@*<L5O*F1LDP4O,,*<2J1<3EZN4U#R-8"6NVO(:+M3-E;GLI'%K[>
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MI2FE*:4II2FE*:4J,SX ,C3=Q( A9E1+S!N(B/FK9PV3[ZB:A3\1$=VI57'
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M@(6A:0I"T*E-)4E25 I4E220I)!!!((M7X_0ZC.H0H 4N=\R@     9/NX
M!Z@  "<V  #U  >S7YZ[\M+_ %5:2?#F)_:J_I Z"O,;]:7F9?$/17[JK[Z1
MO4+[^,S?6A=_TYIORTO]56DGPYB?VJG04YC7K2<S+XAZ*_=5/2-ZA??QF;ZT
M+O\ IS3?EI?ZJM)/AS$_M5.@IS&O6DYF7Q#T5^ZJ>D;U"^_C,WUH7?\ 3FF_
M+2_U5:2?#F)_:J=!3F->M)S,OB'HK]U4](WJ%]_&9OK0N_Z<TWY:7^JK23X<
MQ/[53H*<QKUI.9E\0]%?NJGI&]0OOXS-]:%W_3FF_+2_U5:2?#F)_:J=!3F-
M>M)S,OB'HK]U4](WJ%]_&9OK0N_Z<TWY:7^JK23X<Q/[53H*<QKUI.9E\0]%
M?NJGI&]0OOXS-]:%W_3FF_+2_P!56DGPYB?VJG04YC7K2<S+XAZ*_=5<#=17
M4$<4S'SKF,YDCBHD8V3KL84U!(=(3IB,V(D.*:BB8F+L/!0Y-^)C ,'3'2XV
MOI3I&;&XOCF)FQL1<?QK8;$BXZA(ZM2.8KS&Q>W,EYF8N+&V@>BVT<-C_LK:
M+@'VJY^D;U"^_C,WUH7?].:G?EI?ZJM)/AS$_M51T%.8UZTG,R^(>BOW53TC
M>H7W\9F^M"[_ *<TWY:7^JK23X<Q/[53H*<QKUI.9E\0]%?NJGI&]0OOXS-]
M:%W_ $YIORTO]56DGPYB?VJG04YC7K2<S+XAZ*_=5/2-ZA??QF;ZT+O^G--^
M6E_JJTD^',3^U4Z"G,:]:3F9?$/17[JIZ1O4+[^,S?6A=_TYIORTO]56DGPY
MB?VJG04YC7K2<S+XAZ*_=5/2-ZA??QF;ZT+O^G--^6E_JJTD^',3^U4Z"G,:
M]:3F9?$/17[JIZ1O4+[^,S?6A=_TYIORTO\ 55I)\.8G]JIT%.8UZTG,R^(>
MBOW53TC>H7W\9F^M"[_IS3?EI?ZJM)/AS$_M5.@IS&O6DYF7Q#T5^ZJX!U$]
M0(*&6#.F8P5.1-,ZH9.NP*'32,H9),Q_+?(Q$S++&3*(B4AE5!* "<V\;\=+
MKD[Z=([D $\_,3N0+D G=5[ DV'4N>,U/05YC=K="7F9V!) WAZ+6!-KFW.K
MA-A?CL.*N?I&]0OOXS-]:%W_ $YJ=^6E_JJTD^',3^U5'04YC7K2<S+XAZ*_
M=5/2-ZA??QF;ZT+O^G--^6E_JJTD^',3^U4Z"G,:]:3F9?$/17[JJZ0G5+U'
MP$Q&3;+.>5EW<4];OVZ$K?;1,QBRK90JI49")E91W&R3-42]MRR?-7#5RB8Z
M2R1R&$!OBZ=:91)+$IO2C'EN1W4.H1(Q6=*86I"@H)>CR'W&'VU6LMIU"T+2
M2E22#6ABO,#YB>,8;.PN5S*>9\S'Q"*]$>>P[1' <+GM(?06U.P\1P^!&G09
M3=\[$J(^R^RX$N-N)4D&OTQ='W4JGU/XH1NCBNOJY88=[YOVEN+-V6ONYINV
M176>UB37*9)['N4U4UE6(N%9"$64\"_%9,64A(?:?,]TS3IO@*,25#=A2V'-
MR3FRVX(BY*$)4IR"^L%+K*PH*+>=3T91U3V8:MY[\.?%'<Q%SF$\T%W1AK&8
MN-X/B,7GQ@#XDQSC#&%O/.--1<=@-$.19K"VUM(DAEN'BC2!+B!M6Z8</:S7
M>J\!II2FE*:4II2O:Y]^)//ZJX_NCZ^>F_-&_9I_:%>S+\HKV*OF->*.OH6O
M&::4II2FE*:4II2FE*:4II2FE*:4II2HS=2E-3;:4XD*4U9GBF,H"!DP*,4Z
M 14*Y7;-C$ -Q,#ARW0$NX*KI)\E"ZTS;$E VVQG^'+;S)7#G4E-N/,I*>-0
M%S5\;9)C]7R=K8+W\T3P6"C[B2>($[*DH>P/Z UL#@':%:XX!VA7W4U--*4T
MI32E-*4TI32E-*4TI32E6*T@4:S8P,) *,%+@85 2,0"C'N-Q.5PJ@@)-OG
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MQ3_D6GW&9/\ .-/]41?^9NGC<AZL3\7Q]]T_A,%^LLG^L4_Y%I]QF3_.-/\
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MCH_0D8B*D%,D2B:KY@R>JD3KD9VRBZ0<.#)I@9V)P*0'#$A3&.8?P-8QM_&
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MJOP$'0(MV_?%^LP1_P#"]QG9YXXK#VNS3>IAW79?=&NQ_,]OW>Q7 W1DW$@
M7)LL53MB43C6HHQ15%NV("G#QA=B@Y3=K]OF.Z;E)OS 6PK.&_?%^M0>XO<0
M_..P3[?$!3>KAW7)?=&NS_,]KW.S40R1T?),J!>W[+(LTHNSJ-F>-FX5UJ91
M4[:,EW*3<IX\'3[N*)"S:E49,7;L%4%'#9FNJY39I8.Z:8LZVMLM0DI<0I!*
M&G@H)6% Y27S90!V&QL0#8[:R;T7P]M:%AR42A25 *6T4DI((N-2+BXVBXN#
M:I:'1DW%(@!DV6*IV=C&&M19@%46K8A5.'BRB!2NB.G I\MS).$F_,!;"NOG
MOWQ>WF4'@M?5/<0%_/'&"?;[ K'>KAW7)?=&^"_!YCQ6%S?@XZK#T9LNX ER
M3, GW ,)!KT4)A2!RX.*?<\0  86IVS?N</4J@HYX"#@&Z+?OB_68/<7N,GE
M'%8>UQTWJ8=UV7W1KB_0\>WV[53'HR;B0 +DV6 _;,43C6HH2BJ+9N0JG#Q8
M"!2NB.7';Y#NDNFVY@+<5UF_?%^M0>XO<0V^>./;[=J;U<.ZY+[HUQG^9ZHV
M>U>J@]&;+N 8N29@$NZ4PIC7HH3"D#I=0R8*>(  ,9H=NV!3MCQ614==L07!
MNBW[XOUF"/\ X7N,[//'%8>UV:;U<.ZY+[HUQ</F/'M^2J8]&3?B !DV6 _;
M,43#6HL0%46J"95 +XP-BE=D<.13Y")DEDVO,!0%PLW[XOUJ#W%[B&WSQQ[?
M;M3>KAW7)?=&N/\ 0\6SY:J#T:,A4*(9)F02!4IC)C7HH3BD#M90R8*>( "G
M,R.@U!7MB!5D3N^V)5O#)-^^+W\Q@]K4O<=^47X-G:[.VF]3#NNR^Z-<0_F>
M/;[=N*J8]&3?B !DV6 W;,43#6HH0%46J*95./BPV*5X59T*?(1%%4C7N *(
MN56_?%^M0>XO<5N4<>WV[<%-ZN'=<E]T:X_T/%854'HS9=T#!DF8!+N%,*8U
MZ*$XI [54,F"OB  #&9&1: IVQ JZ1W? 2J@U3;]\7OYC [6I>X[\HXMGM7X
M:;U<.ZY+[HUQ?H?;JF/1DWX@ 9-E@-VQ 3>;44("J+1-,%./C V*#TJKH4]Q
M$45"M.X!D_$G;]\7ZU![B]Q6Y1Q[?;MP4WJX=UR7W1KC_0\6SY:J>AFR[H&#
M),SV>8"*?F]%<^V#Q142=WQ&P&%B9)H!^V( NF9YP$% :DG?OB_68/:U3W'?
ME'%L^7AIO4P[KLONC7%^AX]OR53]#)OQV#)LMR[8AR\VHL0[O@R) IQ\8'R0
M>@=WV]]Q1.5IW-R>)-&_?%^M0>XO<5N4<>WV[<%-ZN'=<E]T:X_T/%85&[OT
M=HM:C;7C;(TRH9M6YYRBW"NLQ44,BV>N4T2J,S.7?<.U!)D!VK)PX[X"[0:K
M'.1EK%>FN++0M!:A +2I)*6G@H!5P2DF0;$ V!(.T UDG1;#T*2H.2B4J"@"
MMH@D6(!&IVBXN1U>"KM&]&B*D9'G/DR6*H>-:B?>M1OJ7-%I$$X@HY(IQ*_Y
M.^V<I%.P(,SF*<!<ZR&F^+@ :J#L%KEI[J)M?SQPWZ;M[."H.BN'$DZR5M-[
M:QKCOL\AXMGRU<O0S9=WE\9,QVNYOV_-Z*Y]KQ@JB3N^(VY^"V:=SM[=X!=]
MO8?# W[XO?S&#VM2]QWMYXXMGRU&]7#NNR^Z-<7Z'CV_)5/T,F^VWQFRV_;V
MW\VHK;N^"!+N;>,^;X[=YV]]^QLS[G(/%"W[XOUJ#W%[BM?SQQ[?DX*;U<.Z
MY+[HWQ_H>+9\M5/0S9=WE\9,QVNYOV_-Z*Y]OQG=X=WQ&W+P/X)W.WMW_P ,
MX<?P73?OB]_,8-N+4O<=^47X-GR\--ZF'==E]T:XOT/'M^2J?H9-]MOC-EM^
MWMOYM16W=\$*7<V\9\WQVSSM[[]C=GW.0^*!OWQ?K4'N+W%:_GCCV_)P4WJX
M=UR7W1KC_0\6SY:J>AFR[O+XR9CM<Q'M^;T5S[?C 5 G=\1MR!B!FG<[>PKB
M#S@ !X46_?%[^8P;<6I>X[\HOP;/EX:;U,.Z[+[HUQ?H>/;\E4_0R;["'QFR
MW+M@ #YM16P*^#,D*FWC/FB^$KOM[[@@46?<Y&\45OWQ?K4'N+W%;E''M^3@
MIO5P[KDONC7'^AXMGRU4]#-EW1,.29CL]P1!/S>BN?;\814"=WQ&PF!B!VG<
M[8 *YP><-B^%,W[XO?S&#;BU+W'?E%^#9\O#3>KAUO-)?;UC7%;K/'M^2J8=
M&3?B(#DV6Y=L"@/FU%@ *@S.D*FWC!W*+X4W?;W 00(9GS$Q_%%;]\7ZU![B
M]Q6Y1Q[?DX*;U<.ZY+[HUQ_H>+9\M6JQ='+9O!SSE/(\RH",5*KI(!76/<,"
M93N$T>XV<"X,H+0AV?-NF"QEU"NT4P,F#8\*TVQ904DM0;*!!LT\#8\1W1<;
M-@/#U>&I&BV')((=E7!!%UM':.,:G:+[;>U7*$Z-D5H6)54R7+D55B(\Y@&M
M, $BYXH"F$Q7#OOB /CIN137$%@23,T4/W%!<D)TVQ=( U4$@  7:>)V"UR=
MT;3>QH=%<.))UDK:2=CC0X3?K/%LJ[AT9LNZ)AR3,"EW#""85Z* X)B[24*0
M5?$" F*R*LT$_;#==4CO@!4A:J3OWQ>_F,'M:E[CORCBV?+PU&]7#NN2^WK&
MN+]#Q[?DJF'1DWXB Y-EA-VP*!@K44  J#55,5./BQ^2+PR+KM\MP12.U[FZ
MH.4V_?%^M0>XO<5N4<>WY."F]7#NN2^Z-<?Z'BV?+50.C-EW!,.29@4NX8P)
MA7HH#@D+M%0J8J>($!,5D5=J*G; #+*D=\ !$6RL[]\7ZS![6J>XP;>>.+9[
M=^*F]7#NNR^Z-<7Z'CV_)5,.C)OQ$!R;+"?ME*!@K46  J#5=,RG'Q@[E,[.
M@Y[?(!!)%1KS$5@<)1OWQ?K4'N+W%;E''M]JW!3>KAW7)?=&N/\ 0\5Q50.C
M-EW!,.29@4NZ8P)A7HH#@D+I!0J8J>($!,5F1PV%7MAR663==L 0%NLW[XOU
MF#P\&I>X+C9YXXKCV^,4WJX=UV7W1KL[?,>T?:JF'1DW @@;)LL)^V4H&"M1
M12@J#9P0R@D\8.Y3.CMG )\@XI(*-N8BX!=!OWQ?K4'N+W$1RCM'MCB-J;U<
M.ZY+[HUV/YGMCV^Q50.C-EW!$V29@4^Z)@(%>BBF!(7+<Y4^YX@P"8&I'+?N
M< W5<)N>  W%!=OWQ?K,'N+W&#RCBN/;XZ;U<.Z[+[HUV=OF/:/M5![3T>^&
ME,>HI9(EU?'7!5FY5+6FY2H$+C^_.!<'(V.Y2%,\DA&'!-^LS9E(F=N#PSUR
MR(-:M,\666R6X=VUEQ-FG0"=6XW97D^U-G,UMG3)3MM<').B^'I"P')1#B<A
MNXUL&=MRZ2&18W1:^WI5$$7L:G!>C-D!Q$V29@4^Z)@(%>BBF!(7#8X)\_$"
M F!L1TAW> ;J.$G';V;"BXLW[XOUF#W%[C'YQV"/;[ K'>IAW79?=&NS_,]K
MW.S5,O1DW FQLFRPJ=L"@<*U%%+W00=$%3AXLP\1<J-%^WSW!-LJAW!%R"S=
MOWQ?K4'N+W$?SCL@^UQ$TWJX=UR7W1OL?S/;'MU4#HS9<Q$<DS D[@F @5Z*
M 02[[4X)\_$#N8&Z;M'N<0W4<HK\-FHHN&_?%^LP3_\ "]QC9YXXKCV^Q3>I
MAW79?=&NS_,]KW.S5,.C)MP$#9-EA/VP*!PK44!>[V'1!4$GBQW*+A1FMV^0
M;)M5D.8BZ!9LW[XOUJ"?_A>XC^<=D'VN(TWJX=UV7W1KL;/,>V/;JH'1FR P
MB;),P)>Z)@*%>BBB"7>:&!/EX@=S @F\1[G'UG=(K<-FHI.6_?%^LP>XO=C\
MX[!'M]@4WJ8=UV7W1KB_0\>WVK53#HR;@00')LL*G; H'"M10%[G9=E$XD\6
M.Y1749J\.8;$:K(\A%T"K9OWQ?K4$_\ PO<1_..R#[79--ZN'=<E]T;['\S_
M (GAKF'1FS PB;)4P)>YR H5V* 02[K0P)[^)'<W93>I]S8/ENT5>&S04W+?
MOB_6H/<7N,?G'%<>WV*;U<.Z[+[HUV=OF/:/M5P#HR;<-AR9+"IV]@.%;B@+
MW.T\*!Q)XL=R]Y5DIV^8?(:+I<]WA5&K?OB_6H/<7NS^<=D>YV33>KAW7)?=
M&NQ_,]OW:A<?T>D-DBULE,C3/@V],Q^\;J^;C8"G5>6&_IND ,H!8\3I-HPP
M&,U>+O &1;*/F;1!HP-+X#33%@ZMW5PR5H;04EI[* VIQ0*1K]BCK5!1N;@)
MV IVYG1?#RA+>LE )4M8(6WF)6E"2"=5Y4:M)2+;"5;3?9- Z,FP$V')LN*G
M 0 _FW% 7GVW@ ?AXH=R@HJQ/PY!N5HNGR 7A3M<]^^+]9@]Q>[/YQV0?:[)
MK#>KAW7)?=&NQ_,]OW:Y!T9M/7ODJ8'Y>X?Y.Q0;$YLAX?C([CP2?$Y[A\IX
M@?C^!F*[;]\7ZS![D]V/SCL'W>P*;U<.Z[+[HUV?YGM>YV:^!T9-N @.3)<3
M\1 #A6XH  XD>@!N'BAW %%6)Q+R]96BY.0"\*=JW[XOUJ#W%[L_G'9'N=DT
MWJX=UR7W1KL?S/;]WL5]]#-IZ_\ \2YC?D A_DY%; 7DR$2B'B?6(E2?EY;A
MZWB!MOP(Q7;?OB_68/<7NQ^<=@^[V!3>KAW79?=&NS_,]KW.S7P.C)KPV')D
MN)^(AR\VXH Y"5Z!3</%>P#*L#"7EZP9KEW#QI1:-^^+]:@]Q>[/YQV1[G9-
M-ZN'=<E]T:['\SV_=[%??0S:;>O)4OON&VU<B@#8!9"(;>)$=Q*D_#??U"\0
M-M^!&!VW[XOUJ#W%[L?G'8/N]@4WJX=UV7W1KL_S/:]SLU\]#)KQV^,R7Y[&
M^5YN16VX@]XCQ\5["BJP$0Y?*!FN&X>-*+1OWQ?K4'N+W9_..R/<[)IO5P[K
MDONC78_F>W[O8K[Z&;3CM\9<OR^3Z_-R*V]0LN7R?%?N@D_ /E>H7C<?7X(P
M.V_?%^M0>XO=C\X[!]WL"F]7#NN2^Z-=G^9[7N=FM=YO$BL3,R\42T++DC)1
M_'D6/$-RG6*R=JMBJG*5WQ*90$P.8I?D@(B >K7=(F*RGXL9Y89"WH[+J@E"
M@ IQM*U6!<)M<FVT[.K76)&'L-2'VDEPI;>=;3=0)RH6I(N0D"]AML!MZE>K
M#[\2>?U5Q_='UXZWYHW[-/[0KTM?E%>Q5\QJV5?]K-=_]"B/^'M]73//DO\
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MM[K1;I)((=7G5 @@@F1%%%'/V5TTD4DR@1-)),EL*1--,A0(0A  I2@!2@
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M&XAJK&1!D'.BZ'F5OPWXLE_?K7+UYI32E-*4TI32E-*4TI32E:!W+]M]J_\
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M_@SW^FM_NX?]>=.A?_QS^S/^H4_A ?\ E+_?S_LRG^#/?Z:W^[A_UYTZ%_\
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M_4*?P@/_ "E_OY_V93_!GO\ 36_W</\ KSIT+_\ CG]F?]0I_" _\I?[^?\
M9E/\&>_TUO\ =P_Z\Z="_P#XY_9G_4*?P@/_ "E_OY_V93_!GO\ 36_W</\
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ML:A&3 $V-\@% K<XC2+6 $=G22:G$8%^ %<J+K-T$VYO8L=9P@D1,3&462(
MG*I5EB)'*18:*[=-Q\80B68@'QEV J?="(:'33*9/%3@O9-(BNT%4IC\&"2,
M@0BRRYHY!2KN,ADSO 4*C11;]TH"J.1; "P(>/63,H" 8N$@JA&%;O"HBX A
MGZJT<*Y6Z!)1PI5$9+*?$!"FX_$_:$1*.2[&!07\ DH"8'#$PB*0R8K,Q6X
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M<2@([%$YA#;D.ZE<M*5Q A"F.8I"E,H("H8"@!CB4H%*)Q -S"!0 H".X@4
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MSV%XSA;Q9E17A<$'IFI$=U-VY,22V4O193*ELOLK2XVHI-90UM5UVFE*:4J
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ME*<0AJ4I1 "4B0V223L  %R3L K^:B3I\SXJ0BB>$,OJ)J%*=-0F-;F<AR'
M#%.0Q842F*8H@8IBB(" @("(#KYAYVXCR";WJ_\ 5U^_V_K0CU8Z*_&'"/ME
M<O1XS_[C<P_5G=/T)ISMQ'D$WO5_ZNF_K0CU8Z*_&'"/ME/1XS_[C<P_5G=/
MT)ISMQ'D$WO5_P"KIOZT(]6.BOQAPC[95=KTW]0[URW9M,#YE<.W:Z+5LW2Q
MC=3JKN%U"I(HI$"$W,HJH<I"%#UF,8 #VZD89B2B$IP^<2H@ "*_<DFP \CZ
MIK!S3[05EMQUW331-#;2%..+5I%A 2A"$E2U*.[-B4I!)/4 K]KGP0/0)?NB
M3#,Z]RI;YE?(67%8BP6#&+27%U1\<>#;*$9LT&R)U64C>G+99-"W6%F<61BL
MXZ"CC/6<,68E?<-#='I&!0G#+>69$PH<<BA=V(UAL2 +I5(((#SB>EZ5+:<P
M1G7^2GBH>;5@O-=TKAM:.87%1@>C"94&#I [&U>,8\'7$J==<<4E+S&#MN(4
MO"X+HUR2[(F/AIV68L;U\UW*OE^FE*:4K'5Y*F:>Q,*@I 8F17!D>X#83"I\
M6V1"[(=]\S4!7M&4$1:(R3GL@J L2MA<OV*E9%TI32E-*4TI32E-*4TI32E8
MXBRI!EV\' 4N\;'&*RJ  -N^"1+/F,4A4$K]1V*0F.L"(+Q;-L!P7\*_DE1>
M-XI2LCZ4II2FE*:4II2FE*:4II2M [E^V^U?^Y)S_B;K7JF'?[O@_P!#C?N4
M5T"9Y\E_TE_]ZJM\GWXD\_JKC^Z/KRYOS1OV:?VA7?5^45[%7S&M2X/JRQ^P
M@X9DXKM[*X:1L>S7(6/KAP(JW;.6ZI@,%IXF3 S%$X"41,))-A\GD22)']ED
MZ+XZY)D.(@W2MYY:3NB(+I4M2@=K_5%MAV[1V;<"QI!A"&66U2CF0TVA7\7E
M6S)0D&QU-CMOMO8V[5[D/5]CH$P.%;OQC"0I^T$=6NX!A38G%(1&U@ES*9VX
M2,(*"D*D6^$JADE(U21IWJ8_R#]9A]C\X[/R&K=\>#\K/>TKZC_7Y;<AZO,<
MAMM7KX.Y^'JC:[ZB\WQ.Z.]I >'%H@KL "IPDV(=ON$D4X]O4Q^]MP?K,2W5
MZNO_ !<4WQX/RL][2OGU-OEZG:OQ'J^QT"8'"MWXQA(!NT$=6NX!A39'%,1-
M; 3Y@9VNB(@H*?<C7HE4%(\<J_;U,?Y!^LP^Q^<=GY#3?%@_*SWM*^H_%^W;
MD/5YCD-MJ_?#;GX;A&U[U%[CXG='>T /#BT06V !5[<FQ#M]U.22CV]3'^0?
MK,/L_G'8^44WQ8/RL][ROJ?Q;LB_ W5_CH$P.%;OYC"GS[18ZM=P#=EDKVA$
MUL*EW.;I=ON"@I=Z->B"O8/'KOV]3'^0?K,/L?G'9^0TWQ8/RL][2OJ/Q?MV
MJ&ZO,<@8 "OWLP"IPY%C:]Q O=>I]X0-:"F[?!J@OL!15[4BR#M=\D@BQ;U,
M?Y!U;>>8?VC@IOBP?E9[WE?4_P"GR7IFZO\ '94P.%:OYC"GS[18ZL]P#=AF
MKV1$UL*EW.;I9MN"@H]^.>#W?#G8+OF]3'^0?K,3L?G'9^0TWQ8/RL][2OJ/
MQ?MVJ&ZO,<%,!0@+V<!5!/F6-KW$""L\2[X@:SE/V@(U0<B4""OV9%F4$1<$
MD$&+>IC_ "#JV\\P_M'!3?%@_*SWO*^I_P!/DO3-U?X[*F!PK5_.84A4[18Z
ML]P#@W9K=D1-;"I=T5'*S0!!04?$1[PPJ@U.P<O6]3'^0?K,3[1[7^FVF^+!
M^5GO:5]1[?\ K50W5YC@IP*$!>SE%4$^X6-KW ""X=HBN(&M!5.T";9%V)03
M%?P[]H4$1=$?-F3>IC_(.K;SS#^T<%-\>#\K/>TKZGY>#9VKTS=7^.RD X5J
M_G,*0J=HL=6>8'!LT7! 1-;"I]TRCE9F @H*(.6#LQEBM#L73UO4Q_D'ZS#[
M'YQV?D--\6#\K/>TKZC\=3JVAV3>J_'S_'E^C&L%?.\_I]ICT'"3*"0*F=U%
MS+%-R"I9F2<HII@D@^YI1$DZ(V>M>W%/7J;R-0Q7HOCJ$*6J"0E"2I1$B*HA
M*022$I?*E6 O9().P $[*E.D.$+4E"91*EJ"4@QY*>F5L )4R -IM<D <)(&
MVI>'5_CLJ)#>;5_,;L=P4RQU9Y@<K1JN" B:V$3[IU7"K(H@<40<LG1CJD9G
M9NW>6]3'^0?K,/[14;XL'Y6>]Y7U/_GJ=6U<W5WC@% ($!>C%%4$^\6-K_;
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M&]3'^0?K,/BORCVNW3?%@_*SWM*^HOV?DX=E5?2[QQWNUY!O7#N"3Q'DVO\
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MQ_D'ZS#XK\H]KMTWQ8/RL][2OJ/QU=NRJI>KO'!E13&!O12@J9,%S1M?[1B
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M,/L_G'8^44WQ8/RL][2OJ/Q;M7Y>EYCG81\WKYZC 7;R;7=Q#DQ+S#_*GYH
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MS\MN+9<VR1M>7MB2AM\[O<%[^9JX+)6;\5D+/$E7 ;H_GAC],UP^S3QJ2/\
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MXEB(,V,K'S]-@7\.E.S]L-^6XZD2&W$H5'S^8K;"%A2>E<*F@"XI*KI#;RK
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M- 7>K5ZX09W+5Z:'L\-'3L9XUBJ"[%Z#&3;NFQ7C)<I5VCHJ8+MEB@J@HF<
M-JMUIIY.1YM#J+A65Q"5INDW!LH$7!V@\(K-MQQI6=IQ;:K$9FUJ0JQX1F20
M;'JB]B-AKOP4#!5>'CJ]686)KL!$-B,HF#@HYG$0\8S2W[;2/C6"+=DR;)[C
MP0;(II%W'B4-]9(0AM*4-I2A"19*$ )2D#J!(L .P!4*4I:BM:E+6HW4I:BI
M2CQJ4HDD]DDFNX#%D#TTD#-J$B=JFQ/( W2!Z=DDJHX29F=<.^9JFNLLLFW%
M04B*JJ*%(!SF,,V%\UAF( *K"]@20+\-@22!P7)XZBYMEN;7O:^RYL";<%R
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M(/(7UIVK[1IO T;Y-([[>\*GCR^;KZ=8)\7,,^KI]P=^#L_(/(7UIVK[1IO
MT;Y-([[>\*GCR^;KZ=8)\7,,^KJNU^ C^#K;.6S@V/+V[*W716,U=91MYFSD
MJ2A5!;N2HO45C(+ 7MK DLDH*9C 15,VQ@D: Z- @[E?-B#8RW[&W4-E V/
M;$=NL'/%D<W5QMQL8]@[16A2 XWHYA0<;*DE(6V5,K2%HOF25(4G,!=*AL/K
MC7*Y 4^ AJK58:,KM:KL8RA8&!A63>.B8>)CFZ;5A'1S!JFDV:,VC9)-%NW1
M3(FFF0I2E  UW!IIMEM#3*$---I2AMMM(2A"$BR4I2D )2 +  6%?,DZ=-Q2
M;+Q+$94B=B$Z0]+FS9;JWY,J5(6IU^0^\X5..NNN*4M:UJ*E*))-7K6=:E-*
M4TI6/;MMY=Q7N)@__$)QL  80,/Q<Y!]1^,<^ "[;B G<1)>0% )$QQ)&R*E
M9"TI32E-*4TI32E-*4TI32E8[C-OC9NOK-O\7>+]P$#\ #SER]L)1&-2()A'
MD!@+,/C@ $$\;% *;J94K(FE*:4II2FE*:4II2FE*:4K0.Y?MOM7_N2<_P")
MNM>J8=_N^#_0XW[E%= F>?)?])?_ 'JJWR??B3S^JN/[H^O+F_-&_9I_:%=]
M7Y17L5?,:\^8OJSN$9%1L:%2K:XQ[)HQ%<S^33%8C1)X@"HD*F($4433BCB4
M!$A3C( &Y?#;>@2-"'WI#[R)S*4NO.N)26G"4I6M2@DG/M(! )ZM=-8TJ::9
M9;5$<4IMIM"E!Q("BA 22!EV D7 ZE=T>L"Y]L-J;6.]VR[[R,KV^[VX_EML
MER[?=\J\?WW;\G[_ "@<B-.\.3Z8,=Q<\.K=]S'(G>ZH\&N0]8%P]7&FUK]D
M]>\C*?L7<D/9LG^R=KR7_P"'N>4/WHM]F\.3Z8,=Q<\.F^YCD3O=4>#7 W6!
M=.V'&FU?N]L-^4C*]ON]IARVV2Y=OO\ E3;]]VO ;_+\1NWAR?3!CN#GATWW
M,<B=[JCP:YCU@7#U<:;6MNYZ]Y&4_8NZ_P#9LE^R=GR7[?D]WQX_-%N -X<G
MTP8[BYX=-]S/(G>ZH\"N!NL"Z=L.--J_>[?KY2,MV^]V&/LV2Y=OQ/E/_P 7
M8\#_  @.-V\.3Z8,=Q<\.F^YCD3O=4>#50W6!;^0<:;6^'<]?*1E.79[S[V;
M);=SP_DW_P />\=^\\/IO#D^F#'<7/#ION8Y$[W5'@U3-U@73MAPIM7[W:]?
M*1ENWWNPQ]FR?+M>*\I?^/L>!_A._IO#D^F#'<7/#ION8Y$[W5'@U4/U@6_D
M'"FUOAW@WYR,GR['??;[;);=[PWDW;?Y'?\ '#^QB@ -X<GTP8[BYX=-]S/(
MG>ZH\"J9^L"Z]L.%-J_=[0[\Y&6[??\ #,MMMDN7:\7Y1WW^7X;P7\*"^[>'
M)],&.XN>'3?<SR)WNJ/ JH;K M_,.%-K?;[P;\I&3Y^'\2\Y;;)<>]X/R?MO
M\CQ/C-_O0H;-X<GTP8[BYX=-]S'(G>ZH\&J9NL"Z]L.%-J_=[)M^4C+=OO\
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MD>:I' ;=5%_=J]%ZP+=WAY4VN>'[IN/&1D^]V?'H\=]TN'=\F>(Y;?(\?V1
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M?NU^P5P&Z-YX8MPZYK]M/Y2?VD^R'#4A,<B:9E#F I"$$YC#["D*7<QA'^(
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MB0GI5I4;V!Z@/4X:V(KJ6'VW5A12@DD)L3M21LN0.KQBM'R=#5]D31L3/7*
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M1%G(>1F4E!4V9#3(-LBBT7,J@K*;UM*9CR#F6IQM4=UI:T(22A<J&MI12DK
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MEM*G% )"EJ2A)-U*"037N7TQ=,5#Z8:&E5ZND62L,D5NZN=S=-R)2MGE4B&
M!$ ,H9C"L3*+)PT,FLHBQ144554=23I^_=_3NA.A.%:$84F#!2'I;P0O$L26
M@)?G/I!V\*BU&:)4(T8**6DDJ4IQY;KKGY6<W3FZ:6\W72US'\?<5"P>$IYC
M1G1EAY2\/P+#UJ!L+A E8E*"&UXEB2VTNRG4H;;0Q#8B1(^RFNYUXE32E-*5
M&9_CY1IW+;?SF5X;CM\KS6LWL_"F^X\>0;=I[ZMQ\*&WBVNN_;61+\H-NWN:
M1^6GJ7ZB_8?RT7->4D?H4W[X8_)5U;=5'LCY14FUL5332E-*4TI32E-*4TI3
M2E1AIQ\\Y_8 Y^;%1Y#OZ^/E6[< V\6?8 'GL/@6^^X_A;W;LL-9%MV/\>YH
MGN:V;;^6>S_[:?9K\JW>KSLUQ:^1^[B_DCL?RU>Q3PKD^MFJ*:4II2FE*:4I
MI2FE*:4II2O:]X F9NRE 3&,V7 I0 1$1%(P   'K$1'U  >L1U\]-FRT$[
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M]DIO[.#I$WL.7=SYPCTS@]],\0/H^(C\7ISLQ'@W#+[W=[/Y/8/X(KF)'!1
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M+NY\X3Z90>^F>P/1_E#W:<[,1Y#+[W=[/Y/8/X(JF JF(*I6DB*8)@J)PC)
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MT$X]Z<1]G%JN/L3-ML<^<(],X'?3/9_+[!_!%4\[,1X-PR^]W>Q^3V1^+US
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G2]9N'97(Q<6R+79BM, ?3\^PLLD*AMU/Q^/Q;@K/^E132E-*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g29248g29n63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g29n63.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !. 2 # 1$  A$! Q$!_\0 '0
M 04  P$             "@ '" D+! 4& __$ $(0   & 0,"! 0#!@0$!04
M  $" P0%!@< "!$2$PD4%B$*%3%!(D*Q%R,R47&!,V-RP1@D4]$T-6%B9F>1
MPM;7_\0 '@$  00# 0$!              4&!P@#! D" 0K_Q !9$0 " 0,!
M! 4&"0<'" 8+   ! @,$!1$ !A(A,0<305&!%"(R87'!"!5"4G*"D:&Q(S-B
MDK+"T0D64V-SDZ(D-$-T@Y3P\1<EHZ33X35$5&5UI;/#TM35_]H # ,!  (1
M Q$ /P _C1HU7+XN.2IC$OAN;N+K7YA]7YI+& UB.F(QVLPD6#C(%C@<?E58
MO6YDW#1V8MG,F@Y;J)N$5#E40435*0Y7AL!1QU^V6S]-+&LT9KNO>-U#HPI(
M9:O#*00RCJ,D$%2!@@C.M*XN8Z&I=25/5[H(X$;[*G ]GI<^S68P!C'Y,8PF
M,83&,8PB)C&$PB)C"/(B(B/(B/N(^XZNA+\KP]VFG3<H_:?Q.N:U.=/I43,8
MBA% .0Y#"4Y#EZ3%,4Q1 Q3%, "4P" @( (#SK2D&3@\01@@]O/2Y3\OK^Y=
M:!OP\^Z>U[A]E$K2\B6N5MUZP!D)]12R<_(N)>=<8^FHMC8Z*I(R3Q15ZZ(Q
M77L]7C/-**F;Q%98M$E10;II(U6Z4K+#:MH4J*6!(*:Z4JU.Y$H2,54;M%4A
M$4!5+ 0S/N@9>9F(R22NZOGU&NC2T:-+1HUY^V6JO46K62[6Z69P-4I\#+VB
MS3D@IVF,- 0$>XE9B4>*<"*;5A'M7#I<X (E22,( (^VLD,4D\L4$*-)+-(D
M44:\6>21@B(OK9B /6=>D1Y'2.-2SR,J(HYL[$*JCUDD :S4?$ WSY0WSY\N
MN1;/8[$GC<D_(-L2XW=R3@(&CTEJNHV@DDH5);Y86R2$>1)_:)@B)G<E,.77
M[\&"+!HULE8K%2V*WT]-%''Y28P:RI"CK)YR 9"7(WNJ5LK$F=U4 X;Q8F:K
M';(+93)$B)UW5J9Y@HWY9#Q?SO2W <A%SA5 X9))@X'T#^@?II3/,^T_CIV1
M<D^B/V=7X_#C14K)>(-(N&#U\V80& <C3DVV:N%T6L@R--TFNM4))%,Y4G3=
M&5L3!V@FX*<B;U!LN0 623,#"Z065;( R@F2NIT0D#*MU<TA*GL)6-@<=A(T
MU^D!D79R,,%+25\"(2 2IW:B0E3S!*QL"1V$CMT>!J$]0?I:-&EHT:6C1I:-
M&EHT:6C1I:-&EHT:6C1I:-&EHT:6C1I:-&EHT:6C1I:-&EHT:6C1I:-&EHT:
M6C1I:-&EHT:6C1JC#XBNW^FO#$R'#=WM_M!R;B"H='5QW_)6]O?>UQR'5QZ(
M[_3[_P"#U<?AY"3^B"GZ[;:DDQGR2BN%1GNWJ<TF?^]8\=)-Z;=H''SY(U^Q
MM_\ =UGF$_A#^_ZCJV,ORO#W:;E-RC]I_$ZYB'\ _P"H?T#6D_/P]YTN4_+Z
M_N71*OPS&<O0^\')V$7[SL16=L3K/8UL)^/.W?%+]2?B4BIB(%-VZ9-9$<F,
M')R]@H 42&.8D-=+]N\IL5'<57+VVMW7/S:>M41.<_ZQ'2CNXGU:7L<">['V
M<='0ZKCKYI:-&EHT:&F^(TWM?LMPI6]GM'E^Q>,[(IV7)1F:XD=PV'X23$K.
M,6%,2*H#D&U1YV8&(<Q%X&JV:,?("VETA/)?1S8_*JV6\3IF"@/54N1YKUCK
MYS#/ ^3Q,#ZI)8G!RFG;LI;^NJ7KI%S'3>;%GDT[#TO]DASZF=".*Z"@U-,G
M9X^[4I0<V]@_'7W#Z!_0/TUJ'F?:?QTLQ<D^B/V=$]?##53SF?-SMY[7/IW$
M%4JG>Z?\/UG<PE^UU<>W=]!]?3R'5V>>!Z?:,NDB7%';X<_G*J27'?U,(3/A
MU_WZ8W2/+BV6J#/YRKGEQW]3$4SX=?\ ?HS?41ZB#2T:-+1HTM&C2T:-+1HT
MM&C2T:-+1HTM&C2T:-+1HTM&C2T:-+1HTM&C2T:-+1HTM&C2T:-+1HTM&C2T
M:-+1HTM&C0QOQ25N\AM"V_4<JO0>S[C4;(<@#P99M3<:WE@H0WOR9(KBYM%#
M%X$O=(B8>#%)J;.@ZGW]H+O58R(+.80>YJFMI7!'KQ3,/83Z]-_:!\04T?SZ
M@MX)%(/Q<:!O)_"']_U'5E)?E>'NTC4W*/VG\3KF(?P#_J'] UI/S\/>=+E/
MR^O[EU,;89G$=MN\C;?FM5YY"*H^6*HO:'7<[712)I[Z:OA.YSP3OTR9G4!$
M_*?[W]X4R?446MM/;OC:PW2WA=YZFBG$(Y_Y1&O6TQQZJB.,]_#AQTX$&0P]
MGOUJ8 (" " \@/N A[@(#]! =4UUXTM&C7CLAWZJ8KH=RR7>Y="!I=!K$W<+
M3,N>11C8&O1SB4E'8D+R=8Z31JJ*3=(#+.5NA! AUE"$-FIJ>:KJ(:6G0R3U
M$L<,2#FTDC!$7U98C)/ #B> U[CC>61(HQO/(ZHB][,0 /M//LUF&[R=SELW
MA[E,J[@[:+ANM>K$NK7H19<5B56E1A"Q=-JS<0,*(!"UYJP;/%FY4DY"5^82
MITP<OUS&M%:+7%9K91VZ'!%/'B20#'6SMY\TI[?/D+$9R53=3DHU+EKI4HJ2
M.G3CU8&\WSY#Q=_K,21W# [-1JUN2=GC[M."#FWL'XZ^X?0/Z!^FM0\S[3^.
MEF+DGT1^SHQ?X7VI>3Q=NVO0I<#8;]B^I%6$O\7HZO6N8.D4_P#[/71#F*'T
MZR"/U#40]),N:NV0?T<%1+C^V>)!_P#0/WZC/I(ES-9X,_FZ>KEQ_;31IG'^
MPT4UJ--1GII<U9XP[MTHS_).;\B5G&M+CA[:DS9'X-_..Q(=5.,AHY$J\K8)
MEPFFH9K"P3&1EG8)G\LR5Z#<;-+1U-=,(*2&2>5N.Z@S@<MYV.%11D9=RJC(
MR=;UOMM?=:E:2W4LU74-Q$<2YW5Y%Y'.$BC!(S)(R(N1EAG0\>>_B7</5J0?
M0VW3 MLR@1!15NC<\AS[?',"N=,P@1]&5QA&VFQ2D>L  *:<NM3Y$ -RLT1,
M7H,\:78>I95>MJXX,XS%"AF<>II"T:*P_1$J]Q.I:M/0Y7U"K)=KK!19 8T]
M)":N4 XRCS.\$4;C/$QK4)W,>>H(R7Q+V\A=V<T+A3;-'LA,84T)2#RG+NB$
M]NDIW;3*<(DH8.!ZC%9) ;D."%X'J4OYE6Y5RU56L>'$- H^PP,?OT]*;H2V
M;<()KG?&9AQ,<M!&N0"3A6H)3_B..\Z=C''Q-F66;]N3+FV+'=CC#J$(Z7QQ
M<++2WS=,QN%%V[6S(WUN\.F4>HC11XQ*L8.@SU #=PNE/L;!_P"KULRG&1UT
M:2#V$IU1'MP?8=8ZOH%MTJGXMO\ 6P29PHKJ6"J0GA@,T#4;+GM8*^/F'D;^
M-E'BA[4]](&A,7V>0J^3VK%1_)8BR"V:P=U*T;$ SQ_!>5>R$+;(ML/6==Q7
MI1Z]8M2INIJ-B"KI$,UKC9JVV',R*\).%GB):/)/ -D!HV/<R@$\%9L'40[6
M]'>TFQWY:XTZ5%N9Q''=*%FFI-YB=Q)MY$FII&X +/&B.V5ADEW2=6*:2=,7
M5:'B->)ICCPZXK&)[90;-DFR95=V<(&OUZ3C81!E$T].#^=RLM+2"3P4!%S9
M(AM&,T(YP9\8S\YEFQ6(]Y3MMLDN)EW)%B6(+O,P+9+[VZ !CL4DG/#ASSJ2
M^CGHSN/2+-<EI*^FMM-:TIC/45$4D[/+5F?J8HH8RF]YM/*TKM(HC'5C=8OP
MJL#XFS%PB ?\*%^]_P#ZFUW_ /5M*9V;D!QY4F?[)O\ \]2VGP7KJX!&UMO
M/_NNISSQ_P"U>_5I^V#Q2\";@-IU\W>7)L^P-CS&5UFJ+<"WB1:2G1,14+6I
M]JG7G4.@#BRN9EE;(AI%P["++.O)HR\8TC'0^4</$JJML]/5)2KB>21%D7<!
M'FEF4[V?1P4.23@#!)'9%FU71+M%L]MA;MC*%H]H;G=:&"OHO((WBS#-/54S
M&I69MVE2"2CF>:>27R=( LKRH-]4I0SW\2M=1LSUAMCP'4$*DR<G1967-SF=
MEYJ?;D.( ]-4Z3/UIM6P4+_A-5+78E.GI5551.<S5)3CL2JH-1,Q8\UAP OJ
MWG5M[]5?'GJP6S/P4K>:1)-KMHZYJUU#/2;/K3004S$?F_+;A35;U6#S<45*
M/DJK ;[6X^$OXE4WXAU$RB-[HT!1\EX?E:JWL9*@O)&J<]#7=O8%:_*Q+*:=
MR4M%.4G-5G64E&N9:7(F5%@]2D/^?,S9IEPHA1O'N.SI(&(WL;P*8W@2  ?2
M!!P.['#)AGILZ):?HNN-F^+;C4W&TWV"L>E-<L0K::HM[4HJH)Y*=(H)T*5M
M-)%*D$!.])&8OR8D=@MVWCV8@VNY^R!@1O@V\Y(D,:R*$#8;.SM,'6HM6P>1
M:O9%A%M'4=+/'+>+.[+'KO7/DC*R#=X1!J=HFW>.O4%LDGB27K%0.,@$$G&<
M G'?ST\=@O@P7[;;9BU;3-M+;;1%>(GJ:2CDH:FLF6E$CQQ2SR)- B/,(S*L
M:"4+$\99PY>-(Z)?$S8K,8G<VJ9 (F)B@<Q,DUQ0Y2<@!C%(:M)%.8 Y$I!4
M3 P@ "<H#U![:TNN?RR\/T#W9[]/8? OOK ;NW5IR> !L]8!GD,D5A(&>9"G
M'<=$FT*X1N0Z+2[_  Z#UK$7FIURX13632(A(MHVS0[.:8H2""2JZ:+U%L]2
M3=I)K+$37*H0BJA0 XI3 JQ4\U)!QRR#CAJG%UMTUHNERM-0\4E1:Z^LMT[P
M,7A>:BJ)*:5X7*J6B9XF,;%5+(02H)QKUFOFM#5!VZ_Q[L0[8\^Y#P.VP7><
MBOL:2Q*[/V=K:H.M1J]@2:-W$HRBV3F-EW:[6,7<?+U'KHS,R[ULZ[+06I&[
MISLI3%E#;P&1G&"?X:N!T=? _P!I-O=D++M<^UMILD-]IC74=!);ZNOG2C:1
MDIY:B6.>FC22=4ZX11B4)$\>])UA>...R?Q,^*Q5(57:ID B8G*"AT\DUQ4Y
M$Q$.LQ$S5M$JAREY$I#*I <P 45" /4'KR5OGC[/_/3^3X!.T4BY3I$LN\0V
MZ&L5< 2,X#,*YB 2.)"L0..Z<8T2G2;7'WRF5&\Q"+UM%7.L0%KC&\DB5M(H
M1]BBFDNR1?MR*+$0>I-GB1'2)%52I+E4(50X% PZA&"1W<-41N]MGLUUN=GJ
MGB>IM5PK;;4/ YD@>>AJ9*65X7*J7B:2)C&Y52R$$J"<:]/HTGZJWWL^+IM/
MV3R#VE6*8D\H9A:I *^+,;^1?R4$JJD"K8MWGWCE"#J(+$.DJ9@NN_LQ6JZ#
MY*MKLUTES^@I/L[]66Z&O@J]*'3)##=[?24VS6R<C'<VFVAZ^"GK41]R0V:A
MACDK;J48,HG1(+<9$>%K@DR,@HDOOQ,&X-](+FQCMRPW58SN#Y="^35VO[\$
MNKV[SJOR>-6XJ&)QST,P*0X^PJ 'O]*8!.>.KR[/_P G!L#'!%_.;I"VON=2
M4_*/8J.RV&#?W>.Y'<*;:.0*&Y;TI)'S3KS]<^):W5M79%+?@7;[., . JMJ
MVGD>JNSI!QU$(]D[M<D4U!#GA0T>J4O("*1N.!%7>'/!SI;K/Y-KHLJ8=VT[
M=[?T%0QW5EN+;.W6%6)P&:"FLMG=@,Y*BH0GEO#GJS?:_P#$0;6\PSD54<Y4
MNR[;YV6609MK)(RS6]8P([6.5%,DK:6,;!3E?376.3A[)5(8-@D*BTM.L6Z!
MG!_+#!QJN?2?_)U=*FR-!67C82\VSI)H*-))I;934DMBVH:%%,C&DM4]37T-
MQ:.-6_(TUW\NJ'"I24$TD@C!!FOFN>N@ZOBL;?URVR>A(J\>589UM\BAS_'Y
M]?%L-#*B7GV[?RZ>( B ]7=, "'2;FQ'033XBVFJB/2>U4Z'NW!7R2 =^=^+
M(]6=-;:)LS4,?<M2Y]>>J5?L\[0B1/X0_O\ J.IXE^5X>[2?3<H_:?Q.I"9D
MP5/X9@<#S\QWCL<[X4ALS0"IT^$R1TI;KG4#LRJ% "F42<TU5V9,1%4C=^T4
M.';61,=OT5SBN$MSBCP&MEPDMTHYDO'3T]1O8YX(J .' E6 X@@+\*;JQGL?
M#C[=W&?#3,I_?^W^^LDG9X^[2]'V^'OUJ#^&YG+_ (CMBFV#+:[SS\Q-XI@(
M.U.S*=Q1Q=:&"U"NCA7W$Q#NK16I9V"9Q$Y4UR<F. @<U/-J[=\5;1WBB"[L
M<=;+)"N,8IZG%33@=^[#,BY[2#RY:^2)N.R]QX>PC(^XC4W=-[7C0MWQ(N]K
MT;CVF[):++=NQ9/(PR%F0[-80588]B)0PTZK.3)&X*>VVF,6G'S<PIN$8VIQ
MY5DU(^Q%[DK=&=CZZIFODZ?DZ7>IJ+>'!JEU'7S#/]#$PC4\06F;!#1:<VSM
M'OS&L<>;&PCBSVR'&^WU4.Z.PESVKH-#4S2=GC[M2'!R;VC\-/[-8+L-9V[4
M;<%8.Y'P^5,EV^AXX8J)]![ PQK#Q#O(%D)U@!CQC":MM8KT<X0$Z2\FWLK9
M;MJQR8'2?+XY;C-;X_.>DIHIZEA_HVJG<4\1_29(99&!P0AB(R&.-VFJ4>LF
MI$XM!!'+,?F&9V$2?2*QR.0>.-PCF=,B'T#^@?IKV>9]I_'3BBY)]$?LZ.R^
M&\J?R#8'9)XZ72K>-P^0)TBPAP91G&57'U413*/W22=U^0,7CGA55;W^P0AT
MA2[]^1.R&@ITQZVDGE/W.NHAZ09>LO<,>>$%OA0CN9IJF4_:LB_8-6I[T-W>
M-=D> K9G;)1SO&\3VHBI51FX2;R][N\FFN,!4XDZI3E24>&;N'LF_P"RX+#P
M,?+3*C9R2/,W5:UJMD]VK8Z.#@6RTLA!*PPKC?E;'=D*HR-YV1,C>SINV.S5
M5^N,-OI?-+^?-,P)2G@4CK)G QG=R%1<C?D9$!&]D9V^[?>1G/>QE22RGFVT
M+2;@57*-4J#!1RVI>/H)94#I5^GPBBZR3!J0B: /GZIG$Q..$2OYR0D'HBOJ
M:J"UT=IITIZ2,*.<DK8,LS\,O*^,D\\*,*@\U% X:M)8;%;K!1BCM\(084S3
ML :BID .99Y, LQ).ZHQ'&#NQJB\-1; !$0  Y$>   #W$1^@ 'U]Q^@:VGY
M>/N.G=%V?1_AJ34+LMWB6&!3MD#M2W(S5840\VC88K"&2W\,NTZ#G%VWDFM9
M5:.&I2$,8[E%51!,.!.<O47E*EN=M0F-J^B63.-QJJ ,#D<""^0?4>.L<>TV
MSD$R4\]_LL,XRIAENE%'(K'("LC3AE8DX"D GNU'E]'OXE^[BY1B\C9*/=+,
MW\=(-EF;YB\;*&2<-'C1P1-PV<H*D,DL@LF15)0IB'*4P" >F(;#*0RE0000
M00<X((X$'L(T[Z9TD$<D;K)&Y5D=&#(ZMNE65E)#*1Q!!((XC7K,?7^XXKN]
M5R1CZ?D*M=J3.QUDK%@C%>T]BYB+<$<M'*8B!DU4^LG;<M7!%6CUL=9H[17:
MKK)'U:B*.9'BE4/'(A5U89!4Y!'\#S!XCCK=JJ&EN5'54%= E31UD+T]1!(,
MI)%(I5E/:#@Y5E(9& 92& (TJMC^YB/W?[6,/;@&C=NPD+O6NW;(EJ(]B&O-
M>?.ZW=(ULF=15=./3LD5(K0WF3>87A%XUTI_X@!&(Z^E-%63TQ.1&_F'OC8!
MXR?7N,-[')LCLU0/;'9Y]E=I;K8V9I(Z.HS2RMZ4U'.B5%'(Q "F0T\L8EW?
M-699%'HZ%R^);M8O=T& :0"HF)7,#K6?M /)4E;CD"T19QX^A5%$Z0@)@_B$
MA4A$.D2B+HV93%+4/\ZHW?U(T/[^K2?!II=S9R_5N,&HOGDV>\4=!2RCP!K6
M]62?7H;L/J']0_72\_I'P_ :M'!Z*>W]XZ=B3S'?Y3$55P6K-*ML85*X63(+
M.KLQ.W92-XM+**B9"T392J"$I*MH2%C82(47+VXB.3>)QZ2"LM+K/M1HHQ,T
MV[F1T5"QXD(I8A1W DDD=IQGD,8J6R6Z*\U>T @#7:LI*6VO5OAI(J"DDEFC
MI("1^2A:HGEGF"\9I2AD+"&%8VNUXD[/'W:=D?;X>_1K_P .AM]EL<;6LCYP
MGF2K!UN#O;$M>363,F9[1<6HS$)$2WXP*<"/+7/WI! O3T*-63=XDHHD[)PU
M+U,'J$B!SU*'>]3R8)'ZH35#?A4;3P7;;&T[.TTBRILO;9/*BI!$=RO)@J)X
M>&02E%36UF.<AY'C(#(<B=;U+6-YWA;IK?W>\C8-PN8I)F?GJ L<OD"?^6)%
M'[IH1X-D$Q'W[:9>>1]]+-.N[3P+VB*,'V[@S]^KX=&M%\6[";$4&[NM2[*V
M&&0?URVJFZYCZVEWV/K)U'%HW6=K-VC9,RSARLFW;HD]SJK+* FDF4!XY,=0
MQ2E]P]Q#7R3Y7L]VI$5UC42.P5$R[L>2JI+,Q]0 ).M4BFUY&HU"JU1MT^7K
M%;@Z\AT!TD[,+&-8U+H#VX+T-B](<>P<!IGL<DGO)/VG.N&MQJVN%PKZ]\[]
M;6556^>>]4SO,V?7ESG7I-?-:>LRK>K:O6^\/=1;2J]U"?W#YDD61^>H C5L
M@V (Q,IOS%1CRMDB#]RD =*R#"(.Y5'W#7=_HIM_Q5T:]']NW=UJ38K9B&48
MP>N6S477L1V%IB['UDZCA$QCJ:F8N&8D[CV7D6,8S3]_QNG[A)HW)^$!'\2R
MI"\  B//TUZ/+V<?LU)/E$=)3254QW8::&>HE;APCA1Y7/$@<%4]NM4V A6=
M;@82NQQ>B/@8B-A6!. #H9Q;-%BU+P'L'2@@0. ]@X]M(^OSP5M7+7UE773G
M,]94SU<Q[Y:B5YI#XNY.JIO&1WTS.RC;"0N/'Y8_-6:I-_1<<R(=!G%58-&)
M'5TOK5%0.A9Y6X]Y'1T0(]16ECL<%)+H.VC)RT6R1)O-QY#B?</'\,ZLS\$_
MH9I.E[I&)OL!GV0V0IX+S?X.(CN4\LS16BR2.O%(KA/%45%5R,MOM];3H\4L
MT<J !R$@_EG[V5E7SR3E)-VYD)&2D'*SU_(/WBQW#MZ]>.3J.'3MTX447<N5
MU%%EUE#JJG,<QC#DUW6H((*6*&FIH8J>FIZ>."GIX(TB@@@B5(XH88HPL<44
M4:JD<:*J(BA5   UZ2A8TR-E>Q)U+%U!NF2+2NB=PC6Z'5YNW3JC=(2$5<%B
M8!C(/Q;I&43!5?L=I(3E[AR]0:\OZ)\/QUEO&TFSVRMN^-=I[]9MG;7&PC>X
MWRYT5IH5D8,4C-57S00"1PK;B;^^V#N@XT]MNV.;S:)&*3%PVI;B*_#I(BLO
M+2&';\G%M4P+U"+R1+ G9LA O(B1TLB< *;DH=)N/*$ <2.?N&D"P=-W0Y?*
MJ*CM/2IT>U]8TRHE)!M?86JI6+@ 0TYKQ-,"< &)'!)''B-2"\)[:!([O-Y^
M.JG)Q:ZN.<:R+;*.6W"S<XM"5FH2+5RTK+OK*!._<[$$95S-1.1V6->R\D@0
MY8IQT_'YCV?QTU_A7=,5-T/="FTMWIJI$VDVFIY=E=D(TD F:Z7BEEBFN<.Z
M2=RRVXU5T$NZT1J8*.F<@U<>=%G7C7YR= C_ !0UO^:[X<,TY)7N-ZCMF@9!
M8G5R",I:<D9)4<I]/(\&-&0T*J)N $Q52!QP4!&TO0A3]7LM<JDCSJB]RIGO
MC@HZ(+_VDLH^W3+V@?-RIT^92Y\7>3/W*-#:D_A#^_ZCJ6Y?E>'NUBIN4?M/
MXG127B^;8/D/A6^%-F9C']J1QIB#&V+;H=!+E3IRMB6OWQHH], =96<1::K8
M6C=4W00'EHZ% [KI(H07L+>>MVVVXM[/E:RX5E939/ ^0UTU*P7]*2&>)B!D
M[L.1P4Z=;)B&F/S5C!\5!/ ^L??H8M/[_P!O]]2Q)V>/NTI1]OA[]&[?#$YR
M]5[9LW8#?O.](X?R?'W&&15/P=&I96ASE(T:D$?QH-+52K,_<&3 127GTP6$
M 60 U=^EZW=1=[=<E7"UU&T$A X&>BDXL3WF&HA49YB/AR.MBL3#(_SD /M7
M_P B-$49?RK3,&XMR!F'(<D$12<:U.;N-E?<$.L6,@V*SU5NR1.=/S<F^,D1
MA%,"'!:0DG+1BW R[A,HQ;14<]PJZ:BIDWYZJ9((E[-Z1@H+'Y*+G>=CP506
M/ '6M'&TLB1(,N[!5'K)QQ]7:3V#67SN@W#7/=;N!REN!OJA@L&2K6\F@CP7
M.X;U^#2!./J]58*J !S1U6K;.*@&)S%!15O'D76ZEU53FM1;+;!:+?1VZG_-
MTL"Q[V #+)Q:69@.&]+(6D;L!; X :D>A@2FA@A3DFZ,_.;>RS'ULQ)/MQRU
MT6"L-7/<-F+&V$<>L_.W')UNAZE"D.50S9HI)N2D=R\B9,ICHQ$''E=S4RZX
M$K.*8/'1_P ")AU\N59#;J.HKJAMV&EADF?EDA1D(N>;R-A$'RG90.)TL-41
MTM-/42G$<*EV[S@<%'Z3'"J.UB!J]GX@&CTS;^KL,VDX^2\O4<$;?+&YBTS$
M33<O5+?:&,-)V*132_=C+VB7QZ_G)EP0 !U*NWJWYN CS8*>:X?'MWJ#F:ON
M$8?B2%ZF(NL:Y^1$E0L:#L15'9I/V.DDJS=KA+QDJJI W<.K0LJ#]%%F"KW*
M!H=X/H'] _33[/,^T_CJ1HN2?1'[.M$SP.ZGZ2\,3;6FHGVWEA0R3;'@\<=W
MY]EB\.8U3CZ_^1EBB<_FZ.H. $ "O^VDO6[27$YX1FGB7U=72PAA^OOGQU!V
MV4O6[1W#CPC-/$OJW*6$,/U]X^.APOB&=U$AE_=ZTP!#R1ST+;9!M8MPS1.;
MRC_)USCXZPVR44$I@(X/%0RU9JZ":R9CQK^+L!6Z@%DG)1>NQ5N%+;#6NOY:
MO8L">8IXF:.)?5O.))#CTE://HC4J]&MI6CLYN+J/*+G,6#'TEI8&,<*<>6_
M()93@X=7BSZ U0*G]_[?[Z=TG9X^[4L1]OA[]&.> KX:%&B,80>]G-E3C[+?
M;PX=.L&PEA9(OHZCT^.=+,$[ZE'.RG0-;+3(-W:T%(.&ZBD+6VL;*0ZZ;FP.
M#MXOVOODK5#VNED*0P@"J9"0TLK#)A)'^CC4@,H/G.65N" :A+I.VQJGK)-F
M[;.\-+3(JW.2)BCU-0ZAC2%UX]1 A42H"!),SQR*1"-XH#3#U#&@N_B5:?C*
M"W(X(LU:9Q+#)ESQA..,E)QR:#=Y)Q,+86T;0I^:10*07,@Z+ZJA4I5R!W;F
M.KS*/,L9M$-4T9"V0DF:DJ4<L88YE$.>(5F3,J*3R _)MNC@"Y.,L<VFZ!ZJ
MOFLMU@G:1Z"EN4"T!<LRQR2Q%ZR&)CG"+_DTIC7"J\[/C>E8D;O3I?GX>\ZL
M-'V^'OT>5\/C&RC'PZJ^ZD.[Y29RYE&2@^X'!/E:4A&PZO8_FE\ZBI?D1X_?
M]X/MJ,MI"#<V YK#$&]N">/U2OAC5->G22-]O9U3&]%:[;'-CGUACDE&]Z^I
MEB\,:'K^(!M?J+Q&[E$=WN>A,8XKJG3U<]GSE?/>.UQ^7GUEWNG_ #>K\VE_
M9]-VVH?Z265_L;J_W-6,^#_2^3]']'+C'EURNM5[=R<46?7_ )GCPQV:I2#Z
MA_4/UTJOZ1\/P&I_@]%/;^\=%>^#MX..,+[C6I[L]U4*QOS2ZH#,XFQ$\6,M
M5$*^FY50:VZ_MD#$)8'LNHV.O#51=96!:PYTG5@;2K^1+&P+4N]UD65J:F)3
M<\V67Y6]SW4^:!GBW,G@, 9:J/31TVW:W7.LV.V1GDMKT+]3>+T@W:QJDJK-
M1VUSDTT<(8+/6*HJ'FRE,T,<1EJ"4Y+;+MPF*N-)E, X6?TX6WDPJSG%])4@
M$VP%$I448D83R*!$P']UV44Q1-P9(2& !!O"HG#;XFEWN>]UC[V?;G.JP0[6
M[4P5@N$.TE^CK@_6>6)=[@*DOG)9IO*.L8G'G;S'>Y'(TXD;%5/&5*:1%>AH
MJJTFBULC2*@H)@VC(>!KE>C^EO'Q<<T(BT9LF#!J"39LB1-))-,I2@4 UC)9
MV)8EF=LEF.268\22>9)YG29+-77>X//4SS5MQN567FJ*B1YIZFKJI?.EFE<L
M\DDLKY9V)8DDZRR9^8=6&=F9]\/+V<E9"8>#R)N74FZ5>N!ZA !'E5<X\B "
M/UXT]0, #N 'V:[76ZG2E@I*6/\ -TT$=/']"&/JT_PJ-/%M=JWKG<IMWI0I
M]X+?G+$U7%(0Z@4"?OT!%"00^X&!V)1#^0CK6J3NQS'NC<_8AUI[9UWQ7L7M
M9<@VZ;?LS?ZX-RW326NKG!SZC'G6G_IHZXH:X,I(M8>,D99\?M,HMB[D7BG_
M $VK)NHY<']Q /P))'-[B'T^NC66""2IGAIH1O2U$L<$2_.DE<1H/%F UE9S
M\RZL4[-6!\/+V=EI*9>#U";EU)O%GK@>H?<W*RYQZA]Q^H^^E@C!([N&OT&6
MZECHJ2DHXOS5)204L7#'Y.GB2).'9YJ#AI]-G=5]<;NMK].,GW4K-N$PW"N2
M]/44&4AD*NMWRIP]_P!TBS.NLK[#PFF<>!XX'Q(<(Y_1;\-(723<?BCHSV^N
M@;=:@V)VJJHSG!,L-EKWA4?I/*$1>]F UIS:2M<"]!?_ !*ULD7FZW!%%544
M&)KFWM"V,D1.(I)R-TR1>H>44(3G@JBK:@PY53\<G*BB B/;#C:@'FD_I8^P
M#^.NMO\ )\6R"+HUVUO*JHJJ_;EK9,V/.,%IL%GJJ92>959+U5%1V%V/:<CC
MZ\ZZ(4_/ZGO71C_PVEOPH&!<R4>,=0+//QLH+V&VL'*C1*U3F.?3=<95!]'@
M<2/']9A9<MG;+(-N^E#3$BX</0;_ #]@+G&^<CN]^N3?\HE:=LOY\;'7JIBK
MIMA/YL1V^TSQK*UKHMH?C&XS7:"<C,,%RK*0VV5'DW&K*.GCCAZSR"?JR6=8
M]<YM>;BJ;4(*<L%FA*I6X:R6SR'JJP14'%Q\Y9OE0.PB_4$LT:HOYGY:#]\#
M#YBX<^3!X[!OV_,+=9I2J[U>*^AM]LKKM<JVVVGRCXJM]77U510VSROJ?*OB
M^DFE>GHO*?)X/*/)HX^NZF'K-[JTW?2:-)NLZ3XA2W^I_%-S/%%5[J="IF'J
M@F("!B$[V,ZY<EDB"'M^[=6]<J@ /)%P5(;@Y3 %P>B2GZG82VR8P:JIN-0?
M7BNFI@3[5IP1WC!Y:85X?>O,PY[D42>S\DLA^]C_ ,]4MH)J*F322(9154Y4
MTTR%$QU%#FZ2$(4H")C&,(%*4 $1$0  YT_YCC>)X 8))[.6LE-_H_:?Q.M+
MOQ']L9,H>%GFC!C%B5W,4#!$-/U)!!,%7 V#!<=$6^,91G2!A!U,)U!>O)]'
M *H2RS<3 FL8=4RV2O)HMM;?<V8B.JN<D4Y)X=5<GD@=GY<(S.)3GD4#8)&G
MJR9CW.X#'M7&/P[M9KZ?W_M_OJV,G9X^[6Q'V^'OU?-\.KG+]EGB#Q5 ?/.Q
M";@,;W'':B2RG;:!9(1LCD2M/#\B!1>&](RL!']0CUK6,[<A1573XC+I3MWE
MFS#5*KF2V5<%5D<^JD)I95^C^621O5%GD#I1JDWH,C_1[K>'!3^.?#5F7Q*6
M]KY=#4C8O19;AW/!%Y1SF+-8![4,T=&5QM2'@IF,7JD)1JO>)9BN1)PW3B:.
M^2,=M)' 65T76'>-3M#4)PCWJ.WY[78 54X]2HPIT8$@EZA2,J-;-DI\R^4L
M. WDC]NZ=YO '=![R>[0@*7V_P!7_;4POS\/>=/*+FGTA^UHN;X;#964Y[WO
MDO$1R*)I/%>#?.(B'!Q3*3)=V8]8!S^[4;46+?H&$OXKW'JAU% 0ASI-O?\
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M!_1CF>-?\*C6<EN0R,YR_N&SKE1VNHX5R)E[(MR*HHH*@E;6*V2LHS03-R(
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M"8H#ADVBLH4_]81'Z*RMV]RQG2C'TB[%0A&DV@I,*I)W(ZJ4\C\F*G=B>/(
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MVW4^,=10TL..[JH(T_=U.ULCZFEIH>754L$?ZD:K[M?;;34_7NXO %%[7?\
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M;>38TIQ*%OO6)JZ< $0[A6UZBK:!!X^H >KD4X'VY( _4 TH6L9K$/S5D/\
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MB=NS(-.3S8LV21S-R7ALYRVNV![7+]:\43#UBIVU5J?.6]^U./48H"F::HT
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MREF>*,7'FXRJOTUDDG3<EIO,JTA+/(,U4E0*ZAX&$K*Y%2 (6)RW,HW.C37
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<M)(S/([,[N[%G=V)9F9F)9F9B2S$DDDDG.O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g29248g30o93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g30o93.jpg
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MT%=-O5&A ];KJC7QCO4RQ@0U,B2&+0Q7DPWS]A-3@B1XP>8(61&>9<6@1O!
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M3A%_,YQC&<YSC&,8\<YS\V,8Q^/.<_\ 3&.$7\0M#B<+;4E:%?.E2%84G/\
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M+GJC8QW;]>K S5=#J=C@EF]QZ6UXR2CA:]7J]!#4N]ZZ'DGHRFA6'Y@,JA)
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M\<EJQEV_.BZ9Z5#7U=:Z_%*M&TGT)V,&UEUB[ ;3[3=1 10CVWKU)/%#UXV
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MK7W4NS4W7,EZ9KVI6"IZ>,UFB3)+_M4B530)&!)%5B2_)_\ $//A(L%UU_\
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M%B#L)] >\/U0;+_@PUPI&H[1ZJC!9-UB==Z1(UW AE+BWKS7?N>"07&;AO\
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M4K+T#2L>ZD=>6+O':A>Q+!?T3*B8;8OE<Z;M )?J$IB*A0R,4H=!3]JQ"+,
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M8=B:T/")$*+(T:W<HLJ,FF?^ V/J(K?K(K7 !!Q*Y\BT=C9A[5]#F2";#E<
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M(T/9\0M6GPB'9QG2G3O0^XZ[E6#^J>\O7G8X;"',M963I,*_V2$UE>/\J79
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M#XN&A\IUGYLHA$7DQ5K3EQE:FW&W.Z[-]G%*ZL2-NBUI7SZ;<]BMJ4*=L]S
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M@]1Z0.HU#L446[.E,3[5)GXD35MJPXG(L8VRRSAEAA'_ (=EM#3[V&L>O?\
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MFZNZ(4_6MLT_;%[&N]ID:$B:^JNK()6'5844-K756INPNH:)3"RQ .%(/3(
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MC,/.6[+$:7_X7"W-?;E._P!HWMEM"M5KFI7PVU(XJI9$.I /IU:75EH&)M3
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MX11>!?EI;2^J]H3[5^R7"G<.T^@7)I\+8^DGI-_L?=G_ '[7//0/L5_,]O\
M[S8?TKE:GTC_ "EK^Q5_F8N05*5+4E"$J6M:L)0A.,J4I2L^"4I3CQRI2LYQ
MC&,8SG.<^&/GYV]:TOUQ.DND4];NH76S1:HJ8D_6>F*!6K VE.$>MMS%>@R+
ME,4A/S)60M<@S/<3CQ\KDE6/,KP\V?$_2#:']J[<VMM$'$V[O[FM2/"@:KA0
M;_IHBFWN72+6EU%M0HZ&G28T_M!HQ'O=)[T[??1/4OK1='OYU- <PZ^D:]Q]
M"I1<*$_'\V>$U48]L]6-$[!E&;O8M?X?M?L,F;-(UH[9*<1L4B'#7[.V<>J9
M8/DT^I#341J423*F-,(:89?0TA*.;#LSI5M[9%(T+':%2G0+<(HO;3K4V S^
M3;5:_J]3&"(.8S)6&O>C^R-H5.NNK.F^ID75&EU-SL.A>6%N++>Z3SR4*=9T
MBIT^L"T5L*+'X(Q6"DE^''SZR5+(MIFON9DOY=ENHR\]GU69$A]W"/*MYUY_
M+CSF'O+VZOZM2O>5WUZU0@NJU#+LC.1_5$Z@89SRA9.VMZ-G1IV]M3;1HTFX
M6,8 !&'#)WN,;W$GFJY=&,O5@NZVUAV3"C8*,IPTEQQ;PAUHFTAI.?#.%N*B
M80G*?#/F5\RL?-SY=(X=NF[O^LB5>5RL.MOM-R&7$NM/MMNLNHSC*'&W4X<;
M6C*?'S-K0K"L*QX84G.?QYX^M/KAZ;D7]>PG++F<X\4^K5C/XO\ +C&?'.?Q
M8^;'S?B_%C/X\<;QWSY:3.\\?2$4Z--^M^2'57K\J4_C6]&P]E><Y7EWXL"_
M697E7SY5E7CE6<_/G/CG/S\E% (!AS MGUR\.2U2""IJ_P#JJ<HC*5.\WC\^
M59F9>\WCG*LJ\<Y_'G/(XSX:Z^)W>!15K&?Q8S_USCY_^GSYQXX^?Y\^'SX_
M_3/AQJ)S\O'ZE%:%7PB1(LY5",9P0LLM#+N$XRI;86) KKF/-\RO)B8)E9;\
M,YQE"O/^#A6,8?#GIP[X\.] 8((U&8[E4K#6P-L%S0MC%1"PR='7&DQI<=MS
M"FWDJ;7A"E8RMM64+5A*T9PI.,YQC/SY\9H/?;5*=:WJOI5:3^LIU6/<'M=O
M(>"#J.,#(<E%1K:U.I2JM;4IU<JC'-!#P9D$1H9TT64.O?4GKX_4J?>INNFB
M1QE+Z6&3QZSGZW[2"+RQT$] J9HU/K<1<U Z.8@H:%I9&+D(]U-0VVVL)V:[
MZ8=([VU^QU]J5S1+2U^ ,IU*K2((JU6-;4J [\3C.]82WZ.;'MJYN*=FPOGW
M!4<^K3ID;Z5*H74Z9F?N-$;H4]\8PG&$X^;&,8QC'_IC&/#'-9B/CQ/:=ZSB
M_O"+A7],A_J0=C/^(?L(U?PKS/NCO]2NPSI/^1GU(^K'H3[*ZIPK1U/:?52<
MX4*(_<W6)J\Z?.66F';#6[]K865M8*76),B*0L@H:W',V+7<U45QJ1("W9D)
M"B2XK;F/63H8QUQ+S++L9^S78ZI1J,9&)S2&SD-0=><0KE)P94:X_=#FDY3I
M.[O_ .EAWIEO"S@M8UJB=A0-GI5M=E7:R"KS;"5<ETRXUBR6JPW6IO!;=%.O
M^])D>FEQ4>8A^%#?0_"=PZQ'4I#.+HT'8%;)!)(F"3ZQN^/PRF)2MWZJV*:G
MUVEW,8=-#8Z)DJ!'1,9=]D<<=:1*CYF1H[<V,I;#F,/PER&O!.%95A*DYS6&
M.+7/ ]UI:''FZ</CA/@J2\!S6G5\EO\ I$GPD?!96Y2JDX1.$3CY?/R0\M5
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M2Y)*49Z(S!D2'%.RIU1*)?779$A:_%:W8#D,G75N*RMU] 1F=(<6]-4K(?\
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MQG&48QF#]>OUX)&_>L"J\/\ KX9_%^/\?_RQCPQG'_IGYO\ _G'U'XZ^2*R
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MV@-5&<#)MNV$@=S$($;B\MN.=41B)6L9/"2HN,M@XXE3[JPT(?\ ^%9;>?\
M;,$'9Q*1.GEN10SO+S^NC$H"P2A[1Q"?7&6]36'WK .6WG/C'M8]B*JO#R#"
M<80][,>;D2G/.ZW7A[3B&D1QCSTWHI+=:*] GL$]C/DATPU-CYKK(:"Y*6]3
MH"7F2,P891.B0)K-B*/X@3";3L&.PS#BB6X2I;/G(SI4:^/HI8<*4X1.$3A$
MX1<*_ID/]2#L9_Q#]A&K^%>9]T=_J5V&=)_R,^I'U8]"?975.%:.I[3ZJ3G"
MA8_M]IL5;9G38U<@RA<)EAY168<<AQ4-K<2W(5*8AARI%E,5*LO*RS#DI<;3
MG\-M7CC!7&-IN!QOPGA$Y<9GN4,;E47]J'HQC9[UIWW#'$'R5+TSK2K8KFJ
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3LC>H]I]F_P ;U/M#I5@0(7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g29248g42k09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g42k09.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( .$!K@,!$0 "$0$#$0'_Q  >  $  @,  P$!            !P@%!@D#
M! H" ?_$ $(0   & @(! P($ P8"" <!  $" P0%!@ '"!$2$Q0A"3$5%B)!
M%S)1(R0X0G>U)6$8)C,T-5)BMC=#<7B!D:&X_\0 '0$!  (" P$!
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M^KPGC*[/+W]5Y]_+?K53I\;74:M:1:@P&RUR#GQ8@O[D&8S$8UD1:@Y])#W
M-_<^CZ_H(^KX>IZ2?EX ,38\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , ]9V\:,&ZCM\Z;,FB/B*KIVNDV;I>9RID]198Q$R>:AR$+Y&#R.8I0[,8
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MA*4)8>)/!>&CUVDXAIX:K17UZBBQ9C96\KHGRR3Q*$EE9A-1DNZ1(.?$?4,
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M^ZNZS0/+;*W& , MOQ#YB;2XA;$:6RE2"TA6'Z[5"[T-ZZ5+ VV'35[.BNF
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MY_%RN:2[ILK7VL2U$?!^J]PY+FU%,;N7_@>[O<^;^'F4<^3P?(KGO<\@C &
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MX\E'CG&HQ^ZN+<12[;+67);?(N/A#;X5PQR^\^'Z)O/F]-4W^9-V=2=@, 8
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M:AI-UL6LYM*"C[)(196EK=T:58I2M-1>6F)4CI]TE$-3OJVU36?G32;P2?@
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M37K%'&#7TU+2]<3;69L+"ZUA](4R_11Q#U8N[U5R>'L;4Y0 .DE7S8\@P/T
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MO@$A8!I-[UY4=CP;R!ML,RE&CMLJW!5=NB=TU!4H@)VRQR&,3H1 QT3>3=<
M]-PBJD)B#RT7W::ZO4:>VRB^J2G5;5.4+*YQZ2A.+4HM>:9QVU57USINKA;5
M9%PLKLBI0G%[.,HM--/U/<T5PGU+?Z!&R+JX[M@ B)*:J=AI]<VG,M*HH_K4
MFXBEE(M9X@^M<1&2[1%M))QT99F:$>5\9DR!%%$@9ND/:%X@C4H37#K;4L?:
MK-##W[?[\HPE#3REYN5#SW3W-8EX-X.Y\T7K:J\Y^SUZN:J2_=3DI71CZ1M6
M.QT:UIJO7FG:NWINLZG%5"NMUE79F48FH99\_<>/N927DG:KF4FY=UX$]W+S
M#U]).O33!PZ4 A/'4]?Q'7<4U$M7Q#4VZJ^24>>QK$8KI"N$5&NJN.7RUU1A
M".7B*RS8='HM+H*8Z?1T5T4QR^6"^])]9SD\RLF^\YRE)[9>R) SXCZA@# &
M , 8 P")=NQL%&TF\7_\JUV6ME2I-HG(*3D(&,D))N_A8-_(1X-W;IJLY)X.
M6Z8E*FH !]@#YZSGAJ=377*JO47UU2SS5PMLC7+/7FA&2B\]\HXI443FK)TU
M3G'[LY5PE...F)--KZ,H+4(UM%UJ';ME#.!49(O73Y4XJN).0?D!Y(2CM<PF
M.X=R+M99XY7.8QE%5C#WUT <!RFR8 P#"RU?BYH6RKQ Y'S!0%XN78KKQ\U$
M.B_)'<3+LE$)".<D-^H%&KA,3=>*@'()BB!-FL=^SM4DXVG;;D0EX&3<H1E:
MV:JFBU<-7K@Y46$+?TD")-$U'2AB-6%L;)MVCIR9)&9;-7"POU@+O8 P!@#
M& 50Y<)'_*^L7I0_LX_<-?.X-UV!$Y&KW.#2$?Z>3R4:)E$?\R@!]Q# *_8
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METU$&\F4AF4@BJ(&7P!@# /2D8YE+L'D9)-DWC!^W5:NVRP>2:R"Q!(H0P?
MAV41Z,40.0W1B&*8 $ +8\8+9*6'73F!GGBTC-ZYL3ZBNI-R<3NY2.8LXZ5K
M<B[./ZE':M:F(E!\N8QSN7[9VN<YCJ&P"QF , 8 P"$>1E6>VW3=T912 N)N
M):,[=!(D 166F*;),[0S:M^@$?7?FBC1Q _S>[$HB &$0 I=%R368C8^68J
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M2G'*CF6L<KUXC_Q.PRJSR8>$\R^94%7@MDC"/H(I!\ !(^ , 8 P!@# & ,
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MK-W+5RF59NX05()B*HK)'(HDH01*<ABF*(@(#@'L8 P!@# & , 8 P!@# &
M, TZJ; IEX?WB,J5ACYU_K:XJ:_O35B90RM9N:-;K=O5KTD"B:8$D"5JX5F8
M,5(54_:3+,?4\S'(0/+UZ?I^J/?J5KK]ZK4+<*I))S%;L3!&4AI-)%TW3?,'
M "*+@B#U!LZ2*< $0(N@DH'^8@8!ZM3O-1O);$>HSS&>+4[9.4:QF8F4,$1;
MJTLFWG8%WZB:?3Z,6633<E)YI@8X>"A@^< R%:L];NE?A[93K#!VRJV*/;2U
M?LU:EF$[7YV*>I@LSDX>9BW#J.DX]VB8JK9ZR<KMETS =)0Y1 < Q\M>:C!6
MFH4F7GF+"UWTEA4IT&N90'L^2J,6\E8C,"E3,F8(E@[;.G7J*)])K$$GF/8
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M)MWK^-=J&^Q$VYSF_24>@)$P!@'Y,4IRF(<I3D.42G(8 ,4Q3!T8IBCV!BF
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M<D >O)S5IZM248J;_P WI-YN:3* A^GW)A 0[$! Z 8 P!@# & , 8 P!@#
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M_P +)7:&Q^2ZE'VQI_;E]WY;+QO/F93)IIR(:KZIBM24R3G^.\3/;-UY'1U
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M?]/H60P0, A2M?X@-N_Z9:/_ -^W=@$UX P#G_O-\K-[Z6:+F$S.AZ]@THQ
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M2KG.>)AD_2(\3?R0++)@?A%%%NDF@W23001(5-)%$A4DDDR!T4B:9 *0A"@
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M/UW0EMXV0C<Z1C:GK$DFI;)/H?;7:9CUB+(TJ*5_E=1#9RFFM;GR(F1.1,D
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MGH [,81,81,81$#)X P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@&-F8EA/P\K!2B(.8R:C7T3(MQ'H'#"2:JLWB(B'R *MUE""/[ ; .7L
MPQE=,J!4-D Z8LXH?8UV]N&J_P"6;7"-_P"RC':LNDFHRBI]-H5%*:AY)9LN
M1Z11RS%VQ<(KB!XHFSA;7 1^NH>8V)**&!,B589*+1*!S?!5)6T.2H5N':@8
M0]19[)%. =^D@NIXIF MUI[02U:E&]_V.Y8SE\3153A(UAZBM9H;9T3TW",(
M+E-):3G720BC)69T@@L=(3,8QJQ9"M[P"S^ , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , ^3WDG]9W;VKOKLZKX@PNYHV)X@IR%0IFVZDOJ-N^LK?8$O6[*
M#B!;2+BDN-EKO9:S*TTL(G6S.FTPC)QRL$H\CI,BJPYE6G6Y?B[;[8RL_ED^
ML$! P 8.^A !#L!*/0AW\E, &*/]0, " _ @ X.$_N , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@'\$ $! 0 0'X$!#L!#^@@/WP 4
MI2@!2@!2A\ 4H   ']  /@/_ ,8!_< 8 P!@# & , 8 P!@# & , 8 P!@#
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M511%*-9S\4Y?J+) <RJ1&:+L[@ZB94U#*$*F)B 0XF  *;H#:, 8 P!@# &
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M5X_OZX6?GC?J7'P0, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , J=PY_^'>SO_NQY
ME?\ ^H]L8)?7Z+]$6QP0, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
5# & , 8 P!@# & , 8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g29248g68t71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g68t71.jpg
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M 0$! 0$! ?_  !$( 1\!4 ,!$0 "$0$#$0'_Q  ?  $  @,! 0 # 0
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MTI32E-*5K[(^6<88?A4;%E3(%/QW!.79&#:5N5AC*\Q<O5 $Q&C9>3<MR.'
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M B0PAR7D.P](AR'OJ62JD@D E<\I(!*YV.#VSWQ7@8,RAE5F"M@, 2 P&X#
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M]>'? C<-L^K:JT;:K+$8H88_WB6,3_VG[P'EDN)0 K,GNQIS(I;G9JCGBCB
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MP<^N3^9^/S%8Z^.V==(*?*9/NFHD;RSICSU<E$# '[0B;]D>XB/N/.K6413
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MF@@']LP8$L0B,"'*ZKQ#Q/#HCV]O'$MU=S.K/!SE!%!W=F"MAW.T:X.<,QV
M#0K#])ZQ5+5U!TVV@WI2Y$+U-V$CD.K_ (>;/!*'"B4ZG +2HI@H'(]$ @J)
M2@ ' ?F+L9\#K@SIYVOV+0(>9)!83M<+TW6-G"(Q'<3=:L5\0%CBD6"RO4:1
M>61!<QQQ2#'1V1B77?&#&1UZU2CO6\0K<+X@=FBGF3EX^K8[KKI=U3L554RQ
M*U".%TA0/*/W+DQG]CL"J'ZH\K(F C9,ZR,6RC6ZZZ*DI\+<(Z)PI"Z6!:XO
MK@<D]]./W\H4YY(P %AB'41INQ +M(P!&CZKKFH:S/'Y_+#;QL3':QD\BG&
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M>-760?/\$8>9'R1D&(3,V,5R5"U6%ECZBNC$,"9V]L4;*B(.0 >K$@;#).
M.I)V&*P?$>IOI6DW%S "UU)R6UFJCF9KFX/)'RJ 2Q7WGY>_+Z;5.+"6)X?%
MU/BH.,BV,4JE&L6BK2/13;L8YFP0]/&PT<W1(5!M'Q;4"-D$4"%3Y*)@#IZ
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MCW^G4/U'G_7/\,;)]]AT&WK\-SG?TK,P#]Y]!VVV'3ICMG(QUQ4DJO&])4Q
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M=:K%_8TWN1\DM[77_@,?#P=,<U^73<2$\M/0\7#(A-@;GS3#Y2>9R"0'S&Y
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MT_[Q_F*JVP&4V'4#\A4HJN0!*W#L'[7 ]@X]]8>4_>^G]!_*LD!F$8Z[[_\
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M"3>W]'$G1D*)P#/R69L001J6QS6?)),FPC**D9B4GW$4_F4DF8Q3<BNX^XN
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M.1;&I,V>BL/3-8R(CGIHN%;IQ+1GRJDPP>N=AUZC;H?B.AJS32NM-*4TI7X
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MT#3);Q55;R1A'91LQ(%P_698';RSY*\TA(C(! &W,*W_ (7XQ\0^,9AP[?\
M$4]QI$NGK8ZS=#3]+BU>[T6*-8OV7J'$L-A'KUW;72+':/;W6IRI-"6219(U
M9:CVM(&.H=0YC'.H8QSF,83&,<XB8QA'GN)A$1$1[B//.H$=RS,[$LS$LY)R
MQ+'))^))R<D=S4W6^@Q"-(T3E55"HJJH554!549[ 8QO\/2OO2LLHE&+0A9-
M^2%</$)%>(*]<!&+R+5)9!L_58@KZ51XW0<N$47)TA622<+)D.4BIRFZ9#;9
M8 D;=B1G!],@$@=]]OC?#3IX+=K6-I/(>03/%S'RFD"E YC!Y.<+D!R,@$C(
M%>]BC".0MXF?,2;/\1MYIU<,TV>*C[7*P<:XD3X_Q(1^DG?LARHI "#",A8K
MSBBY?*HMEES@T*KZE=NDIL7#]B9YQ<NN8+<GE8XPT^%*C'^ 'GVZ'DW.<5(W
MA)P)^TN(1Q)>VZMI^C.Q@Y\<LNK (85Y,'G%K'+[0Q..6;V;<Y-?ZHN"\+T'
M;IAS&>"L70Z<%C[$]+@:-5(Q, ZD8F 8(LDEW)P //D'QTU'\DZ,'F.Y!RY=
M*"*BQA'>:]8UB>ZC;A0=V^W_ "=MZR6V.M5<DUY6*5=(_P#MD)+M5T).N6..
M-R !(5V?91TPT*8?*659@W<%4;K*IGRNB:O=:#JMEJUFV)[.82 '[LD; I-"
M_P#@EB9XV[@-D;@&K6]LX;^UFM+A>:*="C8ZJ>JNI[,C ,I]0,[5_EXYSP5D
MG:7G2_X"RS&&BKGCV<4BWP$*?T,HR5(FZB)^'653(+N'G8M=K)QKH"AYC9R0
M# 14JA"^WM(U>SUW2K?5+"3GMKN'G7?WHW4XDBD"])(F#(ZGH1WVS EY83Z7
MJ$EE< !XG YM^5T.&21/564Y'3N#N"*]:JS1 22'GCN' CW[!S_E^?U^FN9L
M$MZX_$G.=_3N,GI\Z[L._?Y=?G\NOP]*D!7YX (C\P_L_E]OX>XCQ_7^F-P7
MD">I;\OUC\.VU$)#8 '4_P O0;GK^ Q@8K>U;G0()#"<1#O]N![=OX<=OY>V
MNDT ;8Y!],'.P!R?R^G3X7"G/4;CKV^0_7I\JW; 64"@7A3]SV[=_F* "(\?
M3^FL-/",8(SN-QGT]/U^-7$."Q_W<_\ >';];9[5NVK7V3@)",FH.4>14O%.
MV[^-D6"YV[YB\:JD7;.6SA(2J(K(JD(H10A@,!@[#]-64EG%-&\4L0DBD4I)
M&X#*Z,"&5E(W!&01W_"KM&,;+(A*.K!E=3AE8;@@C?(/0]1OZUTB[+?$KI^6
MF<5CS-DI&U'):9$64?97IT(ZMW97N1+J6'RVD)/*% @*-%A182"YN8XR2JA6
M)8/XLX#N-->2^TB.2YL"2[VR@O<6@[X&[30@YPP!>-1^\R 7,@:1Q!'=!8+Q
MEBN1L)#A8YO3T5']5V#'[OH+9 $! ! 0$!#D!#N @/L(#]0'4;5L]?G2E-*4
MTI32E-*5X5FM%;I<!*VJX3\/5ZS!,UI&:L%@DF<1#13!N7K6=R$D_60:-&Z9
M0Y,JNJ0@=@YY$ &K#!-<RI!;Q23S2L$CBB1I)'8]%1%!9B?0"NKNJ*SNRHB@
MLS,0JJ!U))P !ZFN.?Q/O&5O.\:X,MA7AU)SLK%Y+GVM#L>381)TSG\H*RBA
M&RM5HY132?P-).)U362RN2-7LM&MW!">@KH/597T+P5X=VO#ML>*N,#$DEG"
M;N"QD*M%9!!D3W6_+)==/)@!98W92>:7E$<;:[Q+/J<XT70PS&=Q#)<KD-+G
M[R1=TB R993N4!Y<)[QZ9/#]V>5C8OM8QMM^@%&LA+03%68OMD;)>6-KR!.G
M!]9IH3&(191J5T8D9#@N'FH0D=&MS@!DAU"_%7$$_$^N7FK3!D29Q':PDY\B
MUB'+#%Z9Y??DQL9'<]ZWK2M.BTJPM[*+!$2^^^,>9*QYI)#_ +S$XSDA0!VJ
M:.M=K(TTI32E-*4TI32E-*5H7=%MWHF[/;UE[;=DPCH:3F*D3%+FW#$4PD8T
MLBB!F$U&&6(=(LG!R:3*7CS*$,F#QDCU@).0TI50WA/[M<M8^R#D7PFM\D\V
M<;LMKT0S<XBR,\$6+3=%MQ\@I:E>:V=[Y2DQ8ZK%%:1EL30!5V*:7GNO/D(F
MPN4^8R?,4'<?PD_7*G^8^&1_#O8MS0R-&V3$ZEXI"2<-N7B=CT(R&BR<LO.H
M_LLF[&:=D #% P<%$W<1#CV'GZ_7O[\<<<ZR29&2<;L/Z=N^V?7\*Q5Y* .4
M]01GZ _'\^E:G7L4C"/A>1ZGE* 80.0P=2*R8B;Y%4^0 Y1#N'[)BCW*8HAJ
M[\I)E"NN1RC![@[;@]C_ #&QK5'U*YLI_/MVY&!P01E'7)]UUR P_ J=QOO6
MLK[=I6T*(GD#(D3: H5NW;I^6BD)^GS#<F,=0YU!(3D3G-QQTE H=AK6T$<!
MPG-ENI8Y)P#CT'?L!6MZ]K-WJO*UQR!8LB-(P51"<<Y&2S'FY1N6/P&-JC]-
M.NX_3WY'\@^OY_7CO]?;693[HV_E[W7]=OPJ.KV7WCDYV/S_ "Q^/]:U+-O"
M\''D '@>.1#W[C]^>1[_ &^FJ\?KMN1OMCZG^GR[=-0OYQAB" <$C?X=O3]=
M>VH)EX'SCU?NF /;G_$1^G;^(?EK((.IP?NY.VWQ'H?KCI6BW\XPV^Y!],D[
M_P"8^>?D:UC*/  3CR'(%'@.W/\ F'/O]!_EJYMSD$_E@';?IN.W\C]=-U"<
M+D?X3_R^&/E\_2M8R\B/S![B(]P[?<!_H(_Z[CSE@!Y0Q^M^M:)J%V>9\Y&.
MH^H]?Z_+MMKJ3E13ZA[?;@1[\B/O[\!_7\]7<.,^OKZ=#M6G7MX!N3N.NX&<
M]>_Y?*H]9=RNC0J^X?%\I:6=']/$,U#=E5Q#YW"A0-U"V:D_6*\ '4<4T>H@
MJ@;7:]N%M[8'&78\L:9W)[D]^5>I/3MU(K6VN3-)Y<>1G)SN0HQUZ_';L3\J
MJDEI]151TZ>+ 43G5<N'"BO;J'J.JH<Y_P Q$3F,80^_L(!A+9%5&GG8)$JM
M(\DAY$55!9G9F( 50I)). "23W-:*%YI$@A1Y)9&5$CC0O([MA0BHHYF8L0
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M"]DF^4*"TZ$DZM='+A9]'MB!QY$#9B"I*1J9"\%1:N?B4:CQPDP3Y$=:7KG
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MJD@80=-XU^[*+)>^6M $TY0[94KN*AC&@&AC&D)U-6!/$SQ'AXCN3H>D3_\
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M&0#RLZ+%&6V!=@)#SXYN5C6V<+\'ZGKOFKIT<2QPD>;=7+\D7F,/NY".TC
M$JB$(.7(4,H,/[O?G=@ [1J0[&-#N=(3@99R8!#I%P8H '07W*B41*)OF,8P
M@4"1+Q7QW<\0(+&SBDL-+&#)$74S7;!B09V0<J1KL1 A9>;WG9_="^DO#[PZ
ML>')5U&\>/4-58E8I1'B"T4@<PMUDSS2ON#,RJ<>Y&L89RVEW;D  >!Y#D?8
M?KV[" >W?WY]_P"0:T@#)V_IO^OQJ=[:#F)VP!C&WS'?M^=6N[!_!8W=;^H6
M&R774ZUBK!$LY>HMLL7=Z#I.8"*D5XR53J=2B%%YV;<LWS5TT\Q\$)$"Z;+(
M#+D,F;C/:;ITUP@E*JL1R%=P-]]RJC.=\C? ^-2+P_PG?:DBW "6]HQ(6>7!
MY\$AO+C YFPP*Y;E4D8S70'.?HJFU26B,&1;C,V4)4]5R(UG\_+R)FK!GF6A
MI,5U%J-!QL0*)Z$F>90CP+()24P^/$NYA-R\7>!%K,]CM].M[=Q(%YI0,!F
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M G&2,FLTUWK$4TI32E-*4TI32E-*5K#->-@S)A_*&)36.7J!<E4&UT8UI@#
M2:KQ;1"/889>,$QB +M@#P7"1!43!02='F)]766G*GFQO'GEYU*YZXR,9QMG
MXC(STR*R&E7_ .R]3T_4O(BN?8+RVN_9YAF*?V>59?*DV/NOR\I.#C.<'I7^
M;UOQ\#C>OL=^*VM:JFSEA9B*BXY7Q5'R$HC$,2\""]VJ0$7L%1 @& '#Y9*0
MKR9^"%GE#G*4<%-;RP9+K[@_C7=,?$X!7_K #T)KW/P?XM\*<6^7;BX_9&JO
M@?L[472,ROZ6ESD0W.>R I.1_L0!FK8OT9#P[%K)=)W?SE6N.DH2B+/Z?M^;
M2K11%"6MSUDXC[C?&R+@A0=-:W%NSUV&=E*HW&9DY5= Y7T$F=.XL(>=S*WW
M8]E]#)Z_'D'_ 'B.ZU''C[QN(+6'@W3IU,MX$NM::-@6BMT=7M;)B#[K3R*)
MY5V/E1Q*?<F(/0MXB_A&[??$"^#Y#4DYS ^ZBBM02QEN>Q@4K.\014C"=&&M
MC B[-C?JF81.D>&G%0<M$5G"<3)QQ'#I-QE9H8KB-X9XTEB<8>.10RL/B#^(
M/4'<8->1+^PLM4M)K#4;6"\L[A>2:WN(UDCD7MD$;$'!5@0RL RD, :YO,[8
M[\1[P_RG/N_P(&X7"<>X]..ZW:K'/; V81YA$C>3R7B3TJ5AJJ@@4AI*0:-T
M8%NJIY3)=Z84_-C+7?#J*Y6232I_+8Y86MS[T9.<\L<V"RCK@2!OB_4UYPXM
M^S_'+YMYPE?^4P!=-*U$LR$C)Y(+Y<NHQLB7,;YZ/< >\-,5+>SM/R:_;Q%6
MS;30FG0E!"%L#EU4)9501 H-TV=J:PZBKCJ#I%NCYBP&Z2B3DP<Q)J'!W$FF
MDS/I=X(T?F:6W43J N,L6MFD*K_B8 8&<X%>>M?\,N.-*ADEO^&-2%O'GGFM
MX5OHD QEG>R>Y"1C.[MRH,%N; )&\W[/U12>EX5!P4H('0,!BJ^;V3$ABB)3
M ;D!*8HB!N0XYYYUC[?4KQ'55FFYBW+CS''PY2"<@[]"1], 5"NJZ0L@,0BP
M[Y0 * >9O=Q@#UZ^E7B[>/!\;TS)&/\ *64,G1ERBJR]968:#'5IZ@PDI!NV
M,ZB4)&4?2O*K1A*"T>N6XQ0IOR-3,E2E17.;4]:+P?>VMQ:W=]JSW"1E9C:1
MB8*S<O,BL[3?=5R&9?+(?E()P:]3\ _8XL-$XJT#BOB7B.VUNWTFXBU$:##I
M+16UQ<Q1F2S%Q=37CL\=O=>3<.AM@L_DB%P$9LWDK+(MD57#A5)NW;I*++KK
M*$21012()U5553B4B221"F.HH<Q2$(43&$  1U()( ))  !)).  -R23L !U
M->X&945G=E1$4L[L0JJJC+,S' 55 )))  &3M7&QX[<%3;;FO$.X7&TU%6FE
MYAQBYB"6:#7*]B9B?QG:)2!DEFSQ/]4Y!!@]B& *)]11]#UD4.D*0ZBSBKR)
M+^VO[:1)8+VU]V5/>226WD:&0JW0X3RE]-CV.:^<_P!J.;3+CBCA/C'1;FVU
M'2.)-%N+-=0LY!+;W%UH=_-;R-',F8Y L=Q'&&'-GR=B5Y*Y[YM@/!@#N/(<
M\ /T$1'ZB'\=8:%_AMG_ "Z?KUSMFH8TFZ#\AVZ=03N-^PQZ_@*CQ>+!7JB1
M1Y89IA%H<CT%=+D!=<P]BI-6I1,Y=JF$0*5)NDHH81#@O?6;M;>:[Y4@ADD;
M;[H]U?BS'"J.IR6 S4O<)Z#Q!Q!<BWT32KR^8D<\L,9%M$=\-/<N%@A7 V,D
MBDXPO-6\,)[&/$)W7*PO]WS9/G&6KEH IX7*.2*VKBK%9V2PAT3/XMN0QC5]
M&E3'U'1'>H>.41*#9!110A1V&#AJ9BIN9T1=BR1@N_RYCRJ#GN.8=Z]/\/\
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M@0RD;$$'<$'8@[BMJ!! ((((R"-P0>A![@U_;7%<TTI32E-*5^!$  1$0
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M!,T)CD;<#9F(VW%:9KWAYP5Q+*L^L\.Z?<W*2+*+N)'L[LNI# O=63V\THR
M>65Y$)P2I(%=+)"%3(5,@ 4A"E(0H>Q2E "E /R   -9L;;#H*W(    8
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M)P56$Q _(D>2ZBUNGI5,Y>0'A.+5+R4 5'RRB:[MM$TNT'[JSB)_OR@SN?\
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M\5M$:T8HK&'N!U3J"JD0! P@D8W D PZC7Q2D1.'(HV(YI=2MP@[^Y%.[$?
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M0=LD5273+7'W6MQMACC<)O$>'+<>068/T1\I\P<$,!3IKM')5$C%.4HF I5
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M7J^)MEJ\X^O.QVGUS(NX['U0RWFK*5<R4;:G2$<AYIGH2L[=<GWJOQU;J_\
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M=>'4664$  3JK*'54-R=0YCB)AP!XHXE8ECQ#K>223C5;Y1DG.RK.%4>@4
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H_J<_0>@_'>K,-*ZTTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g29248g80p21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g80p21.jpg
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M 0$! 0$! 0'_P  1" $M 8,# 1$  A$! Q$!_\0 'P !  (" P$! 0$
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MO&[XOE(>JB!_D&%&3UGO*>UEXW?%\I#U40/\@PF3UGO*>UEXW?%\I#U40/\
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MEXW?%\I#U40/\@PF3UGO*>UEXW?%\I#U40/\@PF3UGO*>UEXW?%\I#U40/\
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M&7 EIX$ ;W.X[L^OJ7O. _)_E/RU<U49.Z@KXP<GIY![9<+TXP+.*L&?&SA
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M)WYF:W8@ %:0(]D\;&,;NK9'S+WGL:\,OA1%?7Y)_P"HF$\;J^2/F7R&LN&
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M%?E^/MB:H^%T_P"1T_T$^X?_ )/GXOWS\Z+Q^O7Z%=>SJ3GF )(L."G&F;[
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M2:5=/06B6KA9<:N$?9>;[[3TCI96'F9RU[0>8F(YIU1?0IZBZR+02_H_S#Y
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M0<$91I8]>\(!@1!%KWMZWK+,>YCFO8YS'M(<U["6N:1P+7 @@CH(.0H(!!!
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MB_=B>[R]_P W0?W$O[0G[0]SQ^#O'CU?2[^I&/N;^3_X3J3XQHOW8GN\O?\
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ML:(3>;:*9W%08Z@D@)7(BT$SDDE;$10?/GMZ]_S+"RMF3DLS]6V#>V*L:E;
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MU$A2,((#,1O:N([-U+$K0&.N.W)1&-D!&?J0DH]'&,NR0"-TY!3>#"(?9K9
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M:(6=Q#FZ"*+*3(KAR!Q:=8YJU$DZE)35;ZTM(Z\XC3H5JCHV,R5')W\2@VR
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M4)A$PB81,(JV9%S;L9A;CE2NKH:C<8PHY42:;M8)J\.X#:]XNVW6=:.;=#W
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MPBZYT9VE\2@0O36W/"(M>U.A:-T1)G!*6YL3HC?&-Q G5E'%!7LSTW-[PU+
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JJ>:/_(?/KQWP'B4$C#=_[5YG)/"^%\4\-_[.7W/">#_?[G?$5P,#"__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g29248g86z12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g86z12.jpg
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M64_TB>D!X+_'#XS^VVN_S#CWN]OOO+VH_(=R_9T]W;+\;6[Y93_2)Z0'@O\
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MS0S7ZZ21312-+)(I8WU3F21R,<6/8\%KVDM<""0I;;;>QS7-H*)KFD.:YM+
M'-<#D.:0P$$$9!&H.H626<RO:L<.8WJB<J/]W"\/LRD^=-L5_/+9+_::P_\
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M0S/ I4A!)!??&,?<+#WA"WV[W\^J)YJJ>:IJ)'2SU$TD\\KL;TDTSW222.P
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M= +?4Y7(X6*81,(F$3"*&+KY"4]QXCR.1VY-F^+DNZT#5&60M.O?9E-7PW8
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MW6SH74'9WL8[-Y^J7;"NVON#,AUF['M,V*VMD&2(ZC;':&GBA(Y-<^T[/7B
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M "LL .._2-E$.Y!\AI/=\_M.90B5V=MZJ:<1KECR1C<V*I<;1*"V>K9:>PV
MR21W>8R[+8<$;R_O3T ]#%!&I'<T3LI0EZ2@V7EBKJZ2LGJ989*C>I9H[G7Q
MS"DW9-VGE+)F2.?&XPY>][P1%D..\0/K.V'\(&AN.R.R%#LS:;%;KG0604U_
MME;L#L96VT[2"HH347VWMJ[3545/35M/'<2*:DIJ8MEK]V2G:(&2NS_]'%QR
M_P!O\IO^>'F5_P#Y^_7_ $>]F[]P*#[I<ORQ=?VQ?)O?CVQ_R78;_=CV./\
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MMC+'KDML)L-=E(F1K. ^1I[1$K-)@IY T/@"&DUI+-DI;G0$'J ;ZAZP5F]
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M3Q8]CL/_  W";[_A.\Y4#<@.@?TL>0,9:(VKXOQ"H#69\(>B))0"1OJF3+
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M\,2=K1.XZG Y^$.77WGH48NUN]== WEJT51<*'92.JZ*G0V]-6-TDG%S*T+
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MC8^*8%QJLRMHZCGRMR:Y!%^7,@5Q&FTTWDAD%;S(._H),@5D66D:V*;-\69
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M(LZCGN@T:8SD'!\61CSJ^=$L2N*-(X(3RU2)<F(6(U)(N\4H2JB@'ISRA?\
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M1_T!ZSTCGJ=>:]L7X"<5H<\!>6*OW\D:6S6.WV)G6VS<+O$H;.X[*)'-6M=
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8)X7POBGAO_+E]SPG@_Z_<[XBS P,+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g29248g87h41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g87h41.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M[Z=[!3-DVU#L:CT;7KGV;3=*/I=$8=;^PE"SKFKE6<;1J8&;AIHB8OE=JL[
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M;AUGN"IIZ34#7LGLCT?X6UJK6KK0'>PVT56&M7"N5JVUH]MCJON\B/=EJ_<
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M=S;+LMD05]'O"MJL?2?ZF?4C[L>A/PKJG"D[3UGO4.= _P#JNY_W_P#LK_\
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M'^[B>0=AZCW(M+FXOXR_^_\ ^;//-\=^._K]:V$&_P _V+5GMS_2?_\ W/\
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MWV=P>!RN;R'-3'@AF2,AYF+GI^T"BO0$]6QK#AL2:(=99:K10@D\4QRBZ(D
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M$Z$\8*C^#.DGH^&_VK[]:QY/=.UO,-N@]$>^F0B,Y(B#V8/0K[1!A46IB/\
M:$B=E&?>M=0J.)=;]JDR&G@FGT)+2R.YZUXK4O\ ##1+TK&/[$]]FU/&"?\
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M*C%CVMUT5J2R"2Z=&Q<7%QV(]^9RQ_G1 I:UUL#"YHD<YK2YH<0+V83Y9XW
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M$O@DTXQ+&(L;8[2G#<'Q&&44U3AN#Q8E3X?68A 9ZNBDI7NP^6L/-F5<&)5
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MZWU34[UJANR7V@:SGJZ01M2"O>RVZ4S48^OP\?L,$VL+*@98 M\CS<C;LS)
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M=1[0JT/6+,35;JS3+MKB0]ZU.Y1DK7+579^@['NM7F88]@9[(\UB0BY.+E@
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M?B8%ABN5M4BNNU]EJ+$%;:A(!<Q+JA8I"4@12I614"PQDXG+I0O9C8F*AAG
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M?./KS^?E,_M1!_X[CX,Q+YOKO1*CV:>,. ?/F#_2=%[=/G'UY_/RF?VH@_\
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MD=+Z/%]Q/<$%^I8G^K@_[GCG%1\O-^E?]Y.8T7Y'2^CQ?<3W!!?J6)_JX/\
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MD=+Z/%]Q/<$%^I8G^K@_[GCG%1\O-^E?]Y.8T7Y'2^CQ?<3W!!?J6)_JX/\
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M:WZYT6YW_9"]6'1MBF1XJE:]=VB4%%AEGQ(94A/4U(\K5'2Y$"%GV#P2A9C
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MUWUNHD;;Y2ZW+2/6_>5UUS4-;6J9['#[,LESLS(E)?J>_+-L/5*55K8XTA1
M*[,VAVRUZ&C8" O$K?@BG6;8WN21M(!W6&_*WGX[@%('4'H'O?2&F>TU#NKM
M'5.;AZIZXTU4<PUA,/"3<*K!=AHZ45+$.PPBPHC)&SZU[,:VR4Z\VF24H5O(
MK:2"%P):<\CZE#.A/1J]M=!ZRJNDP;14;A#-;BZX;VLNXI2Y% [8GE5_3<AK
MK<.EM@G1M9CD7NF46<CX+YBBE^I $UG(#40V*BT4J-(ERDN!W'81;<,[@C[>
MG/-1/!^BV[YTG4;U6U[?ZM1KI\R59I0LO4-KVNL.#W6L>BSZ]=1HF4:EH:$$
M,:Q#;PUA892'E4)]K K^(NRBMLR!"HX<A>TFY!M?@-FNYQW\#;K6&=^^NW=_
M3M5NM4U3/=G=GURUG=RP^LE/UEN[NK-V_7=GV/6^N2])7BT;/US7=A&RQ]6G
MXC>T/"T'?]ZK6NF6=CGS;5R#C@I]Z!CW]S]G< I:6DC(#XM[ANP7UMIWY; 3
M]OU.-84EMM*\^*TH1A6?'Q\583C"L^.?TY\<^/Z?^WDJTOWPB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(JQ]V/J9]M_NQ[[_"NU\*1M'6.]</1[ZE?4'[KN@/P
MGJ7"':>L]ZM%PH3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$58^['U,^V_W8]]_A7:^%(VCK'>O\V.D?R+J'_NO ?[I$X60=IZSWK*
M.%"<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBQ>[_R
3+M__ +KS_P#NDOA2-HZQWK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g29248g90v08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g90v08.jpg
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M^+YI[#X6/[GX?_\ #]=/Y.$^/^+YK"LU?X0V;%TM?(CHC[]TX4I7NK_W;IG
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MS^3/R_)S+BOEFGQW5UM[R>3?MD ?_P CGAWR74VSMC[)KQPBV]I6AJI[\<,
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M(N';PB8-DFR.NJ*&Z3)GJ\+$5&@D<0?-B<U#Q'N1UZ&%3H%672%X=!2$A%=
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MLFA\F>9E##-9)8:JT5%R::>6*46UU[N,=NJPR1KG4\\4KZN%D<K YA<VF>6
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MPKG5RTT/PTX]CYIMHIKGR50R[99>#'R?I,S 9V--C%G0LDR=+7&2,D!<QP<
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MX&-O#&RVL\*E.$3A%%-[_P"A]R?978/Y2+\D<QZCZJ#R/H?HI6Y"E5G[;]9
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M+\G_ '_[9\O_ /N/EQ__ 'CA%J.L#P:^G1!Q))Y"JVU=6N6)D9*Z)65,YY8
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M3[%JM_(P+A63S/J?JHL[RQWKL7ZZ2X]V=KLW9=<5Z\#3AJ%AZ9].Q&4P:OM
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M#_5I.*-S6BT5,7+ +]KJ/VA6ICW6C)]%3'H.$=F9@&69J9;&(U)!2N<N0LE
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M2:J8PTSG-CIM2TL99;YBYW"QES@'$;74N^'+R744CG.X)(PTA;"F;QH1:-2
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M@<LL&]QUI3"8$XG7>6O8^_NNU?0  E%@*!N1R*7&NN%G%)$?=K"!L); FOJ
MTK5.MF[ I+0WQR-L$#GD ^8V!'COY*XU#7Y/K,LJR:PLBKV=6RNM*NH":2$&
MVES.:;,9/;J=GZ2*.I'1;9L++B(\\KQ/W"/-DF;DV/*:NB0<&]T4&(%3CZD>
MV/S6 5EW0TG/:RWZ&+Q-A&Z]C J7*5!;*Q[TVUIFZ+>0D!VB8JLG#1LR"-JE
MFMG1"'H*8).G14F%L%PNV9,(ZDX=%);MG/3(Z9R1[@'T_%2//.R+Z)WYUKIX
M/6I>30[L&0G#'%WM)1!_>&!?PZM;"G^L98"FLC?3P[*'^D'UW47S$AT(9AWV
MZVDS=R!#,<X48V)SR\/UM\_P50[%\1JQZ>7FZ5G4!#X^N,ITM=@4*UNMV4/U
MQ$6MS5E485WVI:,ZM50IAG(1MG8LYN_BJ]JYQ%:UN4<&9R0C 4USQ5!H/][Q
MQR\B=MQGEC?',=5;SJ#V0SVBJTO8&14599 V3/JVV+U_+WD]KF8*P,SD.XE<
M!EA*,0TH6CK]SJLRWR0C(Y1D;'&1S1<V,:,)"6*DC'Z^JM-PH3A$X1.$3A$X
M1.$7CV[-?.1[!_;?:_Y\/\*^.0]!]%ZH.MOS=J$^Q:K?R,"X5D\SZGZJ:>%"
M<(G")PBT\%^\5U9(RC0'8'6S2$[2P\#!6Z1BLDUA8$Q"J[[*6)*X5N->VX#D
M<U%HMJEK\2-MARRKN-RO=[9I6"BY P'"/<8JL#SSCEGKC'AXYY*]]HS<D;ZM
M'I4[ALA9OYS2A8@3 MTVBKJ&KR.O'I%XF?R_="U-&H%9QNR)*-D%WV%$LY3'
M;[9VTUEO,>H^JH=L#X\QM]?168Y"E.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA%UQ<0)/BR ,Z,'F@I=FX'%1!9DV(BR8]VEL@[8D&#Q-9H\9N4=]T7#9RDHB
MLEOLFIIMKMG&;L,TU--%44\LL$\+VRPSPR/BFBD80YDD4C"U\;V. <U[7!S2
M 0051)%'-&^*:-DL4C2R2*1C7QR,<,.8]C@6N:X'!:X$$;$+7L\Z]W/U-=NI
M3TQ73FU3;N5B,FZ<3F0*-0K75=79P^>==IX4V<J5N545V4<:P0_N\KX@LY=Y
M:9CZWL>FGI4>I;%K)C*/73307D-;%2:XM],'SNX1PQLU/;H0P76( !G[QIPR
MY1M:P/\ M+>,KC7V>Z:><ZHTRX55OXB^?357,6Q-SDN=9JN0N-%)Q9=]DE+J
M-Y<[A[D\"LM0G9NKNP[ OI$'A0%-XDMHQL.I9R-5BUJ5N6SC7&PZ80]]M[:S
MTVWSZ+,RRV?Q\KC&VPLL\QHIC3E=1:3N^F9(36QQ5%OK6F2V7FWRBKM%TA\)
M:*MC'=O.-WP2=W4P[=]"S(SO+1?:"\LD%,Z2*JIR&UENJV&GN%%)_@J:9_QM
MS_=D;QPR?W)';XL)SFEN4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X18/
M):RK:9ODBDPKV#RPF@UT8($9+$P)U\BQ257739I.RC!TX3:IKN7*VC?13".B
MKA=373&ZJF=MA2W:ZT,9AH;G<*.)SS(Z*EK*FGC=(6M:9"R&1C2\M8QI<1Q%
MK6@G#1C%GH:*I>)*FCI:B0-# ^>GBE>&@DAH=(QQ#07.(&< DG&Y6N/OSX6M
M5=O85#V4!90RE;#ALE;.&<L Q%@P9$8@6<M6\N!&1X%NPR37T9(IF(TJY]++
M0T/U8X<,!YLLZU]0[.>UV\:*KZY]RDKK];*ZE>U]%4ULLCXJV%KW451!+4.D
M[IID)AJFM^_!(9.&26"%JXK5^@J#4=+3-I&TUKK:6=I;40T[&-?32%K:F*1D
M36\9#!WD!/W96</$QDLCA<BNNI/7&L8)$J]CM-URX"PX". ,'9N%QDR;?)#V
M^B.Y$R7>BE'9,N16PH^)OW&^57;YPNOMC7*GHXX>Z:SU1=KC6W.JOET;/75$
MM3(RGKZN"GC,CBX100QS!D4$3<1PQM&&1M:T<ETM%IZRT%)3T4%MHS%30LA8
MZ6F@EE>&#!?+(^,NDD><OD>XY<\D^*G(!&X]%!B06+ 0L:#H;K*H"0 MB'&(
MJ.%-EG"B3 <@V:I[KJ[;*K;Z)8V54VVWWSMMG.><]4U5362F>KJ9ZJ=P:'35
M,TD\K@T<+09)7.>0T !H)P!L-EM888:=@B@BB@C!)$<,;(V DY)#&!K02=S@
M;G<K7$#\*CKX : 6C*66MG2.T;4U&,=53<8RAL/J>=5Y-F\^79:1!-EO8\R;
MU+6D*F!W1#1DO"88($A!(-QEZ_=V%?+B<\MR3[Y^6Y7X ^%10$<<39(4;D0\
M%*$I,@'%!X=28 M%D)=9H.TRR2D^"54QL2<88%P*$?C.UARF4;!HB\?CU\DR
MZC8\U)QG]9Z8Z_3"DZ;=$8U-[3DEB*W3=$;"2BWAE^D*ZBCR B@2-O#*'&=<
MT96PDRD#=V(R13KP('<M C>7IC6,P:;25%/UNS=HT)Q''AL,?@23Z<ST7;==
M>E(#K60-EH3:$Q]MF$R 2JP&K"$43"(Y/FL9A,LB \.>B=>5)%8\R?DR$E93
MF83Z+L(]94NE41B@XK+LU\.W@JY03G]';Y_AT\L[KAW7T$IR^)\6L.:')ZW*
MFIE2,N(,094*R%N6U+"K)C&\-<)+Q]V[=0RT83;,WA-H"'+Q94Q'BF- CR/D
M$$B&I XCY_/'T(!'FNH9="Q,**I2FDKYN*E)R[VM8?+9=&V53RE>;16U;ULS
ML-[W#X*PZUED:QO6M@V[/EJK.CA#(N!&2,N.D*\M;$WR;@IXL\P#R^0 _D,_
MR7TB/1-*KIBC+*;[+7_6+=Q :GKV51]LA2,^:3QA43F7NQ)N5'K8IN>31232
M-Q.I,XEY8+)@V2CHCL[:H#W*:2NA1GR'CUVSCS\,;+K(CX8W4V%+56>"U\ T
MLF F928G5OK0FM,V;V0UL6%SN&VN&['21&$([6;'+2S81J42\"[;,AJDK8Q\
MD);BT ;%EH4\1W\\#TP1C'3&,>BLH_Z\5LH>H,O'Q*$%&]<I)*Y+7T.@PP#&
MX:FO+Z\F=;DASL$R$:MVXM$5.2Y-HV";"-]32;9RNJX;>U-')4YY^?YY528U
MX;@B/P.6UZZ[+WK(Q$LF,6M=<H8C'6EO*\7A!+7AESPJYCTO T %DMAS(#-8
M*&QEM9A68QDM'LK1PN!>#&XI(:57%OG Y$>/(@C'/H?!6WHBCF5(BYYC>82.
MP9?:EBD;5LB;R=I&Q;Z1S(A&HI#-%VH*'A([&@0L9$H/%  \>,%:*JHB/=,R
M],2 B6,/RI)RISX1.$3A$X1.$3A$X1>/;LU\Y'L']M]K_GP_PKXY#T'T7J@Z
MV_-VH3[%JM_(P+A63S/J?JIIX4)PB<(G"+#=:ZK[5%ZVU@L-U;DG;%^1;ZQ@
M)A$@^&.\OQKQZEACZ#IV/?9R]8N%]5%FCO.7+?=-;/I\(L;O?_0^Y/LKL'\I
M%^2.8]1]5!Y'T/T4K<A2G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*K'
M87JI";N58SD2[+5I?D.8N<5M>$!(:QJ<Q]UC111L&+DTF)!M*8.^<9]0;B,G
M%'@KE@Z?X;,$';CVC'7Z9UA7V 26^9D-UTY72-_>M@N,?VJWU+"0'SP1.DC=
M27"-OQ4];234\[9&1\<CF-X5H+QI^ENA95QNDH;O3-/V*ZT;^XJX78);%*\-
M>VHI7':6FGCFB<QS\,#CE4%ZNWQXKX32T&O8KJCI<:(&<*!A!:,3*M*E/))C
MA[1,DI$Q$B6% )_"WV/9280^B0%+[OW99GH]*^CJ/ ^C:MT]V.U!M+],ZQ-C
M=46\3S0U5#=;S3N,LKS$*V:F$U3;:^/XXIZ9T4S1$R%YCA_M:GD;%=NT&(5[
M;SI\7,0U1BCD@J:&W2@,8T/^SQS&.&LI7?#)%,'QNXW2-XI?N0VM^'N#CWR6
MUUF[A5"FC\C\P:H@Q/8JSVU_S[^^6FG]D,U&^/EVT543044UUSMJA\GESCO]
M'514_P#8VJ]$WMSMXX*?4,%NK'CP'V6^1VMX=RR 7 $X+ET']+HH?^T+'J2W
M ?>EEM,E73MZGOK:^M;CG@D D#("S&(^('TKFKOW.$]DZM&%?3U3]QIL>Q6Q
MS"VWEY-\A+$1BQ7#G/G_ /399X7\_D]7YXSS"K>S;7E SO9M+7>6'!/?T%/^
M](.$<W=_;'5</!_'Q\/FLFFUAIBJ=P1WN@9)R[NJF^PRYY</=5HIY.+^'AXO
M)6K"2$!)F"92-G \@&+?^21"$F19@KYXQG'JWC!9PWW\\9QG_"IGY,XS^KG'
M5%-44DAAJJ>:FE;]Z*HBDAD'JR1K7#\0N@BFAG8)()8YHSR?$]LC#Z.82T^Z
MYC<@P=N'S-J^9N78M9%N3:MW**S@<X<-47S=!\@GOLJT679.6[Q%)QJGNJU7
M1<::[)*Z;[4.BD8V-[XWL9,USHGN8YK96M>Z-SHW$ /:V1KF.+20'M<T_$"%
M4'L<Y[6N:YT9#7M#@7,):'@/ .6DM<UP!P2T@C8@KF<H52<(G")PB<(G")PB
MQ+:>PC2;I5KO+8[K82\=5EZ,)R888E*D61?Z"U9#H#]?[HY#Z$5-662'L_LV
M7/I)84SOIOC7-%NN!MYNHHJHVQM4*)U?W$GV,5CHS,*8U'#W7?F(&3N^+CX,
M'&",XYJZ450H340BL=":EM+WC/M!IP\1F819X^[#SP\>.'BR,['&6\PED)PB
M<(G")PB<(G")PBU&GNZ%RD;7I4E7L5F\]K^S;R[%L6-65G'*[)S$QUVZH@)E
M4,NL#<A/CT31;*3[L[,ZQD"!1M*FJ+2J1L#&B!#8Y)9@[+E7PC!\@-SGF<''
M(\AG\<E00OW1[.W+8HB/05/L1 XW,[C[9E$8W4=9];Y==%>5)U9UICKFXBTA
M2LS,SKC'OC[0D[8.$3J1.1FL)"5(V%?)B!:F&A1@#IX=<;Y/AORQT\5W%L=E
M;NKV9R**%KB[Q(P6B^JD5O*T)?7G7+JY.K3WF5CR.UY![T;79I4\7K6).:YK
M>NV&4A4/'!/=).0H/2IXDLV6?[%( (_NY+B-R1X#ZY\5)D5O/N?)'77F,M[)
MK"5W)[D]4GMO5A4]>O);$T8_+T8=(.RT\ORRB#9B"I-9*"EI(_H&#1PRRD<N
M,B0QYHPFH&4N8K"B8&_3XL'T^[@>N,G?;IC)MI9';_WB=KX#U$'5LYE4_M2"
MB;'@Y-K,1(X3I$ \K,!;D,S1!=@X)11K781O'"D7P@U/.K5.2C$9!-1248EI
MX,5.-B? ''ORQ\\]%&EJ]P9O6/:RSX@VJVV+0I:G>M4%G<[5JP+5SI&-SZ=2
MRRR"[F4&)_/H$3:XC]<5JU)H#0C@FS6:2W9X4;HN$1F^Y2!D#J3C?/ET]?%4
MKJ'LEW'O@W'6)*6]H8TU$=>^KQR;K];:@ZI2%B'O:]([)KIG<;L A>$6-*C$
M8#5L\H<.'8Q)BAKLFF>-F5"+PJUVT*2 .AW=SSN!L.7B2#S7$GW:_LUI)[7>
M0NV^PS/47VYA?5&@%7E!4D0ZORHR*D-7T+)BEVV<I6#>8M5I'V#0MQK*%X),
M(DB&SN&C$.#-";1!F])@;<N1)P3D;$[#/@,*Z]?W3?;KNY&ZFDTU"FZ^G]1W
M=<P@<(@+1O6+RN(E,ZF"5D0INV&SQS(IY,F BTXNK=&\ET:178A(D5H(-:#D
MF:K@HVX>6^0.>_CG(^GHMDG"I3A$X1.$3A$X1.$3A$X1>/;LU\Y'L']M]K_G
MP_PKXY#T'T7J@ZV_-VH3[%JM_(P+A63S/J?JIIX4)PB<(G")PBBF]_\ 0^Y/
MLKL'\I%^2.8]1]5!Y'T/T4K<A2G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G"+#I=7E?V T]@GD&ATV8^AE/V.71D+)&GH;?YM/9S+)ZCZ&?//G
MKZ'EGS^7',ZBN=RMK^\MUPKJ"3.>.BJYZ5^1R/%!)&[(ZYRL:IHZ2L;P5=+3
M53.7!4P13MQTX96N'R55#GAQ]*S#]0L/HB.P(SOY[:&*B+2JFR#=3SSMJH@K
M5IZ))ZY3WSZ>FFR6Z/I8_P 26VOGKGL*?M0UW!&(9-0U-Q@Y&"]04=\B<.1#
MA=Z>M.XV)!#L<G!<_+HK3$CS(RTPTDOA);I*BVO!Z@T$U.!CGC&.H56:C\*(
MG4]JW;80'N=V>CK:RC MV!TB,M$8DWN<Q;J*80LT].@$Z;V&^&.G*HZ/D%1@
MQ\R#(;>U/';@FZT;]=>NV**\6>PVVIT+I.J?:X)65)K:.8TG>R. XK33V^IM
M[K9'*Q@EJ8Q+-').X<$;&1-+M!;NSY]ON%TK(=37V!M=)&Z$4U1&)^!H)Q73
M5<-6*QS'.+(7]W&]D0/$]SI'!MD?@P=IQ/\ @BOB'6]HAK_D0G5,=>YSYXQ_
MEPL[2@D9(*?]MLIO$,[?K\\9\LXY;^EFD)MZSLTLI=XNM]]U+;_7A8;A51#R
MRQV/-;O]PW^/_9]97$#I5VRSU?N[[+ _V<$_1/XA 3_&)[@TE,_1^75O.NJK
M@-Z7E^K59Y"KF8^EY_MV28H?K^33''[Y[-9]IM$WZA_CM^L&SX]&5]CDQCP!
MD=YDJ?W?K&+^SU):ZKH*K3YBSY%U+<VY]0QOH$]'Q.1WZE.B<OUT_;LE?U?*
MK8Q_W]%6R$DM]O\ \8WTQG_MCD__ +3R^':%1$^>F[DUORM;G ?@<>)*C_UZ
M9XZ3J?PO%&3\ZT9_#"K)%;@\74MV?LB!/Z&H(5 !<'C3P&8D,DF#>HV9!5=;
M&3$=LD1%W4RF)L\KDJU+1-S%6.0+<.*471 84]T9=U=79.Q>'2=KN,>HM1S7
M*6OJF5$%-2T3[T^,-']14VJ:K90T-/3M$+H*QM9(*A\\P:ZIP8J+1P7+M%DO
MM;2/M-HCHV4L#HI)IZEMN:\D_P!;#71P.J:F68]XV2G-.SNFQ1DMA^_4V:][
MWB6GO^F0L[IG72._ZU8M5EP6$10\_P!?HN)-8T08.,Z?^GTA*&-L_P";&,9\
ML<I]I[*J?>*TZYN9'A67>R6V-WJVDME;(W/CB9WEU6\[G7$VSZ_3-$/$T]!<
MJQX]#/6T['?C&U?WX._= M\DC\04N/14_P#/;UOUFIR+?)GR]+1N\EZEE/T?
M+Y<:JZK^M_5G.?UZ\?TFT)#_ ++V;0R.'W7W35=\K/Q<RB%JC=GQ'#CP\T_<
MVIY/[?6,C >;:*Q6VGVZ!U2:YX\B'9\4^ ^<*?\ 4F'=GO!(E=__ #TA5N1J
MNF&_G^O"*%:U_%'C;7/ZO+0EG.,?Y=M>/Z?T\.U#H+0%*!]UTUEJKI*/5UUN
M59&[_P $)_1663>IU1JF8GF([C!1,_ 4-'3N'_/Z+ (+X6M&P'M+&.U#"<7-
M(99%P:K9 =.+'D<Q<DY3ENH+;RDS+S+]>5DD4(^X<"-XN[(+ '.N&NZC?#1%
M<>[V-P[7=07+2-7I"2@L=-1U=0USI;?;*:B9%1\0F=1P44$;:.(NJ6MF%6R,
M5#?C =QN;*S$I-!6JDOT%_;57.:HIXB&QU5;-4N?4<)C;425,KS4/ A)C[AS
MS$?AR. %CMF'/*EW"<(G")PB<(G")PB<(J\4WUK@-/)QYVR;)FY-#4+GCD-E
M#I%=J_C=<7);^UM$( S;:OW++=@.<C84&7*[I8(FTX0'?N]F^^^[70I)S\OD
M,?FL+.=$^KQY^&*JP$\$) 1LF$#2$)MFXZ\>8'3.=';-E+=\Y@5@1M4M[NSZ
M2G)405+;O5UBI!5;UN-$T$TB<1_Z@'D,#GY*4$^NM-Z1:S89O#$W<?N:)LH/
M:*!(Y)2A";1<?7K2JVHLT>)&71]7T((R1";O42:)!=3=V8<.U3A!^3<DR=O+
ME]5B4&Z@T)6M@.[-@\;EL?E3^1'I:_3;V_<CB)/I%)6;A@9*/*[?3]U7KI9R
MU<;)H)KQ=1 ?L@Q6'(M%AH]1L3)/_0?7FLN6ZZTLXL%"V'$"&+66UG#:Q6TY
M5>%U).A*6=?&:K:*(EMB.7:8)K 9$?CK>'Z*8AZ*)LL]3 ZE"#M\J3)Y?KGG
MZKMBM)5:;9W(Q*1%FZ;]@AFX:X<>V%45IL+WA#>N?87CIN_2=#D-(8U2#(ZA
M%AGL^-G!!#*91VZ?+$R=O+DHHWZ4]<OT@%;.91*5@Y>=D$<E)M:+7%=,1 &#
MT2CD7A\>(%85&+#$0HAL/B<*B<:]G=QY9H[! !HI\@Y9-]4>$R>7\@I)TZ_T
M\G$P4&T@PW$3C=FK7('"^U%<MVUG.;"*VNZF"RFQ#+E^3=V*;+2YWH07=,W1
M9\LHX:J)>BEJ3)Z^&/PQC'LL>ICJQ177UQN[JJ&O CG2.,86*6-S2>SQ2)P,
M6OJY&5W -K E$HS75;C7";=5A7D$][L*9;LV&6P)+W/9>SD))Y_0#\3CF?,[
MJP?"A.$3A$X1.$3A$X1.$3A%X]NS7SD>P?VWVO\ GP_PKXY#T'T7J@ZV_-VH
M3[%JM_(P+A63S/J?JIIX4)PB<(G")PBBF]_]#[D^RNP?RD7Y(YCU'U4'D?0_
M12MR%*<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+R_H=B) XL&/=BB-F)J@)%W)ON
MQ-G=<=[;ME5E"NL=$.K>-C8[)>CWN<%H6+5,>K6H!"5A2Q_)Y0XCXR::REF"
MVG)<1J%?KV_7ZV5S&V,8^$#=HQDX_O;G.3T\M@K%L>[_ & CU RF1IS>B(;+
MJBB,YAQWKR<:6?+[NL2TX9UN1L.>GXK,)):4HD,,9I7I* \;K@%/H_*!;J$I
M \E['W,V1#A@ G""?7!R.6"<#(P/#GCVV7.5[V712E:!GH*55I: JK_A5TN2
MIXP/E4G[!8&])JQN&'8ORS;"<61N\4=VIV&J&!Q?4&9@8Y5^.[!P)JXEBTS=
MY>OBCA!/CN =N7Q$;#;P!/L=ES[M[O=BZ0.3J+6UK5-JNZ=-@YW(5ZR%V=2P
MX8X@_5N?7S,X>])(VU*5G<9!V*1ZM#2,HE.7<;4@MOR)Q,( 10&#D5"!H/+.
M^PY'F<#IX9Y9Y+N+M[U]@J9"R9%M=G5BW/>XXELAF<WJ> )K&JWC,%@<5+2Y
MKI3D][1PW6T L>F<TBR)HY5]J3.P180TUB6M4DYFZW+"2!H)\1D;9\?Q V_$
M8\<@*^W7R83"3=@>U@TB05(1:+H]=6#O5/W6T"B+H*U&E(K."1UD;WW?A1>D
M)+4J:V!*X159OCKMZ^1P7)$E5BI/(==_;/C\U<KA0G")PB<(G")PB<(G")PB
M<(G")PB\>W9KYR/8/[;[7_/A_A7QR'H/HO5!UM^;M0GV+5;^1@7"LGF?4_53
M3PH3A$X1.$58^R?8<A0PP6L"@:5@FG4:LV?D!#J5ZPQNT@-/Q/,JFS]B5VCT
MD3(2A75T%$1:-N6HD<8)%<JEI1'!8]X1U*0,^7(?B5D%_P PCK/K_8I1Z2T:
M,Y-6$P;A5%T7&NSQP5A99RP;X3PEMNBJNEGTO17U3QIG&==\Z[8\N2WF/4?5
M4.( /H5DWZ<*I^F0_P#AR7^RXP>A]BIR.H]PGZ<*I^F0_P#AR7^RXP>A]BF1
MU'N$_3A5/TR'_P .2_V7&#T/L4R.H]POPI>E3(I[JJS88DDEILHHHHB1T333
MTUSMOOOOLRQKIIIKC.VVVV<:ZZXSG.<8QQ@]#[%,CJ/<(G>E3+)Z*I388JDK
MIJHFHFB1W343WUQMIOIOJRSKOIOKG&VNVN<Z[:YQG&<XSQ@]#[%,CJ/<+]_I
MPJGZ9#_X<E_LN,'H?8ID=1[A/TX53],A_P##DO\ 9<8/0^Q3(ZCW"?IPJGZ9
M#_X<E_LN,'H?8ID=1[A?%O?%1.T$732<B7+5RDFNW<MTWZR"Z"NN-TED5DV>
MR:J2FFVNZ:FFVVF^N<;:YSC.,\8/0^Q3(ZCW"^WZ<*I^F0_^')?[+C!Z'V*9
M'4>X3].%4_3(?_#DO]EQ@]#[%,CJ/<)^G"J?ID/_ (<E_LN,'H?8ID=1[A?%
M"^*B=)^M;3D2X2]8LEZU!-^LGZUNLHW<)>FFSVU]8@X2506T\_226342WQKO
MIMKA@]#[%,CJ/<+[?IPJGZ9#_P"')?[+C!Z'V*9'4>X3].%4_3(?_#DO]EQ@
M]#[%,CJ/<)^G"J?ID/\ X<E_LN,'H?8ID=1[A?%&^*B<84RWG(E?"2RK=7**
M;]7"3A#;.BR"F=&>V-%D=\9T52V\MT]L9UWUQG'EQ@]#[%,CJ/<+[?IPJGZ9
M#_X<E_LN,'H?8ID=1[A/TX53],A_\.2_V7&#T/L4R.H]PGZ<*I^F0_\ AR7^
MRXP>A]BF1U'N%\4KXJ);=PFC.1*JC1;5N[323?J;M7&S=!WJ@XUU9YV16V:N
MFSG5)3&N^6[A!;&OJU4]MF#T/L4R.H]POM^G"J?ID/\ X<E_LN,'H?8ID=1[
MA/TX53],A_\ #DO]EQ@]#[%,CJ/<)^G"J?ID/_AR7^RXP>A]BF1U'N%\=;XJ
M+==5MI.1.[EOHBHNWU3?[+HIN,JX0452PSRHGHOE%;".V^NNJF4E<:9V]7OY
M,'H?8ID=1[A?;].%4_3(?_#DO]EQ@]#[%,CJ/<)^G"J?ID/_ (<E_LN,'H?8
MID=1[A/TX53],A_\.2_V7&#T/L4R.H]POCB^*BRXV:XG(G+K1'1QNVPF_P N
M-6ZF^Z::^R/L?K-4=U$E4]%<ZXTVW3WUUVSMIMC#!Z'V*9'4>X7V_3A5/TR'
M_P .2_V7&#T/L4R.H]PGZ<*I^F0_^')?[+C!Z'V*9'4>X3].%4_3(?\ PY+_
M &7&#T/L4R.H]PN^CEDP67$5!$<DHXF439+$=AZ6RR3S9@V7:MG+Q-NY2146
M;-G#YD@Y62UWT;JO&FBV=-G*.-V".8*9!Y$+..0I3A$X1.$3A$X184,K6N@F
MI;0- 84(T/LUQQW09%03#4T/=8WPY8EM6C!+!)FXPHIA=L\PLBMC??"FFV-M
MO,BYFT'A6YDM(MX?%MI >:L&)P[M'Q.QDTR%*)*BV98GEIEZ1:C54$%6#=XN
MLDS412W;Z)[)Z9P1?U.$0M%^?*I1"+I%)7LQVE!), )T?R389KKH-V/O-6F'
M!C8?KIIJQR14<9::ZZX0]7C7&,$7.6C<=<KO7+@ %7<DDWB1%PL*8JKOTB+$
M<+()/5=T-E'2;\8'$CGFB^RFKIB+'-%\;MV39-(BQ[2K:R39Q4<G74$T'P5W
ML_A#'2(Q_5G#GVZGKMWL5;:C\(QYWLK_ -79R(T9K;*?X\[YV^7A,_/FOK *
M^C5; E@,9;KZIOS9V4'"3]QL],R.4R@HY-2.2'"&^-=WA0L3=K+;^AH@R8-=
M6H@.S'!!PT:S)S6;<(G")PB<(G")PB<(G")PB<(G")PB\>W9KYR/8/[;[7_/
MA_A7QR'H/HO5!UM^;M0GV+5;^1@7"LGF?4_533PH3A$X1.$486E3-:72)8!+
M-BZ,G&#'3QRU;[$C(G;9,H)?@#@IXY!$1;HC')( *$0,KBQ%=U&Y6#?.0\C%
M%!RV[;) <+/BHD:<$D@19FB^$%Q[P23'K8S[.\&OVRC-XS5UUSKGU+ALJHBI
MKKG7/H;YQC./U\(NQX1.$3A%QW;1L_:.F+Q'1PT>MUFCI!3SSHNV<)[(KH[X
MQG&?042WVTV\LXSY;9\LXX1&C1NP:MF+-+5NT9MT6C5#3S]!%NW3U102T\\Y
MSZ*:6FNFOGG.?+&//.>$4:";JK,Y9ARGQ<DV<V#'6KUV3#Y"2%NPQ@6SB9 P
MS'R=R)1BAHN"8SR%O) ##&R!D UE -<RP8I$6VRA3@XSX?K\E@T?[;==9.B"
M5%6>)QM*I?&X-$FA8;(8\3F!V9,$2T16AXF0!Q9.61J4AU\&H[-XZT)0HT$1
M>&1L@<BV+UVW)@_KRY_]%8SA0NO$"1P$4-"!VB3 2'8-!@QBAC.$&;!B@FU:
M-4<;9VVPD@W232TQMMMGT=<>><Y^7A%V'")PB<(NO%BAP5IEB+:),FF79%]E
M!'&<:>UEB#HJ17\ML[9]-V1>NG:OR^655]\ZXQKY8P3EL%@EI6_7M, F4CL8
MVY##"1)80.P/CTEE10@_:@C<I?I,@,1#G3KM(5%XU(I,9=H#5&@6.@3!TJNS
M%#7CM$@&?UA<I_:];C)3 (0\FD?TEMI-RKRO8^B_2=DY6."!',B*EQ3=GZ_9
M0*Q#M=W*QM7U0G"BK)GJ\V?$&#9R3^2D'A%UXX4.$Z.TQK1)GH^(/2KO5+&<
M87(DE]G+YWOYYSYJN5]]E5,X\L9VSGRQC'R<(NPX1.$3A%U[(2.'.2[QBT2;
M.3Q!(L863QG&Y BB*& TG:_GG.,JZ"0PMAC.N-<>H9(X\O2QMML1=APBP:/6
M7 99+IO XS*PYV75M[@:SP(+<^V.(HXE")%R#8F54==FK0F]:BGCO(K9?)%H
MTPU=/6K9N0'J.B+.>$77HBAS<D_,(-$DR91L/9D'NN,^N=-A6SW<<BKG.<ZY
MT:;$7V4L8UQG&7*GGG/GCR)YKL.$3A$X1=?J*':%5CFK1+!9<>V%+/\ &,^O
M4'-'+IXV:;9\_1]4BY>NEM,8UQGTU]_/.<>6,$\_%=APBKM(>V77B,#Y25(V
M8+=,(18)FK):O'!<BE^0$ZC,':V5+ Y%&)!S:Z"$,@SQ.1S<WZK("%L47^LI
M*"'(LD@T*<'^?\E8?3?17311/?51-377=-33;&^F^F^,;:[Z;:YSKMKMKG&V
MNVN<XSC.,XSG&>%"X*@H<L59'%6B6Y8</)BF3_.,^O;#C+D0\*-$\^?HX2>N
M0(=9;&=<YSNP0]'.N,;8V(NPX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A%X]NS7SD>P?VWVO\ GP_PKXY#T'T7J@ZV_-VH3[%J
MM_(P+A63S/J?JIIX4)PB<(G")PB<(G")PB<(G")PBJF/ZR*"+D*VJ+L)XW8.
M)!))4$ART:'ND IZP]:O86:LJ;V?:.RC$^!K15C'6:C5JK%24[F!59Y(44H>
M+B93G;'Z\<>G/?K[YQ&N.EH>"Q^/A']@FI(M$"/7=C%R60@T0JTKSJ]LI^BR
M'DVZ#AVB4+*>W&W4PEJ>6&QPD9<+#0<?'-1XEJ3/\_GS5VN%"<(G")PB<(G"
M*!KZI1S<PJ*:")HY@,EAAP^6"2) &RDB6B$MKJ;5;(V;D,_<LD%U-HU/2I$(
MZ]JTT&2H8 (D&AP(V*QHT4@X_7XKZCZ-',<T@G[OO=V5!G2[Z%L]&39+54"Z
MKF55@%CQ5;9155SD'')-C;);7*;HF^')+N4D]7"R>"C//S_/*G3A$X1.$3A$
MX1.$3A%'@6NV(6S9]9R1!VL0GT8KV,/1BB:.K-@WKQU.73%TU5UQZ]18AM.7
MFKK57.=$]6+;*/EG=7S)Y?KP_)2'PB<(G")PB<(G")PBIC:73QC8+VQ#0>Q3
M,.D%D3B324L43 BSJ; !.NN,'ZU3*,C6#U=LAJY<QB"");'C[K9SL$FK=HJ0
M%R&,Z$HR8*<\O+E[Y_7E[JX L:S#C1P@>EZA@*8M!K%'.^ZGJ6;%NFU;)>L4
MVV4W]6BEIIZ>^VV^WEZ6VV=LYSPH7.X1.$3A$X1.$3A$X1897EA0ZUH7'[#K
M\VE(X;*6>Q  ;1:OV21%GJX6:;+:-2C5B_1QAPW63]%RT04\],[8T]'.NV2<
ME!V_=#KDG8V]8;3<SDVE/4:I6D^E:6FI4#>U7!!(.A5SB^TX5M1[>R%3ZZ$9
MU@BUA:2GWUKH13(K$C62%[E.#S_'\.N.:S.X>QM344[BXJ?E9.O)9MJ:6B4(
MKNM+-N6Q)"PC.@]23&A=<T]#YU.7,=C>"X?20R36/^X(1P9#-29%JY+C471
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M0F=%MXSI')9N>!0Z:.$H/+K9=/W@62G&+ O$VKDZW'Z"20$H3#>NWAOOR/\
M/'@H@+=@?$#>NXC(=H$2CD@9UN&?2*!I==[V<P@>4E(+K*[*&'TKC:<[6D9]
ML1EMX,0D(#Q\V<@#Z,-$9<.>L(])"DE)@=?'J//\A[J>9O;/:=N>ZH2R,QB9
M(K3:ED'EF5^YHZ</@CRQC\\Z^I.X_*U@<J,"Z"*CHD6M)^P+3N2GV48U&O4"
M#\W[DD6!I^OU_P!4P-_7J.A],[X4/0WM=WQ++1#<W29!%D0L:.IE6N>N-\!)
M(\ADC$U4ON%RS-MF\1B98$:/6<,D9B0SK2(QEK'Q9)M/YVF"61L4IP.OAU!W
MW_'IX?Y8RX[#>(G+*H<Z2.NUX)(3\;E&Z3^O>O\ ?Q64#+ P%J!8;5>!YAB#
M<1EHFZEEJKC;NU3D==[*0D0*W.DW[1][["8;GVYD8QU_RV*M-?%S]MXO9,GC
M525^B7'MU,,HNB^IRP9:"<QA>I"\E_2J0L@')0457(L;E;C*J4I1%R/FSD%N
MXFR:^ Y-L4#E  QO^M^G/EOGEX+\6E<7;>#4;$9$!A2,HLMM=-LQ&6LQ%-6)
M(R$BKF#RVV T /1B"1DF_P!1AFQ0T8KXXF0E\PAU<D&9\CJG/H1[LQIVW)@9
M\L#Q'EX_H^2@VR^Q?<E[)!GO6@,_B32ORQ!(T\:=8KLF@662G<-W0%MXNH)&
M/!*TKA;EQ!.M;Q&;1M^XB0XA/47^TGUU,CU8X0 =>?F-ONY]/%=A,;<\1/$8
MMDOK7H131D*GR48@$>J2PM),YV>3?M'!HHP$V %LM)T^>A(W6U+3M<^!!,7$
M@VL=!X'Q'!QJ.JM28;MS\/$>6<C'F>O+Q6)%[B\0B#'[ ]SQQ>8#7,U-! Z\
MFZYVJ1"PJ*LKL[KKLY*)2K80?D4YV=PV.]6(HV;BAQ3#F*3L9*-5&^ 4KDNI
M3AOR\".?P]>7,^WM*D.NSMHM)I],[1C3J(HU_P!=NR\A>P5"L;!#5B!G48FL
M*WJ7.+./O$@=O*2NOPA*6-MXO@._C"1N5 3*3$CKD8$*,#;S(Z9\<[>'S6'"
M^T_=,BZJ_P!RZY?'HY);*@S$G,%^KMYQ=J;K26NNNS.8GFX7=_(BD+=UHO8%
MW.&&)WI& TQ 5P&D8:4FTAQ,;,R8&^_AU'/?R&0=N6ZQ^L;Y\2%ZC!(B7@(S
M+G:.=<8\>ETSHJXF1[U\N9]>F=O6H710:QZO5B$/DDVN0*6@:,T DTF,&2G*
M8EK&!;Y<Z3#?KXCPSCSZ;[J>H3:G;8; ^S<GG<?-DYI&VT(2J>.#J0EF16V^
M&CF(FY.'"LS:IF:#BQP2[GAN)@#1>5Q4.MHFP82#0K&61HF!M\SGY>6.0Z\U
M5<KWI[G!XO:15[!1#&2U)6MC2@U'B'7*\D@_N;' ':![&K'.RPT3AF!+4TO4
MU1%0M?D047E4S&SDNV$,!VQL0^A93PCKXC&X\OS/LL]?W/WD1G)"3#8),9%$
M4]JZ "#Z],6W&Q&(EB9=I!,XME6BU#367K2N.1+6O3)"N2*ZQJ?[1Z$*1D4$
M>SF*HM"C Z_,?P[9]_3\%^9AV*[S$CI:+Q>(RQI&T1PC#*PD^IER #SC48[J
MJ8+RIC%G[R6"G#&4P\C8D=?QDA( T\&R4?M&<5Z$-B6;J6DP.?RXAY^.WE_G
MX9&)O+O=KM%(P-K-5B5(RRI8F_2DU*6N='1BN96TJO:97>4L1_-F@B0EXM+9
M1/(:_J-8NSE[0''4K#(+LXT")OC1,-Z]?$>>!C&WK^"F.C;E[8'KT1@-NP/1
ME!D LQ';2,+4%BQUJ\)Q,PN.%S0O+9&_S!0PZ;-VF'82.1J1SF1.-B2*;F.
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M_=V#?W&X3@/E\_R3XV#KM]#+I^[L&_N-PG ?+Y_DGQL'7;Z&73]W8-_<;A.
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M_=V#?W&X3@/E\_R3XV#KM]#+I^[L&_N-PG ?+Y_DGQL'7;Z&73]W8-_<;A.
M^7S_ "3XV#KM]#+I^[L&_N-PG ?+Y_DGQL'7;Z&73]W8-_<;A. ^7S_)/C8.
MNWT,NG[NP;^XW"<!\OG^2?&P==OH9=/W=@W]QN$X#Y?/\D^-@Z[?0RZ?N[!O
M[C<)P'R^?Y)\;!UV^AET_=V#?W&X3@/E\_R3XV#KM]#+I^[L&_N-PG ?+Y_D
MGQL'7;Z&73]W8-_<;A. ^7S_ "3XV#KM]#+I^[L&_N-PG ?+Y_DGQL'7;Z&7
M3]W8-_<;A. ^7S_)/C8.NWT,NG[NP;^XW"<!\OG^2?&P==OH9=/W=@W]QN$X
M#Y?/\EYCK\[;5Q(KUNF0,@LV29G;9L8PT2=#06CE-L3F!EZ@FYT2DBZ6B^B2
7^FJVJ2RR>JF-L:*J:XQODK@V 'DO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g29248g95h87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g29248g95h87.jpg
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M)S)YM"4F-3<Z0E%A9Y6FTM?_Q  7 0$! 0$                  @$#_\0
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M-]MC,-'?Z:^T4"&W@TWTT5 HYUIW+X0BR*Y6<EGUM3.I1HPIBCJ(U[@FC5C
M1DU6:NEU[WLWSGW8!5^#.NNAJR60?,Z*4CR;*+CAMR+.P\CJ[S?,TH^4 NK!
MZ14WVV:<BBH1P19S=<=SBF9:)R.%% <)I0,&G&15C9=,,)YO3LQC$F^TF)OQ
MSC?QSF=3$L^\&6:G_ Z9K"V'M%CL8TA[CF=K)EE"2%R0B$DMU7<2, W)2#:
M+:(9E'03E5FF'4R59IFS;13$TB\%2Y57#2 R",GYC&<==RW3KQ<W]N))M.SN
MQQZ]TG)\X5[RV0F-ORU(\MHXJ6@N&*G3C#*> ZA8=S7(9/)Y]DFT%'<"FON^
M+@>F2D[X2IL*O:-$MY^2W%=9)7,FCPYK4S59,=_.7>8O9XV7'4NFM_\ /^W_
M !Y*)*!0*!0*!0*!0*#7%WS]+"5?L-^6S/H[:/IGC[U;/KO(,K Z_P %A%X"
M<)L *'8R#!-8/Z. <#(6#*1,0S&(0R_@,%B-A;$3$,7'$3"V5L<\;96O:QSL
MWN\XWG\,Q=8LM^STX^\*,_>&C,3G/7X.L66_9Z<?>%&?O#0Q.<]?@ZQ9;]GI
MQ]X49^\-#$YSU^#K%EOV>G'WA1G[PT,3G/7X.L66_9Z<?>%&?O#0Q.<]?@ZQ
M9;]GIQ]X49^\-#$YSU^#K%EOV>G'WA1G[PT,3G/7X.L66_9Z<?>%&?O#0Q.<
M]?@ZQ9;]GIQ]X49^\-#$YSU^#K%EOV>G'WA1G[PT,3G/7X.L66_9Z<?>%&?O
M#0Q.<]?@ZQ9;]GIQ]X49^\-#$YSU^#K%EOV>G'WA1G[PT,3G/7X.L66_9Z<?
M>%&?O#0Q.<]?@ZQ9;]GIQ]X49^\-#$YSU^#K%EOV>G'WA1G[PT,3G/7X.L66
M_9Z<?>%&?O#0Q.<]?@ZQ9;]GIQ]X49^\-#$YSU^#K%EOV>G'WA1G[PT,3G/7
MX.L66_9Z<?>%&?O#0Q.<]?@ZQ9;]GIQ]X49^\-#$YSU^#K%EOV>G'WA1G[PT
M,3G/7X.L66_9Z<?>%&?O#0Q.<]?@ZQ9;]GIQ]X49^\-#$YSU^#K%EOV>G'WA
M1G[PT,3G/7X.L66_9Z<?>%&?O#0Q.<]?@ZQ9;]GIQ]X49^\-#$YSU^#K%EOV
M>G'WA1G[PT,3G/7X.L66_9Z<?>%&?O#0Q.<]?@ZQ9;]GIQ]X49^\-#$YSU^#
MK%EOV>G'WA1G[PT,3G/7X.L66_9Z<?>%&?O#0Q.<]?@ZQ9;]GIQ]X49^\-#$
MYSU^#K%EOV>G'WA1G[PT,3G/7X.L66_9Z<?>%&?O#0Q.<]?@ZQ9;]GIQ]X49
M^\-#$YSU^#K%EOV>G'WA1G[PT,3G/7X.L66_9Z<?>%&?O#0Q.<]?@ZQ9;]GI
MQ]X49^\-#$YSU^#K%EOV>G'WA1G[PT,3G/7X.L66_9Z<?>%&?O#0Q.<]?@ZQ
M9;]GIQ]X49^\-#$YSU^&O5O([WZ:VDE <[$JPFF<_@5TA(5VLPSF#S8[:6&'
M.'*JPI?/I \<!K='GES;"6PRY,\<K6.NGZ9X^[8=UM]':!/H6BW\#(5'*\;W
MWW9IHPH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H-<7?/TL)5^PWY;,^CMH^F>/O5Z.MOH[0)]"T6_@9"HY7C>^^[--&%
M H%!&37I24#[UVX!/'SIT%*V;%34P(V:',AIR?;7^ #UB!# ;//$F2L=/'3G
MDI>P8'E1PT8YG3&!L\S;U=WWJ3=&% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H-<7?/TL)5^PWY;,^CMH^F>/O5Z.MOH[0)]"T6_
M@9"HY7C>^^[--&% H%!%?6_Y<[C_ %J!?TZZ[4;>$[OO4J*,*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0:XN^?I82K]AORV9]';
M1],\?>KT=;?1V@3Z%HM_ R%1RO&]]]V::,0_WS=TK1_JK+#]AQ\)C =S,0[N
M(1</M,-W&1D4CG;SDE(8!E:2D]$7%&P@(11R*1)S%$H'$U>S;.FARQL@;,9F
M=T(=A]G)WCV4IT<K&?RBK.>*]AFS"D;:LXIK0,(4GL!;TM0)U/NPP0^#^4E*
M+CL_%UY+1=RH#K*(Q=!B$PU@TW&X#UR42I)B=69G/+]6-]\?_L9HU;F*4S1Z
M5V^C2$L;AIR' ^I$Q-EQ'5.+V\>.OZ=,95#D=E$'&U6^TF:GH:8W&.Q96145
M4*#*J.GR19/+GLT(\U210RSKQT<V\^KSO8KA;G$8XBT:3+N @,#@S2[,*3EM
M XA#3D1=CV6CE"AE+C&*&L0*='C&JZ7->>6TWD!\ &2B@,6#(NXHGX"&LB.9
MXV5T=-D_7)MUR\ZS,N<4;B>)@""*G<"N;EH141"ZDI@@[/,PO=#413!H$5&&
MRO$@_E(P 0 (]S%L2_.Q,XX]!CS>=FY)FF6ZLZI,7$SG><X!\4;B>9M@TM9\
M"N;@U@%:*IH+;OL\R[F#*>,3',#+&)OJDM; $L.$&4R \ERY^8UL^GPYO,R?
MSW.C.E)TIBRWI;XEY#=XHW$\5S"@$J\"N;4 (HBJBB5''V>99K$^H$B]Q2:/
MAC:)"_1"J0MK !C\X3H<K\[H!?\ LUL[\;?R&K3)C&J:LV3;JEZ_!U)'BJ<4
MDT>)EC/ 7G(D7,&BX!@YGM(RQ,"@(HV 8IK(.T/!])B7#RR%RPY^'.MA?'GX
M\O+;%71IDOZ]-[-]W+7>*;Q0DQ:54Y-X$,X+2>1/FBI)7!VA99<)3+ #9A@G
M@P+Q"/T.!D/'$7$/IQ>9;*V/29\G.NK-.F62W7);.%SF=CE+?%&XGB:60!D[
M@53<LC*B,$H*9<+9YF%\D,_F9,@YI(V=XD'\I%#!!",7'MB7Y<3&./0VYO/S
M<F33+=6=4F+B9SO.<?T+BC<3P1LG%K/@53<$L%U@HG@-R^SS+R,&R Y4P..K
M8&^J2UL BHP09;(#R7/GY#XY]-AS>9DZOL=&=*3I3%EO2WQ+R&YQ1N)XKFCH
M"KP*YM;X)9'4U N9'V>99K$X?)%LAB:3AA:)"W1BJ0UK%PQ^?GT667/Z$7DY
ME]G?C;^1MTR3;7+O)B9Z[Q\.+J"7%5XI1@X4+F. M.1, <R ".;SVD98F)4$
M47# 0QEAU/8<_$##+(6^'/PYUL;VYV/+RVQMT:?^II]7.7N*9Q0DM:5$Y,X$
M4WKB>2/&"Q-8!V@998)2+@B98!'0P+Q$8N#@/C:PF(?3B\VU^3I,O[:5FG3+
M);KDMG"YS.QR5KBC<3Q.*( Z?P*YN6!U5)L?4RH6SS, R0CUS1@"Z6-G>)!O
M*1; @A&;C6P+_P (^.'0_P //S<F33+=4NN3%Q+<[S'&>P!Q1N)X(V3ZR)P*
MYN!5RJL2(EF[?9YEY&#I(R7,"F%3 WU28V##)BA! 9@^2B=)D/CETV'-YN6]
M6<[YX?=O1G2DZ<Q9;G%Q,8V\=_(;G%&XGBN<-%U;@5S<WRX"4IG@38^SK,-8
MF3I(KF.33,0[1(6Y@BB-CB6#&Y^?199VSZ(7DYE\C-6F29FN7>3$SPMWOAQ=
M.4XJW%+'-%@!^ K.14$8P"$,9RVD9>>)8(03' 0?+#J>PY^(.%[B7QY^/.MC
MR<['EY;%71I_ZFGU=@X.*7Q04I;5$U+X$<WKJ<2.CER:R!M RRP*D7#SOB&;
M#+WB(Q<' :W\5L.G%YMK\G/R_MI6:=,LENN2V<+G,[&)]D..)NSJG$P4V35P
M:929$=$2B3D[W*N[/-<NF-!57G"&VT9'/"D894S)D=14#2>& *&3"MTAX+#,
M/'#&XUW(TZ)JMDU3,N)M?U;9S/7R3"PX@^_(F& F'",E;+ 3''/&]I\;7)?'
M*ULL;V_ZLO\ &U[7JL:?W>E<>E?VW^>#LH1XE,[RO+DAPBX=$'9'4B1LVF^Z
M7 W#TP$%Y3+IKER"R2A3 !.-R018,T6' ,@BV,CWSP%QQR#PRY:J:--XZ\3J
MN/\ )T[^V_SP2W[0,\^R:Y_OP'[F5O0T?]6?V_Y.E?VWU^'J(OGQUO61C,;O
M")#\;JP#2,N[#)0<V*L,,1!4R26#;$G9O)7-#,#&A^:8\IRYF13/#H<N?SL,
MU:)-/2FKI3I8VF.K/-LU9N,8_G<DW7-10*!0*!0*!0*!0*!0*!0*!0*#7%WS
M]+"5?L-^6S/H[:/IGC[U>CK;Z.T"?0M%OX&0J.5XWOONS31CAGT\@JDC*<J$
M2:DGG L@39 ^6!.$C0.7)S@C)4Q@( .%ER6YP8N&6%^2W+:@Z45ELX=V%7Z.
MTVR,^2*0*WR3S%04L1V$T$<?(T.B%7%F5NL%T@8SED8%30CF!(0?+(;,&XE[
MY4!K,MG,8D<362TVRSTY153RZH$&L@I;?)'EM3RPS4E@X522I0 TJJ&8>&9Y
M0'#S-F\L,,AQA+XVO8(^ZW_+G<?ZU OZ===J-O"=WWJ5%&% H% H% H% H%
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MW&[\EE_K;JA89)9$;-)>?#M42Z3+S-5E0P1;C:(*:P< 3DTD9/'A2Y,3 H4
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M/FNI&SRYH8>.6>7-QQOEER6OR8VO>_Q6O73\+Z]/C[5.OZ;X>\=66VY8(9<
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M>:+-966%)4(&G,J'35,Z9?U[:9MT;T<\Y<XDO^>O#9AHY% H(KZW_+G<?ZU
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M>FR%$S*EU='5B9F)+V3*X&B"@4%1?#I]*SBJ_6B0OY&O5>KAI[OM$:>.KO\
MO5NE0LH% H% H% H-<7?/TL)5^PWY;,^CMH^F>/O5Z.MOH[0)]"T6_@9"HY7
MC>^^[--&% H%!%?6_P"7.X_UJ!?TZZ[4;>$[OO4J*,400^E*D/<;WB(3%+@?
M5A$4H:[ZNHL9R-(1LLSF._UALMI))N1)9;B<(Z>D.53;)PF<"<)!&,G#2#F.
M6R50B>*H0R-G2[_AZ9-[-5X;V3[9]5S'7%$?P7N^.M../@791\SW=_PW;/P7
MLK<WG^:[N#SGYI\X\V]LO(O*_*>;?EZ+D^.B,7ABY5!@,%PREQXV'M%&V3??
MT!M#AHJ40.>2V<\&DY$-"DL[/[N<9!G*8:.MG%(HK'T%4+*Q#$8CB7.$PCPA
M<<2Z<>Q+E\/P\7:]/.,=71PSEOS#LU*KX;SHU^;R\I*6S$8+&B\WK;:N &=C
MA@/]T$EYI;"J XP@71$X 0U">,$SHL38XSAE=*!"*9<N6>!.G&++U?JF>O;>
M>.WDPX?CW9UL[JED)L'Y?:49-"8H"18';S(;$TJ\($M16S%$;)<E-YP&$^6V
MIJVD9YN$K+J0H=:++<,\)ZB*T%R-BCC2TUEIR<;MT>KKSO,VW.+PMY<+C:YQ
MFYQ3!< ;40=#.EK-9&&R!7$> ^&@)-+=<D@R0YTQGOYC;)Z^%IE;)%"<#A44
MJ,DA$A@:1$5^,AB$FVVCS#1!2JXD*&*6&+1N9;JSC^K'EJQPX[XPY[%C[8!S
MMF ;J37W#59_;3ZU?<^TQN:UQ]K$ A3PWWDI'Y!<$4HKW-J! LTT=5\^'@EO
M76R7"0$8GVBEF2QQR$DTJ@&7$MQC&^.>,7&<>&<[Y\6<N&H@[3)KJ,G)V<$Y
MG#8L&M4M-23*[<F4JW>TE9: &73S*<$PRV\&V;$+@W=Q=2QU=9B'KJI(IMJ"
M(IP@(CHJ$&-6.J3CMSQW3[VWGG=<31!0*!0*!0*!0*!0*!0*!0*"@KBX^GIP
M,OKFO?\ "S2HZ:/I_$_[?NOUHYE H*B^'3Z5G%5^M$A?R->J]7#3W?:(T\=7
M?]ZMTJ%E H% H% H%!KB[Y^EA*OV&_+9GT=M'TSQ]ZO1UM]':!/H6BW\#(5'
M*\;WWW9IHPH% H(KZW_+G<?ZU OZ===J-O"=WWJ5%&(7;7</#3'>)09BKM3!
M#<EY3CXFL)[//JRR\$,VBD5\8B95B89AHN-O"FRQHPFDQK J&1O N*'GF5Q
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M..)3"^%\LBM.F6:K^V9BTRB2@4%1?#I]*SBJ_6B0OY&O5>KAI[OM$:>.KO\
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M"AB\KY4[46LWM%05WN,#W@H8O*^5.U%K-[14%=[C ]X*&+ROE6<01@C 00X
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MKB//F&S/NNA_L:!U<1Y\PV9]UT/]C0.KB//F&S/NNA_L:!U<1Y\PV9]UT/\
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MWW9IHPH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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AFANB:B&"'TI@PJ"#"=&"&&%AS\[\P/###'DQQQM8U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g97787g13r37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g97787g13r37.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M"-V5%:GG0K<V1VW@./$%[+CJRK^0/^-8U#.H=A61F% !0 4 % !0 4 % !0
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M?\^GYUA3C=W&CCM#TTZIJL-OC]WG=(?11U_PK:3LB[V0FM.)-;O"O"B4J!Z
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MK8.#BDG9W#8PH_!6EQR*V^X;:<X+C!_2K]HR^=G1UF09FI:!I^J-OGBVR_\
M/1#AO_KU2DT5&;CL9!\"V>>+N<#TP/\ "JYV:>V9?L?"FF6,BR>6TTB]#*<@
M?ATJ7)LEU9,T=0T^'4K-K6<L(V(/RG!XI)V)C)Q=T95MX1TZTNHKA'G+1,&
M9QC(_"GS,T=>35C?J3$BN;:&[MW@G0/&XP0:-AQDXNZ.=?P18ER4N9U7^[P?
MZ57,=2Q<ET-;3=$L=*!-O%F0\&1SEC2O<QJ59U-REJ'A2QOKAIPTD$C'+;,8
M)]<47-:>*G!6W+.E>'[/27,D1>28C&]ST'M1<FKB)U59[%>^\*:?>2M*N^!V
M.3Y9X/X4%T\74@K;E>+P78HX,D\T@_NY I&CQ]2VB1OVUK!9P+#;QK'&.@%!
MQ3G*;O)DU!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
&4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g97787g40a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g97787g40a05.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M6N%M]9U-(;AAN$*J7<#U('2M#PYXFT?Q+9&\T.^BNX5.&*'!0^A!Y% &-?\
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MM]6U:TLYGUFX=4FD"DKD<XIND>+O#L7QCUO4Y-:LELIM.@CCG,HVLP/(!]:
M/0-?\4P:+KVBZ3-;R2/K$KQ1R(1A&49Y]J*X7Q?XAT;7?B+X&&CZG;7IAO9#
M((9 VW*<9HH M7OAS0Y;ZYDET;3G=I"69K5"2<GDG%0?\(SH!X.B:;C/_/I'
D_A110,O^'M T:UURUGM=(L(9D?*R1VR*RG!Z$#(HHHH$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g97787g70z47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g97787g70z47.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M#/9"?_U&N%^$23CQJ/+R(Q;OYOTXQ^M>I:B;:P^(FD3+Q<7UO+ X'<+\P/\
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M_45VE<%\,+&2WT^^N7&%FE"I[[<Y/YFN]KW:":IQN>35:<W8****U,PHHHH
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g97787g78y06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g97787g78y06.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MVMS:VAM+2401#R4+ DD ?.>/XJ -0>!((_%FH>([>_FBO;JU,*84%89" #*
M>-Q"K^5 '3VD4L%G!#/<-<2QH%>9E"F0@<L0.!GKQ0!-0 4 % !0 4 % !0
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M=/O=: )=D N2^U//*8S@;MN?SQDT 5CIFF7%VM\;*VDN%.5G\M2P(XSNZ\4
M2-!900PQM%#'%&X\I2H 5N@QZ'G]: )9X(;F!X)XDEB<89'4,K#T(/6@"H-,
MTFST^:W^Q6D-DW,J>6JH?<CI^= $[6%FT$L+6L)BE_UB% 0_&.1WX _*@" Z
M)I36BVC:;:FV5MRQ&%=H/KC'6@"5+>P,K11Q6_F1LKLJJ,J<84D=C@<'VH E
M@M;>U#BW@CB#L78(H7<QZDX[T 2T % !0 4 % !0!E>([*WO?#]\EQ:Q7&V"
M1D62,/AMIY />@#E)M,\NR\.)8^;8&/39Y"UJ@0[_+CZ\'J1^.* ((M=U^?5
MK1);F.U>2"T>$2N46;> 9?D"'<<Y'48X^M &GK]E>OXUAU'3E8WEEIY>-<X6
M8>9\T1[?,.GH0#0!@6NL:I!IFC_9I#8VTMK-+']H8P@S&4X5OD8D@$?)QG)H
M UI[>66_UBW:]NEGDU*T< -GRU(C^9 1P,Y&?:@"M>:MK%FD%N]]*MO'=W4/
MVF:3RBVPCRPSB-L\%NPSCKZ@%R[?4+NTUJ2\NY76&PBQ#&O[HLR9=@-NX\CC
MT]* (]3\17+^*;5-/N)EB^T6\>PN2LT;XW.J!#\N&^\6'(_, 26\URSA>XM[
MR\N)IK2]81N@95:-P(]H ZX)X[T 4([HK'K%YI^N3-$QM#]IN"4,H"ON0.$^
M4^^#@\4 >B:;,USI=I.\<D;20JQ27[ZD@<'WH M4 % !0 4 % !0 4 % !0
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M5W&QR4&" #R,Y SW% !X=M+VRNU2[MY07L+=#*6##>@8,I.<YY'UH Z2@ H
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MFE=9F8 JJD\8'7B@#)\3^+9]"U&VMHDM_P!Y&KA90Q,Q+A=BD<*>>K<<^QH
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MZTL7UW]AN!(/)RF$WL6.T[<\$G&2>M $D_AJTFO9;SS[B.:2YCNLJ5PKHFP
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M[FYD6U658(I"NV,2,&;&%!/0 9)H VZ "@#(US71HTEC$+5KB6\E,2*'5 "
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L;#GY<ABN#G Q0!L65CJ,.MW=Y/-;-;SHJ!(XV#+M)QR3C^+TH UJ "@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
